Factors That Mediate Expression Of Unique Ggggcc Repeat Expansions In C9orf72-Associated Als/ftd. by Goodman, Lindsey D.
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
2019
Factors That Mediate Expression Of Unique
Ggggcc Repeat Expansions In C9orf72-Associated
Als/ftd.
Lindsey D. Goodman
University of Pennsylvania, lindsey@goodman.net
Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Biology Commons, Genetics Commons, and the Neuroscience and Neurobiology
Commons
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3329
For more information, please contact repository@pobox.upenn.edu.
Recommended Citation
Goodman, Lindsey D., "Factors That Mediate Expression Of Unique Ggggcc Repeat Expansions In C9orf72-Associated Als/ftd."
(2019). Publicly Accessible Penn Dissertations. 3329.
https://repository.upenn.edu/edissertations/3329
Factors That Mediate Expression Of Unique Ggggcc Repeat Expansions
In C9orf72-Associated Als/ftd.
Abstract
Amyotrophic lateral sclerosis and frontotemporal dementia spectrum disorders (ALS/FTD) are characterized
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translation products occurs in diseased tissue. Herein, we developed two Drosophila models that
overexpressed G4C2-repeats. Expression of >30 repeats causes degenerative effects supporting gain-of-
function mechanisms are contributing to disease. To define disease mechanisms, we performed an unbiased,
RNAi-based screen covering ~4000 genes (~25% of the fly genome) and identified the PAF1 complex
(PAF1C), an RNAPII-transcription factor, as a suppressor of G4C2-toxicity. Loss of PAF1C reduced RNA
and peptide expression from sense-G4C2 and antisense-G2C4 transgenes in Drosophila and in yeast.
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interact with C9orf72-chromatin in C9+-patient cells. Expression of PAF1C components became upregulated
in response to expression of >30 G4C2-repeats in flies, mice, patient cells, and FTD tissue, further supporting
their importance in disease. Interestingly, expression from PAF1 and LEO1 in FTD tissue correlated with
expression of the repeat-expansion within C9orf72, supporting that these components of PAF1C are
important for expression of the repeat in disease. In addition to PAF1C, we also identified 11 translation
factors that may be important for peptide production from G4C2-transcripts in a second, targeted screen.
Follow-up studies revealed that eIF4B and eIF4H knockdown reduced GR-peptide levels produced from
G4C2-transcripts and G4C2-toxicity in the fly, defining them as potential RAN-translation factors in C9+
disease. In summary, jumping from unbiased forward genetic screens in Drosophila, we took an
interdisciplinary approach to uncover key players whose activity regulates expression of the unique
G4C2-hexanucleotide repeat expansion found in C9orf72 in a subset of ALS/FTD cases. This work increases
our understanding of disease mechanisms while highlighting potential therapeutic targets.
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ABSTRACT 
 
FACTORS THAT MEDIATE EXPRESSION OF UNIQUE GGGGCC REPEAT 
EXPANSIONS IN C9ORF72-ASSOCIATED ALS/FTD. 
Lindsey D. Goodman 
Nancy M. Bonini 
Amyotrophic lateral sclerosis and frontotemporal dementia spectrum disorders 
(ALS/FTD) are characterized by the degeneration of motor and cortical neurons. 
Recently, a hexanucleotide-repeat expansion of >30 repeats was discovered within 
intron 1 of C9orf72, defining ~40% of familial and ~7% of sporadic ALS/FTD cases. 
Aberrant accumulation of G4C2-RNA and the aggregation of its repeat-associated non-
AUG (RAN-) translation products occurs in diseased tissue. Herein, we developed two 
Drosophila models that overexpressed G4C2-repeats. Expression of >30 repeats causes 
degenerative effects supporting gain-of-function mechanisms are contributing to 
disease. To define disease mechanisms, we performed an unbiased, RNAi-based 
screen covering ~4000 genes (~25% of the fly genome) and identified the PAF1 
complex (PAF1C), an RNAPII-transcription factor, as a suppressor of G4C2-toxicity. 
Loss of PAF1C reduced RNA and peptide expression from sense-G4C2 and antisense-
G2C4 transgenes in Drosophila and in yeast. Importantly, components Paf1 and Leo1 
were selective for expression from toxic (>30) G4C2-repeats versus inert (≤29) repeats, 
arguing selectivity to the disease-associated repeat expansion. Leo1 was also shown to 
interact with C9orf72-chromatin in C9+-patient cells. Expression of PAF1C components 
became upregulated in response to expression of >30 G4C2-repeats in flies, mice, 
patient cells, and FTD tissue, further supporting their importance in disease. 
Interestingly, expression from PAF1 and LEO1 in FTD tissue correlated with expression 
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of the repeat-expansion within C9orf72, supporting that these components of PAF1C are 
important for expression of the repeat in disease. In addition to PAF1C, we also 
identified 11 translation factors that may be important for peptide production from G4C2-
transcripts in a second, targeted screen. Follow-up studies revealed that eIF4B and 
eIF4H knockdown reduced GR-peptide levels produced from G4C2-transcripts and 
G4C2-toxicity in the fly, defining them as potential RAN-translation factors in C9+ 
disease. In summary, jumping from unbiased forward genetic screens in Drosophila, we 
took an interdisciplinary approach to uncover key players whose activity regulates 
expression of the unique G4C2-hexanucleotide repeat expansion found in C9orf72 in a 
subset of ALS/FTD cases. This work increases our understanding of disease 
mechanisms while highlighting potential therapeutic targets. 
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CHAPTER 1: A CURRENT PERSPECTIVE ON C9ORF72-ALS/FTD 
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Introduction 
Amyotrophic lateral sclerosis (ALS) is the most common neurodegenerative disease 
primarily affecting upper and lower motor neurons within the motor cortex, brain stem 
and spinal cord (Al-Chalabi and Hardiman, 2013). In recent years, it has become evident 
that ALS exists as a spectrum disorder with frontotemporal degeneration (FTD) as these 
diseases share clinical and pathological features (Ji et al., 2017a). FTD is the third most 
common neurodegenerative disease primarily affecting frontal and temporal cortical 
neurons (Sieben et al., 2012). Despite a surge in investigations on ALS/FTD, successful 
therapeutics have yet to be developed, supporting that a greater understanding of 
disease mechanisms is needed.  
The discovery of Tar DNA-binding protein 43 (TDP-43) inclusions as the primary 
pathology in ALS and ~50% of FTD drove the hypothesis that these two diseases are 
related (Lee et al., 2011; Neumann et al., 2006). Further evidence came as a number of 
mutations were found to occur in both diseases (Ito et al., 2017a; Ji et al., 2017a; Zhao 
et al., 2018), including a hexanucleotide repeat expansion of (GGGGCC)n (Balendra and 
Isaacs, 2018; Vatsavayai et al., 2019; Yuva-Aydemir et al., 2018). Termed G4C2, this 
mutation is associated with disease when >30 repeats are found within the first intron of 
C9orf72 (DeJesus-Hernandez et al., 2011; Renton et al., 2011), located on chromosome 
9p21. The maximum number of repeats is estimated to be in the thousands (Buchman et 
al., 2013; Dobson-Stone et al., 2013; van Blitterswijk et al., 2013; Hübers et al., 2014). 
The presence of G4C2 is associated with ~40% of familial ALS/FTD and ~7% of 
sporadic ALS/FTD, making it the most common known mutation in these diseases to 
date (Renton et al., 2014). Further, patients bearing the G4C2-mutation also have TDP-
43 pathology, while accumulating evidence suggests that these two etiologies are 
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connected (Chew et al., 2015, 2019; Cooper-Knock et al., 2015a; Edbauer and Haass, 
2016; Steinacker et al., 2018; Vatovec et al., 2014; Vatsavayai et al., 2016). 
Currently, there are three leading hypotheses as to how G4C2 confers toxicity: a 
loss-of-function hypothesis centered around the reduced expression of the C9orf72 
protein and two related gain-of-function hypotheses centered around the aberrant 
expression of the G4C2-containing intron (Balendra and Isaacs, 2018; Yuva-Aydemir et 
al., 2018). Bidirectional transcription of the repeat-containing intron can produce both 
expanded sense-G4C2 and antisense-G2C4 RNA (termed G4C2ǁG2C4). Both RNA 
strands can accumulate to form foci in patient tissue. These foci are hypothesized to 
sequester RNA-binding proteins and cause a depletion of these proteins so they cannot 
function normally, conferring toxicity (Vatovec et al., 2014; Haeusler et al., 2016). 
Interestingly, these RNAs can also be translated into dipeptides, despite the absence of 
a canonical AUG start codon: GA and GR (sense-strand associated), PA and PR 
(antisense-strand associated), and GP (produced from both sense- and antisense- 
strands) (Ash et al., 2013; Mori et al., 2013a; Mann et al., 2013; Gendron et al., 2013; 
Mackenzie et al., 2013, 2015; Niblock et al., 2016). This process is termed Repeat-
Associated Non-AUG (RAN-) translation and has been reported to occur in multiple 
repeat-expansion associated diseases (Nguyen et al., 2019; Zu et al., 2018). Notably, 
the resulting dipeptides can form aggregates in patients and are associated with toxicity 
in model systems, a common feature in neurodegeneration (Balendra and Isaacs, 2018; 
Soto and Estrada, 2008; Yuva-Aydemir et al., 2018).  
There is accumulating evidence that the gain-of-function mechanisms associated 
with the aberrant expression of G4C2-RNA and its resulting dipeptides are contributing 
to toxicity in C9orf72-ALS/FTD (Balendra and Isaacs, 2018; Yuva-Aydemir et al., 2018). 
Significantly, this highlights potential therapeutic avenues for patients with G4C2-
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expansion, focused on disrupting expression of the repeat. Recently proposed 
therapeutics include the use of antisense oligonucleotides (ASOs) (Donnelly et al., 2013; 
Jiang et al., 2016; Lagier-Tourenne et al., 2013) or small molecules (Simone et al., 2018; 
Su et al., 2014; Wang et al., 2018b) to disrupt foci formation by the repeat-RNA and its 
translation. In fact, one such ASO has entered phase I clinical trial (Biogen, 2018). While 
these approaches are promising, multiple variables need to be considered to improve 
efficacy including stability of molecules in vivo, their ability to cross the blood-brain 
barrier (e.g. ASOs cannot cross the BBB and must be directly injected into the CSF), 
and permeability across cell membranes (Gustincich et al., 2017; Longhena et al., 2017; 
Magen and Hornstein, 2014; Mathis and Le Masson, 2018; Mis et al., 2017; Riboldi et 
al., 2014). A limitation relevant to the C9-mutation is that current proposed molecules are 
unable to simultaneously target sense and antisense G4C2ǁG2C4 strands, indicating 
that a cocktail of multiple molecules will be needed (Jiang and Cleveland, 2016; Mathis 
and Le Masson, 2018). This could complicate drug specificity to the mutation, resulting 
in increased side effects in patients. An alternative approach has been proposed upon 
the discovery that G4C2-transcription is sensitive to the loss of specific transcriptional 
machinery, including components of the DSIF and PAF1 complexes (see Chapter 2 and 
(Goodman et al., 2019a; Jiang and Cleveland, 2016; Kramer et al., 2016). 
Pharmacological inhibition of unessential subunits from these complexes could inhibit 
expression from the G4C2ǁG2C4-DNA and downstream toxicity, offering an alternative 
(or additional) therapeutic target. Overall, this work highlights potential mechanisms that 
can simultaneously disrupt expression of potentially toxic RNA and dipeptides produced 
from both strands of the repeat within C9orf72. Herein, I discuss limitations to current 
gain-of-function models, unique features of G4C2 DNA/RNA, and potential mechanisms 
underlying the expression of this distinct repeat expansion. 
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Clinical and pathological features of C9orf72-ALS/FTD 
Amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease and motor 
neuron disease, MND) results from the progressive loss of upper and lower motor 
neurons in the motor cortex, brain stem and spinal cord of patients (Al-Chalabi and 
Hardiman, 2013; Logroscino and Piccininni, 2019). The loss of these neurons causes 
weakness, spasticity, paralysis, and death, usually within 2-5 years of onset. ALS is the 
most common motor-neuron disease, affecting ~2-5 in 100,000 individuals (annually). 
Frontotemporal dementia (FTD), defined pathologically as frontotemporal lobar 
degeneration (FTLD), is also progressive, with neurodegeneration occurring primarily in 
the frontal and temporal cortices (Pottier et al., 2016; Raffaele et al., 2019; Seltman and 
Matthews, 2012). The most common manifestation of FTD is the behavioral variant 
(bvFTD), characterized by behavioral and personality changes in addition to memory 
loss. FTD affects ~3-15 in 100,000 individuals (annually), while the risk for FTD is higher 
among individuals 45-64 years old (Knopman and Roberts, 2011; Pottier et al., 2016). 
The average lifespan for FTD patients varies between ~5 and ~10 years after disease 
onset. As mentioned, ALS and FTD represent two extremes of one spectrum disorder. 
Clinical presentation in patients can fall between these two diagnoses, resulting in both 
motor and cognitive deficits and a diagnosis of ALS/FTD. Interestingly, different families 
carrying the same disease-associated mutation or individuals from the same afflicted 
family can present with ALS only, FTD only, or ALS/FTD symptoms, potentially the result 
of environmental and genetic modifiers (van Blitterswijk et al., 2014a, 2014b; Renton et 
al., 2011). Currently, there are no effective disease modifiers for ALS/FTD and therapies 
are centered around alleviating symptoms. Approved treatments include riluzole (a 
glutamate antagonist; treats glutamate-sensitivity of motor neurons), edaravone (an 
antioxidant; antagonizes oxidative stress pathways), and Nuedexta (a drug cocktail 
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including dextromethorphan, an  NMDA receptor antagonist, and quinidine, an inhibitor 
of Na+/K+ ATPase activity), while other potential drugs have been proposed and/or are 
being tested (Prasad et al., 2019; Smith et al., 2017).  
While there are multiple mutations associated with ALS/FTD, a common theme is 
that there are disruptions in RNA-based pathways (Zhao et al., 2018). In particular, TDP-
43, an RNA-binding protein encoded by the TARDBP gene, is the primary component of 
ubiquitinated inclusions in ALS and a subset of FTD (Neumann et al., 2006). Further, a 
mutation of a hexanucleotide repeat expansion within C9orf72 has been identified as the 
most common mutation known to date. The percentage of reported familial ALS/FTD 
patients harboring this mutation varies between ~25% and ~60%, with a higher 
frequency seen in European populations (van Blitterswijk et al., 2012; DeJesus-
Hernandez et al., 2011; Gijselinck et al., 2012, 2017; Renton et al., 2011). Non-familial 
ALS/FTD, termed sporadic ALS/FTD, can also present with this mutation at a ~5-10% 
frequency. Recently, a number of studies have shown that TDP-43 inclusion formation 
and the aberrant expression of the hexanucleotide repeat expansions in C9orf72 are 
related (Cooper-Knock et al., 2015a; Davidson et al., 2014; Edbauer and Haass, 2016; 
Saberi et al., 2018). Importantly, TDP-43 pathology may be induced by the expression of 
the hexanucleotide repeat (Chew et al., 2015, 2019; Solomon et al. 2018). 
The G4C2 expansion within C9orf72 is located between non-coding exons, 1a 
and 1b, placing it within the first intron of variants 1 and 3 and within the promotor of 
variant 2 (Fig. 1-1A) (Gendron and Petrucelli, 2017; Xiao et al., 2016). The C9orf72 
gene can produce two protein isoforms: C9orf72-Long (produced from mRNA variants 2 
and 3) and C9orf72-Short (produced from mRNA variant 1) (Fig. 1-1B). Investigations 
into the protein encoded by C9orf72 have revealed that it contains a DENN (Differentially 
Expressed in Neoplastic versus Normal cells) domain, which is a common feature of 
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GTP-GDP exchange factors (GEFs) for Rab GTPases (Zhang et al., 2012; Levine et al., 
2013). Consistently, C9orf72 interacts with a number of Rabs in cultured neurons and 
mediates endosomal trafficking and autophagy (Chitiprolu et al., 2018; Farg et al., 2014; 
Frick et al., 2018; Ho et al., 2019; Sellier et al., 2016; Shi et al., 2018; Webster et al., 
2016a).  
Overall, C9orf72 expression is significantly downregulated in ALS/FTD cases 
harboring the G4C2-expansion (van Blitterswijk et al., 2015; DeJesus-Hernandez et al., 
2011; Frick et al., 2018; Renton et al., 2011; Viodé et al., 2018; Xiao et al., 2015). All 
three variants can be downregulated, while variants 1 and 2 show the most robust 
decrease (Balendra and Isaacs, 2018; van Blitterswijk et al., 2015). On the protein level, 
two studies have shown that C9orf72-Long is downregulated in the frontal cortex of C9+ 
ALS/FTD patients (Waite et al., 2014; Xiao et al., 2015). Potential disease mechanisms 
associated with C9orf72 haploinsufficiency are a focus of current investigations 
(Vatsavayai et al., 2019; Webster et al., 2016b; Xiao et al., 2016). However, the extent to 
which C9orf72 downregulation contributes to disease is currently unclear. Mouse models 
with disrupted murine C9orf72 expression do not show phenotypes expected in 
neurodegeneration but rather autoimmune defects (Lagier-Tourenne et al., 2013; 
Koppers et al., 2015; Atanasio et al., 2016; O’Rourke et al., 2016; Sudria-Lopez et al., 
2016; Ji et al., 2017b). In contrast, zebrafish and C. elegan models lacking endogenous 
C9orf72 orthologues develop motor dysfunction (Ciura et al., 2013; Therrien et al., 
2013), potentially the result of deficits during development (Ho et al., 2019; Yeh et al., 
2018). Importantly, in C9+ patients, an upstream CpG island is methylated, shutting 
down the C9orf72 gene and effectively the aberrant expression of the G4C2-RNA (Xi et 
al., 2013; Liu et al., 2014; Xi et al., 2014; Belzil et al., 2014; Russ et al., 2015; McMillan 
et al., 2015). This mechanism is believed to be neuroprotective as increased methylation 
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reduces RNA foci formation, dipeptide aggregation and neuron loss in patient brains (Liu 
et al., 2014; Russ et al., 2015; McMillan et al., 2015). However, if the C9orf72 gene 
product was essential for maintaining neuron health, this would be an unexpected 
response to the G4C2-mutation within C9orf72 as it would also disrupt C9orf72-function. 
That said, a recent study suggested that depleted C9orf72 protein may play a synergistic 
role with dipeptide-associated toxicity in disease (Shi et al, 2018).   
Under normal conditions, intron 1 of C9orf72 is spliced out of nascent C9orf72 
transcripts and immediately degraded. Evidence suggests that the presence of the 
repeat expansion disrupts this process through unknown mechanisms and the stable 
G4C2-RNA remains present. Notably, this RNA could exist in a number of forms, 
including: intronic RNA (Vatovec et al., 2014; Haeusler et al., 2016; Tran et al., 2015), 
C9orf72-mRNA transcripts retaining the intron (Niblock et al., 2016), and aborted 
C9orf72-RNA transcripts (van Blitterswijk et al., 2015; Haeusler et al., 2014) (Fig. 1-1C). 
Both sense G4C2 and antisense G2C4 RNA foci form throughout the nervous system in 
patients, and are predominantly nuclear (DeJesus-Hernandez et al., 2011; Gendron et 
al., 2013; Renton et al., 2011; Vatsavayai et al., 2019; Zu et al., 2013). Foci formation is 
not specific to neurons as they have been reported in glia and non-neuronal cells, albeit 
at lower relative frequencies (Gendron et al., 2013; Mizielinska et al., 2013; Zu et al., 
2013). Investigations into RNA-binding proteins that interact with G4C2-RNA have 
revealed a number of candidates, some of which were further shown to co-localize with 
RNA foci in patients, including: ADARB2, SRSFs (1 and 2), ALYREF, hnRNPs (A1, A3, 
H, and K), Pur-α, nucleolin (Česnik et al., 2019; Kumar et al., 2017). 
G4C2ǁG2C4 RNA can undergo RAN-translation through currently undefined 
mechanisms (discussed later), producing five dipeptides (DPR): GA, GR, GP, PA, PR 
(Fig. 1-1D) (Ash et al., 2013; Gendron et al., 2013; Mori et al., 2013b, 2013a). These 
9 
 
DPR form aggregates in patient neurons but rarely in glia (Vatsavayai et al., 2019). In 
patients, DPR aggregates stain positive for p62 (an autophagic marker), predominantly 
stain negative for TDP-43, and are more frequent in the cytoplasm (Mann et al., 2013; 
Saberi et al., 2018; Vatsavayai et al., 2019). Rare, diffuse DPR staining has also been 
reported in patient neurons, arguing that associations with disease do not require visible 
aggregation (Gendron et al., 2013; Mackenzie et al., 2015; Saberi et al., 2018; Schludi et 
al., 2015). Further, soluble GP can be found in patient cerebral spinal fluid (CSF) and 
blood (Gendron et al., 2017; Lehmer et al., 2017).   
Overall, sense-strand associated aggregates – GA, GR, and GPs – are more 
abundant than antisense-strand associated aggregates – PA, PR, GPAS. Of these, GA 
aggregates are most prominent (Mackenzie et al., 2015; Schludi et al., 2015). Currently, 
GPS and GPAS produced from the separate RNA stands are considered similar, while 
translation of GPS extends beyond the repeat to produce a unique C-terminal fragment 
that is not present in GPAS (Mori et al., 2013b; Zu et al., 2013). This fragment could alter 
stability or toxicity associated with GPS versus GPAS. Unique C-terminal fragments are 
also found in the other reading frames for GA, GR, PA, and PR.  
Investigations into DPR-associated toxicity in model systems have revealed that 
expression of specific DPRs (expressed from non-G4C2 transcripts) may contribute to 
disease: GA, GR, and PR have been associated with toxicity in multiple model systems 
while GR and PR cause consistent, strong degenerative effects across systems 
(Balendra and Isaacs, 2018; Yuva-Aydemir et al., 2018). In patients, targeted 
investigations have shown colocalization of DPR aggregates with specific proteins, 
suggesting mechanistic disruptions to related endogenous pathways may contribute to 
toxicity: GA has been reported to interact with Drosha, Unc119, HR23B (May et al., 
2014; Porta et al., 2015; Zhang et al., 2016b); GR has been reported to interact with 
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eIF3B (also called eIF3η), STAU2, and multiple ribosomal proteins, including S6, S25, 
L19, L21, L36A (Hartmann et al., 2018; Zhang et al., 2018). Despite these findings and 
the observation that DPR aggregation predominantly occurs in neurons (versus glia), 
potential positive correlations between DPR expression and disease still need to be 
defined. Since the discovery of the repeat expansion in C9orf72-ALS/FTD, multiple 
studies have reported that the frequency of DPR aggregates does not correlate with 
degenerating tissue or clinical symptoms (i.e. age-of-onset, disease progression, 
disease severity) (Babić Leko et al., 2019; Vatsavayai et al., 2019). Only recently have 
two compelling studies described positive correlations between GR, but not the other 
DPRs, and diseased tissue (Saberi et al., 2018; Sakae et al., 2018). Overall, it is evident 
that additional, systematic investigations are needed, while consideration of multiple 
factors may help clarify results (i.e. disease stage, soluble versus insoluble DPR). 
 
Current gain-of-function G4C2 models 
Current investigations into disease mechanisms underlying the G4C2-expansion in 
ALS/FTD have relied on model systems expressing sense G4C2-repeat RNA. Antisense 
G2C4-RNA models showing degenerative effects have been limited (Swinnen et al., 
2018). These models have highlighted a large number of potential cellular mechanisms 
that may be disrupted in C9+ patients by the aberrant expression of G4C2-RNA and its 
dipeptide products (Balendra and Isaacs, 2018; Batra and Lee, 2017; Yuva-Aydemir et 
al., 2018). Here, I will discuss pertinent information in regard to current gain-of-function 
models and highlight areas requiring further investigation to elucidate gain-of-function 
disease mechanisms. 
In patients, G4C2-expansions of >30 repeats are associated with ALS/FTD, while 
healthy individuals can maintain short, inert repeats of < 25 within C9orf72. Consistent 
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with human data, expression of < 25 G4C2 repeats does not produce degenerative 
effects in mice, zebrafish, Drosophila, and C. elegans (Balendra and Isaacs, 2018; Batra 
and Lee, 2017; Yuva-Aydemir et al., 2018). Positive correlations between repeat-length 
and repeat-expression level with toxicity are consistent among models, despite no 
correlation in repeat-length and clinical symptoms currently reported in patients with C9+ 
disease. Investigations into intermediate (25-30) repeats in patients have reported 
associations with neuropsychiatric symptoms and potentially other movement disorders 
(Bourinaris and Houlden, 2018; Ng and Tan, 2017). In support of shorter repeat 
expansions being moderately toxic in neurons, expression of a (G4C2)29 transgene in 
Drosophila showed mild degenerative effects (see Chapter 2 and (Goodman et al., 
2019a)). Further, BAC-mice expressing (G4C2)29/36 from a human C9orf72-gene show 
toxic effects (Liu et al., 2016). 
A major on-going debate relevant to gain-of-function disease mechanisms in 
C9orf72-ALS/FTD is whether the RNA is contributing to toxicity or if dipeptides are 
driving gain-of-function disease mechanisms. Based on data from model systems, it is 
evident that the expression of specific dipeptides – GA, GR, and PR – from RNA 
transcripts lacking the G4C2-repeat sequence can cause degenerative effects across 
multiple species (Balendra and Isaacs, 2018; Yuva-Aydemir et al., 2018). However, 
given the lack of strong correlative data in patients for DPR-expression and clinical 
symptoms, whether the DPR are the major contributor to gain-of-function disease 
mechanisms in humans is unclear. In contrast to DPR, the G4C2-RNA could potentially 
contribute to toxicity through the sequestration of RNA binding proteins (RBPs). In fact, 
disruptions in RNA-metabolism is a common theme in neurodegeneration (Conlon and 
Manley, 2017; Ito et al., 2017b). In particular, mutations in RBPs is a reoccurring feature 
of ALS/FTD (Zhao et al., 2018).  
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As one can appreciate, it is technically difficult to separate G4C2-RNA 
associated toxicity from toxicity caused by DPR produced from these RNA transcripts. 
Compelling investigations have depended on the use of G4C2-RNA transcripts 
containing translation stop codons between every 12 repeats of a G4C2-expansion, 
termed “RNA-only” models (Mizielinska et al., 2013). In Drosophila, no appreciable DPR 
or degenerative effects are observed with the expression of these RNA-only transcripts, 
despite the RNA forming similar secondary structures as those formed by a pure G4C2-
expansion, the formation of RNA foci, and the colocalization of Glorund (fly orthologue to 
hnRNPH) with 15% of these foci (Mizielinska et al., 2013; Moens et al., 2018). In 
contrast, these same transgenes disrupted axon morphology in zebrafish, suggesting 
that RNA-only transcripts can be toxic in vertebrates, particularly during 
neurodevelopment (Swinnen et al., 2018). Overall, the full effects of adding interruptions 
between the G4C2-repeats is unclear as such interruptions within the repeat-expansion 
could alter transient versus stable interactions with RBPs. Further, investigations into the 
impact of stress on potential RNA-toxicity needs to be evaluated. Remarkably, recent 
studies have found that RAN-translation is upregulated during stress arguing that even 
these RNA-only models may produce toxic DPR under different conditions (Cheng et al., 
2018; Green et al., 2017; Sonobe et al., 2018). 
A considerable factor of most, current gain-of-function models for C9orf72 is that 
the G4C2-transcript produced is processed into mRNA, containing a 5’ m7G cap and a 3’ 
polyadenylated (poly(A)) tail. As mentioned earlier, the G4C2-RNA within patients could 
exist in several forms: intronic RNA (Vatovec et al., 2014; Haeusler et al., 2016; Tran et 
al., 2015), truncated C9orf72 transcripts (van Blitterswijk et al., 2015; Haeusler et al., 
2014), and C9orf72 transcripts retaining the intron/repeat (Niblock et al., 2016). Of these, 
only the latter would be predicted to be fully processed to include a 5’ cap and a 3’ 
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poly(A) tail. Validating current models, C9orf72-transcripts retaining the G4C2-expansion 
have been reported in patient samples and shown to be shuttled into the cytoplasm, 
where they can undergo RAN-translation to produce toxic DPR (Green et al., 2017; 
Hautbergue et al., 2017; Niblock et al., 2016; Tabet et al., 2018; Tran et al., 2015; 
Westergard et al., 2019). However, as this only represents one potential form of the 
G4C2-RNA in patients, further investigations into the potential contribution of the 
additional forms of G4C2-RNA in disease are needed.  
To our knowledge, only two studies have actively investigated potential toxicity 
associated with G4C2-intronic RNA with conflicting results. One investigation expressed 
a truncated C9orf72-mutant transgene in Drosophila (Tran et al., 2015). Researchers 
confirmed that the G4C2-repeat was properly spliced from the C9orf72-mutant 
transgene but, curiously, it failed to induce toxicity or cause appreciable expression of 
one of the DPRs – GP – at normal temperatures. In contrast, Wen and colleagues 
argued that G4C2-intronic RNA could be toxic ex vivo in neurons (Wen et al., 2014). 
These researchers smartly developed a G4C2-reporter construct that placed the repeat 
within an intron flanked by truncated GFP-exons. Only when the repeat-containing intron 
was properly spliced was the GFP-transcript complete and GFP fluorescence could be 
observed in cells. Importantly, GFP-expressing cortical and motor neurons, but not 
hippocampal neurons, contained G4C2 RNA foci and demonstrated progressive, dose-
dependent cell death. Consistent with Tran and colleagues’ fly data, the G4C2-intronic 
RNA failed to express appreciable amounts of DPR (Tran et al.; 2015). While further 
analysis is needed to confirm that no DPR was present and that all G4C2-containing 
transcripts were indeed properly spliced from the chimeric transgene, this study 
presented compelling data in support of the idea that the G4C2-intronic RNA could be 
toxic in mammalian neurons relevant to disease. 
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To date, only two of five mouse models developed to express either truncated or 
full-length C9orf72-mutant transgenes cause neurodegeneration (Batra and Lee, 2017). 
While differences in these results could be due to several factors, including the genetic 
background of the animals and expression level of the transgenes, I note that these 
studies did not investigate if the G4C2-repeat was properly spliced from the C9orf72-
mutant transgene in vivo. Thus, another variable may be differences in the splicing 
efficiency between the mouse models. Overall, further investigations are needed to rule 
out potential toxicity associated with G4C2-RNA lacking a 5’ cap and 3’ poly(A) tail, while 
considering multiple variables relevant to patients (i.e. impact of stress, effects of age, 
tissue-specificity).  
In summary, while dramatic advances have been made in a relatively short 
amount of time since the discovery of the G4C2-expansion in ALS/FTD, vital areas of 
research remain to be elucidated before we can fully understand disease mechanisms. 
That said, current gain-of-function models have proven to be valuable and have 
highlighted numerous pathways that are worth further investigation in C9+ disease. 
Perturbed endogenous pathways that may be disrupted in C9+ disease by the aberrant 
expression of the G4C2-RNA and/or its dipeptide products currently include: gene 
expression (Cooper-Knock et al., 2015b; Prudencio et al., 2015, 2017), mRNA 
processing (Conlon et al., 2016; Cooper-Knock et al., 2014, 2015a, 2015b; Lee et al., 
2013; Prudencio et al., 2015; Yin et al., 2017), nuclear-cytoplasmic shuttling of mRNAs 
(Boeynaems et al., 2016; Hautbergue et al., 2017; Jovičić et al., 2015; Kramer et al., 
2018; Shi et al., 2017; Zhang et al., 2015), ribosome biogenesis (Haeusler et al., 2014; 
Kwon et al., 2014; Lee et al., 2016; Mizielinska et al., 2017; Suzuki et al., 2018; Tao et 
al., 2015), translation (Hartmann et al., 2018; Kanekura et al., 2016; Rossi et al., 2015; 
Zhang et al., 2018), ubiquitin-proteasome system (Gupta et al., 2017; May et al., 2014), 
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and neuron excitability (Selvaraj et al., 2018; Xu and Xu, 2018). Further, studies have 
shown that multiple stress-induced pathways may be involved in cellular responses to 
G4C2/dipeptide expression, including: the integrated stress response (including ER 
stress and stress granule formation) (Cheng et al., 2018; Chew et al., 2019; Green et al., 
2017; Tabet et al., 2018; Tao et al., 2015; Westergard et al., 2019; Zhang et al., 2014), 
heat-shock response (Mordes et al., 2018; Shaw et al., 2018), DNA damage (Farg et al., 
2017; Lopez-Gonzalez et al., 2016; Walker et al., 2017). Additional investigations will 
begin to highlight key pathways common among models and the role these pathways 
play in disease.  
 
Unique secondary structures formed by G4C2 DNA and RNA 
GC-rich nucleic acid strands have the propensity to form a number of non-canonical 
secondary structures (Bochman et al., 2012; Kaushik et al., 2016). In particular, 
quadruplex and R-loop formation by GC-rich DNA/RNA can mediate disease-relevant 
biological processes, including: transcription, repeat-stability, DNA damage, RNA-
processing, and translation (Bochman et al., 2012; Crossley et al., 2019; Kim and Jinks-
Robertson, 2012; Sauer and Paeschke, 2017). To date, multiple studies have 
investigated G4C2ǁG2C4 DNA and RNA for their abilities to form relevant structures 
(Kumar et al., 2016), discussed here from a biological perspective. 
Typical, duplexed DNA strands preferentially form right-handed double helices 
(e.g. B-form DNA). In contrast, GC-rich DNA can form into unique, stable secondary 
structures as a result of strong interactions between the multiple guanines (G) and/or 
cytosines (C). In vitro investigations into sense G4C2-repeat DNA/RNA have shown that 
short (≤ 5 repeats) strands fold into chair-type G-quadruplexes that exist in equilibrium 
with hairpin structures (Fig. 1-1E-F) (Ash et al., 2013; Wang et al., 2019). G-
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quadruplexes involve the formation of G-tetrads between 4 guanines – a square planar 
structure held together by Hoogsteen hydrogen bonds. These G-tetrads then stack on 
top of each other and are stabilized by cations: particularly potassium (K+) and, to a 
lesser extent, sodium (Na+) then lithium (Li+). In G4C2 structures, the cytosines create 
edgewise loops connecting the stacked G-tetrads. G-quadruplexes can take several 
topologies depending on the direction of the strands: parallel, antiparallel or mixed. 
G4C2-DNA seems to prefer an antiparallel topology (Brčić and Plavec, 2016, 2017; 
Haeusler et al., 2014; Šket et al., 2015; Zhou et al., 2015) and G4C2-RNA, a parallel 
topology (Fratta et al., 2012; Haeusler et al., 2014; Reddy et al., 2013; Su et al., 2014). 
These G-quadruplexes can form within one DNA/RNA strand (termed intermolecular) or 
between multiple strands (termed intramolecular) (Haeusler et al., 2014; Reddy et al., 
2013; Šket et al., 2015; Su et al., 2014; Zhou et al., 2015). Further, G4C2-DNA and its 
RNA transcripts can interact to form hybrid secondary structures known as R-loops (Fig. 
1-1G) (Diab et al., 2018; Haeusler et al., 2014; Reddy et al., 2014), which may be 
stabilized by quadruplex formation on the complementary strand (Zamiri et al., 2015).  
While less studied, the formation of quadruplexes by antisense-G2C4 DNA/RNA 
is more debated (Reddy et al., 2013; Zamiri et al., 2015). Recent reports present 
compelling evidence that G2C4 DNA can form non-canonical quadruplex structures. 
Specifically, Zamiri and colleagues proposed that quadruplexes could result from unique 
G:C-tetrad structures under physiological conditions (Zamiri et al., 2015, 2018). Further, 
in acidic conditions, cytosines can become protonated, driving C:C+ interactions and the 
formation of quadruplex structures termed i-motifs (Kovanda et al., 2015; Zamiri et al., 
2018). At neutral pH, these i-motifs exist in equilibrium with hairpins (Zamiri et al., 2018). 
Last, antisense G2C4 DNA may form e-motifs, a relatively unstudied secondary 
structure (Pan et al., 2018; Zhang et al., 2017b). In contrast to anti-sense DNA, G2C4 
17 
 
RNA may preferentially form more canonical double helices over i-motifs (Dodd et al., 
2016). Further investigations into this RNA are needed to fully elucidate potential 
structures into which it could fold.  
To date, most structural studies have depended on in vitro data currently limited 
to investigating short (typically ≤ 8) repeats. A number of factors could contribute to 
complexity of G4C2-structures in vivo, including the number of repeats (Zhou et al., 
2015), pH of tissue (Brčić and Plavec, 2018; Zamiri et al., 2018), and modification of 
G4C2ǁG2C4 strands (Baral et al., 2013; Mukherjee et al., 2019). In particular, G4C2-
repeat expansions are methylated in patients (Bauer, 2016; Xi et al., 2015) and 
methylation of G4C2ǁG2C4 DNA has been shown to impact resulting structures in vitro 
(Zamiri et al., 2015). Further, as the repeats are expanded to >30 in patients, the impact 
of large stretches of G4C2-repeats on structure formation has yet to be defined. One 
hypothesis is that expanded G4C2ǁG2C4-repeats could form multiple, small quadruplex 
structures in a row (Zamiri et al., 2015). Alternatively, few, very large, compact G-
quadruplexes could form (Abu-Ghazalah and Macgregor, 2009; Pedroso et al., 2007). 
Further, more complex structures could form from a combination of G-quadruplexes and 
hairpins arranging along the same strand (Palumbo et al., 2009).  
G-quadruplexes, hairpins, and R-loops are reported to form in vivo based on 
direct and indirect evidence (Armas et al., 2016; Simone et al., 2015; Vanoosthuyse, 
2018). However, with the exception of one study showing that R-loops can form in a C9+ 
mouse model (Esanov et al., 2017), data supporting the formation of G4C2ǁG2C4 
secondary structures in disease are primarily correlative. Specifically, one study showed 
that the RNA-binding protein nucleolin (NCL) preferentially binds G4C2-associated G-
quadruplexes in vitro and may co-localize with G4C2-RNA foci in C9+ patient-derived 
tissues (Haeusler et al., 2014). Another compelling study identified small molecules that 
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bind G4C2-associated G-quadruplexes in vitro and further showed that these molecules 
could reduce RNA-foci formation, DPR production, and toxicity in patient-derived iPS 
neurons (ex vivo) and in (G4C2)36-expressing Drosophila (in vivo) (Simone et al., 2018). 
A recent study defined a small molecule capable of binding the unique hairpin structure 
of G4C2-RNA (Wang et al., 2019). Exposing (G4C2)66-transfected cells to this molecule 
disrupted G4C2-foci formation and RBP interactions ex vivo. Overall, data are consistent 
with the formation of unique quadruplexes, hairpins, and R-loops by G4C2ǁG2C4 RNA in 
disease, while more direct ex vivo and in vivo studies are needed to fully define their role 
and expand investigations to include G4C2ǁG2C4 DNA. 
 
Role of G-quadruplexes and R-loops in general transcription 
To better understand transcription of expanded G4C2ǁG2C4 DNA, one must first 
understand the impact of GC-rich DNA under normal conditions on RNA polymerase II- 
(RNAPII-) driven transcription. 
RNAPII-transcription has been well studied for decades. Overall, RNAPII activity 
is mediated by a number of factors that can act at multiple stages of transcription in 
metazoans: initiation, promoter:proximal pausing , elongation, or termination (Jonkers 
and Lis, 2015; Luse, 2013). Different genes require different factors that can act at one 
or multiple stages (Hartzog and Fu, 2013; Luo et al., 2012; Soutourina, 2017; Van Oss et 
al., 2017). Throughout the process, duplexed DNA must locally unwind, exposing the 
individual strands to transcriptional machinery. However, this leaves the ssDNA, 
particularly if it is GC-rich, vulnerable to forming secondary structures including 
quadruplexes, hairpins, or R-loops (Duquette et al., 2004; Wu and Brosh, 2010; Zhang 
et al., 2013; Zheng et al., 2013). These structures would need to be resolved, likely by 
transcription activators and helicases, for RNAPII to be able to move along the gene 
19 
 
(Armas et al., 2016; Brázda et al., 2014; Mendoza et al., 2016). Elongating RNAPII 
seems to be particularly sensitive to issues when transcribing GC-rich DNA, evidenced 
by high GC-content causing reduced RNAPII-elongation rates (Jonkers et al., 2014; 
Veloso et al., 2014). Fittingly, there is an array of accessory factors available to help 
RNAPII during elongation (Jonkers and Lis, 2015). These factors can directly stimulate 
RNAPII interactions with DNA and can recruit additional transcriptional machinery 
required to locally open up the chromatin (Izban and Luse, 1992).  
Data indicate that secondary structures formed by GC-rich DNA can have both 
positive and negative effects on RNAPII-driven transcription. G-quadruplexes are found 
throughout the human genome in more than 300,000 genes (Chambers et al., 2015; 
Kudlicki, 2016; Lam et al., 2013). They tend to be located within regulatory gene regions: 
promoters, 5’UTR, 3’UTR, and telomeres. Supporting their regulatory role, the presence 
of a G-quadruplex within the genome of a species may be evolutionarily conserved 
(Capra et al., 2010; Nakken et al., 2009). While there are increasing examples of gene 
regulation by G-quadruplex formation, c-MYC is particularly well studied (Sauer and 
Paeschke, 2017). This proto-oncogene has a G-quadruplex within its promoter that can 
be stabilized with small molecules, causing reduced c-MYC expression by blocking 
transcription factors (Brooks and Hurley, 2010; Brown et al., 2011). Multiple examples of 
G-quadruplex formation within introns show that they can mediate alternative splicing of 
genes (Marcel et al., 2011; Verma and Das, 2018). Moreover, their formation within the 
first intron of TOP1 has been proposed to inhibit RNAPII-transcription (Reinhold et al., 
2010), suggesting that multiple mechanisms may be disrupted when G-quadruplexes 
aberrantly form within the gene-body. Overall, it is hypothesized that the formation of 
quadruplexes on template ssDNA would inhibit transcription by blocking RNAPII and/or 
transcription factors (Agarwal et al., 2014; Armas et al., 2016; Bochman et al., 2012; 
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Miglietta et al., 2016). Their formation on non-template ssDNA could similarly block 
transcription but also could promote transcription by maintaining the open DNA.  
In addition to G-quadruplexes, R-loops also regulate RNAPII-transcription. These 
DNA:RNA hybrids are proposed to facilitate transcription through multiple mechanisms, 
including the protection of ssDNA from methylation and recruitment of transcription 
factors (Crossley et al., 2019). Increasing numbers of studies support that R-loop 
formation by GC-rich DNA/RNA occurs during transcription and that their accumulation 
can disrupt polymerase activity in vitro and in vivo (Belotserkovskii et al., 2010; Duquette 
et al., 2004; Kim and Jinks-Robertson, 2012; Zamft et al., 2012). In support of a high 
requirement for RNAPII to resolve these structures for successful transcription, a 
number of RNA-binding and accessory proteins have been identified that are proposed 
to resolve or prevent R-loop formation (Crossley et al., 2019).  One of the earliest 
examples is the THO/TREX complex. Loss of THO/TREX components causes R-loops 
to accumulate and a reduction in RNAPII elongation rates (Domínguez-Sánchez et al., 
2011; Huertas and Aguilera, 2003; Kim and Jinks-Robertson, 2012). In addition, the 
oncogenes BRCA1 and BRCA2 have been shown to prevent R-loop accumulation and 
thus promote RNAPII-driven transcription (Shivji et al., 2018; Zhang et al., 2017a). Of 
importance, BRCA2 recruits Paf1 (discussed later) to promoter:proximal gene sites and 
overexpression of Paf1 can rescue deficits caused by BRCA2 loss by resolving 
accumulated R-loops (Shivji et al., 2018), suggesting that BRCA1/2 is not directly acting 
on R-loops but rather recruits factors to resolve these hybrids. Overall, the accumulation 
of R-loops can stall transcription, cause DNA breaks, and has been linked to multiple 
diseases (Crossley et al., 2019; Richard and Manley, 2017). 
Generally, due to the complexity of transcribing GC-rich DNA and the ability for 
individual sequences to form unique secondary structures, it is likely that there are a 
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number of factors available to resolve these DNA/RNA structures within cells (e.g. 
senataxin) (Grunseich et al., 2018).  
 
Transcription of G4C2ǁG2C4 repeat expansions 
Regardless of whether the G4C2-repeat RNA is contributing to toxicity or if DPR-induced 
toxicity is the primary contributor to gain-of-function disease mechanisms, a potential 
therapeutic approach would be to inhibit the transcription of the repeat expansion. This 
would prevent expression of both RNA and DPR simultaneously. Given the unique 
secondary structures formed by G4C2ǁG2C4-DNA, it is reasonable to hypothesize that 
these structures could be targeted by small molecules to inhibit transcription (Brown et 
al., 2011; Sun et al., 2019). However, multiple molecules would be needed to 
simultaneously target unique structures formed by sense-G4C2 and antisense-G2C4 
strands. Alternatively, pharmacological (e.g. drugs, small molecules, antisense 
oligonucleotides) inhibition of endogenous machinery required to help RNAPII during 
transcription of GC-rich DNA would prevent expression of both G4C2ǁG2C4 strands 
concurrently. Herein I will discuss complexes found to regulate G4C2ǁG2C4 transcription 
in disease – the DSIF and PAF1 complexes – and potential mechanisms. 
 
The DSIF complex: Spt4 and Spt5 
The DRB-sensitivity-inducing factor (DSIF) complex was recently shown to modulate 
expression from expanded G4C2ǁG2C4 DNA (Kramer et al., 2016). This highly 
conserved complex is comprised of two subunits, Spt4 and Spt5, which form a 
heterodimer (Hartzog and Fu, 2013). Originally described as an RNAPII-activating 
complex in yeast, DSIF has since been implicated in multiple steps of RNAPII 
transcription, including: promoter:proximal pausing, elongation, and RNA 
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processing/termination (Jonkers and Lis, 2015; Yamaguchi et al., 2013). It can have both 
positive and negative impacts on transcription as DSIF interacts with the Negative 
Elongation Factor (NELF) during RNAPII-promoter:proximal pausing. Phosphorylation of 
Spt5 by the positive elongation factor-b (P-TEFb) causes DSIF to release NELF and 
become a positive transcription factor. RNAPII is also phosphorylated by P-TEFb, further 
driving its interactions with phospho-DSIF and other elongation factors (like PAF1C, 
discussed below) while promoting the transition into elongation. During elongation, the 
DSIF complex helps to promote RNAPII-stability on template ssDNA with successful 
transcription of GC-rich DNA being particularly sensitive to its loss in yeast (Rondón et 
al., 2003).  
The involvement of DSIF in the transcription of repeat-expansions in disease was 
originally described in CAG-expansion models for Huntington’s disease (HD) (Cheng et 
al., 2015; Liu et al., 2012). Polyglutamine diseases are known to result from CAG-repeat 
expansions of >30 repeats (Krzyzosiak et al., 2012). Notably, expanded CAG-repeats 
can form similar secondary structures to G4C2-repeats, including hairpins and R-loops 
(Ciesiolka et al., 2017; Freudenreich, 2018; Krzyzosiak et al., 2012; Reddy et al., 2014). 
Cheng and colleagues found that depletion of the DSIF component, Spt4, reduced 
RNA/protein expression and toxicity associated with (CAG)81+ in yeast and cultured 
neurons (Liu et al., 2012). Mechanistic studies in yeast revealed that Spt4 deletion 
caused reduced RNAPII occupancy downstream of a (CAG)99-expansion when the 
CAG was inserted into a reporter gene. This effect was not seen with an inert, (CAG)29-
repeat, arguing repeat-length specificity. Further investigations showed that 50% 
downregulation of SUPT4H (mammalian Spt4) in two HD-mouse model expressing 
expanded (CAG)115+ repeats could reduce RNA/protein expression from transgenes in 
vivo (Cheng et al., 2015). Importantly, in one of these mouse models that expressed the 
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mutant, this reduced expression was associated with reduced neurodegenerative effects 
caused by the mutant-Htt-Q115+. Overall, these data supported DSIF as a 
transcriptional-regulator of expanded CAG-repeats in human disease.  
Kramer and colleagues took a multi-disciplinary approach to extend the discovery 
of DSIF as a transcriptional regulator of expanded CAG-repeats to G4C2-repeats in 
C9orf72-disease (Kramer et al., 2016). Using gain-of-function yeast, worm, and fly 
models that expressed (G4C2)49+ repeats, investigators found that depletion of Spt4 
orthologues could suppress RNA expression and toxicity of expanded G4C2-transgenes. 
Using (G4C2)66- and (G2C4)66-expressing yeast, the effects of Spt4 deletion was 
shown to impact both repeat-transcripts produced bidirectionally from the C9orf72-
mutant gene in patients. In addition, the effects of Spt4 were dose-dependent as 
upregulation of SUPT4H1 (ortholog to Spt4) in C. elegans caused significant increases 
in G4C2-RNA levels and toxicity. Findings from transgenic models were further 
translated to C9+ disease situations. Downregulation of both DSIF components, Spt4 
and Spt5, in C9+ patient-derived cells caused reduced expression of repeat-associated 
C9orf72 transcripts, sense-G4C2 and antisense-G2C4 RNA foci formation as well as 
GP-levels. Finally, positive correlations between SUPT4H1 (mammalian Spt4) and 
SUPT5H (mammalian Spt5) expression and expression of the repeat were defined using 
post-mortem tissue from C9+ ALS/FTD patients. Since this initial paper, we have 
validated Spt4 of the DSIF complex as a transcriptional regulator of G4C2-repeat DNA in 
flies (see Chapter 2 and (Goodman et al., 2019a)). However, our data showed that Spt4 
loss impacted RNA expression from inert (G4C2)8- and (G4C2)29-repeats in addition to 
toxic, (G4C2)49-repeats, arguing that further investigations are needed to validate 
selectivity of DSIF towards expanded G4C2-repeats in higher organisms.   
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Overall, there is accumulating evidence that the DSIF complex is important for 
regulating GC-rich DNA expression, and this effect is particularly impactful in repeat-
expansion diseases. Arguing that this complex may globally affect repeat-associated 
diseases, a recent study further defined DSIF in mediating RNA-expression from 
GGCCTG-repeat expansions in spinocerebellar ataxia type 36 (SCA36) (Furuta et al., 
2019). However, the global impact of downregulating this complex in higher organisms 
needs further investigation (see Chapter 2 and (Goodman et al., 2019a; Naguib et al., 
2019). 
 
The PAF1 complex: Paf1, Leo1, CDC73, Ctr9, and Rtf1 
Similar to DSIF, the Polymerase II Associating Factor 1 complex (PAF1C) was first 
defined as a RNAPII-transcriptional regulator in S. cerevisiae (Van Oss et al., 2017). The 
core components of PAF1C are highly conserved, including: Paf1, Leo1, CDC73, Ctr9 
and Rtf1. Metazoan PAF1C can also include a multifunctional protein, WDR61 (Zhu et 
al., 2005). Since PAF1C’s discovery, accumulating evidence supports conserved roles in 
regulating RNAPII-transcription at multiple stages, including: initiation, promoter:proximal 
pausing, elongation, and RNA processing/termination. During the transition of poised to 
elongating RNAPII, PAF1C displaces NELF upon p-TEFb-mediated phosphorylation of 
DSIF.  In yeast, studies have shown that PAF1C recruitment is dependent on Spt5 
interactions with Rtf1.  However, in metazoans this requirement for Spt5 may not be 
conserved. Importantly, metazoan Rtf1 is not tightly associated with PAF1C (Adelman et 
al, 2006; Cao et al., 2015; Mbogning et al., 2013). Further, Leo1, CDC73, and a 
Paf1:Ctr9 subcomplex have all been shown to recruit the remaining PAF1C components 
to RNAPII, independently of DSIF (Amrich et al., 2012; Dermody and Buratowski, 2010; 
Qiu et al., 2012; Xie et al., 2018). After PAF1C recruitment, structural data shows that 
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PAF1C directly interacts with elongating RNAPII, stimulating its activity (Kim et al., 2010; 
Xu et al., 2017; Chu et al., 2013; Vos et al., 2018). PAF1C can also recruit chromatin 
remodeling factors that promote active transcription (Van Oss et al., 2017). Interestingly, 
only expression from a subset of genes is impacted by PAF1C loss, suggesting that it 
selectively regulates RNAPII-transcription versus having a global impact. Further, like 
DSIF, RNAPII-transcription of GC-rich DNA is particularly susceptible to PAF1C loss 
(Rondón et al., 2004).  
In addition to DSIF, evidence shows that PAF1C may also be important for 
promoting RNAPII-transcription of G4C2ǁG2C4-repeat expansions in C9+ ALS/FTD. We 
identified the components of the PAF1 complex as disease modifiers through a large-
scale RNAi-based screen encompassing ~25% of the fly genome (see Chapter 2 and 
(Goodman et al., 2019a)). Reduced expression of core PAF1C components reduced 
RNA and dipeptide expression from multiple toxic (G4C2)30+ transgenes in the fly and 
caused concomitant reductions in degenerative effects. Of interest, RNA expression 
from inert, short (G4C2)<30 transgenes was unaltered by depletion of two PAF1C 
components – Paf1 and Leo1 (which form a heterodimer within the PAF1 complex (Chu 
et al., 2013) – arguing selectivity for toxic G4C2-repeat expansions. In contrast, 
downregulation of the other PAF1C components and Spt4 of DSIF similarly impacted 
RNA levels produced from all G4C2-transgenes tested: (G4C2)8, (G4C2)29, and 
(G4C2)49. Continued investigations in yeast expressing sense-(G4C2)66 and antisense-
(G2C4)66 transgenes revealed that deletion of PAF1C components, Leo1 and CDC73, 
could impact expression from both products of the mutant C9orf72 gene. Further 
mechanistic investigation in C9+ derived patient cells revealed that Leo1 protein bound 
the C9orf72-intron 1 immediately 3’ of the G4C2 expansion. Last, in post-mortem cortical 
tissue derived from C9+ FTD patients, we found that the expression of Paf1 and Leo1, 
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but not CDC73, positively correlated with the expression of C9orf72 transcripts 
containing the G4C2-repeat expansion, supporting their role in the expression of the 
repeat in disease. This correlation was not seen in FTD cases lacking the G4C2-repeat 
or healthy controls, supporting that it was the direct result of the repeat versus PAF1C 
regulating the normal gene.  
Overall, this work provides strong evidence that PAF1C is a transcriptional 
regulator of expanded G4C2ǁG2C4-DNA in C9orf72-disease. In particular, components 
Paf1 and Leo1 seem to be selective for expanded G4C2-DNA of >30 repeats in the fly, a 
finding that is substantiated by correlation data in C9+ FTD tissue.  
 
Current model for G4C2ǁG2C4-repeat transcription 
Current data from multiple model systems and patient samples support that DSIF and 
PAF1 complexes are important for regulating RNAPII-transcription of G4C2ǁG2C4-
repeat DNA in C9+ situations (see Chapter 2 and (Goodman et al., 2019a; Kramer et 
al., 2016)). Assuming that both complexes work cooperatively to promote RNAPII-
transcription along G4C2ǁG2C4-repeats, this suggests a model where the PAF1C and 
DSIF complexes interact with RNAPII during transcription elongation (Fig. 1-2). 
Moreover, of all the components of these two complexes, only the Paf1:Leo1 
heterodimer shows specificity to disease-associated repeat expansions in metazoans 
(see Chapter 2 and (Goodman et al., 2019a)). Additionally, chromatin 
immunoprecipitation (ChIP) assays confirmed Leo1 binding to C9orf72 chromatin, 
immediately 3’ of the repeat in C9+-derived patient cells, supporting the hypothesis that 
the Paf1:Leo1 heterodimer functions during elongation versus other stages of 
transcription. This suggests a model wherein Paf1:Leo1 downregulation reduces RNAPII 
occupancy along the expanded G4C2ǁG2C4 DNA in C9+ disease. 
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 Recent cryo-EM studies investigated the structure of poised versus elongating 
RNAPII and its binding partners in humans (Vos et al., 2018, 2018). Vos and colleagues 
found that DSIF was bound to RNAPII at both stages, while PAF1C was only bound to 
elongating-RNAPII. The specificity of PAF1C function to elongating RNAPII is further 
reflected by ChIP and ChIP-sequencing studies looking at binding patterns of DSIF and 
PAF1C components along genes (Chen et al., 2009; Mayer et al., 2010; Qiu et al., 2006; 
Van Oss et al., 2016). Overall, Spt4/Spt5 binding is enriched at promoter:proximal 
regions and at the 3’ end of genes. In contrast, PAF1C binding is relatively low at these 
sites and high within the gene body. Whether this binding pattern is the same for 
mutated C9orf72 gene in C9+ disease needs to be determined, but this argues that the 
DSIF and PAF1 complexes may be acting at different stages of its transcription.  
A surprising feature we identified in C9orf72-associated disease is that PAF1C 
components become upregulated in response to expression of toxic (G4C2)30+ repeats 
but not inert (G4C2)<8 repeats in flies, mice, and patient-derived cells (see Chapter 2 
and (Goodman et al., 2019a)).  This is not the effect of toxicity as expression of another, 
related disease gene, TDP-43, did not induce PAF1C upregulation. Supporting our fly 
data that Paf1 and Leo1 play a particularly important role in mediating RNAPII-
transcription of >30 G4C2ǁG2C4 repeats, these two components were found to be 
upregulated in C9+ FTD patient tissue but not in C9- FTD tissue or in healthy tissue. In 
contrast, CDC73 was not upregulated, depletion of this PAF1C component similarly 
impacted G4C2-RNA levels from multiple G4C2-transgenes: (G4C2)8, (G4C2)29 and 
(G4C2)49 (see Chapter 2 and (Goodman et al., 2019a)). Based on these findings, I 
hypothesize that a feed-forward loop exists in C9+ disease wherein the G4C2-repeat 
expansion sequesters the PAF1C components, resulting in the cells upregulating these 
genes to compensate for their depletion at other genes (Fig. 1-2). 
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Additional mechanistic insights  
As mentioned, G4C2ǁG2C4-repeat DNA can form multiple secondary structures that 
may disrupt RNAPII-transcription. Investigations into whether DSIF and/or PAF1C 
activity is needed to help resolve these structures would add additional mechanistic 
insights into C9+ disease.  
Of particular significance, DSIF has been shown to mediate transcription from 
G4C2- and CAG- repeat expansions while both can form hairpins and R-loops (Ciesiolka 
et al., 2017; Freudenreich, 2018; Krzyzosiak et al., 2012; Lin and Wilson, 2011; Reddy et 
al., 2014). More, there are accumulating data showing that R-loop formation is an 
important feature of mutated C9orf72 (van Blitterswijk et al., 2015; Esanov et al., 2017; 
Haeusler et al., 2014; Reddy et al., 2014). Thus, it is tempting to hypothesize that DSIF 
promotes G4C2ǁG2C4 transcription by resolving these structures. Currently, little data 
supports the idea that DSIF directly interacts with GC-rich R-loops with the exception of 
one study (Wang et al., 2018a). Further, DSIF can act on A-rich R-loops (Blythe et al., 
2016; Liu et al., 2012). DSIF may recruit factors important for mediating these secondary 
structures, such as Spt6 (Nojima et al., 2018) and PAF1C (discussed below). It needs to 
be determined if DSIF can act directly on G4C2ǁG2C4 DNA/RNA or if it primarily 
functions by recruiting transcription factors that can act on this DNA/RNA. 
In contrast to DSIF, PAF1C could play a more direct role in helping to resolve G-
quadruplexes and R-loops along G4C2ǁG2C4 DNA/RNA (Hershman et al., 2008). 
Accumulating evidence supports that PAF1C regulates pathways involving these 
secondary structures. In particular, multiple studies have shown that PAF1C 
components can mediate R-loop formation in cells to promote transcription (Landsverk 
et al., 2019; Shivji et al., 2018; Wahba et al., 2011; Wang et al., 2018a). Further, 
components Paf1 and Ctr9 have been shown to regulate telomere repeat containing 
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RNA (TERRA), which is GC-rich and prone to R-loop and G-quadruplex formation 
(Neidle, 2010; Rodrigues and Lydall, 2018; Toubiana and Selig, 2018). PAF1C has also 
been shown to mediate c-MYC expression, a well-characterized proto-oncogene that 
involves a regulatory G-quadruplex within its promoter (Gerlach et al., 2017; Sauer and 
Paeschke, 2017; Zhi et al., 2015). Ultimately, unbiased approaches have shown that 
PAF1C components can directly interact with G-quadruplexes, including those formed by 
G4C2-RNA (in vitro) (Gadaleta and Noguchi, 2017; Gómez Ramos, 2017; Haeusler et 
al., 2014; Lambert et al., 2005; Wanzek, 2016).  
While directed investigations are needed, these data implicate the secondary 
structures formed by G4C2ǁG2C4-repeat DNA as potential variables mediating 
interactions with PAF1C and, potentially, DSIF. PAF1C may act directly on these 
nucleotides and/or may recruit additional factors meant to resolve these structures, such 
as the THO/TREX complex (Dermody and Buratowski, 2010; Domínguez-Sánchez et al., 
2011; Kim and Jinks-Robertson, 2012). Additional investigations into PAF1C as a 
transcriptional regulator of other repeat-expansions, such as CAG-repeats (Krzyzosiak 
et al., 2012), would further define it as a global disease modifier. 
 
Translation of G4C2ǁG2C4 repeat expansions 
As mentioned, G4C2ǁG2C4-repeat RNA can undergo a process termed Repeat-
Associated Non-AUG (RAN-) translation to produce five dipeptides (DPR): GA, GR, GP, 
PA, PR (Fig. 1-1D). As specific dipeptides seem to be particularly toxic in model 
systems (Balendra and Isaacs, 2018; Freibaum and Taylor, 2017), an alternative 
therapeutic approach could be to target translation of repeat-containing RNA to disrupt 
their expression. In fact, a number of small molecules have been proposed that interact 
with G-quadruplex and hairpin structures formed by G4C2-RNA (Simone et al., 2018; Su 
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et al., 2014; Wang et al., 2019). Ex vivo and in vivo data show that these molecules can 
reduce RNA foci formation, dipeptide levels and G4C2-induced toxicity. Herein, I will 
discuss current literature on G4C2ǁG2C4 RAN-translation. 
 
Canonical versus non-canonical translation 
Canonical translation is well studied and involves multiple stages: initiation, elongation, 
and termination (Marygold et al., 2017; Shatsky et al., 2018; Sonenberg and 
Hinnebusch, 2009). Of these, initiation seems to be highly regulated and requires a large 
number of translation factors, termed eukaryotic initiation factors (eIFs). Translation 
initiation involves the formation of two main complexes, a ternary complex and a 
preinitiation complex (PIC). eIF5-mediates the ternary complex formation between the 
eIF2 complex (subunits: eIF2α, eIF2β, eIF2γ) and initiator methionine-transfer 
ribonucleic acid (Met-tRNAi). This complex then forms the PIC with the 40S ribosome 
and eIFs: eIF1, eIF1A, eIF5, eIF3 (a large, multi-subunit complex); this process is 
mediated by multiple translation factors including eIF2A. For translation to initiate, 
another complex, the eIF4F complex (subunits: eIF4E, eIF4G, eIF4A), recognizes the 5’ 
m7G cap on a template mRNA. Specifically, eIF4E recognizes the cap, recruits the 
scaffold protein eIF4G, which then recruits eIF4A, an RNA helicase. It is the helicase 
activity of eIF4A that unwinds secondary structures formed by the mRNA, while this 
activity is significantly stimulated by one of two RNA-binding proteins, eIF4B and eIF4H. 
The exposed mRNA then interacts with the PIC and the 48S scanning complex forms. 
Scanning of the mRNA continues 5’ to 3’ until a start codon is identified. This triggers the 
48S scanning complex to release many of the eIFs and bind the 60S ribosome, forming 
the elongating 80S ribosome (subunits: 40S and 60S ribosomes). The transition into 
elongation is further stimulated by eIF5B (and potentially eIF5). During elongation, a 
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relatively small number of eukaryotic elongation factors (eEFs) associate with the 80S 
ribosome to aid in productive translation.  
Interestingly, non-canonical forms of translation have been described to occur 
under multiple normal and disease-associated contexts (Godet et al., 2019; Leppek et 
al., 2018; Shatsky et al., 2018; Terenin et al., 2017), of which internal ribosome entry-site 
(IRES-) translation is the most studied. The pathway underlying IRES-translation varies 
dramatically between situations. In many cases, IRES-translation is cap-independent 
and circumvents canonical translation initiation steps. A common theme is that 
translation initiation requires a minimal PIC complex, which includes only a small number 
of specific translation factors and the 40S ribosome. Further, secondary structure 
formation within the 5’ untranslated-region (UTR) of RNA templates plays an important 
role in the recruitment of translation initiation machinery (Leppek et al., 2018).  
Like IRES-translation, disease-associated RAN-translation also seems to depend 
on secondary structures and/or unique features within the 5’ UTR. The first paper 
describing mechanisms underlying RAN-translation looked at peptide formation from 
expanded CAGǁCTG-repeats associated with spinocerebellar ataxia type 8 (SCA8) and 
myotonic dystrophy type 1 (DM1) (Zu et al., 2011). Zu and colleagues found that peptide 
formation was repeat-length dependent, with increasing numbers of repeats causing 
more peptide to be expressed. Interestingly, translation required the formation of a 
hairpin structure; in contrast to (CAG)100+ repeats, (CAA)100+ repeats did not form 
hairpins nor undergo translation. Other studies on CGG-repeat expansions associated 
with fragile X-associated tremor ataxia syndrome (FXTAS) utilizing Drosophila and 
tissue-culture models showed that RAN-translation could initiate upstream of the repeat 
in a 5’ UTR region containing a non-canonical CUG start codon (Kearse et al., 2016; 
Todd et al., 2013).  
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Properties of G4C2-RNA that may influence RAN-translation 
While mechanisms underlying G4C2-associated RAN-translation are relatively 
undefined, recent studies have begun to uncover potential variables. Drawing parallels 
between CGG- and G4C2-associated RAN-translation, Todd and colleagues used a 
novel ex vivo reporter system to show that G4C2-RAN translation requires the cap-
recognizing factor, eIF4E, and, subsequently, eIF4A (Green et al., 2017). The 
dependence of G4C2-RAN translation on eIF4E and eIF4A was validated by another 
research group using an independent ex vivo model (Tabet et al., 2018), Moreover, this 
group showed that eIF4G, the scaffold protein between eIF4E and eIF4A, was required. 
To date, multiple studies have demonstrated that G4C2-RAN translation is promoted by 
the presence of a near-cognate start codon within the GA-reading frame, a CUG (Green 
et al., 2017; Sonobe et al., 2018; Tabet et al., 2018). This CUG is found in the G4C2-
RNA transcript, upstream of the G4C2-repeat within the intronic RNA (sequence derived 
from intron 1 of C9orf72 and found upstream of G4C2-repeats in patients). Frame-
shifting is predicted to cause the production of the multiple dipeptides from a single 
G4C2-RNA strand when translation is initiated at this CUG (Tabet et al., 2018).  
In addition to studies showing the dependence of G4C2-RAN translation on cap-
recognizing eIF4F complex components – eIF4E, eIF4G, and eIF4A – translation may 
also be promoted by stress responses expected to inhibit cap-dependent translation 
(Cheng et al., 2018; Green et al., 2017; Tabet et al., 2018; Westergard et al., 2019). 
During neuronal stress, the integrated stress response (ISR) is triggered, resulting in 
eIF2α phosphorylation and activation of pathways hypothesized to protect the cell during 
conflict, such as stress granule formation, which sequesters cap-dependent translation 
machinery (Moon et al., 2018). Under these stress conditions, cap-independent 
translation can persist, allowing for the expression of proteins that help protect the cell 
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(e.g. Heat-shock proteins) (Godet et al., 2019; Shatsky et al., 2018). Interestingly, 
multiple studies have shown that triggering ISR can stimulate dipeptide production from 
expanded G4C2-RNA (Cheng et al., 2018; Green et al., 2017; Sonobe et al., 2018; 
Westergard et al., 2019). Further, translation of G4C2-RNA can occur independent of a 
5’ cap (Cheng et al., 2018). Suggesting a feed-forward loop, G4C2-expression can 
trigger ISR, potentially the result of GR-induced mechanisms (Hartmann et al., 2018; 
Tao et al., 2015; Zhang et al., 2018). 
Overall, a considerable variable when discussing G4C2-RAN translation is that 
the G4C2-RNA may exist in multiple forms in patients (see Fig. 1-1C): a properly spliced 
intron (Vatovec et al., 2014; Haeusler et al., 2016; Tran et al., 2015), aborted transcripts 
(van Blitterswijk et al., 2015; Haeusler et al., 2014), or a retained intron (Niblock et al., 
2016). Each of these forms of RNA may undergo different RAN-translation mechanisms. 
Given that RAN-translation can persist when cap-dependent translation is inhibited (via 
eIF2α phosphorylation) this suggests that there could be multiple pathways driving 
dipeptide production. Speculatively, one pathway may require the 5’ m7G cap, predicted 
to impact G4C2-RNA still retained within the C9orf72-transcript. Another pathway may 
initiate in a cap-independent manner, predicted to impact G4C2-RNA that is within a 
properly spliced intron or aborted C9orf72-transcript. Pertaining to the intron retention 
model, one study suggested that if the G4C2-containing intron was retained in C9orf72-
transcripts then RAN-translation may be significantly downregulated or inhibited by 
upstream sequences found within exon 1a of the C9orf72 gene (Tabet et al., 2018). In 
conflict, two other groups argued that G4C2-RAN translation persisted when the repeat 
was retained within C9orf72-transcripts (Hautbergue et al., 2017; Westergard et al., 
2019). Further, RAN translation can persist in the presence of a properly spliced intron 
containing the G4C2-repeat expansion (Cheng et al., 2018; Tran et al., 2015). When the 
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G4C2-RNA existed in this form, its translation was promoted by ISR (Cheng et al., 
2018).  
While I note that conflicting data may be technical not biological (different G4C2-
models will differ in construct design, cell type, and expression level of constructs), these 
studies have offered the first pieces of valuable mechanistic insights into G4C2-RAN 
translation. Current data suggest that G4C2-RAN translation may involve multiple 
pathways and may vary between cell types (Westergard et al., 2019). With speculation, 
the process might begin with cap-dependent mechanisms but then, as cells become 
stressed, RAN translation could be promoted by ISR-dependent mechanisms, driving 
disease progression. Further investigations will help to confirm and define these 
pathways while shedding light on relevant C9+ disease mechanisms. 
 
Potential G4C2-RAN translation factors and mechanisms 
While continued investigations into mechanisms underlying G4C2ǁG2C4-RAN 
translation are underway, a short-list of translation factors have been proposed that may 
mediate this process. As mentioned, multiple studies have implicated the eIF4F complex 
as an important player (Cheng et al., 2018; Green et al., 2017; Tabet et al., 2018). 
Depletion or inhibition of the subunits of eIF4F – eIF4E, eIF4G, eIF4A – causes reduced 
GA, GP, and GR production from G4C2-transcripts in ex vivo models. Also, eIF2A has 
been proposed to be important for GA-production from G4C2-RNA transcripts, as its 
downregulation in cells could reduce GA-dipeptide levels (Sonobe et al., 2018). Last, 
eIF2α has been proposed by multiple groups to promote ISR and cause an increase in 
GA, GP, and GR production, although the pathway underlying this effect needs 
elucidation (Cheng et al., 2018; Green et al., 2017; Sonobe et al., 2018). In non-G4C2 
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disease, eIF3F, a component of the eIF3 complex, has also been proposed to mediate 
CAGǁCTG-RAN translation (Ayhan et al., 2018).  
 In order to shed light on translation factors that may be involved in the production 
of toxic-GR dipeptide in C9+ ALS/FTD, we took an unbiased, in vivo approach (see 
Chapter 3, (Goodman et al., 2019b)). We developed a fly model that expressed the 
intronic RNA sequence found immediately upstream of a toxic (G4C2)44-repeat. The 
intronic RNA sequence was derived from the 114 bp sequence found 5’ of G4C2-repeats 
within intron 1 of C9orf72 in patients. Further, a GFP tag was inserted immediately 3’ of 
the G4C2-repeats in the GR-reading frame, effectively labeling any GR-dipeptides 
produced from the repeats with this fluorescent marker. We chose to focus on GR as its 
expression, independent of a G4C2-repeat RNA, is particularly toxic in model systems, 
including Drosophila (Freibaum et al., 2015; Mizielinska et al., 2014). No canonical start 
codons were found within the construct, while the near-cognate CUG start codon was 
present in the GA-reading frame, thus mimicking C9+ ALS/FTD. By expressing this 
transgene specifically within the fly eye, we could rapidly screen for genes that impacted 
GR-dipeptide levels produced from the (G4C2)44. Comparisons could then be made 
between GR-levels and toxicity.  
Using established loss-of-function mutant or RNAi lines and this new, more 
patient-relevant (G4C2)44 fly model (described above), we screened 48 of 56 (86%) 
known translation factors in the fly for their ability to alter GR-GFP production and G4C2-
induced toxicity (Marygold et al., 2017). This screen included factors involved in multiple 
stages of translation: initiation, elongation, and termination. After control experiments 
ruled out nonspecific effects and factors that were likely acting downstream of toxic GR-
production, 11 candidate RAN-translation factors were identified: eIF4B, eIF4H, eIF5B, 
eIF5, eIF2β, eIF3D1, eIF3I, and multiple orthologues to eIF4E (E3, E4, E5, E7). 
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Intriguingly, most of the factors identified act with, or are orthologues to, already 
proposed RAN-translation factors: eIF4F components and eIF2α (Fig. 1-3). eIF4B and 
eIF4H became the focus of further investigations as these two proteins have non-
redundant roles in stimulating eIF4A-helicase activity (Rogers et al., 2001; Rozovsky et 
al., 2008; Nielsen et al., 2011; Sun et al., 2012; Harms et al., 2014; García-García et al., 
2015; Vaysse et al., 2015; Sen et al., 2016). These two factors behaved in a manner 
consistent with them acting as G4C2-RAN translation factors. Their depletion reduced 
G4C2-toxicity, reduced GR-levels produced from G4C2-RNA, did not alter G4C2-RNA 
levels, did not reduce toxicity caused by GR-dipeptides. Pertinent to disease, eIF4B and 
eIF4H contain an RNA recognition motif and were previously shown to interact with 
G4C2-RNA (Cooper-Knock et al., 2014; Haeusler et al., 2014; Satoh et al., 2014). 
Further, we found that eIF4H, but not eIF4B, was downregulated in C9+ derived cells. In 
post-mortem C9+ ALS/FTD tissue, eIF4H downregulation was also observed compared 
to C9- ALS/FTD and healthy tissue, arguing that eIF4H downregulation was a response 
to the presence of the G4C2 expansion within C9orf72.  
The importance of eIF4B/H-mediated activation of eIF4A in G4C2-RAN 
translation is further supported by the observation that G4C2-RNA can form unique 
secondary structures (Brázda et al., 2014; Nishida et al., 2017; Simone et al., 2015). G-
quadruplexes and hairpins formed by GC-rich RNA can inhibit translation (Fay et al., 
2017; Maizels, 2015; Wang et al., 2018b). Notably, eIF4A was previously shown to 
promote translation from RNA transcripts predicted to form G-quadruplexes, presumably 
by resolving these secondary structures (Wolfe et al., 2014). Fittingly, stabilizing G4C2-
RNA quadruplexes/hairpins with small molecules can inhibit dipeptide production and 
downstream toxic effects (Simone et al., 2018; Su et al., 2014; Wang et al., 2019); this 
indicates that resolving these structures would be needed to allow translation to occur. 
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Interestingly, eIF4A’s ability to unwind longer, more structured 5’ UTRs on transcripts is 
significantly strengthened by eIF4B or eIF4H (Rozovsky et al., 2008; Sun et al., 2012; 
Vaysse et al., 2015; Sen et al., 2016). Unwound RNA can then interact with ribosomes 
and the 43S scanning complex (Sharma et al., 2015; Spirin, 2009; Walker et al., 2013). 
Overall, these data support a model whereby eIF4A is recruited to G4C2-RNA, 
potentially by eIF4E/G (Fig. 1-3D). Then, with the help of eIF4B/H, eIF4A is able to 
unwind the secondary structures formed by G4C2-RNA, thus allowing PIC to interact 
with the RNA template and promoting scanning by the 48S scanning complex until 
reaching a start translation start site, potentially the near cognate CUG in the GA reading 
frame (Green et al., 2016; Tabet et al., 2018). Alternatively, the GR-dipeptides could be 
formed by unknown mechanisms during this scanning process.  
Overall, our unbiased approach highlighted additional factors that may be 
important for G4C2-associated RAN-translation in the fly. Further investigations are 
needed to validate their involvement in disease mechanisms. Notably, of the 48 
translation factors screened, only downregulation of a subset impacted GR-production 
from G4C2-transcripts. This argues that, like with IRES translation, RAN translation can 
circumvent canonical translation steps and may utilize only a small number of translation 
factors. 
 
Thesis work 
The following chapters describe our detailed investigations into PAF1C and eIF4B/H, 
factors that mediate expression from unique G4C2-repeat expansions (>30 repeats) 
found within C9orf72 in a subset of ALS/FTD cases. When I began this project, the 
discovery of the G4C2-repeat expansion was relatively new and no disease mechanisms 
were known (DeJesus-Hernandez et al., 2011; Renton et al., 2011). The goal of my 
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thesis work was to define potential disease mechanisms associated with gain-of-function 
toxicity in C9+ ALS/FTD. By using the powerful genetic tool, Drosophila melanogaster, I 
could test for genetic modifiers of G4C2-associated toxicity in an unbiased manner 
(Bilen and Bonini, 2007; Jung et al., 2011; Lessing and Bonini, 2008; Li et al., 2008). 
Overall, I hypothesized that proteins or complexes could be identified that were 
particularly important in C9+ disease by using this approach. Follow-up, interdisciplinary 
studies would then allow me to define potential mechanisms associated with identified 
genes-of-interest. Specifically, the lab was well positioned to perform studies in flies, 
yeast, mice, patient-derived cells, and/or post-mortem patient tissue, allowing me to 
define how these genes functioned in the context of human C9+ disease (Elden et al., 
2010; Kim et al., 2014). 
Drawing parallels with other known repeat-expansions associated with 
neurodegenerative diseases (Krzyzosiak et al., 2012; Nguyen et al., 2019), Dr. Bonini 
had developed a novel fly model expressing an expanded, pure G4C2 repeat (see Fig. 
2-1a). These constructs lacked any known start codons or additional sequences from 
human C9orf72. The goal was to develop a control line expressing inert (G4C2)12 and a 
disease line expressing (G4C2)48. Overall, in the (G4C2)48 cohort, expression of these 
repeats could cause degenerative effects, supporting that gain-of-function mechanisms 
were contributing to toxicity in C9+ ALS/FTD (Balendra and Isaacs, 2018; Batra and Lee, 
2017; Yuva-Aydemir et al., 2018). Interestingly, not all fly lines developed showed this 
effect and, as a whole, they needed extensive, comprehensive characterization. My 
early work characterized these flies, defining the exact number of G4C2-repeats inserted 
into the genome of each line (see Fig. 2-1b), which lines expressed transgenes at 
similar levels (see Fig. 2-1c), showing that (G4C2)49 expression in all tissues was toxic 
(data not shown), and defining progressive degenerative effects of expressing (G4C2)n 
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in neurons (see Fig. 2-3; data not shown). This work allowed me to master applicable 
techniques that resulted in my first publication from the lab (Yu et al., 2015). Due to 
instability of the G4C2-repeat expansion during molecular cloning, we found that the 
(G4C2)48 cohort expressed an array of repeat lengths, a finding that we then used to 
our advantage. Notably, fly lines that had degenerative effects expressed ≥ 29 repeats 
(see Fig. 2-1d), showing that toxicity was dependent on the repeat length.  
While the lab had performed targeted, small-scale screens for specific pathways 
on (G4C2)49 flies, I wanted to define disease mechanisms from an impartial 
perspective. With Dr. Bonini’s input, I developed an unbiased approach to define genes 
that were able to alter (G4C2)49-induced toxicity in the fly eye (see Fig. 2-1e). By using 
established shRNA fly lines, I tested for effects of downregulating individual genes on 
toxicity in flies expressing (G4C2)49 within their optic system. In total, ~4000 genes were 
tested (~25% of the fly genome). To accomplish this seemingly daunting task, I 
developed an efficient protocol for determining effects and defined 119 genes that could 
modify (G4C2)49-toxicity, while ruling out lines that had unspecific effects (see 
Appendix 4). Gene-ontology term analyses allowed me to define components, 
processes, or functions that were enriched among these genes, highlighting the PAF1 
complex (PAF1C) as a suppressor of G4C2-toxicity when depleted (see Fig. 2-1g-h). 
Spt4, one of the components of the DSIF complex (Hartzog and Fu, 2013), was 
among the 119 (G4C2)49 modifiers, and a collaboration with Dr. Aaron Gitler’s 
laboratory at Stanford University further defined it as a transcriptional regulator of 
G4C2ǁG2C4-repeat expansions in C9+ ALS/FTD (Kramer et al., 2016). As components 
of PAF1C were enriched in our screen and PAF1C is known to interact with the DSIF 
complex, I hypothesized that PAF1C could also be acting on RNAPII during transcription 
of (G4C2)49.  Like DSIF, PAF1C is a transcription factor important for stabilizing 
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elongating RNAPII, particularly along GC-rich DNA (Rondón et al., 2004; Van Oss et al., 
2017). This hypothesis was tested in flies, yeast, mice, patient-derived cells, and post-
mortem patient tissue. Importantly, fly data revealed that PAF1C components, Paf1 and 
Leo1, selectively impacted expression from toxic G4C2-DNA (> 30) versus inert G4C2-
DNA (≤ 29), unlike other PAf1C components and Spt4. Overall, this argued that these 
components may be of special importance in C9+ disease. The accumulation of data 
supporting that PAF1C plays a role in expression of expanded G4C2ǁG2C4-repeat DNA 
was the basis for my primary research manuscript, “Toxic expanded GGGGCC repeat 
transcription is mediated by the PAF1 complex in C9orf72-associated FTD” (see 
Chapter 2 and (Goodman et al., 2019a)). 
While we had focused on PAF1C in post-screen studies, I also noted that a 
select list of translation factors was enriched among the 119 (G4C2)49-modifers (see 
Fig. 2-2c). This observation led to the development of a second G4C2 fly model meant 
to test for RAN-translation of toxic GR-dipeptides (see Fig. 3-1). This model contained a 
5’ leader sequence (the 114 bp sequence found immediately upstream of the repeat in 
intron 1 of C9orf72 in patients) upstream of the repeat expansion, placing the repeat in a 
more patient-relevant context. This sequence is hypothesized to be important for RAN-
translation (Kearse et al., 2016; Todd et al., 2013). To aid in experimentation, the GR-
dipeptide was tagged with a fluorescent marker, GFP. To test for translation factors that 
may be involved in G4C2-RAN translation, I developed a novel approach to allow for the 
rapid screening of genes that altered GR-GFP levels and toxicity in the fly (see Fig. 3-
2A). This work defined 11 candidate translation factors of 48 genes tested whose loss 
resulted in reduced GR-GFP levels and (G4C2)44-toxicity in vivo. Ensuing investigations 
focused on two factors, eIF4B and eIF4H, as these had previously been reported to 
interact with G4C2-RNA and they function with eIF4A, a previously reported G4C2-RAN 
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translation factor (Cooper-Knock et al., 2014; Haeusler et al., 2014; Marygold et al., 
2017; Satoh et al., 2014; Shatsky et al., 2018; Sonenberg and Hinnebusch, 2009). Using 
flies, patient-derived cells, and post-mortem patient tissue, evidence that eIF4B and 
eIF4H play a role in C9+ ALS/FTD resulted in the publication, “eIF4B and eIF4H mediate 
GR production from expanded G4C2 in a Drosophila model for C9orf72-associated 
ALS.” (see Chapter 3 and (Goodman et al., 2019b)). 
While the direct results of my thesis work centered around defining factors 
important for the expression of G4C2ǁG2C4-repeat expansions in C9+ ALS/FTD, other 
pathways were also tested in our G4C2-fly models. Notably, in collaboration with Dr. 
Kevin Eggan’s laboratory at Harvard University, we found that stress-genes were 
upregulated in C9+ ALS/FTD patient tissue, likely the result of the repeat expansion 
being expressed as gene orthologues were also upregulated (G4C2)49- and (GR)100- 
expressing flies (Mordes et al., 2018). In another study with co-first author Dr. Amit 
Berson in the Bonini lab, we found that the mRNA-export factor, ALYREF, may also 
regulate expression from expanded G4C2-repeats while showing overlapping effects 
with a TDP-43 fly model (Berson et al., 2019).  
 
Concluding remarks 
In C9+ ALS/FTD, there is a rapid surge in studies defining disease mechanisms 
associated with the G4C2-repeat expansion in C9orf72. Breakthroughs in the field have 
centered around gain-of-function disease mechanisms associated with the aberrant 
expression of G4C2ǁG2C4-RNA and its dipeptide products. In particular, data in 
Drosophila showing that the dipeptide products, particularly GR and PR, could cause 
degenerative effects independent of a G4C2-RNA transcript promoted the idea that 
these dipeptides may be a key contributor to disease (Mizielinska et al., 2014). A key 
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breakthrough in the field was made using a mouse model which overexpressed >30 
G4C2-repeats (Chew et al., 2015, 2019). Along with multiple progressive, 
neurodegenerative phenotypes, expression of the G4C2-repeat expansion induced TDP-
43 cytoplasmic aggregates in the mouse brain, introducing the first mechanistic link 
between G4C2-repeat expression and TDP-43 pathology, a hallmark of ALS/FTD 
(Cooper-Knock et al., 2015a; Edbauer and Haass, 2016; Steinacker et al., 2018; 
Vatovec et al., 2014; Vatsavayai et al., 2016). In addition to this work, a number of 
groups have performed unbiased screens in simple systems, such as my own, to define 
pathways perturbed by expression of G4C2-repeats and/or its dipeptide products 
(Boeynaems et al., 2016; Freibaum et al., 2015; Jovičić et al., 2015; Kramer et al., 2018; 
Zhang et al., 2015). This work has generated a new and large focus on perturbed 
nuclear-cytoplasmic shuttling in disease (Zhang et al., 2016a). Evidence from ex vivo, in 
vivo and patient-derived samples shows this essential process to be disrupted in C9+ 
ALS/FTD. Last, multiple groups have defined proteins that can interact with G4C2-RNA 
and/or its dipeptide products, while disruptions to their normal function(s) may be 
contributing to C9+ disease (Balendra and Isaacs, 2018; Yuva-Aydemir et al., 2018).  
Currently, there seems to be a complex number of pathways underlying disease 
mechanisms associated with the aberrant expression of expanded G4C2ǁG2C4-DNA. 
However, as investigations are pursued, key pathways will become more evident while, 
hopefully, highlighting effective therapeutic targets.  
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Chapter 1: Figures and Legends 
Figure 1-1 
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Figure 1-1: C9orf72-associated ALS/FTD.  
A. A hexanucleotide expansion of >30 (G4C2)n repeats is found within the C9orf72 gene 
in ~40% of familial ALS/FTD cases and ~7% of sporadic ALS/FTD cases. Three mRNA 
variants are produced from C9orf72, while the repeat expansion is found within intron 1 
of mRNA Variants 1 and 3. For mRNA Variant 2, it is in the promoter. B. Two protein 
products are made from C9orf72, C9orf72-long and C9orf72 short. mRNA Variants 2 
and 3 code for C9orf72-Long and mRNA Variant 1 codes C9orf72-Short. C. Three RNA 
products could be produced from mutant C9orf72, each carrying the G4C2-exansion in 
different contexts. Only RNA produced based on the “retained intron” hypothesis would 
be predicted to include a 5’ m7G-cap and a 3’ polyadenylated tail. D. Repeat-associated 
Non-AUG (RAN-) translation occurs in C9+ ALS/FTD, producing 5 dipeptide products 
from the sense-G4C2 and antisense-G2C4 repeat RNA. The reading frame determined 
with dipeptide is produced while frameshifting could occur. All five dipeptides can form 
insoluble aggregates in diseased tissue. E. (G4C2)4 DNA and RNA can form chair-type 
G-quadruplex secondary structures in vitro. DNA prefers an anti-parallel confirmation 
and RNA prefers a parallel confirmation. How these structures look in vivo and with >30 
G4C2 repeats still needs to be investigated. F. G-quadruplex structures formed by G4C2 
D/RNA can coexist with another secondary structure, a short hairpin. These structures 
have been implicated in RAN-translation when found in repeat-containing RNA. G. 
During RNAPII-driven transcription of G4C2-DNA, unique DNA:RNA hybrids known as 
R-loops can form between the ssDNA and nascent RNA. R-loops can promote 
transcription while their accumulation can inhibit RNAPII, cause genomic instability, and 
cause DNA damage. 
 
45 
 
Figure 1-2 
 
Figure 1-2: A model for G4C2ǁG2C4 transcription.  
Transcription elongation factors, DSIF (Spt4/5) and PAF1C (Paf1/ Leo1/ CDC73/ Ctr9/ 
Rtf1), are recruited to, and important for, elongating RNAPII at G4C2-repeats. In flies, 
PAF1C components Paf1 and Leo1 (which form a heterodimer within PAF1C) seem 
most important for this transcription, showing specificity to >30 G4C2 repeats. Our data 
show that PAF1C components are upregulated in response to the expression of >30 
G4C2 repeats in flies, in mice, and in patient-derived cells. Further, hPAF1 and hLEO1 
are upregulated in patient tissue, in contrast to hCDC73, potentially the result of an 
increased requirement for them within the cell. I hypothesize that transcription of the 
expanded G4C2 DNA requires PAF1C along with RNAPII, for elongation through the 
repeat expansion while we show that PAF1C is bound to C9orf72 through the repeat. 
DSIF may be important for recruiting PAF1C to the G4C2-repeat expansion, while 
additional mechanistic studies are needed. 
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Figure 1-3 
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Figure 1-3: A potential model for G4C2 RAN-translation of GR-dipeptides.  
Here I draw comparisons between canonical translation and RAN-translation based on 
current literature and known functions of translation factors. Note that mechanisms 
underlying RAN-translation are still relatively unknown.  A. In normal translation and 
potentially in RAN-translation, ternary complex formation requires eIF5-mediated 
exchange of GDP to GTP on eIF2 complex (includes eIFs 2α, 2β, 2γ). eIF2α is highly 
regulated during stress and is reported to mediate G4C2 translation (Cheng et al., 2018; 
Green et al., 2017). eIF2β and eIF5 were identified as modifiers in this study. B. In 
normal translation, the formation of the 43S pre-initiation complex (PIC) involves the 
joining of a number of factors, including Ternary complex (formed in A) and eIFs 1, 1A, 
3, and 5. C. A minimal PIC complex may potentially mediate RAN-translation (Akulich et 
al., 2016; Leppek et al., 2018; Shatsky et al., 2018; Terenin et al., 2017).  D. mRNA 
transcripts are recognized by the eIF4F complex, includes eIFs 4E, 4G, 4A; all of which 
have been defined as G4C2 translation factors arguing that G4C2 RAN-translation is 
cap-dependent (Cheng et al., 2018; Tabet et al., 2018). eIF4E recognizes the 5-prime 
m7G cap on mRNAs (Browning and Bailey-Serres, 2015; Sonenberg and Hinnebusch, 
2009; Spilka et al., 2013); notably, 4 of 6 eIF4E components were identified in our 
screen. eIF4A is recruited by eIF4E to mRNA transcripts (via the scaffold protein eIF4G). 
mRNA is then unwound by eIF4A, an activity that is significantly promoted by eIF4B or 
eIF4H, identified herein (Rogers et al., 2001; Rozovsky et al., 2008; Sun et al., 2012; 
García-García et al., 2015; Vaysse et al., 2015). This action allows for the formation of 
the 48S scanning complex. E. In canonical translation, the 48S scanning complex moves 
down a transcript until identifying an AUG start codon. A CUG codon in the LDS 
sequence upstream of G4C2 may function as a start codon in the GA-reading frame 
(Green et al., 2017; Tabet et al., 2018). Frame-shifting could allow for translation of the 
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GR and GP from this codon. Candidate RAN translation factors eIF5B and potentially 
eIF5, mediate ribosome scanning, start codon recognition, and translation activation 
(Browning and Bailey-Serres, 2015; Lin et al., 2018; Pisareva and Pisarev, 2014). (This 
model was published in (Goodman et al., 2019b)) 
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Abstract 
An expanded (G4C2)30+ repeat within C9orf72 is the most prominent mutation in 
familial FTD and ALS. Through an unbiased, large-scale screen in (G4C2)49-expressing 
Drosophila we identified the CDC73/PAF1 complex (PAF1C), a transcriptional regulator 
of RNAPII, as a suppressor of G4C2-associated toxicity when depleted. Mechanistically, 
PAF1C knockdown reduces RNA and GR-dipeptide production from (G4C2)30+ 
transgenes. Interestingly, dPAF1C components, dPaf1 and dLeo1 appear selective for 
transcription of long, toxic repeat expansions, but not shorter, non-toxic expansions. In 
yeast, scPAF1C components regulate expression of both sense and anti-sense repeats. 
PAF1C is upregulated upon expression of (G4C2)30+ in flies and mice. hPaf1 is also 
upregulated in C9+-derived cells and its heterodimer partner, hLeo1, binds C9+ repeat 
chromatin. In C9+ FTD, hPAF1 and hLEO1 are upregulated and their expression 
positively correlates with expression of repeat-containing C9orf72 transcripts. These 
data indicate that PAF1C activity is an important factor for transcription of the long, toxic 
repeat in C9+ FTD. 
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Introduction 
An intronic GGGGCC hexanucleotide (G4C2) expansion of >30 repeats found 
within C9orf72 is the most prominent mutation in familial frontotemporal degeneration 
(FTD) and amyotrophic lateral sclerosis (ALS) (DeJesus-Hernandez et al., 2011; Renton 
et al., 2011). These devastating neurodegenerative disorders represent a continuum of 
the same disease (van Blitterswijk et al., 2014a, 2014b).  
While the presence of the expanded G4C2 can confer toxicity through a number 
of aberrant pathways, amassing evidence supports contributions by gain-of-function 
mechanisms (Balendra and Isaacs, 2018; Vatovec et al., 2014; Yuva-Aydemir et al., 
2018). Accumulation of sense-strand G4C2- and antisense-strand G2C4-containing 
RNA results in RNA foci throughout the nervous system and may be toxic (Vatsavayai et 
al., 2019). Further, these RNAs undergo repeat-associated non-AUG (RAN) translation 
to produce dipeptide-repeats (DPRs) – GA, GR, GP, PA, PR – which form potentially 
toxic aggregates (Vatsavayai et al., 2019). Expressing (G4C2)30+ repeats, independent 
of changes to expression of the C9orf72 gene product, causes toxicity in multiple model 
systems (Balendra and Isaacs, 2018; Vatovec et al., 2014; Yuva-Aydemir et al., 2018). 
In Drosophila, expression of (G4C2)30+ transgenes results in RNA foci formation, DPR 
expression, and neurodegenerative effects (Balendra and Isaacs, 2018; Yuva-Aydemir 
et al., 2018).  
Repeat-expansions, like (G4C2)n, have been defined in a number of 
neurodegenerative diseases. As these repeats tend to be GC-rich, they can form 
secondary structures (e.g. G-quadraplexes) and R-loops which are thought to diminish 
RNA polymerase II (RNAPII)-driven transcription (Vatovec et al., 2014; Rhodes and 
Lipps, 2015; Simone et al., 2015; Hall et al., 2017; Freudenreich, 2018; Sauer and 
Paeschke, 2017). Specialized transcriptional machinery may be required to promote the 
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activity of RNAPII through such long repeat expansions (Hall et al., 2017; Sauer and 
Paeschke, 2017). Of note, DRB-sensitivity-inducing factor complex (DSIF)  and the 
CDC73/PAF1 complex (PAF1C; PAF1 complex) are RNAPII regulators that may be 
involved since transcription of GC-rich DNA is sensitive to their loss (Rondón et al., 
2003, 2004; Zhou et al., 2012).  
DSIF and PAF1C are highly conserved and have non-redundant roles in 
activating RNAPII during elongation (Chen et al., 2009; Hartzog and Fu, 2013; Jaehning, 
2010; Van Oss et al., 2017). DSIF is composed of two proteins, Spt4 and Spt5 
(SPT4H/5H in humans) (Hartzog and Fu, 2013). SPT4H is implicated as a transcriptional 
regulator of expanded CAG and G4C2 repeats in disease (Liu et al., 2012; Cheng et al., 
2015; Kramer et al., 2016).  PAF1C is composed of five proteins – Paf1, Leo1, CDC73, 
Ctr9, and Rtf1 – and it was unknown if hPAF1C had a role in repeat expansion diseases 
(Jaehning, 2010; Van Oss et al., 2017). PAF1C downregulation can impact elongation 
rates of RNAPII, although only a subset of genes are known to require its function for 
expression (Porter et al., 2002; Yang et al., 2016; Fischl et al., 2017). In the nervous 
system, PAF1C is critical during development although it remains expressed in mature 
neurons (Bahrampour and Thor, 2016; Chaturvedi et al., 2016; Moniaux et al., 2009; 
Nguyen et al., 2010; Tan et al., 2013; Wang et al., 2008).  
Here, we identified PAF1C components as modifiers of C9orf72-associated 
disease in an unbiased, large scale RNAi-based screen in Drosophila expressing toxic 
(G4C2)49. Downregulation of PAF1C components disrupted transcription of the G4C2 
RNA in both Drosophila and S. cerevisiae and resulted in reduced toxicity in Drosophila. 
Importantly, components dPaf1 and dLeo1 were selective for transcription of long repeat 
transgenes, unlike the other dPAF1C subunits and dSpt4. Furthermore, PAF1C is 
upregulated in response to expression of the expanded repeat in flies, mouse models, 
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C9+ patient-derived cells and C9+ FTD tissue. Notably, expression of hPAF1 and 
hLEO1 positively correlate with expression of repeat-containing C9orf72-transcripts in 
patient tissue and hLeo1 is bound to C9orf72 chromatin in C9+ cells. These data 
highlight hPAF1C as an important transcriptional regulator of expanded G4C2 within 
C9orf72. 
 
Results 
RNAPII transcriptional complexes are enriched among suppressors of (G4C2)49-toxicity. 
To define cellular mechanisms underlying (G4C2)30+ toxicity in vivo, a fly model was 
developed that expresses (G4C2)n repeats, utilizing the GAL4/UAS expression system 
(Fig. 2-1a). Quantification of the number of repeats inserted into individual transgenic 
lines highlighted four lines: control (G4C2)8, intermediate (G4C2)29, and two expanded 
(G4C2)49 lines with different insertion sites (Fig. 2-1b). These lines were analyzed for 
RNA level by northern blot to confirm similar expression (Fig. 2-1c). Expression of 
(G4C2)8, (G4C2)29, or (G4C2)49 transgenes in the fly optic system (Gmr-GAL4) 
revealed that (G4C2)49 expression caused degenerative effects: disruptions to the 
external ommatidial organization, red pigmentation, eye size, and internal retinal tissue 
loss (Fig. 2-1d). (G4C2)29 expression caused mild toxicity in 80% of animals: 
disruptions to the ommatidial organization and gaps within the internal retinal tissue.  
An unbiased fly screen was developed that utilized the degenerative eye caused 
by (G4C2)49 expression with Gmr-GAL4 (Fig. 2-1e; Appendix 2: Fig. S2-1a). Using 
transgenic UAS-RNAi fly lines (see methods) we defined individual genes whose 
downregulation altered this toxicity with enhancement or suppression. Overall, 3,932 
genes were tested: ~25% of the fly genome (Appendix 2: Sup. Data). 350 (8.9%) of 
these altered (G4C2)49-toxicity. Positive RNAi lines were then rigorously assessed to 
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exclude those with unspecific effects: RNAi lines that altered normal eye morphology in 
control animals or altered expression of a control UAS-LacZ transgene (Appendix 2: 
Fig. S2-1b-c) (Kramer et al., 2016). Overall, 119 modifiers of (G4C2)49-toxicity were 
identified: 55 suppressors and 64 enhancers (Fig. 2-1f).  
To define enriched processes, functions or components within these 119 
modifiers, gene ontology (GO)-term analyses were performed (see methods). 
Enrichment scores (the degree to which a list of genes in a GO-term are represented 
within the modifier list) were plotted for GO-terms that were significantly represented 
within the panel of modifiers, p-value threshold of 10^-3 (Appendix 2: Fig. S2-1d). 
Among suppressors, there was strong enrichment for genes associated with RNAPII-
driven transcription (Fig. 2-1g, green), including components of the dCDC73/PAF1 
complex (dPAF1C; PAF1 complex) and dMediator complex (Soutourina, 2017). 
Additional transcription regulators included dELL and dEar of the dSuper Elongation 
Complex (dSEC) (Zhou et al., 2012) and dSpt4 of the dDSIF complex.  By contrast, 
enhancers of (G4C2)49-toxicity varied in GO-terms. Genes involved in RNA processing 
and splicing were identified, with components of the pre-catalytic spliceosome being the 
most enriched complex (Fig. 2-1h, red).  
Overall, dPAF1C was the most enriched complex of transcriptional regulators 
that suppress (G4C2)49-toxicity.  
 
PAF1C is selective for toxicity from a G4C2-encoding RNA. 
Expanded G4C2 RNA can produce dipeptide-repeat proteins GR, GA, and GP in the fly 
(Balendra and Isaacs, 2018; Vatovec et al., 2014; Vatsavayai et al., 2019; Yuva-Aydemir 
et al., 2018). Of these, (GR)30+ is strongly toxic (Mizielinska et al., 2014). As modifiers 
of (G4C2)49-toxicity may be acting downstream of GR-peptide production, we analyzed 
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the 119 RNAi lines for their ability to modulate (GR)36-toxicity (Fig. 2-2a). GR models 
express a GR-peptide from a non-G4C2 RNA transcript, thus avoiding potential toxicity 
caused by a G4C2 repeat-bearing RNA (Mizielinska et al., 2014). As the PAF1 and DSIF 
complexes may be of particular interest in repeat-associated disease, dPAF1C and 
dSpt4 RNAi were rigorously examined for modification of (GR)n-toxicity in flies and yeast 
(Appendix 2: Fig. S2-2a-c; for scSpt4 (Kramer et al., 2016)). Results showed no 
consistent or significant effects indicating that these modifiers have a minimal effect on 
(GR)n-associated toxicity.  
In Drosophila, 48 of the 119 modifiers (40.3%) did not alter (GR)36-toxicity in the 
same manner that they altered G4C2-repeat toxicity, suggesting that they modulate 
expression of the RNA or RNA-derived toxicity (Fig. 2-2b). GO-term analysis of these 
modifiers revealed that suppression by dPAF1C components was selective to the 
(G4C2)49 model (Fig. 2-2c). In contrast, the dMediator complex and dELL and dEar of 
dSEC similarly suppressed both (G4C2)49- and (GR)36-toxicity in the external eye.  
Overall, data suggested that dPAF1C suppression of (G4C2)49-toxicity was the 
result of effects upstream of toxic GR-peptide production. 
 
dPAF1C is selective for the G4C2 expansion. 
Biological connections between (G4C2)30+ expression and TAR DNA binding protein 43 
(TDP43) pathology have been reported in C9+ FTD/ALS (Balendra and Isaacs, 2018; 
Vatsavayai et al., 2019). Thus, we examined the (G4C2)49 modifiers in a TDP43 model 
to define G4C2-unique pathways (Fig. 2-2a). Expression of human TDP43 in the fly eye 
causes toxicity (Chung et al., 2018). Rigorous assessment of dPAF1C and dSpt4 RNAi 
showed that they had no significant effect on TDP43-toxicity (Appendix 2: Fig. S2-3a-
b). 56 of the 119 (G4C2)49 modifiers (47.1%) were unique to (G4C2)49 (Fig. 2-2b; 
82 
 
Appendix 2: Sup. Data). GO-term analysis indicated that dPAF1C was again highly 
enriched, underscoring specificity of this complex to the expanded G4C2 (Fig. 2-2d). By 
contrast, other RNAPII-regulators, such as the dMediator complex and dELL and dEar of 
dSEC, similarly suppressed (G4C2)49- or TDP43-toxicity in the external eye (also 
(Chung et al., 2018)). Furthermore, dPAF1C RNAi did not alter TDP43 protein levels 
(Appendix 2: Fig. S2-3c).  
Taken together, these data highlight dPAF1C selectivity for (G4C2)49-associated 
toxicity.  
 
dPAF1C downregulation suppresses (G4C2)49-induced toxicity in fly. 
We further examined if dPAF1C downregulation could impact (G4C2)49-toxicity in 
multiple fly tissues. First, we confirmed that the RNAi lines targeting dPAF1C 
components – dPaf1 (ATMS), dLeo1 (ATU), dCDC73 (HYX), dCtr9 and dRtf1 –resulted 
in significant downregulation of the target gene, while extending reagents to include an 
independent set of dPAF1C RNAi lines (Appendix 2: Fig. S2-4). 
Consistent with effects in the external eye, co-expression of dPAF1C RNAi with 
(G4C2)49 rescued internal tissue loss (Fig. 2-3a-b). dPaf1, dLeo1, and dRtf1 RNAi 
caused ~80% recovery and dCDC73 and dCtr9 RNAi caused ~100% recovery of tissue 
depth: control =13.4±6.2μm, dPaf1 =44.4±4.7μm, dLeo1 =47.2±10.8μm, dCDC73 
=63±6.1μm, dCtr9 =69.1±18.0μm, dRtf1 =41.8±12.7μm. This indicates that dPAF1C 
depletion is markedly effective in mitigating (G4C2)49-toxicity in the eye. Downregulating 
dPAF1C components did not affect the external or internal eye on their own (Fig. 2-3c-
d). The second set of dPAf1C RNAi lines also suppressed (G4C2)49-toxicity, while not 
affecting the normal fly eye, affirming that suppression is indeed the result of targeting 
dPAF1C (Appendix 2: Fig. S2-5a-b). To confirm the effect on G4C2-induced toxicity, an 
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independent (G4C2)30+ disease fly model was examined for interactions with dPAF1C. 
This model contains 114bp of the intronic sequence found upstream of G4C2 repeat in 
patients (termed “leader sequence”; LDS). Again, dPAF1C RNAi suppressed toxicity 
caused by LDS-(G4C2)44GR-GFP expression within the fly optic system (Appendix 2: Fig. 
S2-5c). 
To examine effects of downregulating dPAF1C components in the nervous 
system, we expressed the (G4C2)49 transgene using a conditional neuronal GAL4 
driver, ElavGS. First, we assessed climbing ability of animals with adult-onset 
expression. At 14d, only 41% of (G4C2)49-expressing animals were able to climb 4cm 
up the wall of a vial within 20s (Fig. 2-3e). dPAF1C RNAi significantly suppressed this 
effect, causing climbing abilities to be maintained at 92-96%. Suppression was again 
seen when using the second set of dPAF1C RNAi lines (Appendix 2: Fig. S2-5d). 
Next, we analyzed animals for age-dependent vacuole formation in the fly brain, 
an indicator of neurodegeneration. (G4C2)49 expression in the adult-fly nervous system 
caused large vacuoles throughout the brain at 28d. dCDC73, dCtr9, and dRtf1 RNAi 
significantly reduced both vacuole size and number:  mean degeneration score (3.4±0.5) 
was reduced to 2.10±0.6 (dCDC73 RNAi), 2.38±0.5 (dCtr9 RNAi), and 1.78±0.8 (dRtf1 
RNAi), with the normal brain being 1.1±0.4 (Fig. 2-3f; Appendix 2: Fig. S2-6).  Further, 
the strong suppressor dCDC73 increased adult survival of (G4C2)49-expressing 
animals, with 50% survival extended by 24h and end point extended 72h (Fig. 2-3g). 
RNAi targeting other dPAF1C components showed reduced lifespan in control flies, 
making it inaccurate to evaluate their activity as suppressors of (G4C2)49 lifespan 
(Appendix 2: Fig. S2-7a). We further rigorously ruled out any possible genetic 
background effects of the RNAi lines within the context of (G4C2)49-expression 
(Appendix 2: Fig. S2-8). 
84 
 
Together, data support that dPAF1C plays an important role in (G4C2)49-
induced toxicity in disease-relevant tissues in the fly.  
 
PAF1C mediates expression of expanded G4C2 in fly and yeast.    
Given that PAF1C regulates RNAPII-elongation and is important for transcription of GC-
rich DNA (Jaehning, 2010; Rondón et al., 2004; Van Oss et al., 2017), we hypothesized 
that PAF1C may be important for successful transcription of long G4C2 repeats.  
We first determined whether downregulation of dPAF1C components – dPaf1, 
dLeo1, dCDC73, dCtr9, and dRtf1 – affected the amount of RNA produced from 
expanded (G4C2)49 transgenes in the fly nervous system, using dSpt4 RNAi as a 
positive control (Kramer et al., 2016) (Fig. 2-4a, red). dPAF1C RNAi caused significant 
reductions in (G4C2)49 RNA: dPaf1 =41±8% reduction, dLeo1 =54±4% reduction, 
dCDC73 =57±5% reduction, dCtr9 =62±6% reduction, dRtf1 =62±5% reduction. These 
values were similar to dSpt4 RNAi which caused a 52±5% reduction (also (Kramer et al., 
2016)). This effect was consistent in a second (G4C2)49-fly model (Appendix 2: Fig. 
S2-9a).  
We evaluated the specificity of dPAF1C alterations on expanded (G4C2)49-RNA, 
by assessing expression from a nontoxic (G4C2)8 and an intermediate (G4C2)29 
repeat.  Surprisingly, dPaf1 and dLeo1 were selective for expanded (G4C2)49 as these 
RNAi did not significantly reduce expression from the shorter, nontoxic repeat 
transgenes (Fig. 2-4a, black and green). By contrast, dSpt4, dCDC73, dCtr9, and dRtf1 
RNAi caused significant reductions in expression from (G4C2)8 and (G4C2)29 of >30%, 
similar to effects on the (G4C2)49 transgene. Statistical comparisons between each 
(G4C2)n transcript levels with individual RNAi (Fig. 2-4a, top), confirmed that dPaf1 and 
dLeo1 RNAi show no significant difference between the expression level of (G4C2)8 and 
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(G4C2)29 but caused a statistically significant drop between (G4C2)<30 and (G4C2)49 
RNA levels. By contrast, dSpt4 RNAi and other dPAF1C RNAi had statistically similar 
decreases in RNA levels among short and expanded G4C2 repeat lengths. These 
findings suggest that, of the dPAF1C components, dPaf1 and dLeo1 appear of special 
importance for expression of longer repeats in the fly. We further confirmed that the 
reduced expression was specific to the G4C2 construct by examining expression of an 
alternative disease transgene, TDP43. TDP43 transcript levels were not affected by 
dPAF1C RNAi in the fly brain, consistent with protein data (Fig. 2-4b; Appendix 2: Fig. 
S2-3c).  
As (G4C2)30+ RNA can produce a toxic GR-dipeptide, we next asked if reduced 
expression of dPAF1C could alter GR production in the LDS-(G4C2)44GR-GFP fly model 
(Fig. 2-4c). The GFP tag in the GR reading frame allows for fluorescence imaging and 
quantitation of GR-levels in the eye with Gmr-GAL4. Congruent with RNA data, dPAF1C 
RNAi significantly downregulated GR-GFP: dPaf1 =40±3% reduction, dLeo1 =42±2% 
reduction, dCDC73 =56±1% reduction, dCtr9 =50±3% reduction, dRtf1 =51±2% 
reduction. 
These findings were then extended to yeast to assess if scPAF1C could regulate 
expression of expanded G4C2 in another model system. Transgenes were expressed 
from a galactose-inducible promoter. scLeo1 (leo1Δ) or scCDC73 (cdc73Δ) deletion had 
mild or no effect on expression from a control eYFP transgene (Fig. 2-4d, black). 
Deletion of other scPAF1C components had growth defects and/or significantly 
repressed expression of control eYFP so could not be assessed (data not shown). 
Interestingly, RNA levels from an expanded (G4C2)66 transgene were significantly 
decreased by leo1Δ or cdc73Δ: 40±14% and 38±2.5% reduction, respectively (Fig. 2-4d, 
red). Further, as the hexanucleotide repeat in C9+ FTD/ALS patients can be transcribed 
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bidirectionally (Vatsavayai et al., 2019), we determined if scPAF1C mutants could also 
regulate expression from an antisense-(G2C4)66 transgene. Notably, leo1Δ or cdc73Δ 
had an even stronger effect on expression from this transgene with leo1Δ showing a 
significantly stronger effect than cdc73Δ: 77±4% and 52±11% reduction, respectively 
(Fig. 2-4d, orange). These data confirmed that PAF1C downregulation impaired 
expression of expanded G4C2 repeats in an independent model system, and extended 
data to expanded antisense-G2C4 repeat.  
Effects of PAF1C RNAi could be the result of co-regulation of PAF1C 
components – Paf1, Leo1, CDC73, Ctr9, and Rtf1 – with each other and/or Spt4. To 
examine this, we expressed dPaf1, dLeo1, or dCDC73 RNAi in adult flies using the drug-
inducible ubiquitous driver, DaGS. qPCR was used to determine changes in expression 
from dPAF1C components not targeted by the RNAi or dSpt4 (Appendix 2: Fig. S2-7b). 
Data indicated that depleting these dPAF1C components does not alter expression of 
dSpt4 or alternative dPAF1C components. Further, we confirmed that downregulating 
PAF1C in flies and in yeast did not alter general RNAPII transcription of endogenous 
housekeeping genes (Appendix 2: Fig. S2-9b-c) (Jaehning, 2010; Van Oss et al., 2017; 
Porter et al., 2002; Yang et al., 2016; Fischl et al., 2017).  
These data support that PAF1C mediates transcription of expanded G4C2 and 
G2C4. Further, data in the fly argues that dPaf1 and dLeo1 confer repeat-length 
specificity to the transcriptional machinery, promoting RNAPII-driven transcription of 
expanded (G4C2)30+ repeats.  
 
PAF1C is upregulated in response to expanded G4C2. 
Given the important role dPAF1C is playing in (G4C2)49-expressing animals, we 
considered that the complex may be dysregulated in C9+ situations. Thus, we examined 
87 
 
the expression of endogenous dPAF1C components – dPaf1, dLeo1, dCDC73, dCtr9, 
and dRtf1 – in animals expressing (G4C2)49 in the adult fly nervous system (ElavGS, 
16d). Surprisingly, all components were upregulated by qPCR (Fig. 2-5a): dPaf1 
=69±10% upregulation, dLeo1 =58±13% upregulation, dCDC73 =71±17%upregulation, 
dCtr9 =49±12% upregulation, and dRtf1 =64±5% upregulation. This effect did not occur 
in response to short (G4C2)8 repeat expression. Further, dPAF1C upregulation 
appeared selective to G4C2 as dPAF1C components were not upregulated in TDP43 
expressing animals, but rather downregulated (Fig. 2-5b).  
 To determine if this same response to expression of the expanded G4C2 repeat 
occurred in mammals, protein levels of mLeo1 were measured in cortical tissue from 
(G4C2)2 or (G4C2)149 expressing mice (Fig. 2-5c). Transgenes were expressed using 
an AAV2/9 vector which predominantly transduces into neurons (see methods). At 3mo 
post-injection, no significant differences in mLeo1 were detected between cohorts. 
However, at 6mo a significant upregulation of 30±8% in mLeo1 was observed in 
(G4C2)149 animals compared to (G4C2)2 animals.   
 
hPaf1 is upregulated in C9+ patient-derived cells. 
Our data from flies and mice indicated that PAF1C is upregulated in response to 
expression of an expanded G4C2 repeat in the brain. To better understand this effect in 
C9+ disease, we extended our studies to patient-derived cells. Protein expression levels 
of four of the hPAF1C components – hPaf1, hLeo1, hCDC73, and hRtf1 – were 
assessed by western immunoblot in iPS cells (Fig. 2-6a). The mean expression from 
three C9+ patient-derived cell lines was compared to three control cell lines. Notably, 
hPaf1 and hRtf1 were significantly upregulated by 46±14% and 54±14%, respectively, in 
C9+ derived iPS cells.  
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hLeo1 binds C9orf72 within the genome. 
Thus far, data supported that the levels of select PAF1C components are modulated in 
response to expression of the repeat in flies, mice, and C9+ patient-derived cells. 
Further, PAF1C is important for expression of expanded G4C2 in flies and yeast. 
Therefore, we considered that hPAF1C may be recruited and bound to C9orf72 within 
the genome of patient-derived cells. 
To assess this, chromatin immunoprecipitation (ChIP) studies were performed. 
Four, independent C9+-derived fibroblast lines (Appendix 2: Fig. S2-10a) were 
assayed, using a hLeo1 antibody (Fig. 2-6b). Importantly, Leo1 forms a heterodimer with 
Paf1 within PAF1C when bound to RNAPII (Chu et al., 2013; Xu et al., 2017). After pull-
down, the presence of the C9orf72 gene or an intergenic (noncoding) sequence was 
assessed by qPCR and the mean enrichment was calculated from the four lines. Primers 
used to detect chromatin fragments from the C9orf72 gene targeted the intronic region 
immediately 3’ of the repeat expansion. Notably, there was a 4.9±1.8-fold enrichment of 
C9orf72-sequence over the intergenic-sequence and IgG controls with hLeo1 ChIP, 
indicating that hLeo1 was bound to the C9orf72 gene in patient-derived C9+ cells. 
Overall, data support that hLeo1 binds the C9orf72 gene and that it is bound through the 
repeat. 
 
hPAF1 and hLEO1 are upregulated in C9+ FTD and FTD/ALS. 
Our data from multiple model systems indicated that PAF1C is important for expression 
of the expanded G4C2 and that PAF1C is upregulated in response to expression of the 
repeat. To better understand the role of hPAF1C in human disease, we extended our 
studies to FTD/ALS patient tissue.  
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RNA was extracted from frontal cortex tissue of C9+ patients (n=67), C9- patients 
(n=56), or healthy controls (n=27) and the level of hPAF1 and hLEO1 expression were 
assessed by qPCR (Fig. 2-6c; Appendix 2: Fig. S2-10b). In patients diagnosed with 
FTD (cortical disease), hPAF1 and hLEO1 were significantly upregulated only when the 
repeat expansion was present: hPAF1 was upregulated 39% versus healthy controls 
and 28% versus C9- FTD; hLEO1 was upregulated 23% versus healthy controls and 
25% versus C9- FTD. Interestingly, in the frontal cortex of C9+ ALS cases (motor neuron 
disease), neither hPAF1 nor hLEO1 showed upregulation, independent of the presence 
of the G4C2-repeat expansion. Patients showing symptoms of both FTD and ALS fell 
between FTD only and ALS only, with C9+ FTD/ALS cases showing weaker 
upregulation of hPAF1 and hLEO1 versus healthy controls: 28% and 22%, respectively. 
In contrast to hPAF1 and hLEO1, hCDC73 did not show altered expression in C9+ FTD 
(Appendix 2: Fig. S2-10c), supporting data in Drosophila and patient-derived cells that 
Paf1 and Leo1 may play a unique role over other components.  
Upregulation of hPAF1 and hLEO1 in C9+ FTD is congruent with data in flies, 
mice, and iPS cells. Interestingly, in cortical tissue this upregulation is unique to C9+ 
FTD patients compared to C9+ ALS patients (which lack cortical diagnosis).   
 
Expression of hPAF1 and hLEO1 positively correlate with repeat-containing C9orf72 
transcripts. 
As Paf1 and Leo1 activity were important for the expression of the expanded G4C2 
repeat in flies and yeast, and hLeo1 is bound to C9orf72 in C9+ cells, we considered 
that hPAF1 and hLEO1 upregulation in C9+ FTD may positively correlate with the 
expression of C9orf72 transcripts containing the repeat.  
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To examine this, Spearman r correlations were performed between transcript 
levels of hPAF1 and hLEO1 versus C9orf72 pre-mRNA (Fig. 2-6d). Results showed 
strong (r>0.3 to r>0.6) and significant (p-value <0.0005) positive correlations between 
transcripts in C9+ FTD cases – for hPAF1 vs C9orf72: r=0.74, 95% CI 0.5 to 0.9; for 
hLEO1 vs C9orf72: r=0.63, 95% CI 0.3 to 0.8. No correlations were observed in C9- FTD 
cases or healthy controls supporting that this effect was in response to the presence of 
the repeat expansion. Further, no correlations between hCDC73 transcripts and C9orf72 
pre-mRNA were observed, arguing that this effect was unique to hPAF1 and hLEO1 
(Appendix 2: Fig. S2-10d). No correlations were observed in C9+ ALS cases 
(Appendix 2: Fig. S2-10e).   
Altogether, data from multiple models and FTD cortical tissue indicate that 
PAF1C regulates expression of the expanded G4C2 repeats within C9orf72 in C9+ 
situations. 
 
Discussion 
An unbiased, RNAi-based screen in Drosophila covering ~4000 genes revealed the 
CDC73/PAF1 complex (PAF1C) as a C9orf72-disease modifier. Downregulation of 
dPAF1C components – dPaf1, dLeo1, dCDC73, dCtr9, and dRtf1 – selectively 
suppressed (G4C2)49-toxicity in multiple fly tissues. Mechanistically, PAF1C 
suppression was associated with reduced RNA and GR-dipeptide production from 
expanded (G4C2)n transgenes. In particular, depletion of dPaf1 and dLeo1, which form 
a heterodimer (Chu et al., 2013; Xu et al., 2017), in the fly nervous system selectively 
reduced expression of long, toxic (G4C2)49 repeats versus shorter, non-toxic repeats. 
Moreover, scLeo1 and scCDC73 deletion in yeast reduced RNA production from sense-
(G4C2)66 and antisense-(G2C4)66 transgenes. Additional investigations into dPAF1C in 
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Drosophila revealed that endogenous dPAF1C was upregulated upon expression of 
expanded (G4C2)30+ in neurons. This was not the result of toxicity or stress, as 
upregulation was selective to (G4C2)30+ versus TDP43. Interestingly, mLeo1 is also 
upregulated in the brain of mice expressing (G4C2)149, while hPaf1 and hRtf1 are 
upregulated in C9+-derived iPS cells. Further, we provide evidence that hPAF1C binds 
C9orf72, with ChIP for hLeo1 (of the Paf1/Leo1 heterodimer) in C9+ cells. Using human 
post-mortem cortical tissue, we further found that hPAF1 and hLEO1 RNA levels were 
upregulated in C9+ FTD patients. This upregulation positively correlated with expression 
of the repeat-containing C9orf72 transcripts. Overall, these data from flies, yeast, mice, 
C9+ patient-derived cells, and post-mortem patient tissue support a mechanistic link 
between PAF1C activity, expression of a G4C2-repeat, and C9+ disease.   
A total of 119 modifiers of (G4C2)49-toxicity were identified in our screen (see 
Fig 2-1). Remarkably, GO term analysis of the 55 suppressors showed significant 
enrichment for RNAPII transcriptional regulators – including dPAF1C, the dMediator 
complex, dELL and dEar of the dSuper Elongation Complex (dSEC), and dSpt4 of the 
dDSIF complex. Not all transcription-related genes tested in the screen modify (G4C2)49 
toxicity, arguing that the complexes identified are unique (see Appendix 2: Sup. Data). 
Although we focused on dPAF1C, the other RNAPII regulators may also be important in 
disease (Balendra and Isaacs, 2018; Vatovec et al., 2014; Vatsavayai et al., 2019; Yuva-
Aydemir et al., 2018). Among the 64 enhancers of (G4C2)49-toxicity, RNA processing 
and splicing factors were prominent. Curiously, the majority of these enhancers similarly 
modulate (GR)36-toxicity (see Fig. 2-2). These data are consistent with reports of RNA 
dysregulation and splicing deficits in C9+ FTD/ALS, while suggesting that disruptions in 
RNA metabolism may result from toxic GR (Balendra and Isaacs, 2018; Vatovec et al., 
2014; Vatsavayai et al., 2019; Yuva-Aydemir et al., 2018).  
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RNAPII-driven transcription across GC-rich DNA is hypothesized to be 
problematic due to the propensity of the DNA/RNA to form secondary structures, such 
as R-loops and G-quadraplexes (Vatovec et al., 2014; Rhodes and Lipps, 2015; Simone 
et al., 2015; Hall et al., 2017; Freudenreich, 2018; Sauer and Paeschke, 2017). Given 
this, the activity of multiple elongation factors may be required for efficient transcription 
through expansions like (G4C2)30+ (Hall et al., 2017; Sauer and Paeschke, 2017). Spt4 
was previously implicated as a transcriptional regulator of CAG and G4C2 repeat 
expansions (Liu et al., 2012; Cheng et al., 2015; Kramer et al., 2016). Our data indicates 
that PAF1C regulates expression of G4C2 repeats in FTD/ALS (see Fig. 2-4). dPaf1 and 
dLeo1 of dPAF1C seem particularly important for RNAPII-transcription of expanded 
G4C2 as loss of these two components selectively reduced expression of a (G4C2)49 
transgene in fly. While this could be the result of level of knockdown, it is compelling that 
Paf1 and Leo1 form a heterodimer that is important for PAF1C activation of elongating 
RNAPII (Yang et al., 2016; Chu et al., 2013; Xu et al., 2017; Kim et al., 2010; Yu et al., 
2015a). Further, Paf1 is consistently upregulated in C9+-derived patient cells and tissue 
over other components and upregulation positively correlates to expression of repeat-
containing transcripts in patient tissue (see Fig. 2-6c-d and Appendix 2: Fig. S2-10). 
Overall, these data argue that Paf1 and Leo1 are mechanistically special in C9+ 
disease. 
In contrast to dPaf1/Leo1, dSpt4 showed similar effects on different G4C2 repeat 
lengths in flies (see Fig. 2-4). Differences in how Spt4 and Paf1/Leo1 loss impact 
expanded G4C2 expression may be due to their distinct roles during transcription (Chen 
et al., 2009; Hartzog and Fu, 2013; Jaehning, 2010; Van Oss et al., 2017). Evidence 
suggests that Spt4 primarily acts during the transition of RNAPII from poised to 
elongation or during transcription termination (Chen et al., 2009; Fischl et al., 2017; 
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Yang et al., 2016). In contrast, Paf1/Leo1 seems to act primarily during elongation (Chen 
et al., 2009; Fischl et al., 2017; Kim et al., 2010; Mayer et al., 2010; Yang et al., 2016). 
Notably, DSIF (composed of Spt4 and Spt5) and PAF1C may interact. In yeast, scDSIF 
recruits scPAF1C via the scRtf1 subunit during the transition of RNAPII from initiation to 
elongation (Mayekar et al., 2013). However, in higher organisms, including Drosophila, 
the dependence of PAF1C on DSIF for recruitment to elongating RNAPII is less clear. 
Rtf1 is less tightly associated with other PAF1C components while recent work shows 
that PAF1C recruitment can be DSIF-independent in mammals (Amrich et al., 2012; Cao 
et al., 2015; Dermody and Buratowski, 2010; Qiu et al., 2012; Xie et al., 2018). Further, 
Leo1 of PAF1C directly interacts with elongating RNAPII (Xu et al., 2017) and the 
C9orf72 gene (see Fig. 2-6b). Together, these data suggest that PAF1C is playing a 
unique role in transcription elongation across the G4C2-repeat expansion. 
FTD and ALS represent the extremes of a continuous disease spectrum. It 
remains unclear how one patient presents with FTD and another with ALS or combined 
FTD/ALS. Among many factors, unique genetic backgrounds of individuals may 
contribute to specific presentation (van Blitterswijk et al., 2014a, 2014b). For example, 
ATXN2 and TMEM106B have been suggested as disease modifiers underlying the 
different diagnoses (van Blitterswijk et al., 2014a, 2014b). Curiously, we see selective 
upregulation of hPAF1 and hLEO1 in the frontal cortex of C9+ FTD disease, but not C9+ 
ALS (see Fig. 2-6c). Importantly, the frontal cortex is thought to be a primary brain 
region resulting in FTD-associated symptoms (Omer et al., 2017; Schönecker et al., 
2018). Stage of disease progression could also contribute. Analysis of hPAF1 and 
hLEO1 expression in motor neurons from ALS patients will define if PAF1C plays a 
tissue-specific role. Based on current data, it is tempting to hypothesize that cortical 
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modulation of Paf1 or Leo1 in response to the repeat may be among several 
mechanisms contributing to the spectrum of disease phenotypes in C9orf72-associated 
disorders.   
PAF1C may be an attractive therapeutic candidate for C9+ FTD. In yeast, 
scPAF1C has been reported to be non-essential (Jaehning, 2010; Van Oss et al., 2017). 
In flies, dLeo1 is not essential to get viable adults (Gerlach et al., 2017). In mice, 
mPAF1+/- or mLEO1+/- heterozygosity yields no obvious abnormalities, although mPAF1-/- 
or mLEO1-/- null animals show pre-weaning lethality (Meehan et al., 2017).  Other 
components of mPAF1C follow this same trend, with heterozygous mice showing no or 
few effects (Meehan et al., 2017). While SUPT4H1 (human Spt4; non-essential in yeast) 
was previously proposed as a potential therapeutic target in C9+ FTD/ALS (Kramer et 
al., 2016), it may have more critical organismal functions than PAF1C in higher 
organisms: SUPT4A+/- (murine Spt4) heterozygous mice are viable but show a number 
of abnormalities and SUPT4A-/- null mice are embryonic lethal (Meehan et al., 2017). 
These investigations do not consider effects of PAF1C or Spt4 loss in a tissue- or age-
specific manner, arguing that further analyses are required. Altogether, we hypothesize 
that specific components of PAF1C, like Paf1 or Leo1, may represent a potential 
therapeutic target for C9orf72-associated disease. 
This study presents the first evidence that PAF1C is an important player in 
C9orf72-associated disease, particularly in C9+ FTD. Further investigations into PAF1C 
may define the mechanisms by which it becomes upregulated—potentially in a tissue-
specific manner— and its impact in other neurodegenerative situations that result from 
aberrant expression of repeat expansions. 
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protocols. 
 
Methods and materials 
Nomenclature 
For clarity “d” for Drosophila melanogaster, “h” for Homo sapiens, “m” for Mus musculus, 
or “sc” for Saccharomyces cerevisiae was added in front of gene/protein symbols when 
discussing endogenous PAF1C components in individual species.  
Patient sample consents and approvals 
Participants or authorized family members provided written informed consent prior to 
information gathering. Post-consent, autopsies were performed postmortem. Protocols 
were approved by the Mayo Clinic Institutional Review Board and Ethics Committee. 
Clinical, genetic and pathological assessments 
Patients were diagnosed with FTD and/or ALS by trained neurologists after reviewing 
neurological and pathological information (Appendix 2: Fig. S2-10). Repeat-primed 
polymerase chain reaction was used to determine the presence/absence of a C9orf72 
repeat expansion (DeJesus-Hernandez et al., 2011). 
Mouse model and approvals 
All mouse procedures were performed in agreement with the National Institutes of 
Health Guide for Care and Use of Experimental Animals. Approved by the Mayo Clinic 
Institutional Animal Care and Use Committee. The G4C2 mouse model (C57BL/6J, male 
mice) were previously established (Chew et al., 2019). 
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Drosophila work and disease models 
Stocks were maintained on standard cornmeal-molasses medium. See Appendix 2: 
Table S2-2 for primary fly lines used. For all experiments, multiple w- and w+ controls 
were analyzed in parallel and showed similar results. Appendix 2: Table S2-3 details 
shown controls. 
Fly RNAi efficacy 
All control and PAF1C RNAi lines defined in Appendix 2: Table S2-2. RNAi efficacy 
was determined using Da-GAL4 (larvae) or DaGS (adult animals), previously described 
(Kramer et al., 2016; McGurk and Bonini, 2012). For Paf1 RNAi: larvae were collected 
using 20% sucrose solution. For Leo1 RNAi: wandering 3rd instar larvae were collected.  
Characterization of (G4C2)n fly models 
All G4C2 fly models: Transgenes inserted into pUAST vectors and randomly inserted 
into w1118 fly genomes. Original G4C2 model detailed in Fig. 2-1a and previously 
established (Burguete et al.; Kramer et al., 2016; Mordes et al., 2018). LDS-G4C2 model 
includes: 5’ leader sequence (LDS; 114bp of sequence found upstream of the repeat in 
intron 1 of C9orf72 in patients); 3’-GFP tag in the GR-reading frame.  
Repeat-length determination: Inserted transgenes were amplified from genomic DNA 
using construct-specific primers that flanked the repeat (Appendix 2: Table S2-4) by 
PCR: KAPA HiFi HotStart kit (Kappa #KK2501) with GC buffer, 1M Betaine, 5% DMSO. 
PCR products lengths were analyzed: 1.5% agarose/TAE gel, Bioanalyzer. Repeat 
number was calculated from PCR product length (subtracting 5’ and 3’ non-G4C2 
flanking sequence). Control w1118 animals were included and showed no signal.  
RNA expression for original UAS-G4C2 model:  UAS-G4C2 transgenes were expressed 
using HS-GAL4, 30min at 37ᵒC. RNA was extracted 3hr post-HS and analyzed by 
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northern blot, probing for the SV40 terminal sequence, previously described (Yu et al., 
2015b). Control w1118 animals were included and showed no signal.  
RNAi external fly eye screen 
UAS-RNAi lines developed by the Transgenic RNAi Project (TRiP) (Ni et al., 2011; 
Perkins et al., 2015) were purchased through Bloomington Drosophila Stock Center 
(BDSC). All available Valium 20 UAS-shRNA lines targeting unique genes were used for 
screening (Appendix 2: Sup. Data). When multiple Valium 20 fly lines were available 
targeting a single gene, one line was randomly selected for screening. Additional UAS-
RNAi lines targeting dPaf1 and dLeo1 were obtained from Vienna Drosophila Resource 
Center (VDRC) (Dietzl et al., 2007).  
External eye screening and imaging:  UAS-RNAi males were crossed to recombinant 
females: UAS-(G4C2)49, Gmr-GAL4 (III) (25ᵒC). Multiple controls were setup with every 
experiment to account for natural variability in (G4C2)49-toxicity, including: UAS-Luc 
RNAi (BDSC #31603) and w1118; UAS-DSRED. The external eye phenotype for >5 1-2d 
progeny was observed using a standard dissection microscope. Any changes to the 
ommatidial organization, eye size, pigmentation, and ability to eclose from pupae were 
noted. Resulting phenotype was categorized into one of six groups: suppressors, mild 
suppressors, no effect, mild enhancers, enhancers, and lethal enhancers (Appendix 2: 
Fig. S2-1a). Animals expressing RNAi that altered (G4C2)49-toxicity were imaged on a 
Leica Apo16 microscope (Berson et al., 2017; Chung et al., 2018; Elden et al., 2010; 
Kim et al., 2014). Researchers were blinded to the RNAi targets during screening. 
Modifiers of (G4C2)49-toxicity were further assessed in Gmr-GAL4 > UAS-(GR)36 
(Mizielinska et al., 2014) or UAS-TDP43 (Elden et al., 2010; Kim et al., 2014) animals. 
Modifier crosses were repeated 3+ independent times to confirm reproducibility of 
results.   
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Control experiments defining unspecific RNAi: To determine if RNAi caused toxicity in 
control scenarios: UAS-RNAi lines that enhanced (G4C2)49-toxicity were tested for 
effects in a line expressing short repeats, Gmr-GAL4 > (G4C2)6/8, and with Gmr-GAL4 
only. UAS-RNAi lines were analyzed for effects on the GAL4/UAS system using β-
galactosidase western immunoblots, described (Berson et al., 2017; Chung et al., 2018; 
Kramer et al., 2016; Mordes et al., 2018).  
Gene ontology (GO) enrichment analysis 
GO-term enrichment analyses were done using GOrilla software with a p-value threshold 
of 10^-3 (Eden et al., 2007, 2009; Subramanian et al., 2005). All genes included in the 
RNAi library, excluding unspecific RNAi, were set as the background. GO-terms with 
enrichment scores < 3.0 were excluded as these associated with umbrella categories. 
For final figures, redundant GO-terms were excluded using Revigo, prioritizing terms 
with high enrichment scores (Subramanian et al., 2005; Supek et al., 2011).  
Internal eye and vacuole formation 
Heads were paraffin embedded and sectioned at 8μm, described (Auluck et al., 2002; 
Berson et al., 2017; Chung et al., 2018; Kramer et al., 2016). Quantification of internal 
eye: measured depth of the retinal tissue at a consistent level of the brain (when the 
optic chiasm, antennal lobe and ventrolateral protocerebrum were present); retinal tissue 
depth was measured at the point of the optic chiasm. Animals with collapsed eyes were 
excluded. Quantification of vacuole formation was done using a scoring schematic 
(Appendix 2: Fig. S2-6a). The whole brain was reviewed for scoring with researchers 
blinded to genotype.  
Drug-inducible expression using geneswitch- (GS-) GAL4 drivers 
0-2d adult flies were collected and aged for 24-48h prior to transfer to 0.04mg RU486-
containing food (made by pipetting 100μl of 4mg/ml RU486 in 100% ethanol onto 
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standard food and incubating at RT for 1-2d with slow rotation). Flies were transferred to 
fresh RU486-containing food every 2d.  
Lifespan and negative geotaxis (climbing) 
Lifespan and climbing assays were done as described with minor changes (Berson et 
al., 2017; Kramer et al., 2016). Assays were done at 24ᵒC. For the climbing assay, flies 
were tapped to the bottom of an empty vial and immediately video recorded. Each vial 
was subjected to 3 consecutive trials with a 20-30min recovery between trials. For 
analysis, the number of flies in a vial that crossed a 4cm line after 15 or 20s post-tapping 
were counted. The mean value from the 3 trials per vial was used to account for 
technical variability.  
Western immunoblots (WB) 
Fly lysates and reagents: For assays involving Gmr-GAL4 (3d animals), triplicate 
samples of 5-10 heads per genotype were homogenized in 1X NuPAGE LDS sample 
buffer using disposable pellet/pestles tissue grinders (Kimble Chase #749520-0000) and 
motor (Kimble Chase #749540-0000). WBs were run using a standard protocol with 
Invitrogen’s XCell SureLock blot system, 4-12% Bis-Tris NuPAGE gels, and a iBlot dry 
transfer system with nitrocellulose membrane.  
iPSC lysates and reagents: iPSC (described in Appendix 2: Fig. S2-10a) were 
cultured as previously described (Kramer et al., 2018) and lysates were prepared using 
RIPA buffer. 20μg of total protein was run using a standard WB protocol with Invitrogen’s 
XCell SureLock blot system, 4-12% Bis-Tris NuPAGE gels and wet transfer with PVDF 
membrane.  
Mouse lysates and reagents: Mice expressing either (G4C2)2 or (G4C2)149 were 
generated by intracerebroventricular administration of AAV2/9 vectors, previously 
described (Chew et al., 2019). Cortical tissues were harvested at 3mo and 6mo. Protein 
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lysates were prepped using a 1:5 weight/volume of ice-cold buffer (50mM Tris pH 7.4, 
50mM NaCl, 1mM EDTA) with 2x protease and phosphatase inhibitors. 1% Triton X-100 
and 2% SDS were added. Tissue homogenates were sonicated on ice and centrifuged 
at 4°C for 20min at 16,000xg. 30μg of total protein was run using a standard WB 
protocol with 10% Tris-Glycine gels and wet transfer with nitrocellulose membrane.  
Fly antibodies: anti-βgalactosidase (Promega #Z3781, 1:2,000), anti-TDP43 
(ProteinTech #10782-2-AP, 1:2,000), anti-αTubulin (DSHB #AA4.3, 1:2,000) (Berson et 
al., 2017; Chung et al., 2018; Kramer et al., 2016; Mordes et al., 2018). Antibodies 
targeting dCDC73 or dRtf1 were previously developed (Adelman et al., 2006).  
Mammalian antibodies: anti-Paf1 (Cell Signaling #12883, 1:1,000) (Yu et al., 2015a), 
anti-Leo1 (ProteinTech #12281-1-AP, 1:2,000), anti-CDC73 (Cell Signaling #8126, 
1:2,000) (Herr et al., 2015), anti-Rtf1 (Cell Signaling #14737, 1:2,000), anti-αTubulin-
HRP (Cell Signaling #9099, 1:2,000), anti-GAPDH (IPSCs: Abcam # G8795, 1:5,000; 
Mice: Meridian Life Science # H86504M, 1:10,000). Antibodies validated by siRNA in 
fibroblast cells (data not shown): anti-Paf1, anti-Leo1, anti-Rtf1.  
Secondary antibodies and imaging: Mouse or Rabbit HRP-conjugated secondary 
antibodies (Jackson Immunoresearch Labs  #115-035-146 and  111-035-144) were used 
at 1:5,000 (Berson et al., 2017; Chung et al., 2018; Kramer et al., 2016; Mordes et al., 
2018). Blots were analyzed using Amersham ECL Prime Detection Reagent and imaged 
on an Amersham Imager 600. 
Real-time quantitative PCR (qPCR) 
All primers are defined in Appendix 2: Table S2-4.  
Flies: Total RNA was collected using TRIzol. For DaGS or Da-GAL4 assays, biological 
triplicate samples of 10 whole animals were processed per condition. For ElavGS 
assays, biological triplicate samples of 20-30 fly heads (16d) were processed per 
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condition. qPCRs were run using standard protocols. cDNA was made from 200-400ng 
of total RNA using random primers, High Capacity cDNA Reverse Transcription Kit 
(ThermoFisher #4368814). qPCR reactions were setup using SYBR Green Fast 
reagents, 384-welled plate, and analyzed on an Applied Biosystem’s ViiA 7 Real-Time 
PCR System. Mean fold change was determined using the ∆∆Ct method. The 
housekeeping gene, RP49 (RNAPI-driven), was used. Primers targeting the G4C2 fly 
transgenes utilized unique restriction enzyme sequences in our construct found 
immediately 3’ of the repeat. All primers were validated using a serial dilution curve. 
Appendix 2: Fig. S2-12 shows primer efficiencies between G4C2 and loading control 
used, RP49, to be similar.  
Humans: Total RNA was extracted from frozen postmortem tissue from the frontal cortex 
using the RNAeasy Plus Mini Kit (QIAGEN), previously described (Prudencio et al., 
2015). RNA integrity (RIN) was verified on an Agilent 2100 bioanalyzer. qPCRs were run 
using standard protocols. cDNA was made from 500ng of total RNA (RIN ≥7.0, mean 
RIN for all samples =9.3) using random primers, High Capacity cDNA Reverse 
Transcription Kit (ThermoFisher). qPCR was conducted using SYBR GreenER qPCR 
SuperMix (Invitrogen) for all samples in triplicate. qPCRs were run in an ABI Prism 
7900HT Fast Real-Time PCR System (Applied Biosystems). Fold change was 
determined using the ∆∆Ct method, comparing relative expression to healthy controls 
(mean=1). Housekeeping genes included RPLP0 and GAPDH. Primers targeting the 
C9orf72 transcript were previously described (Niblock et al., 2016).  
Yeast: Centromeric galactose-inducible plasmids that express C9orf72 hexanucleotide 
repeats – sense (G4C2)66 or antisense (G2C4)66 – were transformed into yeast, 
described (Kramer et al., 2016). Overnight cultures were grown from transformants in 
2% raffinose-containing media, then diluted into 2% galactose-containing liquid media 
102 
 
the next morning, and further grown at 30°C for 6 hours to allow for transgene 
expression. RNA was harvested from these cultures using a MasterPure Yeast RNA 
Extraction kit (Lucigen), including DNAseI digestions during the purification. Equal 
amounts of RNA were reverse transcribed using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) and analyzed by qPCR using SYBR green 
reagents. 
External fly eye GR-GFP imaging 
y1 sc* v1;; Gmr-GAL4, UAS-LDS-(G4C2)44GR-GFP animals were crossed to RNAi lines or 
controls. Heads from 1-2d progeny were isolated and positioned for imaging on a glass 
slide using Vaseline. GFP imaging was immediately performed on a Leica DM6000B 
microscope using Z-stacks. Total GFP fluorescence in the compiled images was 
measured in ImageJ and normalized relative to control. Only expanded (G4C2)30+ 
transgenes produce GR-GFP; lines containing ≤ 22 repeats have no GFP signal by 
external eye fluorescence imaging or by western immunoblot.  
Yeast strains and spotting assays 
All yeast strains are derivatives of the haploid wildtype BY4741 strain, and all deletion 
strains were verified by PCR genotyping and qPCR. Centromeric galactose-inducible 
plasmids expressing codon-optimized C9orf72 dipeptide repeat proteins – (PR)50 and 
(GR)100 (Chai and Gitler; Jovičić et al., 2015; Kramer et al., 2016) – or a control protein 
(CCDB) were transformed into yeast using standard methods and selected for on SD-
URA agar plates. For serial dilution growth analysis, transformants were grown overnight 
in 2% raffinose-containing media. Overnight cultures were all normalized to OD600 = 
0.8, and then each strain was diluted serially 5-fold in a 96-well plate. Yeast were 
spotted onto either 2% glucose or 2% galactose containing agar plates with a multi-pin 
‘frogger’ and allowed to grow for 48h at 30°C before photographed. 
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Fibroblast cells and chromatin immunoprecipitation (ChIP) 
Primary fibroblast cells (described in Appendix 2: Fig. S2-10a) were cultured in a 
standard 37ᵒC / 5% CO2 incubator using DMEM (with L-GLUT, hi glucose and sodium 
pyruvate) supplemented with 15% heat-inactivated FBS, 1% amino-acids, and 1% 
pen/strep. For ChIP, cells were collected from a confluent T-75 flask using trypsin, 
washed in DPBS and fixed in 1.1% formaldehyde, 10min. ChIPs were then performed as 
described (Lee et al., 2006) with the following details. DNA was fragmented using a 
bucket sonicator for 20min. Dynabeads protein A (Invitrogen # 10001D) were used at 
30μl per IP. The primary antibody against hLeo1 (ProteinTech #12281-1-AP) was used 
at 5μg for 100μg DNA, with overnight incubation. An overnight decrosslinking was done 
and DNA was isolated using a standard Phenol/Chloroform/Isoamyl alcohol (PCA) 
protocol into 50μl. 4μl was run per reaction by qPCR using Sybr green. Ct values were 
normalized to input and transformed relative to Rb IgG control (Cell Signaling #2729). 
Intergenic sequence was as described (Kim et al., 2013). A positive control gene, p21, 
was used to validate Leo1 ChIPs (Kim et al., 2010). All primers are defined in Appendix 
2: Table S2-4. 
Statistical analysis, sampling, and randomization 
GraphPad Prism 7.00 or 8.00 software was used to develop all graphs and for all 
statistical analyses. P-values ≤ 0.05 were considered significant. See Appendix 2: 
Table S2-1 for details on statistics and Life Sciences Reporting Summary for 
additional information. No data were excluded from this study. Flies, yeast, mice, and 
cell lines: Data was assumed to be normal. A two-tailed unpaired student t-test, one-
way ANOVA, or two-way ANOVA statistical analysis were performed when 
appropriate based on the experiment design. For ANOVA’s Tukey's multiple 
comparisons tests were predominantly used. No statistical methods were used to 
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predetermine sample sizes and numbers were similar to previous work (Elden et al., 
2010; Kim et al., 2014; Kramer et al., 2016; McGurk and Bonini, 2012; Mizielinska et 
al., 2014). Researchers were blinded to the genotype of all samples to maintain 
unbiased scoring. Humans: Data was found to not fit a normal distribution. Kruskal–
Wallis, 1-way ANOVAs with Dunn’s multiple comparisons test were performed to 
assess changes in expression of genes. Follow-up Spearman r correlations were 
performed. No statistical methods were used to predetermine sample sizes and 
numbers were similar to previous work (Kramer et al., 2016; Prudencio et al., 2015, 
2017). Researchers were not blinded as data is inherently unbiased.  
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Chapter 2: Figures and legends 
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Figure 2-1 
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Figure 1: A genetic screen reveals PAF1C as a suppressor of (G4C2)49-toxicity in 
the fly eye.   
(a) UAS-(G4C2)n transgenes were designed expressing a pure repeat. (b) PCR 
reactions were used to quantify of the number of repeats in individual UAS-G4C2 
transgenic fly lines. Shown: individual data points with mean from 2 experiments (30 
flies/experiment). (c) RNA expression of UAS-(G4C2)n transgenes using HS-GAL4 were 
compared by northern blots. Statistics: ANOVA with Tukey’s correction, p-value: no 
significance >0.05. Shown: individual data points with mean±SEM; mean value of 
biological triplicates (n=30 flies) from 3 independent experiments. (d) Expression of 
UAS-(G4C2)n transgenes in the fly eye compared to controls: (G4C2)8 had no effect, 
(G4C2)29 caused mild disruptions in 80% of animals, (G4C2)49 caused strong 
degeneration. Shown: data from one experiment; data reproduced in 3+ independent 
experiments. Arrows: internal tissue depth, lost tissue. (e) RNAi were co-expressed with 
(G4C2)49 (III) within the fly optic system. Effects of RNAi were recorded: “suppressors” 
reduced degeneration, “enhancers” increased degeneration. Shown: representative 
images. Hits were independently tested 3+ times to confirm reproducibility (>5 flies 
examined/cross). (f) 119 modifiers were identified. Control experiments excluded 231 
RNAi lines with unspecific effects. (g-h) GO analyses revealed terms enriched in 
suppressors (55/3582 genes) or enhancers (64/3582 genes). Plotted: significant (p-value 
≤10^-3) enrichment scores of >3.00. (d-e) Scale bars: external eye =100μm, internal eye 
=25μm. (a-h) Additional details for this and subsequent figures: Appendix 2: Fig. S2-1 
(extended screen data), Appendix 2: Sup. Data (all screen results), Appendix 2: Table 
S2-1 (detailed sampling/reproducibility/statistics), methods. 
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Figure 2-2 
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Figure 2: PAF1C is not a modifier of (GR)36 or TDP43 toxicity in Drosophila. 
(a) The 119 (G4C2)49 modifiers were analyzed in (GR)36 and TDP43 models to 
determine if they could act on GR-dipeptide toxicity or had overlapping effects on 
TDP43-toxicity. All were independently tested 3+ times to confirm reproducibility of 
results (>5 flies examined/cross). Scale bars: 100μm. (b) Of the 119 modifiers of 
(G4C2)49 toxicity, 71 (59.7%) similarly modified (GR)36, arguing they may be acting on 
toxic DPR. 63 (52.9%) similarly affected TDP-43 toxicity, arguing overlap between these 
disease models. (c) GO analyses revealed terms enriched in the modifiers that did not 
similarly alter (GR)36 toxicity (48/3582 genes), revealing those acting selectively on the 
(G4C2)49 RNA model. (d) GO analyses revealed terms enriched in the modifiers that 
did not similarly alter TDP43 toxicity (56/3582 genes), revealing those specific to the 
expanded G4C2 repeat in C9+ FTD/ALS. (c-d) Plotted: GO-terms with significant (p-
value ≤ 10^-3) enrichment scores of >3.00.  
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Figure 2-3 
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Figure 3:  Reduced expression of components of PAF1C suppress (G4C2)49-
induced toxicity in multiple contexts in the fly. 
(a-b) dPAF1C RNAi mitigates toxicity associated with (G4C2)49 expression in the eye. N 
flies: control=9, dPaf1=7, dLeo1=6, dCDC73=8, dCtr9=6, dRtf1=5. (c-d) dPAF1C RNAi 
has no effect on control fly eyes. N flies: control=9, dPaf1=5, dLeo1=9, dCDC73=9, 
dCtr9=5, dRtf1=4. (a-d) Internal retina depth (arrows) quantified for individual animals. 
Scale bars: external eye =100μm, internal eye =45μm. (e) Climbing deficits caused by 
(G4C2)49 expression in the adult nervous system (ElavGS, 14d) are rescued by 
dPAF1C RNAi. N flies: control=117, dPaf1=98, dLeo1=108, dCDC73=103, dCtr9=120, 
dRtf1=115. Individual data points are mean % of animals that could climb per tube; 
average of 19±2 animals per tube. (f) dPAF1C RNAi mitigated vacuole formation 
(arrowheads) in the brain with ElavGS driven expression of (G4C2)49. For quantification, 
a vacuole severity scoring system was developed where 0=no vacuoles and 
4=medium/large, frequent (>5) vacuoles (see Sup. Fig. 6a). N flies: (G4C2)0=9, 
(G4C2)49: control=10, dPaf1=10, dLeo1=7, dCDC73=10, dCtr9=8, dRtf1=9. Scale bars: 
50μm. (g) Knockdown of dCDC73 in adult flies ubiquitously expressing (G4C2)49 results 
in lifespan extension. N flies: control=198, dCDC73=197. (b,d,f) each data point 
represents one animal. Statistics: (a-f) ANOVAs with Tukey’s correction, (g) log-rank; p-
values: ****<0.0001, ***<0.001, **<0.01, *<0.05, no significance (n.s.) >0.05. Shown on 
graphs: individual data points with mean±SD; data from one experiment; all experiments 
were repeated twice with similar results. 
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Figure 2-4 
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Figure 4: Downregulation of components of PAF1C selectively alter (G4C2)30+ 
transgene expression. 
(a) (G4C2)n transgenes were co-expressed with dPAF1C RNAi lines in the adult brain 
using a drug inducible, neuronal driver (ElavGS, 16d). Transgene expression levels in 
heads measured by qPCR. dPaf1 and dLeo1 RNAi did not affect RNA levels of (G4C2)8 
and (G4C2)29 but significantly reduced (G4C2)49 expression. dSpt4, dCDC73, dCtr9, 
dRtf1 RNAi altered expression of all (G4C2)n transgenes. Shown: individual data points 
with mean±SEM; mean value of 3 biological replicates (n=25 flies/replicate) from 2-3 
independent experiments. (b) dPAF1C RNAi did not alter TDP43 (ElavGS, 16d, heads) 
RNA levels by qPCR. Shown: individual data points with mean±SEM; mean value of 3 
biological replicates (n=25 flies/replicate) from 2 independent experiments. (c) 
Downregulation of dPAF1C components reduces GR-GFP signal in LDS-(G4C2)44GR-
GFP animals. Quantification of total GFP fluorescence relative to control animals. N flies: 
control=8, dPaf1=7, dLeo1=4, dCDC73=6, dCtr9=6, dRtf1=6. Each data point represents 
one eye of one animal. Shown: data from one experiment; data reproduced in two 
independent experiments. Scale bars: 100μm. (d) Effects of deleting scCDC73 (cdc73Δ) 
or scLeo1 (leo1Δ) in S. cerevisiae on RNA levels from transgenes assessed by qPCR. 
Transgenes included eYFP (control), sense-(G4C2)66 (disease) and antisense-
(G2C4)66 (disease). Shown: individual data points with mean±SD; mean value of 
biological duplicates from 2 independent experiments. Statistics: ANOVAs with Tukey’s 
correction, p-values: ****<0.0001, ***<0.001, **<0.01, *<0.05, no significance (n.s.) 
>0.05. 
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Figure 2-5 
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Figure 5: Endogenous PAF1C is upregulated in response to (G4C2)49 expression 
in the brain in flies and mice. 
(a) Endogenous dPAF1C RNA expression is upregulated in (G4C2)49 expressing flies 
compared to control or (G4C2)8 expressing flies (qPCR). Transgenes expressed in the 
adult fly nervous system (ElavGS, 16d).  Differences in expression are likely 
underestimated as RNA was extracted from whole head tissue, while transgenes were 
expressed selectively in neurons. (b) A non-G4C2 disease transgene, TDP43, was 
expressed with ElavGS (16d). Whole head analysis showed no upregulation of PAF1C 
components. (a-b) Shown: individual data points with mean±SEM; mean value of 
biological triplicates (n=25 flies/replicate) from 2 independent experiments. (c) Mouse 
endogenous mLeo1 protein levels measured in cortical tissue by western immunoblot 
using lysates from mice injected intracerebroventricularly with AAV2/9-(G4C2)2 or -
(G4C2)149 at postnatal day 0. mLeo1 is upregulated by 6mo in response to expression 
of expanded (G4C2)149. Differences in expression are likely underestimated as protein 
was extracted from total cortical tissue while transgenes were expressed using AAV2/9 
which predominantly transduces neurons.  3mo N animals: (G4C2)2=6, (G4C2)149=6. 
6mo N animals: (G4C2)2=6, (G4C2)149=7. Shown: individual data points (each 
representing 1 animal) with mean±SEM. Data reproduced in two independent 
experiments. Statistics: (a) ANOVAs with Tukey’s correction, (b-c) unpaired 2-tailed 
student t-test; p-values: ****<0.0001, ***<0.001, **<0.01, *<0.05, no significance (n.s.) 
>0.05. See Supplementary Figure 11 for uncropped western images for this and 
subsequent figures. 
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Figure 2-6 
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Figure 6: Upregulated hPAF1 and hLEO1 positively correlate with expression of 
repeat-containing C9orf72 transcripts and hLeo1 binds C9orf72. 
(a) Western immunoblots for hPAF1C components in iPS cells. hPAF1C band densities 
were normalized to the mean of loading controls: hTubulin, hGAPDH. Shown: individual 
data points with mean±SEM; mean value of 2 biological replicates from 2 independent 
experiments per cell line relative to the mean signal in controls. (b) Chromatin 
immunoprecipitation studies using a hLeo1 antibody on 4 independent C9+-derived 
fibroblast lines. Data: relative to IgG controls after normalizing by input. Shown: 
individual data points (each representing 1 cell line) with mean±SEM; mean value of 
technical quadruplicates from 1 experiment. Data reproduced in 2 independent 
experiments per line. (c) qPCR analysis of hPAF1 and hLEO1 expression from healthy 
control (n=27), C9- (n=56), and C9+ patients (n=67) frontal cortex tissue. Shown: 
individual data points (each representing 1 individual) with mean±SEM. (d) Spearman r 
coefficients defined correlations in expression from hPAF1 or hLEO1 expression with 
C9orf72 transcripts in individuals. r values: 0=no correlation, 1.0=100% correlated. 
Shown: individual data points (each representing 1 individual) with linear regression±SE. 
Statistics: (a) unpaired 2-tailed student t-test, (b) ANOVA with Sidak’s correction, (c) 
Kruskal-Wallis ANOVA with Dunn’s correction, (d) Spearman R correlation; p-values: 
****<0.0001, ***<0.001, **<0.01, *<0.05, no significance >0.05. C9orf72 intron 1: intronic 
region immediately 3’ of the G4C2 repeat in the C9orf72 gene. See Supplementary 
Figure 10 for cell line and patient characteristics. 
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Abstract 
The discovery of an expanded (GGGGCC)n repeat (termed G4C2) within the first intron 
of C9orf72 in familial ALS/FTD has led to a number of studies showing that the aberrant 
expression of G4C2 RNA can produce toxic dipeptides through repeat-associated non-
AUG (RAN-) translation. To reveal canonical translation factors that impact this process, 
an unbiased loss-of-function screen was performed in a G4C2 fly model that maintained 
the upstream intronic sequence of the human gene and contained a GFP tag in the GR 
reading frame.  11 of 48 translation factors were identified that impact production of the 
GR-GFP protein. Further investigations into two of these, eIF4B and eIF4H, revealed 
that downregulation of these factors reduced toxicity caused by the expression of 
expanded G4C2 and reduced production of toxic GR dipeptides from G4C2 transcripts. 
In patient-derived cells and in post-mortem tissue from ALS/FTD patients, EIF4H was 
found to be downregulated in cases harboring the G4C2 mutation compared to patients 
lacking the mutation and healthy individuals. Overall, these data define eIF4B and eIF4H 
as disease modifiers whose activity is important for RAN-translation of the GR peptide 
from G4C2-transcripts. 
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Introduction 
In Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD), the 
presence of a hexanucleotide expansion of >30 GGGGCC repeats (termed G4C2) within 
the C9orf72 gene is the most prominent mutation in familial disease (DeJesus-
Hernandez et al., 2011; Renton et al., 2011). The mechanisms underlying potential 
toxicity associated with G4C2 are still being defined with two leading hypotheses 
centering around gain-of-function mechanisms (Yuva-Aydemir et al., 2018; Balendra and 
Isaacs, 2018): sequestration of RNA-binding proteins by the aberrant expression of 
sense- and antisense- G4C2 RNA  (Vatovec et al., 2014; Haeusler et al., 2016); repeat-
associated non-AUG (RAN-) translation of repeat-containing transcripts produce 
dipeptides that are toxic to neurons (Ash et al., 2013; Mori et al., 2013; Mann et al., 
2013; Gendron et al., 2013; Mackenzie et al., 2013, 2015; Niblock et al., 2016). Five 
dipeptides can be produced from these transcripts, depending on the reading frame: GA 
and GR (sense strand associated), PA and PR (antisense strand associated), and GP 
(produced from both sense and antisense strands).  
In recent years, it has become clear that dipeptides produced from G4C2 RNA 
transcripts cause neurodegenerative effects (Yuva-Aydemir et al., 2018; Balendra and 
Isaacs, 2018). Of the 5 potential RAN-translation products, GR and PR cause 
particularly strong degenerative phenotypes in multiple model systems, including 
Drosophila (Freibaum et al., 2015; Mizielinska et al., 2014). Therefore, increasing 
understanding of the mechanisms underlying expression of these dipeptides would 
highlight potential therapeutic avenues centered around preventing their expression.  
Many mechanistic questions remain regarding RAN-translation in G4C2-
associated disease. Recent investigations have drawn a number of parallels between 
mechanisms underlying general translation (Browning and Bailey-Serres, 2015; 
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Sonenberg and Hinnebusch, 2009; Spilka et al., 2013) and RAN-translation (Kearse and 
Wilusz, 2017; Zu et al., 2018), finding that dipeptide production is sensitive to the 
inhibition/downregulation of canonical translation factors: eIF4E, eIF4G, eIF4A, eIF2α 
(Green et al., 2017; Tabet et al., 2018; Cheng et al., 2018). Of interest, eIF4A is a 
DEAD-Box helicase (Andreou and Klostermeier, 2013), and thus may be important for 
the unwinding of G4C2-RNA for translation. While eIF4A has relative weak helicase 
activity, this can be significantly stimulated by accessory proteins eIF4B and eIF4H 
(Rogers et al., 2001; Rozovsky et al., 2008; Nielsen et al., 2011; Sun et al., 2012; Harms 
et al., 2014; García-García et al., 2015; Vaysse et al., 2015; Sen et al., 2016). These 
latter factors contain RRM-domains and, importantly, have been reported to interact 
directly with the G4C2 RNA (Cooper-Knock et al., 2014; Haeusler et al., 2014; Satoh et 
al., 2014).  
In an unbiased, directed screen for canonical translation factors, we identified 11 
potential translation factors that modulate GR-production in G4C2-expressing flies. 
Further investigations into two of these, eIF4B and eIF4H1 (fly orthologue to eIF4H), 
further defined them as modifiers of G4C2-toxicity. Their downregulation significantly 
reduced GR-levels in animals expressing the repeat. Further investigations into eIF4B 
and eIF4H in C9+ derived cells revealed that eIF4H was significantly downregulated. 
EIF4H downregulation also occurred in post-mortem tissue from C9+ ALS/FTD 
compared to C9- ALS/FTD and healthy individuals. This work identifies eIF4B and eIF4H 
as important disease modifiers that alter RAN-translation of the GR-reading frame. 
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Results 
GFP-tagged GR dipeptides are produced in LDS-(G4C2)n flies with expanded (>30) 
repeats. 
We previously identified a number of translation factors as modifiers of G4C2-toxicity 
(Goodman et al., 2019a). To investigate these and other factors in the context of RAN-
translation, a new C9orf72 fly model for ALS/FTD was designed (Fig. 3-1A). This model 
contained the 114-base pair sequence immediately upstream of the repeat in intron 1 of 
C9orf72 in ALS/FTD patient genomes (termed a “leader” sequence; LDS). The addition 
of this sequence puts the repeat in a more patient-relevant context while this region is 
likely to influence pathological mechanisms, including RAN-translation (Kearse et al., 
2016; Sellier et al., 2017; Todd et al., 2013; Zu et al., 2018).  G4C2 expansions can 
produce three sense-strand associated dipeptides: GA, GR, and GP. Importantly, of 
these GR is associated with extreme toxicity in multiple models, including flies 
(Mizielinska et al., 2014; Freibaum et al., 2015). To facilitate investigations into genes 
that may impact RAN-translation of GR, a GFP tag (lacking an ATG initiation codon) was 
added 3’-prime of the repeat in the GR-reading frame.  
 LDS-G4C2 transgenes were randomly inserted into the genome of w1118 animals. 
To define the number of repeats inserted into individual lines, primers that flanked the 
G4C2 repeat were used to PCR amplify the region (Goodman et al., 2019a).   The 
number of repeats was then calculated from the length of the PCR products, resolved by 
agarose gel electrophoresis and Bioanalyzer. Two primary fly transgenic lines were 
defined: a control (CTRL) line containing short (G4C2)≤12 repeats and an expanded 
(EXP) line containing (G4C2)≤44 repeats (Fig. 3-1B).  By quantitative-real time PCR 
(qPCR), these two lines expressed significantly different G4C2 RNA levels (Fig. 3-1C), 
131 
 
most likely the result of variability in insertion site within the fly genome (Levis et al., 
1985).  
Western immunoblots were used to determine whether a (GR)n dipeptide was 
produced from the LDS-G4C2 transgenes, despite the absence of an AUG in the GR-
reading frame. LDS-G4C2 transgenes were expressed in the fly eye using GMR-GAL4 
and protein lysates were prepared from heads. Using an antibody designed to target the 
GR-dipeptide (Liu et al., 2014), we found that a GR peptide was produced only from the 
expanded LDS-(G4C2)EXP fly line (Fig. 3-1D). Re-probing with an anti-GFP antibody 
confirmed that the GR-dipeptides produced were tagged with GFP. GFP expressing 
control flies confirmed that the molecular weight of the GR/GFP band in LDS-(G4C2)EXP 
animals was higher than GFP alone. As LDS-(G4C2)EXP lines had 2.5-fold higher RNA 
expression than the LDS-(G4C2)CTRL, longer exposure times were also evaluated and 
continued to show no GR/GFP signal in LDS-(G4C2)CTRL expressing animals (Appendix 
3: Fig. S3-1).  
 To define potential toxicity associated with LDS-(G4C2)EXP, transgenes were 
expressed in the fly optic system using GMR-GAL4 (Fig. 3-1E).  LDS-(G4C2)CTRL 
animals showed external and internal eye morphologies similar to controls, supporting 
that the short repeat was not toxic (Freibaum et al., 2015; Goodman et al., 2019a; 
Kramer et al., 2016a; Mizielinska et al., 2014). In contrast, expression of LDS-(G4C2)EXP 
caused mild pigment loss externally and dramatic loss of retinal tissue internally, 
indicative of neurodegeneration.  
To further assess GR production, fluorescence imaging of the fly eyes revealed 
that the LDS-(G4C2)EXP expressing animals produced GFP-positive puncta (Fig. 3-1F). 
In contrast, a control fluorescence protein (DSRED) did not show puncta formation but 
rather had a uniform diffuse signal, indicating that the unique punctate fluorescence 
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pattern seen with LDS-(G4C2)EXP was the result of the GR. LDS-(G4C2)CTRL animals 
were also imaged and showed no GFP signal, even with 5-10x longer exposure time 
(data not shown).  
 Overall, these data indicate that expression of LDS-(G4C2)EXP in flies can induce 
toxicity and that GFP-tagged GR are produced by an expanded LDS-G4C2 transcript.  
  
A loss of function screen for candidate RAN-translation factors. 
Despite recent advances into mechanisms underlying G4C2-associated RAN-
translation, a full understanding of which canonical translation factors are involved 
remains unclear (Green et al., 2017; Tabet et al., 2018; Cheng et al., 2018; Kearse and 
Wilusz, 2017; Zu et al., 2018).  To define translation factors that may mediate GR-
associated RAN-translation, we designed a loss-of-function (LOF) fly screen utilizing 
external eye imaging for toxicity, and GR-GFP fluorescence of the eyes for protein, in 
LDS-(G4C2)EXP expressing animals (Fig. 3-2A). 48 RNAi (Ni et al., 2011; Perkins et al., 
2015) or LOF mutant (Spradling et al., 1995, 1999; Bellen et al., 2004, 2011) fly lines 
were obtained that target specific translation factors, covering 86% of the 56 known 
translation factors in the fly (Marygold et al., 2017). 40 of 48 (83.3%) lines were RNAi 
and 8 of 48 (16.6%) were mutant lines.  
28 of the 48 tested LOF lines altered toxicity and/or GR-GFP levels caused by 
LDS-(G4C2)EXP expression in the fly eye, assessed by comparing images with controls 
(Fig. 3-2A, step 1). These 28 lines were further examined in a fly model that expresses 
(GR)36 from a non-G4C2 transcript (Mizielinska et al., 2014), to determine if they acted 
downstream of toxic GR-production in the LDS-(G4C2)EXP animals (Fig. 3-2A, step 2). 6 
of the LOF lines targeting translation factors were found to similarly alter GR-induced 
toxicity in this model and were not further studied. The remaining 22 LOF lines were 
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further tested for unspecific effects using quality control experiments (Fig. 3-2A, step 3) 
(Chung et al., 2018; Goodman et al., 2019a; Kramer et al., 2016a; Mordes et al., 2018). 
Specifically, lines were examined to eliminate those that cause an effect when 
expressed on their own in the eye and tested to confirm no effect on the protein levels of 
a control (LacZ) transgene.  
In summary, 20 of the lines did not alter toxicity or GR-GFP levels in LDS-(G4C2)EXP 
expressing animals (Fig. 3-2B). 17 lines were excluded from further study because they 
either caused increased GR-GFP levels (1 line), altered LDS-(G4C2)EXP toxicity but not 
GR-GFP signal (4 lines), could alter GR-toxicity independent of G4C2-RNA (6 lines), or 
failed quality control experiments (6 lines; termed “unspecific modifiers”). Thus, from the 
screen of 48 factors, 11 candidate RAN-translation factors were identified (Table 3-1, 
Appendix 3: Table S3-2). 
 
Depletion of eIF4B or eIF4H1 mitigates toxicity in LDS-(G4C2)EXP animals. 
Of the 11 factors that reduced GR-GFP levels, eIF4B and eIF4H1 (fly orthologue to 
human eIF4H) were intriguing. These two factors have independent and redundant roles 
in activating eIF4A (Rogers et al., 2001; Rozovsky et al., 2008; Nielsen et al., 2011; Sun 
et al., 2012; Harms et al., 2014; García-García et al., 2015; Vaysse et al., 2015; Sen et 
al., 2016) which was recently identified as a RAN-translation factor in a G4C2-model 
(Green et al., 2017; Tabet et al., 2018).  Further, eIF4B and eIF4H had previously been 
reported to bind G4C2 RNA through RNA recognition motifs (RRMs) (Cooper-Knock et 
al., 2014; Haeusler et al., 2014; Satoh et al., 2014).  
 To further investigate eIF4B and eIF4H1 as modifiers of LDS-(G4C2)EXP in flies, a 
second, independent set of RNAi lines targeting these genes was obtained (termed 
RNAi-2). All RNAi lines were confirmed to downregulate the expected targets, eIF4B or 
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eIF4H1 (Fig. 3-3A, Appendix 3: Fig. S3-3A). Further, eIF4B RNAi did not cause 
reduced expression of eIF4H1, and vice versa, indicating that expression of these two 
genes is independent and that the RNAi lines are specific. Interestingly, ubiquitous 
downregulation of eIF4B or eIF4H1 by RNAi produced viable adults with no obvious 
phenotype (Fig. 3-3B), supporting that these genes are not essential in the fly (also 
(Hernández et al., 2004)).  
The effects of co-expressing eIF4B, eIF4H1, or control (Luc) RNAi with LDS-
(G4C2)EXP using GMR-GAL4 were analyzed in the eye. Externally, eIF4B or eIF4H1 
RNAi caused reduced toxicity compared to the control RNAi, seen by recovered red 
pigment and ommatidial organization (Fig. 3-4A).  Internally, retinal tissue loss caused 
by LDS-(G4C2)EXP was also mitigated by depletion of eIF4B or eIF4H1. Blinded 
quantification of the total surface area for retina tissue or of tissue depth (at the point of 
the optic chiasm) revealed that suppression was consistent and significant (Fig. 3-4B). 
Suppression was recapitulated with a second set of RNAi lines, supporting that the 
effects seen are the result of downregulating these target genes (Appendix 3: Fig. S3-
4B-C).    
 To further assess if eIF4B and eIF4H1 could be acting downstream of toxic GR-
production, RNAi lines targeting eIF4B, eIF4H1, or control (Luc) were co-expressed with 
(GR)36 in the fly eye using GMR-GAL4. The (GR)36 transgene produces a GR dipeptide 
from a non-G4C2 repeat transcript (Mizielinska et al., 2014).  In contrast to the effect in 
LDS-(G4C2)EXP animals, eIF4B and eIF4H1 RNAi increased GR-toxicity in both the 
external and internal eye (Fig. 3-4C-D). This argues that these genes do not act on the 
same pathway in GR animals as in LDS-(G4C2)EXP animals. Depletion of either eIF4B or 
eIF4H1 on their own did not alter normal eye morphology (Fig. 3-4E-F). 
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Depletion of eIF4B or eIF4H1 reduces GR-production in LDS-(G4C2)EXP animals. 
As eIF4B and eIF4H1 are canonical translation factors we hypothesized that they 
modified LDS-(G4C2)EXP toxicity by mediating translation from the G4C2 transcript. To 
further test if depletion of these factors reduced GR production, eIF4B, eIF4H1, or 
control (Luc) RNAi were co-expressed with LDS-(G4C2)EXP in the fly eye and 
fluorescence imaging was performed (Fig. 3-5A). Blinded quantification of GR-GFP 
signal in LDS-(G4C2)EXP flies revealed that eIF4B depletion caused a 48.3±13% 
decrease in total GR-GFP fluorescence (Fig. 3-5B, grey). Further, eIF4H1 depletion 
caused a 65.5±3.7% decrease in GR-GFP fluorescence levels. As puncta formation was 
associated with fluorescently tagged GR (see Fig 3-1.), additional analyses were 
performed to define changes in the number of bright GR-GFP puncta and the average 
size of these puncta (Fig. 3-5B, black). eIF4B RNAi reduced the number of puncta from 
233 per eye to 44 per eye, an 81% reduction. Additionally, the average size of the 
puncta per eye was reduced by 63% (7.6μm2 to 2.8μm2). eIFH1 RNAi caused a 91% 
reduction in the number of GR-GFP puncta per eye (233 to 20) and the size of the 
puncta was reduced from 7.6μm2 to 2.4 μm2, a 68% reduction. Effects on GR-GFP levels 
and puncta were also seen using the second set of RNAi lines targeting eIF4B and 
eIF4H1 (Appendix 3: Fig. S3-3D-E).  
While we had already determined that eIF4B and eIF4H1 RNAi did not alter 
toxicity downstream of GR production (see Fig. 3-4C-D), we considered whether their 
depletion could modify LDS-(G4C2)EXP upstream of translation, on the transcriptional 
level. To assess this, we used qPCR to measure transcript levels of the LDS-(G4C2)EXP 
transgene in animals co-expressing control RNAi (Luc), eIF4B or eIF4H1 RNAi (Fig. 3-
5B, light grey). Depletion of eIF4B or eIF4H1 did not alter LDS-(G4C2)EXP RNA levels, 
further supporting that they act on the translational level.  
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To test the specificity of eIF4B and eIF4H1 to translation of a G4C2 transcript, we 
first confirmed specificity of the effect of eIF4B and eIF4H1 RNAi, by assessing whether 
their depletion had an effect on eye fluorescence of a control DsRed transgene in the fly 
optic system (GMR-GAL4) (Fig. 3-5C). Blinded quantification supported that total 
fluorescence was unchanged,  arguing that the effect in LDS-(G4C2)EXP animals was 
specific to the GR-tagged fluorescent protein (Fig. 3-5D). We further used western 
immunoblots to analyze protein levels produced from a control (LacZ) transgene in 
animals co-expressing eIF4B, eIF4H1, or control (Luc) RNAi (Fig. 3-5E). Transgenes 
were expressed using GMR-GAL4 and protein was extracted from whole heads. 
Consistent with fluorescence data using DsRed, no significant difference in the amount 
of β-galactosidase protein translated from the LacZ transcript was seen. The second set 
of RNAi lines targeting eIF4B and eIF4H1 also did not alter protein expression from a 
control (LacZ) gene (Appendix 3: Fig. S3-3F). These data are consistent with previous 
reports that these factors are not essential for general translation (Altmann et al., 1993; 
Capossela et al., 2012; Coppolecchia et al., 1993; Hernández et al., 2004). 
Overall, these data support that eIF4B or eIF4H1 modify LDS-(G4C2)EXP toxicity 
by mediating toxic GR production. Importantly, translation from the G4C2 transcript is 
particularly sensitive to their depletion as expression from a control transcript was 
unaltered under similar conditions. 
 
EIF4H is downregulated in ALS/FTD cases harboring a G4C2 expansion in C9orf72. 
Data in the fly supported that eIF4B and eIF4H1 were modifiers of LDS-(G4C2)EXP that 
could alter the amount of GR produced from the repeat-containing transcript.  To further 
investigate these translation factors in disease, we considered that the expression of the 
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human orthologues to these factors, eIF4B and eIF4H, could be dysregulated if they 
played a critical role in G4C2-associated expression.  
eIF4B and eIF4H protein levels were assessed by western immunoblot in primary 
fibroblast cell lines (Fig. 3-6.A; lines described in Appendix 3: Table S3-3). The mean 
expression from four independent C9+-patient derived lines was compared to the mean 
expression from five independent lines derived from healthy individuals. Interestingly, 
eIF4B total levels were unchanged while eIF4H levels were reduced by 47.5%. As eIF4B 
is inhibited by phosphorylation at Ser422 (Raught et al., 2004; Roux and Topisirovic, 
2018), we further examined levels of phospho-eIF4B to determine whether this factor 
was dysregulated by protein modification. No obvious changes were observed in 
phospho-eIF4B levels visually or relative to total eIF4B in C9+ versus healthy cells.  
 Data from patient-derived cells supported that eIF4H is dysregulated in C9+ 
situations. To further assess this finding in patients, total RNA was extracted from post-
mortem, cerebellar tissue from 112 ALS/FTD individuals or 22 healthy individuals and 
the expression from EIF4B or EIF4H were defined by qPCR (Fig. 3-6B; individuals 
described in Appendix 3: Table S3-4). The ALS/FTD cohort were further broken down 
based on the presence or absence of the G4C2-repeat expansion in C9orf72 into 46 C9- 
ALS/FTD and 66 C9+ ALS/FTD cases. Consistent with protein data from fibroblast lines, 
eIF4B expression was unaltered in disease. Importantly, eIF4H was significantly 
downregulated by 71.2% in C9+ ALS/FTD compared to healthy controls and 54.4% 
compared to C9- ALS/FTD cases.  
 These data indicate a significant decrease in eIF4H expression in response to 
the presence of expanded G4C2 in ALS/FTD. 
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Discussion 
Mechanisms underlying repeat-associated non-AUG (RAN-) translation remain unclear 
despite evidence that this form of translation occurs in disease (Kearse and Wilusz, 
2017; Zu et al., 2018). To help define potential RAN-translation factors, we developed a 
gain-of-function fly model for C9orf72-associated ALS/FTD that expressed an expanded 
GGGGCC hexanucleotide repeat (termed G4C2) downstream of the sequence normally 
found upstream of the repeat in patients (114bp of intronic DNA found 5’-prime of the 
repeat in intron 1 of C9orf72 in ALS/FTD); the transgene expressed also contained a 
GFP tag downstream of the repeat in the GR reading frame (see Fig. 3-1). Using this 
model, we screened 48 of 56 canonical translation factors in flies (Marygold et al., 2017) 
to define those that could impact expression of the GR dipeptide (see Fig. 3-2 and 
Appendix 3: Table S3-2).  11 candidate RAN-translation factors were defined (see 
Table 3-1). When depleted, these factors reduced GR-GFP levels, reduced G4C2-
induced toxicity, and did not reduce toxicity associated with a non-G4C2 transcript 
generated toxic GR protein.  Further investigations into two of these, eIF4B and eIF4H1 
(fly orthologue to eIF4H), revealed that their depletion reduced G4C2-induced toxicity 
and GR-GFP levels, but did not alter G4C2 RNA levels (see Fig. 3-5 and Appendix 3: 
Fig. S3-3). Investigations into EIF4B and EIF4H expression in patient-derived cells and 
in post-mortem tissue revealed that EIF4H is significantly downregulated in ALS/FTD 
patients harboring the G4C2 expansion (C9+ ALS/FTD) (see Fig. 3-6). This effect was 
not seen in ALS/FTD patients lacking the G4C2 mutation (C9- ALS/FTD), arguing that it 
is a response to the presence of the repeat. These data highlight eIF4B and eIF4H as 
novel factors mediating disease-associated pathways.   
To our knowledge, this is the first in vivo investigation into canonical translation 
factors that impact dipeptide production in a C9orf72-associated disease model. The 
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simplest hypothesis is that these factors impact the process of RAN translation from the 
G4C2 repeat-containing transcript. Interestingly, our data suggest that production of the 
GR dipeptide requires specific factors as only 11 of 48 canonical translation factors 
screened altered GR-GFP levels in G4C2-expressing animals. Further, investigations 
into mammalian systems using DPR-specific antibodies will determine if eIF4B or eIF4H 
depletion disrupts expression of multiple DPR and confirm effects on GR production. 
Although these factors could function to alter GR-production through alternative means 
versus RAN-translation (i.e. stability of the protein, altered expression of more direct 
RAN-translation factors), it is compelling that the factors identified converge at key 
regulatory steps of translation and that the majority of these factors function together or 
with previously suggested RAN-translation factors (see Fig. 3-7). We ruled out factors 
that similarly altered toxicity caused by the GR dipeptide, supporting that they act on 
pathways not associated with toxicity of the GR protein. We also ruled out mechanisms 
underlying G4C2 transcription and RNA stability for eIF4B and eIF4H, as G4C2 
transcript levels are unaltered by their depletion (see Fig. 3-5B). Although our 
investigations here focused on eIF4B and eIF4H, we note that we defined a number of 
other intriguing factors that act on either on G4C2- and/or GR-associated toxicity (see 
Table 3-1).  
The fly model developed herein expresses the LDS-G4C2 transcript as an 
mRNA, containing a 5’-prime m7G cap and polyadenylated (poly(A)-) tail. In disease, the 
G4C2-RNA could exist in multiple forms (Yuva-Aydemir et al., 2018), including: 
improperly spliced C9orf72-mRNA transcripts retaining the repeat (Niblock et al., 2016), 
properly spliced intronic sequence kept stable by the repeat (Vatovec et al., 2014; 
Haeusler et al., 2016), altered transcription initiation products (Sareen et al., 2013), or 
aborted C9orf72-transcript products (Haeusler et al., 2014). Interestingly, fly models that 
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express expanded G4C2 within properly spliced introns do not show dipeptide 
expression nor toxicity, despite the formation of RNA foci (Tran et al., 2015). Further, 
improperly spliced C9orf72-transcripts can be shuttled from the nucleus to the cytoplasm 
where they undergo RAN-translation (Hautbergue et al., 2017). Overall, these data 
support that G4C2 repeats retained in capped and polyadenylated C9orf72-mRNA are 
able to produce toxic dipeptides and are relevant to patients. Whether or not G4C2-
associated RAN translation is dependent on the presence of this 5’-prime cap (and 
poly(A)-tail) is still debated (Cheng et al., 2018; Green et al., 2017; Tabet et al., 2018) 
(Cheng et al., 2018; Green et al., 2017; Tabet et al., 2018).  
Our investigations draw parallels between the canonical functions of translation 
factors (Marygold et al., 2017) and RAN-translation (see Model, Figure 1-3).  However, 
there are multiple types of translation that may be pertinent to disease, including cap-
independent mechanisms, such as IRES translation (Green et al., 2016; Kearse and 
Wilusz, 2017; Shatsky et al., 2018; Sonenberg and Hinnebusch, 2009). Of the 11 
candidate RAN-translation factors we identified, 4 have been reported to function in cap-
independent translation: eIF4B (Khan and Goss, 2012; Sharma et al., 2015), eIF4H 
(Vaysse et al., 2015), eIF5B (Galmozzi et al., 2012), eIF2β (Liberman et al., 2015). 
Interestingly, eIF4B or eIF4H significantly strengthen eIF4A-mediated unwinding of 
longer, more complex 5’ UTRs in transcripts (Rozovsky et al., 2008; Sun et al., 2012; 
Vaysse et al., 2015; Sen et al., 2016). This activity is thought to mediate scanning of the 
5’ UTR for translation start sites (Spirin, 2009) and recruitment of ribosomal subunits 
(Sharma et al., 2015; Walker et al., 2013). Overall, these data suggest a model for 
G4C2-associated RAN-translation where eIF4B/eIF4H and eIF4A mediate dipeptide 
production during this scanning process (Green et al., 2016; Tabet et al., 2018). Further, 
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frame-shifting during scanning could result in the production of all three sense-strand 
associated dipeptides (GA, GR, GP) from a near-cognate alternative start codon, CUG, 
found upstream of the repeat in the GA-reading frame (Tabet et al., 2018).       
In addition to their involvement in non-canonical translation and in stimulating 
eIF4A (previously reported as a RAN-translation factor (Green et al., 2017; Tabet et al., 
2018), we chose to focus on eIF4B and eIF4H as they are RNA-binding proteins (RBPs) 
containing homologous RNA recognition motifs (RRMs) (Richter-Cook et al., 1998). 
Screens for RBPs that interact with G4C2-RNA identified both eIF4B and eIF4H, 
supporting our data that they function in translation from G4C2 transcripts (Cooper-
Knock et al., 2014; Haeusler et al., 2014; Satoh et al., 2014). Both eIF4B and eIF4H can 
independently stimulate the helicase activity of eIF4A during translation (Rogers et al., 
2001; Rozovsky et al., 2008; Nielsen et al., 2011; Sun et al., 2012; Harms et al., 2014; 
García-García et al., 2015; Vaysse et al., 2015; Sen et al., 2016) while key differences 
between them are noted. Structural data supports that eIF4H is constitutively active 
while eIF4B contains a regulatory carboxyl domain containing multiple phosphorylation 
sites (Méthot et al., 1996; Raught et al., 2004).  This may explain why EIF4H is 
downregulated in C9+ ALS/FTD but not EIF4B (see Fig. 3-6), as eIF4B can be regulated 
by de/phosphorylation.  However, no significant changes were observed for phospho-
eIF4B at Ser422, an inhibitory modification (Sonenberg and Hinnebusch, 2009; Roux 
and Topisirovic, 2018), in four C9+ derived cell lines versus five control cell lines. 
Extended analyses are needed to increase the sample size and to test for eIF4B 
phosphorylation at other marks (Bettegazzi et al., 2017; van Gorp et al., 2009). Overall, 
we hypothesize that EIF4H is downregulated as the result of compensatory 
mechanisms: cells may actively downregulate EIF4H to reduce expression of toxic GR 
dipeptide.  Alternatively, as eIF4H had previously been reported to bind G4C2-RNA 
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(Cooper-Knock et al., 2014; Haeusler et al., 2014; Satoh et al., 2014), the reduced 
EIF4H RNA levels could be the result of a more complex feedback loop: as eIF4H 
protein is sequestered by G4C2 RNA foci, cells may respond by downregulating EIF4H 
transcription under the assumption that there is plenty of this translation factor present.  
Localization studies in patient tissue are needed to determine if eIF4H is indeed 
sequestered into G4C2-foci. In either scenario, data supports that eIF4H plays an 
important role in C9+ disease while further investigations would help define its role in 
disease progression.  
Studies in multiple model systems support that eIF4B and eIF4H loss does not 
inhibit global translation, including yeast (Altmann et al., 1993; Coppolecchia et al., 
1993), flies (Hernández et al., 2004), and mice (Capossela et al., 2012). Interestingly, 
yeast and flies (see Fig. 3-3B) with downregulated eIF4B or eIF4H are viable (Altmann 
et al., 1993; Coppolecchia et al., 1993; Hernández et al., 2004) and EIF4H+/- mice do not 
have notable deficits (Capossela et al., 2012); although eIF4B and eIF4H have been 
suggested to be important for brain development (Bettegazzi et al., 2017; Capossela et 
al., 2012; Eom et al., 2014; Rode et al., 2018). The downstream consequences of EIF4H 
downregulation in C9+ ALS/FTD may be broader than simply altering RAN-translation: 
depletion of eIF4B and eIF4H in cultured cells has been shown to induce stress granule 
formation (Mokas et al., 2009). Interestingly, as EIF4H expression is reduced  in C9+ 
ALS/FTD and C9+ derived cells, this raises a potential connection between that 
downregulation and mechanisms underlying  TDP-43 pathology/toxicity (Coyne et al., 
2017; Fernandes et al., 2018). Further, our data in GR-expressing flies argues that the 
depletion of these factors downstream of GR-production can feed into pathways 
disrupted by this toxic dipeptide (see Fig. 3-4C-D) (Kanekura et al., 2016; Suzuki et al., 
2018; Tao et al., 2015; Zhang et al., 2018).  
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In conclusion, in an unbiased, targeted screen we identified eIF4B and eIF4H as 
canonical translation factors that, when depleted in flies, disrupted toxicity caused by the 
expression of expanded G4C2 RNA. Interestingly, EIF4H was downregulated in C9+ 
ALS/FTD patients, indicating a distinct role in C9orf72-associated disease. These factors 
may represent unique G4C2 modifiers that couple RAN-translation to dysregulation of 
RNA metabolism in disease (Coyne et al., 2017; Ito et al., 2017; Zhao et al., 2018). 
 
Methods and materials 
Patient samples and clinical, genetic and pathological assessments 
Participant information is summarized in Appendix 3: Table S3-4. Protocols were 
approved by the Mayo Clinic Institutional Review Board and Ethics Committee. All 
participants (or authorized family members) were provided written informed consent 
before information gathering, autopsies and postmortem analyses. Trained neurologists 
diagnosed patients with ALS and/or FTD after reviewing neurological and pathological 
information. The presence or absence of an expanded G4C2 within intron 1 of C9orf72 
was done using a previously established protocol for repeat-primed polymerase chain 
reaction (DeJesus-Hernandez et al., 2011). 
Drosophila work  
Stocks were maintained on standard cornmeal-molasses medium. Fly lines used are 
detailed in Appendix 3: Tables S3-2 and S3-5. Fly lines obtained from Bloomington 
Drosophila Stock Center (BDSC) and Vienna Drosophila Resource Center (VDRC) are 
noted.  
Characterization of LDS-(G4C2)n fly models 
Transgenes were inserted into pUAST vectors and randomly inserted into w1118 fly 
genomes. The LDS-G4C2 model has a 5’ leader sequence (LDS) inserted immediately 
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upstream of the G4C2 repeats, 114bp of sequence upstream of the repeat in intron 1 of 
C9orf72 in patients, and a 3’ GFP tag in the GR reading frame. Repeat-length 
determination: Genomic DNA was extracted from individual fly lines and the transgenes 
present were amplified by PCR using primers designed to flank the repeat (Appendix 3:  
Table S3-6). Amplification was done using a KAPA HiFi HotStart kit (Kappa #KK2501) 
and PCR product sizes were quantified using agarose gels and a Bioanalyzer, 
previously described (Goodman et al., 2019a). Control w1118 animals were included in 
experiments and showed no signal. RNA expression:  Transgenes were expressed as 
previously described using HS-Gal4 (Goodman et al., 2019a) and RNA levels were 
assessed by qPCR, using primers designed to amplify the GFP tag (Appendix 3: Table 
S3-6). Control w1118 animals were included in experiments and showed no signal.  
LOF external fly eye screen 
Publicly available RNAi (Ni et al., 2011; Perkins et al., 2015) or mutant (Bellen et al., 
2004, 2011; Spradling et al., 1995, 1999) loss-of-function (LOF) fly lines targeting 
canonical translation factors were obtained from the Bloomington Drosophila Stock 
Center (BDSC). Additional UAS-RNAi lines targeting eIF4B and eIF4H1 were obtained 
from Vienna Drosophila Resource Center (VDRC) (Dietzl et al., 2007).  
External eye imaging:  LOF males were crossed to recombinant females: UAS-LDS-
(G4C2)EXP, GMR-GAL4 (III) (26ᵒC). Multiple w
- and w+ controls were setup with every 
experiment to assess any natural variability, including a UAS-Luc RNAi (BDSC # 31603) 
and w1118; UAS-DSRED. External eyes for 1-2d progeny were imaged on a Leica APO16 
microscope as described (Goodman et al., 2019a). Any changes to the ommatidia 
organization, eye size, pigmentation, and ability to eclose from pupae were noted. 
Resulting phenotype was categorized into one of six groups: suppressors, mild 
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suppressors, no effect, mild enhancers, enhancers, and lethal enhancers (Appendix 3: 
Fig. S3-2). 
External eye fluorescence imaging: LOF males were crossed to recombinant females: 
UAS-LDS-(G4C2)EXP, GMR-GAL4 (III) (26ᵒC) and 1-2d progeny were imaged on a Leica 
DM6000B and quantified as previously described (Goodman et al., 2019a). w- or w+ 
controls were used for accurate comparisons depending on the background of the LOF 
lines and the final genotypes of animals. Any changes to the GR-GFP levels using LUT 
Z-stacked images were noted. Resulting phenotype was categorized into one of six 
groups: suppressors, mild suppressors, no effect, mild enhancers, enhancers, and lethal 
enhancers (Appendix 3: Fig. S3-2). Researchers were blinded to the LOF targets during 
screening. Modifiers of LDS-(G4C2)EXP toxicity and/or GR-GFP levels were further 
assessed in GMR-GAL4 > UAS-(GR)36 animals. Modifier crosses were repeated 3+ 
independent times to confirm reproducibility of results.   
Quality control experiments defining unspecific LOF lines were performed as previously 
described (Goodman et al., 2019a).  
Fly RNAi efficacy 
All control and RNAi lines are defined in Appendix 3: Table S3-5. RNAi efficacy was 
determined using Da-GAL4 (adults or larvae) as previously described (Goodman et al., 
2019a; McGurk and Bonini, 2012). 
Fibroblast cells 
Cultured using standard protocols in DMEM complete media: 15% FBS (Sigma), 1x 
MEM Amino Acids (ThermoSci # 11130051), 1% pen/strep, DMEM (high glucose, plus 
sodium pyruvate). Cells were maintained in a 5% CO2 incubator at 37ᵒC.  
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Western immunoblots (WB) 
Fly tissue: Triplicate samples of 5-10 heads per genotype were homogenized using 
disposable pellet/pestles tissue grinders (Kimble Chase #749520-0000) and motor 
(Kimble Chase #749540-0000). For βgal: heads were directly homogenized into 1X 
NuPAGE LDS sample buffer. For GR/GFP: heads were homogenized into RIPA buffer 
(50mM Tris-HCL (pH 7.5), 150mM NaCl, 1% NP-40, 50mM NaF, 0.5% DOC), plus 
protease inhibitors (Sigma # 05892970001), 1mM PMSF, and 1mM DTT.  
Fibroblast cells: cells were lysed in RIPA buffer plus protease, 1mM PMSF, and 1mM 
DTT, and phosphatase inhibitors (Sigma # 04906845001) for 30min at 4ᵒC. All RIPA 
lysates: quantified by Bradford; 20μg of protein was run per lane. All WBs: run using a 
standard protocol with Invitrogen’s XCell SureLock blot system, 4-12% Bis-Tris NuPAGE 
gels and a wet transfer with PVDF membrane, except βgal which was transferred with 
an iBlot dry transfer system (program 2, 8min) and nitrocellulose membrane. Antibodies: 
anti-βgalactosidase (Promega #Z3781, 1:2,000), anti-αTubulin (DSHB #AA4.3, 1:2,000), 
anti-GFPJL8 (Takara #632380, 1:10,000), anti-GR (gift from V. M-Y. Lee #2316, 1:1,000). 
H. sapiens antibodies: anti-eIF4B (Cell Signaling #3592, 1:1,000), anti-eIF4H (Cell 
Signaling #3469,1:1,000), anti-phospho-eIF4B (Cell Signaling #3591,1:1,000), anti-
GAPDH (Sigma #G8795, 1:5,000). Secondary antibodies: Mouse-HRP (Jackson 
Immunoresearch Labs #115-035-146, 1:5000), Rabbit-HRP (Jackson Immunoresearch 
Labs #111-035-144, 1:5000) (Berson et al., 2017). Blots were analyzed using Amersham 
ECL Prime Detection Reagent and imaged on an Amersham Imager 600.  
Quantitative real-time PCR (qPCR)  
All primers are defined in Appendix 3: Table S3-6. For both fly and human qPCRs, 
protocols are previously described with the following changes (Goodman et al., 2019a). 
Flies: For Da-GAL4 assays, triplicate samples of 5 whole animals were processed per 
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condition. For GMR-GAL4 assays, triplicate samples of 20 fly heads (1-2d) were 
processed per condition. Humans: Total RNA was extracted from frozen postmortem 
tissue from the cerebellum using the RNAeasy Plus Mini Kit (QIAGEN), previously 
described (Prudencio et al., 2015). RNA integrity (RIN) was verified on an Agilent 2100 
bioanalyzer. RIN values ranged from 6.7 to 10, with most of the samples falling between 
9.1 and 9.8.  
Statistical analysis and data availability 
GraphPad Prism 8.00 software was used to develop all graphs and for all statistical 
analyses. P-values < 0.05 were considered significant. All relevant data is included 
within the manuscript and Appendix 3. Additional inquiries can be directed to the 
corresponding author, including reagent requests. No statistical methods were used to 
predetermine sample sizes and data distributions were assumed to be normal, similar 
to previous work (Berson et al., 2017; Elden et al., 2010; Goodman et al., 2019a; Kim et 
al., 2014; Kramer et al., 2016b; McGurk and Bonini, 2012; Mizielinska et al., 2014; 
Prudencio et al., 2015, 2017). Fly and fibroblast data: A two-tailed unpaired student t-
test or one-way ANOVA with Tukey’s multiple comparisons test was performed when 
appropriate. Researchers were blinded to the genotype of all samples to maintain 
unbiased scoring. Human qPCRs: Nonparametric, one-way ANOVAs with Dunn’s 
multiple comparisons test were performed as data distribution was not normal. 
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Chapter 3: Tables 
 
 
Table 3-1: Candidate RAN translation factors. 
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Chapter 3: Figures and legends 
 
 
 
Figure 3-1 
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Figure 3-1:  Expanded G4C2 transgenes produce GFP-tagged GR. 
A. A new transgenic (G4C2)n model was developed to look at RAN-translation of the GR 
reading frame. A “leader” sequence (LDS) was added 5’ of the repeat: 114bp of intronic 
sequence found upstream of the repeat in patient samples. The GR reading frame has 
an in-frame GFP coding sequence 3’ of the repeat that lacks an ATG initiation. B. To 
define the number of repeats inserted into genomes of w1118 transgenic flies, PCR 
reactions were developed that amplified the repeat and its flanking region. The number 
of repeats were calculated from PCR product lengths measured on a Bioanalyzer and 
agarose gel. Shown: the maximum number of repeats found in the control (CTRL) or 
expanded (EXP) G4C2 fly lines; individual data points from 2 independent DNA preps 
with mean. C. qPCR analysis for RNA levels between control and expanded G4C2 fly 
lines. Shown: individual data points with mean±SD. Statistics: unpaired student t-test, p-
value ****<0.0001. D. Western immunoblots confirmed GR is produced and successfully 
tagged with GFP in EXP-G4C2 flies. No GR/GFP was detected in control G4C2 flies, 
even with overexposure (Appendix 3: Fig. S3-1). Uncropped westerns (Appendix 3: 
Fig. S3-4) E. External and internal eye analysis in animals expressing G4C2 or control 
(DSRED) transgenes using GMR-GAL4. Degeneration was seen only in LDS-(G4C2)EXP 
animals: external pigment loss and reduced integrity of internal retina tissue. F. External 
eye imaging for fluorescence caused by transgene expression. Positive (DSRED) control 
flies show uniform diffuse signal. Control G4C2 flies show no signal, even with increased 
exposure (data not shown). Expanded G4C2 flies show GFP puncta. Shown (E-F): 
representative images while all conditions were tested 2+ times. For full genotypes see 
Appendix 3: Table S3-1. 
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Figure 3-2 
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Figure 3-2: A screen of translation factors reveals those important for expression 
of GR from (G4C2)EXP. 
A. To identify canonical translation factors that may be involved in RAN translation of 
G4C2 in the GR reading frame, a loss-of-function (LOF) based screen was designed 
utilizing previously developed RNAi (Ni et al., 2011; Perkins et al., 2015) or LOF mutant 
fly lines (Spradling et al., 1995, 1999; Bellen et al., 2004, 2011) targeting 48 of 56 (86%) 
known translation factors (Marygold et al., 2017). Individual translation factors were 
downregulated in animals expressing LDS-(G4C2)EXP and any that altered the external 
eye phenotype and/or GR-GFP levels were defined (Step 1). These 28 LOF lines were 
further tested in (GR)36 expressing animals, defining 6 that acted similarly on GR-
associated toxicity (Step 2). Additional quality control experiments excluded LOF lines 
that altered expression from a control (LacZ) transgene by western immunoblot and/or 
altered a WT eye morphology when expressed alone, as described (Step 3) (Chung et 
al., 2018; Goodman et al., 2019a; Kramer et al., 2016a). B. Summary of screen results. 
Overall, 11 translation factors were identified as candidate RAN translation factors as 
their depletion reduced GR-GFP levels. Overall, excluded LOF lines either: altered 
toxicity of G4C2 flies but did not alter GR-GFP levels, similarly altered toxicity in a non-
G4C2, GR fly model arguing that these acted downstream of GR production, had no 
effect on G4C2 toxicity or GR-GFP levels, or were “unspecific” modifiers identified by 
quality control experiments. Shown: representative images while all RNAi were tested 2+ 
times for effects under each condition. Details on LOF lines used and complete results 
with each line can be found in Appendix 3: Table S3-2. For full genotypes and RNAi 
lines see Appendix 3: Table S3-1. 
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Figure 3-3 
 
Figure 3-3: Analysis of eIF4B and eIF4H1 RNAi in control flies.  
A. RNA levels produced from eIF4B or eIF4H1 were assessed by qPCR in flies 
ubiquitously expressing RNAi (by Daughterless-GAL4). Statistics: one-way ANOVAs 
with Tukey’s multiple comparison correction, p-values ****<0.0001, ***<0.001, **<0.01, 
*<0.05, no significance >0.05. Shown: individual data points from 2 independent 
experiments with mean±SEM. B. Viability studies in Drosophila reveal that RNAi-
depletion of eIF4B or eIF4H1 do not significantly alter the number of adult flies expected 
to eclose. Shown: ratio of progeny from two individual crosses with RNAi compared to 
sibling animals with the balancer chromosome that reach adulthood (1-2d adult animals). 
Comparing the # progeny that eclose from a single vial compensates for differences in 
mating variability, fertilized eggs laid, among other variables. However, we note that the 
presence of the balancer chromosome could potentially cause mild sub-viability to 
adulthood. Crosses: RNAi/CyO x Da-GAL4 (III); counted progeny: RNAi/+; Da-GAL4/+ 
and CyO/+; Da-GAL4/+. RNAi lines: control (JF01355), eIF4B RNAi (HMS04503), 
eIF4H1 RNAi (HMS04504). For full genotypes see Appendix 3: Table S3-1. 
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Figure 3-4 
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Figure 3-4: Depletion of eIF4B and eIF4H1 selectively suppresses LDS-(G4C2)EXP 
associated toxicity. 
A. Using GMR-GAL4, RNAi-mediated depletion of eIF4B or eIF4H1 in LDS-(G4C2)EXP 
expressing flies results in reduced toxicity in both the external and internal eye: seen  
externally by recovered pigment and ommatidial structure, seen internally by recovered 
retinal tissue integrity. B. Blinded quantification of internal retina tissue was done by 
measuring the total surface area of tissue present and by measuring the depth of the 
tissue at the position where the optic chiasm occurs. n=9-10 animals per genotype. C. 
eIF4B or eIF4H1 RNAi was expressed in (GR)36 flies (GMR-GAL4) and effects on GR-
associated toxicity were observed in the external and internal eye. D. Blinded 
quantification of internal retina tissue. n=5-9 animals per genotype. E. eIF4B or eIF4H1 
RNAi was expressed in control flies (GMR-GAL4) and effects on the normal eye were 
observed externally and internally. F. Blinded quantification of internal retina tissue. n=4 
animals per genotype. For graphs, shown are individual data points representing 1 
animal with mean±SD. Statistics: one-way ANOVAs with Tukey’s multiple comparison 
correction, p-values ****<0.0001, ***<0.001, **<0.01, *<0.05, no significance >0.05. RNAi 
lines: control (JF01355), eIF4B (HMS04503), eIF4H1 (HMS04504). For full genotypes 
see Appendix 3: Table S3-1. 
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Figure 3-5 
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Figure 3-5: eIF4B and eIF4H1 RNAi selectively reduce GR-GFP levels produced 
from LDS-(G4C2)EXP. 
A. Fluorescence imaging in LDS-(G4C2)EXP expressing flies shows that depletion of 
eIF4B or eIF4H by RNAi results in reduced GR-GFP levels (GMR-GAL4). B. Blinded 
quantification of GR-GFP signal in LDS-(G4C2)EXP animals relative to the signal in 
control RNAi animals. Analysis of GR-GFP puncta number and size are shown in black. 
Total GR-GFP signal is shown in grey. n=6-7 animals per genotype. Further, qPCR was 
used to quantify RNA levels in LDS-(G4C2)EXP flies co-expressing control, eIF4B, or 
eIF4H1 RNAi, shown in light grey. C. A control fluorescent protein, DsRed, was similarly 
expressed in the fly eye with RNAi to control, eIF4B, or eIF4H. D. Blinded quantification 
of DsRed fluorescence shows no effect by RNAi. n=6 animals per genotype. E. A 
representative western immunoblot image for β-Galactosidase in LacZ flies co-
expressing control, eIF4B, or eIF4H1 RNAi. Uncropped westerns (Appendix 3: Fig. S3-
4). Blinded quantification of β-Galactosidase western immunoblots normalized to the 
loading control, Tubulin.  For graphs, shown are individual data points from 2 
independent assays with mean±SEM. Statistics: one-way ANOVAs with Tukey’s multiple 
comparison correction, p-values ****<0.0001, ***<0.001, **<0.01, *<0.05, no significance 
>0.05. RNAi lines: control (JF01355), eIF4B (HMS04503), eIF4H1 (HMS04504). For full 
genotypes see Appendix 3: Table S3-1. 
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Figure 3-6 
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Figure 3-6: EIF4H is downregulated in C9+ ALS/FTD.  
A. Western immunoblots were used to define changes in eIF4B or eIF4H protein levels 
from 5 independent control or 4 independent C9+ derived fibroblast cell lines. Data are 
relative to controls. Quantification of total protein was done after normalizing to loading, 
using GAPDH. Phospho-eIF4B quantification was further normalized to total eIF4B. 
Statistics: unpaired student t-tests. Shown: each data point represents 1 cell line with 
mean±SEM; the mean data from 2 independent protein preparations is shown per line. 
B. RNA levels of EIF4B or EIF4H were assessed by qPCR in human cerebellar tissue 
from healthy individuals or ALS/FTD patients with (C9+) or without (C9-) the G4C2 
expansion in C9orf72. n = 22 (healthy), 46 (C9- ALS/FTD), 66 (C9+ ALS/FTD). 
Statistics: one-way ANOVAs with Dunn’s multiple comparison correction. Shown: 
individual data points representing 1 individual with mean±SEM. Cell line details: 
Appendix 3: Table S3-3. Patient details: Appendix 3: Table S3-4. p-values 
****<0.0001, ***<0.001, **<0.01, *<0.05, no significance >0.05. 
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An unbiased, RNAi-based screen 
The discovery that an expanded hexanucleotide repeat of (G4C2)n exists within C9orf72 
and that expansions of >30 repeats are associated with ALS/FTD were made by two 
independent groups in 2011 (DeJesus-Hernandez et al., 2011; Renton et al., 2011). 
When I began this project in 2013, little was known about the impact this mutation may 
have on neuronal health and disease progression. Drawing parallels from previous 
examples of nucleotide expansions and disease (Krzyzosiak et al., 2012; Nguyen et al., 
2019), multiple groups developed gain-of-function models, including ours described in 
Chapter 2 (Freibaum et al., 2015; Kramer et al., 2016; Mizielinska et al., 2014; Xu et al., 
2013). By using Drosophila, investigators could rapidly define degenerative effects 
associated with gain-of-function mechanisms that resulted with expression >30 G4C2 
repeats in vivo.  
While each research group uniquely used their G4C2 fly model(s) to uncover 
disease mechanisms only two groups, to my knowledge, took on the task of performing 
unbiased, forward-screens to define disease modifiers (Freibaum et al., 2015; Goodman 
et al., 2019a). Of these, our screen on (G4C2)49-expressing flies was unique as we 
analyzed individual genes whose RNAi-mediated loss may impact G4C2-associated 
toxicity in Drosophila (see Chapter 2: Fig. 2-1e and (Goodman et al., 2019a)). (The 
other report utilized chromatin deficiency fly lines that targeted multiple genes 
simultaneously and are predicted to result in only a 50% downregulation of 
encompassed genes (Freibaum et al., 2015).) We identified 119 genes whose 
downregulation could increase or decrease (G4C2)49-induced toxicity in the fly eye (see 
Chapter 2: Fig. 2-1f and (Goodman et al., 2019a)). Further investigations tested G4C2-
associated genes in a second fly model that expressed the toxic GR-dipeptide from a 
non-G4C2 transcript (see Chapter 2: Fig. 2-2a and (Goodman et al., 2019a; Mizielinska 
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et al., 2014). This defined pathways selective to the G4C2-RNA (see Chapter 2: Fig. 2-
2c and (Goodman et al., 2019a)) and genes whose loss impacted both the G4C2-RNA 
and its dipeptide product (see Appendix 2: Supplementary data and (Goodman et al., 
2019a)). Last, by testing G4C2-associated genes in a fly model that overexpressed a 
related disease gene, TDP-43 (see Chapter 2: Fig. 2-2a and (Goodman et al., 2019a)), 
we also defined pathways selective for the C9orf72-mutation in C9+ ALS/FTD (see 
Chapter 2: Fig. 2-2d and (Goodman et al., 2019a)) and genes that could target both co-
existing disease etiologies (see Appendix 2: Supplementary data and (Chew et al., 
2015, 2019; DeJesus-Hernandez et al., 2011; Goodman et al., 2019a; Renton et al., 
2011)). In total, our large-scale, unbiased screen highlighted genes and pathways worth 
further investigation to improve understanding of C9+ ALS/FTD disease mechanisms. Of 
these, pathways involving multiple genes identified in the screen included the following 
and may be worth further investigation: splicing dysfunction (Cooper-Knock et al., 2015; 
Prudencio et al., 2015; Yin et al., 2017), DNA damage (Farg et al., 2017; Higelin et al., 
2018; Lopez-Gonzalez et al., 2016; Riemslagh et al., 2019; Walker et al., 2017), and 
perturbed nucleolar function (Haeusler et al., 2014; Herrmann and Parlato, 2018; Kwon 
et al., 2014; Mizielinska et al., 2017; Tao et al., 2015). Below I will discuss one of these, 
splicing dysfunction.   
 
Splicing dysfunction 
Dysregulation of RNA-metabolism is a re-occurring theme in ALS/FTD, and mutations in 
multiple RNA-binding proteins are linked to disease (Coyne et al., 2017; Ito et al., 2017; 
Zhao et al., 2018). Interestingly, 17 of 119 genes whose downregulation impacted 
(G4C2)49-toxicity are involved in mRNA-processing, the majority of which increased 
toxicity and similarly enhanced (GR)36-toxicity when depleted. In particular, GO-term 
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analyses revealed that reduced expression of precatalytic spliceosome components 
using RNAi increased (G4C2)49-toxicity (see Chapter 2. Fig. 2-1h and (Goodman et 
al., 2019a)). This included fly orthologues to snRNP-U1-70K, SAP30BP, SF3A1, SF3B5, 
HSPA8, RACK1, and HNRNPUL1. These same RNAi lines similarly enhanced (GR)36-
toxicity in the fly eye, suggesting that perturbations to the spliceosome may be the result 
of toxic GR-dipeptide expressed from the (G4C2)49-transgene. Of these, SF3A1, 
HSPA8, RACK1, and HNRNPUL1 did not similarly alter toxicity in TDP-43 expressing 
flies.  
Currently, multiple studies have reported that splicing errors occur in C9+ 
ALS/FTD compared to C9- ALS/FTD (Cooper-Knock et al., 2015; Prudencio et al., 2015; 
Yin et al., 2017). Of these, Cooper-Knock and colleagues suggested that splicing 
dysfunction correlated with disease progression. The majority of papers in the current 
literature associate changes in RNA metabolism to sequestration of RNA-binding 
proteins by the G4C2-RNA in C9+ disease (Conlon et al., 2016; Cooper-Knock et al., 
2014; Lee et al., 2013; Mori et al., 2013; Sareen et al., 2013). However, the GR- (and 
PR-) dipeptide can also interact with relevant RNA binding proteins (RBPs) (Davidson et 
al., 2017; Kwon et al., 2014; Lee et al., 2016). As C9+ ALS/FTD is an progressive 
disorder and splicing dysfunction may be correlated with disease progression (Cooper-
Knock et al., 2015), it is reasonable to hypothesize that initial splicing errors may be 
induced by G4C2-RNA while the accumulation of toxic GR-dipeptides within cells with 
age may further perturb this process, resulting in a rapid decline in neuron health and 
disease. 
In support of this, a recent study presented a compelling argument that GR-
dipeptides can directly interfere with splicing (Yin et al., 2017). In an in vitro assay, the 
authors found that flag-tagged GR can interact with 5 of 7 components of the precatalytic 
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spliceosome that we had identified as enhancers of G4C2/GR-toxicity in the fly: snRNP-
U1-70K, SAP30BP, SF3A1, HSPA8, HNRNPUL1. Their focused studies revealed that 
SF3A1 was mis-localized to the cytoplasm of cells exposed to GR-dipeptides and in 
C9+-derived iPS neurons, suggesting a potential mechanism underlying SF3A1 RNAi’s 
ability to increase toxicity in our G4C2/GR animals. Notably, among the genes identified 
in our screen, snRNP-U1-70K is mis-localized to the cytoplasm, forms insoluble tangles, 
and contributes to splicing defects in Alzheimer’s disease (Bai et al., 2013, 2014; Hales 
et al., 2014; Johnson et al., 2018). Suggesting a parallel mechanism may occur in ALS, 
snRNP-U1-70K mis-localization has also been associated with FUS mutations found in 
ALS (Yu et al., 2015a). In C9orf72-associated disease, Yin and colleagues have argued 
that GR could act specifically act on U2 snRNP over U1 snRNP (Yin et al., 2017). 
However, our data would suggest that U1 snRNP (of which snRNP-U1-70K is the 
primary component) may also be playing a role in C9+ disease. In fact, these 
researchers showed that blocks in splicing that resulted from exposure to GR-dipeptides 
occurred in the early steps of the process in vitro. While they argue that this is when the 
U2 snRNP is functioning, literature supports that both U1 and U2 snRNPs are important 
in early stages of splicing, with U1 acting before U2 (Wahl et al., 2009; Yan et al., 2019). 
Further, U1 snRNP and U2 snRNP interact while U1 recognizes the 5’ splice site and U2 
the 3’ splice site of introns (Nik and Bowman, 2019; Plaschka et al., 2018; Shao et al., 
2012; Zhan et al., 2018).  
Overall, a directed study looking into the precatalytic spliceosome components 
identified in our screen whose loss enhances G4C2/GR toxicity may further elucidate 
how splicing errors occur in C9+ disease. snRNP-U1-70K may be of particular interest 
and it will be used as an example herein (Bai et al., 2013, 2014; Hales et al., 2014; 
Johnson et al., 2018). Follow-up investigations would need to confirm that altered 
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expression of snRNP-U1-70K can modify (G4C2)49- and (GR)36-induced toxicity 
specifically in the fly, using available RNAi and UAS-upregulation lines. By testing for 
effects of modulating snRNP-U1-70K expression on degenerative phenotypes caused by 
expressing (G4C2)49 or (GR)36 in the fly optic system and brain, one could determine if 
snRNP-U1-70K was a dose-dependent modifier of G4C2/GR toxicity in vivo. Follow-up 
RNA-sequencing studies in the fly would define genes that may be mis-spliced in 
disease and if snRNP-U1-70K plays a role. The fly offers the strong advantage of 
allowing for relatively rapid age progression studies in vivo. Thus, by comparing flies 
expressing toxic (G4C2)49, toxic (GR)36, or inert (G4C2)8 within the fly brain (ElavGS), 
genes that are mis-spliced in response to the toxic repeat expansion and/or its GR-
dipeptide product with age would be revealed. Follow-up studies could then involve 
modulating snRNP-U1-70K, using RNAi and UAS lines, in G4C2/GR expressing 
animals. One would expect that if normal snRNP-U1-70K function was disrupted by the 
GR-dipeptide that increasing the expression of snRNP-U1-70K would alleviate splicing 
errors seen in GR-expressing animals alone. Further, downregulating snRNP-U1-70K in 
GR animals would likely cause an increase in splicing errors, demonstrating that the GR-
dipeptide was disrupting snRNP-U1-70K’s normal function. Using the fly model 
containing a GFP-tag in the GR reading frame (see Chapter 3. Fig. 3-1 and (Goodman 
et al., 2019a)), one could perform a number of directed mechanistic studies to define 
interactions between snRNP-U1-70K and the GR-dipeptide in vivo (e.g. 
immunoprecipitation studies, co-localization immunofluorescence staining). Translating 
findings to C9+ mouse models (Chew et al., 2015, 2019), C9+-derived cell lines and/or 
post-mortem tissue would explain snRNP-U1-70K’s role in disease. Additional 
investigations could look for potential connections with splicing deficits caused by TDP-
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43 mis-localization in ALS or other factors associated with splicing and 
neurodegeneration (e.g. SMN) (Nik and Bowman, 2019; Nussbacher et al., 2019).  
  
The PAF1 complex 
Compellingly, among the ~4000 genes screened for effects on (G4C2)-49 toxicity in 
Drosophila (see Chapter 2: Fig. 2-1e-h and (Goodman et al., 2019a)), RNAi-mediated 
depletion of 3 of the 5 core components to the PAF1 complex (PAF1C) were found to 
suppress (G4C2)49-toxicity – CDC73, Ctr9, and Rtf1. (The sixth, minor component of 
PAF1C, WDR61, was also identified as a suppressor of G4C2-toxicity in our screen; see 
Appendix 2: Supplementary data and (Goodman et al., 2019a).) Ensuing 
investigations expanded reagents to include the 2 remaining PAF1C components – Paf1 
and Leo1 – and defined PAF1C depletion for its ability to specifically suppress (G4C2)49 
toxicity versus GR-induced or TDP-43-induced toxicity (see Chapter 2: Fig. 2-2, 2-3 
and (Goodman et al., 2019a)). As PAF1C is a transcriptional regulator of RNAPII 
(Jaehning, 2010), mechanistic studies defined the importance of PAF1C components in 
G4C2ǁG2C4-DNA expression, using multiple fly and yeast models (see Chapter 2: Fig. 
2-4 and (Goodman et al., 2019a)). (RNAi to WDR61 caused similar effects on 
(G4C2)49-toxicity and RNA levels in the fly; data not shown.) A key finding was that loss 
of Paf1 and Leo1, which form a heterodimer within the PAF1C complex (Chu et al., 
2013), selectively impacted expression from toxic (>30) G4C2-repeat expansions versus 
inert (≤ 29) G4C2-repeats in the fly (see Chapter 2: Fig. 2-4a and (Goodman et al., 
2019a)). The effect was remarkably consistent between G4C2-fly models arguing that it 
was biological rather than technical (compare data in Chapter 2: Fig. 2-4a and 2-4c 
and (Goodman et al., 2019a)). In contrast, RNAi targeting Spt4 (of the DSIF complex; 
(Hartzog and Fu, 2013)) or the other PAF1C components – CDC73, Ctr9, Rtf1 (and 
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WDR61; data not shown) – similarly altered expression from all G4C2-transgenes 
independent of the repeat-length. Additionally, we showed that Leo1, of the Paf1/Leo1 
heterodimer, was bound to C9orf72-chromatin in C9+ ALS/FTD patient cells (see 
Chapter 2: Fig. 2-6b and (Goodman et al., 2019a)). Further supporting that both Paf1 
and Leo1 play a special role in disease, these components were upregulated in FTD 
cortical tissue only when the toxic (>30) G4C2-repeat expansion was present (see 
Chapter 2: Fig. 2-6c and (Goodman et al., 2019a)). This was not true for another 
PAF1C component, CDC73 (see Appendix 2: Fig. S2-10 and (Goodman et al., 
2019a)). Notably, the expression of Paf1 and Leo1 in C9+ FTD tissue positively 
correlated to expression of the G4C2-postive C9orf72 gene (see Chapter 2: Fig. 2-6d 
and (Goodman et al., 2019a)).  
In total, these investigations revealed the PAF1C as a transcriptional regulator of 
G4C2-repeats in C9+ ALS/FTD. Further investigations into Paf1 and Leo1 may reveal 
them to be effective therapeutic targets, while current data supports their loss in flies, 
yeast, and mice may be better tolerated than the previously proposed target, Spt4 
(Gerlach et al., 2017; Jaehning, 2010; Kramer et al., 2016; Meehan et al., 2017; Van 
Oss et al., 2017). Here, I will describe key next steps that are needed to further define 
PAF1C’s role in C9+ ALS/FTD. 
 
PAF1C in C9+ FTD versus C9+ ALS 
A surprising feature of PAF1C in C9+ disease that we found during our investigations 
was that components Paf1 and Leo1 were selectively upregulated in C9+ post-mortem 
cortical tissue derived from FTD patients versus ALS patients. We hypothesized that this 
difference was the result of the tissue assayed. Specifically, RNA was extracted from the 
frontal cortex of individuals, while only FTD and FTD/ALS cases have cognitive deficits 
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associated with neurodegeneration in the frontal and temporal cortices. In contrast, ALS 
patients have motor deficits associated degeneration of upper and lower motor neurons 
in the motor cortex, brain stem, and spinal cord. Fittingly, brain scans of FTD versus ALS 
patients show different atrophy patterns (Boeve et al., 2012; Omer et al., 2017; 
Schönecker et al., 2018). In total, further investigations into why we saw a change in 
Paf1/Leo1 expression based on different patient diagnoses need to be explored. 
 Upregulation of PAF1C in frontal cortex tissue from FTD patients but not ALS 
patients could be the result of the type of tissue assayed and/or PAF1C gene variants. 
As mentioned, FTD affects neurons in the frontal and temporal cortices while ALS 
affects motor neurons. However, we analyzed Paf1/Leo1 levels in cortical tissue from 
both. Further investigations are needed to determine if PAF1C components are 
upregulated in tissue relevant to ALS: motor neurons in the spinal cord. Thorough 
investigations into PAF1 and LEO1 using patient data may also define any unique 
features underlying PAF1 and LEO1 that contribute to C9+ patients developing FTD 
versus ALS, thus defining them as disease modifiers. For example, expression of gene 
variants, isoforms, or other unique genetic features may underly these genes’ ability to 
mediate RNAPII-transcription of expanded G4C2-DNA. Examples of disease modifiers in 
ALS/FTD are ATXN2 and TMEM106B. ATXN2 can carry an intermediate-length CAG-
repeat associated with an increased risk for C9+ patients to develop ALS (van 
Blitterswijk et al., 2014a). TMEM106B can produce multiple mRNA variants, while 
homozygosity for the recessive variant rs3173615 may protect C9+ patients from 
developing FTD (van Blitterswijk et al., 2014b). In total, thorough clinical investigations 
are needed while comparing PAF1 and LEO1 in FTD versus ALS patients and 
considering factors such as tissue specificity, disease progression (discussed below), 
and disease severity. 
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An alternative hypothesis that could explain why Paf1 and Leo1 were 
upregulated in C9+ FTD cases but not C9+ ALS cases is that expression levels may 
change during disease progression. Interestingly, neuronal expression of (G4C2)149 
compared to (G4C2)2 in mice caused no change in Leo1 levels at 3 months of 
transgene expression (see Chapter 2: Fig. 2-5c and (Goodman et al., 2019a)). 
However, Leo1 was significantly upregulated after 6 months of transgene expression. 
This argues that PAF1C upregulation occurred in a progressive manner as a response 
to the toxic, expanded G4C2-transgene expression. In our fly investigations, we saw that 
PAF1C components were upregulated in brains of (G4C2)49-expressing flies before 
degenerative phenotypes are expected (see Chapter 2: Fig. 2-5a and (Goodman et al., 
2019a)). Specifically, we analyzed PAF1C expression after 16 days of transgene 
expression in adult fly neurons, which is before vacuole formation and animal death 
occurs. In total, these data argue that PAF1C expression may change over time while a 
more directed study is needed. A straightforward approach would be to define PAF1C 
expression with a time course in flies and mice. By comparing PAF1C levels to 
phenotypic data (e.g. lifespans, motor deficits, vacuole formation), one could define how 
PAF1C expression changes in response to (G4C2)30+ expression in neurons during 
early-, mid-, or late-stage disease progression.  
While the above hypotheses focus on potential direct roles Paf1 and Leo1 may 
be playing in defining if C9+ patients develop FTD versus ALS, I note that these proteins 
may play an indirect role. Importantly, PAF1C is a transcriptional regulator that acts on 
multiple RNAPII-regulated genes (Jaehning, 2010). Thus, while our data show that Paf1 
and Leo1 are upregulated in response to expanded (>30) G4C2-expression, its 
upregulation is likely to contribute to unique expression profiles in C9+ FTD patients and 
may affect disease relevant pathways (Cooper-Knock et al., 2015; Prudencio et al., 
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2015).  For example, expression of repetitive elements are increased in C9+ ALS/FTD 
compared to C9- ALS/FTD (Prudencio et al., 2017). PAF1C may further define 
differences between C9+ ALS and C9+ FTD patients in this pathway.  
Overall, directed studies are needed to further define PAF1C’s role in ALS/FTD 
while considering multiple factors such as tissue type, disease stage, and the 
supposition that different components of PAF1C may behave differently. 
 
Additional mechanistic studies 
In Chapter 2, we present compelling data that loss of PAF1C impacts expression from 
expanded G4C2-repeats using mice and yeast models. Importantly, Paf1 and Leo1 
seem to be of particular importance as their depletion selectively impacted expression 
from toxic (>30) repeats compared to inert (≤ 29) repeats in the fly. Additional 
investigations are needed to further define the mechanism(s) underlying these effects in 
human cells and C9+ disease.  
Specifically, the impact of downregulating PAF1C components on expression 
from an endogenous mutant C9orf72 gene would further define its role in mediating 
expression of >30 G4C2-repeat expansions. Our data used overexpression G4C2-
models that expressed the repeats in the absence of, or with minimal amounts of, the 
surrounding gene sequence in patients (see Chapter 2: Fig. 2-4 and (Goodman et al., 
2019a)). Additional studies are needed to define if loss of PAF1C components can 
disrupt expression from the endogenous C9orf72 gene harboring the G4C2-repeat 
expansion (>30). Utilizing C9+ versus control iPS cells and/or iPS neurons, one could 
downregulate expression of PAF1C components, particularly Paf1 and Leo1, using RNAi 
or CRISPR/Cas9. Then established quantitative reverse-transcriptase PCR (qPCR) 
assays would define if the depletion of these genes impacted RNA expression from the 
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C9orf72 gene (Kramer et al., 2016; Niblock et al., 2016). Such investigations should also 
consider if multiple PAF1C subunits need to be depleted to see strong effects. If G4C2-
expression is mediated by PAF1C in disease, one would expect that C9orf72-RNA 
transcripts would be reduced when these subunits are downregulated. This effect should 
only be seen in C9+ cells versus control cells if it were the result of the presence of the 
repeat expansion (>30).  
Optimization of the above studies would also allow for follow-up chromatin 
immunoprecipitation (ChIP) investigations. Specifically, if PAF1C is important for 
regulating RNAPII during transcription of expanded G4C2-repeats (>30), one would 
expect that when PAF1C subunits are downregulated that RNAPII’s ability to bind the 
C9orf72 gene would decrease. This effect should only be seen in C9+ cells versus 
control cells if it is a response to the presence of the G4C2-repeat expansion (>30). 
Studies should also consider: whether effects are unique to components Paf1 and Leo1, 
whether PAF1C recruitment to mutant-C9orf72 is independent of DSIF-activity, and 
whether full knockdown of PAF1C genes is needed to significantly impact G4C2-repeat 
expression. Last, in C9+-derived patient cells, we found that the PAF1C component, 
Leo1, is bound to the C9orf72-chromatin immediately downstream of the G4C2-repeat 
expansion (see Chapter 2: Fig. 2-6b and (Goodman et al., 2019a)). The specificity or 
enrichment of this binding to a C9orf72 gene harboring the repeat needs to be 
determined. 
Follow-up investigations could also explore the mechanism underlying PAF1C-
regulation of RNAPII during transcription of the G4C2-repeat expansion. For example, 
as discussed in Chapter 1, PAF1C may play a role in resolving G-quadruplexes and/or 
R-loops that may form as RNAPII moves across the G4C2-repeat expansion (Gerlach et 
al., 2017; Landsverk et al., 2019; Reddy et al., 2014; Shivji et al., 2018; Wahba et al., 
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2011). Note that R-loop formation by the C9orf72-mutant gene occurs in vivo and the 
PAF1C component, Paf1, can regulate R-loop formation in human cells (Esanov et al., 
2017; Shivji et al., 2018). Further, this could explain the selectivity of Paf1 and Leo1 to 
expanded repeats of >30 as one would expect a positive correlation between the repeat-
length and formation of these inhibitory secondary structures (Shivji et al., 2018). In total, 
targeted studies designed to define interactions of PAF1C to G4C2-repeat DNA in vitro, 
ex vivo, and/or in flies would determine if PAF1C activity on G4C2-transcription involved 
the secondary structures these repeats can form.  
PAF1C may not be acting alone to promote RNAPII-transcription across 
expanded G4C2-repeats as it can recruit factors meant to promote RNAPII-driven 
transcription (e.g. opening up the chromatin, recruiting RNA processing complexes) 
(Adelman et al., 2006; Jaehning, 2010). Interestingly, in our ~4000 gene screen we 
tested a number of relevant factors, the majority of which did not modify (G4C2)49-
toxicity at all or in a manner consistent with their involvement in G4C2-transcription, 
including TFIIS, P-TEFb, Chd1, Set1, and components of the CCR4-NOT complex. 
However, this is not an extensive list and more directed studies are required to 
determine if PAF1C function during G4C2-transcription requires, or is impacted by, 
additional proteins in C9+ disease. Among potential candidates, ATXN2 may be of 
particular interest (van Blitterswijk et al., 2014a). Recent publications reported that this 
gene prevents R-loop accumulation in GC-rich ribosomal DNA and PAF1C may also 
regulate RNAPI-transcription, suggesting that PAF1C and ATXN2 may interact to 
regulated transcription of GC-rich DNA (Abraham et al., 2016; Ostrowski et al., 2018; 
Zhang et al., 2010, 2010). As this would be a relatively novel role of ATXN2, typically 
considered a cytoplasmic RNA-binding protein that mediates stress-responses (Lee et 
al., 2018), extensive validation of a potential role in transcription would be needed while 
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considering how the insertion of an intermediate polyQ within the protein mediates its 
role in disease. 
Last, PAF1C may have effects in C9+ disease that are independent of its role as 
a transcriptional regulator of the G4C2-repeat expansion. As mentioned earlier, the 
upregulation of Paf1 and Leo1 may contribute to unique expression profiles of C9+ 
patients versus C9- patients (Cooper-Knock et al., 2015; Prudencio et al., 2015, 2017). 
In addition, if PAF1C is indeed able to resolve secondary structures formed by GC-rich 
DNA, then it may play a role in DNA damage reported to occur in C9+ disease (Konopka 
and Atkin, 2018). Accumulation of R-loops at GC-rich DNA/RNA during transcription can 
leave DNA vulnerable to breaks and induce cellular stress while the upregulation of 
Paf1/Leo1 may be a protective mechanism in C9+ tissue (Crossley et al., 2019; Esanov 
et al., 2017; Lin and Wilson, 2011; McKay and Cabrita, 2013). Last, instability of the 
G4C2-repeat expansion within patient cells is a pathological feature of C9+ disease 
(Vatsavayai et al., 2019). R-loop formation can stimulate expansion or contraction of 
disease-related repeat expansions (Nakamori et al., 2011; Reddy et al., 2014; Salinas-
Rios et al., 2011; Thys and Wang, 2015). A recent study implicated PAF1C in helping to 
remove stalled RNAPII at R-loops during replication stress, arguing that it may also 
regulate genomic instability in C9+ disease (Poli et al., 2016). Overall, directed 
investigations into how expression of expanded G4C2ǁG2C4 influences these pathways 
and whether upregulated PAF1C is involved would further elucidate the role of PAF1C in 
C9+ disease. 
 
Candidate G4C2-RAN translation factors 
Herein, we developed an important, novel G4C2-fly model that includes 114bp intronic 
sequence found upstream of the G4C2-repeat in C9+ patients, thus putting the repeat in 
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a more patient-relevant context (see Chapter 3: Fig. 3-1 and (Goodman et al., 2019b)). 
Further, the inclusion of a GFP tag within the GR reading frame makes this unique 
model a valuable tool for studies on toxic GR-dipeptides produced from a G4C2-RNA in 
vivo. Using this model, an unbiased, targeted screen was performed to identify 
translation factors whose depletion caused reduced expression of the GR-GFP dipeptide 
from G4C2-RNA (see Chapter 3: Fig. 3-2 and (Goodman et al., 2019b)). To my 
knowledge, this represents the first in vivo screen for potential RAN-translation factors in 
disease, encompassing 48 of 56 (86%) known translation factors in Drosophila 
(Marygold et al., 2017). From this screen, 11 factors were identified that may mediate 
expression of toxic GR-dipeptides in G4C2-expressing models. As very little is currently 
known about the mechanisms underlying G4C2-RAN translation, the results from this 
screen will, undoubtedly, be of value to the scientific community as additional 
investigations are pursued (Nguyen et al., 2019). While we focused on two of these, 
eIF4B and eIF4H (discussed below), additional investigations into these other translation 
factors would further define them as RAN-translation factors. Aside from their role in 
RAN-translation, recent studies have also implicated the toxic GR-dipeptide in 
translation dysfunctions in C9+ disease (Hartmann et al., 2018; Zhang et al., 2018). 
Thus, as our screen also tested translation factors for their effects on toxicity caused by 
the GR-dipeptide, independently from a G4C2-RNA, we further highlighted potential 
factors involved in GR-associated disease mechanisms (see Appendix 3: Table S3-2 
and (Goodman et al., 2019b)). Validating our data, eIF3B (also known as eIF3η) was 
previously shown to interact with GR-dipeptides while our screen revealed that loss of 
this factor could enhance GR-toxicity in the fly (Zhang et al., 2018).  
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Our focused investigations into eIF4B and eIF4H offers the first evidence that 
these two translation factors are players in G4C2-RAN translation (see Chapter 3: Fig. 
3-4, 3-5 and (Goodman et al., 2019b)). However, additional investigations are needed to 
fully define their role in this mechanism. Specifically, studies utilizing antibodies specific 
to each of the 3 sense-strand associated dipeptides – GA, GR, GP – would show that 
depleted eIF4B and eIF4H could impact expression of GR dipeptides, independent of 
the GFP tag, and whether this was specific to the GR-reading frame in G4C2-expressing 
flies. Ensuing investigations should use human cells, ideally C9+-derived iPS cells 
and/or neurons, to determine if depletion of eIF4B alone, eIF4H alone, or co-depletion of 
these factors (using RNAi or CRISPR/Cas9) could impact dipeptide expression from an 
endogenous mutant C9orf72-gene. Additional variables that should be considered are: 
the impact of stress on translation mechanisms, whether loss of these factors causes a 
global reduction in translation, the impact of age, and tissue specificity. Of these, the 
impact of stress is of particular importance as G4C2-RAN translation may be promoted 
by the integrated stress response (Cheng et al., 2018; Green et al., 2017; Tabet et al., 
2018). Also, a recent manuscript reported the levels of dipeptide varies between cell 
types and that mechanisms specific to neurons may impact G4C2-RAN translation 
(Westergard et al., 2019).  
In Chapter 3, we also show that eIF4H is downregulated in C9+-derived patient 
cells and in C9+ ALS/FTD post-mortem cerebellar tissue (see Chapter 3: Fig. 3-6 and 
(Goodman et al., 2019b)). The simplest hypothesis is that this was a protective response 
by cells as reducing expression of this translation factor may help to reduce expression 
of toxic GR-dipeptide. However, eIF4H’s downregulation could also be the response of a 
more complicated process since it may be sequestered by G4C2-RNA foci (Cooper-
Knock et al., 2014; Haeusler et al., 2014; Satoh et al., 2014). Thus, cells may mistakenly 
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sense that there is plenty of eIF4H available and thus downregulate the gene’s 
expression. However, the eIF4H that is within the cell is, in fact, unavailable to perform 
its normal duties as it is sequestered by G4C2-RNA. Directed investigations are needed 
to define which of these pathways may be occurring in C9+ disease. While it may be 
difficult to differentiate these mechanisms, confirmation that eIF4H is sequestered into 
G4C2-RNA foci, as is predicted by in vitro data, would add to the possibility that the 
more complicated hypothesis is at play. eIF4H could also be disrupted through other 
mechanisms independent of direct interactions with G4C2-RNA (e.g. mis-localization). 
Overall, this may put eIF4H in a unique position to couple RNA dysregulation in disease 
to RAN-translation. Aside from this, depletion of eIF4B and eIF4H had previously been 
reported to induce stress granule formation ex vivo (Mokas et al., 2009). Thus, the 
depletion of eIF4H may have multiple implications in C9+ disease, such as linking G4C2-
disease mechanisms to the onset of TDP-43 pathology (Chew et al., 2015; McGurk et 
al., 2018; Zhang et al., 2018).  
 
Other repeat diseases 
Thus far, I have focused on the role of PAF1C and identified translation factors in C9+ 
ALS/FTD that harbor a hexanucleotide repeat expansion of >30 G4C2. However, the 
identified mechanisms described that mediate transcription/translation from G4C2-repeat 
RNA may also impact other nucleotide-repeat expansions. There are multiple examples 
of GC-rich repeat expansions associated with neurodegenerative disease (ND), 
including: CAG-repeats found in polyglutamine diseases (polyQ diseases are a 
heterogenous group of NDs that includes Huntington’s disease (HD) and multiple spinal 
cerebellar ataxias (SCAs)), CTG-repeats found in myotonic dystrophy 1 (DM1), CCTG-
repeats found in myotonic dystrophy 2 (DM2), and CGG-repeats found in Fragile-X-
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associated tremor and ataxia syndrome (FXTAS) (Chen et al., 2018; Krzyzosiak et al., 
2012; Nguyen et al., 2019; Todd Peter K. and Paulson Henry L., 2010). The location of 
the expanded repeat within the afflicted genes can vary amid promotors (e.g. CAG-
repeat in SCA12), 5’UTR of genes (e.g. FXTAS), introns (e.g. DM2), exons (e.g. CAG-
repeat multiple polyQ diseases), and 3’ UTR of genes (e.g. DM1). Based on location, the 
repeats can cause gain-of-function toxicity, such as that described for G4C2-repeats 
herein, or can disrupt the normal function of the afflicted gene/gene product causing 
loss-of-function disease mechanisms.  
Unique transcriptional machinery required to promote RNAPII-activity as it moves 
through GC-rich repeat expansions may be common among diseases. For example, the 
DSIF complex has been suggested to regulate RNAPII-transcription of multiple repetitive 
DNA elements, including (G4C2)8+, (CAG)99+, (CTG)105, (CAA)90 and (AAA)24+ 
sequences (see Chapter 2 and (Cheng et al., 2015; Goodman et al., 2019a; Kramer et 
al., 2016; Liu et al., 2012)). Thus, it is reasonable to expand investigations of PAF1C to 
additional repeat-associated diseases. In particular, fly studies described in Chapter 2 
can be extended to existing fly models that harbor CAG, CTG, or CTGG-repeat 
expansions (Shieh and Bonini, 2011; Yu et al., 2015b).  One could define whether 
downregulation of PAF1C components, particularly Paf1 and Leo1, using RNAi can 
suppress toxicity caused by the expression of these repeats in the fly. Mechanistic 
studies would also reveal if the RNA-transcript levels produced from the transgenes are 
reduced with knockdown of PAF1C components and if this knockdown disrupts RNAPII-
binding to the transgene. Notably, interactions could depend on unique secondary 
structures formed by these repeats as they are predicted to form G-quadruplexes, R-
loops, and hairpins like G4C2-DNA, which may need to be resolved during transcription 
(Childs-Disney et al., 2014; Cruchten et al., 2019; Freudenreich, 2018; Krzyzosiak et al., 
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2012; Reddy et al., 2014). Overall, these investigations would explore if PAF1C plays a 
global role in multiple repeat-associated diseases while increasing our understandings of 
its function in C9+ ALS/FTD. 
 In addition to G4C2-repeats, RNA-transcripts produced by the mentioned repeat-
expansions can also undergo RAN-translation. Of note, CAG repeats can produce three 
peptides, depending on the reading frame (Zu et al., 2011). Interestingly, peptide 
production was dependent on repeat-length and the RNA’s ability to form hairpin 
structures, like ones potentially formed by G4C2 RNA (Su et al., 2014; Wang et al., 
2019). Moreover, CGG-repeats can also produce peptides through mechanisms 
independent of an AUG-start codon (Kearse et al., 2016; Todd et al., 2013). Recently, 
Todd and colleagues drew parallels between CGG- and G4C2-RAN translation 
mechanisms, highlighting that both require eIF4E and eIF4A (Green et al., 2017; Kearse 
et al., 2016). Intriguingly, our studies highlight eIF4B and eIF4H for playing a role in 
G4C2-RAN translation (see Chapter 3 and (Goodman et al., 2019b)) while these two 
factors act on eIF4A to promote unwinding of secondary structures formed by RNA 
(Rogers et al., 2001; Rozovsky et al., 2008; Nielsen et al., 2011; Sun et al., 2012; Harms 
et al., 2014; García-García et al., 2015; Vaysse et al., 2015; Sen et al., 2016). This 
activity by eIF4B and eIF4H is particularly important at highly structured, repetitive RNA 
sequences (Sen et al., 2016; Sun et al., 2012). Thus, it is reasonable to hypothesize that 
these two factors may also play a role in CGG- and/or CAG-RAN translation. The 
connection between G4C2-, CGG-, and CAG-RAN translation may be their ability to 
form unique hairpin structures (Krzyzosiak et al., 2012; Wang et al., 2019). In total, while 
directed studies are needed to define the role of eIF4B, eIF4H, and other potential 
translation factors we identified in our screen as G4C2-RAN translation factors (see 
Chapter 3 and (Goodman et al., 2019b)), ensuing investigations that expand findings to 
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other repeat-RNAs that undergo RAN-translation may help to define common 
mechanisms underlying this unique process. 
 
Closing statements 
The devastation of neurodegenerative diseases impacts individuals and society, pushing 
the need for scientists and clinicians to rapidly elucidate disease mechanisms while 
innately uncovering potential therapeutic targets. The aberrant expression of a 
hexanucleotide expansion of >30 G4C2-repeats within C9orf72 is currently the most 
prominent known mutation in familial ALS/FTD. Accumulating evidence suggests that 
this mutation confers toxicity through gain-of-function mechanisms, a finding that may 
prove advantageous in terms of developing an effective therapy. In fact, research is 
currently underway to define pharmacological reagents, such as small molecules and 
antisense oligonucleotides, that may be able to disrupt G4C2-associated disease 
mechanisms when administered to patients (Donnelly et al., 2013; Hu et al., 2016; Jiang 
et al., 2016; Perego et al., 2018; Simone et al., 2018; Su et al., 2014; Wang et al., 2019; 
Zamiri et al., 2014). While promising, there are limitations to these current approaches, 
such as their inability to simultaneously target both sense- and antisense- transcripts 
produced from the G4C2ǁG2C4 DNA in patients (Jiang and Cleveland, 2016). 
Accordingly, inhibiting the transcription or translation of mutant-C9orf72 in patients may 
be a more effective approach. Recent work has proposed using epigenetic modifiers to 
shut down the gene (Belzil et al., 2014; Liu et al., 2014; McMillan et al., 2015; Russ et 
al., 2015; Xi et al., 2013, 2014, 2015; Zeier et al., 2015). Alternatively, herein we define 
unique transcription and translation factors that may be important for the expression of 
the G4C2ǁG2C4-repeat expansion in disease. Speculatively, inhibiting Paf1 or Leo1 of 
PAF1C may be an acceptable approach to downregulating bidirectional transcription of 
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mutant-C9orf72. Our data shows that these components are selective to >30 G4C2-
repeats, unlike previously proposed Spt4 (see Chapter 2 and (Goodman et al., 2019a; 
Kramer et al., 2016; Naguib et al., 2019)). Further, partial inhibition of these genes may 
impact G4C2-transcripton while being well tolerated for cell viability. Note that PAF1C 
only regulates expression from a subset of genes and mice that are heterozygous null 
for Paf1 or Leo1 are relatively normal (Porter et al., 2002; Mueller et al., 2004; Penheiter 
et al., 2005; Cao et al., 2015; Yang et al., 2016; Fischl et al., 2017; Meehan et al., 2017; 
Ringwald et al., 2011; Skarnes et al., 2011).  
Overall, the included studies help to uncover gain-of-function disease 
mechanisms in C9orf72-associated ALS/FTD while highlighting machinery important for 
G4C2ǁG2C4 DNA/RNA expression in the context of disease. These findings have the 
potential to elucidate mechanisms pertinent to multiple repeat-associated diseases.  
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80S ribosome (subunits: 40S and 60S ribosomes) 
ALS (amyotrophic lateral sclerosis) 
ASO (antisense oligonucleotides) 
C9- ALS/FTD (ALS/FTD cases lacking the G4C2 expansion in C9orf72) 
C9+ ALS/FTD (ALS/FTD cases harboring the G4C2 expansion in C9orf72) 
CAG (expanded (CAG)30+ mutation found in multiple neurological disorders) 
CDC73 (component of PAF1C) 
Ctr9 (component of PAF1C) 
DPR (dipeptide repeats; includes GA, GR, GP, PA, PR) 
DSIF (DRB-sensitivity-inducing transcription factor complex; subunits: Spt4 and Spt5) 
eIF (eukaryotic initiation factor) 
eIF4F complex (subunits: eIF4E, eIF4G, eIF4A) 
FTD (frontotemporal degeneration) 
G4C2 (expanded (GGGGCC)30+ mutation found within C9orf72) 
G4C2ǁG2C4 (sense-G4C2 and antisense-G2C4; bidirectional gene products from the 
G4C2 mutation within C9orrf72) 
GA (glycine-alanine dipeptide; RAN-translation product from sense-G4C2 RNA) 
GC-rich (DNA or RNA enriched for guanine and cytosine bases) 
GFP (green fluorescent protein) 
GP (glycine-proline dipeptide; RAN-translation product from sense-G4C2 and antisense-
G2C4 RNA) 
GR (glycine-arginine dipeptide; RAN-translation product from sense-G4C2 RNA; highly 
toxic) 
IRES-translation (internal ribosome entry-site translation) 
ISR (integrated stress response) 
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Leo1 (component of PAF1C) 
LDS (“leader sequence”; truncated 5’ UTR derived from the 114bp sequence found 
upstream of G4C2 in intron 1 of C9orf72 in C9+ ALS/FTD patients) 
NELF (Negative Elongation Factor) 
P-TEFb (positive elongation factor-b; also called CDK9) 
PA (proline-alanine dipeptide; RAN-translation product from antisense-G2C4 RNA) 
Paf1 (component of PAF1C) 
PAF1C (Polymerase II Associating Factor 1 transcription elongation complex; subunits: 
Paf1, Leo1, CDC73, Ctr9, Rtf1) 
PIC (preinitiation complex; subunits: 40s ribosome, eIF1, eIF1A, eIF5, eIF3 complex) 
poly(A) tail (3’ mRNA modification of a polyadenylated tail) 
PR (proline-arginine dipeptide; RAN-translation product from antisense-G2C4 RNA; 
highly toxic) 
qPCR (quantitative reverse transcribed polymerase chain reaction; also qRT-PCR) 
RAN-translation (Repeat Associated Non-AUG translation; also RANT) 
RBP (RNA binding protein) 
RNAPII (RNA polymerase II) 
RRM (RNA recognition motif) 
Rtf1 (component of PAF1C) 
Spt4 (component of DSIF) 
Spt5 (component of DSIF) 
TDP-43 (Tar DNA-binding protein -43) 
UTR (untranslated-region) 
WB (western immunoblot) 
WT (wild-type) 
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Chapter 2: Supplementary tables  
 
Table S2-1: detailed sampling/ reproducibility/ statistics 
Fig. 1b: (no statistics) 
Sample size (n) 30 per sample  
Independent Expt. 
Runs 
2 runs 
Data point 
Total repeat length calculated from PCR-product size minus non-G4C2 
surrounding sequence and divided by 6 for 6 nucleotides per repeat  
Fig. 1c: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
0.1391 3 0.04637 
F (3, 46) 
= 0.9539 
P=0.4225   
Residual (within 
columns) 
2.236 46 0.04861       
Total 2.375 49         
Sample size (n) 30 per sample 
Independent Expt. 
Runs 
3-5 runs w/ biological triplicates 
Data point normalized band density per well 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. Significant? 
Summar
y 
Adjusted P 
Value 
  
(G4C2)8 vs. 
(G4C2)29 -0.1222 
-0.3525 to 
0.1080 No ns 0.4856 
  
(G4C2)8 vs. 
(G4C2)49 (II) 
-
0.09463 
-0.3249 to 
0.1356 No ns 0.6839 
  
(G4C2)8 vs. 
(G4C2)49 (III) 0.01956 
-0.2107 to 
0.2498 No ns 0.9956 
  
(G4C2)29 vs. 
(G4C2)49 (II) 0.02758 
-0.2027 to 
0.2578 No ns 0.9880 
  
(G4C2)29 vs. 
(G4C2)49 (III) 0.1418 
-0.08847 
to 0.3720 No ns 0.3566 
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(G4C2)49 (II) vs. 
(G4C2)49 (III) 0.1142 
-0.1160 to 
0.3444 No ns 0.5428 
  
GO-term analyses (Fig. 1g-h, Fig. 2c-d, and Sup Fig. 1d) 
p-value cut-off > 0.001           
Enrichment score 
cut-off 
< 3.00           
Fig. 3b: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
15173 5 3035 
F (5, 35) 
= 30.19 
P<0.0001   
Residual (within 
columns) 
3518 35 100.5       
Total 18691 40         
Sample sizes (n) 
Control (9); Paf1 RNAi (7); Leo1 RNAi (6), CDC73 RNAi (8); Ctr9 RNAi 
(6); Rtf1 RNAi (5) 
Independent Expt. 
Runs 
2 with >4 animals per genotype 
Data point retina depth from 1 eye per animal 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. Paf1 -31.02 
-46.25 to -
15.8 
Yes **** <0.0001   
Control vs. Leo1 -33.82 
-49.75 to -
17.9 
Yes **** <0.0001   
Control vs. CDC73 -49.71 
-64.39 to -
35.03 
Yes **** <0.0001   
Control vs. Ctr9 -55.68 
-71.61 to -
39.76 
Yes **** <0.0001   
Control vs. Rtf1 -28.4 
-45.25 to -
11.55 
Yes *** 0.0002   
Paf1 vs. Leo1 -2.799 
-19.61 to 
14.01 
No ns 0.9958   
Paf1 vs. CDC73 -18.68 
-34.32 to -
3.048 
Yes * 0.0115   
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Paf1 vs. Ctr9 -24.66 
-41.47 to -
7.851 
Yes ** 0.0012   
Paf1 vs. Rtf1 2.621 
-15.07 to 
20.31 
No ns 0.9976   
Leo1 vs. CDC73 -15.89 
-32.2 to 
0.431 
No ns 0.0601   
Leo1 vs. Ctr9 -21.86 
-39.3 to -
4.418 
Yes ** 0.0072   
Leo1 vs. Rtf1 5.42 
-12.87 to 
23.71 
No ns 0.9457   
CDC73 vs. Ctr9 -5.975 
-22.29 to 
10.34 
No ns 0.8766   
CDC73 vs. Rtf1 21.3 
4.081 to 
38.53 
Yes ** 0.0082   
Ctr9 vs. Rtf1 27.28 
8.986 to 
45.57 
Yes *** 0.001   
Fig. 3d: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
449.3 5 89.87 
F (5, 35) 
= 2.209 
P=0.0754   
Residual (within 
columns) 
1424 35 40.68       
Total 1873 40         
Sample sizes (n) 
Control (9); Paf1 RNAi (5); Leo1 RNAi (9), CDC73 RNAi (9); Ctr9 RNAi 
(5); Rtf1 RNAi (4) 
Independent Expt. 
Runs 
2 with >4 animals per genotype 
Data point retina depth from 1 eye per animal 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. Paf1 -1.877 
-12.6 to 
8.843 
No ns 0.9947   
Control vs. Leo1 -9.136 
-18.2 to -
0.0763 
Yes * 0.0471   
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Control vs. CDC73 -5.15 
-14.21 to 
3.91 
No ns 0.5328   
Control vs. Ctr9 -7.211 
-17.93 to 
3.509 
No ns 0.3483   
Control vs. Rtf1 -4.944 
-16.49 to 
6.606 
No ns 0.7884   
Paf1 vs. Leo1 -7.26 
-17.98 to 
3.46 
No ns 0.3411   
Paf1 vs. CDC73 -3.273 
-13.99 to 
7.447 
No ns 0.9387   
Paf1 vs. Ctr9 -5.334 
-17.49 to 
6.822 
No ns 0.7709   
Paf1 vs. Rtf1 -3.067 
-15.96 to 
9.826 
No ns 0.9786   
Leo1 vs. CDC73 3.986 
-5.074 to 
13.05 
No ns 0.769   
Leo1 vs. Ctr9 1.926 
-8.794 to 
12.65 
No ns 0.994   
Leo1 vs. Rtf1 4.193 
-7.357 to 
15.74 
No ns 0.8805   
CDC73 vs. Ctr9 -2.061 
-12.78 to 
8.659 
No ns 0.9918   
CDC73 vs. Rtf1 0.2064 
-11.34 to 
11.76 
No ns >0.9999   
Ctr9 vs. Rtf1 2.267 
-10.63 to 
15.16 
No ns 0.9946   
Fig. 3e: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 14205 5 2841 
F (5, 29) 
= 107.9 P<0.0001 
  
Residual (within 
columns) 763.8 29 26.34     
  
Total 14969 34         
Sample sizes (n) 
Control (117); Paf1 RNAi (98); Leo1 RNAi (108), CDC73 RNAi (103); Ctr9 
RNAi (120); Rtf1 RNAi (115) 
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Independent Expt. 
Runs 
2 with >90 animals per genotype 
Data point 
mean % animals that climb per tube; 19+/-2.1 animals per tube for each 
genotype 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. dRtf1 -55.67 
-64.7 to -
46.63 Yes **** <0.0001   
Control vs. dCDC73 -54.83 
-63.87 to -
45.8 Yes **** <0.0001   
Control vs. dLeo1 -52.17 
-61.2 to -
43.13 Yes **** <0.0001   
Control vs. dPaf1 -51.33 
-60.81 to -
41.86 Yes **** <0.0001   
Control vs. dCtr9 -52.17 
-61.2 to -
43.13 Yes **** <0.0001   
dRtf1 vs. dCDC73 0.8333 
-8.199 to 
9.866 No ns 0.9997   
dRtf1 vs. dLeo1 3.5 
-5.533 to 
12.53 No ns 0.8421   
dRtf1 vs. dPaf1 4.333 
-5.14 to 
13.81 No ns 0.7299   
dRtf1 vs. dCtr9 3.5 
-5.533 to 
12.53 No ns 0.8421   
dCDC73 vs. dLeo1 2.667 
-6.366 to 
11.7 No ns 0.9434   
dCDC73 vs. dPaf1 3.5 
-5.974 to 
12.97 No ns 0.8665   
dCDC73 vs. dCtr9 2.667 
-6.366 to 
11.7 No ns 0.9434   
dLeo1 vs. dPaf1 0.8333 
-8.64 to 
10.31 No ns 0.9998   
dLeo1 vs. dCtr9 0 
-9.033 to 
9.033 No ns >0.9999   
dPaf1 vs. dCtr9 -0.8333 
-10.31 to 
8.64 No ns 0.9998   
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Fig. 3f: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 38.13 6 6.354 
F (6, 56) 
= 15.66 P<0.0001 
  
Residual (within 
columns) 22.73 56 0.4059     
  
Total 60.86 62         
Sample sizes (n) 
(G4C2)0 (9); (G4C2)49 (10); Paf1 RNAi (10); Leo1 RNAi (7), CDC73 
RNAi (10); Ctr9 RNAi (8); Rtf1 RNAi (9) 
Independent Expt. 
Runs 
2 with >5 animals per genotype 
Data point vacuole score for 1 animal 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
(G4C2)49 vs. dPaf1 0.4 
-0.4713 to 
1.271 No ns 0.7974   
(G4C2)49 vs. dLeo1 0.4 
-0.5601 to 
1.36 No ns 0.8608   
(G4C2)49 vs. 
dCDC73 1.3 
0.4287 to 
2.171 Yes *** 0.0005   
(G4C2)49 vs. dCtr9 1.025 
0.1009 to 
1.949 Yes * 0.0205   
(G4C2)49 vs. dRtf1 1.622 
0.7271 to 
2.517 Yes **** <0.0001   
(G4C2)49 vs. 
(G4C2)0 2.4 
1.505 to 
3.295 Yes **** <0.0001   
dPaf1 vs. dLeo1 0 
-0.9601 to 
0.9601 No ns >0.9999   
dPaf1 vs. dCDC73 0.9 
0.02871 to 
1.771 Yes * 0.0386   
dPaf1 vs. dCtr9 0.625 
-0.2991 to 
1.549 No ns 0.3854   
dPaf1 vs. dRtf1 1.222 
0.3271 to 
2.117 Yes ** 0.0019   
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dPaf1 vs. (G4C2)0 2 
1.105 to 
2.895 Yes **** <0.0001   
dLeo1 vs. dCDC73 0.9 
-0.06012 
to 1.86 No ns 0.08   
dLeo1 vs. dCtr9 0.625 
-0.3833 to 
1.633 No ns 0.4918   
dLeo1 vs. dRtf1 1.222 
0.2404 to 
2.204 Yes ** 0.0061   
dLeo1 vs. (G4C2)0 2 
1.018 to 
2.982 Yes **** <0.0001   
dCDC73 vs. dCtr9 -0.275 
-1.199 to 
0.6491 No ns 0.9695   
dCDC73 vs. dRtf1 0.3222 
-0.5729 to 
1.217 No ns 0.9253   
dCDC73 vs. 
(G4C2)0 1.1 
0.2048 to 
1.995 Yes ** 0.0071   
dCtr9 vs. dRtf1 0.5972 
-0.3495 to 
1.544 No ns 0.4703   
dCtr9 vs. (G4C2)0 1.375 
0.4283 to 
2.322 Yes *** 0.0008   
dRtf1 vs. (G4C2)0 0.7778 
-0.1406 to 
1.696 No ns 0.1489   
Fig. 3g: Log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test 
Sample Sizes (n) Control (198); CDC73 RNAi (197) 
Independent Expt Runs 2 repeats with >150 animals per genotype 
Test 
Chi 
square 
df P value 
Significa
nt? 
Summary 
95% 
CI of 
ratio 
Log-rank (Mantel-
Cox)  
62.43 1 <0.0001 Yes **** 
0.818
5 to 
1.222/
0.818
5 to 
1.222 
Gehan-Breslow-
Wilcoxon  
49.24 1 <0.0001 Yes **** 
Fig. 4a, top: 2-way ANOVA 
ANOVA table, Top SS DF MS 
F (DFn, 
DFd) 
P value   
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Interaction 0.7888 12 0.06573 
F (12, 
126) = 
2.309 
P=0.0107   
Row Factor 4.781 6 0.7969 
F (6, 
126) = 
28 
P<0.0001   
Column Factor 1.222 2 0.6109 
F (2, 
126) = 
21.46 
P<0.0001   
Residual 3.586 126 0.02846       
Sample size (n) 25 
Independent Expt. 
Runs 
2 for (G4C2)8 and (G4C2)29; 3 for (G4C2)49; all runs included biological 
triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value   
Control 
(G4C2)8 vs. 
(G4C2)29 
-
0.02547 
-0.2364 to 
0.1854 
No ns 0.9558   
(G4C2)8 vs. 
(G4C2)49 
-
0.02856 
-0.2172 to 
0.1601 
No ns 0.9314   
(G4C2)29 vs. 
(G4C2)49 
-
0.00308
8 
-0.214 to 
0.2078 
No ns 0.9993   
dSpt4 
(G4C2)8 vs. 
(G4C2)29 
-0.0468 
-0.2778 to 
0.1842 
No ns 0.8807   
(G4C2)8 vs. 
(G4C2)49 
0.1073 
-0.1036 to 
0.3182 
No ns 0.4512   
(G4C2)29 vs. 
(G4C2)49 
0.1541 
-0.05676 
to 0.365 
No ns 0.1968   
dPaf1 
(G4C2)8 vs. 
(G4C2)29 
0.00604
8 
-0.225 to 
0.2371 
No ns 0.9979   
(G4C2)8 vs. 
(G4C2)49 
0.2943 
0.06331 to 
0.5254 
Yes ** 0.0085   
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(G4C2)29 vs. 
(G4C2)49 
0.2883 
0.05727 to 
0.5193 
Yes * 0.0102   
dLeo1 
(G4C2)8 vs. 
(G4C2)29 
0.1915 
-0.03957 
to 0.4225 
No ns 0.1251   
(G4C2)8 vs. 
(G4C2)49 
0.4914 
0.2805 to 
0.7023 
Yes **** <0.0001   
(G4C2)29 vs. 
(G4C2)49 
0.3 
0.08907 to 
0.5109 
Yes ** 0.0028   
dCDC73 
(G4C2)8 vs. 
(G4C2)29 
-
0.06161 
-0.2926 to 
0.1694 
No ns 0.8025   
(G4C2)8 vs. 
(G4C2)49 
0.1718 
-0.03906 
to 0.3827 
No ns 0.1338   
(G4C2)29 vs. 
(G4C2)49 
0.2334 
0.02256 to 
0.4443 
Yes * 0.0261   
dCtr9 
(G4C2)8 vs. 
(G4C2)29 
-0.1007 
-0.3317 to 
0.1303 
No ns 0.5568   
(G4C2)8 vs. 
(G4C2)49 
0.1994 
-0.01145 
to 0.4103 
No ns 0.068   
(G4C2)29 vs. 
(G4C2)49 
0.3002 
0.08928 to 
0.5111 
Yes ** 0.0028   
dRtf1 
(G4C2)8 vs. 
(G4C2)29 
-
0.00819
5 
-0.2392 to 
0.2228 
No ns 0.9961   
(G4C2)8 vs. 
(G4C2)49 
0.05067 
-0.1602 to 
0.2616 
No ns 0.8364   
(G4C2)29 vs. 
(G4C2)49 
0.05886 
-0.152 to 
0.2698 
No ns 0.7859   
Fig. 4a, bottom, (G4C2)8: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
1.898 6 0.3163 
F (6, 38) 
P<0.0001   
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columns) = 13.99 
Residual (within 
columns) 0.8592 38 0.02261     
  
Total 2.757 44         
Independent Expt. 
Runs 
(same data as 4a, top) 
Data point (same data as 4a, top) 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. dSpt4 0.3869 
0.1403 to 
0.6335 Yes *** 0.0004   
Control vs. dPaf1 0.08589 
-0.1607 to 
0.3325 No ns 0.9291   
Control vs. dLeo1 0.0158 
-0.2308 to 
0.2624 No ns >0.9999   
Control vs. dCDC73 0.3731 
0.1265 to 
0.6196 Yes *** 0.0006   
Control vs. dCtr9 0.3926 
0.146 to 
0.6391 Yes *** 0.0003   
Control vs. dRtf1 0.5456 
0.299 to 
0.7921 Yes **** <0.0001   
dSpt4 vs. dPaf1 -0.301 
-0.5711 to 
-0.03088 Yes * 0.0206   
dSpt4 vs. dLeo1 -0.3711 
-0.6412 to 
-0.101 Yes ** 0.0022   
dSpt4 vs. dCDC73 
-
0.01383 
-0.284 to 
0.2563 No ns >0.9999   
dSpt4 vs. dCtr9 
0.00566
7 
-0.2645 to 
0.2758 No ns >0.9999   
dSpt4 vs. dRtf1 0.1587 
-0.1115 to 
0.4288 No ns 0.5385   
dPaf1 vs. dLeo1 
-
0.07009 
-0.3402 to 
0.2 No ns 0.9828   
dPaf1 vs. dCDC73 0.2872 
0.01705 to 
0.5573 Yes * 0.0309   
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dPaf1 vs. dCtr9 0.3067 
0.03655 to 
0.5768 Yes * 0.0173   
dPaf1 vs. dRtf1 0.4597 
0.1895 to 
0.7298 Yes *** 0.0001   
dLeo1 vs. dCDC73 0.3573 
0.08713 to 
0.6274 Yes ** 0.0035   
dLeo1 vs. dCtr9 0.3768 
0.1066 to 
0.6469 Yes ** 0.0018   
dLeo1 vs. dRtf1 0.5298 
0.2596 to 
0.7999 Yes **** <0.0001   
dCDC73 vs. dCtr9 0.0195 
-0.2506 to 
0.2896 No ns >0.9999   
dCDC73 vs. dRtf1 0.1725 
-0.09762 
to 0.4426 No ns 0.4391   
dCtr9 vs. dRtf1 0.153 
-0.1171 to 
0.4231 No ns 0.5803   
Fig. 4a, bottom, (G4C2)29: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value 
Indep
enden
t Expt. 
Runs 
Treatment (between 
columns) 
1.193 6 0.1989 
F (6, 35) 
= 6.968 P<0.0001 
2-3 w/ 
triplica
tes 
Residual (within 
columns) 0.9991 35 0.02855     
  
Total 2.193 41         
Independent Expt. 
Runs 
(same data as 4a, top) 
Data point (same data as 4a, top) 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. dSpt4 0.3656 
0.06063 to 
0.6705 Yes * 0.0104   
Control vs. dPaf1 0.1174 
-0.1875 to 
0.4223 No ns 0.8881   
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Control vs. dLeo1 0.2327 
-0.0722 to 
0.5377 No ns 0.2347   
Control vs. dCDC73 0.3369 
0.03198 to 
0.6418 Yes * 0.0224   
Control vs. dCtr9 0.3173 
0.01237 to 
0.6222 Yes * 0.0369   
Control vs. dRtf1 0.5628 
0.2579 to 
0.8678 Yes **** <0.0001   
dSpt4 vs. dPaf1 -0.2482 
-0.5531 to 
0.05677 No ns 0.1751   
dSpt4 vs. dLeo1 -0.1328 
-0.4378 to 
0.1721 No ns 0.8177   
dSpt4 vs. dCDC73 
-
0.02865 
-0.3336 to 
0.2763 No ns >0.9999   
dSpt4 vs. dCtr9 
-
0.04826 
-0.3532 to 
0.2567 No ns 0.9988   
dSpt4 vs. dRtf1 0.1973 
-0.1077 to 
0.5022 No ns 0.4195   
dPaf1 vs. dLeo1 0.1153 
-0.1896 to 
0.4202 No ns 0.8961   
dPaf1 vs. dCDC73 0.2195 
-0.08542 
to 0.5244 No ns 0.2962   
dPaf1 vs. dCtr9 0.1999 
-0.105 to 
0.5048 No ns 0.4038   
dPaf1 vs. dRtf1 0.4454 
0.1405 to 
0.7504 Yes ** 0.0011   
dLeo1 vs. dCDC73 0.1042 
-0.2007 to 
0.4091 No ns 0.9333   
dLeo1 vs. dCtr9 0.08457 
-0.2204 to 
0.3895 No ns 0.9752   
dLeo1 vs. dRtf1 0.3301 
0.02517 to 
0.635 Yes * 0.0267   
dCDC73 vs. dCtr9 
-
0.01961 
-0.3245 to 
0.2853 No ns >0.9999   
dCDC73 vs. dRtf1 0.2259 
-0.07901 
to 0.5308 No ns 0.2652   
217 
 
dCtr9 vs. dRtf1 0.2455 
-0.0594 to 
0.5505 No ns 0.1843   
Fig. 4a, bottom, (G4C2)49: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 2.59 6 0.4317 
F (6, 53) 
= 13.24 P<0.0001 
  
Residual (within 
columns) 1.728 53 0.03261     
  
Total 4.318 59         
Independent Expt. 
Runs 
(same data as 4a, top) 
Data point (same data as 4a, top) 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. dSpt4 0.5228 
0.2619 to 
0.7836 Yes **** <0.0001   
Control vs. dPaf1 0.4088 
0.1171 to 
0.7004 Yes ** 0.0014   
Control vs. dLeo1 0.5358 
0.2749 to 
0.7966 Yes **** <0.0001   
Control vs. dCDC73 0.5734 
0.3126 to 
0.8343 Yes **** <0.0001   
Control vs. dCtr9 0.6206 
0.3597 to 
0.8814 Yes **** <0.0001   
Control vs. dRtf1 0.6248 
0.3639 to 
0.8856 Yes **** <0.0001   
dSpt4 vs. dPaf1 -0.114 
-0.4056 to 
0.1776 No ns 0.8919   
dSpt4 vs. dLeo1 0.013 
-0.2478 to 
0.2738 No ns >0.9999   
dSpt4 vs. dCDC73 0.05067 
-0.2102 to 
0.3115 No ns 0.9967   
dSpt4 vs. dCtr9 0.09778 
-0.1631 to 
0.3586 No ns 0.9097   
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dSpt4 vs. dRtf1 0.102 
-0.1588 to 
0.3628 No ns 0.8917   
dPaf1 vs. dLeo1 0.127 
-0.1646 to 
0.4186 No ns 0.8326   
dPaf1 vs. dCDC73 0.1647 
-0.127 to 
0.4563 No ns 0.5994   
dPaf1 vs. dCtr9 0.2118 
-0.07985 
to 0.5034 No ns 0.2999   
dPaf1 vs. dRtf1 0.216 
-0.07563 
to 0.5076 No ns 0.2778   
dLeo1 vs. dCDC73 0.03767 
-0.2232 to 
0.2985 No ns 0.9994   
dLeo1 vs. dCtr9 0.08478 
-0.1761 to 
0.3456 No ns 0.9527   
dLeo1 vs. dRtf1 0.089 
-0.1718 to 
0.3498 No ns 0.9407   
dCDC73 vs. dCtr9 0.04711 
-0.2137 to 
0.308 No ns 0.9978   
dCDC73 vs. dRtf1 0.05133 
-0.2095 to 
0.3122 No ns 0.9965   
dCtr9 vs. dRtf1 
0.00422
2 
-0.2566 to 
0.2651 No ns >0.9999   
Fig. 4b: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 0.9645 6 0.1608 
F (6, 53) 
= 4.235 P=0.0015 
  
Residual (within 
columns) 2.012 53 0.03796     
  
Total 2.976 59         
Sample Size (n) 25 
Independent Expt. 
Runs 
2 runs w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple Mean 95.00% CI 
Significant? 
Summar Adjusted P 
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comparisons test Diff. of diff. y Value 
Controls vs. dSpt4 -0.2208 
-0.4933 
to 
0.05168 No ns 0.1863   
Controls vs. dPaf1 
0.0342
7 
-0.2382 
to 0.3068 No ns 0.9997   
Controls vs. dLeo1 0.2632 
-
0.009266 
to 0.5358 No ns 0.0647   
Controls vs. 
dCDC73 -0.1495 
-0.422 to 
0.123 No ns 0.6312   
Controls vs. dCtr9 -0.1402 
-0.4127 
to 0.1323 No ns 0.6973   
Controls vs. dRtf1 
-
0.0947
3 
-0.3672 
to 0.1778 No ns 0.9354   
dSpt4 vs. dPaf1 0.2551 
-0.0896 
to 0.5998 No ns 0.2787   
dSpt4 vs. dLeo1 0.4841 
0.1394 to 
0.8288 Yes ** 0.0013   
dSpt4 vs. dCDC73 
0.0713
2 
-0.2734 
to 0.416 No ns 0.9953   
dSpt4 vs. dCtr9 0.0806 
-0.2641 
to 0.4253 No ns 0.991   
dSpt4 vs. dRtf1 0.1261 
-0.2186 
to 0.4708 No ns 0.9188   
dPaf1 vs. dLeo1 0.229 
-0.1157 
to 0.5737 No ns 0.4054   
dPaf1 vs. dCDC73 -0.1838 
-0.5285 
to 0.1609 No ns 0.6615   
dPaf1 vs. dCtr9 -0.1745 
-0.5192 
to 0.1702 No ns 0.7129   
dPaf1 vs. dRtf1 -0.129 
-0.4737 
to 0.2157 No ns 0.9103   
dLeo1 vs. dCDC73 -0.4128 
-0.7575 
Yes ** 0.0096   
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to -
0.06805 
dLeo1 vs. dCtr9 -0.4035 
-0.7482 
to -
0.05877 Yes * 0.0121   
dLeo1 vs. dRtf1 -0.358 
-0.7027 
to -
0.01327 Yes * 0.037   
dCDC73 vs. dCtr9 
0.0092
83 
-0.3354 
to 0.354 No ns >0.9999   
dCDC73 vs. dRtf1 
0.0547
8 
-0.2899 
to 0.3995 No ns 0.9989   
dCtr9 vs. dRtf1 0.0455 
-0.2992 
to 0.3902 No ns 0.9996   
Fig. 4c: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 1.546 5 0.3092 
F (5, 31) 
= 21.2 P<0.0001 
  
Residual (within 
columns) 0.4523 31 0.01459     
  
Total 1.998 36         
Sample sizes (n) 
Control (8); Paf1 RNAi (7); Leo1 RNAi (4), CDC73 RNAi (6); Ctr9 RNAi 
(6); Rtf1 RNAi (6) 
Independent Expt. 
Runs 
2 w/ >4 animals per genotype 
Data point total fluorescence per animal relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. dPaf1 0.3824 
0.1927 to 
0.5722 Yes **** <0.0001   
Control vs. dLeo1 0.4228 
0.1983 to 
0.6473 Yes **** <0.0001   
Control vs. 
dCDC73 0.5605 
0.3625 to 
0.7585 Yes **** <0.0001   
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Control vs. dCtr9 0.4994 
0.3015 to 
0.6974 Yes **** <0.0001   
Control vs. dRtf1 0.5118 
0.3138 to 
0.7098 Yes **** <0.0001   
dPaf1 vs. dLeo1 
0.0404
3 
-0.1894 
to 0.2702 No ns 0.9943   
dPaf1 vs. dCDC73 0.1781 
-0.02586 
to 0.3821 No ns 0.1151   
dPaf1 vs. dCtr9 0.117 
-0.08694 
to 0.321 No ns 0.5163   
dPaf1 vs. dRtf1 0.1294 
-0.07456 
to 0.3334 No ns 0.4064   
dLeo1 vs. dCDC73 0.1377 
-0.09897 
to 0.3743 No ns 0.5013   
dLeo1 vs. dCtr9 
0.0765
9 
-0.16 to 
0.3132 No ns 0.9201   
dLeo1 vs. dRtf1 
0.0889
7 
-0.1477 
to 0.3256 No ns 0.8603   
dCDC73 vs. dCtr9 
-
0.0610
8 
-0.2727 
to 0.1506 No ns 0.9495   
dCDC73 vs. dRtf1 -0.0487 
-0.2604 
to 0.163 No ns 0.9808   
dCtr9 vs. dRtf1 
0.0123
8 
-0.1993 
to 0.224 No ns >0.9999   
Fig. 4d, eYFP: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 0.04774 2 0.02387 
F (2, 6) 
= 4.589 P=0.0618 
  
Residual (within 
columns) 0.03121 6 0.005202     
  
Total 0.07895 8         
Independent Expt. 
Runs 
1 with biological triplicates 
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Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
WT vs. leo1Δ 0.1783 
-
0.002355 
to 0.359 No ns 0.0525   
WT vs. cdc73Δ 0.085 
-0.09569 
to 0.2657 No ns 0.3794   
leo1Δ vs. cdc73Δ 
-
0.0933
3 
-0.274 to 
0.08735 No ns 0.3217   
Fig. 4d, sense (G4C2)66: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 0.6141 2 0.307 
F (2, 13) 
= 51.44 P<0.0001 
  
Residual (within 
columns) 0.0776 13 0.005969     
  
Total 0.6917 15         
Independent Expt. 
Runs 
2 with biological duplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
WT vs. leo1Δ 0.3993 
0.2743 to 
0.5242 Yes **** <0.0001   
WT vs. cdc73Δ 0.3841 
0.2592 to 
0.509 Yes **** <0.0001   
leo1Δ vs. cdc73Δ 
-
0.0151
7 
-0.1594 
to 0.1291 No ns 0.9585   
Fig. 4d, antisense (G2C4)66: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
1.802 2 0.9012 
F (2, 13) 
P<0.0001   
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columns) = 55.8 
Residual (within 
columns) 0.21 13 0.01615     
  
Total 2.012 15         
Independent Expt. 
Runs 
2 with biological duplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
WT vs. leo1Δ 0.7723 
0.5668 to 
0.9778 Yes **** <0.0001   
WT vs. cdc73Δ 0.5232 
0.3177 to 
0.7287 Yes **** <0.0001   
leo1Δ vs. cdc73Δ -0.2491 
-0.4864 
to -
0.01182 Yes * 0.0394   
Fig. 5a, dPaf1: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 1.803 2 0.9015 
F (2, 15) 
= 38.41 P<0.0001 
  
Residual (within 
columns) 0.3521 15 0.02347     
  
Total 2.155 17         
Sample size (n) 25 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. 
(G4C2)8 
-
0.0440
3 
-0.2738 
to 0.1857 No ns 0.8734   
Control vs. 
-0.6923 
-0.922 to 
Yes **** <0.0001   
224 
 
(G4C2)49 -0.4626 
(G4C2)8 vs. 
(G4C2)49 -0.6483 
-0.878 to 
-0.4185 Yes **** <0.0001   
Fig. 5a, dLeo1: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 1.257 2 0.6285 
F (2, 15) 
= 15.74 P<0.0001 
  
Residual (within 
columns) 0.5989 15 0.03993     
  
Total 1.856 17         
Sample size (n) 25 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. 
(G4C2)8 
-
0.0362
3 
-0.3359 
to 0.2634 No ns 0.9473   
Control vs. 
(G4C2)49 -0.5778 
-0.8775 
to -
0.2782 Yes *** 0.0004   
(G4C2)8 vs. 
(G4C2)49 -0.5416 
-0.8412 
to -
0.2419 Yes *** 0.0008   
Fig. 5a, dCDC73: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 2.143 2 1.071 
F (2, 15) 
= 16.13 P=0.0002 
  
Residual (within 
columns) 0.9963 15 0.06642     
  
Total 3.139 17         
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Sample size (n) 25 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. 
(G4C2)8 
0.0467
5 
-0.3397 
to 0.4332 No ns 0.9472   
Control vs. 
(G4C2)49 -0.7074 
-1.094 to 
-0.3209 Yes *** 0.0007   
(G4C2)8 vs. 
(G4C2)49 -0.7542 
-1.141 to 
-0.3677 Yes *** 0.0004   
Fig. 5a, dCtr9: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 0.7279 2 0.364 
F (2, 15) 
= 10.35 P=0.0015 
  
Residual (within 
columns) 0.5273 15 0.03515     
  
Total 1.255 17         
Sample size (n) 25 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. 
(G4C2)8 -0.2668 
-0.548 to 
0.01439 No ns 0.0641   
Control vs. 
(G4C2)49 -0.492 
-0.7732 
to -
0.2108 Yes ** 0.0011   
(G4C2)8 vs. 
(G4C2)49 -0.2252 
-0.5064 
to 
0.05596 No ns 0.1277   
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Fig. 5a, dRtf1: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 1.465 2 0.7324 
F (2, 15) 
= 56.77 P<0.0001 
  
Residual (within 
columns) 0.1935 15 0.0129     
  
Total 1.658 17         
Sample size (n) 25 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. 
(G4C2)8 
-
0.0646
8 
-0.235 to 
0.1056 No ns 0.5963   
Control vs. 
(G4C2)49 -0.6349 
-0.8052 
to -
0.4646 Yes **** <0.0001   
(G4C2)8 vs. 
(G4C2)49 -0.5702 
-0.7405 
to -
0.3999 Yes **** <0.0001   
Fig. 5b: unpaired, two-tailed student t-tests 
Sample size (n) 25 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
  P value 
Significant
?  
Summary 
F, DFn, 
Dfd 
F test P 
value 
F test 
signifi
cant? 
Control vs. Paf1 
RNAi 
<0.0001 Yes **** 
1.043, 5, 
5 
0.9647 No 
Control vs. Leo1 
RNAi 
<0.0001 Yes **** 
1.925, 5, 
5 
0.4897 No 
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Control vs. CDC73 
shRNA 
<0.0001 Yes **** 
1.035, 5, 
5 
0.9708 No 
Control vs. Ctr9 
shRNA 
<0.0001 Yes **** 
2.088, 5, 
5 
0.4382 No 
Control vs. Rtf1 
shRNA 
<0.0001 Yes **** 
2.827, 5, 
5 
0.2786 No 
Fig. 5c: unpaired, two-tailed student t-tests 
Independent Expt. 
Runs 
2 w/ > 3 animals per run 
Sample sizes (n) 3mo: (G4C2)2 (6), (G4C2)149 (6); 6mo: (G4C2)2 (6), (G4C2)149 (7) 
Data point relative band density normalized to mGAPDH 
  P value 
Significant
?  
Summary 
F, DFn, 
Dfd 
F test P 
value 
F test 
signifi
cant? 
(G4C2)2 vs. 
(G4C2)149 (3mo) 
0.1585 No 
ns 
3.931, 5, 
5 
0.1593 No 
(G4C2)2 vs. 
(G4C2)149 (6mo) 
0.0292 Yes * 
1.94, 5, 
6 
0.4432 No 
Fig. 6a: unpaired, two-tailed student t-tests 
Independent Expt. 
Runs 
2 w/ technical triplicates 
Data point relative band density normalized to mean of hTub and hGAPDH 
  P value 
Significant
?  
Summary 
F, DFn, 
Dfd 
F test P 
value 
F test 
signifi
cant? 
hPaf1: Cntrl vs. C9+ 0.0178 Yes 
* 
2.996, 5, 
5 0.2537 
No 
hLeo1: Cntrl vs. C9+ 0.4751 No 
ns 
5.62, 5, 
5 0.0812 
No 
hCDC73: Cntrl vs. 
C9+ 
0.5874 No 
ns 
4.455, 5, 
5 0.1267 
No 
hRtf1: Cntrl vs. C9+ 0.0419 Yes 
* 
1.808, 5, 
5 0.5316 
No 
Fig. 6b: 2-way ANOVA 
ANOVA table, Top SS DF MS 
F (DFn, 
P value   
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DFd) 
Interaction 14.42 1 14.42 
F (1, 12) 
= 3.704 
P=0.0783   
Row Factor 16.24 1 16.24 
F (1, 12) 
= 4.169 
P=0.0638   
Column Factor 14.42 1 14.42 
F (1, 12) 
= 3.704 
P=0.0783   
Residual 46.73 12 3.894       
Independent Expt. 
Runs 
2 per line w/ technical quadruplicates 
Data point 
relative signal normalized to % input relative to IgG; mean for individual 
lines 
Sidak’s multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value   
hLeo1 - IgG 
C9orf72 Intron 1 3.914 
0.351 to 
7.476 
Yes * 0.0316   
Intergenic 0.1158 
-3.447 to 
3.678 
No ns 0.9958   
C9orf72 Intron 1 - Intergenic 
hLeo1 3.798 
0.2353 to 
7.36 Yes * 0.0368   
IgG 0 
-3.563 to 
3.563 No ns >0.9999   
Fig. 6c, Paf1, FTD cases: 1-way Kruskal-Wallis ANOVA (see Supplementary Fig. 10a for sample 
sizes and patient details) 
P value 
Exact or 
approx? 
Summary 
medians vary 
signif. (P < 
0.05)? 
Number 
of 
groups 
Kruskal-
Wallis 
statistic 
  
<0.0001 
Approxi
mate **** Yes 3 18.57 
  
Independent Expt. 
Runs 
2 for individual patients w/ technical duplicates 
Data point mean fold change for 1 patient relative to mean of healthy controls 
Dunn’s multiple Mean Significant
Summary 
Adjusted 
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comparisons test rank 
diff. 
? P Value 
Healthy vs. C9- -7.029 No ns 0.7859     
Healthy vs. C9+ -25.45 Yes **** 
<0.000
1     
C9- vs. C9+ -18.42 Yes * 0.0107     
Fig. 6c, Paf1, FTD/ALS cases: 1-way Kruskal-Wallis ANOVA (see Supplementary Fig. 10a for 
sample sizes and patient details) 
P value 
Exact or 
approx? 
Summary 
medians vary 
signif. (P < 
0.05)? 
Number 
of 
groups 
Kruskal-
Wallis 
statistic 
  
0.0074 
Approxi
mate ** Yes 3 9.823 
  
Independent Expt. 
Runs 
2 for individual patients w/ technical duplicates 
Data point mean fold change for 1 patient relative to mean of healthy controls 
Dunn’s multiple 
comparisons test 
Mean 
rank 
diff. 
Significant
? 
Summary 
Adjusted 
P Value 
    
Healthy vs. C9- -13.99 No ns 0.0682     
Healthy vs. C9+ -14.11 Yes * 0.0143     
C9- vs. C9+ -0.1126 No ns 
>0.999
9     
Fig. 6c, Paf1, ALS cases: 1-way Kruskal-Wallis ANOVA (see Supplementary Fig. 10a for sample 
sizes and patient details) 
P value 
Exact or 
approx? 
Summary 
medians vary 
signif. (P < 
0.05)? 
Number 
of 
groups 
Kruskal-
Wallis 
statistic 
  
0.0285 
Approxi
mate * Yes 3 7.119 
  
Independent Expt. 
Runs 
2 for individual patients w/ technical duplicates 
Data point mean fold change for 1 patient relative to mean of healthy controls 
Dunn’s multiple 
comparisons test 
Mean 
rank 
Significant
? 
Summary 
Adjusted 
P Value 
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diff. 
Healthy vs. C9- 13.26 No ns 0.064     
Healthy vs. C9+ 13.14 No ns 0.0794     
C9- vs. C9+ -0.1273 No ns 
>0.999
9     
Fig. 6c, Leo1, FTD cases: 1-way Kruskal-Wallis ANOVA (see Supplementary Fig. 10a for sample 
sizes and patient details) 
P value 
Exact or 
approx? 
Summary 
medians vary 
signif. (P < 
0.05)? 
Number 
of 
groups 
Kruskal-
Wallis 
statistic 
  
0.0077 
Approxi
mate ** Yes 3 9.74 
  
Independent Expt. 
Runs 
2 for individual patients w/ technical duplicates 
Data point mean fold change for 1 patient relative to mean of healthy controls 
Dunn’s multiple 
comparisons test 
Mean 
rank 
diff. 
Significant
? 
Summary 
Adjusted 
P Value 
    
Healthy vs. C9- 4.317 No ns 
>0.999
9     
Healthy vs. C9+ -14.27 No ns 0.0561     
C9- vs. C9+ -18.58 Yes ** 0.0099     
Fig. 6c, Leo1, FTD/ALS cases: 1-way Kruskal-Wallis ANOVA (see Supplementary Fig. 10a for 
sample sizes and patient details) 
P value 
Exact or 
approx? 
Summary 
medians vary 
signif. (P < 
0.05)? 
Number 
of 
groups 
Kruskal-
Wallis 
statistic 
  
0.0588 
Approxi
mate ns No 3 5.668 
  
Independent Expt. 
Runs 
1-2 for individual patients w/ replicates 
Data point mean fold change for 1 patient relative to mean of healthy controls 
Dunn’s multiple 
comparisons test 
Mean 
rank 
diff. 
Significant
? 
Summary 
Adjusted 
P Value 
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Healthy vs. C9- -4.529 No ns 
>0.999
9     
Healthy vs. C9+ -11.88 No ns 0.0522     
C9- vs. C9+ -7.355 No ns 0.7498     
Fig. 6c, Leo1, ALS cases: 1-way Kruskal-Wallis ANOVA (see Supplementary Fig. 10a for sample 
sizes and patient details) 
P value 
Exact or 
approx? 
Summary 
medians vary 
signif. (P < 
0.05)? 
Number 
of 
groups 
Kruskal-
Wallis 
statistic 
  
0.0534 
Approxi
mate ns No 3 5.859 
  
Independent Expt. 
Runs 
2 for individual patients w/ technical duplicates 
Data point mean fold change for 1 patient relative to mean of healthy controls 
Dunn’s multiple 
comparisons test 
Mean 
rank 
diff. 
Significant
? 
Summary 
Adjusted 
P Value 
    
Healthy vs. C9- 13.5 No ns 0.0574     
Healthy vs. C9+ 9.3 No ns 0.3484     
C9- vs. C9+ -4.2 No ns 
>0.999
9     
Fig. 6d: Spearman r correlations (see Supplementary Fig. 10a for sample sizes and patient 
details) 
Independent Expt. 
Runs 
For C9orf72-intron 1: 2 for individual patients w/ technical duplicates; For 
Paf1, Leo1: same data as Fig. 6c. 
Data point mean fold change for 1 patient relative to mean of healthy controls 
  
Spearm
an r 
P value 
(two-
tailed) 
Summary 
Exact or 
Approx? 
Significant
? (α = 
0.05) 
95% 
CI 
C9+ FTD only: 
C9orf72 Intron 1 vs 
PAF1 
0.7374 <0.0001 **** Approx. Yes 
0.480
8 to 
0.877
7 
C9- FTD only: 
C9orf72 Intron 1 vs 
PAF1 
0.2787 0.1979 ns Approx. No 
-
0.163
5 to 
0.627
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6 
Healthy Cntrls: 
C9orf72 Intron 1 vs 
PAF1 
0.07937 0.6939 ns Approx. No 
-
0.320
6 to 
0.455
4 
C9+ FTD only: 
C9orf72 Intron 1 vs 
LEO1 
0.6321 0.0005 *** Approx. Yes 
0.313
3 to 
0.822
9 
C9- FTD only: 
C9orf72 Intron 1 vs 
LEO1 
0.3538 0.0977 ns Approx. No 
-
0.081
31 to 
0.675
6 
Healthy Cntrls: 
C9orf72 Intron 1 vs 
LEO1 
0.03114 0.8775 ns Approx. No 
-
0.363
4 to 
0.416
2 
Sup. Fig 2b: 1-way ANOVA 
RNAi lines 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 1118 6 186.3 
F (6, 53) 
= 5.729 P=0.0001 
  
Residual (within 
columns) 1724 53 32.52     
  
Total 2842 59         
Sample sizes (n) 
w+ control RNAi (9), Paf1 RNAi (10), Leo1 RNAi (9), CDC73 RNAi (4), 
Ctr9 RNAi (8), Rtf1 RNAi (6), Spt4 RNAi (14) 
Independent Expt. 
Runs 
>3   
Data point retina depth from 1 eye per animal 
Dunnett's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
w+ Control vs. 
dCDC73 9.77 
0.6823 to 
18.86 Yes * 0.0305   
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w+ Control vs. 
dRtf1 5.473 
-2.498 to 
13.44 No ns 0.2854   
w+ Control vs. 
dCtr9 -3.253 
-10.6 to 
4.096 No ns 0.705   
w+ Control vs. 
dLeo1 2.247 
-4.883 to 
9.376 No ns 0.9073   
w+ Control vs. 
dPaf1 5.883 
-1.066 to 
12.83 No ns 0.1259   
w+ Control vs. 
dSpt4 -3.536 
-9.998 to 
2.925 No ns 0.5073   
RNAi-2 lines 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 251.2 5 50.24 
F (5, 18) 
= 2.616 P=0.0602 
  
Residual (within 
columns) 345.7 18 19.2     
  
Total 596.9 23         
Sample sizes (n) 
w- control (4), Paf1 RNAi-2 (4), Leo1 RNAi-2 (4), CDC73 RNAi-2 (4), Ctr9 
RNAi-2 (4), Rtf1 RNAi-2 (4) 
Independent Expt. 
Runs 
>2 
Data point retina depth from 1 eye per animal 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
w- Control vs. 
dPaf1 9.036 
-0.8125 
to 18.88 No ns 0.0831   
w- Control vs. 
dLeo1 3.161 
-6.687 to 
13.01 No ns 0.9051   
w- Control vs. 
dCDC73 0.5823 
-9.266 to 
10.43 No ns >0.9999   
w- Control vs. 
dCtr9 6.508 
-3.341 to 
16.36 No ns 0.3302   
w- Control vs. 
5.715 
-4.134 to 
No ns 0.4645   
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dRtf1 15.56 
dPaf1 vs. dLeo1 -5.875 
-15.72 to 
3.974 No ns 0.4356   
dPaf1 vs. dCDC73 -8.453 
-18.3 to 
1.395 No ns 0.1177   
dPaf1 vs. dCtr9 -2.528 
-12.38 to 
7.32 No ns 0.9608   
dPaf1 vs. dRtf1 -3.321 
-13.17 to 
6.527 No ns 0.8862   
dLeo1 vs. dCDC73 -2.579 
-12.43 to 
7.269 No ns 0.9574   
dLeo1 vs. dCtr9 3.347 
-6.502 to 
13.19 No ns 0.883   
dLeo1 vs. dRtf1 2.554 
-7.295 to 
12.4 No ns 0.9591   
dCDC73 vs. dCtr9 5.925 
-3.923 to 
15.77 No ns 0.4266   
dCDC73 vs. dRtf1 5.132 
-4.716 to 
14.98 No ns 0.575   
dCtr9 vs. dRtf1 -0.793 
-10.64 to 
9.055 No ns 0.9998   
Sup. Fig 3b: 1-way ANOVA 
RNAi lines 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 3259 6 543.1 
F (6, 41) 
= 11.29 P<0.0001 
  
Residual (within 
columns) 1973 41 48.12     
  
Total 5231 47         
Sample sizes (n) 
w+ control RNAi (13), Paf1 RNAi (9), Leo1 RNAi (4), CDC73 RNAi (5), 
Ctr9 RNAi (4), Rtf1 RNAi (4), Spt4 RNAi (9) 
Independent Expt. 
Runs 
>3   
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Data point retina depth from 1 eye per animal 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
w+ Control vs. 
dPaf1 -0.3164 
-9.639 to 
9.006 No ns >0.9999   
w+ Control vs. 
dLeo1 -7.64 
-19.93 to 
4.652 No ns 0.4754   
w+ Control vs. 
dCDC73 -26.81 
-38.12 to 
-15.5 Yes **** <0.0001   
w+ Control vs. 
dCtr9 -2.375 
-14.67 to 
9.917 No ns 0.9965   
w+ Control vs. 
dRtf1 3.072 
-9.22 to 
15.36 No ns 0.9862   
w+ Control vs. 
dSpt4 -1.241 
-10.56 to 
8.081 No ns 0.9996   
dPaf1 vs. dLeo1 -7.324 
-20.24 to 
5.595 No ns 0.5833   
dPaf1 vs. dCDC73 -26.5 
-38.49 to 
-14.5 Yes **** <0.0001   
dPaf1 vs. dCtr9 -2.059 
-14.98 to 
10.86 No ns 0.9988   
dPaf1 vs. dRtf1 3.388 
-9.531 to 
16.31 No ns 0.9823   
dPaf1 vs. dSpt4 -0.9246 
-11.06 to 
9.21 No ns >0.9999   
dLeo1 vs. dCDC73 -19.17 
-33.59 to 
-4.75 Yes ** 0.0031   
dLeo1 vs. dCtr9 5.265 
-9.936 to 
20.47 No ns 0.9323   
dLeo1 vs. dRtf1 10.71 
-4.49 to 
25.91 No ns 0.3261   
dLeo1 vs. dSpt4 6.399 
-6.52 to 
19.32 No ns 0.7225   
dCDC73 vs. dCtr9 24.44 
10.01 to 
Yes **** <0.0001   
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38.86 
dCDC73 vs. dRtf1 29.88 
15.46 to 
44.3 Yes **** <0.0001   
dCDC73 vs. dSpt4 25.57 
13.58 to 
37.56 Yes **** <0.0001   
dCtr9 vs. dRtf1 5.447 
-9.755 to 
20.65 No ns 0.9213   
dCtr9 vs. dSpt4 1.134 
-11.78 to 
14.05 No ns >0.9999   
dRtf1 vs. dSpt4 -4.313 
-17.23 to 
8.606 No ns 0.9428   
RNAi-2 lines 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 234.6 5 46.91 
F (5, 28) 
= 2.695 P=0.0414 
  
Residual (within 
columns) 487.4 28 17.41     
  
Total 722 33         
Sample sizes (n) 
w- control (6), Paf1 RNAi-2 (4), Leo1 RNAi-2 (6), CDC73 RNAi-2 (6), Ctr9 
RNAi-2 (6), Rtf1 RNAi-2 (6) 
Independent Expt. 
Runs 
>2 
Data point retina depth from 1 eye per animal 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
w- Control vs. 
dPaf1 -1.265 
-9.495 to 
6.965 No ns 0.9968   
w- Control vs. 
dLeo1 1.952 
-5.409 to 
9.313 No ns 0.9632   
w- Control vs. 
dCDC73 2.304 
-5.057 to 
9.665 No ns 0.9276   
w- Control vs. 
dCtr9 1.869 
-5.492 to 
9.23 No ns 0.9694   
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w- Control vs. 
dRtf1 -5.042 
-12.4 to 
2.319 No ns 0.3194   
dPaf1 vs. dLeo1 3.217 
-5.013 to 
11.45 No ns 0.8357   
dPaf1 vs. dCDC73 3.57 
-4.66 to 
11.8 No ns 0.7688   
dPaf1 vs. dCtr9 3.134 
-5.096 to 
11.36 No ns 0.8499   
dPaf1 vs. dRtf1 -3.777 
-12.01 to 
4.453 No ns 0.7252   
dLeo1 vs. dCDC73 0.3523 
-7.009 to 
7.713 No ns >0.9999   
dLeo1 vs. dCtr9 
-
0.0833
3 
-7.444 to 
7.278 No ns >0.9999   
dLeo1 vs. dRtf1 -6.994 
-14.36 to 
0.3668 No ns 0.0698   
dCDC73 vs. dCtr9 -0.4357 
-7.797 to 
6.925 No ns >0.9999   
dCDC73 vs. dRtf1 -7.347 
-14.71 to 
0.01449 No ns 0.0507   
dCtr9 vs. dRtf1 -6.911 
-14.27 to 
0.4502 No ns 0.0752   
Sup. Fig 3c: 1-way ANOVA 
RNAi lines 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 1.398 5 0.2796 
F (5, 12) 
= 1.647 P=0.2217 
  
Residual (within 
columns) 2.038 12 0.1698     
  
Total 3.436 17         
Sample size (n) 10 
Independent Expt. 
2 w/ biological triplicates 
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Runs 
Data point normalized band density per lane 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
w+ Control vs. 
dPaf1 
-
0.0001
803 
-1.13 to 
1.13 No ns >0.9999   
w+ Control vs. 
dLeo1 
0.0647
4 
-1.065 to 
1.195 No ns >0.9999   
w+ Control vs. 
dCDC73 0.5331 
-0.5971 
to 1.663 No ns 0.6224   
w+ Control vs. 
dCtr9 0.6254 
-0.5048 
to 1.756 No ns 0.4682   
w+ Control vs. 
dRtf1 0.5654 
-0.5647 
to 1.696 No ns 0.5672   
dPaf1 vs. dLeo1 
0.0649
2 
-1.065 to 
1.195 No ns >0.9999   
dPaf1 vs. dCDC73 0.5333 
-0.5969 
to 1.663 No ns 0.6221   
dPaf1 vs. dCtr9 0.6255 
-0.5046 
to 1.756 No ns 0.4679   
dPaf1 vs. dRtf1 0.5656 
-0.5645 
to 1.696 No ns 0.5669   
dLeo1 vs. dCDC73 0.4683 
-0.6618 
to 1.598 No ns 0.7311   
dLeo1 vs. dCtr9 0.5606 
-0.5695 
to 1.691 No ns 0.5754   
dLeo1 vs. dRtf1 0.5007 
-0.6294 
to 1.631 No ns 0.6775   
dCDC73 vs. dCtr9 
0.0922
9 
-1.038 to 
1.222 No ns 0.9997   
dCDC73 vs. dRtf1 
0.0323
7 
-1.098 to 
1.163 No ns >0.9999   
dCtr9 vs. dRtf1 -
0.0599 -1.19 to 
No ns >0.9999   
239 
 
2 1.07 
RNAi-2 lines 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 1.241 5 0.2483 
F (5, 12) 
= 0.9149 P=0.5035 
  
Residual (within 
columns) 3.256 12 0.2714     
  
Total 4.498 17         
Sample size (n) 10 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point normalized band density per lane 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
w- Control vs. 
dPaf1 0.1544 
-1.274 to 
1.583 No ns 0.9989   
w- Control vs. 
dLeo1 0.2261 
-1.203 to 
1.655 No ns 0.9937   
w- Control vs. 
dCDC73 -0.2988 
-1.727 to 
1.13 No ns 0.9781   
w- Control vs. 
dCtr9 -0.2684 
-1.697 to 
1.16 No ns 0.9863   
w- Control vs. 
dRtf1 -0.5079 
-1.936 to 
0.9208 No ns 0.8316   
dPaf1 vs. dLeo1 
0.0716
2 
-1.357 to 
1.5 No ns >0.9999   
dPaf1 vs. dCDC73 -0.4532 
-1.882 to 
0.9754 No ns 0.8858   
dPaf1 vs. dCtr9 -0.4228 
-1.851 to 
1.006 No ns 0.9112   
dPaf1 vs. dRtf1 -0.6623 
-2.091 to 
0.7663 No ns 0.6381   
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dLeo1 vs. dCDC73 -0.5249 
-1.953 to 
0.9038 No ns 0.8128   
dLeo1 vs. dCtr9 -0.4944 
-1.923 to 
0.9342 No ns 0.8459   
dLeo1 vs. dRtf1 -0.7339 
-2.163 to 
0.6947 No ns 0.5417   
dCDC73 vs. dCtr9 
0.0304
2 
-1.398 to 
1.459 No ns >0.9999   
dCDC73 vs. dRtf1 -0.2091 
-1.638 to 
1.22 No ns 0.9956   
dCtr9 vs. dRtf1 -0.2395 
-1.668 to 
1.189 No ns 0.9917   
Sup. Fig 4a, Paf1: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 3.236 2 1.618 
F (2, 21) 
= 175.6 P<0.0001 
  
Residual (within 
columns) 0.1935 21 0.009215     
  
Total 3.43 23         
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% 
CI of diff. Significant? 
Summa
ry 
Adjusted 
P Value   
w- Control vs. w- 
RNAi 0.8853 
0.7644 to 
1.006 Yes **** <0.0001   
w- Control vs. w- 
RNAi-2 0.445 
0.324 to 
0.566 Yes **** <0.0001   
w- RNAi vs. w- 
RNAi-2 -0.4403 
-0.58 to -
0.3006 Yes **** <0.0001   
Sup. Fig 4a, Leo1: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
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Treatment (between 
columns) 3.867 2 1.933 
F (2, 18) 
= 115.1 P<0.0001 
  
Residual (within 
columns) 0.3023 18 0.0168     
  
Total 4.169 20         
Independent Expt. 
Runs 
2 w/ triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% 
CI of diff. Significant? 
Summa
ry 
Adjusted 
P Value   
w- Control vs. w- 
RNAi 0.9047 
0.7303 to 
1.079 Yes **** <0.0001   
w- Control vs. w- 
RNAi-2 0.8253 
0.651 to 
0.9997 Yes **** <0.0001   
w- RNAi vs. w- 
RNAi-2 
-
0.0793
3 
-0.2703 
to 0.1116 No ns 0.5499   
Sup. Fig 4a, CDC73: unpaired, two-tailed student t-test 
Independent Expt. 
Runs 
2 w/ triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
  P value 
Significant
?  
Summary 
F, DFn, 
Dfd 
F test P 
value 
F test 
signifi
cant? 
w+ Control vs. w+ 
RNAi 
<0.000
1 Yes **** 
15.18, 
2, 2 0.1236 No 
w- Control vs. w- 
RNAi 
<0.000
1 Yes **** 
2.525, 
5, 5 0.3324 No 
Sup. Fig 4a, Ctr9: unpaired, two-tailed student t-test 
Independent Expt. 
Runs 
2 w/ triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
  P value 
Significant
?  
Summary 
F, DFn, 
Dfd 
F test P 
value 
F test 
signifi
cant? 
242 
 
w+ Control vs. w+ 
RNAi 0.0002 Yes *** 
27.15, 
2, 2 0.0711 No 
w- Control vs. w- 
RNAi 0.0459 Yes * 
34.8, 8, 
5 0.0011 Yes 
Sup. Fig 4a, Rtf1: unpaired, two-tailed student t-test 
Independent Expt. 
Runs 
2 w/ triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
  P value 
Significant
?  
Summary 
F, DFn, 
Dfd 
F test P 
value 
F test 
signifi
cant? 
w+ Control vs. w+ 
RNAi 0.0005 Yes *** 
5.439, 
2, 2 0.3106 No 
w- Control vs. w- 
RNAi 0.023 Yes * 
2.27, 2, 
2 0.6116 No 
Sup. Fig 4b: unpaired, two-tailed student t-test 
Independent Expt. 
Runs 
2 w/ triplicates 
Data point normalized band density per lane relative to mean of controls 
  P value 
Significant
?  
Summary 
F, DFn, 
Dfd 
F test P 
value 
F test 
signifi
cant? 
w+ Control vs. w+ 
RNAi 0.0285 Yes * 
4.041, 
2, 2 0.3967 No 
w- Control vs. w- 
RNAi 0.0281 Yes * 
2.861, 
5, 5 0.2734 No 
Sup. Fig 4c: unpaired, two-tailed student t-test 
Independent Expt. 
Runs 
2 w/ triplicates 
Data point normalized band density per lane relative to mean of controls 
  P value 
Significant
?  
Summary 
F, DFn, 
Dfd 
F test P 
value 
F test 
signifi
cant? 
w+ Control vs. w+ 
RNAi 0.0026 Yes ** 
2.027, 
2, 2 0.6608 No 
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w- Control vs. w- 
RNAi 0.0026 Yes ** 
2.235, 
5, 5 0.398 No 
Sup. Fig 5a: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
10728 5 2146 
F (5, 32) 
= 32.34 
P<0.0001   
Residual (within 
columns) 
2123 32 66.35       
Total 12851 37         
Sample sizes (n) 
w- Control (12); Paf1 RNAi-2 (5); Leo1 RNAi-2 (6), CDC73 RNAi-2 (6); 
Ctr9 RNAi-2 (6); Rtf1 RNAi-2 (3) 
Independent Expt. 
Runs 
2  with > 4 animals per genotype 
Data point retina depth from 1 eye per animal 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
w- Control vs. dPaf1 -18.42 
-31.55 to -
5.284 
Yes ** 0.0022   
w- Control vs. dLeo1 -42.18 
-54.52 to -
29.84 
Yes **** <0.0001   
w- Control vs. 
dCDC73 
-39.4 
-51.73 to -
27.06 
Yes **** <0.0001   
w- Control vs. dCtr9 -26.82 
-39.16 to -
14.48 
Yes **** <0.0001   
w- Control vs. dRtf1 -34.38 
-50.31 to -
18.46 
Yes **** <0.0001   
dPaf1 vs. dLeo1 -23.76 
-38.7 to -
8.818 
Yes *** 0.0004   
dPaf1 vs. dCDC73 -20.98 
-35.92 to -
6.036 
Yes ** 0.0022   
dPaf1 vs. dCtr9 -8.404 
-23.35 to 
6.538 
No ns 0.5394   
dPaf1 vs. dRtf1 -15.96 
-33.98 to 
2.056 
No ns 0.1067   
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dLeo1 vs. dCDC73 2.782 
-11.46 to 
17.03 
No ns 0.9909   
dLeo1 vs. dCtr9 15.36 
1.109 to 
29.6 
Yes * 0.0286   
dLeo1 vs. dRtf1 7.795 
-9.653 to 
25.24 
No ns 0.7535   
dCDC73 vs. dCtr9 12.57 
-1.672 to 
26.82 
No ns 0.1089   
dCDC73 vs. dRtf1 5.013 
-12.43 to 
22.46 
No ns 0.9509   
dCtr9 vs. dRtf1 -7.561 
-25.01 to 
9.887 
No ns 0.776   
Sup. Fig 5b: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
203.3 5 40.65 
F (5, 17) 
= 1.997 
P=0.1307   
Residual (within 
columns) 
346.1 17 20.36       
Total 549.3 22         
Sample sizes (n) 
w- Control (4); Paf1 RNAi-2 (3); Leo1 RNAi-2 (4), CDC73 RNAi-2 (4); Ctr9 
RNAi-2 (3); Rtf1 RNAi-2 (5) 
Independent Expt. 
Runs 
2  with > 4 animals per genotype 
Data point retina depth from 1 eye per animal 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
w- Control vs. dPaf1 -0.3168 
-11.34 to 
10.71 
No ns >0.9999   
w- Control vs. dLeo1 -2.17 
-12.37 to 
8.035 
No ns 0.9818   
w- Control vs. 
dCDC73 
-1.276 
-11.48 to 
8.929 
No ns 0.9984   
w- Control vs. dCtr9 1.859 
-9.164 to 
12.88 
No ns 0.9936   
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w- Control vs. dRtf1 -7.137 
-16.82 to 
2.544 
No ns 0.2252   
dPaf1 vs. dLeo1 -1.853 
-12.88 to 
9.169 
No ns 0.9937   
dPaf1 vs. dCDC73 -0.9592 
-11.98 to 
10.06 
No ns 0.9997   
dPaf1 vs. dCtr9 2.176 
-9.608 to 
13.96 
No ns 0.9903   
dPaf1 vs. dRtf1 -6.82 
-17.36 to 
3.719 
No ns 0.3469   
dLeo1 vs. dCDC73 0.894 
-9.311 to 
11.1 
No ns 0.9997   
dLeo1 vs. dCtr9 4.029 
-6.994 to 
15.05 
No ns 0.8451   
dLeo1 vs. dRtf1 -4.967 
-14.65 to 
4.714 
No ns 0.5848   
dCDC73 vs. dCtr9 3.135 
-7.888 to 
14.16 
No ns 0.9387   
dCDC73 vs. dRtf1 -5.861 
-15.54 to 
3.82 
No ns 0.4151   
dCtr9 vs. dRtf1 -8.996 
-19.54 to 
1.544 
No ns 0.1199   
Sup. Fig 5c: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
2096 5 419.2 
F (5, 27) 
= 32.81 
P<0.0001   
Residual (within 
columns) 
345 27 12.78       
Total 2441 32         
Sample sizes (n) 
w- Control (6); Paf1 RNAi-2 (5); Leo1 RNAi-2 (5), CDC73 RNAi-2 (5); Ctr9 
RNAi-2 (6); Rtf1 RNAi-2 (6) 
Independent Expt. 
Runs 
2 with > 4 animals per genotype 
Data point retina depth from 1 eye per animal 
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Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. dPaf1 -19.16 
-25.79 to -
12.53 
Yes **** <0.0001   
Control vs. dLeo1 -12.03 
-18.66 to -
5.394 
Yes **** <0.0001   
Control vs. dCDC73 -24.63 
-31.26 to -
18 
Yes **** <0.0001   
Control vs. dCtr9 -19.74 
-26.07 to -
13.42 
Yes **** <0.0001   
Control vs. dRtf1 -12.78 
-19.11 to -
6.461 
Yes **** <0.0001   
dPaf1 vs. dLeo1 7.137 
0.2107 to 
14.06 
Yes * 0.0406   
dPaf1 vs. dCDC73 -5.467 
-12.39 to 
1.46 
No ns 0.1856   
dPaf1 vs. dCtr9 -0.5815 
-7.213 to 
6.05 
No ns 0.9998   
dPaf1 vs. dRtf1 6.378 
-0.2533 to 
13.01 
No ns 0.0646   
dLeo1 vs. dCDC73 -12.6 
-19.53 to -
5.678 
Yes **** <0.0001   
dLeo1 vs. dCtr9 -7.719 
-14.35 to -
1.087 
Yes * 0.0156   
dLeo1 vs. dRtf1 -0.7589 
-7.391 to 
5.873 
No ns 0.9992   
dCDC73 vs. dCtr9 4.885 
-1.747 to 
11.52 
No ns 0.2461   
dCDC73 vs. dRtf1 11.85 
5.213 to 
18.48 
Yes *** 0.0001   
dCtr9 vs. dRtf1 6.96 
0.6368 to 
13.28 
Yes * 0.0247   
Sup. Fig 5d: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
2290 5 457.9 
F (5, 19) 
P<0.0001   
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columns) = 10.68 
Residual (within 
columns) 
815 19 42.89       
Total 3105 24         
Sample sizes (n) 
Control (51); Paf1 RNAi-2 (85); Leo1 RNAi-2 (73), CDC73 RNAi-2 (67); 
Ctr9 RNAi-2 (87); Rtf1 RNAi-2 (31) 
Independent Expt. 
Runs 
2 with > 30 animals per genotype 
Data point 
mean % animals that climb per tube; 10-20 animals per tube for each 
genotype 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
w- Control vs. dPaf1 -28.5 
-43.13 to -
13.87 
Yes **** <0.0001   
w- Control vs. dLeo1 -23.5 
-39.3 to -
7.695 
Yes ** 0.0019   
w- Control vs. 
dCDC73 
-30.5 
-46.3 to -
14.7 
Yes **** <0.0001   
w- Control vs. dCtr9 -29.8 
-44.91 to -
14.69 
Yes **** <0.0001   
w- Control vs. dRtf1 -30.67 
-47.56 to -
13.77 
Yes *** 0.0002   
dPaf1 vs. dLeo1 5 
-8.358 to 
18.36 
No ns 0.8395   
dPaf1 vs. dCDC73 -2 
-15.36 to 
11.36 
No ns 0.9966   
dPaf1 vs. dCtr9 -1.3 
-13.83 to 
11.23 
No ns 0.9994   
dPaf1 vs. dRtf1 -2.167 
-16.8 to 
12.47 
No ns 0.9968   
dLeo1 vs. dCDC73 -7 
-21.63 to 
7.633 
No ns 0.6615   
dLeo1 vs. dCtr9 -6.3 
-20.18 to 
7.582 
No ns 0.7071   
dLeo1 vs. dRtf1 -7.167 
-22.97 to 
8.638 
No ns 0.7078   
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dCDC73 vs. dCtr9 0.7 
-13.18 to 
14.58 
No ns >0.9999   
dCDC73 vs. dRtf1 -0.1667 
-15.97 to 
15.64 
No ns >0.9999   
dCtr9 vs. dRtf1 -0.8667 
-15.98 to 
14.25 
No ns >0.9999   
Sup. Fig 7b, Paf1: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
0.2299 2 0.115 
F (2, 18) 
= 1.864 
P=0.1837   
Residual (within 
columns) 
1.11 18 0.06167       
Total 1.34 20         
Sample size (n) 10 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Controls vs. dLeo1 
0.0903
4 
-0.2437 
to 0.4244 No ns 0.7721   
Controls vs. 
dCDC73 0.2525 
-0.08157 
to 0.5865 No ns 0.1594   
dLeo1 vs. dCDC73 0.1621 
-0.2038 
to 0.528 No ns 0.5082   
Sup. Fig 7b, Leo1: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
0.5062 2 0.2531 
F (2, 15) 
= 9.4 
P=0.0023   
Residual (within 
columns) 
0.4039 15 0.02693       
Total 0.9101 17         
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Sample size (n) 10 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. dPaf1 -0.2364 
-0.4825 
to 
0.009665 No ns 0.0606   
Control vs. 
dCDC73 0.1727 
-0.07338 
to 0.4188 No ns 0.1959   
dPaf1 vs. dCDC73 0.4091 
0.163 to 
0.6552 Yes ** 0.0017   
Sup. Fig 7b, Cdc73: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
0.3349 2 0.1675 
F (2, 15) 
= 1.59 
P=0.2365   
Residual (within 
columns) 
1.58 15 0.1053       
Total 1.915 17         
Sample size (n) 10 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. dPaf1 -0.1228 
-0.6095 
to 0.3639 No ns 0.7921   
Control vs. dLeo1 0.2077 
-0.279 to 
0.6944 No ns 0.5237   
dPaf1 vs. dLeo1 0.3305 
-0.1562 
to 0.8172 No ns 0.2151   
Sup. Fig 7b, Ctr9: 1-way ANOVA 
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ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
0.671 3 0.2237 
F (3, 20) 
= 6.055 
P=0.0042   
Residual (within 
columns) 
0.7388 20 0.03694       
Total 1.41 23         
Sample size (n) 10 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. dPaf1 
-
0.0530
3 
-0.3636 
to 0.2576 No ns 0.9631   
Control vs. dLeo1 0.1977 
-0.1129 
to 0.5083 No ns 0.3107   
Control vs. 
dCDC73 0.3685 
0.05788 
to 0.6791 Yes * 0.0165   
dPaf1 vs. dLeo1 0.2508 
-0.05983 
to 0.5613 No ns 0.1415   
dPaf1 vs. dCDC73 0.4215 
0.1109 to 
0.7321 Yes ** 0.0057   
dLeo1 vs. dCDC73 0.1708 
-0.1398 
to 0.4813 No ns 0.4343   
Sup. Fig 7b, Rtf1: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
0.9819 3 0.3273 
F (3, 20) 
= 4.88 
P=0.0105   
Residual (within 
columns) 
1.341 20 0.06706       
Total 2.323 23         
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Sample size (n) 10 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Controls vs. dPaf1 -0.2141 
-0.6326 
to 0.2044 No ns 0.495   
Controls vs. dLeo1 
0.0440
7 
-0.3744 
to 0.4625 No ns 0.9908   
Controls vs. 
dCDC73 0.3524 
-0.06609 
to 0.7709 No ns 0.1185   
dPaf1 vs. dLeo1 0.2582 
-0.1603 
to 0.6766 No ns 0.3366   
dPaf1 vs. dCDC73 0.5665 
0.148 to 
0.985 Yes ** 0.0058   
dLeo1 vs. dCDC73 0.3083 
-0.1102 
to 0.7268 No ns 0.1995   
Sup. Fig 7b, Spt4: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
0.5222 3 0.1741 
F (3, 23) 
= 2.823 
P=0.0612   
Residual (within 
columns) 
1.418 23 0.06165       
Total 1.94 26         
Sample size (n) 10 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. dPaf1 -0.1918 
-0.5539 
to 0.1703 No ns 0.4735   
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Control vs. dLeo1 
-
0.0461
7 
-0.4083 
to 0.316 No ns 0.9846   
Control vs. 
dCDC73 0.2195 
-0.1426 
to 0.5817 No ns 0.3578   
dPaf1 vs. dLeo1 0.1456 
-0.2511 
to 0.5423 No ns 0.7419   
dPaf1 vs. dCDC73 0.4113 
0.01462 
to 0.808 Yes * 0.0402   
dLeo1 vs. dCDC73 0.2657 
-0.131 to 
0.6624 No ns 0.2752   
Sup Fig 7a, Control vs. Paf1 RNAi: Log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test 
Sample Sizes (n) Control (301); Paf1 RNAi (200) 
Independent Expt Runs 2 with > 150 animals per genotype 
Test 
Chi 
square 
df P value 
Significa
nt? 
Summary 
95% 
CI of 
ratio 
Log-rank (Mantel-
Cox)  
133 1 <0.0001 Yes **** 
1.119 
to 
1.653/
0.605 
to 
0.893
6 
Gehan-Breslow-
Wilcoxon  
72.23 1 <0.0001 Yes **** 
Sup Fig 7a, Control vs. Leo1 RNAi: Log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test 
Sample Sizes (n) Control (301); Leo1 RNAi (275) 
Independent Expt Runs 2 with > 150 animals per genotype 
Test 
Chi 
square 
df P value 
Significa
nt? 
Summary 
95% 
CI of 
ratio 
Log-rank (Mantel-
Cox)  
86.2 1 <0.0001 Yes **** 
1.081 
to 
1.582/
0.632
2 to 
0.924
9 
Gehan-Breslow-
Wilcoxon  
59.88 1 <0.0001 Yes **** 
Sup Fig 7a, Control vs. CDC73 RNAi: Log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon 
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test 
Sample Sizes (n) Control (301); CDC73 RNAi (200) 
Independent Expt Runs 2 with > 150 animals per genotype 
Test 
Chi 
square 
df P value 
Significa
nt? 
Summary 
95% 
CI of 
ratio 
Log-rank (Mantel-
Cox)  
2.125 1 0.1449 No ns 
0.796
6 to 
1.185/
0.844
2 to 
1.255 
Gehan-Breslow-
Wilcoxon  
2.474 1 0.1158 No ns 
Sup Fig 7a, Control vs. Ctr9 RNAi: Log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test 
Sample Sizes (n) Control (301); Ctr9 RNAi (210) 
Independent Expt Runs 2 with > 150 animals per genotype 
Test 
Chi 
square 
df P value 
Significa
nt? 
Summary 
95% 
CI of 
ratio 
Log-rank (Mantel-
Cox)  
207.8 1 <0.0001 Yes **** 
1.272 
to 
1.878/
0.532
4 to 
0.786
4 
Gehan-Breslow-
Wilcoxon  
163.8 1 <0.0001 Yes **** 
Sup Fig 7a, Control vs. Rtf1 RNAi: Log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test 
Sample Sizes (n) Control (301); Rtf1 RNAi (200) 
Independent Expt Runs 2 with > 150 animals per genotype 
Test 
Chi 
square 
df P value 
Significa
nt? 
Summary 
95% 
CI of 
ratio 
Log-rank (Mantel-
Cox)  
48.15 1 <0.0001 Yes **** 
0.905
5 to 
1.328/
0.752
8 to 
1.104 
Gehan-Breslow-
Wilcoxon  
19.29 1 <0.0001 Yes **** 
Sup. Fig 8a: unpaired, two-tailed student t-test 
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Sample sizes (n) w+ Control (9); w- Control (12) 
Independent Expt. 
Runs 
>3  with >4 animals per genotype 
Data point retina depth from 1 eye per animal 
  P value 
Significant
?  
Summary 
F, DFn, 
Dfd 
F test P 
value 
F test 
signifi
cant? 
w+ control vs. w- 
control 0.8479 No ns 
1.465, 
8, 11 0.5451 No 
Sup Fig 8b: Log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test 
Sample Sizes (n) w- Control (188); w+ control (106) 
Independent Expt Runs 2 with >100 animals per genotype 
Test 
Chi 
square 
df P value 
Significa
nt? 
Summary 
95% 
CI of 
ratio 
Log-rank (Mantel-
Cox)  
0.5859 1 0.444 No ns 
0.882
2 to 
1.435/
0.697 
to 
1.134 
Gehan-Breslow-
Wilcoxon  
0.04529 1 0.8315 No ns 
Sup. Fig 8c: unpaired, two-tailed student t-test 
Sample sizes (n) w+ Control (72); w- Control (51) 
Independent Expt. 
Runs 
2 with >50 animals per genotype 
Data point 
mean % animals that climb per tube; 10-20 animals per tube for each 
genotype 
  P value 
Significant
?  
Summary 
F, DFn, 
Dfd 
F test P 
value 
F test 
signifi
cant? 
w+ control vs. w- 
control 0.3479 No ns 
4.687, 
6, 5 0.1111 No 
Sup. Fig 8d: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
0.6252 3 0.2084 
F (3, 20) 
P=0.1584   
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columns) = 1.923 
Residual (within 
columns) 
2.167 20 0.1084       
Total 2.792 23         
Sample size (n) 25 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
w- Control 1 vs. w- 
Control 2 -0.3957 
-0.9276 
to 0.1363 No ns 0.193   
w- Control 1 vs. 
w+ Control 1 
-
0.0628
3 
-0.5948 
to 0.4691 No ns 0.9872   
w- Control 1 vs. 
w+ Control 2 
-
0.0173
3 
-0.5493 
to 0.5146 No ns 0.9997   
w- Control 2 vs. 
w+ Control 1 0.3328 
-0.1991 
to 0.8648 No ns 0.3249   
w- Control 2 vs. 
w+ Control 2 0.3783 
-0.1536 
to 0.9103 No ns 0.2245   
w+ Control 1 vs. 
w+ Control 2 0.0455 
-0.4864 
to 0.5774 No ns 0.995   
Sup. Fig 8e: unpaired, two-tailed student t-test 
Sample sizes (n) w+ Control (8); w- Control (8) 
Independent Expt. 
Runs 
2 with >4 animals per genotype 
Data point total fluorescence per animal relative to mean of w- control 
  P value 
Significant
?  
Summary 
F, DFn, 
Dfd 
F test P 
value 
F test 
signifi
cant? 
w+ control vs. w- 
control 0.0688 No ns 
8.09, 7, 
7 0.0132 Yes 
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Sup. Fig 9a: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
2.065 5 0.4131 
F (5, 30) 
= 11.67 
P<0.0001   
Residual (within 
columns) 
1.062 30 0.03539       
Total 3.127 35         
Sample size (n) 25 
Independent Expt. 
Runs 
2 w/ biological triplicates for all except Rtf1 which was run once 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. dPaf1 0.4965 
0.1949 to 
0.7981 Yes *** 0.0003   
Control vs. dLeo1 0.3727 
0.07111 
to 0.6742 Yes ** 0.0087   
Control vs. 
dCDC73 0.4903 
0.1888 to 
0.7919 Yes *** 0.0004   
Control vs. dCtr9 0.4308 
0.1293 to 
0.7324 Yes ** 0.0019   
Control vs. dRtf1 0.8277 
0.4462 to 
1.209 Yes **** <0.0001   
dPaf1 vs. dLeo1 -0.1238 
-0.4542 
to 0.2065 No ns 0.8606   
dPaf1 vs. dCDC73 
-
0.0061
67 
-0.3365 
to 0.3242 No ns >0.9999   
dPaf1 vs. dCtr9 
-
0.0656
7 
-0.396 to 
0.2647 No ns 0.9899   
dPaf1 vs. dRtf1 0.3312 
-0.07342 
to 0.7358 No ns 0.1593   
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dLeo1 vs. dCDC73 0.1177 
-0.2127 
to 0.448 No ns 0.8841   
dLeo1 vs. dCtr9 
0.0581
7 
-0.2722 
to 0.3885 No ns 0.9942   
dLeo1 vs. dRtf1 0.455 
0.05041 
to 0.8596 Yes * 0.0204   
dCDC73 vs. dCtr9 -0.0595 
-0.3898 
to 0.2708 No ns 0.9936   
dCDC73 vs. dRtf1 0.3373 
-0.06725 
to 0.7419 No ns 0.1457   
dCtr9 vs. dRtf1 0.3968 
-
0.007752 
to 0.8014 No ns 0.057   
Sup. Fig 9b, Tub: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
0.278 6 0.04633 
F (6, 14) 
= 0.8653 
P=0.5433   
Residual (within 
columns) 
0.7496 14 0.05354       
Total 1.028 20         
Sample size (n) 10 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. dSpt4 0.0787 
-0.5664 
to 0.7238 No ns 0.9994   
Control vs. 
dCDC73 0.2742 
-0.3709 
to 0.9194 No ns 0.7668   
Control vs. dRtf1 -0.0189 
-0.664 to 
0.6262 No ns >0.9999   
Control vs. dCtr9 -
0.0877 -0.7329 
No ns 0.999   
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3 to 0.5574 
Control vs. dPaf1 -0.0849 
-0.73 to 
0.5602 No ns 0.9991   
Control vs. dLeo1 
0.0471
3 
-0.598 to 
0.6923 No ns >0.9999   
dSpt4 vs. dCDC73 0.1955 
-0.4496 
to 0.8407 No ns 0.9369   
dSpt4 vs. dRtf1 -0.0976 
-0.7427 
to 0.5475 No ns 0.9981   
dSpt4 vs. dCtr9 -0.1664 
-0.8116 
to 0.4787 No ns 0.9698   
dSpt4 vs. dPaf1 -0.1636 
-0.8087 
to 0.4815 No ns 0.9722   
dSpt4 vs. dLeo1 
-
0.0315
7 
-0.6767 
to 0.6136 No ns >0.9999   
dCDC73 vs. dRtf1 -0.2931 
-0.9383 
to 0.352 No ns 0.7122   
dCDC73 vs. dCtr9 -0.362 
-1.007 to 
0.2832 No ns 0.5018   
dCDC73 vs. dPaf1 -0.3591 
-1.004 to 
0.286 No ns 0.5103   
dCDC73 vs. dLeo1 -0.2271 
-0.8722 
to 0.418 No ns 0.8822   
dRtf1 vs. dCtr9 
-
0.0688
3 
-0.714 to 
0.5763 No ns 0.9997   
dRtf1 vs. dPaf1 -0.066 
-0.7111 
to 0.5791 No ns 0.9998   
dRtf1 vs. dLeo1 
0.0660
3 
-0.5791 
to 0.7112 No ns 0.9998   
dCtr9 vs. dPaf1 
0.0028
33 
-0.6423 
to 0.648 No ns >0.9999   
dCtr9 vs. dLeo1 0.1349 
-0.5103 
No ns 0.9894   
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to 0.78 
dPaf1 vs. dLeo1 0.132 
-0.5131 
to 0.7772 No ns 0.9905   
Sup. Fig 9b, Actin: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
0.1481 6 0.02469 
F (6, 17) 
= 0.484 
P=0.8112   
Residual (within 
columns) 
0.8672 17 0.05101       
Total 1.015 23         
Sample size (n) 10 
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
Control vs. dSpt4 0.1449 
-0.3864 
to 0.6762 No ns 0.9663   
Control vs. 
dCDC73 
0.0481
8 
-0.4831 
to 0.5795 No ns >0.9999   
Control vs. dRtf1 0.1723 
-0.359 to 
0.7035 No ns 0.9261   
Control vs. dCtr9 0.1424 
-0.3889 
to 0.6737 No ns 0.969   
Control vs. dPaf1 
0.0659
8 
-0.4653 
to 0.5973 No ns 0.9995   
Control vs. dLeo1 0.2285 
-0.3028 
to 0.7598 No ns 0.7787   
dSpt4 vs. dCDC73 -0.0967 
-0.7102 
to 0.5168 No ns 0.9981   
dSpt4 vs. dRtf1 
0.0273
7 
-0.5861 
to 0.6408 No ns >0.9999   
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dSpt4 vs. dCtr9 -0.0025 
-0.616 to 
0.611 No ns >0.9999   
dSpt4 vs. dPaf1 -0.0789 
-0.6924 
to 0.5346 No ns 0.9994   
dSpt4 vs. dLeo1 0.0836 
-0.5299 
to 0.6971 No ns 0.9991   
dCDC73 vs. dRtf1 0.1241 
-0.4894 
to 0.7375 No ns 0.9925   
dCDC73 vs. dCtr9 0.0942 
-0.5193 
to 0.7077 No ns 0.9983   
dCDC73 vs. dPaf1 0.0178 
-0.5957 
to 0.6313 No ns >0.9999   
dCDC73 vs. dLeo1 0.1803 
-0.4332 
to 0.7938 No ns 0.9523   
dRtf1 vs. dCtr9 
-
0.0298
7 
-0.6433 
to 0.5836 No ns >0.9999   
dRtf1 vs. dPaf1 -0.1063 
-0.7197 
to 0.5072 No ns 0.9967   
dRtf1 vs. dLeo1 
0.0562
3 
-0.5572 
to 0.6697 No ns >0.9999   
dCtr9 vs. dPaf1 -0.0764 
-0.6899 
to 0.5371 No ns 0.9995   
dCtr9 vs. dLeo1 0.0861 
-0.5274 
to 0.6996 No ns 0.999   
dPaf1 vs. dLeo1 0.1625 
-0.451 to 
0.776 No ns 0.9707   
Sup. Fig 9c, TDH3: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
0.00264
5 
2 0.001323 
F (2, 9) 
= 0.2174 
P=0.8087   
Residual (within 
columns) 
0.05475 9 0.006083       
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Total 0.05739 11         
Independent Expt. 
Runs 
1 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
WT vs. leo1Δ 
0.0039
41 
-0.15 to 
0.1579 No ns 0.9972   
WT vs. cdc73Δ 
-
0.0293
4 
-0.1833 
to 0.1246 No ns 0.8579   
leo1Δ vs. cdc73Δ 
-
0.0332
8 
-0.1873 
to 0.1207 No ns 0.8218   
Sup. Fig 9c, FBA1: 1-way ANOVA 
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value   
Treatment (between 
columns) 
0.1229 2 0.06147 
F (2, 9) 
= 2.248 
P=0.1615   
Residual (within 
columns) 
0.2461 9 0.02734       
Total 0.369 11         
Independent Expt. 
Runs 
2 w/ biological triplicates 
Data point mean fold change for 1 replicate relative to mean of controls 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI 
of diff. 
Significant? 
Summar
y 
Adjusted P 
Value 
  
WT vs. leo1Δ 
-
0.0686
5 
-0.3951 
to 0.2578 No ns 0.8303   
WT vs. cdc73Δ -0.2406 
-0.5671 
to 0.0858 No ns 0.154   
leo1Δ vs. cdc73Δ -0.172 
-0.4984 
to 0.1544 No ns 0.3485   
Sup. Fig 10c: 1-way Kruskal-Wallis ANOVA (see Supplementary Fig. 10a for sample sizes and 
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patient details) 
P value 
Exact or 
approx? 
Summary 
medians vary 
signif. (P < 
0.05)? 
Number 
of 
groups 
Kruskal-
Wallis 
statistic 
  
0.0167 
Approxi
mate ns Yes 3 8.186 
  
Independent Expt. 
Runs 
1-2 for individual patients w/ technical replicates 
Data point mean fold change for 1 patient relative to mean of healthy controls 
Dunn’s multiple 
comparisons test 
Mean 
rank 
diff. 
Significant
? 
Summary 
Adjusted 
P Value 
    
Healthy vs. C9- -17.78 Yes * 0.0152     
Healthy vs. C9+ -11 No ns 0.2017     
C9- vs. C9+ 6.783 No ns 0.8547     
Sup. Fig. 10d-e: Spearman r correlations (see Supplementary Fig. 10a for sample sizes and 
patient details) 
Independent Expt. 
Runs 
1-2 for individual patients w/ technical replicates 
Data point mean fold change for 1 patient relative to mean of healthy controls 
  
Spearm
an r 
P value 
(two-
tailed) 
Summary 
Exact or 
Approx? 
Significant
? (α = 
0.05) 
95% 
CI 
C9+ FTD only: 
C9orf72 Intron 1 vs 
CDC73 
0.1338 0.5527 ns Approx. No 
-0.317 
to 
0.535
3 
C9- FTD only: 
C9orf72 Intron 1 vs 
CDC73 
0.09289 0.6734 ns Approx. No 
-
0.343
5 to 
0.496
3 
C9+ ALS only: 
C9orf72 Intron 1 vs 
Paf1 
-0.2857 0.9048 
ns Approx. No 
-
0.476
1 to 
0.430
8 
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C9+ ALS only: 
C9orf72 Intron 1 vs 
Leo1 
0.3293 0.1562 
ns Approx. No 
-
0.146
3 to 
0.681
3 
C9- ALS only: 
C9orf72 Intron 1 vs 
Paf1 
0.6183 0.0022 
Yes Approx. ** 
0.253
6 to 
0.829
1 
C9- ALS only: 
C9orf72 Intron 1 vs 
Leo1 0.4952 0.0191 
Yes Approx. * 
0.079
82 to 
0.764 
Sup. Fig. 12: linear regression 
Independent Expt. 
Runs 
2 
  
Slope 
95% CI of 
slope 
F (DFn, DFd) 
Significa
nt? P-value   
G4C2 primers 
-3.622 
± 
0.1514 
-5.546 to 
-1.699 572.4 (1, 1) 
Yes 
0.0266   
RP49 primers 
-3.487 
± 
0.1511 
-5.407 to 
-1.568 532.8 (1, 1) 
Yes 
0.0276   
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Table S2-2: Fly lines 
Name Collection ID # Full genotype References 
Gmr-GAL4 n/a n/a w*;; Gmr-GAL4YH3 1 
ElavGS BDSC 43642 y[1] w[*];; P{w[+mC]=elav-
Switch.O}GSG301 
2 
DaGS n/a n/a w*; Da-GAL4[Geneswitch]; 2 
Da-GAL4 n/a n/a w*;; Da-GAL4 3 
HS-GAL4 BDSC 2077 w[*]; P{w[+mC]=GAL4-Hsp70.PB}2; 4 
Control n/a n/a w[1118]; UAS-DSRED; 5 
(G4C2)8 n/a n/a w[1118];; UAS-(G4C2)8 this paper 
(G4C2)29 n/a n/a w[1118]; UAS-(G4C2)29; 6 
(G4C2)49 (II) n/a n/a w[1118]; UAS-(G4C2)49; this paper 
(G4C2)49  n/a n/a w[1118];; UAS-(G4C2)49 6 
LDS-
(G4C2)44GR-
GFP 
n/a n/a w[1118];; UAS-LDS-(G4C2)4,42,44[GR-
GFP] 
this paper 
TDP4352S n/a n/a w[1118];; UAS-TDP43 7 
TDP4337M n/a n/a w[1118]; UAS-TDP43; 7 
w- Control BDSC 5905 w[1118];;  
Control 
RNAi/w+ 
control 1 
BDSC 31603 y[1] v[1];; P{y[+t7.7] 
v[+t1.8]=TRiP.JF01355}attP2 
previously 
used in8,9 
w+ control 2 BDSC 35788 y[1] v[1]; P{y[+t7.7] v[+t1.8]=UAS-
LUC.VALIUM10}attP2 
 
(GR)36 BDSC 58692 w[1118]; P{{y[+t7.7] w[+mC]=UAS-
poly-GR.PO-36}attP40; 
10 
Paf1 RNAi VDRC 20876 w[1118]; P{GD9782}v20876; previously 
used in11 
Paf1 RNAi-2 VDRC 108826 w[1118]; P{KK100080}VIE-260B;  
Leo1 RNAi VDRC 17490 w[1118];; P{GD8296}v17490 previously 
used in11 
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Leo1 RNAi-2 VDRC 106074 w[1118]; P{KK104959}VIE-260B;  
CDC73 RNAi BDSC 53278 y[1] v[1]; P{y[+t7.7] 
v[+t1.8]=TRiP.HMC03494}attP40; 
 
CDC73 
RNAi-2 
VDRC 28318 w[1118];; P{GD12640}v28318  
Ctr9 RNAi BDSC 33736 y[1] sc[*] v[1];; P{y[+t7.7] 
v[+t1.8]=TRiP.HMS00619}attP2 
 
Ctr9 RNAi-2 VDRC 108874 w[1118]; P{KK101412}VIE-260B;  
Rtf1 RNAi BDSC 34850 y[1] sc[*] v[1];; P{y[+t7.7] 
v[+t1.8]=TRiP.HMS00168}attP2 
 
Rtf1 RNAi-2 VDRC 110392 w[1118]; P{KK101209}VIE-260B;  
Spt4 RNAi BDSC 32896 y[1] sc[*] v[1]; P{y[+t7.7] 
v[+t1.8]=TRiP.HMS00685}attP2 
previously 
used in6 
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Table S2-3: Full Genotypes 
Fig. 1c 
Genotype (driver: HS-GAL4, 
BL2077) Includes Temp 
Control w1118/w*; HS-GAL4/+; n/a 25ᵒC 
UAS-G4C2  
(II) w1118/w*; HS-GAL4/UAS-(G4C2)n; (G4C2)29 and (G4C2)49 (II) 25ᵒC 
UAS-G4C2  
(III) 
w1118/w*; HS-GAL4/+; UAS-
(G4C2)n/+ (G4C2)8 and (G4C2)49 (III) 25ᵒC 
Fig. 1d Genotype (driver: Gmr-GAL4YH3) Includes Temp 
Control w1118/Y;; Gmr-GAL4/+ n/a 25ᵒC 
UAS-G4C2  
(II) 
w1118/Y; UAS-(G4C2)n/+; Gmr-
GAL4/+ (G4C2)29 and (G4C2)49 (II) 25ᵒC 
UAS-G4C2  
(III) 
w1118/Y;; UAS-(G4C2)n/Gmr-
GAL4 (G4C2)8 and (G4C2)49 (III) 25ᵒC 
Fig. 1e Genotype (driver: Gmr-GAL4YH3) Shown RNAi lines Temp 
Control 
 w1118/Y;; Gmr-GAL4, UAS-
(G4C2)n/UAS-RNAi Luc (BL31603) 25ᵒC 
UAS-RNAi  (II) 
 w1118/Y; UAS-RNAi/+; Gmr-
GAL4, UAS-(G4C2)n/+ CNOT7 (BL52947) 25ᵒC 
UAS-RNAi  
(III) 
 w1118/Y;; Gmr-GAL4, UAS-
(G4C2)n/UAS-RNAi Ctr9 (BL33736) 25ᵒC 
Fig. 2a Genotype (driver: Gmr-GAL4YH3) Shown RNAi lines Temp 
(GR)36 
Control 
 w1118/y1v1;UAS-(GR)36/+; Gmr-
GAL4/UAS-RNAi Luc (BL31603) 25ᵒC 
UAS-RNAi  (II) 
 w1118/y1v1;UAS-(GR)36/UAS-
RNAi; Gmr-GAL4/+ Fib (BL42553) 25ᵒC 
UAS-RNAi  
(III) 
 w1118/y1v1;UAS-(GR)36/+; Gmr-
GAL4/UAS-RNAi ELL (BL33399) 25ᵒC 
TDP43 
Control 
 w1118/y1v1;UAS-TDP4337M/+; 
Gmr-GAL4/UAS-RNAi Luc (BL31603) 25ᵒC 
UAS-RNAi  
(III) 
 w1118/y1v1;UAS-TDP4337M/+; 
Gmr-GAL4/UAS-RNAi MPI (BL34379), CPSF6 (BL34804) 25ᵒC 
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Figure 3a-b Genotype (driver: Gmr-GAL4YH3) Line Temp 
Control 
 w1118/Y;; Gmr-GAL4, UAS-
(G4C2)49/UAS-RNAi Luc RNAi (BL31603) 24ᵒC 
UAS-RNAi  (II) 
 w1118/Y; UAS-RNAi/+; Gmr-
GAL4, UAS-(G4C2)49/+ 
Paf1 RNAi (v20876), CDC73 RNAi 
(BL53278) 24ᵒC 
UAS-RNAi  
(III) 
 w1118/Y;; Gmr-GAL4, UAS-
(G4C2)49/UAS-RNAi 
Leo1 RNAi (v17490), Ctr9 RNAi 
(BL33736), Rtf1 RNAi (BL34850) 24ᵒC 
Figure 3c-d Genotype (driver: Gmr-GAL4YH3) Line Temp 
Control  w1118/Y;; Gmr-GAL4/UAS-RNAi Luc RNAi (BL31603) 24ᵒC 
UAS-RNAi  (II) 
 w1118/Y; UAS-RNAi/+; Gmr-
GAL4/+ 
Paf1 RNAi (v20876), CDC73 RNAi 
(BL53278) 24ᵒC 
UAS-RNAi  
(III)  w1118/Y;; Gmr-GAL4/UAS-RNAi 
Leo1 RNAi (v17490), Ctr9 RNAi 
(BL33736), Rtf1 RNAi (BL34850) 24ᵒC 
Figure 3e Genotype (driver: Elav-GS) Line Temp 
Control 
 w1118; UAS-DSRED/+; Elav-GS, 
UAS-(G4C2)49/+ UAS-DSRED 24ᵒC 
dPaf1 RNAi 
 w1118; UAS-RNAi/+; Elav-GS, 
UAS-(G4C2)49/+ v20876 24ᵒC 
dLeo1 RNAi 
 w1118;; Elav-GS, UAS-
(G4C2)49/UAS-RNAi v17490 24ᵒC 
dCDC73 RNAi 
 w1118/y1v1; UAS-RNAi/+; Elav-
GS, UAS-(G4C2)49/+ BL53278 24ᵒC 
UAS-TRiP  
(III) 
 w1118/y1sc*v1;;  Elav-GS, UAS-
(G4C2)49/UAS-RNAi 
Ctr9 RNAi (BL33736), Rtf1 RNAi 
(BL34850) 24ᵒC 
Figure 3f and 
Supplemental 
Fig 6 Genotype (driver: Elav-GS) Line Temp 
(G4C2)0 
Control  w1118; UAS-DSRED/+; Elav-GS/+ UAS-DSRED 24ᵒC 
(G4C2)49 
Control 
 w1118; UAS-DSRED/+; Elav-GS, 
UAS-(G4C2)49/+ UAS-DSRED 24ᵒC 
dPaf1 RNAi 
 w1118; UAS-RNAi/+; Elav-GS, 
UAS-(G4C2)49/+ v20876 24ᵒC 
dLeo1 RNAi 
 w1118;; Elav-GS, UAS-
(G4C2)49/UAS-RNAi v17490 24ᵒC 
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dCDC73 RNAi 
 w1118/y1v1; UAS-RNAi/+; Elav-
GS, UAS-(G4C2)49/+ BL53278 24ᵒC 
UAS-TRiP  
(III) 
 w1118/y1sc*v1;;  Elav-GS, UAS-
(G4C2)49/UAS-RNAi 
Ctr9 RNAi (BL33736), Rtf1 RNAi 
(BL34850) 24ᵒC 
Figure 3g Genotype (driver: Da-GS) Line Temp 
Control 
 w1118/Y; Da-GS, UAS-
(G4C2)49/UAS-DSRED; UAS-DSRED 24ᵒC 
dCDC73 RNAi 
 w1118/Y; Da-GS, UAS-
(G4C2)49/UAS-RNAi; BL53278 24ᵒC 
Figure 4a Genotype (driver: Elav-GS) Line Temp 
(G4C2)8 and (G4C2)49 
Control 
 w1118; UAS-DSRED/+; Elav-GS, 
UAS-(G4C2)n/+ UAS-DSRED 24ᵒC 
dPaf1 RNAi 
 w1118; UAS-RNAi/+; Elav-GS, 
UAS-(G4C2)n/+ v20876 24ᵒC 
dLeo1 RNAi 
 w1118;; Elav-GS, UAS-
(G4C2)n/UAS-RNAi v17490 24ᵒC 
dCDC73 RNAi 
 w1118/y1v1; UAS-RNAi/+; Elav-
GS, UAS-(G4C2)n/+ BL53278 24ᵒC 
UAS-TRiP  
(III) 
 w1118/y1sc*v1;;  Elav-GS, UAS-
(G4C2)n/UAS-RNAi 
Ctr9 RNAi (BL33736), Rtf1 RNAi 
(BL34850) 24ᵒC 
(G4C2)29 
Control 
 w1118; UAS-DSRED/UAS-
(G4C2)29; Elav-GS/+ UAS-DSRED 24ᵒC 
dPaf1 RNAi 
 w1118; UAS-RNAi/UAS-
(G4C2)29; Elav-GS/+ v20876 24ᵒC 
dLeo1 RNAi 
 w1118; UAS-(G4C2)29/+; Elav-
GS/UAS-RNAi v17490 24ᵒC 
dCDC73 RNAi 
 w1118/y1v1; UAS-RNAi/UAS-
(G4C2)29; Elav-GS/+ BL53278 24ᵒC 
UAS-TRiP  
(III) 
 w1118/y1sc*v1; UAS-(G4C2)29/+;  
Elav-GS/UAS-RNAi 
Ctr9 RNAi (BL33736), Rtf1 RNAi 
(BL34850) 24ᵒC 
Figure 4b Genotype (driver: Elav-GS) Line Temp 
Control 1* 
 w1118;; Elav-GS, UAS-
TDP4352S/+ (n/a) 24ᵒC 
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Control 2* 
 w1118; UAS-DSRED/+; Elav-GS, 
UAS-TDP4352S/+ UAS-DSRED 24ᵒC 
dPaf1 RNAi 
 w1118; UAS-RNAi/+; Elav-GS, 
UAS-TDP4352S/+ v20876 24ᵒC 
dCDC73 RNAi 
 w1118/y1v1; UAS-RNAi/+; Elav-
GS, UAS-TDP4352S/+ BL53278 24ᵒC 
dLeo1 RNAi 
 w1118;; Elav-GS, UAS-
TDP4352S/UAS-RNAi v17490 24ᵒC 
UAS-TRiP 
RNAi  (III) 
 w1118/y1sc*v1;;  Elav-GS, UAS-
TDP4352S/UAS-RNAi 
Ctr9 RNAi (BL33736), Rtf1 RNAi 
(BL34850) 24ᵒC 
* all controls merged to compensate for technical variability; results further validated (Sup Fig 3c) 
Figure 4c Genotype (driver: Gmr-GAL4YH3) Line Temp 
Control 
y1sc*v1/Y;; Gmr-GAL4, UAS-
(G4C2)4,42,44GR-GFP/+ (n/a) 26ᵒC 
UAS-RNAi  (II) 
y1sc*v1/Y; UAS-RNAi/+; Gmr-
GAL4, UAS-(G4C2)4,42,44GR-GFP/+ 
Paf1 RNAi (v20876), CDC73 RNAi 
(BL53278) 26ᵒC 
UAS-RNAi  
(III) 
y1sc*v1/Y;; Gmr-GAL4, UAS-
(G4C2)4,42,44GR-GFP/UAS-RNAi 
Leo1 RNAi (v17490), Ctr9 RNAi 
(BL33736), Rtf1 RNAi (BL34850) 26ᵒC 
Figure 4d Genotype Strain   
WT 
MATa his3Δ1 leu2Δ0 met15Δ0 
ura3Δ0  BY4741   
leo1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 
ura3Δ0 leo1Δ::KanMX  BY4741   
cdc73Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 
ura3Δ0 cdc73Δ::KanMX BY4741   
Figure 5a Genotype (driver: Elav-GS) Line Temp 
Control  w1118;; Elav-GS/+ (n/a) 24ᵒC 
(G4C2)8 and 
(G4C2)49  w1118;; Elav-GS/UAS-(G4C2)n (n/a) 24ᵒC 
Figure 5b Genotype (driver: Elav-GS) Line Temp 
Control  w1118;; Elav-GS/+ (n/a) 24ᵒC 
TDP43 
 w1118; UAS-TDP4337m/+; Elav-
GS/+ (n/a) 24ᵒC 
Supplemental 
Genotype (driver: Gmr-GAL4YH3) Shown RNAi lines Temp 
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Figure 1a 
UAS-RNAi  (II) 
 w1118/Y; UAS-RNAi/+; Gmr-
GAL4, UAS-(G4C2)n/+ 
Trs33 (BL51393), NXF1 
(BL42013), His2Av (BL44056) 25ᵒC 
UAS-RNAi  
(III) 
 w1118/Y;; Gmr-GAL4, UAS-
(G4C2)n/UAS-RNAi 
Med17 (BL34664), Med6 
(BL33743), Hel25E (BL33666), 
SMC2 (BL32369), RagC-D 
(BL32342), CG3829 (BL55245), 
Cdk12 (BL34838), Brd8 
(BL42658), Hrg (BL33378), Atg3 
(BL34359), Dom (BL38385), Not3 
(BL33002) 25ᵒC 
Supplemental 
Figure 1b Genotype (driver: Gmr-GAL4YH3) Shown RNAi lines Temp 
(G4C2)8 and (G4C2)49 
Control 
 w1118/Y;; Gmr-GAL4, UAS-
(G4C2)n/UAS-RNAi Luc RNAi (BL31603) 25ᵒC 
UAS-RNAi  (II) 
 w1118/Y; UAS-RNAi/+; Gmr-
GAL4, UAS-(G4C2)n/+ Fib (BL42553) 25ᵒC 
UAS-RNAi  
(III) 
 w1118/Y;; Gmr-GAL4, UAS-
(G4C2)n/UAS-RNAi Ct (BL33967) 25ᵒC 
Control 
Control  w1118/Y;; Gmr-GAL4/UAS-RNAi Luc RNAi (BL31603) 25ᵒC 
UAS-RNAi  (II) 
 w1118/Y; UAS-RNAi/+; Gmr-
GAL4/+ Fib (BL42553) 25ᵒC 
UAS-RNAi  
(III)  w1118/Y;; Gmr-GAL4/UAS-RNAi Ct (BL33967) 25ᵒC 
Supplemental 
Figure 1c 
Genotype (driver: Gmr-GAL4, 
BL1104) Shown RNAi lines Temp 
Control 
 w1118/Y; Gmr-GAL4, UAS-
LacZ/+; UAS-RNAi/+ Luc RNAi (BL31603) 25ᵒC 
UAS-RNAi  (II) 
 w1118/Y; UAS-RNAi/Gmr-GAL4, 
UAS-LacZ; (n/a) 25ᵒC 
UAS-RNAi  
(III) 
 w1118/Y; Gmr-GAL4, UAS-
LacZ/+; UAS-RNAi/+ 
AFF1-4 (BL34592), MRTO4 
(BL33730) 25ᵒC 
Supplemental 
Figure 2a-b Genotype (driver: Gmr-GAL4YH3) Line Temp 
w- control 
 w1118; UAS-DSRED/UAS-
UAS-DSRED 24ᵒC 
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(GR)36; Gmr-GAL4/+ 
w+ control 
 w1118/y1v1;UAS-(GR)36/+; Gmr-
GAL4/UAS-RNAi Luc RNAi (BL31603) 24ᵒC 
UAS-GD/KK 
RNAi (II) 
 w1118; UAS-RNAi/UAS-(GR)36; 
Gmr-GAL4/+ 
Paf1 RNAi (v20876), Paf1 RNAi-2 
(v108826), Leo1 RNAi-2 
(v106074), Ctr9 RNAi-2 (v108874), 
Rtf1 RNAi-2 (v110932) 24ᵒC 
UAS-RNAi  
(III) 
 w1118; UAS-(GR)36/+; Gmr-
GAL4/UAS-RNAi 
Leo1 RNAi (v17490), Cdc73 RNAi-
2 (v28318) 24ᵒC 
UAS-TRiP 
RNAi  (II) 
 w1118/y1v1; UAS-RNAi/UAS-
(GR)36; Gmr-GAL4/+ Cdc73 RNAi (BL53278) 24ᵒC 
UAS-TRiP 
RNAi  (III) 
 w1118/y1sc*v1;UAS-(GR)36/+; 
Gmr-GAL4/UAS-RNAi 
Ctr9 RNAi (BL33736), Rtf1 RNAi 
(BL34850), Spt4 RNAi (BL32896) 24ᵒC 
Supplemental 
Figure 3 Genotype (driver: Gmr-GAL4YH3) Line Temp 
 w- control 
 w1118; UAS-TDP4337M/+; Gmr-
GAL4/+ (n/a) 26ᵒC 
 w+ control 
 w1118/y1v1;UAS-TDP4337M/+; 
Gmr-GAL4/UAS-RNAi Luc RNAi (BL31603) 26ᵒC 
UAS-GD/KK 
RNAi  (II) 
 w1118; UAS-RNAi/UAS-
TDP4337M; Gmr-GAL4/+ 
Paf1 RNAi (v20876), Paf1 RNAi-2 
(v108826), Leo1 RNAi-2 
(v106074), Ctr9 RNAi-2 (v108874), 
Rtf1 RNAi-2 (v110932) 26ᵒC 
UAS-GD RNAi  
(III) 
 w1118; UAS-TDP4337M/+; Gmr-
GAL4/UAS-RNAi 
Leo1 RNAi (v17490), Cdc73 RNAi-
2 (v28318) 26ᵒC 
UAS-TRiP 
RNAi  (II) 
 w1118/y1v1; UAS-RNAi/UAS-
TDP4337M; Gmr-GAL4/+ Cdc73 RNAi (BL53278) 26ᵒC 
UAS-TRiP 
RNAi  (III) 
 w1118/y1sc*v1;UAS-TDP4337M/+; 
Gmr-GAL4/UAS-RNAi 
Ctr9 RNAi (BL33736), Rtf1 RNAi 
(BL34850), Spt4 RNAi (BL32896) 26ᵒC 
Supplemental 
Figure 4a Genotype Line Temp 
Da-GAL4 
w- control w1118;; Da-GAL4/+ (n/a) 26ᵒC 
w- RNAi  (II) w1118; UAS-RNAi/+; Da-GAL4/+ 
Paf1 RNAi (v20876), Paf1 RNAi-2 
(v108826), Ctr9 RNAi-2 (v108874), 
Leo1 RNAi-2 (v106074) 26ᵒC 
w- RNAi  (III) w1118;; Da-GAL4/UAS-RNAi Leo1 RNAi (v17490) 26ᵒC 
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Da-GS 
w- control w1118; Da-GS/+; (n/a) 26ᵒC 
w- RNAi  (II) w1118; UAS-RNAi/Da-GS; Rtf1 RNAi-2 (v110932) 26ᵒC 
w- RNAi  (III) w1118; Da-GS/+; UAS-RNAi/+ Cdc73 RNAi-2 (v28318) 26ᵒC 
w+ control 
 w1118/y1v1; Da-GS/+; UAS-
RNAi/+ Luc RNAi (BL31603) 26ᵒC 
w+ RNAi  (II)  w1118/y1v1; UAS-RNAi/Da-GS;  Cdc73 RNAi (BL53278) 26ᵒC 
w+ RNAi  (III) 
 w1118/y1sc*v1; Da-GS/+; UAS-
RNAi/+ 
Ctr9 RNAi (BL33736), Rtf1 RNAi 
(BL34850), Spt4 RNAi (BL32896) 26ᵒC 
Supplemental 
Figure 4b Genotype (driver: Da-GS) Line Temp 
w- control w1118/Y; Da-GS/+; (n/a) 26ᵒC 
w+ control w1118/Y; Da-GS/+; UAS-RNAi/+ Luc RNAi (BL31603) 26ᵒC 
w- RNAi w1118/Y; Da-GS/+; UAS-RNAi/+ v28318 26ᵒC 
w+ RNAi w1118/Y; UAS-RNAi/Da-GS; BL53278 26ᵒC 
Supplemental 
Figure 4c Genotype (driver: Da-GS) Line Temp 
w- control w1118/Y; Da-GS/+; (n/a) 26ᵒC 
w+ control w1118/Y; Da-GS/+; UAS-RNAi/+ Luc RNAi (BL31603) 26ᵒC 
w- RNAi w1118/Y; UAS-RNAi/Da-GS; v110392 26ᵒC 
w+ RNAi w1118/Y; Da-GS/+; UAS-RNAi/+ BL34850 26ᵒC 
Supplemental 
Figure 5a Genotype (driver: Gmr-GAL4YH3) Line Temp 
w- control 
 w1118/Y;; Gmr-GAL4, UAS-
(G4C2)49/+ (n/a) 25ᵒC 
UAS-GD/KK 
RNAi  (II) 
w1118/Y; UAS-RNAi/+; Gmr-GAL4, 
UAS-(G4C2)49/+ 
Paf1 RNAi-2 (v108826), Leo1 
RNAi-2 (v106074), Ctr9 RNAi-2 
(v108874), Rtf1 RNAi-2 (v110932) 25ᵒC 
UAS-GD RNAi  
(III) 
w1118/Y;; Gmr-GAL4, UAS-
(G4C2)49/UAS-RNAi Cdc73 RNAi-2 (v28318) 25ᵒC 
Supplemental 
Figure 5b Genotype (driver: Gmr-GAL4YH3) Line Temp 
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w- control  w1118/Y;; Gmr-GAL4/+ (n/a) 25ᵒC 
UAS-GD/KK 
RNAi  (II) 
w1118/Y; UAS-RNAi/+; Gmr-
GAL4/+ 
Paf1 RNAi-2 (v108826), Leo1 
RNAi-2 (v106074), Ctr9 RNAi-2 
(v108874), Rtf1 RNAi-2 (v110932) 25ᵒC 
UAS-GD RNAi  
(III) w1118/Y;; Gmr-GAL4/UAS-RNAi Cdc73 RNAi-2 (v28318) 25ᵒC 
Supplemental 
Figure 5c Genotype (driver: Gmr-GAL4YH3) Line Temp 
Control 
 w1118/Y;; Gmr-GAL4, UAS-
(G4C2)4,42,44GR-GFP/UAS-RNAi Luc RNAi (BL31603) 26ᵒC 
UAS-RNAi  (II) 
 w1118/Y; UAS-RNAi/+; Gmr-
GAL4, UAS-(G4C2)4,42,44GR-GFP/+ 
Paf1 RNAi (v20876), CDC73 RNAi 
(BL53278) 26ᵒC 
UAS-RNAi  
(III) 
 w1118/Y;; Gmr-GAL4, UAS-
(G4C2)4,42,44GR-GFP/UAS-RNAi 
Leo1 RNAi (v17490), Ctr9 RNAi 
(BL33736), Rtf1 RNAi (BL34850) 26ᵒC 
Supplemental 
Figure 5d Genotype (driver: Elav-GS) Line Temp 
Control 
 w1118/Y; UAS-DSRED/+; Elav-
GS, UAS-(G4C2)49/+ UAS-DSRED 24ᵒC 
RNAi (II) 
 w1118/Y; UAS-RNAi/+; Elav-GS, 
UAS-(G4C2)49/+ 
Paf1 RNAi-2 (v108826), Leo1 
RNAi-2 (v106074), Ctr9 RNAi-2 
(v108874), Rtf1 RNAi-2 (v110932) 24ᵒC 
RNAi (III) 
 w1118/Y;; Elav-GS, UAS-
(G4C2)49/UAS-RNAi Cdc73 RNAi-2 (v28318) 24ᵒC 
Supplemental 
Figure 7a Genotype (driver: Da-GS) Line Temp 
Control  w1118; UAS-DSRED/Da-GS;  UAS-DSRED 25ᵒC 
dPaf1 RNAi  w1118; UAS-RNAi/Da-GS; v20876 25ᵒC 
dCDC73 RNAi  w1118/y1v1; UAS-RNAi/Da-GS;  BL53278 25ᵒC 
dLeo1 RNAi  w1118; Da-GS/+; UAS-RNAi/+ v17490 25ᵒC 
Supplemental 
Figure 7b Genotype (driver: Elav-GS) Line Temp 
Control  w1118/Y;; Elav-GS/+ (n/a) 24ᵒC 
UAS-RNAi  (II)  w1118/Y; UAS-RNAi/+; Elav-GS/+ 
Paf1 RNAi (v20876), CDC73 RNAi 
(BL53278) 24ᵒC 
UAS-RNAi  
 w1118/Y;; Elav-GS/UAS-RNAi 
Leo1 RNAi (v17490), Ctr9 RNAi 
24ᵒC 
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(III) (BL33736), Rtf1 RNAi (BL34850) 
Supplemental 
Figure 8a Genotype (driver: Gmr-GAL4YH3) Line Temp 
w- control 
 w1118/Y;; Gmr-GAL4, UAS-
(G4C2)49/+ (n/a) 25ᵒC 
w+ control 
w1118/Y;; Gmr-GAL4, UAS-
(G4C2)49/UAS-RNAi Luc RNAi (BL31603) 25ᵒC 
Supplemental 
Figure 8b Genotype (driver: Da-GS) Line Temp 
w- control 
 w1118/Y; Da-GS, UAS-
(G4C2)49/UAS-DSRED; UAS-DSRED 24ᵒC 
w+ control 
 w1118/Y; Da-GS, UAS-
(G4C2)49/+; UAS-RNAi/+ Luc RNAi (BL31603) 24ᵒC 
Supplemental 
Figure 8c Genotype (driver: Elav-GS) Line Temp 
w- control 
 w1118/Y; UAS-DSRED/+; Elav-
GS, UAS-(G4C2)49/+ UAS-DSRED 24ᵒC 
w+ control 
 w1118/Y;; Elav-GS, UAS-
(G4C2)49/UAS-Luc Luc (BL35788) 24ᵒC 
Supplemental 
Figure 8d Genotype (driver: Elav-GS) Line Temp 
w- control 1 
 w1118;; Elav-GS, UAS-
(G4C2)49/+ (n/a) 24ᵒC 
w- control 2 
 w1118; UAS-DSRED/+; Elav-GS, 
UAS-(G4C2)49/+ UAS-DSRED 24ᵒC 
w+ control 1 
 w1118/y1v1;; Elav-GS, UAS-
(G4C2)49/UAS-RNAi Luc RNAi (BL31603) 24ᵒC 
w+ control 2 
 w1118/y1v1;; Elav-GS, UAS-
(G4C2)49/UAS-Luc Luc (BL35788) 24ᵒC 
Supplemental 
Figure 8e Genotype (driver: Gmr-GAL4YH3) Line Temp 
w- control 
y1sc*v1/Y;; Gmr-GAL4, UAS-
(G4C2)4,42,44GR-GFP/+ (n/a) 26ᵒC 
w+ control 
y1sc*v1/Y;; Gmr-GAL4, UAS-
(G4C2)4,42,44GR-GFP/UAS-RNAi Luc RNAi (BL31603) 26ᵒC 
Supplemental 
Genotype (driver: ElavGS) Line Temp 
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Figure 9a 
Control 
 w1118; UAS-DSRED/UAS-
(G4C2)49; Elav-GS/+ UAS-DSRED 24ᵒC 
dPaf1 RNAi 
 w1118; UAS-RNAi/UAS-
(G4C2)49; Elav-GS/+ v20876 24ᵒC 
dCDC73 RNAi 
 w1118/y1v1; UAS-RNAi/UAS-
(G4C2)49; Elav-GS/+ BL53278 24ᵒC 
dLeo1 RNAi 
 w1118; UAS-(G4C2)49/+; Elav-
GS/UAS-RNAi v17490 24ᵒC 
UAS-TRiP 
RNAi  (III) 
 w1118/y1sc*v1; UAS-(G4C2)49/+; 
Elav-GS/UAS-RNAi 
Ctr9 RNAi (BL33736), Rtf1 RNAi 
(BL34850) 24ᵒC 
Supplemental 
Figure 9b Genotype (driver: Da-GS) Line Temp 
Control  w1118; UAS-DSRED/Da-GS;  UAS-DSRED 25ᵒC 
dPaf1 RNAi  w1118; UAS-RNAi/Da-GS; v20876 25ᵒC 
dCDC73 RNAi  w1118/y1v1; UAS-RNAi/Da-GS;  BL53278 25ᵒC 
dLeo1 RNAi  w1118; Da-GS/+; UAS-RNAi/+ v17490 25ᵒC 
UAS-TRiP 
RNAi  (III) 
 w1118/y1sc*v1; Da-GS/+; UAS-
RNAi/+ 
Ctr9 RNAi (BL33736), Rtf1 RNAi 
(BL34850) 25ᵒC 
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Table S2-4: Primers 
Target Species Assay Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
UAS-
G4C2 
n/a  PCR GAATTCGAGCTCAGATCTCCC
G 
TCTAGAGGATCCGGTACCGA
GTCTCGAG 
UAS-
LDS-
G4C2 
n/a PCR CTCGCTGAGGGTGAACAAGA ACTTGTGGCCGTTTACGTCG 
Actin5C Dmel. qPCR CGAAGAAGTTGCTGCTCTGGT
TGT 
GGACGTCCCACAATCGATGG
GAAG 
dCDC73 Dmel. qPCR AGCGTGAAGACCAACTATCTC
A 
CGCACGTAGACCGAGTGTT 
dCtr9 Dmel. qPCR ATTGCGCACGTTTATGTCGA GACGGGCCTTAAGTAGCACT 
dLeo1 Dmel. qPCR ACGGCTGATCGACACTGATA TGGCTCTCGACTTTATCCCG 
dPaf1 Dmel. qPCR CCAAAGCTTCCAAGGGCTAC CGATAGCGCTGCATACGATG 
dRP49 Dmel. qPCR TGTCCTTCCAGCTTCAAGATG
ACCATC 
CTTGGGCTTGCGCCATTTGT
G 
dRtf1 Dmel. qPCR CGGACGCAATCCCTGATCG CCGTTTGGGGCTTCTTTCG 
βTub56D Dmel. qPCR CATCCAAGCTGGTCAGTG GCCATGCTCATCGGAGAT 
UAS-
G4C2 
n/a qPCR AGACTCGGTACCGGATCCTC GCTCCCATTCATCAGTTCCA 
UAS-
TDP43 
n/a qPCR TGTCTTCATCCCCAAGCCAT TGTGCTTAGGTTCGGCATTG 
hRPLP0 Hsap qPCR TCTACAACCCTGAAGTGCTTG
AT 
CAATCTGCAGACAGACACTG
G 
hGAPDH Hsap qPCR GTTCGACAGTCAGCCGCATC GGAATTTGCCATGGGTGGA 
C9orf72 
3'-repeat 
Hsap. qPCR 
& ChIP 
CCTGATAGGAGATAACAGGAT
TCCAC 
CGACATCACTGCATTCCAAC
TGTC 
hPAF1 Hsap. qPCR CCACTGAGTTCAACCGTTATG
G 
TCCTCGGTAAACTGCTGCTT
C 
hLEO1 Hsap qPCR CAAGTGGTCAGATGGAAGCA TGGGGCTTTGTACACATCAA 
hCDC73 Hsap. qPCR GGGGCACTGCAATTAGTGTT CTGCACAAAAACGGCTACAA 
Intergenic Hsap. ChIP CCAACTGGGTGCTGCCTAGA  AGGGTGCCCATCACAGATGG 
scACT1 Sce. qPCR ATTCTGAGGTTGCTGCTTTGG TGTCTTGGTCTACCGACGAT
AG 
scTDH3 Sce. qPCR TTGCCATGGGGTTCTTCCAA CACCAGCGTCAATGTGCTTT 
scFBA1 Sce. qPCR AACCTCTAACGGTGGTGCTG ATCTGATGTAGTGGGCAGCG 
eYFP Sce. qPCR GAGCTGAAGGGCATCGACTT TTCTTCTGCTTGTCGGCCAT 
C9 repeat Sce. qPCR AGCTTAGTACTCGCTGAGGGT
G 
GACTCCTGAGTTCCAGAGCT
TG 
scLEO1 Sce. qPCR AGGGAGGATCAACTGGACGA ATGTACCGTCTGACCACTGC 
scCDC73 Sce. qPCR ATCTGAAAGCACCCGGTCAG CCACCACAACTGGATCGGAA 
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Chapter 2: Supplementary figures and legends 
 
Figure S2-1 
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Supplementary Figure S2-1: Screen extended data. 
(a) Representative images for the categories identified during the RNAi-based screen in 
Gmr-GAL4 > (G4C2)49 expressing animals: “suppressors” (strong recovery of 
ommatidial organization, eye color, and eye size), “mild suppressors” (recovery of 
ommatidial organization, eye color, and eye size while degenerative effects were still 
present), “no effect” (indistinguishable from controls), “mild enhancers” (increased 
disruptions in ommatidial organization and pigment loss), “enhancers” (strongly 
increased disruptions in ommatidial organization, pigment loss, and eye size), and “lethal 
enhancers” (lethality in the late pupal stage ; rare (n<2) escapers’ eyes looked like 
“enhancers”). All hits were independently tested 2+ times to confirm reproducibility (n>5 
flies/cross). (b) Mild enhancers, enhancers, and lethal enhancers were expressed alone 
or in control (G4C2)8 expressing animals to define those that were toxic in control 
scenarios. Shown are representative images for an “unspecific enhancer” (RNAi line that 
caused toxicity in controls) and a “true enhancer” (RNAi line that had no effect in controls 
while enhancing (G4C2)49-toxicity). Unspecific enhancers were excluded. (a-b) Scale 
bars: 100μm (c) To identify RNAi lines that altered (G4C2)49-toxicity indirectly by 
effecting the GAL4/UAS expression system, RNAi lines were co-expressed with a 
control LacZ transgene. β-Galactosidase protein levels were quantified by western 
immunoblot. RNAi lines that significantly increased or decreased LacZ expression in a 
manner consistent with its effect on (G4C2)49-toxicity were reclassified as either “LacZ-
suppressors” or “LacZ-enhancers” and excluded. Shown is a representative western 
immunoblot. All lines with potential effects were independently tested twice with 
biological duplicates to confirm reproducibility. (d) Gene ontology analyses revealed GO 
terms enriched in the panel of modifiers identified in the screen that alter (G4C2)49-
toxicity (119/3582 genes). To compensate for any biases introduced in the RNAi library, 
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the genes screened were used as the background. RNAi lines that failed control 
scenarios (b-c) were excluded. Plotted: significant (p-value ≤ 10^-3) enrichment scores 
of >3.00. Additional details for this and subsequent figures: Supplemental Data (all 
screen data and significant GO-terms), Supplemental Table S2-1 (detailed sampling, 
reproducibility and statistics), methods (sampling methods). 
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Figure S2-2 
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Supplementary Figure S2-2: Downregulation of PAF1C and dSpt4 does not 
suppress toxicity caused by expression of (GR)30+ or (PR)50. 
(a-b) dPAF1C components and dSpt4 were examined for modification of (GR)36-toxicity 
in the fly optic system (Gmr-GAL4). Internally, there was no significant recovery in retinal 
tissue loss with multiple RNAi lines targeting dPaf1, dLeo1, dCtr9, and dRtf1. dCDC73 
RNAi enhanced toxicity both externally and internally while this effect was not 
reproducible with dCDC73 RNAi-2. Internal retina depth (arrows) was quantified for 
individual animals. N flies for RNAi: control=9, dPaf1=10, dLeo1=9, dCDC73=4, dCtr9=8, 
dRtf1=6, dSpt4=14. N flies for RNAi-2 = 4 for all genotypes. Shown: individual data 
points (each representing 1 animal) with mean±SD. Statistics: ANOVAs with Dunnett’s 
correction (RNAi), ANOVA with Tukey’s correction (RNAi-2), p-values: *=0.03, no 
significance (n.s.) >0.05. Scale bars: external eye = 100μm, internal eye = 35μm. (c-d) 
To further assess the specificity of PAF1C to (G4C2)30+ RNA models, yeast spotting 
assays were used. Control (CCDB), (PR)50 or (GR)100 were expressed in yeast using 
galactose-inducible transgenes (see methods). Expression of (PR)50 and (GR)100 
reduced colony formation in WT cells. This effect was unaltered in leo1Δ yeast. 
Interestingly, cdc73Δ caused further reduced growth in (GR)100 expressing yeast but 
had no effect on yeast expressing (PR)50. This is consistent with dCDC73 RNAi data in 
(GR)36-expressing flies where loss of this component, in one RNAi line, increased GR-
associated toxicity. Note that any mild effects observed with individual PAF1C 
components and dSpt4 can be explained by the fact that a GR-producing mRNA 
transcript, despite being G4C2-independent, will still be GC-rich based on the standard 
codon table. PAF1C and Spt4 are important for transcription of GC-rich DNA (Rondón, 
A. G. et al, 2004; Rondón, A. G. et al, 2003). Shown: data from one experiment; all 
experiments were independently repeated with similar results. 
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Figure S2-3 
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Supplementary Figure S2-3: Downregulation of dPAF1C and dSpt4 does not 
suppress toxicity caused by expression of TDP43 in the fly eye. 
(a-b) dPAF1C and Spt4 RNAi were tested as modifiers of TDP43-toxicity in the fly optic 
system (Gmr-GAL4). Only dCDC73 RNAi caused significant suppression of the external 
and internal eye in these animals. This effect was not reproduced with a second, 
independent RNAi lines targeting dCDC73. Internal retina depth (arrows) was quantified 
for individual animals. N flies for RNAi: control=13, dPaf1=9, dLeo1=4, dCDC73=5, 
dCtr9=4, dRtf1=4, dSpt4=9. N flies for RNAi-2: control=6, dPaf1=4, dLeo1=6, 
dCDC73=6, dCtr9=6, dRtf1=6. Shown: individual data points (each representing 1 
animal) with mean±SD. Scale bars: external eye = 100μm, internal eye = 35μm. (c) 
Expression from the TDP43 transgene was analyzed by western immunoblot when 
dPAF1C was downregulated revealing no change in TDP43 protein levels. Shown: 
individual data points with mean±SD; mean value of biological triplicates (n=10 
flies/replicate). Statistics: ANOVAs with Tukey’s correction, p-values: ****< 0.0001, no 
significance (n.s.) >0.05. Shown: data from one experiment while all experiments were 
independently repeated with similar results. See Supplemental Figure S2-11 for 
uncropped western images for this and subsequent figures. 
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Figure S2-4 
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Supplementary Figure S2-4: Characterization of dPAF1C RNAi fly lines.  
(a) RNA levels of dPAF1C components were assessed by qPCR to define RNAi efficacy 
in flies. UAS-RNAi fly lines were ubiquitously expressed and compared to background-
matched controls. For samples analyzed with Da-GAL4, expression was measured in 
larvae. For samples analyzed with Da-GS, expression was measured in adult animals 
(n=10) after 5d or 10d of drug-induced expression. Shown: individual data points with 
mean±SD; mean value of 3-6 biological replicates. (b-c) RNAi lines targeting dCDC73 or 
dRtf1 were analyzed for level of protein knockdown by western immunoblot. Shown: 
individual data points with mean±SD; mean value of 3 biological replicates (n=10 
flies/replicate). Statistics: ANOVAs with Tukey’s correction (dPaf1 and dLeo1 RNAi 
only), unpaired 2-tailed student t-test; p-values: ****<0.0001, ***<0.001, **<0.01, *<0.05. 
Shown: data from one experiment while all experiments were independently repeated 
with similar results. 
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Figure S2-5 
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Supplementary Figure S2-5: Extended data showing dPAF1C RNAi lines suppress 
(G4C2)30+ toxicity in the fly. 
(a) Downregulation of each of the components of dPAF1C with a second set of RNAi 
lines mitigates toxicity associated with (G4C2)49 expression in the fly eye, seen 
externally by reduced pigment loss and reduced disruption in ommatidial organization 
and internally by increased integrity of the retinal tissue. All RNAi-2 lines are in a w- 
genetic background. Internal retina depth (arrows) was quantified for individual animals. 
N flies: control=12, dPaf1=5, dLeo1=6, dCDC73=6, dCtr9=6, dRtf1=3. (b) 
Downregulation of components of dPAF1C with a second set of RNAi lines has no effect 
on control fly eyes. Internal retina depth (arrows) was quantified for individual animals. N 
flies: control=4, dPaf1=3, dLeo1=4, dCDC73=4, dCtr9=3, dRtf1=5. (c) dPAF1C RNAi 
were tested in a second, independent fly model expressing expanded (G4C2)30+ in the 
fly eye. This model contains a sequence 5’ of the repeat (leader sequence, LDS; 114bp 
of intronic sequence found upstream of the repeat in C9orf72) and a 3’ GFP tag in the 
GR reading frame. Toxicity in this model is also suppressed by dPAF1C RNAi co-
expression, seen externally by reduced pigment loss and reduced disruption in 
ommatidial organization and internally by increased integrity of the retinal tissue. Internal 
retina depth (arrows) was quantified for individual animals. N flies: control=6, dPaf1=5, 
dLeo1=5, dCDC73=5, dCtr9=6, dRtf1=6. (a-c) each data point represents one animal. 
Scale bars: external eye = 100μm, internal eye = 35μm. (d) At 20d, climbing deficits 
caused by (G4C2)49 expression in the adult male nervous system are rescued when 
dPAF1C RNAi-2 lines are co-expressed. N flies: control=51, dPaf1=85, dLeo1=73, 
dCDC73=67, dCtr9=87, dRtf1=31. Individual data points are the mean % of animals that 
could climb per tube. Average of 16±3.6 animals per tube. Statistics: ANOVAs with 
Tukey’s correction, p-values: ****<0.0001, ***<0.001, **<0.01, *<0.05. Shown: individual 
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data points with mean±SD; data from one experiment; all experiments were 
independently repeated twice with similar results. 
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Figure S2-6 
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Supplementary Figure S2-6: Vacuole formation scoring schematic and additional 
examples of genotypes reported.    
(a) Scoring of vacuole formation (arrowheads) in the adult fly brain. A scale was 
developed from 0-4 where 0 = no vacuoles and 4 = frequent medium-large vacuoles. 
“rare” means ≤5 vacuoles and “frequent” means >5 vacuoles. Sections through the 
entire brain of each animal were assessed in scoring. (G4C2)49 expression in 8d 
animals typically receives a score of 1. (G4C2)49 expression in 28d animals typically 
receives a score of 3-4.  Expression is driven by the drug-inducible neuronal driver, 
ElavGS. (b) Additional representative images of non-G4C2, age matched controls at 
28d. (c) Additional representative images of vacuoles observed in (G4C2)49 brains at 
28d (see Fig 3f). dPAF1C components are targeted by RNAi and result in suppression of 
vacuole formation in (G4C2)49 expressing animals. Shown: data from one experiment; 
experiment was repeated twice with similar results. Scale bars: 50μm 
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Figure S2-7 
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Supplementary Figure S2-7: Characterization of the dPAF1C in the fly. 
(a) RNAi for dPAF1C components were expressed in the adult fly nervous system using 
the drug-inducible neuronal driver, ElavGS. Survival of animals with age was evaluated. 
All RNAi but dCDC73 RNAi results in reduced lifespan compared to control animals. N 
flies: control=301, dPaf1=200, dLeo1=275, dCDC73=200, dCtr9=210, dRtf1=200. (b) 
Co-regulation of dPAF1C components and dSpt4 were determined by looking for 
reduced expression of components when dPaf1, dLeo1, or dCDC73 were 
downregulated by RNAi ubiquitously in adult animals (DaGS, 6d). No significance was 
detected except for dCtr9 showing downregulation with dCDC73 RNAi. Shown: 
individual data points with mean±SD; mean value of biological triplicates (n=10 
flies/replicate). Statistics: (a) log-rank tests, (b) ANOVA with Tukey’s correction; p-
values: ****<0.0001, ***<0.001, **<0.01, *<0.05, no significance (n.s.) >0.05. Shown: 
data from one experiment; all experiments were independently repeated with similar 
results. 
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Figure S2-8 
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Supplementary Figure S2-1: Comparisons of w- vs w+ genetic background controls 
in (G4C2)30+ expressing flies shows no significant differences. 
To address potential concerns of different RNAi genetic backgrounds of the lines used in 
this study, multiple controls with different genetic backgrounds were examined. Here we 
show representative data. (a) Toxicity associated with (G4C2)49 expression looks 
similar both externally and internally in the fly eye when the transgene is expressed in 
the optic system (Gmr-GAL4) in w- vs w+ genetic backgrounds. Internal retina depth 
(arrows) was quantified for individual animals. N flies: w-=12, w+=9. Shown: individual 
data points (each representing 1 animal) with mean±SD. Scale bars: external eye = 
100μm, internal eye = 35μm. (b) Ubiquitous expression of (G4C2)49 in adult flies results 
in similar lifespans in w- vs w+ genetic backgrounds. N flies: w-=188, w+=106. (c) 
Climbing deficits develop with age in animals expressing (G4C2)49 in the adult fly 
nervous system, ElavGS. The % flies that can climb is comparable in w- and w+ controls 
(20d, males). N flies: w-=51, w+=72. Shown: Individual data points are mean % of 
animals that could climb per tube; individual data points with mean±SD. (d) qPCR 
analysis of (G4C2)49 RNA levels in the adult fly nervous system is statistically similar in 
multiple genetic backgrounds. Shown: individual data points with mean±SD; mean value 
of biological triplicates (n=25 flies/replicate) from 2 independent experiments. (e) 
External eye imaging of GR-GFP in Gmr-GAL4 > LDS-(G4C2)44GR-GFP animals results in 
similar GFP fluorescence independent of genetic background. N flies: w-=8, w+=8. 
Shown: individual data points (each representing 1 animal) with mean±SD. Scale bars: 
100μm. Statistics: (a,c,e) unpaired 2-tailed student t-tests, (b) log-rank test, (d) ANOVA 
with Tukey’s correction; p-value: no significance >0.05. See Supplemental Figure 12 for 
optimization of fly G4C2 qPCR reactions for this and subsequent figures. 
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Figure S2-9 
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Supplementary Figure S2-9: Extended qPCR fly and yeast data. 
(a) A second, independent (G4C2)49 transgene was co-expressed with dPAF1C RNAi 
lines in the adult brain using a drug inducible, neuronal driver (ElavGS, 16d). 
Downregulation of all dPAF1C components caused significantly less RNA to be 
produced from the (G4C2)49 transgene by qPCR, consistent with data in Fig. 4a. 
Shown: individual data points with mean±SEM; mean value of biological triplicates (n=25 
flies/replicate) from 2 independent experiments. (b) RNA levels for endogenous dRNAPII 
driven genes βTUB56D (β-Tubulin) and ACT5C (β-Actin) are unchanged upon 
knockdown of dPAF1C by qPCR. The ubiquitous, drug-inducible driver, DaGS, was used 
to drive RNAi expression in whole animals (6d). Shown: individual data points with 
mean±SD; mean value of biological triplicates (n=10 flies/replicate); data from 1 
experiment while data reproduced in a second, independent experiment. (c) leo1Δ or 
cdc73Δ yeast strains do not alter RNA levels produced from endogenous scRNAPII 
genes, TDH3 and FBA1. RNA levels were measured by qPCR.  Shown: individual data 
points with mean±SD; mean value of biological triplicates from 1 experiment. Statistics: 
ANOVAs with Tukey’s correction, p-values: ****<0.0001, ***<0.001, **<0.01, *<0.05, no 
significance >0.05. 
 
 
 
 
 
 
 
 
297 
 
Figure S2-10 
 
 
298 
 
Supplementary Figure S2-10: Extended patient data. 
(a) Summary of iPS and fibroblast cell lines used in Fig 6a-b, respectively. (b) Summary 
of patient cohort used in this study. Total number, cases that were male (%) and 
average age at onset/death/duration: median (minimum, 25th percentile, 75th percentile, 
and maximum). (c) In frontal cortex tissue from FTD cases qPCR analysis of 
endogenous expression of hCDC73 revealed no significant change in expression in C9+ 
versus C9- cases. C9- cases did show a significant upregulation of hCDC73 compared 
to healthy controls.  Shown: individual data points (each representing 1 individual) with 
mean±SEM. (d) Spearman correlation coefficients for C9+ or C9- FTD cases show no 
correlation in hCDC73 expression and C9orf72 expression in the frontal cortex of 
patients. (e) Spearman correlation coefficients for C9+ or C9- ALS cases showed no 
correlation in expression of hPAF1 and hLEO1 and expression of C9orf72 in the frontal 
cortex of C9+ patients. In C9- ALS patients, there were weak correlations that were 
markedly lower than those in C9+ FTD patients (see Fig. 6d). C9orf72 intron 1: the 
intronic gene region immediately 3’ of the G4C2 repeat in the C9orf72 pre-mRNA 
transcript. (d,e) Shown: individual data points (each representing 1 individual) with linear 
regression±SE. Statistics: (c) ANOVA with Tukey’s correction, (d,e) Spearman R 
correlations; p-values: ****<0.0001, ***<0.001, **<0.01, *<0.05, no significance (n.s.) 
>0.05. 
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Figure S2-11 
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Supplementary Figure S2-11: Full, uncropped western immunoblot images with 
protein standards. 
Uncropped western immunoblot images for all relevant figures. (a) protein ladder shown 
is SuperSignal Enhanced Molecular Weight Protein Ladder (Fisher Sci #84786). (b-f) 
protein ladder shown is Novex Sharp Pre-stained Protein Standard (Invitrogen 
#LC5800). 
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Figure S2-12 
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Supplementary Figure S2-12. G4C2 and RP49 primer optimization for qPCR. 
During optimization of primers for qPCR reactions used in this study, primer efficiencies 
and melt curves were closely examined to ensure validity of all reactions. (a) For 
measuring (G4C2)n mRNA levels in flies, qPCR primers were designed that utilized 
unique restriction enzyme sequences located 3’ of the repeat. (b) RP49, a common 
housekeeping gene, shows a similar primer efficiency to the G4C2 primers, both ~90%, 
and was used as the main reference gene. Primer efficiencies were calculated using 
serial dilutions of cDNA made from control samples expressing (G4C2)49 in the fly 
nervous system (using ElavGS). Shown: mean value of biological triplicates from 2 
independent experiments and the resulting trendline is shown±SD. Representative melt 
curves from one of the biological triplicates is shown. Further, qPCR products were run 
on an agarose gel to confirm that there was one product and that it was the expected 
size (data not shown). 
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Chapter 2: Supplementary data 
KEY     
NE = no effect 
MS = mild suppression 
S = suppression 
ME = mild enhancer 
E = enhancer 
E-L = lethal enhancer 
A = additive enhancer 
LacZ-E = enhancer of Gal4/UAS system 
LacZ-S = suppressor of Gal4/UAS system 
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05672 
spi 
BL34645 
HMS0
1120 A E E   E  
CG1071
9 
FBgn00
10300 
brat 
BL34646 
HMS0
1121 E E NE NE NE  NE 
CG3242 FBgn00
04892 
sob 
BL34648 
HMS0
1123  NE      
CG4212 FBgn00
15791 
Rab14 
BL34654 
HMS0
1130  NE      
CG3469 FBgn00
15000 
betaggt-I 
BL34687 
HMS0
1165  NE      
CG7111 FBgn00
20618 
Rack1 
BL34694 
HMS0
1173 
E E NE NE ME  
(ME 
POSSIBL
E) 
CG4579 FBgn00
21761 
Nup154 
BL34710 
HMS0
1189  NE      
CG5848 FBgn00
00250 
cact 
BL34775 
HMS0
0084  NE      
CG1338
9 
FBgn00
10265 
RpS13 
BL34820 
HMS0
0135 A E E   E  
CG7793 FBgn00
01965 
Sos 
BL34833 
HMS0
0149  NE      
CG1149
0 
FBgn00
31233 
CG11490 
BL34859 
HMS0
0177  NE      
CG1324
3 
FBgn00
28903 
CG13243 
BL34861 
HMS0
0179  NE      
CG6122 FBgn00
04872 
piwi 
BL34866 
HMS0
0185 A E ME   E  
306 
 
CG1802
8 
FBgn00
02566 
lt 
BL34871 
HMS0
0190  NE      
CG1137
2 
FBgn00
31213 
galectin 
BL34880 
HMS0
1225  NE      
CG9242 FBgn00
00239 
bur 
BL34889 
HMS0
1234  NE      
CG1862
7 
FBgn00
28970 
betaggt-II 
BL34902 
HMS0
1247  NE      
CG3956 FBgn00
03448 
sna 
BL34906 
HMS0
1252  NE      
CG3166 FBgn00
00097 
aop 
BL34909 
HMS0
1256 A E-L E   E  
CG7082 FBgn00
31401 
papi 
BL34932 
HMS0
1282  NE      
CG1069
9 
FBgn00
02023 
Lim3 
BL34962 
HMS0
0596  NE      
CG4114 FBgn00
04583 
ex 
BL34968 
HMS0
0874  NE      
CG3352 FBgn00
01075 
ft 
BL34970 
HMS0
0932  NE      
CG3752 FBgn00
12036 
Aldh 
BL34989 
HMS0
1399  NE      
CG1725
9 
FBgn00
31497 
CG17259 
BL34992 
HMS0
1402  NE      
CG1278
9 
FBgn00
25697 
santa-maria 
BL34995 
HMS0
1405 
(ME 
POSSIBL
E) NE NE  ME   
CG4824 FBgn00
00182 
BicC 
BL34997 
HMS0
1407  NE      
CG6521 FBgn00
27363 
Stam 
BL35016 
HMS0
1429  NE      
CG4952 FBgn00
05677 
dac 
BL35022 
HMS0
1435  NE      
CG1374 FBgn00
03866 
tsh 
BL35030 
HMS0
1443  NE      
CG1850
7 
FBgn00
28527 
CG18507 
BL35033 
HMS0
1447  NE      
CG3779 FBgn00
02973 
numb 
BL35045 
HMS0
1459  NE      
CG4428 FBgn00
31298 
Atg4 
BL35740 
HMS0
1482  NE      
CG6601 FBgn00
15797 
Rab6 
BL35744 
HMS0
1486  NE      
CG3523 FBgn00
27571 
CG3523 
BL35775 
HMS0
1524  NE      
CG1263
0 
FBgn00
28979 
tio 
BL35812 
HMS0
1527  NE      
CG1036
0 
FBgn00
03231 
ref(2)P 
BL36111 
HMS0
0551  NE      
CG6699 FBgn00
25724 
beta'Cop 
BL36113 
HMS0
1038  NE NE NE NE NE NE 
CG5363 FBgn00
04106 
cdc2 
BL36117 
HMS0
1531 A E ME MS E ME  
CG5686 FBgn00
24248 
chico 
BL36665 
HMS0
1553 E-L E-L NE NE ME  NE 
CG1071 FBgn00
24371 
E2f2 
BL36674 
HMS0
1562  NE      
CG9127 FBgn00
00052 
ade2 
BL36686 
HMS0
1574  NE      
CG1726
5 
FBgn00
31488 
CG17265 
BL36687 
HMS0
1575  NE      
CG3309
0 
FBgn00
28916 
CG33090 
BL36688 
HMS0
1576  NE      
CG3214 FBgn00
31436 
CG3214 
BL36695 
HMS0
1584  NE      
CG6382 FBgn00
20443 
Elf 
BL36703 
HMS0
1592  NE      
CG5304 FBgn00
10497 
dmGlut 
BL36724 
HMS0
1615  NE      
307 
 
CG8827 FBgn00
12037 
Ance 
BL36749 
HMS0
3009 A E-L E-L   E-L  
CG9261 FBgn00
15777 
nrv2 
BL37495 
HMS0
1637  NE      
CG5722 FBgn00
24320 
Npc1a 
BL37504 
HMS0
1646  NE      
CG3018 FBgn00
10602 
lwr 
BL37506 
HMS0
1648  NE      
CG1069
2 
FBgn00
28707 
Mt2 
BL38224 
HMS0
1667  NE      
CG7291 FBgn00
31381 
Npc2a 
BL38237 
HMS0
1681  NE  S E   
CG1267
6 
FBgn00
00547 
ed 
BL38243 
HMS0
1687  NE      
CG2855 FBgn00
31458 
aph-1 
BL38249 
HMS0
1693  NE      
CG3326 FBgn00
31519 
CG3326 
BL38266 
HMS0
1711  NE      
CG9258 FBgn00
15776 
nrv1 
BL38275 
HMS0
1725  NE      
CG3903 FBgn00
01987 
Gli 
BL38284 
HMS0
1737  NE      
CG2774 FBgn00
31534 
Snx1 
BL38301 
HMS0
1763  NE      
CG1535
8 
FBgn00
31373 
CG15358 
BL38313 
HMS0
1777  NE      
CG1063
7 
FBgn00
15772 
Nak 
BL38326 
HMS0
1793  NE      
CG7109 FBgn00
04177 
mts 
BL38337 
HMS0
1804 E-L E-L ME MS E-L ME NE 
CG9115 FBgn00
25742 
mtm 
BL38339 
HMS0
1806  NE      
CG4993 FBgn00
24734 
PRL-1 
BL38358 
HMS0
1826  NE      
CG5102 FBgn00
00413 
da 
BL38382 
HMS0
1851  NE      
CG1809
5 
FBgn00
28872 
CG18095 
BL38521 
HMS0
1705  NE      
CG8667 FBgn00
23091 
dimm 
BL38530 
HMS0
1742  NE      
CG3365 FBgn00
20304 
drongo 
BL38960 
HMS0
1874  NE      
CG4764 FBgn00
31310 
CG4764 
BL38963 
HMS0
1877  NE      
CG3176
2 
FBgn00
00114 
aret 
BL38983 
HMS0
1899  NE      
CG2671 FBgn00
02121 
l(2)gl 
BL38989 
HMS0
1905  NE      
CG2699 FBgn00
20622 
Pi3K21B 
BL38991 
HMS0
1907  NE      
CG3766 FBgn00
11232 
scat 
BL38994 
HMS0
1910  NE      
CG1734
8 
FBgn00
15380 
drl 
BL39002 
HMS0
1918  NE      
CG1038
5 
FBgn00
05617 
msl-1 
BL39012 
HMS0
1930  NE      
CG6137 FBgn00
00146 
aub 
BL39026 
HMS0
1945  NE      
CG1692
8 
FBgn00
20270 
mre11 
BL39028 
HMS0
1947  NE      
CG3994 FBgn00
28516 
ZnT35C 
BL39049 
HMS0
1969  NE      
CG7115 FBgn00
27515 
CG7115 
BL39065 
HMS0
1985 A ME ME   E  
CG2914 FBgn00
05660 
Ets21C 
BL39069 
HMS0
1989  NE      
CG4280 FBgn00
15924 
crq 
BL40831 
HMS0
1997  NE      
CG3159 FBgn00
26438 
Eaat2 
BL40832 
HMS0
1998  NE      
308 
 
CG2718 FBgn00
01142 
Gs1 
BL40836 
HMS0
2002  NE      
CG1402
9 
FBgn00
16076 
vri 
BL40862 
HMS0
2029  NE      
CG3234 FBgn00
14396 
tim 
BL40864 
HMS0
2031  NE      
CG2843 FBgn00
31452 
Cwc25 
BL40887 
HMS0
2135  NE      
CG1733
2 
FBgn00
27779 
VhaSFD 
BL40896 
HMS0
2144  NE      
CG9884 FBgn00
11818 
oaf 
BL40926 
HMS0
2174  NE      
CG9887 FBgn00
31424 
VGlut 
BL40927 
HMS0
2175  NE      
CG4274 FBgn00
01086 
fzy 
BL40933 
HMS0
2181  NE      
CG1402
6 
FBgn00
03716 
tkv 
BL40937 
HMS0
2185  NE      
CG1044
3 
FBgn00
00464 
Lar 
BL40938 
HMS0
2186  NE      
CG1493
8 
FBgn00
20309 
crol 
BL41669 
HMS0
2202  NE      
CG7595 FBgn00
00317 
ck 
BL41690 
HMS0
2254  NE      
CG1231
7 
FBgn00
28425 
JhI-21 
BL41706 
HMS0
2271 A E-L E   E  
CG9019 FBgn00
15381 
dsf 
BL41707 
HMS0
2272 MS MS  NE E  NE 
CG1183
5 
FBgn00
31264 
CG11835 
BL41725 
HMS0
2291  NE      
CG1132
4 
FBgn00
25777 
homer 
BL41908 
HMS0
2301  NE      
CG1159
2 
FBgn00
25686 
CG11592 
BL41956 
HMS0
2353  NE      
CG4220 FBgn00
04858 
elB 
BL41960 
HMS0
2357  NE      
CG5655 FBgn00
11305 
Rsf1 
BL41971 
HMS0
2368  NE      
CG7100 FBgn00
15609 
CadN 
BL41982 
HMS0
2380  NE      
CG1172
3 
FBgn00
31391 
CG11723 
BL42514 
HMJ0
2079  NE      
CG1161
7 
FBgn00
31232 
CG11617 
BL42525 
HMJ0
2091  NE      
CG1338
8 
FBgn00
27932 
Akap200 
BL42539 
HMJ0
2109  NE      
CG1001
6 
FBgn00
24244 
drm 
BL42548 
HMJ0
2120  NE      
CG1866
0 
FBgn00
28704 
Nckx30C 
BL42581 
HMS0
1955  NE      
CG5556 FBgn00
31332 
CG5556 
BL42594 
HMS0
2426  NE      
CG1065
5 
FBgn00
02021 
l(2)37Bb 
BL42608 
HMS0
2443  NE      
CG3758 FBgn00
01981 
esg 
BL42846 
HMS0
2538  NE      
CG1240
3 
FBgn00
20368 
Vha68-1 
BL42888 
HMS0
2581  NE      
CG1224
5 
FBgn00
14179 
gcm 
BL42889 
HMS0
2582  NE      
CG5353 FBgn00
27081 
Aats-thr 
BL42902 
HMS0
2595  NE      
CG9092 FBgn00
01089 
Gal 
BL42922 
HMS0
2615  NE      
CG6605 FBgn00
00183 
BicD 
BL42929 
HMS0
2622  NE      
CG9564 FBgn00
15316 
Try29F 
BL42949 
HMS0
2642  NE      
CG3747 FBgn00
26439 
Eaat1 
BL43287 
HMS0
2659  NE      
309 
 
CG2975 FBgn00
31468 
CG2975 
BL43290 
HMS0
2662  NE      
CG1060
4 
FBgn00
00529 
bsh 
BL43994 
HMS0
2708  NE      
CG5371 FBgn00
11703 
RnrL 
BL44022 
HMS0
2737  NE      
CG8867 FBgn00
20906 
Jon25Bi 
BL44025 
HMS0
2740  NE      
CG2762 FBgn00
03963 
ush 
BL44041 
HMS0
2757  NE      
CG3647 FBgn00
01978 
stc 
BL44051 
HMS0
2768  NE      
CG3763 FBgn00
00640 
Fbp2 
BL44052 
HMS0
2769  NE   E   
CG6176 FBgn00
26431 
Grip75 
BL44072 
HMS0
2789  NE      
CG1724
0 
FBgn00
11832 
Ser12 
BL44086 
HMS0
2803  NE      
CG3179
5 
FBgn00
31294 
IA-2 
BL44099 
HMS0
2819  NE      
CG9643 FBgn00
31485 
CG9643 
BL44110 
HMS0
2831  NE      
CG1864
1 
FBgn00
31426 
CG18641 
BL44492 
HMC0
2414  NE      
CG1073
9 
FBgn00
10309 
pigeon 
BL44507 
HMC0
2897  NE      
CG4341 FBgn00
28481 
CG4341 
BL44509 
HMC0
2899  NE      
CG4145 FBgn00
00299 
Cg25C 
BL44520 
HMC0
2910  NE      
CG4180 FBgn00
01977 
l(2)35Bg 
BL44644 
HMC0
2348  NE      
CG4892 FBgn00
28884 
CG4892 
BL44648 
HMC0
2356  NE      
CG3178
3 
FBgn00
02939 
ninaD 
BL44652 
HMC0
2392  NE      
CG3022 FBgn00
31275 
GABA-B-R3 
BL50622 
HMC0
2989  NE      
CG4491 FBgn00
05771 
noc 
BL50659 
HMC0
3060  NE      
CG3167
0 
FBgn00
31375 
erm 
BL50661 
HMC0
3062  NE      
CG1228
7 
FBgn00
04394 
pdm2 
BL50665 
HMC0
3066  NE      
CG1689
0 
FBgn00
28932 
CG16890 
BL50671 
HMC0
3072  NE      
CG6713 FBgn00
11676 
Nos 
BL50675 
HMC0
3076  NE      
CG1878
3 
FBgn00
28420 
Kr-h1 
BL50685 
HMC0
3086  NE      
CG1160
7 
FBgn00
01170 
H2.0 
BL50690 
HMC0
3091  NE      
CG1439
6 
FBgn00
11829 
Ret 
BL50700 
HMC0
3102  NE      
CG7400 FBgn00
21953 
Fatp 
BL50709 
HMC0
3111  NE      
CG2851 FBgn00
10323 
Gsc 
BL50894 
HMC0
2397  NE      
CG1685
8 
FBgn00
16075 
vkg 
BL50895 
HMC0
2400  NE      
CG1698
7 
FBgn00
31461 
daw 
BL50911 
HMJ0
3135  NE      
CG1538
7 
FBgn00
31403 
CG15387 
BL50952 
HMJ2
1053  NE      
CG1715
8 
FBgn00
11570 
cpb 
BL50954 
HMJ2
1056  NE      
CG5813 FBgn00
00307 
chif 
BL51016 
HMJ2
1138  NE      
CG1190
7 
FBgn00
31250 
Ent1 
BL51055 
HMJ2
1190  NE      
310 
 
CG1687
3 
FBgn00
28936 
nimB5 
BL51162 
HMC0
2406  NE      
CG3047 FBgn00
03372 
Sgs1 
BL51421 
HMC0
2393  NE      
CG1133
1 
FBgn00
28990 
Spn27A 
BL51445 
HMC0
3159  NE      
CG1080
0 
FBgn00
17551 
Rca1 
BL51450 
HMC0
3180  NE      
CG5869 FBgn00
28894 
CG5869 
BL51452 
HMC0
3184  NE      
CG1069
7 
FBgn00
00422 
Ddc 
BL51462 
HMC0
3200  NE      
CG1020
3 
FBgn00
28554 
x16 
BL51468 
HMC0
3209  NE      
CG9042 FBgn00
01128 
Gpdh 
BL51474 
HMC0
3218  NE      
CG4162 FBgn00
02524 
lace 
BL51475 
HMC0
3219  NE      
CG1732
0 
FBgn00
15808 
ScpX 
BL51479 
HMC0
3224  NE      
CG3210 FBgn00
26479 
Drp1 
BL51483 
HMC0
3230  NE      
CG1526
9 
FBgn00
28878 
CG15269 
BL51506 
HMC0
3273  NE      
CG4426 FBgn00
15905 
ast 
BL51700 
HMC0
3173  NE      
CG1132
5 
FBgn00
25595 
GRHR 
BL51710 
HMC0
3228  NE      
CG4163 FBgn00
01992 
Cyp303a1 
BL51716 
HMC0
3249  NE      
CG1102
0 
FBgn00
16920 
nompC 
BL51722 
HMC0
3261  NE      
CG5526 FBgn00
13810 
Dhc36C 
BL51726 
HMC0
3270 
(ME 
POSSIBL
E) NE NE     
CG1061
9 
FBgn00
03896 
tup 
BL51763 
HMC0
3317  NE      
CG4488 FBgn00
11737 
wee 
BL51776 
HMC0
3331  NE      
CG5876 FBgn00
28375 
heix 
BL51780 
HMC0
3335  NE      
CG3057 FBgn00
19830 
colt 
BL51798 
HMC0
3354  NE      
CG1339
7 
FBgn00
14417 
CG13397 
BL51808 
HMC0
3368  NE      
CG1156
7 
FBgn00
15623 
Cpr 
BL51809 
HMC0
3369  NE      
CG3664 FBgn00
14010 
Rab5 
BL51847 
HMC0
3420  NE      
CG1767
8 
FBgn00
00384 
cta 
BL51848 
HMC0
3421  NE      
CG7144 FBgn00
25687 
LKR 
BL51850 
HMC0
3424  NE      
CG9886 FBgn00
31428 
CG9886 
BL51857 
HMC0
3431 A ME ME  E ME  
CG1544
4 
FBgn00
11603 
ine 
BL51919 
HMS0
3378 A E E   E  
CG4271 FBgn00
31409 
CG4271 
BL52873 
HMC0
3611  NE      
CG1191
1 
FBgn00
31249 
CG11911 
BL52894 
HMC0
3633  NE      
CG1008
4 
FBgn00
02044 
swm 
BL52935 
HMC0
3677 MS MS  S ME  NE 
CG4276 FBgn00
29095 
aru 
BL52976 
HMJ2
1663  NE      
CG6206 FBgn00
27611 
CG6206 
BL53294 
HMC0
3510 E E-L NE S E ME NE 
CG3639 FBgn00
31282 
Pex12 
BL53308 
HMC0
3536  NE      
311 
 
CG5680 FBgn00
00229 
bsk 
BL53310 
HMC0
3539  NE      
CG5920 FBgn00
04867 
RpS2 
BL53319 
HMC0
3548 A E-L E   E  
CG1369
0 
FBgn00
31252 
CG13690 
BL53326 
HMC0
3555  NE      
CG1678
4 
FBgn00
03141 
pr 
BL53346 
HMC0
3575 MS MS ME E E-L ME NE 
CG1156
1 
FBgn00
03444 
smo 
BL53348 
HMC0
3577  NE      
CG8674 FBgn00
21856 
l(2)k14505 
BL53352 
HMC0
3581  NE      
CG1701
2 
FBgn00
31406 
Send1 
BL53369 
HMC0
3598  NE      
CG1855
7 
FBgn00
31470 
CG18557 
BL53373 
HMC0
3602  NE      
CG3117 FBgn00
31471 
CG3117 
BL53673 
HMC0
3606  NE      
CG5216 FBgn00
24291 
Sir2 
BL53697 
HMJ2
1708 
(ME 
POSSIBL
E) NE NE     
CG1536
2 
FBgn00
31378 
CG15362 
BL53919 
HMJ2
1254 MS MS  S E  NE 
CG1137
6 
FBgn00
31216 
Zir 
BL53946 
HMJ2
1308 A ME ME   ME  
CG3625 FBgn00
31245 
CG3625 
BL53962 
HMJ2
1344  NE      
CG7364 FBgn00
28541 
TM9SF4 
BL54019 
HMJ2
1445  NE      
CG4164 FBgn00
31256 
CG4164 
BL54797 
HMJ2
1390  NE      
CG4846 FBgn00
13433 
beat-Ia 
BL54820 
HMJ2
1539  NE      
CG3557 FBgn00
31423 
CG3557 
BL54829 
HMJ2
1548  NE      
CG1542
7 
FBgn00
10473 
tutl 
BL54850 
HMJ2
1587  NE      
CG1191
2 
FBgn00
31248 
CG11912 
BL55141 
HMC0
3737  NE      
CG1145
5 
FBgn00
31228 
CG11455 
BL55180 
HMC0
3861  NE      
CG6582 FBgn00
27885 
Aac11 
BL55187 
HMC0
3881  NE      
CG3436 FBgn00
31229 
CG3436 
BL55207 
HMC0
3922  NE      
CG4602 FBgn00
24285 
Srp54 
BL55254 
HMC0
3941  NE      
CG1020
6 
FBgn00
26196 
nop5 
BL55262 
HMC0
3949  NE      
CG1765
2 
FBgn00
31361 
CG17652 
BL55287 
HMC0
3974  NE      
CG3433 FBgn00
21944 
Coprox 
BL55318 
HMC0
4005  NE      
CG7061 FBgn00
27505 
rab3-GAP 
BL55328 
HMC0
4015  NE      
CG5125 FBgn00
02938 
ninaC 
BL55335 
HMC0
4022  NE      
CG3151 FBgn00
10263 
Rbp9 
BL55360 
HMC0
4047  NE      
CG1044
9 
FBgn00
02022 
Catsup 
BL55396 
HMC0
4084  NE      
CG7210 FBgn00
01301 
kel 
BL55612 
HMC0
3751  NE      
CG4793 FBgn00
28514 
CG4793 
BL55621 
HMC0
3765  NE      
CR3287
9 
FBgn00
03931 
snRNA:U4:38AB 
BL55689 
HMC0
3903  NE      
CG4629 FBgn00
31299 
CG4629 
BL55889 
HMC0
4163  NE      
312 
 
CG4501 FBgn00
27348 
bgm 
BL55918 
HMC0
4204 A ME ME S NE ME  
CG1761
0 
FBgn00
01137 
grk 
BL55926 
HMC0
4213  NE      
CG9280 FBgn00
01114 
Glt 
BL55929 
HMC0
4217  NE      
CG5430 FBgn00
11294 
a5 
BL55932 
HMC0
4220  NE      
CG4475 FBgn00
20415 
Idgf2 
BL55935 
HMC0
4223  NE      
CG3311
9 
FBgn00
27929 
nimB1 
BL55937 
HMC0
4225  NE      
CG7644 FBgn00
28645 
beat-Ib 
BL55938 
HMC0
4226  NE      
CG1699
5 
FBgn00
31412 
CG16995 
BL55942 
HMC0
4230  NE      
CG3311
5 
FBgn00
28542 
nimB4 
BL55963 
HMC0
4257  NE      
CG4099 FBgn00
14033 
Sr-CI 
BL56012 
HMC0
4308  NE      
CG5619 FBgn00
03751 
trk 
BL56040 
HMC0
4348  NE      
CG4267 FBgn02
64979 
CG4267 
BL32332 
HMS0
0323  NE      
CG5337 FBgn00
32249 
CG5337 
BL32333 
HMS0
0324  NE      
CG7627 FBgn00
32026 
CG7627 
BL32337 
HMS0
0328 A ME ME   ME  
CG9548 FBgn00
31822 
CG9548 
BL32344 
HMS0
0335  NE      
CG6181 FBgn00
32340 
Ge-1 
BL32349 
HMS0
0340  NE      
CG1162
8 
FBgn00
86779 
step 
BL32374 
HMS0
0365 A E E   E  
CG9252 FBgn00
86251 
del 
BL32375 
HMS0
0366  NE      
CG4276
8 
FBgn02
61836 
Msp-300 
BL32377 
HMS0
0368  NE      
CG4386
0 
FBgn02
64442 
ab 
BL32378 
HMS0
0369  NE      
CG7840 FBgn00
32014 
CG7840 
BL32379 
HMS0
0370  NE      
CG1494
5 
FBgn00
32402 
CG14945 
BL32384 
HMS0
0376  NE      
CG1733
1 
FBgn00
32596 
CG17331 
BL32390 
HMS0
0384  NE      
CG4738 FBgn02
62647 
Nup160 
BL32391 
HMS0
0385  NE      
CG3175
3 
FBgn00
45852 
ham 
BL32470 
HMS0
0470  NE      
CG1697
5 
FBgn00
32475 
Sfmbt 
BL32473 
HMS0
0473  NE      
CG1749
4 
FBgn00
40011 
CG17494 
BL32509 
HMS0
0513  NE      
CG7787 FBgn00
32020 
CG7787 
BL32843 
HMS0
0625  NE      
CG1809
6 
FBgn00
41183 
Tep1 
BL32856 
HMS0
0641  NE      
CG4260 FBgn02
64855 
alpha-Adaptin 
BL32866 
HMS0
0653  NE      
CG1310
9 
FBgn00
41092 
tai 
BL32885 
HMS0
0673  NE      
CG5181 FBgn00
31909 
CG5181 
BL32888 
HMS0
0676 
(ME 
POSSIBL
E) NE NE ME NE NE  
CG1729
3 
FBgn00
32030 
Wdr82 
BL32926 
HMS0
0718  NE      
CG3397
9 
FBgn02
61458 
capt 
BL33010 
HMS0
0810  NE      
313 
 
CG3187
3 
FBgn02
60750 
Mulk 
BL33046 
HMS0
0699  NE      
CG1710
7 
FBgn00
32281 
CG17107 
BL33057 
HMS0
0717  NE      
CG5022 FBgn00
32225 
CG5022 
BL33359 
HMS0
0231  NE      
CG9226 FBgn00
31782 
WDR79 
BL33363 
HMS0
0235  NE      
CG4252
2 
FBgn02
61437 
CSN8 
BL33370 
HMS0
0243  NE      
CG1278
7 
FBgn00
41150 
hoe1 
BL33377 
HMS0
0251  NE      
CG1030
5 
FBgn02
61597 
RpS26 
BL33393 
HMS0
0270 A E E   E  
CG1239
3 
FBgn00
31768 
CG12393 
BL33428 
HMS0
0312  NE      
CG8676 FBgn02
61239 
Hr39 
BL33624 
HMS0
0018  NE      
CG3127 FBgn02
50906 
Pgk 
BL33632 
HMS0
0030 ME ME NE ME NE  NE 
CG3166
6 
FBgn00
86758 
chinmo 
BL33638 
HMS0
0036  NE      
CG1859
1 
FBgn02
61790 
SmE 
BL33664 
HMS0
0074  NE      
CG9188 FBgn00
31878 
sip2 
BL33691 
HMS0
0559  NE      
CG3753 FBgn00
31655 
Marcal1 
BL33709 
HMS0
0587  NE      
CG6464 FBgn02
61648 
salm 
BL33714 
HMS0
0594  NE      
CG3188
4 
FBgn00
40070 
Trx-2 
BL33721 
HMS0
0603  NE      
CG1403
4 
FBgn02
50847 
CG14034 
BL33732 
HMS0
0615  NE      
CG5034 FBgn00
32223 
GATAd 
BL33747 
HMS0
1086  NE      
CG3312
9 
FBgn00
53129 
CG33129 
BL33751 
HMS0
1091  NE      
CG4284
0 
FBgn02
62029 
d 
BL33754 
HMS0
1096  NE      
CG1067
9 
FBgn00
32725 
Nedd8 
BL33881 
HMS0
0818  NE      
CG1839
8 
FBgn00
32728 
Tango6 
BL33883 
HMS0
0820  NE      
CG5899 FBgn00
32157 
Etl1 
BL33891 
HMS0
0829  NE      
CG9493 FBgn00
31799 
Pez 
BL33918 
HMS0
0861  NE      
CG1229
9 
FBgn00
32295 
CG12299 
BL33957 
HMS0
0912  NE      
CG7438 FBgn00
86347 
Myo31DF 
BL33971 
HMS0
0928  NE      
CG7830 FBgn00
32015 
CG7830 
BL33979 
HMS0
0939  NE      
CG1493
9 
FBgn00
32378 
CycY 
BL34009 
HMS0
0974  NE      
CG1541
4 
FBgn00
31542 
CG15414 
BL34010 
HMS0
0975  NE      
CG7851 FBgn00
32013 
Scgalpha 
BL34027 
HMS0
0997  NE      
CG9270 FBgn00
32908 
CG9270 
BL34029 
HMS0
0999  NE      
CG5640 FBgn02
60749 
Utx 
BL34076 
HMS0
0575  NE      
CG7870 FBgn02
61020 
wol 
BL34365 
HMS0
1354  NE      
CG6116 FBgn00
32499 
Uvrag 
BL34368 
HMS0
1357  NE      
CG3312
3 
FBgn00
53123 
CG33123 
BL34483 
HMS0
1335  NE      
314 
 
CG7392 FBgn00
44323 
Cka 
BL34522 
HMS0
0081  NE      
CG1030
2 
FBgn00
32679 
bsf 
BL34550 
HMS0
1022  NE      
CG1562
8 
FBgn00
31632 
CG15628 
BL34555 
HMS0
1027  NE      
CG4264
1 
FBgn02
61396 
Rpn3 
BL34561 
HMS0
1033  NE      
CG9282 FBgn00
32518 
RpL24 
BL34569 
HMS0
1043  NE      
CG3762 FBgn02
63598 
Vha68-2 
BL34582 
HMS0
1056  NE      
CG9273 FBgn00
32906 
RPA2 
BL34587 
HMS0
1061  NE      
CG8817 FBgn00
41111 
lilli 
BL34592 
HMS0
1066 LacZ-S S  S S  S 
CG1399
8 
FBgn00
40949 
CG13998 
BL34599 
HMS0
1073  NE      
CG3434
1 
FBgn00
85370 
Pde11 
BL34611 
HMS0
1286  NE      
CG3733 FBgn02
50786 
Chd1 
BL34665 
HMS0
1142 E-L E-L NE ME E-L  NE 
CG4000
6 
FBgn00
58006 
CG40006 
BL34691 
HMS0
1170  NE      
CG2615 FBgn00
86657 
ik2 
BL34709 
HMS0
1188  NE      
CG8678 FBgn00
32935 
Atg18b 
BL34715 
HMS0
1194  NE      
CG7138 FBgn00
31951 
r2d2 
BL34784 
HMS0
0093 
ME ME NE NE NE  
(ME 
POSSIBL
E) 
CG9267 FBgn00
32524 
CG9267 
BL34800 
HMS0
0109  NE      
CG6866 FBgn00
32515 
loqs 
BL34851 
HMS0
0169  NE      
CG1033
3 
FBgn00
32690 
CG10333 
BL34857 
HMS0
0175  NE      
CG3185
5 
FBgn00
51855 
CG31855 
BL34903 
HMS0
1248  NE      
CG8475 FBgn00
31995 
CG8475 
BL34904 
HMS0
1249  NE      
CG1541
5 
FBgn00
31549 
Spindly 
BL34933 
HMS0
1283  NE      
CG6724 FBgn00
32298 
CG6724 
BL34934 
HMS0
1284  NE      
CG6667 FBgn02
60632 
dl 
BL34938 
HMS0
0028  NE      
CG3179
2 
FBgn00
51792 
CG31792 
BL34942 
HMS0
0219  NE      
CG4308
1 
FBgn02
62526 
vas 
BL34950 
HMS0
0373  NE      
CG1402
3 
FBgn00
31698 
Ncoa6 
BL34964 
HMS0
0664 A ME ME MS NE E  
CG4063 FBgn02
63933 
ebi 
BL34981 
HMS0
1390  NE      
CG3163
2 
FBgn00
51632 
sens-2 
BL34984 
HMS0
1394  NE      
CG1512 FBgn00
32956 
Cul-2 
BL34988 
HMS0
1398  NE      
CG4268
5 
FBgn02
61571 
CG42685 
BL35005 
HMS0
1415  NE      
CG6453 FBgn00
32643 
CG6453 
BL35008 
HMS0
1418  NE      
CG1072
2 
FBgn00
32848 
nesd 
BL35009 
HMS0
1419  NE      
CG1515
4 
FBgn00
41184 
Socs36E 
BL35036 
HMS0
1450  NE      
CG3167
6 
FBgn00
51676 
CG31676 
BL35727 
HMS0
1469  NE      
315 
 
CG1792
7 
FBgn02
64695 
Mhc 
BL35729 
HMS0
1471  NE      
CG9539 FBgn00
86357 
Sec61alpha 
BL35730 
HMS0
1472 A E-L E-L   E-L  
CG4644 FBgn02
61938 
mtRNApol 
BL35732 
HMS0
1474  NE      
CG1790
6 
FBgn00
32086 
CG17906 
BL35767 
HMS0
1516  NE      
CG6055 FBgn00
31918 
CG6055 
BL35778 
HMS0
1528  NE      
CG7380 FBgn00
31977 
baf 
BL36108 
HMS0
0195  NE      
CG4236
6 
FBgn02
59712 
CG42366 
BL36112 
HMS0
0987 A ME ME   E  
CG4494 FBgn02
64922 
smt3 
BL36125 
HMS0
1540 A E ME   E  
CG8846 FBgn02
61560 
Thor/4E-BP 
BL36667 
HMS0
1555  NE      
CG1401
6 
FBgn00
31715 
tomb 
BL36669 
HMS0
1557  NE      
CG3319
6 
FBgn00
53196 
dp 
BL36673 
HMS0
1561  NE      
CG9573 FBgn00
32089 
Rcd-1r 
BL36683 
HMS0
1571  NE      
CG4261
6 
FBgn02
61268 
Cul-3 
BL36684 
HMS0
1572 A ME ME  NE ME  
CG1716
1 
FBgn02
61278 
grp/Chk1 
BL36685 
HMS0
1573 S S  S MS  NE 
CG1866
2 
FBgn00
40963 
CG18662 
BL36710 
HMS0
1600  NE      
CG8902 FBgn00
31886 
Nuf2 
BL36725 
HMS0
1616  NE      
CG1231
4 
FBgn02
61266 
zuc 
BL36742 
HMS0
3002  NE      
CG1396
9 
FBgn00
45064 
bwa 
BL36765 
HMS0
3026  NE      
CG3188
6 
FBgn00
32079 
CG31886 
BL36769 
HMS0
3030  NE      
CG1229
2 
FBgn00
32451 
spict 
BL37505 
HMS0
1647  NE      
CG8222 FBgn00
32006 
Pvr 
BL37520 
HMS0
1662  NE      
CG3170
8 
FBgn00
51708 
CG31708 
BL38227 
HMS0
1671  NE      
CG3169
4 
FBgn00
51694 
CG31694 
BL38228 
HMS0
1672  NE      
CG1401
0 
FBgn00
31725 
CG14010 
BL38229 
HMS0
1673  NE      
CG1132
0 
FBgn00
31837 
CG11320 
BL38231 
HMS0
1675  NE      
CG3193
0 
FBgn00
45498 
Gr22d 
BL38248 
HMS0
1692  NE      
CG3305 FBgn00
32949 
Lamp1 
BL38254 
HMS0
1698  NE      
CG3338 FBgn00
31598 
CG3338 
BL38267 
HMS0
1712  NE      
CG7371 FBgn00
31710 
CG7371 
BL38268 
HMS0
1713  NE      
CG4427 FBgn00
43364 
cbt 
BL38276 
HMS0
1726  NE      
CG8282 FBgn00
32005 
Snx6 
BL38278 
HMS0
1729  NE      
CG1053
8 
FBgn00
32821 
CdGAPr 
BL38279 
HMS0
1730  NE      
CG1784
0 
FBgn00
31611 
CG17840 
BL38291 
HMS0
1749  NE      
CG9298 FBgn02
60861 
Trs23 
BL38303 
HMS0
1765  NE      
CG3186
0 
FBgn00
51860 
CG31860 
BL38312 
HMS0
1776  NE      
316 
 
CG6214 FBgn00
32456 
MRP 
BL38316 
HMS0
1780  NE      
CG3179
3 
FBgn00
51793 
CG31793 
BL38319 
HMS0
1783  NE      
CG8679 FBgn00
32934 
CG8679 
BL38348 
HMS0
1816  NE      
CG9138 FBgn00
31879 
uif 
BL38354 
HMS0
1822 A E ME   E  
CG1041
3 
FBgn00
32689 
CG10413 
BL38364 
HMS0
1833  NE      
CG4236
8 
FBgn02
59714 
CG42368 
BL38936 
HMS0
1718  NE      
CG7102 FBgn00
31961 
CG7102 
BL38939 
HMS0
1789  NE      
CG1018
8 
FBgn00
32796 
CG10188 
BL38942 
HMS0
1856  NE      
CG9426 FBgn00
32485 
CG9426 
BL38946 
HMS0
1860  NE      
CG3437
8 
FBgn00
85407 
Pvf3 
BL38962 
HMS0
1876  NE      
CG5198 FBgn00
32250 
holn1 
BL38968 
HMS0
1882  NE      
CG7806 FBgn00
32018 
CG7806 
BL38997 
HMS0
1913  NE      
CG9496 FBgn00
32075 
Tsp29Fb 
BL39042 
HMS0
1962  NE      
CG1493
6 
FBgn00
32376 
Tsp33B 
BL39043 
HMS0
1963  NE      
CG5446 FBgn00
32429 
CG5446 
BL40824 
HMS0
0624  NE      
CG9494 FBgn00
32074 
Tsp29Fa 
BL40829 
HMS0
1995  NE      
CG5603 FBgn00
32210 
CYLD 
BL40840 
HMS0
2006  NE      
CG4282
9 
FBgn02
62018 
CadN2 
BL40889 
HMS0
2137  NE      
CG5261 FBgn00
31912 
CG5261 
BL40922 
HMS0
2170  NE      
CG3434
5 
FBgn00
85374 
CG34345 
BL40941 
HMS0
2189  NE      
CG5300 FBgn00
32243 
Klp31E 
BL40943 
HMS0
2191  NE      
CG9093 FBgn00
31760 
Tsp26A 
BL40946 
HMS0
2194  NE      
CG6750 FBgn00
32292 
CG6750 
BL41678 
HMS0
2242  NE      
CG4747 FBgn00
43456 
CG4747 
BL41698 
HMS0
2263  NE      
CG1338
4 
FBgn00
32036 
CG13384 
BL41703 
HMS0
2268  NE      
CG6976 FBgn00
40299 
Myo28B1 
BL41717 
HMS0
2282  NE      
CG1037
6 
FBgn00
32702 
CG10376 
BL41907 
HMS0
2300  NE      
CG4495 FBgn00
31893 
CG4495 
BL41909 
HMS0
2302  NE      
CG3513 FBgn00
31559 
CG3513 
BL41918 
HMS0
2315  NE      
CG1399
6 
FBgn00
31763 
CG13996 
BL41921 
HMS0
2318  NE      
CG6444 FBgn00
32293 
Dpy-30L1 
BL41946 
HMS0
2343  NE      
CG1754
0 
FBgn00
86683 
Spf45 
BL41954 
HMS0
2351  NE      
CG1309
4 
FBgn00
32048 
Dh31 
BL41957 
HMS0
2354  NE      
CG8671 FBgn00
32938 
CG8671 
BL41965 
HMS0
2362  NE      
CG1856
3 
FBgn00
32639 
CG18563 
BL41974 
HMS0
2372  NE      
317 
 
CG1240
4 
FBgn00
32465 
CG12404 
BL41989 
HMS0
2388  NE      
CG1062
1 
FBgn00
32726 
CG10621 
BL42011 
HMS0
2412  NE      
CG3171
6 
FBgn00
51716 
Cnot4 
BL42513 
HMJ0
2078  NE      
CG3172
0 
FBgn00
51720 
mthl15 
BL42515 
HMJ0
2080  NE      
CG1400
1 
FBgn00
43362 
bchs 
BL42517 
HMJ0
2083  NE      
CG5545 FBgn00
32651 
Oli 
BL42560 
HMJ0
2216  NE      
CG9257 FBgn00
32916 
CG9257 
BL42582 
HMS0
2123  NE      
CG1563
0 
FBgn00
31627 
CG15630 
BL42589 
HMS0
2421  NE      
CG1697
4 
FBgn00
32479 
CG16974 
BL42590 
HMS0
2422  NE      
CG9029 FBgn00
31746 
CG9029 
BL42593 
HMS0
2425  NE      
CG3179
4 
FBgn00
41789 
Pax 
BL42614 
HMS0
2449  NE      
CG7123 FBgn02
61800 
LanB1 
BL42616 
HMS0
2451  NE      
CG3177
4 
FBgn00
51774 
fred 
BL42621 
HMS0
2456  NE      
CG4282
0 
FBgn02
62002 
CG42820 
BL42623 
HMS0
2458  NE      
CG1080
6 
FBgn00
31865 
Nha1 
BL42648 
HMS0
2484  NE      
CG7094 FBgn00
32650 
CG7094 
BL42653 
HMS0
2489  NE      
CG1017
8 
FBgn00
32684 
CG10178 
BL42657 
HMS0
2493  NE      
CG1070
2 
FBgn00
32752 
CG10702 
BL42663 
HMS0
2499  NE      
CG3364
3 
FBgn00
53643 
CG33643 
BL42823 
HMS0
2505  NE      
CG3604 FBgn00
31562 
CG3604 
BL42829 
HMS0
2513  NE      
CG4584 FBgn02
50837 
dUTPase 
BL42835 
HMS0
2527  NE      
CG3173
0 
FBgn00
51730 
CG31730 
BL42848 
HMS0
2540  NE      
CG1812
5 
FBgn02
64253 
Send2 
BL42850 
HMS0
2542  NE      
CG1544
3 
FBgn00
31609 
CG15443 
BL42864 
HMS0
2557  NE      
CG4482 FBgn00
86711 
mol 
BL42867 
HMS0
2560  NE      
CG5972 FBgn00
31781 
Arpc4 
BL42875 
HMS0
2568  NE      
CG1065
1 
FBgn00
32853 
CG10651 
BL42885 
HMS0
2578  NE      
CG1047
0 
FBgn00
32746 
CG10470 
BL42896 
HMS0
2589  NE      
CG3177
6 
FBgn00
51776 
CG31776 
BL42897 
HMS0
2590  NE      
CG3190
1 
FBgn00
51901 
Mur29B 
BL42918 
HMS0
2611  NE      
CG6766 FBgn00
32398 
CG6766 
BL42924 
HMS0
2617  NE      
CG1710
4 
FBgn00
40496 
CG17104 
BL42925 
HMS0
2618  NE      
CG3312
0 
FBgn00
53120 
CG33120 
BL42934 
HMS0
2627  NE      
CG9994 FBgn00
32782 
Rab9 
BL42942 
HMS0
2635  NE      
CG5075 FBgn00
32464 
Vha68-3 
BL42954 
HMS0
2647  NE      
318 
 
CG1729
1 
FBgn02
60439 
Pp2A-29B 
BL43283 
HMS0
1921  NE      
CG4240
3 
FBgn02
59822 
Ca-beta 
BL43292 
HMS0
2664  NE      
CG5776 FBgn00
32450 
CG5776 
BL43299 
HMS0
2672  NE      
CG4988 FBgn00
32372 
CG4988 
BL43303 
HMS0
2676  NE      
CG1710
8 
FBgn00
32285 
CG17108 
BL43313 
HMS0
2697  NE      
CG9107 FBgn00
31764 
CG9107 
BL43547 
HMS0
2555 S S  S E  NE 
CG1562
7 
FBgn00
31634 
Ir25a 
BL43985 
HMC0
2682  NE      
CG1062
3 
FBgn00
32727 
CG10623 
BL43986 
HMC0
2683  NE      
CG1396
5 
FBgn00
32834 
CG13965 
BL44015 
HMS0
2729  NE      
CG6153 FBgn00
32445 
CG6153 
BL44017 
HMS0
2732  NE      
CG3184
9 
FBgn00
51849 
CG31849 
BL44020 
HMS0
2735  NE      
CG1547
9 
FBgn00
32493 
CG15479 
BL44024 
HMS0
2739  NE      
CG4229
6 
FBgn02
59192 
CG42296 
BL44028 
HMS0
2744  NE      
CG2976 FBgn00
31633 
CG2976 
BL44032 
HMS0
2748  NE      
CG1226
4 
FBgn00
32393 
CG12264 
BL44037 
HMS0
2753  NE      
CG1677
1 
FBgn00
32779 
CG16771 
BL44042 
HMS0
2758  NE      
CG3351
0 
FBgn00
53510 
CG33510 
BL44069 
HMS0
2786  NE      
CG3438
0 
FBgn00
85409 
CG34380 
BL44089 
HMS0
2806  NE      
CG1034
8 
FBgn00
32707 
CG10348 
BL44091 
HMS0
2808  NE      
CG1132
6 
FBgn00
31850 
Tsp 
BL44116 
HMS0
2838  NE      
CG1043
1 
FBgn00
32730 
CG10431 
BL44470 
HMC0
2345  NE      
CG5322 FBgn00
32253 
Lysosomal α-
mannosidase I BL44473 
HMC0
2357 E E NE S NE  NE 
CG4322
7 
FBgn02
62872 
milt 
BL44477 
HMC0
2365  NE      
CG8869 FBgn00
31654 
Jon25Bii 
BL44504 
HMC0
2890  NE      
CG3174
1 
FBgn00
51741 
CG31741 
BL44518 
HMC0
2908  NE      
CG3169
0 
FBgn00
51690 
CG31690 
BL44525 
HMC0
2919  NE      
CG5423 FBgn00
41097 
robo3 
BL44539 
HMC0
2934  NE      
CG3696 FBgn00
86902 
kis 
BL44542 
HMC0
2937  NE      
CG5352 FBgn02
62601 
SmB 
BL44544 
HMC0
2939 A ME ME   ME  
CG4140 FBgn02
61881 
l(2)35Be 
BL44545 
HMC0
2941  NE      
CG7221 FBgn00
31972 
Wwox 
BL44546 
HMC0
2942  NE      
CG1394
8 
FBgn00
41250 
Gr21a 
BL44554 
HMS0
2850  NE      
CG9547 FBgn00
31824 
CG9547 
BL44556 
HMS0
2852  NE      
CG7299 FBgn00
32282 
CG7299 
BL44557 
HMS0
2853  NE      
CG1163
0 
FBgn00
32964 
CG11630 
BL44566 
HMS0
2862  NE      
319 
 
CG2637 FBgn02
62743 
Fs(2)Ket 
BL44576 
HMS0
2872 
A E-L ME E ME ME  
CG3380
1 
FBgn00
53801 
His1:CG33801 
BL44582 
HMS0
2879  NE      
CG7309 FBgn00
32314 
CG7309 
BL44653 
HMC0
2417 S S  S MS  NE 
CG7228 FBgn00
31969 
pes 
BL50612 
HMC0
2979  NE      
CG7227 FBgn00
31970 
CG7227 
BL50613 
HMC0
2980  NE      
CG4306
5 
FBgn02
62475 
bru-2 
BL50627 
HMC0
2994  NE      
CG1861
9 
FBgn00
32202 
Reptor-BP 
BL50658 
HMC0
3059 ME ME NE ME ME  NE 
CG7219 FBgn00
31973 
Spn28D 
BL50670 
HMC0
3071  NE      
CG6634 FBgn02
61963 
mid 
BL50681 
HMC0
3082  NE      
CG1686
9 
FBgn00
32535 
Ance-2 
BL50691 
HMC0
3092  NE      
CG5325 FBgn00
32407 
Pex19 
BL50702 
HMC0
3104  NE      
CG1016
6 
FBgn00
32799 
CG10166 
BL50713 
HMS0
2947  NE      
CG1428 FBgn00
32967 
CG1428 
BL50715 
HMS0
2949  NE      
CG1403
6 
FBgn00
31677 
CG14036 
BL50717 
HMS0
2951  NE      
CG8663 FBgn00
32946 
nrv3 
BL50725 
HMS0
2961  NE      
CG5427 FBgn00
32433 
Oatp33Ea 
BL50736 
HMS0
2972  NE      
CG6860 FBgn00
32633 
Lrch 
BL50901 
HMJ0
3119  NE      
CG9246 FBgn00
32925 
CG9246 
BL50907 
HMJ0
3129  NE      
CG3413
6 
FBgn00
83972 
CG34136 
BL50936 
HMJ2
1031  NE      
CG3539 FBgn02
64978 
Slh 
BL50940 
HMJ2
1035  NE      
CG1513
8 
FBgn00
32629 
beat-IIIc 
BL50941 
HMJ2
1036  NE      
CG1709
8 
FBgn00
32276 
CG17098 
BL50950 
HMJ2
1051 A ME ME MS E E  
CG1026
8 
FBgn00
32811 
CG10268 
BL50955 
HMJ2
1057 A E E   E  
CG5439 FBgn00
32476 
CG5439 
BL50957 
HMJ2
1059  NE      
CG3319
4 
FBgn00
53194 
CheA29a 
BL50978 
HMJ2
1084  NE      
CG6717 FBgn00
83141 
Spn28B 
BL50996 
HMJ2
1109  NE      
CG4223
8 
FBgn02
50867 
CG42238 
BL51023 
HMJ2
1149  NE      
CG9568 FBgn00
32087 
CG9568 
BL51025 
HMJ2
1151 
(MS 
POSSIBL
E) NE  S E   
CG1378
4 
FBgn00
31897 
CG13784 
BL51027 
HMJ2
1154  NE      
CG4247
4 
FBgn02
59964 
Sfp33A3 
BL51052 
HMJ2
1186  NE      
CG4496 FBgn00
31894 
CG4496 
BL51428 
HMC0
3034 ME ME NE ME NE  NE 
CG1435
1 
FBgn02
61509 
haf 
BL51438 
HMC0
3152  NE      
CG9256 FBgn00
40297 
Nhe2 
BL51491 
HMC0
3243  NE      
CG6504 FBgn00
41195 
Pkd2 
BL51502 
HMC0
3263  NE      
320 
 
CG3166
0 
FBgn00
51660 
pog 
BL51705 
HMC0
3192  NE      
CG1401
4 
FBgn00
31718 
CG14014 
BL51737 
HMS0
3168  NE      
CG4636 FBgn00
41781 
SCAR 
BL51803 
HMC0
3361  NE      
CG1527
4 
FBgn02
60446 
GABA-B-R1 
BL51817 
HMC0
3388  NE      
CG3172
9 
FBgn00
51729 
CG31729 
BL51819 
HMC0
3390  NE      
CG3176
0 
FBgn00
51760 
CG31760 
BL51838 
HMC0
3410  NE      
CG3329
8 
FBgn00
32120 
CG33298 
BL51841 
HMC0
3414  NE   NE   
CG1404
3 
FBgn00
31659 
CG14043 
BL51858 
HMC0
3432  NE      
CG8891 FBgn00
31663 
CG8891 
BL51859 
HMC0
3433  NE      
CG8680 FBgn00
31684 
CG8680 
BL51860 
HMC0
3434  NE      
CG1039
9 
FBgn00
31877 
CG10399 
BL51861 
HMC0
3435  NE      
CG1377
8 
FBgn00
31885 
Mnn1 
BL51862 
HMC0
3436  NE      
CG4908 FBgn00
32195 
CG4908 
BL51863 
HMC0
3437  NE      
CG5037 FBgn00
32222 
CG5037 
BL51864 
HMC0
3438  NE      
CG5091 FBgn00
32234 
gny 
BL51865 
HMC0
3439  NE      
CG6415 FBgn00
32287 
CG6415 
BL51867 
HMC0
3441  NE      
CG1703
6 
FBgn00
32449 
CG17036 
BL51868 
HMC0
3442  NE      
CG5287 FBgn00
32477 
CG5287 
BL51869 
HMC0
3443  NE      
CG1063
9 
FBgn00
32729 
CG10639 
BL51870 
HMC0
3444  NE      
CG3169
2 
FBgn00
32820 
fbp 
BL51871 
HMC0
3445  NE      
CG9342 FBgn00
32904 
Mtp 
BL51872 
HMC0
3446  NE      
CG3262 FBgn00
32986 
CG3262 
BL51873 
HMC0
3447  NE      
CG8349 FBgn00
32003 
CG8349 
BL51914 
HMS0
3372  NE      
CG8353 FBgn00
32002 
CG8353 
BL51915 
HMS0
3373  NE      
CG8360 FBgn00
32001 
CG8360 
BL51916 
HMS0
3374  NE      
CG1453
5 
FBgn00
31955 
CG14535 
BL51936 
HMC0
3285  NE      
CG1582
8 
FBgn00
32136 
CG15828 
BL51937 
HMC0
3294  NE      
CG3160
5 
FBgn02
61822 
Bsg 
BL52110 
HMC0
3195  NE      
CG5390 FBgn00
32213 
CG5390 
BL52875 
HMC0
3613  NE      
CG4128 FBgn00
32151 
nAcRalpha-30D 
BL52885 
HMC0
3623  NE      
CG1759
7 
FBgn00
32715 
cad 
BL52886 
HMC0
3624  NE      
CG3355 FBgn00
31619 
CG3355 
BL52897 
HMC0
3636  NE      
CG3173
9 
FBgn00
51739 
CG31739 
BL52909 
HMC0
3649  NE      
CG1543
4 
FBgn00
40705 
CG15434 
BL52913 
HMC0
3653  NE      
CG6287 FBgn00
32350 
CG6287 
BL52928 
HMC0
3669  NE      
321 
 
CG1327
7 
FBgn02
61068 
LSm7 
BL52932 
HMC0
3674  NE      
CG9140 FBgn00
31771 
CG9140 
BL52939 
HMJ2
1591  NE      
CG3417
4 
FBgn00
85203 
CG34174 
BL52943 
HMJ2
1610  NE      
CG1105
0 
FBgn00
31836 
CG11050 
BL52970 
HMJ2
1655  NE      
CG1279
5 
FBgn00
31535 
CG12795 
BL52988 
HMJ2
1680  NE      
CG1713
4 
FBgn00
32304 
CG17134 
BL53023 
HMJ2
1746  NE      
CG3651 FBgn00
32974 
CG3651 
BL53028 
HMJ2
1753  NE      
CG1516
7 
FBgn00
32709 
CG15167 
BL53031 
HMJ2
1757  NE      
CG1711
8 
FBgn00
32291 
CG17118 
BL53304 
HMC0
3531  NE      
CG5996 FBgn00
32593 
trpgamma 
BL53313 
HMC0
3542  NE      
CG3180
3 
FBgn00
51803 
CG31803 
BL53338 
HMC0
3567  NE      
CG3195
4 
FBgn00
51954 
CG31954 
BL53674 
HMC0
3607  NE      
CG1047
3 
FBgn02
63198 
Acn 
BL53676 
HMC0
3673  NE      
CG7456 FBgn00
32258 
CG7456 
BL53679 
HMJ2
1592  NE      
CG1119
9 
FBgn00
46704 
Liprin-alpha 
BL53868 
HMC0
3183  NE      
CG1083
3 
FBgn00
31689 
Cyp28d1 
BL53892 
HMJ2
1210  NE      
CG3180
2 
FBgn00
51802 
CG31802 
BL53893 
HMJ2
1211  NE      
CG8890 FBgn00
31661 
Gmd 
BL53912 
HMJ2
1245 A E-L E   E  
CG1033
8 
FBgn00
32700 
CG10338 
BL53913 
HMJ2
1246  NE      
CG9305 FBgn00
32512 
CG9305 
BL53915 
HMJ2
1248  NE      
CG1041
4 
FBgn00
32691 
Atac2 
BL53918 
HMJ2
1253  NE      
CG3164
1 
FBgn00
51641 
stai 
BL53925 
HMJ2
1270  NE      
CG1327
0 
FBgn00
40262 
Ugt36Ba 
BL53931 
HMJ2
1279  NE      
CG1682
5 
FBgn00
32503 
CG16825 
BL53973 
HMJ2
1358  NE      
CG4904 FBgn02
50843 
Pros35 
BL53974 
HMJ2
1359 A ME ME MS E ME  
CG1401
1 
FBgn00
31722 
CG14011 
BL53993 
HMJ2
1397 MS MS  NE E  NE 
CG6392 FBgn00
40232 
cmet 
BL54004 
HMJ2
1427 A ME E   E  
CG5727 FBgn00
32193 
CG5727 
BL54021 
HMJ2
1447  NE      
CG1403
1 
FBgn00
31695 
Cyp4ac3 
BL54023 
HMJ2
1449  NE      
CG4372
0 
FBgn02
63873 
sick 
BL54037 
HMJ2
1480  NE      
CG1017
4 
FBgn00
32680 
Ntf-2r 
BL54462 
HMS0
3723  NE      
CG1699
7 
FBgn02
63235 
Phae2 
BL54805 
HMJ2
1499  NE      
CG4253
3 
FBgn02
60486 
CG42533 
BL54817 
HMJ2
1536  NE      
CG1514
5 
FBgn00
32649 
CG15145 
BL54837 
HMJ2
1556  NE      
CG5381 FBgn00
32218 
CG5381 
BL54847 
HMJ2
1584  NE      
322 
 
CG3195
0 
FBgn00
51950 
CG31950 
BL55161 
HMC0
3836  NE      
CG3058 FBgn00
31601 
Dim1 
BL55171 
HMC0
3851  NE      
CG1399
9 
FBgn00
31753 
CG13999 
BL55177 
HMC0
3858  NE      
CG8885 FBgn02
62467 
Scox 
BL55179 
HMC0
3860  NE      
CG9232 FBgn02
63200 
Galt 
BL55191 
HMC0
3885  NE      
CG6488 FBgn00
32361 
CG6488 
BL55192 
HMC0
3886  NE      
CG1724
2 
FBgn02
50841 
CG17242 
BL55198 
HMC0
3896 A ME ME   E  
CG6686 FBgn00
32388 
CG6686 
BL55202 
HMC0
3913 A ME ME  E ME  
CG5648 FBgn00
32492 
Prosalpha6T 
BL55243 
HMC0
2418  NE      
CG5343 FBgn00
32248 
CG5343 
BL55258 
HMC0
3945  NE      
CG1046
6 
FBgn00
32822 
CG10466 
BL55263 
HMC0
3950  NE      
CG1251
2 
FBgn00
31703 
CG12512 
BL55269 
HMC0
3956  NE      
CG3161
9 
FBgn00
51619 
CG31619 
BL55296 
HMC0
3983  NE      
CG1798
8 
FBgn00
32536 
Ance-3 
BL55298 
HMC0
3985  NE      
CG3439
5 
FBgn00
85424 
nub 
BL55305 
HMC0
3992  NE      
CG4132 FBgn00
40079 
pkaap 
BL55333 
HMC0
4020  NE      
CG1723
9 
FBgn00
42186 
CG17239 
BL55336 
HMC0
4023  NE      
CG8871 FBgn00
31653 
Jon25Biii 
BL55344 
HMC0
4031  NE      
CG1493
4 
FBgn00
32381 
Mal-B1 
BL55346 
HMC0
4033  NE      
CR3288
1 
FBgn00
43022 
snRNA:U5:38AB
a BL55361 
HMC0
4048  NE      
CG3225 FBgn00
31631 
CG3225 
BL55365 
HMC0
4053  NE      
CG1878
7 
FBgn00
42125 
CG18787 
BL55375 
HMC0
4063  NE      
CG1757
1 
FBgn02
59998 
CG17571 
BL55408 
HMC0
4096  NE      
CG1723
4 
FBgn00
42187 
CG17234 
BL55611 
HMC0
3750  NE      
CG9377 FBgn00
32507 
CG9377 
BL55623 
HMC0
3767  NE      
CG3185
2 
FBgn00
51852 
Tap42 
BL55625 
HMC0
3769  NE      
CG3172
8 
FBgn00
51728 
CG31728 
BL55628 
HMC0
3773  NE      
CG4779 FBgn00
40211 
hgo 
BL55629 
HMC0
3775  NE      
CG1765
7 
FBgn00
86698 
frtz 
BL55649 
HMC0
3798  NE      
CG3181
2 
FBgn00
51812 
CG31812 
BL55659 
HMC0
3813  NE      
CR3298
9 
FBgn00
41717 
snRNA:U6atac:2
9B BL55666 
HMC0
3821  NE      
CG3294 FBgn00
31628 
CG3294 
BL55691 
HMC0
3905  NE      
CG1126
6 
FBgn00
31883 
Caper 
BL55742 
HMC0
3924 
(MS 
POSSIBL
E) NE   E   
CG6639 FBgn00
32638 
CG6639 
BL55853 
HMC0
3740  NE      
323 
 
CG9333 FBgn00
32891 
Oseg5 
BL55856 
HMC0
3888  NE      
CG4375
6 
FBgn02
64087 
Slob 
BL55879 
HMC0
4152  NE      
CG9222 FBgn00
31784 
CG9222 
BL55890 
HMC0
4165  NE      
CG4839 FBgn00
32187 
CG4839 
BL55891 
HMC0
4168  NE      
CG3353
1 
FBgn00
53531 
Ddr 
BL55906 
HMC0
4190  NE      
CG1528
4 
FBgn02
64810 
pburs 
BL55924 
HMC0
4211  NE      
CG4400
7 
FBgn02
64815 
Pde1c 
BL55925 
HMC0
4212  NE      
CG6431 FBgn00
32289 
CG6431 
BL55943 
HMC0
4231  NE      
CG1790
5 
FBgn00
32598 
ChLD3 
BL55944 
HMC0
4232  NE      
CG1440
5 
FBgn00
32888 
CheB38c 
BL55945 
HMC0
4233 A ME ME MS  ME  
CG3311
7 
FBgn00
53117 
Victoria 
BL55953 
HMC0
4242  NE      
CG1399
0 
FBgn00
40950 
Muc26B 
BL55986 
HMC0
4282  NE      
CG1781
4 
FBgn00
40959 
Peritrophin-15a 
BL55987 
HMC0
4283  NE      
CG3168
1 
FBgn00
51681 
CG31681 
BL55994 
HMC0
4290  NE      
CG3170
4 
FBgn00
51704 
CG31704 
BL55995 
HMC0
4291  NE      
CG3197
3 
FBgn00
51973 
Cda5 
BL55996 
HMC0
4292  NE      
CG3410
2 
FBgn00
83938 
BG642163 
BL56001 
HMC0
4297  NE      
CG3444
7 
FBgn00
85476 
CG34447 
BL56002 
HMC0
4298  NE      
CG3444
8 
FBgn00
85477 
CG34448 
BL56003 
HMC0
4299 A E E   E  
CG3189
3 
FBgn00
40958 
Peritrophin-15b 
BL56019 
HMC0
4315  NE      
CG7068 FBgn00
41181 
Tep3 
BL56020 
HMC0
4316  NE      
CG7532 FBgn02
61534 
l(2)34Fc 
BL56023 
HMC0
4319  NE   E   
CG1682
0 
FBgn00
32495 
CG16820 
BL56027 
HMC0
4323  NE      
CG1073
0 
FBgn00
32843 
CG10730 
BL56028 
HMC0
4324  NE      
CG3175
1 
FBgn00
86909 
CG31751 
BL56030 
HMC0
4338  NE      
CG1228
8 
FBgn00
32620 
CG12288 
BL56037 
HMC0
4345  NE      
CG1671
2 
FBgn00
31561 
CG16712 
BL56047 
HMS0
4250  NE      
CG5726 FBgn00
34313 
CG5726 
BL32335 
HMS0
0326  NE      
CG8707 FBgn00
33272 
RagC-D 
BL32342 
HMS0
0333  NE      
CG3845 FBgn00
10488 
NAT1 
BL32357 
HMS0
0348 S S  NE ME  NE 
CG2173 FBgn00
21995 
Rs1 
BL32363 
HMS0
0354  NE      
CG8815 FBgn00
22764 
Sin3A 
BL32368 
HMS0
0359  NE      
CG1021
2 
FBgn00
27783 
SMC2 
BL32369 
HMS0
0360  NE      
CG6805 FBgn00
34179 
CG6805 
BL32380 
HMS0
0371  NE      
CG8416 FBgn00
14020 
Rho1 
BL32383 
HMS0
0375 A E E   E  
324 
 
CG3288
5 
FBgn00
16053 
pgc 
BL32386 
HMS0
0378  NE      
CG3420
7 
FBgn00
85236 
CG34207 
BL32387 
HMS0
0379  NE      
CG5820 FBgn00
13272 
Gp150 
BL32400 
HMS0
0395  NE      
CG3879 FBgn00
04512 
Mdr49 
BL32405 
HMS0
0400  NE      
CG1770
4 
FBgn00
26401 
Nipped-B 
BL32406 
HMS0
0401 ME ME NE NE NE  NE 
CG2917 FBgn00
23181 
Orc4 
BL32409 
HMS0
0404  NE      
CG1108
4 
FBgn00
03090 
pk 
BL32413 
HMS0
0408  NE      
CG8804 FBgn00
16078 
wun 
BL32429 
HMS0
0424  NE      
CG1008
2 
FBgn00
34644 
CG10082 
BL32431 
HMS0
0427  NE      
CG3439
9 
FBgn00
85428 
Nox 
BL32433 
HMS0
0429  NE      
CG2044 FBgn00
02535 
Lcp4 
BL32455 
HMS0
0454  NE      
CG1825 FBgn00
10342 
Map60 
BL32458 
HMS0
0457  NE      
CG6061 FBgn00
33846 
mip120 
BL32461 
HMS0
0461  NE      
CG7200 FBgn00
32671 
CG7200 
BL32485 
HMS0
0488  NE      
CG8411 FBgn00
05695 
gcl 
BL32492 
HMS0
0495  NE      
CG3035
6 
FBgn00
50356 
CG30356 
BL32493 
HMS0
0496  NE      
CG8905 FBgn00
10213 
Sod2 
BL32496 
HMS0
0499  NE      
CG1240
5 
FBgn00
33520 
Prx2540-1 
BL32497 
HMS0
0500  NE      
CG1511
9 
FBgn00
34430 
mip40 
BL32834 
HMS0
0524  NE      
CG3440
7 
FBgn00
85436 
Not1 
BL32836 
HMS0
0526 A E ME ME  E  
CG1211
0 
FBgn00
33075 
Pld 
BL32839 
HMS0
0529  NE      
CG7843 FBgn00
33062 
Ars2 
BL32844 
HMS0
0626  NE      
CG8625 FBgn00
11604 
Iswi 
BL32845 
HMS0
0628  NE      
CG1015
5 
FBgn00
20767 
Spred 
BL32852 
HMS0
0637  NE      
CG8975 FBgn00
11704 
RnrS 
BL32864 
HMS0
0651  NE      
CG6050 FBgn00
24556 
EfTuM 
BL32868 
HMS0
0655  NE      
CG5170 FBgn00
27835 
Dp1 
BL32872 
HMS0
0659  NE      
CG8266 FBgn00
33339 
sec31 
BL32878 
HMS0
0666  NE      
CG8309 FBgn00
33902 
Tango7/eIF3m 
BL32879 
HMS0
0667 A ME ME   ME  
CG4878 FBgn00
34237 
eIF3-S9 
BL32880 
HMS0
0668 E E NE E-L E-L  NE 
CG5174 FBgn00
34345 
CG5174 
BL32881 
HMS0
0669  NE      
CG9862 FBgn00
34646 
Rae1 
BL32882 
HMS0
0670  NE      
CG1057
8 
FBgn02
63106 
DnaJ-1 
BL32899 
HMS0
0688  NE      
CG3722 FBgn00
03391 
shg 
BL32904 
HMS0
0693 A E E   E  
CG1225
2 
FBgn00
35026 
Fcp1 
BL32925 
HMS0
0716  NE      
325 
 
CG8529 FBgn00
33739 
Dyb 
BL32935 
HMS0
0728  NE      
CG1148
2 
FBgn00
11659 
Mlh1 
BL32940 
HMS0
0734  NE      
CG8274 FBgn00
13756 
Mtor 
BL32941 
HMS0
0735  NE      
CG8068 FBgn00
03612 
Su(var)2-10 
BL32956 
HMS0
0750 A ME ME   ME  
CG1335
0 
FBgn00
33890 
Ctf4 
BL32968 
HMS0
0764  NE      
CG1374
5 
FBgn00
33354 
FANCI 
BL32972 
HMS0
0769 ME ME NE NE E-L  NE 
CG1242 FBgn00
01233 
Hsp83 
BL32996 
HMS0
0796  NE      
CG8426 FBgn00
33029 
l(2)NC136/Not3 
BL33002 
HMS0
0802 LacZ-E E NE ME E-L  E 
CG4466 FBgn00
01226 
Hsp27 
BL33007 
HMS0
0807  NE      
CG3825 FBgn00
34948 
Gadd34/PPP1R1
5 BL33011 
HMS0
0811  NE      
CG9193 FBgn00
05655 
mus209 
BL33043 
HMS0
0634  NE      
CG5859 FBgn00
25830 
IntS8 
BL33048 
HMS0
0721 E E NE NE ME NE NE 
CG1234
0 
FBgn00
27499 
wde 
BL33339 
HMS0
0205  NE      
CG1309
6 
FBgn00
32050 
CG13096 
BL33340 
HMS0
0206  NE      
CG4415
3 
FBgn02
65002 
CG44153 
BL33350 
HMS0
0218  NE      
CG3253 FBgn00
41706 
CG3253 
BL33351 
HMS0
0220  NE      
CG9005 FBgn00
33638 
CG9005 
BL33362 
HMS0
0234  NE      
CG6556 FBgn00
21818 
cnk 
BL33366 
HMS0
0238  NE      
CG8710 FBgn00
33265 
coil 
BL33368 
HMS0
0240  NE      
CG4654 FBgn00
11763 
Dp 
BL33372 
HMS0
0245  NE      
CG9854 FBgn00
15949 
hrg 
BL33378 
HMS0
0252 
ME ME NE E ME  
(MS 
POSSIBL
E) 
CG5373 FBgn00
15277 
Pi3K59F 
BL33384 
HMS0
0261  NE      
CG1236
7 
FBgn00
33686 
Hen1 
BL33385 
HMS0
0262  NE      
CG8991 FBgn00
33654 
Sobp 
BL33397 
HMS0
0275  NE      
CG3905 FBgn00
08654 
Su(z)2 
BL33403 
HMS0
0281  NE      
CG3038
8 
FBgn00
34590 
Magi 
BL33411 
HMS0
0291  NE      
CG1024
9 
FBgn00
27596 
CG10249 
BL33432 
HMS0
0319  NE      
CG1389 FBgn00
03733 
tor 
BL33627 
HMS0
0021  NE      
CG6493 FBgn00
34246 
Dcr-2 
BL33656 
HMS0
0062  NE      
CG8730 FBgn00
26722 
drosha 
BL33657 
HMS0
0064  NE      
CG1519 FBgn00
23175 
Prosalpha7 
BL33660 
HMS0
0068 A E E   E  
CG2038 FBgn00
28836 
CSN7 
BL33663 
HMS0
0073  NE      
CG4254 FBgn00
11726 
tsr 
BL33670 
HMS0
0534  NE      
CG1406 FBgn00
33210 
U2A 
BL33671 
HMS0
0535  NE      
326 
 
CG1511
7 
FBgn00
34417 
CG15117 
BL33693 
HMS0
0562  NE      
CG9015 FBgn00
00577 
en 
BL33715 
HMS0
0595  NE      
CG1381 FBgn00
33485 
RpLP0-like 
BL33730 
HMS0
0613 E E NE NE ME  NE 
CG1738
5 
FBgn00
33934 
CG17385 
BL33734 
HMS0
0617  NE      
CG1844
6 
FBgn00
33458 
CG18446 
BL33735 
HMS0
0618  NE      
CG6370 FBgn00
34277 
CG6370 
BL33752 
HMS0
1092  NE      
CG8166 FBgn00
34013 
unc-5 
BL33756 
HMS0
1099  NE      
CG4921 FBgn00
16701 
Rab4 
BL33757 
HMS0
1100  NE      
CG6518 FBgn00
04784 
inaC 
BL33768 
JF029
58  NE      
CG8397 FBgn00
34066 
CG8397 
BL33877 
HMS0
0814  NE      
CG1672
0 
FBgn00
04168 
5-HT1A 
BL33885 
HMS0
0823  NE      
CG1024
1 
FBgn00
15714 
Cyp6a17 
BL33887 
HMS0
0825  NE      
CG3820 FBgn00
10660 
Nup214 
BL33897 
HMS0
0837  NE      
CG8243 FBgn00
33349 
CG8243 
BL33927 
HMS0
0876  NE      
CG1706
4 
FBgn00
33845 
mars 
BL33929 
HMS0
0878  NE      
CG1341 FBgn00
28687 
Rpt1 
BL33930 
HMS0
0879 A E E   E  
CG8983 FBgn00
33663 
ERp60 
BL33935 
HMS0
0885  NE      
CG1693
2 
FBgn00
35060 
Eps-15 
BL33942 
HMS0
0893  NE      
CG5109 FBgn00
03044 
Pcl 
BL33946 
HMS0
0897  NE      
CG8280 FBgn00
00556 
Ef1alpha48D 
BL33960 
HMS0
0917  NE      
CG1219
0 
FBgn00
34763 
RYBP 
BL33974 
HMS0
0931  NE      
CG3034
5 
FBgn00
50345 
CG30345 
BL33994 
HMS0
0957  NE      
CG1212
8 
FBgn00
33473 
CG12128 
BL33997 
HMS0
0960  NE      
CG1509
5 
FBgn00
10651 
l(2)08717 
BL33999 
HMS0
0962  NE      
CG3351
9 
FBgn00
53519 
Unc-89 
BL34000 
HMS0
0963  NE      
CG1020
7 
FBgn00
16684 
NaPi-T 
BL34003 
HMS0
0966  NE      
CG1232
4 
FBgn00
33555 
RpS15Ab 
BL34008 
HMS0
0973  NE      
CG5465 FBgn00
34707 
MED16 
BL34012 
HMS0
0978  NE      
CG4038 FBgn00
11824 
CG4038 
BL34013 
HMS0
0979 
(ME 
POSSIBL
E) NE      
CG3006
7 
FBgn00
50067 
Obp50a 
BL34023 
HMS0
0993  NE      
CG4005 FBgn00
34970 
yki 
BL34067 
HMS0
0041 A ME ME NE NE ME  
CG1068
3 
FBgn00
04400 
rhi 
BL34071 
HMS0
0069  NE      
CG8728 FBgn00
33235 
CG8728 
BL34074 
HMS0
0561  NE      
CG4049 FBgn00
34976 
CG4049 
BL34077 
HMS0
0584  NE      
327 
 
CG3334
8 
FBgn00
53348 
CheB42a 
BL34078 
HMS0
0590  NE      
CG2065 FBgn00
33204 
CG2065 
BL34098 
HMS0
0984  NE      
CG1091
7 
FBgn00
00658 
fj 
BL34323 
HMS0
1310  NE      
CG2328 FBgn00
00606 
eve 
BL34325 
HMS0
1312  NE      
CG9485 FBgn00
34618 
CG9485 
BL34333 
HMS0
1321  NE      
CG4001 FBgn00
03071 
Pfk 
BL34336 
HMS0
1324  NE      
CG4062 FBgn00
27079 
Aats-val 
BL34338 
HMS0
1326  NE      
CG1025
3 
FBgn00
33983 
CG10253 
BL34350 
HMS0
1339  NE      
CG8075 FBgn00
15838 
Vang 
BL34354 
HMS0
1343  NE      
CG5489 FBgn00
34366 
Atg7 
BL34369 
HMS0
1358  NE      
CG8261 FBgn00
04921 
Ggamma1 
BL34372 
HMS0
1361  NE      
CG6562 FBgn00
34691 
synj 
BL34378 
HMS0
1368  NE      
CG3045
6 
FBgn00
50456 
CG30456 
BL34380 
HMS0
1370  NE      
CG1319
2 
FBgn00
33653 
CG13192 
BL34390 
HMS0
1384  NE      
CG8298 FBgn00
33673 
CG8298 
BL34524 
HMS0
0813  NE      
CG4581 FBgn00
25352 
Thiolase 
BL34546 
HMS0
1017  NE      
CG1355
1 
FBgn00
40660 
CG13551 
BL34554 
HMS0
1026  NE      
CG2158 FBgn00
33264 
Nup50 
BL34580 
HMS0
1054  NE      
CG6459 FBgn00
34259 
P32 
BL34585 
HMS0
1059  NE      
CG2163 FBgn00
05648 
Pabp2 
BL34602 
HMS0
0553  NE      
CG8472 FBgn00
00253 
Cam 
BL34609 
HMS0
1318  NE      
CG4029
3 
FBgn00
46692 
Stlk 
BL34620 
HMS0
1295  NE      
CG8877 FBgn00
33688 
Prp8 
BL34622 
HMS0
1297  NE      
CG1583
5 
FBgn00
33233 
Kdm4A 
BL34629 
HMS0
1304  NE      
CG3340 FBgn00
01325 
Kr 
BL34632 
HMS0
1106  NE      
CG9635 FBgn00
23172 
RhoGEF2 
BL34643 
HMS0
1118  NE      
CG1677
8 
FBgn00
03715 
CG16778 
BL34651 
HMS0
1126  NE      
CG8819 FBgn00
33749 
achi 
BL34652 
HMS0
1127  NE      
CG2204 FBgn00
01122 
G-oalpha47A 
BL34653 
HMS0
1129  NE      
CG7576 FBgn00
05586 
Rab3 
BL34655 
HMS0
1131  NE      
CG8367 FBgn00
00289 
cg 
BL34668 
HMS0
1145  NE      
CG1510
4 
FBgn00
34410 
Topors 
BL34671 
HMS0
1149 MS MS  NE NE  NE 
CG1476
7 
FBgn00
40777 
CG14767 
BL34679 
HMS0
1157  NE      
CG7734 FBgn00
03396 
shn 
BL34689 
HMS0
1167  NE      
CG8980 FBgn00
26402 
NiPp1 
BL34696 
HMS0
1175  NE      
328 
 
CG6622 FBgn00
03091 
Pkc53E 
BL34716 
HMS0
1195  NE      
CG1832
4 
FBgn00
33905 
CG18324 
BL34720 
HMS0
1199  NE      
CG8791 FBgn00
33234 
CG8791 
BL34728 
HMS0
1207  NE      
CG8920 FBgn00
27529 
CG8920 
BL34738 
HMS0
1218  NE      
CG5575 FBgn00
11236 
ken 
BL34739 
HMS0
1219 E E NE ME ME  NE 
CG8293 FBgn00
15247 
Iap2 
BL34776 
HMS0
0085  NE      
CG1093
8 
FBgn00
16697 
Prosalpha5 
BL34786 
HMS0
0095 A E E   E  
CG3644 FBgn00
00181 
bic 
BL34790 
HMS0
0099  NE      
CG3090 FBgn00
05612 
Sox14 
BL34794 
HMS0
0103  NE      
CG1232
3 
FBgn00
29134 
Prosbeta5 
BL34810 
HMS0
0119 A E-L E   E  
CG9291 FBgn00
23211 
Elongin-C 
BL34818 
HMS0
0128  NE      
CG9646 FBgn00
34184 
CG9646 
BL34819 
HMS0
0134  NE      
CG8639 FBgn00
33313 
Cirl 
BL34821 
HMS0
0136  NE      
CG8392 FBgn00
10590 
Prosbeta1 
BL34824 
HMS0
0139 A E E   E-L  
CG8912 FBgn00
14870 
Psi 
BL34825 
HMS0
0140  NE      
CG2910 FBgn00
27548 
nito 
BL34848 
HMS0
0166  NE      
CG3355
4 
FBgn00
53554 
Nipped-A 
BL34849 
HMS0
0167  NE      
CG1141
9 
FBgn00
34231 
Apc10 
BL34858 
HMS0
0176  NE      
CG1168
0 
FBgn00
02774 
mle/nap 
BL34864 
HMS0
0182 
(MS 
POSSIBL
E) NE NE MS    
CG1091
5 
FBgn00
34308 
CG10915 
BL34879 
HMS0
0199  NE      
CG1119
8 
FBgn00
33246 
ACC 
BL34885 
HMS0
1230  NE      
CG1566
7 
FBgn00
26369 
Sara 
BL34894 
HMS0
1239  NE      
CG1825
0 
FBgn00
34072 
Dg 
BL34895 
HMS0
1240  NE      
CG4816 FBgn00
22987 
qkr54B 
BL34896 
HMS0
1241  NE      
CG5562 FBgn00
24234 
gbb 
BL34898 
HMS0
1243  NE      
CG3615 FBgn00
34110 
Atg9 
BL34901 
HMS0
1246  NE      
CG1008
0 
FBgn00
34641 
mahj 
BL34912 
HMS0
1260  NE NE NE NE   
CG8996 FBgn00
10516 
wal 
BL34915 
HMS0
1263  NE      
CG3269 FBgn00
14009 
Rab2 
BL34922 
HMS0
1271  NE      
CG1386
7 
FBgn00
34503 
MED8 
BL34926 
HMS0
1275 MS MS  S MS  NE 
CG9834 FBgn00
34433 
endoB 
BL34935 
HMS0
1285  NE      
CG4696 FBgn00
02789 
Mp20 
BL34963 
HMS0
0630  NE      
CG8858 FBgn00
33698 
CG8858 
BL34975 
HMS0
1128 E E NE NE NE  NE 
CG1334
5 
FBgn00
86356 
tum 
BL35007 
HMS0
1417  NE      
329 
 
CG1108
6 
FBgn00
33153 
Gadd45 
BL35023 
HMS0
1436  NE      
CG1112
1 
FBgn00
03460 
so 
BL35028 
HMS0
1441 E-L E-L NE E E-L  NE 
CG1318
3 
FBgn00
33667 
CG13183 
BL35031 
HMS0
1444  NE      
CG1318
8 
FBgn00
33668 
CG13188 
BL35032 
HMS0
1445  NE      
CG8523 FBgn00
10241 
Mdr50 
BL35034 
HMS0
1448  NE      
CG8440 FBgn00
15754 
Lis-1 
BL35043 
HMS0
1457  NE      
CG1189
5 
FBgn00
24836 
stan 
BL35050 
HMS0
1464  NE      
CG3017
3 
FBgn00
61198 
HSPC300 
BL35051 
HMS0
1465  NE      
CG8821 FBgn00
33748 
vis 
BL35738 
HMS0
1480  NE      
CG8238 FBgn00
40491 
Buffy 
BL35742 
HMS0
1484  NE      
CG3017
6 
FBgn00
34918 
wibg 
BL35746 
HMS0
1488  NE      
CG9397 FBgn00
86655 
jing 
BL35750 
HMS0
1493 A E ME   E  
CG8988 FBgn00
33656 
S2P 
BL35760 
HMS0
1508  NE      
CG4832 FBgn00
13765 
cnn 
BL35761 
HMS0
1509  NE      
CG8648 FBgn00
25832 
Fen1 
BL35764 
HMS0
1512  NE      
CG1344
2 
FBgn00
34546 
CG13442 
BL35769 
HMS0
1518  NE      
CG7765 FBgn00
01308 
Khc 
BL35770 
HMS0
1519  NE      
CG9083 FBgn00
35077 
CG9083 
BL35791 
HMS0
1505 E-L E-L ME E ME ME NE 
CG2078 FBgn00
33402 
Myd88 
BL36107 
HMS0
0183  NE      
CG3044
3 
FBgn00
50443 
Opbp 
BL36120 
HMS0
1535  NE      
CG1840
8 
FBgn00
33504 
CAP 
BL36663 
HMS0
1551  NE      
CG1693
5 
FBgn00
33883 
CG16935 
BL36671 
HMS0
1559  NE      
CG1010
5 
FBgn00
33935 
Sin1 
BL36677 
HMS0
1565  NE      
CG3037
9 
FBgn00
50379 
CG30379 
BL36679 
HMS0
1567  NE      
CG8200 FBgn00
24754 
Flo-1 
BL36700 
HMS0
1589  NE      
CG1772 FBgn00
10316 
dap 
BL36720 
HMS0
1610  NE      
CG3318 FBgn00
19643 
Dat 
BL36726 
HMS0
1617  NE      
CG3624 FBgn00
34724 
babos 
BL36728 
HMS0
1619  NE      
CG8183 FBgn00
19968 
Khc-73 
BL36733 
HMS0
1624  NE      
CG1344
1 
FBgn00
41240 
Gr57a 
BL36738 
HMS0
1629  NE      
CG3032
4 
FBgn00
50324 
CG30324 
BL36751 
HMS0
3011  NE      
CG3398
8 
FBgn00
53988 
CG33988 
BL36754 
HMS0
3014  NE      
CG9415 FBgn00
21872 
Xbp1 
BL36755 
HMS0
3015  NE      
CG3376 FBgn00
34997 
CG3376 
BL36760 
HMS0
3021  NE      
CG5345 FBgn00
00566 
Eip55E 
BL36766 
HMS0
3027  NE      
330 
 
CG8430 FBgn00
01124 
Got1 
BL36768 
HMS0
3029  NE      
CG1007
9 
FBgn00
03731 
Egfr 
BL36773 
JF023
84 A E E   E  
CG1775
9 
FBgn00
04435 
Galpha49B 
BL36775 
JF023
90  NE      
CG1092
4 
FBgn00
34356 
CG10924 
BL36915 
HMS0
0200  NE      
CG6542 FBgn00
27506 
EDTP 
BL36917 
HMS0
1577  NE      
CG4589 FBgn00
19886 
Letm1 
BL37502 
HMS0
1644 A ME ME   E  
CG3691 FBgn00
35047 
Pof 
BL37508 
HMS0
1650  NE      
CG1570
7 
FBgn00
34098 
krimp 
BL37511 
HMS0
1653  NE      
CG1567
1 
FBgn00
00395 
cv-2 
BL37514 
HMS0
1656  NE      
CG5473 FBgn00
34371 
SP2637 
BL37522 
HMS0
1664  NE      
CG1846
8 
FBgn00
34217 
Lhr 
BL38240 
HMS0
1684  NE      
CG3355
8 
FBgn00
53558 
mim 
BL38246 
HMS0
1690  NE      
CG1429 FBgn00
11656 
Mef2 
BL38247 
HMS0
1691  NE      
CG1286
4 
FBgn00
26427 
Su(var)2-HP2 
BL38255 
HMS0
1699  NE      
CG5330 FBgn00
15268 
Nap1 
BL38257 
HMS0
1701  NE      
CG1579
2 
FBgn00
05634 
zip 
BL38259 
HMS0
1703 A E E   E  
CG3886 FBgn00
05624 
Psc 
BL38261 
HMS0
1706  NE      
CG1093
3 
FBgn00
34264 
CG10933 
BL38263 
HMS0
1708  NE      
CG2093 FBgn00
33194 
Vps13 
BL38270 
HMS0
1715  NE  S E-L   
CG1080
8 
FBgn00
33876 
synaptogyrin 
BL38274 
HMS0
1724  NE      
CG1508
7 
FBgn00
34380 
CG15087 
BL38280 
HMS0
1731  NE      
CG1298 FBgn00
33032 
kune 
BL38295 
HMS0
1755  NE      
CG1599 FBgn00
33452 
CG1599 
BL38300 
HMS0
1762  NE      
CG8055 FBgn00
86656 
shrb 
BL38305 
HMS0
1767  NE      
CG5370 FBgn00
10501 
Dcp-1 
BL38315 
HMS0
1779  NE      
CG1050
5 
FBgn00
34612 
CG10505 
BL38317 
HMS0
1781  NE      
CG3346
5 
FBgn00
53465 
CG33465 
BL38323 
HMS0
1787  NE      
CG3530 FBgn00
28497 
CG3530 
BL38340 
HMS0
1807  NE      
CG1131
2 
FBgn00
11674 
insc 
BL38351 
HMS0
1819  NE      
CG8722 FBgn00
33247 
Nup44A 
BL38357 
HMS0
1825  NE      
CG3419 FBgn00
35002 
CG3419 
BL38360 
HMS0
1828  NE      
CG1357
0 
FBgn00
15544 
spag 
BL38371 
HMS0
1840  NE      
CG9696 FBgn00
20306 
dom 
BL38385 
HMS0
1854 E E NE E ME  NE 
CG3121 FBgn00
34957 
CG3121 
BL38524 
HMS0
1721  NE      
CG9236 FBgn00
34558 
CG9236 
BL38532 
HMS0
1745  NE      
331 
 
CG1236
9 
FBgn00
10238 
Lac 
BL38536 
HMS0
1756 ME ME NE NE E  NE 
CG1509
7 
FBgn00
34396 
CG15097 
BL38538 
HMS0
1790  NE      
CG5576 FBgn00
13983 
imd 
BL38933 
HMS0
0253  NE      
CG5625 FBgn00
34708 
Vps35 
BL38944 
HMS0
1858  NE      
CG1780
0 
FBgn00
33159 
Dscam 
BL38945 
HMS0
1859  NE      
CG1227
3 
FBgn00
16762 
angel 
BL38947 
HMS0
1861  NE      
CG8024 FBgn00
02567 
ltd 
BL38956 
HMS0
1870  NE      
CG8095 FBgn00
03328 
scb 
BL38959 
HMS0
1873  NE      
CG1121
7 
FBgn00
15614 
CanB2 
BL38971 
HMS0
1886  NE      
CG8964 FBgn00
33674 
CG8964 
BL38973 
HMS0
1889  NE      
CG6410 FBgn00
34265 
Snx16 
BL38992 
HMS0
1908  NE      
CG3039
0 
FBgn00
50390 
Sgf29 
BL39000 
HMS0
1916  NE      
CG5581 FBgn00
03022 
Ote 
BL39009 
HMS0
1926  NE      
CG1032
7 
FBgn00
25790 
TBPH 
BL39014 
HMS0
1932  NE   E   
CG8604 FBgn00
27356 
Amph 
BL39015 
HMS0
1933  NE      
CG1352
1 
FBgn00
05631 
robo 
BL39027 
HMS0
1946  NE      
CG1680
1 
FBgn00
34012 
Hr51 
BL39032 
HMS0
1951  NE      
CG1511
2 
FBgn00
00578 
ena 
BL39034 
HMS0
1953  NE      
CG1881
7 
FBgn00
29508 
Tsp42Ea 
BL39044 
HMS0
1964  NE      
CG1130
3 
FBgn00
20372 
TM4SF 
BL39048 
HMS0
1968  NE      
CG1041
7 
FBgn00
33021 
CG10417 
BL39051 
HMS0
1971  NE      
CG1319
7 
FBgn00
62449 
CG13197 
BL39052 
HMS0
1972  NE      
CG3419
1 
FBgn00
85220 
CG34191 
BL39054 
HMS0
1974  NE      
CG1221
0 
FBgn00
03660 
Syb 
BL39067 
HMS0
1987 
(ME 
POSSIBL
E) NE NE MS E  NE 
CG3009
2 
FBgn00
28371 
jbug 
BL39070 
HMS0
1990  NE      
CG8581 FBgn00
11592 
fra 
BL40826 
HMS0
1147  NE      
CG1508
1 
FBgn00
10551 
l(2)03709 
BL40835 
HMS0
2001  NE      
CG9446 FBgn00
33109 
coro 
BL40841 
HMS0
2007 MS MS  S E  NE 
CG1239
1 
FBgn00
33581 
CG12391 
BL40847 
HMS0
2014  NE      
CG9954 FBgn00
34534 
maf-S 
BL40853 
HMS0
2020  NE      
CG3060 FBgn00
02791 
mr 
BL40856 
HMS0
2023  NE      
CG1282
1 
FBgn00
40780 
CG12821 
BL40859 
HMS0
2026  NE      
CG3313
8 
FBgn00
53138 
CG33138 
BL40860 
HMS0
2027  NE      
CG8224 FBgn00
11300 
babo 
BL40866 
HMS0
2033  NE      
332 
 
CG1359
4 
FBgn00
35041 
CG13594 
BL40891 
HMS0
2139  NE      
CG4071 FBgn00
34744 
Vps20 
BL40894 
HMS0
2142 A ME ME   ME  
CG1446
8 
FBgn00
33042 
Tsp42A 
BL40900 
HMS0
2148  NE NE MS E   
CG4943 FBgn00
29006 
lack 
BL40905 
HMS0
2153 
(MS 
POSSIBL
E) NE  NE E   
CG3048
3 
FBgn00
40752 
Prosap 
BL40909 
HMS0
2157  NE      
CG1332
9 
FBgn00
40477 
cid 
BL40912 
HMS0
2160  NE      
CG3510 FBgn00
00405 
CycB 
BL40915 
HMS0
2163  NE      
CG3001
1 
FBgn00
50011 
gem 
BL40934 
HMS0
2182  NE      
CG1177
0 
FBgn00
02552 
lin 
BL40939 
HMS0
2187  NE      
CG3437
9 
FBgn00
85408 
Shroom 
BL40942 
HMS0
2190  NE      
CG2727 FBgn00
10435 
emp 
BL40947 
HMS0
2195  NE      
CG8376 FBgn00
00099 
ap 
BL41673 
HMS0
2207  NE      
CG1783
5 
FBgn00
01269 
inv 
BL41675 
HMS0
2209  NE      
CG9422 FBgn00
33092 
CG9422 
BL41679 
HMS0
2243 MS MS  NE NE  NE 
CG1054
0 
FBgn00
34577 
cpa 
BL41685 
HMS0
2249  NE      
CG1399 FBgn00
33212 
CG1399 
BL41686 
HMS0
2250  NE      
CG2105 FBgn00
33192 
Corin 
BL41721 
HMS0
2287  NE      
CG9453 FBgn00
28985 
Spn4 
BL41722 
HMS0
2288  NE      
CG6530 FBgn00
28956 
mthl3 
BL41887 
HMS0
2309  NE      
CG4812 FBgn00
19928 
Ser8 
BL41920 
HMS0
2317  NE      
CG7229 FBgn00
34423 
CG7229 
BL41922 
HMS0
2319  NE      
CG8589 FBgn00
33921 
tej 
BL41929 
HMS0
2326  NE      
CG5179 FBgn00
19949 
Cdk9/p-TEFb 
BL41932 
HMS0
2329  NE      
CG6692 FBgn00
13770 
Cp1 
BL41939 
HMS0
2336  NE      
CG3313
3 
FBgn00
01133 
grau 
BL41940 
HMS0
2337  NE      
CG3436
1 
FBgn00
85390 
Dgk 
BL41944 
HMS0
2341  NE      
CG8190 FBgn00
34029 
eIF2B-gamma 
BL41948 
HMS0
2345  NE      
CG8856 FBgn00
20377 
Sr-CII 
BL41949 
HMS0
2346  NE      
CG3405
4 
FBgn00
54054 
CG34054 
BL41951 
HMS0
2348  NE      
CG4302 FBgn00
27073 
CG4302 
BL41967 
HMS0
2364  NE      
CG1217
2 
FBgn00
24294 
Spn43Aa 
BL41972 
HMS0
2370  NE      
CG3016
1 
FBgn00
50161 
CG30161 
BL41977 
HMS0
2375  NE      
CG1110
7 
FBgn00
33160 
CG11107 
BL41992 
HMS0
2393  NE      
CG3572 FBgn00
22960 
vimar 
BL41996 
HMS0
2397  NE      
333 
 
CG9441 FBgn00
03162 
Pu 
BL41998 
HMS0
2399  NE      
CG2040 FBgn00
10114 
hig 
BL42000 
HMS0
2401  NE      
CG8453 FBgn00
25454 
Cyp6g1 
BL42006 
HMS0
2407  NE      
CG8834 FBgn00
33733 
CG8834 
BL42010 
HMS0
2411  NE      
CG1845 FBgn00
33155 
Br140 
BL42502 
HMJ0
2067  NE      
CG1034
4 
FBgn00
34729 
CG10344 
BL42505 
HMJ0
2070  NE      
CG8090 FBgn00
33995 
CG8090 
BL42507 
HMJ0
2072  NE      
CG1349
3 
FBgn00
34667 
comr 
BL42522 
HMJ0
2088  NE      
CG3260 FBgn00
21875 
Zfrp8 
BL42528 
HMJ0
2095  NE      
CG9418 FBgn00
26582 
CG9418 
BL42542 
HMJ0
2112  NE      
CG9304 FBgn00
34674 
CG9304 
BL42544 
HMJ0
2115  NE      
CG1891 FBgn00
03317 
sax 
BL42546 
HMJ0
2118  NE      
CG9888 FBgn00
03062 
Fib 
BL42553 
HMJ0
2126 E-L E-L NE NE E  NE 
CG1824
7 
FBgn00
15295 
shark 
BL42555 
HMJ0
2128  NE      
CG9480 FBgn00
34603 
Glycogenin 
BL42565 
HMJ0
2222  NE      
CG2049 FBgn00
20621 
Pkn 
BL42567 
HMJ0
2226  NE      
CG1560
5 
FBgn00
34196 
CG15605 
BL42586 
HMS0
2418  NE      
CG9896 FBgn00
34808 
CG9896 
BL42587 
HMS0
2419  NE      
CG1142
3 
FBgn00
34251 
CG11423 
BL42591 
HMS0
2423  NE      
CG7865 FBgn00
33050 
Pngl 
BL42592 
HMS0
2424  NE      
CG1810
8 
FBgn00
34329 
IM1 
BL42599 
HMS0
2431  NE      
CG4905 FBgn00
34135 
Syn2 
BL42601 
HMS0
2433  NE      
CG3821 FBgn00
02069 
Aats-asp 
BL42606 
HMS0
2439  NE      
CG3894 FBgn00
35059 
CG3894 
BL42618 
HMS0
2453  NE      
CG5825 FBgn00
14857 
His3.3A 
BL42620 
HMS0
2455  NE      
CG4294 FBgn00
34742 
CG4294 
BL42624 
HMS0
2459  NE      
CG1847
1 
FBgn00
24232 
gprs 
BL42630 
HMS0
2465  NE      
CG8427 FBgn00
23167 
SmD3 
BL42633 
HMS0
2469  NE      
CG4847 FBgn00
34229 
CG4847 
BL42655 
HMS0
2491  NE      
CG1362 FBgn00
13435 
cdc2rk 
BL42661 
HMS0
2497  NE      
CG1510
5 
FBgn00
34412 
abba 
BL42826 
HMS0
2508  NE      
CG2160 FBgn00
33266 
Socs44A 
BL42830 
HMS0
2515  NE      
CG3502 FBgn00
46253 
CG3502 
BL42839 
HMS0
2531  NE      
CG3608 FBgn00
35039 
CG3608 
BL42841 
HMS0
2533  NE      
CG3814 FBgn00
25692 
CG3814 
BL42852 
HMS0
2544  NE      
334 
 
CG6033 FBgn00
04638 
drk 
BL42855 
HMS0
2547  NE      
CG3025
9 
FBgn00
50259 
CG30259 
BL42856 
HMS0
2548  NE      
CG3209 FBgn00
34971 
CG3209 
BL42863 
HMS0
2556  NE      
CG3003
5 
FBgn00
50035 
Tret1-1 
BL42880 
HMS0
2573  NE      
CG8315 FBgn00
34058 
Pex11 
BL42883 
HMS0
2576  NE      
CG3495 FBgn00
34794 
Gmer 
BL42884 
HMS0
2577  NE      
CG1318
9 
FBgn00
33665 
CG13189 
BL42894 
HMS0
2587  NE      
CG8399 FBgn00
34067 
CG8399 
BL42910 
HMS0
2603  NE      
CG5033 FBgn00
28744 
CG5033 
BL42930 
HMS0
2623  NE      
CG8929 FBgn00
34504 
CG8929 
BL42936 
HMS0
2629  NE      
CG3633 FBgn00
34727 
mRpS29 
BL42938 
HMS0
2631  NE      
CG1560
9 
FBgn00
34180 
Ehbp1 
BL42939 
HMS0
2632  NE      
CG1138
8 
FBgn00
34959 
CG11388 
BL42940 
HMS0
2633  NE      
CG1129
0 
FBgn00
34975 
enok 
BL42941 
HMS0
2634  NE      
CG3803 FBgn00
34938 
CG3803 
BL42948 
HMS0
2641  NE      
CG1882 FBgn00
33226 
CG1882 
BL42957 
HMS0
2650  NE      
CG1508
4 
FBgn00
34402 
CG15084 
BL42958 
HMS0
2651  NE      
CG1285
8 
FBgn00
33958 
CG12858 
BL43284 
HMS0
2655 A E ME   E  
CG1825
5 
FBgn00
13988 
Strn-Mlck 
BL43291 
HMS0
2663  NE      
CG3001
0 
FBgn00
50010 
CG30010 
BL43293 
HMS0
2665  NE      
CG1026
5 
FBgn00
33990 
CG10265 
BL43294 
HMS0
2667  NE      
CG8946 FBgn00
10591 
Sply 
BL43304 
HMS0
2684  NE      
CG3037
1 
FBgn00
50371 
CG30371 
BL43307 
HMS0
2691  NE      
CG1091
3 
FBgn00
28983 
Spn6 
BL43309 
HMS0
2693  NE      
CG1213
3 
FBgn00
33469 
CG12133 
BL43312 
HMS0
2696  NE      
CG9456 FBgn00
28988 
Spn1 
BL43991 
HMS0
2704  NE      
CG1342
4 
FBgn00
34520 
lms 
BL43995 
HMS0
2709  NE      
CG1809 FBgn00
33423 
CG1809 
BL44016 
HMS0
2731  NE  NE E   
CG8400 FBgn00
34068 
casp 
BL44027 
HMS0
2742  NE      
CG1373
9 
FBgn00
33403 
CG13739 
BL44030 
HMS0
2746  NE      
CG1865 FBgn00
24293 
Spn43Ab 
BL44043 
HMS0
2759  NE      
CG6155 FBgn00
14877 
Roe1 
BL44060 
HMS0
2777  NE      
CG1002
3 
FBgn00
20440 
Fak56D 
BL44075 
HMS0
2792  NE      
CG3036
1 
FBgn00
50361 
mtt 
BL44076 
HMS0
2793 A ME ME   E  
CG3049
6 
FBgn00
50496 
CG30496 
BL44078 
HMS0
2795  NE      
335 
 
CG1269
9 
FBgn00
46294 
CG12699 
BL44111 
HMS0
2833  NE      
CG9428 FBgn00
33096 
ZIP1 
BL44120 
HMS0
2842  NE      
CG3027
7 
FBgn00
50277 
Oatp58Da 
BL44122 
HMS0
2844  NE      
CG1916 FBgn00
04360 
Wnt2 
BL44271 
HMS0
2826  NE      
CG4356 FBgn00
00037 
mAcR-60C 
BL44469 
HMC0
2343  NE      
CG1708 FBgn00
00352 
cos 
BL44472 
HMC0
2347  NE      
CG8325 FBgn00
21847 
l(2)k14710 
BL44482 
HMC0
2372  NE      
CG8579 FBgn00
01285 
Jon44E 
BL44486 
HMC0
2391  NE      
CG1030
6 
FBgn00
34654 
CG10306 
BL44493 
HMC0
2415 MS MS  NE NE  NE 
CG5190 FBgn00
34351 
CG5190 
BL44494 
HMC0
2423  NE      
CG9090 FBgn00
34497 
CG9090 
BL44495 
HMC0
2425  NE      
CG3412
3 
FBgn00
83959 
trpm 
BL44503 
HMC0
2889  NE      
CG7881 FBgn00
33048 
CG7881 
BL44505 
HMC0
2891  NE      
CG1860
9 
FBgn00
34382 
CG18609 
BL44510 
HMC0
2900  NE      
CG1249
0 
FBgn00
34782 
CG12490 
BL44511 
HMC0
2901  NE      
CG1781
8 
FBgn00
27872 
rdgBbeta 
BL44523 
HMC0
2916  NE      
CG4871 FBgn00
35050 
ST6Gal 
BL44528 
HMC0
2922  NE      
CG3049
5 
FBgn00
50495 
CG30495 
BL44531 
HMC0
2925  NE      
CG2070 FBgn00
33203 
CG2070 
BL44532 
HMC0
2926  NE      
CG8520 FBgn00
33734 
CG8520 
BL44533 
HMC0
2927  NE      
CG1682
7 
FBgn00
34005 
alphaPS4 
BL44534 
HMC0
2928  NE      
CG3388 FBgn00
01148 
gsb 
BL44548 
HMC0
2944  NE      
CG3649 FBgn00
34785 
CG3649 
BL44549 
HMC0
2946  NE      
CG1810
7 
FBgn00
34330 
CG18107 
BL44562 
HMS0
2858  NE      
CG1118
4 
FBgn00
34923 
Upf3 
BL44565 
HMS0
2861  NE  NE E   
CG8746 FBgn00
33330 
CG8746 
BL44567 
HMS0
2863  NE      
CG7861 FBgn00
33055 
tbce 
BL44569 
HMS0
2865  NE      
CG3308
7 
FBgn00
53087 
LRP1 
BL44579 
HMS0
2875  NE      
CG5409 FBgn00
11743 
Arp53D 
BL44580 
HMS0
2876  NE      
CG3380 FBgn00
34716 
Oatp58Dc 
BL44583 
HMS0
2880  NE      
CG5036 FBgn00
28743 
CG5036 
BL44632 
HMC0
2405  NE      
CG5709 FBgn00
25186 
ari-2 
BL44646 
HMC0
2353  NE      
CG1821 FBgn00
25286 
RpL31 
BL44647 
HMC0
2354  NE      
CG1290
9 
FBgn00
33507 
CG12909 
BL44654 
HMC0
2419  NE      
CG2736 FBgn00
35090 
CG2736 
BL44655 
HMC0
2427 S S  MS NE  NE 
336 
 
CG3019
4 
FBgn00
50194 
CG44252 
BL44658 
HMC0
2440 A ME ME MS NE ME  
CG9023 FBgn00
15872 
Drip 
BL44661 
HMC0
2945  NE      
CG8711 FBgn00
33260 
Cul-4 
BL50614 
HMC0
2981  NE      
CG3046
3 
FBgn00
50463 
CG30463 
BL50617 
HMC0
2984  NE      
CG8380 FBgn00
34136 
DAT 
BL50619 
HMC0
2986  NE      
CG1205
1 
FBgn00
00043 
Act42A 
BL50625 
HMC0
2992  NE      
CG1013
0 
FBgn00
10638 
Sec61beta 
BL50626 
HMC0
2993 A E-L E   E  
CG6953 FBgn00
26721 
fat-spondin 
BL50629 
HMC0
2996  NE      
CG3049
1 
FBgn00
50491 
CG30491 
BL50630 
HMC0
2997  NE      
CG5436 FBgn00
01230 
Hsp68 
BL50637 
HMC0
3036  NE      
CG9825 FBgn00
34783 
CG9825 
BL50639 
HMC0
3039  NE      
CG9876 FBgn00
34821 
CG9876 
BL50655 
HMC0
3056  NE      
CG1510
1 
FBgn00
10053 
Jheh1 
BL50676 
HMC0
3077  NE      
CG7230 FBgn00
03254 
rib 
BL50682 
HMC0
3083  NE      
CG9858 FBgn00
00326 
clt 
BL50683 
HMC0
3084  NE      
CG7777 FBgn00
33635 
CG7777 
BL50695 
HMC0
3097  NE      
CG4663 FBgn00
33812 
Pex13 
BL50697 
HMC0
3099  NE      
CG1014
2 
FBgn00
35076 
Ance-5 
BL50703 
HMC0
3105  NE      
CG2835 FBgn00
01123 
G-salpha60A 
BL50704 
HMC0
3106  NE      
CG1765 FBgn00
00546 
EcR 
BL50712 
HMC0
3114 A E-L E   E  
CG5770 FBgn00
34291 
CG5770 
BL50719 
HMS0
2953  NE      
CG3183 FBgn00
33081 
geminin 
BL50720 
HMS0
2954  NE      
CG1322
1 
FBgn00
41174 
Vhl 
BL50727 
HMS0
2963  NE      
CG3026
5 
FBgn00
50265 
CG30265 
BL50731 
HMS0
2967  NE      
CG8950 FBgn00
34186 
CG8950 
BL50897 
HMC0
2421  NE      
CG1782
1 
FBgn00
34383 
CG17821 
BL50898 
HMC0
2424  NE      
CG1801
1 
FBgn00
33491 
CG18011 
BL50900 
HMJ0
3118  NE      
CG9001 FBgn00
34175 
ste24b 
BL50913 
HMJ2
1002  NE      
CG1006
2 
FBgn00
34439 
CG10062 
BL50970 
HMJ2
1076  NE      
CG1256
7 
FBgn00
39958 
CG12567 
BL50973 
HMJ2
1079  NE      
CG1663 FBgn00
33449 
CG1663 
BL50974 
HMJ2
1080  NE      
CG8457 FBgn00
33697 
Cyp6t3 
BL50976 
HMJ2
1082  NE      
CG1356
1 
FBgn00
34906 
CG13561 
BL50995 
HMJ2
1108  NE      
CG8735 FBgn00
33309 
CG8735 
BL50998 
HMJ2
1111  NE      
CG2121 FBgn00
33289 
CG2121 
BL51014 
HMJ2
1133  NE      
337 
 
CG1850 FBgn00
33154 
CG1850 
BL51046 
HMJ2
1179  NE      
CG3008
5 
FBgn00
50085 
Rif1 
BL51051 
HMJ2
1185  NE      
CG1357
9 
FBgn00
35010 
CG13579 
BL51053 
HMJ2
1188  NE      
CG2956 FBgn00
03900 
twi 
BL51164 
HMJ0
3122  NE      
CG3010
6 
FBgn00
50106 
CCHa1r 
BL51168 
HMJ2
1029  NE      
CR4245
2 
FBgn00
83123 
Uhg5 
BL51176 
HMJ2
1153  NE      
CG6646 FBgn00
33885 
DJ-1alpha 
BL51177 
HMJ2
1180  NE      
CG8704 FBgn00
10109 
dpn 
BL51440 
HMC0
3154  NE      
CG3668 FBgn00
04896 
fd59A 
BL51441 
HMC0
3155  NE      
CG3318
3 
FBgn00
00448 
Hr46 
BL51442 
HMC0
3156  NE      
CG1047
4 
FBgn00
34427 
CG10474 
BL51444 
HMC0
3158  NE      
CG9033 FBgn00
33629 
Tsp47F 
BL51458 
HMC0
3194  NE      
CG1011
7 
FBgn00
20245 
ttv 
BL51480 
HMC0
3225  NE      
CG8766 FBgn00
26619 
Taz 
BL51484 
HMC0
3231  NE      
CG3027
2 
FBgn00
50272 
CG30272 
BL51493 
HMC0
3245  NE      
CG1225
1 
FBgn00
33807 
AQP 
BL51504 
HMC0
3266  NE      
CG1129
5 
FBgn00
13548 
l(2)dtl 
BL51510 
HMC0
3280  NE      
CG4817 FBgn00
10278 
Ssrp 
BL51519 
HMS0
3169  NE      
CG2064 FBgn00
33205 
CG2064 
BL51693 
HMC0
3137  NE      
CG2827 FBgn00
23477 
Tal 
BL51709 
HMC0
3227  NE      
CG3006
0 
FBgn00
50060 
CG30060 
BL51712 
HMC0
3235  NE      
CG1049
7 
FBgn00
10415 
Sdc 
BL51723 
HMC0
3265  NE NE NE E   
CG9826 FBgn00
34784 
CG9826 
BL51728 
HMC0
3274  NE      
CG8403 FBgn00
34070 
SP2353 
BL51732 
HMC0
3287  NE      
CG3499 FBgn00
34792 
CG3499 
BL51752 
HMC0
3303 MS MS  NE NE  NE 
CG1109
9 
FBgn00
34485 
CG11099 
BL51766 
HMC0
3321  NE      
CG9450 FBgn00
03891 
tud 
BL51771 
HMC0
3326  NE      
CG3298 FBgn00
28426 
JhI-1 
BL51781 
HMC0
3336  NE      
CG3043
8 
FBgn00
50438 
CG30438 
BL51790 
HMC0
3346  NE      
CG8251 FBgn00
03074 
Pgi/gpi 
BL51804 
HMC0
3362  NE      
CG9364 FBgn00
03748 
Treh 
BL51810 
HMC0
3381  NE      
CG4533 FBgn00
11296 
l(2)efl 
BL51816 
HMC0
3387  NE      
CG1114
0 
FBgn00
10548 
Aldh-III 
BL51820 
HMC0
3391  NE      
CG3005
4 
FBgn00
50054 
CG30054 
BL51823 
HMC0
3395  NE      
CG1844
4 
FBgn00
03863 
alphaTry 
BL51824 
HMC0
3396  NE      
338 
 
CG1118
2 
FBgn00
25334 
PHDP 
BL51832 
HMC0
3404  NE      
CG1586
0 
FBgn00
60296 
pain 
BL51835 
HMC0
3407  NE      
CG3204 FBgn00
25806 
Rap2l 
BL51840 
HMC0
3412  NE      
CG9183 FBgn00
03114 
plu 
BL51844 
HMC0
3417  NE      
CG1194
9 
FBgn00
10434 
cora 
BL51845 
HMC0
3418  NE      
CG8432 FBgn00
26378 
Rep 
BL51851 
HMC0
3425  NE      
CG8235 FBgn00
33351 
CG8235 
BL51874 
HMC0
3448  NE      
CG2292 FBgn00
33479 
CG2292 
BL51875 
HMC0
3449  NE      
CG1289
5 
FBgn00
33523 
CG12895 
BL51876 
HMC0
3450  NE      
CG8594 FBgn00
33755 
ClC-b 
BL51877 
HMC0
3451  NE      
CG1827
8 
FBgn00
33836 
CG18278 
BL51878 
HMC0
3452  NE      
CG8067 FBgn00
33891 
CG8067 
BL51879 
HMC0
3453  NE      
CG9000 FBgn00
34176 
ste24a 
BL51880 
HMC0
3454  NE      
CG6550 FBgn00
34214 
CG6550 
BL51881 
HMC0
3455  NE      
CG6401 FBgn00
34270 
CG6401 
BL51882 
HMC0
3456  NE      
CG6385 FBgn00
34276 
CG6385 
BL51883 
HMC0
3457  NE      
CG1511
1 
FBgn00
34419 
CG15111 
BL51885 
HMC0
3459  NE      
CG7735 FBgn00
34446 
CG7735 
BL51886 
HMC0
3460  NE      
CG1123
7 
FBgn00
34452 
Oseg6 
BL51887 
HMC0
3461  NE      
CG9313 FBgn00
34566 
CG9313 
BL51888 
HMC0
3462  NE      
CG1565
1 
FBgn00
34567 
CG15651 
BL51889 
HMC0
3463  NE      
CG1031
5 
FBgn00
34858 
eIF2B-delta 
BL51891 
HMC0
3465 A E ME ME E-L E  
CG5411 FBgn00
34886 
Pde8 
BL51892 
HMC0
3466  NE      
CG1117
3 
FBgn00
34913 
usnp 
BL51893 
HMC0
3467  NE      
CG5569 FBgn00
34919 
CG5569 
BL51894 
HMC0
3468  NE      
CG1691
2 
FBgn00
35064 
CG16912 
BL51895 
HMC0
3469  NE      
CG3290
4 
FBgn00
28991 
seq 
BL51923 
HMC0
3316 A ME ME   ME  
CG3613 FBgn00
22986 
qkr58E-1 
BL51934 
HMC0
3215  NE      
CG3504 FBgn00
01263 
inaD 
BL52313 
HMC0
3170 A E E   E  
CG3009
0 
FBgn00
50090 
CG30090 
BL52878 
HMC0
3616  NE      
CG5009 FBgn00
27572 
CG5009 
BL52882 
HMC0
3620  NE      
CG3270 FBgn00
33093 
CG3270 
BL52887 
HMC0
3625  NE      
CG1474
9 
FBgn00
33316 
CG14749 
BL52888 
HMC0
3626  NE      
CG1212
9 
FBgn00
33475 
CG12129 
BL52889 
HMC0
3627  NE      
CG1332
0 
FBgn00
33785 
Sans 
BL52890 
HMC0
3628  NE      
339 
 
CG1119
2 
FBgn00
34507 
CG11192 
BL52893 
HMC0
3631  NE      
CG4386 FBgn00
34661 
CG4386 
BL52898 
HMC0
3637  NE      
CG3346
0 
FBgn00
53460 
CG33460 
BL52900 
HMC0
3639  NE      
CG1166
5 
FBgn00
33028 
CG11665 
BL52902 
HMC0
3642  NE      
CG3319
8 
FBgn00
53198 
pen-2 
BL52908 
HMC0
3648  NE      
CG3035
9 
FBgn00
50359 
Mal-A5 
BL52910 
HMC0
3650  NE      
CG3267 FBgn00
42083 
CG3267 
BL52912 
HMC0
3652  NE      
CG8311 FBgn00
34141 
CG8311 
BL52926 
HMC0
3667  NE      
CG6251 FBgn00
34118 
Nup62 
BL52927 
HMC0
3668  NE      
CG1021
5 
FBgn00
28434 
Ercc1 
BL52929 
HMC0
3670  NE      
CG2072 FBgn00
26326 
Mad1 
BL52930 
HMC0
3671  NE      
CG3045
7 
FBgn00
50457 
CG30457 
BL52964 
HMJ2
1647  NE      
CG2921 FBgn00
34689 
CG2921 
BL52965 
HMJ2
1649  NE      
CG1342
7 
FBgn00
34514 
CG13427 
BL52967 
HMJ2
1652  NE      
CG9235 FBgn00
34560 
CG9235 
BL52971 
HMJ2
1656  NE      
CG1342
3 
FBgn00
34513 
CG13423 
BL52972 
HMJ2
1657  NE      
CG1343
4 
FBgn00
34523 
Nnf1a 
BL52973 
HMJ2
1658  NE      
CG1322
0 
FBgn00
33608 
CG13220 
BL52984 
HMJ2
1671  NE      
CG9993 FBgn00
34553 
CG9993 
BL52985 
HMJ2
1675  NE      
CG8824 FBgn00
45063 
fdl 
BL52987 
HMJ2
1679  NE      
CG3012
8 
FBgn00
46879 
Obp56c 
BL53001 
HMJ2
1717  NE      
CG1120
9 
FBgn00
34489 
ppk6 
BL53010 
HMJ2
1728  NE      
CR3288
6 
FBgn00
45800 
Uhg1 
BL53014 
HMJ2
1736  NE      
CG8694 FBgn00
02569 
Mal-A2 
BL53017 
HMJ2
1740  NE      
CG6967 FBgn00
34187 
CG6967 
BL53030 
HMJ2
1756  NE      
CG1795
2 
FBgn00
34657 
LBR 
BL53269 
HMC0
2426  NE      
CG4554 FBgn00
34734 
CG4554 
BL53270 
HMC0
3176  NE      
CG8800 FBgn00
33408 
CG8800 
BL53295 
HMC0
3511  NE      
CG8566 FBgn00
34155 
unc-104 
BL53296 
HMC0
3512  NE      
CG3661 FBgn00
10078 
RpL23 
BL53300 
HMC0
3527 A E-L E   E  
CG1323
2 
FBgn00
33578 
BBS4 
BL53305 
HMC0
3532  NE      
CG4354 FBgn00
05638 
slbo 
BL53309 
HMC0
3538  NE      
CG9856 FBgn00
16641 
PTP-ER 
BL53311 
HMC0
3540  NE      
CG1143
0 
FBgn00
41585 
olf186-F 
BL53333 
HMC0
3562  NE      
CG3002
2 
FBgn00
50022 
CG30022 
BL53334 
HMC0
3563  NE      
340 
 
CG3049
3 
FBgn00
50493 
CG30493 
BL53336 
HMC0
3565  NE      
CG5912 FBgn00
00119 
arr 
BL53342 
HMC0
3571  NE      
CG1154
6 
FBgn00
10504 
kermit 
BL53349 
HMC0
3578  NE      
CG4084 FBgn00
11297 
l(2)not 
BL53350 
HMC0
3579  NE      
CG1238
5 
FBgn00
11555 
thetaTry 
BL53362 
HMC0
3591  NE      
CG1352
7 
FBgn00
34776 
CG13527 
BL53364 
HMC0
3593  NE      
CG1476
0 
FBgn00
33277 
CG14760 
BL53366 
HMC0
3595  NE      
CG1773 FBgn00
33439 
CG1773 
BL53371 
HMC0
3600  NE      
CG1868
1 
FBgn00
10425 
epsilonTry 
BL53374 
HMC0
3603  NE      
CG1873
5 
FBgn00
42098 
CG18735 
BL53375 
HMC0
3604  NE      
CG9640 FBgn00
34182 
CG9640 
BL53681 
HMJ2
1594  NE      
CG3028
0 
FBgn00
50280 
CG30280 
BL53693 
HMJ2
1678  NE      
CG1592
0 
FBgn00
34157 
resilin 
BL53702 
HMJ2
1733  NE      
CG1548 FBgn00
29093 
cathD 
BL53882 
HMJ2
1197  NE      
CG1276
3 
FBgn00
04240 
Dpt 
BL53923 
HMJ2
1267  NE      
CG7137 FBgn00
34422 
CG7137 
BL53924 
HMJ2
1269  NE      
CG1586
2 
FBgn00
22382 
Pka 
BL53930 
HMJ2
1276 A ME E   E  
CG1358
5 
FBgn00
35020 
CG13585 
BL53933 
HMJ2
1281  NE      
CG5721 FBgn00
34315 
CG5721 
BL53949 
HMJ2
1313  NE      
CG1853
7 
FBgn00
34323 
CG18537 
BL53960 
HMJ2
1342  NE      
CG1024
0 
FBgn00
13773 
Cyp6a22 
BL53963 
HMJ2
1345  NE      
CG1106
1 
FBgn00
34697 
GM130 
BL53966 
HMJ2
1349  NE      
CG1358
9 
FBgn00
35011 
CG13589 
BL53978 
HMJ2
1367  NE      
CG6262 FBgn00
34121 
CG6262 
BL53987 
HMJ2
1391  NE      
CG1246
4 
FBgn00
33861 
CG12464 
BL53988 
HMJ2
1392  NE      
CG3570 FBgn00
35035 
CG3570 
BL54010 
HMJ2
1433  NE      
CG3074 FBgn00
34709 
Swim 
BL54015 
HMJ2
1440  NE      
CG4329 FBgn00
34745 
CG4329 
BL54035 
HMJ2
1478  NE      
CG1447
8 
FBgn00
28953 
CG14478 
BL54040 
HMJ2
1483  NE      
CG1178
8 
FBgn00
34495 
CG11788 
BL54043 
HMJ2
1486  NE      
CG1092
7 
FBgn00
34360 
CG10927 
BL54050 
HMS0
3521  NE      
CG6477 FBgn00
34249 
RhoGAP54D 
BL54051 
HMS0
3522  NE      
CG3403
3 
FBgn00
54033 
CG34033 
BL54055 
HMS0
3716  NE      
CG7863 FBgn00
33051 
dream 
BL54059 
HMJ2
1268  NE      
CG1475
7 
FBgn00
33274 
CG14757 
BL54465 
HMC0
3733  NE      
341 
 
CG1836
9 
FBgn00
33860 
S-Lap5 
BL54796 
HMJ2
1193  NE      
CG9344 FBgn00
34564 
CG9344 
BL54798 
HMJ2
1492  NE      
CG3033
8 
FBgn00
50338 
CG30338 
BL54809 
HMJ2
1503  NE      
CG7759 FBgn00
33633 
CG7759 
BL54811 
HMJ2
1530  NE      
CG3017 FBgn00
20764 
Alas 
BL54815 
HMJ2
1534  NE      
CG1054
3 
FBgn00
34570 
CG10543 
BL54816 
HMJ2
1535  NE      
CG3004
2 
FBgn00
50042 
Cpr49Ab 
BL54825 
HMJ2
1544  NE      
CG1475
0 
FBgn00
22027 
Vps25 
BL54831 
HMJ2
1550  NE      
CG3162 FBgn00
34834 
LS2 
BL54832 
HMJ2
1551  NE      
CG4688 FBgn00
33817 
GstE14 
BL54836 
HMJ2
1555  NE      
CG9460 FBgn00
33115 
Spn42De 
BL54840 
HMJ2
1559  NE      
CG3018
7 
FBgn00
50187 
CG30187 
BL54841 
HMJ2
1560  NE      
CG3313
9 
FBgn00
53139 
Ranbp11 
BL55142 
HMC0
3738  NE      
CG1238
8 
FBgn00
43471 
kappaTry 
BL55148 
HMC0
3772  NE      
CG2063 FBgn00
33400 
CG2063/SAP30B
P BL55173 
HMC0
3853 E E NE E E  NE 
CG3041
4 
FBgn00
50414 
CG30414 
BL55176 
HMC0
3857  NE      
CG3850 FBgn00
33782 
sug 
BL55182 
HMC0
3866  NE      
CG4007 FBgn00
20391 
Nrk 
BL55184 
HMC0
3875  NE      
CG8690 FBgn00
33297 
Mal-A8 
BL55193 
HMC0
3889  NE      
CG7637 FBgn00
33548 
CG7637 
BL55194 
HMC0
3890  NE      
CG4827 FBgn00
34225 
veil 
BL55195 
HMC0
3891  NE      
CG2852 FBgn00
34753 
CG2852 
BL55196 
HMC0
3892  NE      
CG6209 FBgn00
33862 
CG6209 
BL55203 
HMC0
3916  NE      
CG2980 FBgn00
34939 
thoc5 
BL55206 
HMC0
3921  NE      
CG3012
2 
FBgn00
50122 
CG30122 
BL55209 
HMC0
3927 
E E NE NE E  
(ME 
POSSIBL
E) 
CG6536 FBgn00
34219 
mthl4 
BL55244 
HMC0
2422  NE      
CG3829 FBgn00
35091 
CG3829 
BL55245 
HMC0
2428  NE      
CG1275
9 
FBgn00
10220 
Dbp45A 
BL55253 
HMC0
3940  NE      
CG9401 FBgn00
02736 
mago 
BL55260 
HMC0
3947  NE      
CG1291
9 
FBgn00
33483 
egr 
BL55276 
HMC0
3963  NE      
CG5821 FBgn00
22985 
qkr58E-2 
BL55279 
HMC0
3966  NE      
CG1316
8 
FBgn00
33705 
CG13168 
BL55288 
HMC0
3975  NE      
CG1845
5 
FBgn00
25360 
Optix 
BL55306 
HMC0
3993 S S  MS NE  NE 
CG8643 FBgn00
33310 
rgr 
BL55307 
HMC0
3994  NE      
342 
 
CG1005
2 
FBgn00
20617 
Rx 
BL55308 
HMC0
3995  NE      
CG8256 FBgn00
22160 
Gpo-1 
BL55319 
HMC0
4006  NE      
CG3140 FBgn00
22708 
Adk2 
BL55320 
HMC0
4007  NE      
CG8230 FBgn00
27607 
CG8230 
BL55329 
HMC0
4016  NE      
CG7461 FBgn00
34432 
CG7461 
BL55347 
HMC0
4034  NE      
CG8213 FBgn00
33359 
CG8213 
BL55350 
HMC0
4037  NE      
CG8738 FBgn00
33321 
CG8738 
BL55351 
HMC0
4038  NE      
CG4266 FBgn00
34598 
CG4266 
BL55354 
HMC0
4041  NE      
CG5002 FBgn00
34275 
CG5002 
BL55359 
HMC0
4046  NE      
CG8781 FBgn00
33378 
tsu 
BL55367 
HMC0
4055 MS MS  MS E  NE 
CG1806
7 
FBgn00
34512 
CG18067 
BL55383 
HMC0
4071  NE      
CG2668 FBgn00
04181 
Peb 
BL55390 
HMC0
4078  NE      
CG3832 FBgn00
19948 
Phm 
BL55392 
HMC0
4080  NE      
CG1238
7 
FBgn00
11556 
zetaTry 
BL55407 
HMC0
4095 A ME ME   E  
CG4927 FBgn00
34139 
CG4927 
BL55409 
HMC0
4097  NE      
CG8172 FBgn00
33362 
CG8172 
BL55608 
HMC0
3746  NE      
CG8169 FBgn00
11660 
Pms2 
BL55614 
HMC0
3753  NE      
CG9294 FBgn00
34666 
CG9294 
BL55618 
HMC0
3761  NE      
CG4527 FBgn00
35001 
slik 
BL55626 
HMC0
3770  NE      
CG1837
5 
FBgn00
34606 
ASPP 
BL55639 
HMC0
3787 E E NE MS E  NE 
CG8079 FBgn00
34002 
CG8079 
BL55654 
HMC0
3804  NE      
CG6315 FBgn00
00662 
fl(2)d 
BL55674 
HMC0
3833  NE      
CG3594 FBgn00
35063 
Eap 
BL55678 
HMC0
3845  NE      
CG3010
4 
FBgn00
50104 
NT5E-2 
BL55684 
HMC0
3869  NE      
CG4016 FBgn00
86532 
Spt-I 
BL55685 
HMC0
3870  NE      
CG2411 FBgn00
03892 
ptc 
BL55686 
HMC0
3872  NE      
CG3496 FBgn00
03977 
vir 
BL55694 
HMC0
3908  NE      
CG1106
6 
FBgn00
33033 
scaf 
BL55695 
HMC0
3909  NE      
CG1234
3 
FBgn00
33556 
CG12343 
BL55697 
HMC0
3911  NE      
CG1011
0 
FBgn00
24698 
Cpsf160 
BL55698 
HMC0
3912  NE      
CG1842
6 
FBgn00
21895 
ytr 
BL55704 
HMC0
3929  NE      
CG1238
6 
FBgn00
11554 
etaTry 
BL55731 
HMC0
3744  NE      
CG6701 FBgn00
33889 
CG6701 
BL55854 
HMC0
3849  NE      
CG8967 FBgn00
04839 
otk 
BL55869 
HMC0
4139  NE      
CG3915 FBgn00
33791 
Drl-2 
BL55893 
HMC0
4172  NE      
343 
 
CG4945 FBgn00
34137 
CG4945 
BL55894 
HMC0
4173  NE      
CG3216 FBgn00
34568 
CG3216 
BL55895 
HMC0
4174  NE      
CG3346
7 
FBgn00
53467 
CG33467 
BL55905 
HMC0
4189  NE      
CG9874 FBgn00
03687 
Tbp 
BL55911 
HMC0
4197  NE      
CG8205 FBgn00
23441 
fus 
BL55921 
HMC0
4208  NE      
CG3584 FBgn00
22984 
qkr58E-3 
BL55922 
HMC0
4209  NE      
CG1139
0 
FBgn00
11695 
PebIII 
BL55933 
HMC0
4221  NE      
CG7754 FBgn00
15001 
iotaTry 
BL55934 
HMC0
4222  NE      
CG8642 FBgn00
33312 
CG8642 
BL55946 
HMC0
4234 A E-L E-L   E-L  
CG1014
3 
FBgn00
33952 
Adgf-E 
BL55947 
HMC0
4236  NE      
CG9849 FBgn00
34803 
CG9849 
BL55948 
HMC0
4237  NE      
CG5756 FBgn00
34301 
CG5756 
BL55964 
HMC0
4259  NE      
CG3029
3 
FBgn00
50293 
Cht12 
BL55989 
HMC0
4285  NE      
CG3048
6 
FBgn00
50486 
CG30486 
BL55990 
HMC0
4286  NE      
CG9070 FBgn00
86519 
Cpr47Eg 
BL56004 
HMC0
4300  NE      
CG1510
0 
FBgn00
34401 
CG15100 
BL56007 
HMC0
4303  NE      
CG4802 FBgn00
34215 
CG4802 
BL56010 
HMC0
4306  NE      
CG3666 FBgn00
34094 
Tsf3 
BL56015 
HMC0
4311  NE      
CG1656 FBgn00
40093 
lectin-46Ca 
BL56016 
HMC0
4312  NE      
CG1523
1 
FBgn00
40653 
IM4 
BL56018 
HMC0
4314  NE      
CG3046
7 
FBgn00
50467 
CG30467 
BL56021 
HMC0
4317  NE      
CG3004
0 
FBgn00
86677 
jeb 
BL56022 
HMC0
4318  NE      
CG3394 FBgn00
34999 
CG3394 
BL56032 
HMC0
4340  NE      
CG5589 FBgn00
36754 
CG5589 
BL32334 
HMS0
0325  NE      
CG6914 FBgn00
37172 
CG6914 
BL32336 
HMS0
0327  NE      
CG7692 FBgn00
36714 
CG7692 
BL32338 
HMS0
0329  NE      
CG8765 FBgn00
36900 
CG8765 
BL32343 
HMS0
0334  NE      
CG8479 FBgn02
61276 
opa1-like 
BL32358 
HMS0
0349  NE      
CG1007
7 
FBgn00
35720 
CG10077 
BL32388 
HMS0
0380  NE      
CG1010
7 
FBgn00
35713 
velo 
BL32389 
HMS0
0383  NE      
CG5144 FBgn00
35957 
CG5144 
BL32393 
HMS0
0387  NE      
CG3217
2 
FBgn00
26197 
noe 
BL32407 
HMS0
0402  NE      
CG8201 FBgn02
60934 
par-1 
BL32410 
HMS0
0405 A E E   E  
CG1022
8 
FBgn02
64962 
Inr-a/Pcf11 
BL32411 
HMS0
0406 A E-L E-L   E-L  
CG9750 FBgn00
40075 
rept 
BL32415 
HMS0
0410  NE      
344 
 
CG3214
9 
FBgn00
36518 
RhoGAP71E 
BL32417 
HMS0
0412  NE      
CG1411
2 
FBgn00
36349 
SNCF 
BL32420 
HMS0
0415  NE      
CG9181 FBgn00
03138 
Ptp61F 
BL32426 
HMS0
0421  NE      
CG1226
2 
FBgn00
35811 
CG12262 
BL32436 
HMS0
0434  NE      
CG6418 FBgn00
36104 
CG6418 
BL32441 
HMS0
0439  NE      
CG3213
8 
FBgn00
52138 
CG32138 
BL32447 
HMS0
0445  NE      
CG1110
0 
FBgn00
37207 
Mes2 
BL32460 
HMS0
0460  NE      
CG2103 FBgn00
35375 
pgant6 
BL32463 
HMS0
0463  NE      
CG4879 FBgn00
27375 
RecQ5 
BL32466 
HMS0
0466  NE      
CG8167 FBgn00
36046 
Ilp2 
BL32475 
HMS0
0476  NE      
CG3206
2 
FBgn00
52062 
A2bp1 
BL32476 
HMS0
0478  NE      
CG8567 FBgn00
13799 
Deaf1 
BL32512 
HMS0
0516  NE      
CG1144
0 
FBgn00
37163 
laza 
BL32515 
HMS0
0519  NE      
CG3215
6 
FBgn00
05536 
Mbs 
BL32516 
HMS0
0521  NE      
CG5994 FBgn00
17430 
Nelf-E 
BL32835 
HMS0
0525  NE      
CG8241 FBgn00
86895 
pea 
BL32838 
HMS0
0528 A E ME   ME  
CG6586 FBgn00
28980 
tan 
BL32855 
HMS0
0640  NE      
CG1417
3 
FBgn00
44051 
Ilp1 
BL32861 
HMS0
0648  NE      
CG5519 FBgn02
61119 
Prp19 
BL32865 
HMS0
0652 A ME ME ME  ME  
CG4978 FBgn00
20633 
Mcm7 
BL32867 
HMS0
0654  NE      
CG2331 FBgn02
61014 
TER94 
BL32869 
HMS0
0656  NE      
CG3689 FBgn00
35987 
CG3689 
BL32883 
HMS0
0671  NE      
CG1179
3 
FBgn00
03462 
Sod 
BL32909 
HMS0
0698  NE      
CG9311 FBgn00
36448 
mop 
BL32916 
HMS0
0706  NE      
CG1388
7 
FBgn00
35165 
CG13887 
BL32917 
HMS0
0707  NE      
CG1159
3 
FBgn00
35488 
CG11593 
BL32924 
HMS0
0715  NE      
CG1817
8 
FBgn00
36035 
CG18178 
BL32927 
HMS0
0719  NE      
CG7324 FBgn00
37074 
CG7324 
BL32929 
HMS0
0722  NE      
CG8108 FBgn00
27567 
CG8108 
BL32930 
HMS0
0723  NE      
CG6143 FBgn00
04401 
Pep 
BL32944 
HMS0
0738  NE      
CG1796
2 
FBgn00
04052 
Z600 
BL32953 
HMS0
0747  NE      
CG1067
2 
FBgn00
35588 
CG10672 
BL32958 
HMS0
0753  NE      
CG1016
3 
FBgn00
35697 
CG10163 
BL32959 
HMS0
0754  NE      
CG6964 FBgn00
10825 
Gug 
BL32961 
HMS0
0756 A ME ME   E  
CG1275
5 
FBgn00
02440 
l(3)mbn 
BL32962 
HMS0
0757  NE      
345 
 
CG8091 FBgn00
26404 
Nc 
BL32963 
HMS0
0758  NE      
CG3210
9 
FBgn00
52109 
CG32109 
BL32970 
HMS0
0767  NE      
CG6292 FBgn00
25455 
CycT 
BL32976 
HMS0
0776 A E E   E  
CG1456
3 
FBgn00
37139 
CG14563 
BL33045 
HMS0
0643  NE      
CG1372
0 
FBgn00
35555 
CG13720 
BL33342 
HMS0
0208  NE      
CG1774
6 
FBgn00
35425 
CG17746 
BL33347 
HMS0
0214  NE      
CG3919 FBgn00
36423 
CG3919 
BL33355 
HMS0
0226  NE      
CG1833
2 
FBgn00
27055 
CSN3 
BL33369 
HMS0
0242  NE      
CG1026
9 
FBgn00
22935 
D19A 
BL33371 
HMS0
0244  NE      
CG4432 FBgn00
35976 
PGRP-LC 
BL33383 
HMS0
0259  NE      
CG8865 FBgn00
26376 
Rgl 
BL33389 
HMS0
0266  NE      
CG3395 FBgn00
10408 
RpS9 
BL33394 
HMS0
0271  NE      
CG3221
7 
FBgn00
14037 
ELL 
BL33399 
HMS0
0277 S S  S S  NE 
CG8013 FBgn00
20887 
Su(z)12 
BL33402 
HMS0
0280  NE      
CG1162
4 
FBgn00
03943 
Ubi-p63E 
BL33405 
HMS0
0284 A E-L E-L   E-L  
CG6539 FBgn00
11802 
Gem3 
BL33408 
HMS0
0287  NE      
CG7143 FBgn00
37141 
DNApol-eta 
BL33410 
HMS0
0290  NE      
CG9594 FBgn00
23395 
Chd3 
BL33420 
HMS0
0302  NE      
CG8057 FBgn02
60972 
alc 
BL33429 
HMS0
0316  NE      
CG4225
7 
FBgn02
59142 
Snp 
BL33434 
HMS0
0321  NE      
CG1122
8 
FBgn02
61456 
hpo 
BL33614 
HMS0
0006  NE      
CG3244
3 
FBgn00
03042 
Pc 
BL33622 
HMS0
0016  NE      
CG4059 FBgn00
01078 
ftz-f1 
BL33625 
HMS0
0019 A ME ME   ME  
CG7935 FBgn00
26252 
msk 
BL33626 
HMS0
0020  NE      
CG1016
0 
FBgn00
01258 
ImpL3 
BL33640 
HMS0
0039  NE      
CG6272 FBgn00
36126 
CG6272 
BL33652 
HMS0
0057  NE      
CG3234
6 
FBgn00
00541 
E(bx) 
BL33658 
HMS0
0065  NE      
CG6502 FBgn00
00629 
E(z) 
BL33659 
HMS0
0066  NE   MS   
CG1063
0 
FBgn00
35608 
blanks 
BL33667 
HMS0
0078  NE      
CG1416
7 
FBgn00
44050 
Ilp3 
BL33681 
HMS0
0546  NE      
CG3327
3 
FBgn00
44048 
Ilp5 
BL33683 
HMS0
0548  NE      
CG9191 FBgn00
04378 
Klp61F 
BL33685 
HMS0
0552 A ME ME   ME  
CG1166
1 
FBgn00
10352 
Nc73EF 
BL33686 
HMS0
0554  NE      
CG4609 FBgn00
14163 
fax 
BL33687 
HMS0
0555  NE      
CG7421 FBgn00
37137 
Nopp140 
BL33694 
HMS0
0564 E-L E-L NE E E-L  NE 
346 
 
CG1013
3 
FBgn00
36366 
CG10133 
BL33701 
HMS0
0578  NE      
CG1390
2 
FBgn00
35166 
CG13902 
BL33702 
HMS0
0579  NE      
CG8887 FBgn00
05386 
ash1 
BL33705 
HMS0
0582  NE      
CG5546 FBgn00
36761 
MED19 
BL33710 
HMS0
0588 S S  S MS  NE 
CG1502
2 
FBgn00
35547 
CG15022 
BL33713 
HMS0
0593  NE      
CG1390
0 
FBgn00
35162 
CG13900 
BL33731 
HMS0
0614  NE      
CG6603 FBgn00
26418 
Hsc70Cb 
BL33742 
HMS0
1080  NE      
CG7999 FBgn00
35851 
MED24 
BL33755 
HMS0
1097  NE      
CG8048 FBgn02
62511 
Vha44 
BL33884 
HMS0
0821  NE      
CG1275
6 
FBgn00
35624 
Eaf6 
BL33904 
HMS0
0846  NE      
CG6829 FBgn02
63864 
Ark 
BL33924 
HMS0
0870  NE      
CG4108 FBgn00
36805 
Chmp1 
BL33928 
HMS0
0877  NE      
CG1200
8 
FBgn00
04167 
kst 
BL33933 
HMS0
0882  NE      
CG1201
3 
FBgn00
35438 
PHGPx 
BL33939 
HMS0
0890  NE      
CG1499
2 
FBgn00
28484 
Ack 
BL33941 
HMS0
0892  NE      
CG1703
5 
FBgn00
36545 
GXIVsPLA2 
BL33961 
HMS0
0918  NE      
CG4107 FBgn00
20388 
Pcaf 
BL33981 
HMS0
0941  NE      
CG4118 FBgn00
36640 
nxf2 
BL33985 
HMS0
0945  NE      
CG3316
2 
FBgn00
11509 
SrpRbeta 
BL34011 
HMS0
0977  NE      
CG1201
2 
FBgn00
35444 
CG12012 
BL34015 
HMS0
0982  NE      
CG6871 FBgn00
00261 
Cat 
BL34020 
HMS0
0990  NE      
CG1496
6 
FBgn00
35415 
CG14966 
BL34022 
HMS0
0992  NE      
CG6497 FBgn00
36704 
CG6497 
BL34026 
HMS0
0996  NE      
CG5057 FBgn00
36581 
MED10 
BL34031 
HMS0
1001  NE      
CG7497 FBgn00
36742 
CG7497 
BL34035 
HMS0
1008  NE      
CG1289
1 
FBgn02
61862 
whd 
BL34066 
HMS0
0040  NE      
CG1057
9 
FBgn00
05640 
Eip63E 
BL34075 
HMS0
0569  NE      
CG5830 FBgn00
36556 
CG5830 
BL34079 
HMS0
1077  NE      
CG7809 FBgn00
36919 
Grasp65 
BL34082 
HMS0
1093  NE      
CG6884 FBgn00
36811 
MED11 
BL34083 
HMS0
1094  NE      
CG3214
6 
FBgn00
41604 
dlp 
BL34089 
HMS0
0875  NE      
CG4035 FBgn00
15218 
eIF-4E 
BL34096 
HMS0
0969  NE      
CG9425 FBgn00
36451 
CG9425 
BL34099 
HMS0
1002  NE      
CG1769
7 
FBgn00
01085 
fz 
BL34321 
HMS0
1308  NE      
CG6494 FBgn00
01168 
h 
BL34326 
HMS0
1313  NE      
347 
 
CG9148 FBgn00
25682 
scf 
BL34331 
HMS0
1319  NE      
CG5660 FBgn00
35942 
CG5660 
BL34339 
HMS0
1327 A E E   E  
CG6512 FBgn00
36702 
CG6512 
BL34343 
HMS0
1331  NE      
CG5165 FBgn00
03076 
Pgm 
BL34345 
HMS0
1333  NE      
CG7762 FBgn00
28695 
Rpn1 
BL34348 
HMS0
1337 A E-L E   E  
CG1751
4 
FBgn00
39959 
CG17514 
BL34355 
HMS0
1344  NE      
CG6877 FBgn00
36813 
Aut1/Atg3 
BL34359 
HMS0
1348 E E NE S ME  NE 
CG1041
9 
FBgn00
36850 
Gem2 
BL34366 
HMS0
1355  NE      
CG4372
2 
FBgn02
63934 
esn 
BL34371 
HMS0
1360  NE      
CG5186 FBgn02
61477 
slim 
BL34376 
HMS0
1366  NE      
CG4045
2 
FBgn00
11288 
Snap25 
BL34377 
HMS0
1367  NE      
CG1153
4 
FBgn00
46296 
CG11534 
BL34384 
HMS0
1374  NE      
CG1057
6 
FBgn00
35630 
CG10576 
BL34388 
HMS0
1382  NE      
CG1074
1 
FBgn00
36373 
CG10741 
BL34394 
HMS0
0981  NE      
CG4877 FBgn00
36624 
RAF2 
BL34395 
HMS0
1012  NE      
CG5942 FBgn00
00212 
brm 
BL34520 
HMS0
0050  NE      
CG8937 FBgn00
01216 
Hsc70-1 
BL34527 
HMS0
0888  NE      
CG9451 FBgn00
36876 
CG9451 
BL34545 
HMS0
1016 A E E   E  
CG1048
3 
FBgn00
35649 
CG10483 
BL34551 
HMS0
1023  NE      
CG1085
0 
FBgn00
41147 
ida 
BL34552 
HMS0
1024  NE      
CG1208
4 
FBgn00
43458 
CG12084 
BL34553 
HMS0
1025  NE      
CG4098 FBgn00
36648 
CG4098 
BL34559 
HMS0
1031  NE      
CG4157 FBgn00
28693 
Rpn12 
BL34560 
HMS0
1032 A E ME MS E-L ME  
CG7619 FBgn00
15283 
Pros54 
BL34566 
HMS0
1039  NE      
CG8268 FBgn00
35827 
Srp9 
BL34568 
HMS0
1041  NE      
CG1203
1 
FBgn00
35145 
MED14 
BL34575 
HMS0
1049 S S  S MS  NE 
CG1028
9 
FBgn00
35688 
CG10289 
BL34579 
HMS0
1053  NE      
CG4769 FBgn00
35600 
CG4769 
BL34583 
HMS0
1057  NE      
CG5594 FBgn02
61794 
kcc 
BL34584 
HMS0
1058  NE      
CG8491 FBgn00
01324 
kto/MED12 
BL34588 
HMS0
1062  NE      
CG1096
0 
FBgn00
36316 
CG10960 
BL34598 
HMS0
1072  NE      
CG8339 FBgn00
20251 
sfl 
BL34601 
HMS0
0543  NE      
CG1100
9 
FBgn00
36318 
Wbp2 
BL34603 
HMS0
0563  NE      
CG7062 FBgn00
15793 
Rab19 
BL34607 
HMS0
0592  NE      
CG9614 FBgn00
03089 
pip 
BL34613 
HMS0
1288  NE      
348 
 
CG1162
1 
FBgn00
15278 
Pi3K68D 
BL34621 
HMS0
1296  NE      
CG1207
6 
FBgn00
27616 
YT521-B 
BL34627 
HMS0
1302  NE      
CG5069 FBgn00
14143 
croc 
BL34647 
HMS0
1122  NE      
CG1152
6 
FBgn00
35437 
CG11526 
BL34657 
HMS0
1134  NE      
CG7162 FBgn00
37109 
MED1 
BL34662 
HMS0
1139  NE      
CG3243
5 
FBgn00
21760 
chb 
BL34669 
HMS0
1146  NE      
CG5893 FBgn00
00411 
D 
BL34672 
HMS0
1150  NE      
CG1086
1 
FBgn00
36255 
Atg12 
BL34675 
HMS0
1153  NE      
CG3207
6 
FBgn00
52076 
Alg10 
BL34681 
HMS0
1159  NE      
CG7504 FBgn00
35842 
CG7504 
BL34683 
HMS0
1161  NE      
CG3014
9 
FBgn02
50850 
rig 
BL34684 
HMS0
1162  NE      
CG6896 FBgn00
36801 
MYPT-75D 
BL34688 
HMS0
1166  NE      
CG7283 FBgn00
36213 
RpL10Ab 
BL34695 
HMS0
1174 A E-L E   E  
CG8609 FBgn00
35754 
MED4 
BL34697 
HMS0
1176  NE      
CG4717 FBgn00
01320 
kni 
BL34705 
HMS0
1184 A E ME   E  
CG7986 FBgn00
35850 
Atg18 
BL34714 
HMS0
1193  NE      
CG1864
7 
FBgn00
45759 
bin 
BL34718 
HMS0
1197  NE      
CG1241 FBgn00
44452 
Atg2 
BL34719 
HMS0
1198  NE      
CG6662 FBgn00
35907 
GstO1 
BL34727 
HMS0
1206  NE      
CG7405 FBgn00
22936 
CycH 
BL34732 
HMS0
1212  NE      
CG6975 FBgn00
05198 
gig 
BL34737 
HMS0
1217  NE      
CG1208
5 
FBgn00
28577 
pUf68 
BL34785 
HMS0
0094 
(ME 
POSSIBL
E) NE NE     
CG1151
3 
FBgn00
41164 
armi 
BL34789 
HMS0
0098  NE      
CG1125
4 
FBgn00
16034 
mael 
BL34793 
HMS0
0102  NE      
CG4097 FBgn00
02284 
Pros26 
BL34801 
HMS0
0110 A E E   E  
CG1501
0 
FBgn00
41171 
ago 
BL34802 
HMS0
0111  NE      
CG1219
6 
FBgn00
86908 
egg 
BL34803 
HMS0
0112  NE      
CG7185 FBgn00
35872 
CPSF6 
BL34804 
HMS0
0113 E E NE E E  NE 
CG6169 FBgn00
36534 
Dcp2 
BL34806 
HMS0
0115  NE      
CG7597 FBgn00
37093 
Cdk12 
BL34838 
HMS0
0155 ME ME NE ME ME  MS 
CG7471 FBgn00
15805 
Rpd3 
BL34846 
HMS0
0164  NE      
CG5528 FBgn00
36978 
Toll-9 
BL34853 
HMS0
0171 A ME ME   E  
CG1255
9 
FBgn00
03256 
rl 
BL34855 
HMS0
0173  NE      
CG7008 FBgn00
35121 
Tudor-SN 
BL34865 
HMS0
0184  NE      
349 
 
CG1086
3 
FBgn00
27552 
CG10863 
BL34878 
HMS0
0198  NE      
CG5103 FBgn00
36784 
CG5103 
BL34882 
HMS0
1227  NE      
CG2248 FBgn00
10333 
Rac1 
BL34910 
HMS0
1258  NE      
CG6199 FBgn00
36147 
Plod 
BL34911 
HMS0
1259  NE      
CG7961 FBgn00
25725 
alphaCop 
BL34923 
HMS0
1272 A E-L E-L   E-L  
CG1210 FBgn00
20386 
Pdk1 
BL34936 
HMS0
1250  NE      
CG6311 FBgn00
36735 
Edc3 
BL34953 
HMS0
0392  NE      
CG4086 FBgn00
04465 
Su(P) 
BL34955 
HMS0
0430  NE      
CG1171 FBgn00
04552 
Akh 
BL34960 
HMS0
0477  NE      
CG8993 FBgn00
35334 
CG8993 
BL34973 
HMS0
1042  NE      
CG7112 FBgn00
35879 
CG7112 
BL34976 
HMS0
1132  NE      
CG1010
3 
FBgn00
35715 
CG10103 
BL34979 
HMS0
1388  NE      
CG7659 FBgn00
15550 
tap 
BL34985 
HMS0
1395  NE      
CG8487 FBgn02
64560 
garz 
BL34987 
HMS0
1397 A E-L E-L   E-L  
CG1201
9 
FBgn00
11573 
Cdc37 
BL34991 
HMS0
1401  NE      
CG1126
8 
FBgn00
36336 
ste14 
BL34996 
HMS0
1406  NE      
CG3202
9 
FBgn00
52029 
Cpr66D 
BL35011 
HMS0
1421  NE      
CG3422
9 
FBgn02
59832 
CG34229 
BL35019 
HMS0
1432  NE      
CG1018
1 
FBgn00
04513 
Mdr65 
BL35035 
HMS0
1449  NE      
CG1234
2 
FBgn00
86898 
dgo 
BL35040 
HMS0
1454  NE      
CG1956 FBgn00
04636 
R 
BL35047 
HMS0
1461  NE      
CG1769
8 
FBgn00
40056 
CG17698 
BL35733 
HMS0
1475  NE      
CG5582 FBgn00
36756 
cln3 
BL35734 
HMS0
1476  NE      
CG7003 FBgn00
36486 
Msh6 
BL35737 
HMS0
1479  NE      
CG3348
6 
FBgn00
41607 
asparagine-
synthetase BL35739 
HMS0
1481  NE      
CG6776 FBgn00
35904 
GstO3 
BL35762 
HMS0
1510  NE      
CG3371 FBgn00
35153 
ebd1 
BL35765 
HMS0
1513  NE      
CG4012
7 
FBgn02
62116 
CG40127 
BL35779 
HMS0
1529  NE      
CG8127 FBgn00
00568 
Eip75B 
BL35780 
HMS0
1530 A E-L E-L   E-L  
CG4259
5 
FBgn02
62124 
uex 
BL36116 
HMS0
1492  NE      
CG1347
4 
FBgn00
36439 
CG13474 
BL36124 
HMS0
1539  NE      
CG5119 FBgn02
61619 
pAbp 
BL36127 
HMS0
1542  NE      
CG6718 FBgn00
36053 
iPLA2-VIA 
BL36129 
HMS0
1544  NE      
CG6114 FBgn00
36544 
sff 
BL36656 
HMS0
1280  NE      
CG3313
0 
FBgn02
63197 
Patronin 
BL36659 
HMS0
1547  NE      
350 
 
CG1145
1 
FBgn00
37025 
Spc105R 
BL36660 
HMS0
1548  NE      
CG4761 FBgn00
01323 
knrl 
BL36664 
HMS0
1552  NE      
CG4999 FBgn00
35936 
Tsp66E 
BL36696 
HMS0
1585  NE      
CG1230
6 
FBgn00
03124 
polo 
BL36702 
HMS0
1591  NE      
CG1350
3 
FBgn02
43516 
Vrp1 
BL36704 
HMS0
1593  NE      
CG1921 FBgn00
14388 
sty 
BL36709 
HMS0
1599 A E E E NE E  
CG1718
3 
FBgn00
35149 
MED30 
BL36711 
HMS0
1601  NE      
CG1704
6 
FBgn00
01316 
klar 
BL36721 
HMS0
1612  NE      
CG2075 FBgn00
04372 
aly 
BL36723 
HMS0
1614  NE      
CG1130
8 
FBgn00
02842 
sa 
BL36730 
HMS0
1621  NE      
CG2086 FBgn00
27594 
drpr 
BL36732 
HMS0
1623  NE      
CG9006 FBgn00
86712 
Egm 
BL36739 
HMS0
1630  NE      
CG1203
4 
FBgn00
35421 
CG12034 
BL36759 
HMS0
3020  NE      
CG3205
2 
FBgn00
44328 
CG32052 
BL36763 
HMS0
3024  NE      
CG5962 FBgn00
00121 
Arr2 
BL36772 
JF022
90  NE      
CG5751 FBgn00
35934 
TrpA1 
BL36780 
JF024
61  NE      
CG7478 FBgn00
00045 
Act79B 
BL36857 
HMS0
0303  NE      
CG9160 FBgn00
11361 
mtacp1 
BL37492 
HMS0
1634  NE      
CG7314 FBgn00
36199 
Bmcp 
BL37498 
HMS0
1640  NE      
CG4267
8 
FBgn02
61564 
CG42678 
BL37500 
HMS0
1642  NE      
CG7540 FBgn00
37092 
M6 
BL37503 
HMS0
1645 MS MS  MS E  NE 
CG1052
3 
FBgn00
41100 
park 
BL37509 
HMS0
1651  NE      
CG5665 FBgn00
36977 
CG5665 
BL37517 
HMS0
1659  NE      
CG9186 FBgn00
35206 
CG9186 
BL37518 
HMS0
1660  NE      
CG1030
8 
FBgn00
10317 
CycJ 
BL37521 
HMS0
1663  NE      
CG3243
3 
FBgn00
45474 
Gr77a 
BL38236 
HMS0
1680  NE      
CG4257
2 
FBgn02
60959 
MCPH1 
BL38244 
HMS0
1688  NE      
CG4278
3 
FBgn02
61854 
aPKC 
BL38245 
HMS0
1689  NE      
CG5654 FBgn00
22959 
yps 
BL38250 
HMS0
1694  NE      
CG1062
4 
FBgn00
10894 
sinu 
BL38258 
HMS0
1702  NE      
CG1501
4 
FBgn00
35532 
CG15014 
BL38273 
HMS0
1722  NE      
CG1008
3 
FBgn00
36372 
CG10083 
BL38282 
HMS0
1735  NE      
CG4344
3 
FBgn02
63391 
hts 
BL38283 
HMS0
1736  NE      
CG4893 FBgn00
36616 
CG4893 
BL38287 
HMS0
1740  NE      
CG9712 FBgn00
36666 
TSG101 
BL38306 
HMS0
1768  NE      
351 
 
CG7565 FBgn00
35833 
CG7565 
BL38307 
HMS0
1770  NE      
CG5026 FBgn00
35945 
CG5026 
BL38309 
HMS0
1773  NE      
CG3211
3 
FBgn00
52113 
CG32113 
BL38320 
HMS0
1784  NE      
CG8194 FBgn00
10406 
RNaseX25 
BL38322 
HMS0
1786  NE      
CG3705 FBgn00
23129 
aay 
BL38338 
HMS0
1805  NE      
CG1073
8 
FBgn00
36368 
CG10738 
BL38346 
HMS0
1814  NE      
CG7804 FBgn00
36496 
CG7804 
BL38355 
HMS0
1823 
(MS 
POSSIBL
E) NE   E   
CG1200
6 
FBgn00
35464 
CG12006 
BL38359 
HMS0
1827  NE      
CG1097
5 
FBgn00
14007 
Ptp69D 
BL38370 
HMS0
1839  NE      
CG1880
3 
FBgn00
19947 
Psn 
BL38374 
HMS0
1843  NE      
CG4618 FBgn00
35589 
CHMP2B 
BL38375 
HMS0
1844  NE      
CG1367
6 
FBgn00
35844 
CG13676 
BL38376 
HMS0
1845  NE      
CG1097
1 
FBgn00
36309 
Hip1 
BL38377 
HMS0
1846  NE      
CG1329
3 
FBgn00
35677 
CG13293 
BL38380 
HMS0
1849  NE      
CG7446 FBgn00
01134 
Grd 
BL38384 
HMS0
1853  NE      
CG8029 FBgn02
62515 
VhaAC45 
BL38522 
HMS0
1717  NE      
CG1127
8 
FBgn00
36341 
Syx13 
BL38525 
HMS0
1723  NE      
CG1815
6 
FBgn00
35725 
Mis12 
BL38535 
HMS0
1753  NE      
CG6224 FBgn00
40230 
dbo 
BL38940 
HMS0
1791  NE      
CG8104 FBgn00
36059 
nudE 
BL38954 
HMS0
1868 A ME ME   ME  
CG7067 FBgn00
24945 
NitFhit 
BL38961 
HMS0
1875  NE      
CG3230
0 
FBgn00
15360 
oxt 
BL38985 
HMS0
1901  NE      
CG6851 FBgn00
27786 
Mtch 
BL38986 
HMS0
1902  NE      
CG1794
7 
FBgn00
10215 
alpha-Cat 
BL38987 
HMS0
1903  NE      
CG4285
6 
FBgn02
62103 
Sik3 
BL39005 
HMS0
1922  NE      
CG1232
7 
FBgn00
36492 
Best3 
BL39040 
HMS0
1960  NE      
CG3213
6 
FBgn00
43550 
Tsp68C 
BL39045 
HMS0
1965  NE      
CG5492 FBgn00
36769 
Tsp74F 
BL39046 
HMS0
1966  NE      
CG6117 FBgn00
00489 
Pka-C3 
BL39050 
HMS0
1970  NE      
CG3243
4 
FBgn00
26179 
siz 
BL39060 
HMS0
1980  NE      
CG8739 FBgn00
86784 
stmA 
BL39062 
HMS0
1982  NE      
CG6827 FBgn00
13997 
Nrx-IV 
BL39071 
HMS0
1991  NE      
CG8798 FBgn00
36892 
Lon 
BL40162 
HMS0
1940  NE      
CG9949 FBgn00
03410 
sina 
BL40842 
HMS0
2008  NE      
352 
 
CG8442 FBgn00
04619 
Glu-RI 
BL40844 
HMS0
2010  NE      
CG4233
2 
FBgn02
59234 
Camta 
BL40849 
HMS0
2016  NE      
CG8591 FBgn00
35769 
CTCF 
BL40850 
HMS0
2017  NE      
CG9648 FBgn00
17578 
Max 
BL40851 
HMS0
2018  NE      
CG3654 FBgn00
36004 
Jarid2 
BL40855 
HMS0
2022  NE      
CG1788
8 
FBgn00
16694 
Pdp1 
BL40863 
HMS0
2030  NE      
CG8786 FBgn00
36897 
CG8786 
BL40882 
HMS0
2130  NE      
CG1006
0 
FBgn00
01104 
G-ialpha65A 
BL40890 
HMS0
2138  NE      
CG7259 FBgn00
36491 
Best4 
BL40897 
HMS0
2145  NE      
CG7823 FBgn00
36921 
RhoGDI 
BL40902 
HMS0
2150  NE      
CG8005 FBgn00
35854 
CG8005 
BL40921 
HMS0
2169  NE      
CG3161 FBgn02
62736 
Vha16-1 
BL40923 
HMS0
2171  NE      
CG4415
4 
FBgn02
65003 
koi 
BL40924 
HMS0
2172  NE      
CG8390 FBgn02
59978 
vlc 
BL40925 
HMS0
2173  NE      
CG1209
1 
FBgn00
35228 
CG12091 
BL40936 
HMS0
2184  NE      
CG1064
2 
FBgn00
04380 
Klp64D 
BL40945 
HMS0
2193  NE      
CG1074
3 
FBgn00
36376 
Liprin-beta 
BL41672 
HMS0
2206  NE      
CG5714 FBgn00
00543 
ecd 
BL41676 
HMS0
2211  NE      
CG6456 FBgn00
36713 
Mip 
BL41680 
HMS0
2244  NE      
CG7018 FBgn00
05658 
Ets65A 
BL41682 
HMS0
2246  NE      
CG5837 FBgn00
11771 
Hem 
BL41688 
HMS0
2252  NE      
CG9155 FBgn00
10246 
Myo61F 
BL41689 
HMS0
2253  NE      
CG3323
2 
FBgn00
35347 
CG33232 
BL41696 
HMS0
2261  NE      
CG3203
1 
FBgn00
00116 
Argk 
BL41697 
HMS0
2262  NE      
CG1004 FBgn00
04635 
rho 
BL41699 
HMS0
2264  NE      
CG1042
6 
FBgn00
36273 
CG10426 
BL41701 
HMS0
2266  NE      
CG7176 FBgn00
01248 
Idh 
BL41708 
HMS0
2273  NE      
CG8732 FBgn02
63120 
Acsl 
BL41885 
HMS0
2307 A E-L E-L   E  
CG1077
6 
FBgn00
24179 
wit 
BL41906 
HMS0
2298  NE      
CG9390 FBgn00
12034 
AcCoAS 
BL41917 
HMS0
2314  NE      
CG1062
5 
FBgn00
35612 
CG10625 
BL41923 
HMS0
2320  NE      
CG4334
0 
FBgn02
63077 
CG43340 
BL41926 
HMS0
2323 A E E   E  
CG4374
1 
FBgn02
63998 
PR2 
BL41931 
HMS0
2328  NE      
CG7729 FBgn00
36688 
Fit2 
BL41941 
HMS0
2338  NE      
CG7272 FBgn00
36501 
CG7272 
BL41950 
HMS0
2347  NE      
353 
 
CG1200
9 
FBgn00
35430 
CG12009 
BL41968 
HMS0
2365  NE      
CG1216
9 
FBgn00
35143 
Ppm1 
BL41987 
HMS0
2386  NE      
CG6811 FBgn00
36257 
RhoGAP68F 
BL41990 
HMS0
2390  NE      
CG6642 FBgn00
11293 
a10 
BL41993 
HMS0
2394  NE      
CG1148
6 
FBgn00
35397 
CG11486 
BL42492 
HMJ0
2056  NE      
CG5059 FBgn00
37007 
CG5059 
BL42494 
HMJ0
2058  NE      
CG4933 FBgn00
36615 
CG4933 
BL42496 
HMJ0
2060  NE      
CG9238 FBgn00
36428 
CG9238 
BL42498 
HMJ0
2062  NE      
CG6049 FBgn00
37081 
barc 
BL42504 
HMJ0
2069  NE      
CG1697
3 
FBgn00
10909 
msn 
BL42518 
HMJ0
2084  NE      
CG7177 FBgn00
37098 
Wnk 
BL42521 
HMJ0
2087  NE      
CG5408 FBgn00
28978 
trbl 
BL42523 
HMJ0
2089  NE      
CG8606 FBgn00
35761 
RhoGEF4 
BL42550 
HMJ0
2122  NE      
CG9619 FBgn00
36862 
Gbs-76A 
BL42551 
HMJ0
2124  NE      
CG6064 FBgn00
36746 
Crtc 
BL42561 
HMJ0
2217  NE      
CG7450 FBgn00
04396 
CrebA 
BL42562 
HMJ0
2218  NE      
CG8727 FBgn00
23094 
cyc 
BL42563 
HMJ0
2219  NE      
CG7391 FBgn00
23076 
Clk 
BL42566 
HMJ0
2224  NE      
CG7892 FBgn00
11817 
nmo 
BL42570 
HMJ0
2229  NE      
CG6297 FBgn00
20412 
JIL-1 
BL42571 
HMJ0
2230  NE      
CG1053
9 
FBgn00
15806 
S6k 
BL42572 
HMJ0
2231  NE      
CG1258 FBgn00
11692 
pav 
BL42573 
HMJ0
2232  NE      
CG1752
8 
FBgn02
61387 
CG17528 
BL42575 
HMJ0
2234  NE      
CG1876
9 
FBgn00
42185 
CG18769 
BL42580 
HMS0
1927  NE      
CG9205 FBgn00
35181 
CG9205 
BL42588 
HMS0
2420  NE      
CG5433 FBgn00
10235 
Klc 
BL42597 
HMS0
2429  NE      
CG7020 FBgn00
24806 
DIP2 
BL42598 
HMS0
2430  NE      
CG9018 FBgn00
35318 
CG9018 
BL42603 
HMS0
2436  NE      
CG4190 FBgn00
01229 
Hsp67Bc 
BL42607 
HMS0
2440  NE      
CG4183 FBgn00
01225 
Hsp26 
BL42610 
HMS0
2445  NE      
CG4231
1 
FBgn02
59211 
grh 
BL42611 
HMS0
2446  NE      
CG4320
2 
FBgn02
62838 
CG43202 
BL42617 
HMS0
2452  NE      
CG8368 FBgn00
35707 
CG8368 
BL42635 
HMS0
2471  NE      
CG8620 FBgn00
40837 
CG8620 
BL42638 
HMS0
2474  NE      
CG7989 FBgn02
62560 
wcd 
BL42642 
HMS0
2478 A E ME E  E  
354 
 
CG9695 FBgn00
00414 
Dab 
BL42646 
HMS0
2482  NE      
CG4821 FBgn00
23479 
Tequila 
BL42650 
HMS0
2486  NE      
CG1017
3 
FBgn00
35696 
Best2 
BL42654 
HMS0
2490  NE      
CG3922 FBgn00
05533 
RpS17 
BL42656 
HMS0
2492 A E E   E  
CG1135
2 
FBgn00
27339 
jim 
BL42662 
HMS0
2498  NE      
CG5585 FBgn00
36973 
Rbbp5 
BL42819 
HMJ0
2113  NE      
CG7133 FBgn00
37150 
CG7133 
BL42820 
HMS0
2502  NE      
CG7460 FBgn00
36749 
CG7460 
BL42827 
HMS0
2509  NE      
CG1123
8 
FBgn00
10830 
l(3)04053 
BL42859 
HMS0
2551  NE      
CG3231
5 
FBgn00
24510 
dlt 
BL42866 
HMS0
2559  NE      
CG1329
8 
FBgn00
35692 
CG13298 
BL42873 
HMS0
2566 A E ME MS E E  
CG1416
8 
FBgn00
36044 
CG14168 
BL42874 
HMS0
2567 A E ME ME E ME  
CG7266 FBgn00
00565 
Eip71CD 
BL42877 
HMS0
2570  NE      
CG1373
7 
FBgn00
36382 
CG13737 
BL42886 
HMS0
2579  NE      
CG1371
6 
FBgn00
35563 
CG13716 
BL42895 
HMS0
2588  NE      
CG1391
7 
FBgn00
35237 
CG13917 
BL42903 
HMS0
2596 A E ME S E ME  
CG4216 FBgn00
03683 
term 
BL42921 
HMS0
2614  NE      
CG1699
8 
FBgn00
35795 
CG16998 
BL42923 
HMS0
2616  NE      
CG1413
7 
FBgn00
36178 
CG14137 
BL42937 
HMS0
2630  NE      
CG1068
8 
FBgn00
36300 
CG10688 
BL42956 
HMS0
2649  NE      
CG6736 FBgn00
44049 
Ilp4 
BL43288 
HMS0
2660  NE      
CG1165
8 
FBgn00
36196 
CG11658 
BL43298 
HMS0
2671  NE      
CG1058
5 
FBgn00
37044 
CG10585 
BL43301 
HMS0
2674  NE      
CG3223
6 
FBgn00
46793 
CG32236 
BL43305 
HMS0
2685  NE      
CG3213
4 
FBgn00
05592 
btl 
BL43544 
HMS0
2656  NE      
CG1047
2 
FBgn00
35670 
CG10472 
BL43548 
HMS0
2654  NE      
CG1821
4 
FBgn00
24277 
trio 
BL43549 
HMS0
2690  NE      
CG1060
5 
FBgn00
15919 
caup 
BL44002 
HMS0
2716  NE      
CG7139 FBgn00
27532 
CG7139 
BL44007 
HMS0
2721  NE      
CG4195 FBgn00
02283 
l(3)73Ah 
BL44011 
HMS0
2725  NE      
CG4463 FBgn00
01224 
Hsp23 
BL44029 
HMS0
2745  NE      
CG4026
3 
FBgn00
58263 
MFS17 
BL44033 
HMS0
2749  NE      
CG3399
1 
FBgn00
13718 
nuf 
BL44035 
HMS0
2751  NE      
CG4412
8 
FBgn02
64959 
Src42A 
BL44039 
HMS0
2755  NE      
CG1262 FBgn00
20509 
Acp62F 
BL44047 
HMS0
2763  NE      
355 
 
CG1057
4 
FBgn00
28429 
I-2 
BL44050 
HMS0
2767  NE      
CG5187 FBgn00
35956 
Doc2 
BL44087 
HMS0
2804  NE      
CG6451 FBgn00
41161 
blue 
BL44094 
HMS0
2814  NE      
CG1072 FBgn00
13751 
Awh 
BL44097 
HMS0
2817  NE      
CG1672
4 
FBgn00
03741 
tra 
BL44109 
HMS0
2830  NE      
CG3352
8 
FBgn02
60964 
Vmat 
BL44471 
HMC0
2346  NE      
CG1061
6 
FBgn00
36286 
CG10616 
BL44474 
HMC0
2359  NE      
CG5701 FBgn00
36980 
RhoBTB 
BL44478 
HMC0
2368  NE      
CG1203
0 
FBgn00
35147 
Gale 
BL44496 
HMC0
2429  NE      
CG1699
2 
FBgn00
35789 
mthl6 
BL44497 
HMC0
2432  NE      
CG7476 FBgn00
35847 
mthl7 
BL44498 
HMC0
2433  NE      
CG1833
1 
FBgn00
36181 
Muc68Ca 
BL44499 
HMC0
2435  NE      
CG4994 FBgn00
26409 
Mpcp 
BL44508 
HMC0
2898  NE      
CG1036
1 
FBgn00
36208 
CG10361 
BL44512 
HMC0
2902  NE      
CG1435
3 
FBgn00
36771 
CG14353 
BL44513 
HMC0
2903  NE      
CG6905 FBgn00
35136 
CG6905 
BL44524 
HMC0
2918 A ME ME   E  
CG3208
2 
FBgn00
52082 
CG32082 
BL44526 
HMC0
2920  NE      
CG1207
9 
FBgn00
35404 
CG12079 
BL44535 
HMC0
2929  NE      
CG1499
1 
FBgn00
35498 
Fit1 
BL44536 
HMC0
2930  NE      
CG6498 FBgn00
36511 
CG6498 
BL44547 
HMC0
2943  NE      
CG1068
1 
FBgn00
36291 
CG10681 
BL44558 
HMS0
2854  NE      
CG6289 FBgn00
36970 
Spn77Bc 
BL44563 
HMS0
2859  NE      
CG3725 FBgn02
63006 
Ca-P60A 
BL44581 
HMS0
2878  NE      
CG5486 FBgn00
16756 
Ubp64E 
BL44645 
HMC0
2352  NE      
CG1047
5 
FBgn00
35667 
Jon65Ai 
BL44656 
HMC0
2430  NE      
CG6449 FBgn00
36101 
NijA 
BL50632 
HMC0
2999  NE      
CG8474 FBgn00
25874 
Meics 
BL50636 
HMC0
3035  NE      
CG1059
0 
FBgn00
35622 
CG10590 
BL50638 
HMC0
3038  NE      
CG7002 FBgn00
29167 
Hml 
BL50640 
HMC0
3040  NE      
CG6592 FBgn00
35669 
CG6592 
BL50645 
HMC0
3045  NE      
CG1180
1 
FBgn00
36128 
Elo68beta 
BL50646 
HMC0
3046  NE      
CG7414 FBgn00
37135 
CG7414 
BL50649 
HMC0
3050  NE      
CG6391 FBgn00
36111 
Aps 
BL50651 
HMC0
3052  NE      
CG1070
4 
FBgn00
36285 
toe 
BL50660 
HMC0
3061  NE      
CG7499 FBgn00
28699 
Rh50 
BL50666 
HMC0
3067  NE      
356 
 
CG7140 FBgn00
37147 
CG7140 
BL50677 
HMC0
3078  NE      
CG1733
4 
FBgn00
35626 
lin-28 
BL50679 
HMC0
3080  NE      
CG7404 FBgn00
35849 
ERR 
BL50686 
HMC0
3087  NE      
CG7960 FBgn00
13755 
Bro 
BL50689 
HMC0
3090  NE      
CG3205
5 
FBgn00
52055 
CG32055 
BL50692 
HMC0
3093  NE      
CG6859 FBgn00
36484 
Pex3 
BL50694 
HMC0
3096  NE      
CG6749 FBgn00
36040 
CG6749 
BL50696 
HMC0
3098 A ME ME   ME  
CG5485 FBgn00
36770 
Prestin 
BL50706 
HMC0
3108  NE      
CG3210
5 
FBgn00
52105 
CG32105 
BL50711 
HMC0
3113  NE      
CG5690 FBgn00
35295 
Cnb 
BL50714 
HMS0
2948  NE      
CG1059
1 
FBgn00
35621 
CG10591 
BL50722 
HMS0
2956  NE      
CG4416
7 
FBgn02
65052 
St3 
BL50728 
HMS0
2964  NE      
CG7398 FBgn00
24921 
Trn 
BL50732 
HMS0
2968  NE      
CG4347 FBgn00
35978 
UGP 
BL50902 
HMJ0
3120  NE      
CG7260 FBgn00
11723 
byn 
BL50906 
HMJ0
3127  NE      
CG1039
2 
FBgn02
61403 
sxc 
BL50909 
HMJ0
3131  NE      
CG9279 FBgn00
36882 
CG9279 
BL50914 
HMJ2
1003  NE      
CG1062
2 
FBgn00
29118 
Sucb 
BL50939 
HMJ2
1034  NE      
CG5290 FBgn00
36772 
CG5290 
BL50949 
HMJ2
1050  NE      
CG1012
4 
FBgn00
35709 
eIF4E-4 
BL50951 
HMJ2
1052  NE      
CG5642 FBgn00
36258 
eIF3l 
BL50959 
HMJ2
1061  NE      
CG1417
7 
FBgn00
36013 
CG14177 
BL50984 
HMJ2
1094  NE      
CG5444 FBgn00
10280 
Taf4 
BL50985 
HMJ2
1095 A E E   E  
CG6527 FBgn00
36085 
CG6527 
BL50994 
HMJ2
1107  NE      
CG1496
2 
FBgn00
35407 
CG14962 
BL51002 
HMJ2
1116  NE      
CG1291
8 
FBgn02
63260 
sel 
BL51015 
HMJ2
1136  NE      
CG1059
6 
FBgn00
15766 
Msr-110 
BL51034 
HMJ2
1161  NE      
CG9670 FBgn00
28380 
fal 
BL51048 
HMJ2
1182  NE      
CG1457
2 
FBgn00
37128 
CG14572 
BL51050 
HMJ2
1184  NE      
CG1163
7 
FBgn00
36822 
CG11637 
BL51156 
HMC0
2367  NE      
CG4457 FBgn00
15298 
Srp19 
BL51160 
HMC0
2399 A E E   E  
CG6298 FBgn00
23197 
Jon74E 
BL51161 
HMC0
2401  NE      
CG1111
5 
FBgn00
37202 
Ssl1 
BL51165 
HMJ0
3124  NE      
CG1027
0 
FBgn00
22699 
D19B 
BL51166 
HMJ0
3125  NE      
CG2264 FBgn02
62169 
magu 
BL51169 
HMJ2
1055  NE      
357 
 
CG1483
8 
FBgn00
35799 
CG14838 
BL51175 
HMJ2
1140  NE      
CG7580 FBgn00
36728 
CG7580 
BL51357 
HMC0
3242  NE      
CG8276 FBgn02
63144 
bin3 
BL51427 
HMC0
2940  NE      
CG7542 FBgn00
36738 
CG7542 
BL51429 
HMC0
3048  NE      
CG7422 FBgn00
35815 
Snmp2 
BL51432 
HMC0
3144  NE      
CG7409 FBgn00
35817 
CG7409 
BL51433 
HMC0
3145  NE      
CG9007 FBgn00
36398 
CG9007 
BL51447 
HMC0
3177  NE      
CG1817
9 
FBgn00
36023 
CG18179 
BL51451 
HMC0
3181  NE      
CG1683
8 
FBgn00
36574 
CG16838 
BL51453 
HMC0
3187  NE      
CG7510 FBgn00
36741 
CG7510 
BL51463 
HMC0
3201  NE      
CG1152
9 
FBgn00
36264 
CG11529 
BL51469 
HMC0
3210  NE      
CG4379
5 
FBgn02
64339 
CG43795 
BL51472 
HMC0
3214  NE      
CG8782 FBgn00
22774 
Oat 
BL51481 
HMC0
3226  NE      
CG1007
8 
FBgn00
41194 
Prat2 
BL51492 
HMC0
3244  NE      
CG1059
4 
FBgn00
03486 
spo 
BL51496 
HMC0
3251  NE      
CG6760 FBgn00
13563 
Pex1 
BL51497 
HMC0
3252  NE      
CG6765 FBgn00
35903 
CG6765 
BL51500 
HMC0
3258  NE      
CG1718
1 
FBgn00
35144 
CG17181 
BL51517 
HMS0
3165  NE      
CG6483 FBgn00
35665 
Jon65Aiii 
BL51692 
HMC0
2917  NE      
CG1708
4 
FBgn00
35131 
mthl9 
BL51695 
HMC0
3141  NE      
CG7955 FBgn00
35244 
ABCB7 
BL51696 
HMC0
3142  NE      
CG1047
7 
FBgn00
35661 
CG10477 
BL51697 
HMC0
3143  NE      
CG8329 FBgn00
36022 
CG8329 
BL51698 
HMC0
3146  NE      
CG1702
7 
FBgn00
36553 
CG17027 
BL51701 
HMC0
3174  NE      
CG5272 FBgn00
01120 
gnu 
BL51703 
HMC0
3185  NE      
CG6869 FBgn00
36485 
FucTA 
BL51715 
HMC0
3247  NE      
CG1748
4 
FBgn02
60799 
p120ctn 
BL51729 
HMC0
3276  NE      
CG9701 FBgn00
36659 
CG9701 
BL51733 
HMC0
3293  NE      
CG1706
1 
FBgn00
35132 
mthl10 
BL51753 
HMC0
3304  NE      
CG7118 FBgn00
35886 
Jon66Ci 
BL51754 
HMC0
3305  NE      
CG5262 FBgn00
36988 
CG5262 
BL51755 
HMC0
3306  NE      
CG8585 FBgn02
63397 
Ih 
BL51765 
HMC0
3319  NE      
CG5747 FBgn00
35935 
mfr 
BL51769 
HMC0
3324  NE      
CG7758 FBgn00
27945 
ppl 
BL51778 
HMC0
3333  NE      
CG9943 FBgn00
29117 
Surf1 
BL51783 
HMC0
3338  NE      
358 
 
CG5258 FBgn00
29148 
NHP2 
BL51784 
HMC0
3339  NE      
CG1499
4 
FBgn00
04516 
Gad1 
BL51794 
HMC0
3350  NE      
CG1499
3 
FBgn00
16013 
Faa 
BL51796 
HMC0
3352  NE      
CG1714
6 
FBgn00
22709 
Adk1 
BL51799 
HMC0
3355  NE      
CG6097 FBgn00
03292 
rt 
BL51805 
HMC0
3363  NE      
CG8615 FBgn00
35753 
RpL18 
BL51812 
HMC0
3383 A E E     
CG7977 FBgn00
26372 
RpL23A 
BL51818 
HMC0
3389  NE      
CG9384 FBgn00
36446 
CG9384 
BL51821 
HMC0
3393  NE      
CG7864 FBgn00
35233 
Pex10 
BL51826 
HMC0
3398  NE      
CG8177 FBgn00
36043 
CG8177 
BL51827 
HMC0
3399  NE      
CG1714
2 
FBgn00
35113 
pyx 
BL51836 
HMC0
3408  NE      
CG4319 FBgn00
11706 
rpr 
BL51846 
HMC0
3419  NE      
CG1837
4 
FBgn00
25592 
Gyk 
BL51849 
HMC0
3423  NE      
CG7049 FBgn00
35102 
CG7049 
BL51896 
HMC0
3470  NE      
CG1392
7 
FBgn00
35245 
GC 
BL51897 
HMC0
3471  NE      
CG2069 FBgn00
35264 
Oseg4 
BL51898 
HMC0
3472  NE      
CG1140 FBgn00
35298 
CG1140 
BL51899 
HMC0
3473  NE      
CG2107 FBgn00
35383 
CG2107 
BL51900 
HMC0
3474  NE      
CG1201
4 
FBgn00
35445 
CG12014 
BL51901 
HMC0
3475  NE      
CG1084
9 
FBgn00
35471 
Sc2 
BL51902 
HMC0
3476  NE      
CG4623 FBgn00
35587 
CG4623 
BL51903 
HMC0
3477  NE      
CG7161 FBgn00
35891 
Oseg1 
BL51904 
HMC0
3478  NE      
CG1227
2 
FBgn00
36571 
CG12272 
BL51906 
HMC0
3481  NE      
CG9706 FBgn00
36662 
CG9706 
BL51908 
HMC0
3483  NE      
CG6841 FBgn00
36828 
CG6841 
BL51909 
HMC0
3484  NE      
CG7470 FBgn00
37146 
CG7470 
BL51911 
HMC0
3487  NE      
CG6951 FBgn00
36959 
CG6951 
BL51913 
HMS0
3371  NE      
CG1581
1 
FBgn00
04574 
Rop 
BL51925 
HMC0
3422 A E-L E-L   E-L  
CG7757 FBgn00
36915 
CG7757 
BL51940 
HMC0
3485 A E ME ME  ME  
CG1058
6 
FBgn00
37036 
Sems 
BL52892 
HMC0
3630  NE      
CG1053
7 
FBgn00
04244 
Rdl 
BL52903 
HMC0
3643  NE      
CG6020 FBgn00
37001 
CG6020 
BL52922 
HMC0
3662  NE      
CG1179
6 
FBgn00
36992 
CG11796 
BL52923 
HMC0
3663  NE      
CG4300 FBgn00
36272 
CG4300 
BL52924 
HMC0
3665  NE      
CG8583 FBgn00
35771 
sec63 
BL52925 
HMC0
3666  NE      
359 
 
CG7971 FBgn00
35253 
CG7971 
BL52936 
HMC0
3678 A E-L E   E-L  
CG5684 FBgn00
36239 
Pop2/CNOT7 
BL52947 
HMJ2
1614 E E NE NE E  NE 
CG1389
1 
FBgn00
35139 
CG13891 
BL52950 
HMJ2
1619  NE      
CG5602 FBgn02
62619 
DNA-ligI 
BL52951 
HMJ2
1620  NE      
CG4260
0 
FBgn02
61016 
clos 
BL52966 
HMJ2
1651  NE      
CG3208
8 
FBgn00
52088 
CG32088 
BL52969 
HMJ2
1654  NE      
CG3210
2 
FBgn00
52102 
CG32102 
BL52975 
HMJ2
1661  NE      
CG1058
8 
FBgn00
37037 
CG10588 
BL52977 
HMJ2
1664  NE      
CG9710 FBgn00
21768 
nudC 
BL52980 
HMJ2
1667  NE      
CG3743 FBgn00
40305 
MTF-1 
BL52986 
HMJ2
1677  NE      
CG9129 FBgn00
35196 
CG9129 
BL52995 
HMJ2
1707  NE      
CG4372
9 
FBgn02
63980 
CG43729 
BL52999 
HMJ2
1714  NE      
CG4167 FBgn00
01227 
Hsp67Ba 
BL53007 
HMJ2
1725  NE      
CG3529 FBgn00
35995 
CG3529 
BL53008 
HMJ2
1726  NE      
CG1392
4 
FBgn00
35286 
CG13924 
BL53013 
HMJ2
1735  NE      
CG8001 FBgn00
35268 
CG8001 
BL53021 
HMJ2
1744  NE      
CG7327 FBgn00
14849 
Eig71Ei 
BL53022 
HMJ2
1745  NE      
CG6215 FBgn00
15025 
CkIIalpha-i1 
BL53025 
HMJ2
1750  NE      
CG6850 FBgn00
14075 
Ugt 
BL53027 
HMJ2
1752  NE      
CG4153 FBgn00
04926 
eIF-2beta 
BL53268 
HMC0
2396  NE      
CG4365 FBgn00
37024 
CG4365 
BL53290 
HMC0
3506 A E E   E  
CG6671 FBgn02
62739 
AGO1 
BL53293 
HMC0
3509 A E E   E  
CG7506 FBgn00
35805 
CG7506 
BL53297 
HMC0
3513 A ME ME   E  
CG4461 FBgn00
35982 
CG4461 
BL53298 
HMC0
3517  NE      
CG1407
7 
FBgn00
36830 
CG14077 
BL53303 
HMC0
3530  NE      
CG3207
2 
FBgn00
52072 
Elo68alpha 
BL53307 
HMC0
3535  NE      
CG5842 FBgn00
36414 
nan 
BL53312 
HMC0
3541  NE      
CG1035
9 
FBgn00
35452 
CG10359 
BL53316 
HMC0
3545  NE      
CG1702
8 
FBgn00
36552 
CG17028 
BL53320 
HMC0
3549  NE      
CG1501
5 
FBgn00
35533 
Cip4 
BL53321 
HMC0
3550  NE      
CG8019 FBgn00
01179 
hay 
BL53345 
HMC0
3574  NE      
CG1052
2 
FBgn00
02466 
sti 
BL53357 
HMC0
3586  NE      
CG2092 FBgn02
61385 
scra 
BL53358 
HMC0
3587  NE      
CG1058
7 
FBgn00
37039 
CG10587 
BL53359 
HMC0
3588 A ME ME   ME  
CG1103
7 
FBgn00
37038 
CG11037 
BL53360 
HMC0
3589  NE      
360 
 
CG1499
0 
FBgn00
35496 
CG14990 
BL53367 
HMC0
3596  NE      
CG3028
3 
FBgn02
60477 
CG30283 
BL53376 
HMC0
3605  NE      
CG7328 FBgn00
36942 
CG7328 
BL53675 
HMC0
3664  NE      
CG1328
5 
FBgn00
35611 
CG13285 
BL53680 
HMJ2
1593  NE      
CG1412
2 
FBgn00
36282 
Smyd4 
BL53682 
HMJ2
1595  NE      
CG1482
1 
FBgn00
35719 
tow 
BL53704 
HMJ2
1747  NE      
CG4818 FBgn00
36617 
Cpr72Ea 
BL53878 
HMJ2
1191  NE      
CG1142
6 
FBgn00
37166 
CG11426 
BL53879 
HMJ2
1194  NE      
CG7097 FBgn02
63395 
hppy 
BL53884 
HMJ2
1199  NE      
CG4269
8 
FBgn02
61588 
pdm3 
BL53887 
HMJ2
1205  NE      
CG7202 FBgn00
37086 
CG7202 
BL53895 
HMJ2
1214  NE      
CG3244
4 
FBgn00
43783 
CG32444 
BL53929 
HMJ2
1275  NE      
CG2140 FBgn02
64294 
Cyt-b5 
BL53950 
HMJ2
1314  NE      
CG3202
6 
FBgn00
52026 
CG32026 
BL53953 
HMJ2
1319  NE      
CG1068
6 
FBgn00
41775 
tral 
BL53961 
HMJ2
1343 A E E-L   E-L  
CG1105
1 
FBgn00
40813 
Nplp2 
BL53967 
HMJ2
1350  NE      
CG1693
1 
FBgn00
04588 
Eig71Ea 
BL53984 
HMJ2
1384  NE      
CG7345 FBgn00
36411 
Sox21a 
BL53991 
HMJ2
1395  NE      
CG9433 FBgn02
61850 
Xpd 
BL53992 
HMJ2
1396 ME ME NE NE E  NE 
CG7525 FBgn00
14073 
Tie 
BL54005 
HMJ2
1428  NE      
CG1511
3 
FBgn02
63116 
5-HT1B 
BL54006 
HMJ2
1429 A E E   E  
CG2021 FBgn00
35271 
CG2021 
BL54007 
HMJ2
1430  NE      
CG4750 FBgn02
59795 
loopin-1 
BL54012 
HMJ2
1436  NE      
CG3217
7 
FBgn00
52177 
Ndfip 
BL54018 
HMJ2
1444  NE      
CG1388
8 
FBgn00
35167 
Gr61a 
BL54030 
HMJ2
1473  NE      
CG1414
7 
FBgn00
36112 
CG14147 
BL54046 
HMJ2
1489  NE      
CG8549 FBgn00
35714 
CG8549 
BL54466 
HMC0
3734  NE      
CG1500
2 
FBgn00
11653 
mas 
BL54475 
HMC0
3732 
MS MS  S S  
(ME 
POSSIBL
E) 
CG1381
0 
FBgn00
35313 
CG13810 
BL54802 
HMJ2
1496  NE      
CG4266
3 
FBgn02
61545 
CG42663 
BL54808 
HMJ2
1502  NE      
CG1014 FBgn00
28567 
robl62A 
BL54813 
HMJ2
1532  NE      
CG7641 FBgn00
13303 
Nca 
BL54814 
HMJ2
1533  NE      
CG3203
6 
FBgn00
52036 
CG32036 
BL54818 
HMJ2
1537  NE      
CG8833 FBgn00
36386 
CG8833 
BL54824 
HMJ2
1543  NE      
361 
 
CG6757 FBgn00
40475 
SH3PX1 
BL54833 
HMJ2
1552  NE      
CG6933 FBgn00
36952 
CG6933 
BL54842 
HMJ2
1579  NE      
CG7385 FBgn00
36937 
Ir76b 
BL54846 
HMJ2
1583  NE      
CG1919 FBgn00
35281 
Cpr62Bc 
BL54849 
HMJ2
1586  NE      
CG3396 FBgn00
40296 
Ocho 
BL54851 
HMJ2
1588 A E E   E  
CG1828 FBgn00
02183 
dre4 
BL54855 
HMS0
2240  NE      
CG7433 FBgn00
36927 
CG7433 
BL54993 
HMC0
3730  NE      
CG3088 FBgn00
36015 
CG3088 
BL55145 
HMC0
3755  NE      
CG8610 FBgn00
12058 
Cdc27 
BL55155 
HMC0
3814 A ME E   E  
CG1672
5 
FBgn00
36641 
Smn 
BL55158 
HMC0
3832  NE      
CR3216
2 
FBgn00
41721 
snRNA:U12:73B 
BL55164 
HMC0
3841  NE      
CG1090
7 
FBgn00
36207 
CG10907 
BL55204 
HMC0
3919  NE      
CG1127
4 
FBgn00
36340 
SRm160 
BL55205 
HMC0
3920  NE      
CG6322 FBgn00
36733 
U4-U6-60K 
BL55210 
HMC0
3931  NE      
CG9383 FBgn00
29094 
asf1 
BL55250 
HMC0
3937  NE      
CG7564 FBgn00
36734 
CG7564 
BL55252 
HMC0
3939  NE      
CG1858
6 
FBgn00
35642 
CG18586 
BL55270 
HMC0
3957  NE      
CG4425
2 
FBgn02
65187 
CG44252 
BL55271 
HMC0
3958  NE      
CG1094
8 
FBgn00
36317 
CG10948 
BL55280 
HMC0
3967  NE      
CG6817 FBgn00
24236 
foi 
BL55281 
HMC0
3968  NE      
CG1046
9 
FBgn00
35678 
CG10469 
BL55291 
HMC0
3978  NE      
CG6457 FBgn00
40060 
yip7 
BL55293 
HMC0
3980 ME ME NE ME NE  NE 
CG1130 FBgn00
04880 
scrt 
BL55309 
HMC0
3996  NE      
CG3212
0 
FBgn00
02573 
sens 
BL55310 
HMC0
3997  NE      
CG1056
4 
FBgn00
24150 
Ac78C 
BL55312 
HMC0
3999  NE      
CG4561 FBgn00
27080 
Aats-tyr 
BL55326 
HMC0
4013  NE      
CG6778 FBgn00
27088 
Aats-gly 
BL55327 
HMC0
4014  NE      
CG6580 FBgn00
35666 
Jon65Aii 
BL55343 
HMC0
4030 A ME E   E  
CG6865 FBgn00
36817 
CG6865 
BL55349 
HMC0
4036  NE      
CG4911 FBgn00
35959 
CG4911 
BL55353 
HMC0
4040  NE      
CG6876 FBgn00
36487 
Prp31 
BL55364 
HMC0
4052  NE      
CG3322
8 
FBgn02
61373 
CG33228 
BL55372 
HMC0
4060  NE      
CG1000
6 
FBgn00
36461 
CG10006 
BL55376 
HMC0
4064  NE      
CG1307
6 
FBgn00
44028 
Notum 
BL55379 
HMC0
4067  NE      
CG1934 FBgn00
01254 
ImpE2 
BL55380 
HMC0
4068  NE      
362 
 
CG8783 FBgn00
36397 
CG8783 
BL55384 
HMC0
4072  NE      
CG1071
7 
FBgn00
01256 
ImpL1 
BL55387 
HMC0
4075  NE      
CG3322 FBgn00
02528 
LanB2 
BL55388 
HMC0
4076  NE      
CG6821 FBgn00
02564 
Lsp1gamma 
BL55389 
HMC0
4077  NE      
CG1081
0 
FBgn00
10381 
Drs 
BL55391 
HMC0
4079  NE      
CG1832
1 
FBgn00
29002 
miple2 
BL55393 
HMC0
4081  NE      
CG1390
6 
FBgn00
28999 
nerfin-1 
BL55395 
HMC0
4083  NE      
CG1887 FBgn00
35290 
CG1887 
BL55401 
HMC0
4089  NE      
CG9116 FBgn00
04429 
LysP 
BL55606 
HMC0
3743  NE      
CG7028 FBgn00
27587 
CG7028 
BL55640 
HMC0
3788  NE      
CG6664 FBgn00
36685 
CG6664 
BL55643 
HMC0
3792  NE      
CG1075
4 
FBgn00
36314 
CG10754 
BL55650 
HMC0
3799  NE      
CG4238
2 
FBgn02
59728 
CG42382 
BL55652 
HMC0
3801  NE      
CG1058
2 
FBgn00
28402 
Sin 
BL55656 
HMC0
3807  NE      
CG6822 FBgn00
35909 
ergic53 
BL55657 
HMC0
3809  NE      
CG7942 FBgn00
35838 
ldbr 
BL55661 
HMC0
3816  NE      
CG8596 FBgn00
35767 
CG8596 
BL55664 
HMC0
3819  NE      
CG1148
9 
FBgn00
25702 
srpk79D 
BL55667 
HMC0
3822  NE      
CG1291 FBgn00
35401 
CG1291 
BL55671 
HMC0
3827  NE      
CR3290
8 
FBgn00
03938 
snRNA:U5:63BC 
BL55676 
HMC0
3840  NE      
CG1818
0 
FBgn00
36024 
CG18180 
BL55680 
HMC0
3862  NE      
CG4083 FBgn00
17572 
Mo25 
BL55681 
HMC0
3865  NE      
CG5649 FBgn00
24887 
kin17 
BL55692 
HMC0
3906 A E ME   E  
CG5971 FBgn00
35918 
Cdc6 
BL55734 
HMC0
3802 A ME ME   ME  
CG1066
3 
FBgn00
36287 
CG10663 
BL55737 
HMC0
3876  NE      
CG2146 FBgn02
61397 
didum 
BL55740 
HMC0
3900  NE      
CG9054 FBgn00
15075 
Ddx1 
BL55744 
HMC0
3930  NE      
CG1041
8 
FBgn00
36277 
CG10418 
BL55746 
HMC0
3933  NE      
CG1500
9 
FBgn00
01257 
ImpL2 
BL55855 
HMC0
3863  NE      
CG4279 FBgn02
61067 
LSm1 
BL55912 
HMC0
4198  NE      
CG3217
6 
FBgn00
52176 
CG32176 
BL55923 
HMC0
4210  NE      
CG6917 FBgn00
00592 
Est-6 
BL55927 
HMC0
4215  NE      
CG1714
8 
FBgn00
00594 
Est-P 
BL55928 
HMC0
4216  NE      
CG7599 FBgn00
04593 
Eig71Ef 
BL55930 
HMC0
4218 MS MS  S E  E 
CG1331
2 
FBgn00
35931 
CG13312 
BL55949 
HMC0
4238  NE      
363 
 
CG6628 FBgn00
36072 
CG6628 
BL55950 
HMC0
4239  NE      
CG1782
6 
FBgn00
36227 
CG17826 
BL55951 
HMC0
4240  NE      
CG1011
6 
FBgn00
36367 
CG10116 
BL55952 
HMC0
4241  NE      
CG4073
3 
FBgn00
85512 
RYamide 
BL55957 
HMC0
4246  NE      
CG1757
5 
FBgn02
50842 
CG17575 
BL55958 
HMC0
4247  NE      
CG8614 FBgn00
24542 
Neos 
BL55960 
HMC0
4254  NE      
CG1380
6 
FBgn00
35325 
CG13806 
BL55965 
HMC0
4260  NE      
CG1495
7 
FBgn00
35412 
CG14957 
BL55966 
HMC0
4261  NE      
CG1495
9 
FBgn00
35427 
ckd 
BL55967 
HMC0
4262  NE      
CG8072 FBgn00
36070 
CG8072 
BL55968 
HMC0
4263  NE      
CG5897 FBgn00
36220 
CG5897 
BL55969 
HMC0
4264  NE      
CG5883 FBgn00
36225 
CG5883 
BL55970 
HMC0
4265  NE      
CG1015
4 
FBgn00
36361 
CG10154 
BL55971 
HMC0
4266 A E E   E  
CG6996 FBgn00
36950 
CG6996 
BL55972 
HMC0
4267  NE      
CG1714
5 
FBgn00
36953 
CG17145 
BL55974 
HMC0
4269  NE      
CG5008 FBgn00
40321 
GNBP3 
BL55984 
HMC0
4280  NE      
CG3202
4 
FBgn00
52024 
CG32024 
BL55997 
HMC0
4293  NE      
CG3206
8 
FBgn00
52068 
CG32068 
BL56008 
HMC0
4304 A ME ME   ME  
CG9128 FBgn00
35195 
Sac1 
BL56013 
HMC0
4309  NE      
CG1059
2 
FBgn00
35619 
CG10592 
BL56014 
HMC0
4310  NE      
CG1274 FBgn00
40308 
Jafrac2 
BL56043 
HMC0
4351  NE      
CG3217
8 
FBgn00
43025 
Msi 
BL56044 
HMC0
4352  NE      
CG7250 FBgn00
36494 
Toll-6 
BL56048 
HMS0
4251  NE      
CG8021 FBgn00
37602 
CG8021 
BL32339 
HMS0
0330  NE      
CG6226 FBgn00
13269 
FK506-bp1 
BL32348 
HMS0
0339  NE      
CG9983 FBgn00
01215 
Hrb98DE 
BL32351 
HMS0
0342 E E NE E ME  NE 
CG9484 FBgn00
02431 
hyd 
BL32352 
HMS0
0343 ME ME NE E E  NE 
CG1224
9 
FBgn00
21776 
mira 
BL32356 
HMS0
0347  NE      
CG1064 FBgn00
11715 
Snr1 
BL32372 
HMS0
0363  NE      
CG6791 FBgn00
37918 
CG6791 
BL32395 
HMS0
0389  NE      
CG9775 FBgn00
37261 
CG9775 
BL32396 
HMS0
0390  NE      
CG4279
9 
FBgn02
61934 
dikar 
BL32397 
HMS0
0391  NE      
CG3355
6 
FBgn00
53556 
form3 
BL32398 
HMS0
0393 A E E   E  
CG7788 FBgn00
19972 
Ice 
BL32403 
HMS0
0398 A E E   E  
CG5650 FBgn00
04103 
Pp1-87B 
BL32414 
HMS0
0409 A E-L E   E  
364 
 
CG1760
3 
FBgn00
10355 
Taf1 
BL32421 
HMS0
0416 ME ME NE E ME  NE 
CG3143 FBgn00
38197 
foxo 
BL32427 
HMS0
0422  NE      
CG7483 FBgn00
37573 
eIF4AIII 
BL32444 
HMS0
0442 
(MS 
POSSIBL
E) NE      
CG6923 FBgn00
37944 
CG6923 
BL32448 
HMS0
0447  NE      
CG5248 FBgn00
20278 
loco 
BL32456 
HMS0
0455  NE      
CG4720 FBgn00
14006 
Pk92B 
BL32464 
HMS0
0464  NE      
CG6773 FBgn00
24509 
sec13 
BL32468 
HMS0
0468  NE      
CG1207
3 
FBgn00
04573 
5-HT7 
BL32471 
HMS0
0471  NE      
CG5422 FBgn00
05649 
Rox8 
BL32472 
HMS0
0472  NE      
CG7771 FBgn00
04666 
sim 
BL32488 
HMS0
0491  NE      
CG4637 FBgn00
04644 
hh 
BL32489 
HMS0
0492  NE      
CG3113
7 
FBgn00
11725 
twin 
BL32490 
HMS0
0493  NE      
CG7015 FBgn02
63352 
Unr 
BL32491 
HMS0
0494  NE      
CG8308 FBgn00
87040 
alphaTub67C 
BL32502 
HMS0
0506  NE      
CG1193 FBgn00
37375 
kat-60L1 
BL32506 
HMS0
0510  NE      
CG1198
4 
FBgn00
37655 
CG11984 
BL32507 
HMS0
0511  NE      
CG9366 FBgn00
14380 
RhoL 
BL32841 
HMS0
0532  NE      
CG3354 FBgn00
86915 
Mst77F 
BL32849 
HMS0
0633  NE      
CG5374 FBgn00
03676 
T-cp1 
BL32854 
HMS0
0639  NE      
CG3637 FBgn00
25865 
Cortactin 
BL32871 
HMS0
0658  NE      
CG8036 FBgn00
37607 
CG8036 
BL32884 
HMS0
0672  NE      
CG7583 FBgn00
20496 
CtBP 
BL32889 
HMS0
0677  NE      
CG4565 FBgn00
37841 
CG4565 
BL32893 
HMS0
0682  NE      
CG4261 FBgn00
22787 
Hel89B 
BL32895 
HMS0
0684  NE      
CG3508 FBgn00
38251 
CG3508 
BL32898 
HMS0
0687  NE      
CG4800 FBgn00
37874 
Tctp 
BL32911 
HMS0
0701 A E-L E-L   E-L  
CG2899 FBgn00
15402 
ksr 
BL32937 
HMS0
0730  NE      
CG1483 FBgn00
02645 
Map205 
BL32939 
HMS0
0733  NE      
CG1281
9 
FBgn00
37810 
sle 
BL32969 
HMS0
0766  NE      
CG3225
1 
FBgn00
52251 
CG32251 
BL32974 
HMS0
0772  NE      
CG8165 FBgn00
37703 
JHDM2 
BL32975 
HMS0
0775  NE      
CG5637 FBgn00
02962 
nos 
BL32985 
HMS0
0785  NE      
CG3249
1 
FBgn00
02781 
mod(mdg4) 
BL32995 
HMS0
0795  NE      
CG6343 FBgn00
19957 
ND42 
BL32998 
HMS0
0798  NE      
365 
 
CG6831 FBgn02
60442 
rhea 
BL32999 
HMS0
0799  NE      
CG5252 FBgn00
37894 
Ranbp9 
BL33004 
HMS0
0804  NE      
CG1281
2 
FBgn00
37781 
Fancl 
BL33050 
HMS0
0771  NE      
CG1220
1 
FBgn00
37970 
CG12201 
BL33338 
HMS0
0204  NE      
CG1437
7 
FBgn00
38148 
CG14377 
BL33344 
HMS0
0210  NE      
CG9386 FBgn00
37708 
CG9386 
BL33364 
HMS0
0236  NE      
CG4266
5 
FBgn02
61547 
Exn 
BL33373 
HMS0
0246  NE      
CG9351 FBgn00
24555 
flfl 
BL33374 
HMS0
0247  NE      
CG8874 FBgn00
00723 
Fps85D 
BL33375 
HMS0
0249  NE      
CG9434 FBgn00
37724 
Fst 
BL33376 
HMS0
0250  NE      
CG3395
6 
FBgn00
01297 
kay 
BL33379 
HMS0
0254  NE      
CG9412 FBgn00
15778 
rin 
BL33392 
HMS0
0269  NE      
CG4273
4 
FBgn02
61788 
Ank2 
BL33414 
HMS0
0295  NE      
CG6993 FBgn00
03513 
ss 
BL33415 
HMS0
0296  NE      
CG2198 FBgn00
00071 
Ama 
BL33416 
HMS0
0297 A ME ME   E  
CG3113
2 
FBgn00
11785 
BRWD3 
BL33421 
HMS0
0304  NE      
CG1228
4 
FBgn02
60635 
th 
BL33597 
HMS0
0752  NE      
CG4286
5 
FBgn02
62139 
trh 
BL33612 
HMS0
0002  NE      
CG4006 FBgn00
10379 
Akt1 
BL33615 
HMS0
0007 E-L E-L ME MS E-L ME NE 
CG1042
2 
FBgn00
00158 
bam 
BL33631 
HMS0
0029  NE      
CG4257 FBgn00
16917 
Stat92E 
BL33637 
HMS0
0035  NE      
CG3220
6 
FBgn00
52206 
CG32206 
BL33645 
HMS0
0046  NE      
CG5670 FBgn00
02921 
Atpalpha 
BL33646 
HMS0
0047 
E-L E-L 
NE NE E-L  NE 
CG9745 FBgn00
00412 
D1 
BL33655 
HMS0
0061 A E E   E  
CG1199
2 
FBgn00
14018 
Rel 
BL33661 
HMS0
0070  NE      
CG1462 FBgn00
16123 
Aph-4 
BL33673 
HMS0
0537  NE      
CG7917 FBgn00
16685 
Nlp 
BL33688 
HMS0
0556  NE      
CG6148 FBgn00
16693 
Past1 
BL33689 
HMS0
0557  NE      
CG3978 FBgn00
03117 
pnr 
BL33697 
HMS0
0570  NE      
CG1103
3 
FBgn00
37659 
Kdm2 
BL33699 
HMS0
0574  NE      
CG8651 FBgn00
03862 
trx 
BL33703 
HMS0
0580  NE      
CG1714
9 
FBgn02
60397 
Su(var)3-3 
BL33726 
HMS0
0608  NE      
CG6030 FBgn00
16120 
ATPsyn-d 
BL33740 
HMS0
1078  NE      
CG9473 FBgn00
24330 
MED6 
BL33743 
HMS0
1081 MS MS  S MS  NE 
CG7281 FBgn00
04597 
CycC 
BL33753 
HMS0
1095  NE      
366 
 
CG5201 FBgn00
20493 
Dad 
BL33759 
HMS0
1102  NE      
CG1000
2 
FBgn00
00659 
fkh 
BL33760 
HMS0
1103  NE      
CG2047 FBgn00
01077 
ftz 
BL33761 
HMS0
1104  NE      
CG1034 FBgn00
00166 
bcd 
BL33886 
HMS0
0824  NE      
CG1759
4 
FBgn00
28993 
scro 
BL33890 
HMS0
0828  NE      
CG7951 FBgn00
15542 
sima 
BL33894 
HMS0
0832  NE      
CG3412 FBgn00
23423 
slmb 
BL33898 
HMS0
0838  NE      
CG8573 FBgn00
03567 
su(Hw) 
BL33906 
HMS0
0848  NE      
CG9809 FBgn00
37248 
Spargel 
BL33914 
HMS0
0857  NE      
CG9809 FBgn00
37248 
Spargel 
BL33915 
HMS0
0858  NE      
CG4974 FBgn02
63930 
dally 
BL33952 
HMS0
0905  NE      
CG9769 FBgn00
37270 
eIF3f1 
BL33980 
HMS0
0940  NE      
CG1112 FBgn00
15575 
alpha-Est7 
BL33992 
HMS0
0955  NE      
CG1727
3 
FBgn00
27493 
CG17273 
BL33993 
HMS0
0956  NE      
CG9656 FBgn00
01138 
grn 
BL34014 
HMS0
0980  NE      
CG4266
9 
FBgn02
61551 
CG42669 
BL34016 
HMS0
0985  NE      
CG1023
0 
FBgn00
28691 
Rpn9 
BL34034 
HMS0
1007  NE      
CG8580 FBgn00
82598 
akirin 
BL34036 
HMS0
1010  NE      
CG3348
4 
FBgn00
52311 
zormin 
BL34039 
HMS0
1014  NE      
CG1207
2 
FBgn00
11739 
wts 
BL34064 
HMS0
0026  NE      
CG8522 FBgn02
61283 
HLH106 
BL34073 
HMS0
0080  NE      
CG6625 FBgn02
50791 
Snap 
BL34088 
HMS0
0872  NE      
CG2017 FBgn00
37391 
CG2017 
BL34097 
HMS0
0976  NE      
CG3619 FBgn00
00463 
Dl 
BL34322 
HMS0
1309 A E-L E-L   E-L  
CG1378 FBgn00
03720 
tll 
BL34329 
HMS0
1316  NE      
CG1236
0 
FBgn00
38111 
CG12360 
BL34341 
HMS0
1329  NE      
CG9805 FBgn00
37249 
eIF3-S10 
BL34353 
HMS0
1342 
(MS 
POSSIBL
E) NE ME MS ME E  
CG5232 FBgn00
38045 
Sas 
BL34357 
HMS0
1346  NE      
CG9374 FBgn00
38167 
lkb1 
BL34362 
HMS0
1351  NE      
CG3222
6 
FBgn00
52226 
Pex23 
BL34370 
HMS0
1359  NE      
CG8287 FBgn02
62518 
Rab8 
BL34373 
HMS0
1363  NE      
CG8417 FBgn00
37744 
MPI 
BL34379 
HMS0
1369 E E NE S NE  NE 
CG1852
5 
FBgn00
28984 
Spn5 
BL34381 
HMS0
1371  NE      
CG1218 FBgn00
37377 
CG1218 
BL34389 
HMS0
1383  NE      
367 
 
CG1854
9 
FBgn00
38053 
CG18549 
BL34391 
HMS0
1385  NE      
CG6284 FBgn00
37802 
Sirt6 
BL34530 
HMS0
1009  NE      
CG1100 FBgn00
28690 
Rpn5 
BL34532 
HMS0
0971  NE      
CG4257
5 
FBgn02
60795 
CG42575 
BL34549 
HMS0
1021  NE      
CG1982 FBgn00
24289 
Sodh-1 
BL34556 
HMS0
1028  NE      
CG3027 FBgn00
37513 
pyd3 
BL34557 
HMS0
1029  NE      
CG9773 FBgn00
37609 
CG9773 
BL34570 
HMS0
1044  NE      
CG4608 FBgn00
14135 
bnl 
BL34572 
HMS0
1046  NE      
CG1057 FBgn00
37262 
MED31 
BL34574 
HMS0
1048  NE      
CG1245 FBgn00
37359 
MED27 
BL34576 
HMS0
1050  NE      
CG2943 FBgn00
37530 
CG2943 
BL34581 
HMS0
1055  NE      
CG1196
8 
FBgn00
37647 
RagA 
BL34590 
HMS0
1064  NE      
CG1199
9 
FBgn00
37312 
CG11999 
BL34604 
HMS0
0565  NE      
CG9375 FBgn00
03205 
Ras85D 
BL34619 
HMS0
1294  NE      
CG1101 FBgn00
10774 
Ref1 
BL34626 
HMS0
1301  NE      
CG1046 FBgn00
04053 
zen 
BL34635 
HMS0
1109  NE      
CG1711
7 
FBgn00
01235 
hth 
BL34637 
HMS0
1112  NE      
CG1048 FBgn00
04054 
zen2 
BL34649 
HMS0
1124  NE      
CG4674 FBgn00
37856 
CG4674 
BL34660 
HMS0
1137  NE      
CG5208 FBgn00
28470 
Patr-1 
BL34667 
HMS0
1144  NE      
CG3320 FBgn00
16700 
Rab1 
BL34670 
HMS0
1148  NE      
CG3397
6 
FBgn00
38063 
Octbeta2R 
BL34673 
HMS0
1151  NE      
CG1009 FBgn02
61243 
Psa 
BL34674 
HMS0
1152  NE      
CG4258
4 
FBgn02
60874 
Ir76a 
BL34678 
HMS0
1156  NE      
CG8412 FBgn00
37743 
CG8412 
BL34680 
HMS0
1158  NE      
CG1702
3 
FBgn00
24804 
Dbp80 
BL34682 
HMS0
1160  NE      
CG2023 FBgn00
37383 
CG2023 
BL34693 
HMS0
1172  NE      
CG6134 FBgn00
03495 
spz 
BL34699 
HMS0
1178  NE      
CG6127 FBgn00
04197 
Ser 
BL34700 
HMS0
1179  NE      
CG2102 FBgn00
04878 
cas 
BL34701 
HMS0
1180  NE      
CG5460 FBgn00
01169 
H 
BL34703 
HMS0
1182 A ME ME   ME  
CG9786 FBgn00
01180 
hb 
BL34704 
HMS0
1183  NE      
CG1133 FBgn00
03002 
opa 
BL34706 
HMS0
1185  NE      
CG9475 FBgn00
37742 
Rpt3R 
BL34713 
HMS0
1192  NE      
CG1739
7 
FBgn00
40020 
MED21 
BL34731 
HMS0
1211 S S  S MS  NE 
368 
 
CG4227
9 
FBgn02
59174 
Nedd4 
BL34741 
HMS0
1221  NE      
CG5475 FBgn00
15765 
Mpk2 
BL34744 
HMS0
1224  NE      
CG2128 FBgn00
25825 
Hdac3 
BL34778 
HMS0
0087  NE      
CG5378 FBgn00
28688 
Rpn7 
BL34787 
HMS0
0096 A E-L E   E  
CG5289 FBgn00
15282 
Pros26.4 
BL34795 
HMS0
0104 A E-L E   E  
CG4913 FBgn00
26441 
ear 
BL34798 
HMS0
0107 MS MS  MS MS  NE 
CG7439 FBgn00
87035 
AGO2 
BL34799 
HMS0
0108  NE      
CG8273 FBgn00
37716 
CG8273 
BL34805 
HMS0
0114  NE      
CG9772 FBgn00
37236 
Skp2 
BL34807 
HMS0
0116  NE      
CG3158 FBgn00
03483 
spn-E 
BL34808 
HMS0
0117  NE      
CG1027
9 
FBgn00
03261 
Rm62 
BL34829 
HMS0
0144  NE      
CG1395 FBgn00
03525 
stg 
BL34831 
HMS0
0146 A E E   E  
CG1075
3 
FBgn02
61933 
SmD1 
BL34834 
HMS0
0150  NE      
CG2925 FBgn00
14366 
noi 
BL34845 
HMS0
0163  NE      
CG1735
8 
FBgn00
11290 
Taf12 
BL34852 
HMS0
0170  NE      
CG4377
2 
FBgn02
64272 
mwh 
BL34862 
HMS0
0180  NE      
CG8120 FBgn00
37675 
HP1e 
BL34863 
HMS0
0181  NE      
CG1084 FBgn00
37240 
Cont 
BL34867 
HMS0
0186 E-L E-L NE MS MS  NE 
CG1198
1 
FBgn00
26380 
Prosbeta3 
BL34868 
HMS0
0187 A E-L ME S E-L E  
CG1451 FBgn00
15589 
Apc 
BL34869 
HMS0
0188  NE      
CG7437 FBgn02
62737 
mub 
BL34870 
HMS0
0189  NE      
CG3119
6 
FBgn00
20238 
14-3-3epsilon 
BL34884 
HMS0
1229  NE      
CG2244 FBgn00
27951 
MTA1-like 
BL34905 
HMS0
1251  NE      
CG3310
1 
FBgn00
13998 
Nsf2 
BL34914 
HMS0
1262  NE      
CG1874
0 
FBgn00
02783 
mor 
BL34919 
HMS0
1267  NE      
CG3321
4 
FBgn02
64561 
Glg1 
BL34921 
HMS0
1270  NE      
CG7508 FBgn00
10433 
ato 
BL34929 
HMS0
1278  NE      
CG8351 FBgn00
37632 
Tcp-1eta 
BL34931 
HMS0
1281  NE      
CG6598 FBgn00
11768 
Fdh 
BL34937 
HMS0
1268  NE      
CG2926 FBgn00
37344 
CG2926 
BL34941 
HMS0
0216  NE      
CG4267
4 
FBgn02
61556 
CG42674 
BL34943 
HMS0
0228  NE      
CG6203 FBgn00
28734 
Fmr1 
BL34944 
HMS0
0248  NE      
CG1827
1 
FBgn00
37263 
slx1 
BL34949 
HMS0
0313  NE      
CG1188
8 
FBgn00
28692 
Rpn2 
BL34961 
HMS0
0533  NE      
CG8977 FBgn00
15019 
Cctgamma 
BL34969 
HMS0
0884  NE      
369 
 
CG2684 FBgn00
02542 
lds 
BL34980 
HMS0
1389  NE      
CG1038
8 
FBgn00
03944 
Ubx 
BL34993 
HMS0
1403  NE      
CG9347 FBgn00
02937 
ninaB 
BL34994 
HMS0
1404 A ME ME   E  
CG6017 FBgn02
59824 
Hip14 
BL35012 
HMS0
1422  NE      
CG1488
7 
FBgn00
04087 
Dhfr 
BL35015 
HMS0
1428  NE      
CG7937 FBgn00
04863 
C15 
BL35018 
HMS0
1431  NE      
CG7223 FBgn00
10389 
htl 
BL35024 
HMS0
1437  NE      
CG1135 FBgn02
63832 
Rcd5 
BL35026 
HMS0
1439  NE      
CG1707
7 
FBgn00
03118 
pnt 
BL35038 
HMS0
1452 A E E   E  
CG1006
1 
FBgn00
11020 
Sas-4 
BL35049 
HMS0
1463  NE      
CG5954 FBgn00
02441 
l(3)mbt 
BL35052 
HMS0
1466  NE      
CG1945 FBgn00
05632 
faf 
BL35728 
HMS0
1470  NE      
CG8279 FBgn00
38237 
Pde6 
BL35743 
HMS0
1485  NE      
CG1202
1 
FBgn00
67864 
Patj 
BL35747 
HMS0
1489  NE      
CG6338 FBgn00
04510 
Ets97D 
BL35749 
HMS0
1491  NE      
CG1588
7 
FBgn00
38132 
CG15887 
BL35751 
HMS0
1494  NE      
CG3937 FBgn00
14141 
cher 
BL35755 
HMS0
1501  NE      
CG8384 FBgn00
01139 
gro 
BL35759 
HMS0
1506  NE      
CG7538 FBgn00
14861 
Mcm2 
BL35771 
HMS0
1520  NE      
CG5844 FBgn00
38049 
CG5844 
BL35776 
HMS0
1525  NE      
CG9925 FBgn00
38191 
CG9925 
BL35811 
HMS0
1514  NE      
CG3992 FBgn00
03507 
srp 
BL35813 
HMS0
1208  NE      
CG4115 FBgn00
38017 
CG4115 
BL35814 
HMS0
1446 A E-L E   E  
CG9764 FBgn00
04049 
yrt 
BL36118 
HMS0
1532  NE      
CG6376 FBgn00
11766 
E2f 
BL36126 
HMS0
1541  NE      
CG1049
8 
FBgn00
04107 
cdc2c 
BL36128 
HMS0
1543  NE      
CG7643 FBgn00
00063 
ald 
BL36658 
HMS0
1546  NE      
CG9734 FBgn00
27657 
glob1 
BL36668 
HMS0
1556  NE      
CG1467
5 
FBgn00
37385 
glob3 
BL36670 
HMS0
1558  NE      
CG6008 FBgn00
27785 
NP15.6 
BL36672 
HMS0
1560  NE      
CG3265 FBgn00
27066 
Eb1 
BL36680 
HMS0
1568  NE      
CG6235 FBgn00
04889 
tws 
BL36689 
HMS0
1578  NE      
CG2184 FBgn00
02773 
Mlc2 
BL36694 
HMS0
1583 S S  MS NE  NE 
CG7507 FBgn02
61797 
Dhc64C 
BL36698 
HMS0
1587  NE      
CG3246
4 
FBgn00
13576 
mtd/OXR1 
BL36718 
HMS0
1608  NE      
370 
 
CG3248
4 
FBgn00
52484 
Sk2 
BL36741 
HMS0
3001  NE      
CG1856 FBgn00
03870 
ttk 
BL36748 
HMS0
3008  NE      
CG1466
9 
FBgn00
37326 
CG14669 
BL36750 
HMS0
3010  NE      
CG3236
4 
FBgn00
52364 
CG32364 
BL36752 
HMS0
3012 A E ME   E  
CG1199
7 
FBgn00
37662 
CG11997 
BL36753 
HMS0
3013  NE      
CG1347 FBgn00
37363 
CG1347 
BL36918 
HMS0
1611  NE      
CG5518 FBgn00
15541 
sda 
BL37494 
HMS0
1636  NE      
CG1200
1 
FBgn00
37265 
CG12001 
BL37499 
HMS0
1641  NE      
CG5206 FBgn00
23097 
bon 
BL37515 
HMS0
1657  NE      
CG1085
1 
FBgn00
04587 
B52 
BL37519 
HMS0
1661  NE      
CG1173
9 
FBgn00
37239 
CG11739 
BL38230 
HMS0
1674  NE      
CG6213 FBgn00
26753 
Vha13 
BL38233 
HMS0
1677  NE      
CG3153 FBgn00
38198 
Npc2b 
BL38238 
HMS0
1682  NE      
CG8208 FBgn00
27950 
MBD-like 
BL38239 
HMS0
1683  NE      
CG9755 FBgn00
03165 
pum 
BL38241 
HMS0
1685  NE      
CG1012
0 
FBgn00
02719 
Men 
BL38256 
HMS0
1700  NE      
CG9779 FBgn00
37231 
vps24 
BL38281 
HMS0
1733  NE      
CG1071
1 
FBgn00
86785 
Vps36 
BL38286 
HMS0
1739  NE      
CG9379 FBgn00
00244 
by 
BL38288 
HMS0
1743  NE      
CG3911 FBgn02
60859 
Bet3 
BL38302 
HMS0
1764  NE      
CG9424 FBgn00
37719 
bocksbeutel 
BL38349 
HMS0
1817  NE      
CG3571 FBgn00
37978 
KLHL18 
BL38352 
HMS0
1820  NE      
CG5730 FBgn00
00083 
AnnIX 
BL38523 
HMS0
1719  NE      
CG3279 FBgn02
60862 
Vti1 
BL38526 
HMS0
1727  NE      
CG4848 FBgn00
37998 
CG4848 
BL38943 
HMS0
1857  NE      
CG6238 FBgn00
29157 
ssh 
BL38948 
HMS0
1862 A E E   E  
CG5643 FBgn00
27492 
wdb 
BL38950 
HMS0
1864  NE      
CG4224
7 
FBgn02
59099 
DCX-EMAP 
BL38964 
HMS0
1878  NE      
CG3101
2 
FBgn00
27598 
cindr 
BL38976 
HMS0
1892  NE      
CG1715 FBgn00
10808 
l(3)03670 
BL38984 
HMS0
1900  NE      
CG5000 FBgn00
27948 
msps 
BL38990 
HMS0
1906  NE      
CG1088 FBgn00
15324 
Vha26 
BL38996 
HMS0
1912  NE      
CG9601 FBgn00
37578 
CG9601 
BL39003 
HMS0
1919  NE      
CG1151
6 
FBgn00
04369 
Ptp99A 
BL39006 
HMS0
1923 MS MS  S NE  NE 
CG1228 FBgn02
61985 
Ptpmeg 
BL39007 
HMS0
1924  NE      
371 
 
CG5720 FBgn00
28471 
Nab2 
BL39008 
HMS0
1925  NE      
CG1004
7 
FBgn00
28400 
Syt4 
BL39016 
HMS0
1934  NE      
CG1471
8 
FBgn00
37939 
CG14718 
BL39018 
HMS0
1936  NE      
CG7904 FBgn00
03169 
put 
BL39025 
HMS0
1944  NE      
CG8478 FBgn00
37746 
CG8478 
BL39033 
HMS0
1952  NE      
CG5658 FBgn00
04387 
Klp98A 
BL39037 
HMS0
1957  NE      
CG2097 FBgn00
37371 
Sym 
BL39041 
HMS0
1961  NE      
CG1058 FBgn00
22981 
rpk 
BL39053 
HMS0
1973 MS MS ME S E ME NE 
CG1499
8 
FBgn02
64693 
ens 
BL40825 
HMS0
0933  NE      
CG2185 FBgn00
37358 
elm 
BL40843 
HMS0
2009  NE      
CG5505 FBgn02
60936 
scny 
BL40865 
HMS0
2032  NE      
CG1217
0 
FBgn00
37356 
CG12170 
BL40867 
HMS0
2034  NE      
CG1736
9 
FBgn00
05671 
Vha55 
BL40884 
HMS0
2132  NE      
CG6378 FBgn00
26562 
BM-40-SPARC 
BL40885 
HMS0
2133  NE      
CG7749 FBgn02
61574 
kug 
BL40888 
HMS0
2136  NE      
CG5608 FBgn00
38058 
CG5608 
BL40892 
HMS0
2140  NE      
CG6120 FBgn00
27865 
Tsp96F 
BL40901 
HMS0
2149  NE      
CG2330 FBgn00
37447 
Neurochondrin 
BL40903 
HMS0
2151  NE      
CG4394
6 
FBgn02
64574 
Glut1 
BL40904 
HMS0
2152  NE      
CG6593 FBgn00
03134 
Pp1alpha-96A 
BL40906 
HMS0
2154  NE      
CG4374
3 
FBgn02
64000 
Glu-RIB 
BL40908 
HMS0
2156  NE      
CG7581 FBgn00
25457 
Bub3 
BL40910 
HMS0
2158  NE      
CG7807 FBgn02
61953 
AP-2 
BL40911 
HMS0
2159  NE      
CG8136 FBgn00
37616 
CG8136 
BL40918 
HMS0
2166  NE      
CG1128
6 
FBgn00
37516 
CG11286 
BL40919 
HMS0
2167  NE      
CG4035
1 
FBgn00
40022 
Set1 
BL40931 
HMS0
2179  NE      
CG2902 FBgn00
10399 
Nmdar1 
BL41667 
HMS0
2200  NE      
CG5507 FBgn00
04359 
T48 
BL41684 
HMS0
2248  NE      
CG4843 FBgn00
04117 
Tm2 
BL41695 
HMS0
2260  NE      
CG4409
9 
FBgn02
64908 
pHCl 
BL41700 
HMS0
2265  NE      
CG1106 FBgn00
10225 
Gel 
BL41704 
HMS0
2269  NE      
CG1029
5 
FBgn00
14001 
Pak 
BL41714 
HMS0
2279  NE      
CG7996 FBgn00
03450 
snk 
BL41723 
HMS0
2289  NE      
CG8342 FBgn00
02578 
m1 
BL41886 
HMS0
2308  NE      
CG3068 FBgn00
00147 
aur 
BL41889 
HMS0
2205  NE      
372 
 
CG1195
8 
FBgn00
15622 
Cnx99A 
BL41911 
HMS0
2304  NE      
CG3218
3 
FBgn00
52183 
Ccn 
BL41913 
HMS0
2310  NE      
CG1077
2 
FBgn00
04509 
Fur1 
BL41914 
HMS0
2311  NE      
CG3373 FBgn00
15737 
Hmu 
BL41915 
HMS0
2312  NE      
CG1408
4 
FBgn02
60857 
Bet1 
BL41927 
HMS0
2324  NE      
CG5974 FBgn00
10441 
pll 
BL41935 
HMS0
2332  NE      
CG9797 FBgn00
37621 
CG9797 
BL41937 
HMS0
2334  NE      
CG6359 FBgn00
38065 
Snx3 
BL41947 
HMS0
2344  NE      
CG5814 FBgn00
15625 
CycB3 
BL41979 
HMS0
2377  NE      
CG6932 FBgn00
28837 
CSN6 
BL41991 
HMS0
2392  NE      
CG4312
8 
FBgn02
62593 
Shab 
BL41999 
HMS0
2400  NE      
CG7756 FBgn00
01217 
Hsc70-2 
BL42014 
HMS0
2415  NE      
CG2051 FBgn00
37376 
CG2051 
BL42488 
HMJ0
2050  NE      
CG9727 FBgn00
37445 
CG9727 
BL42495 
HMJ0
2059  NE      
CG2087 FBgn00
37327 
PERK/PEK 
BL42499 
HMJ0
2063  NE      
CG4245
8 
FBgn02
59935 
CG42458 
BL42506 
HMJ0
2071  NE      
CG4397
6 
FBgn02
64707 
RhoGEF3 
BL42526 
HMJ0
2092  NE      
CG1098 FBgn00
27497 
Madm 
BL42529 
HMJ0
2096  NE      
CG5264 FBgn00
14949 
btn 
BL42530 
HMJ0
2097  NE      
CG1176
2 
FBgn00
37618 
CG11762 
BL42531 
HMJ0
2098  NE      
CG2210 FBgn00
00150 
awd 
BL42532 
HMJ0
2099  NE      
CG6384 FBgn00
00283 
Cp190 
BL42536 
HMJ0
2105  NE      
CG3229
6 
FBgn00
52296 
Mrtf 
BL42537 
HMJ0
2106 MS MS  MS E  NE 
CG1722
8 
FBgn00
04595 
pros 
BL42538 
HMJ0
2107 A ME E S  E-L  
CG3213
0 
FBgn00
86708 
stv 
BL42564 
HMJ0
2221  NE      
CG6027 FBgn00
04876 
cdi 
BL42568 
HMJ0
2227  NE      
CG7693 FBgn00
23083 
fray 
BL42569 
HMJ0
2228  NE      
CG4317
3 
FBgn02
62792 
CG43173 
BL42584 
HMS0
2369  NE      
CG4389
6 
FBgn02
64488 
CG43896 
BL42585 
HMS0
2417  NE      
CG1235
7 
FBgn00
22943 
Cbp20 
BL42596 
HMS0
2428  NE      
CG1214
7 
FBgn00
37325 
CG12147 
BL42612 
HMS0
2447  NE      
CG1736
7 
FBgn00
28717 
Lnk 
BL42613 
HMS0
2448  NE      
CG6014 FBgn02
61258 
rgn 
BL42619 
HMS0
2454  NE      
CG6489 FBgn00
13279 
Hsp70Bc 
BL42626 
HMS0
2461  NE      
CG2530 FBgn00
10313 
corto 
BL42629 
HMS0
2464  NE      
373 
 
CG2013 FBgn00
04436 
UbcD6 
BL42631 
HMS0
2466 A E-L E   E  
CG6188 FBgn00
38074 
CG6188 
BL42637 
HMS0
2473  NE      
CG4316 FBgn00
03319 
Sb 
BL42647 
HMS0
2483  NE      
CG1829
0 
FBgn00
00046 
Act87E 
BL42652 
HMS0
2488  NE      
CG9738 FBgn00
24326 
Mkk4 
BL42832 
HMS0
2524  NE      
CG1224
2 
FBgn00
10041 
GstD5 
BL42842 
HMS0
2534  NE      
CG1435
5 
FBgn00
38208 
CG14355 
BL42857 
HMS0
2549  NE      
CG8793 FBgn02
60655 
l(3)76BDm 
BL42870 
HMS0
2563  NE      
CG1897 FBgn00
00492 
Dr 
BL42891 
HMS0
2584  NE      
CG9476 FBgn00
03886 
alphaTub85E 
BL42905 
HMS0
2598  NE      
CG1239 FBgn00
37368 
CG1239 
BL42912 
HMS0
2605  NE      
CG1167
2 
FBgn00
37563 
CG11672 
BL42913 
HMS0
2606  NE      
CG9345 FBgn00
38173 
Adgf-C 
BL42915 
HMS0
2608 E-L E-L ME ME E NE NE 
CG4067 FBgn00
20385 
pug 
BL42950 
HMS0
2643  NE      
CG8489 FBgn00
38225 
soti 
BL42955 
HMS0
2648  NE      
CG3144
9 
FBgn00
13277 
Hsp70Ba 
BL43289 
HMS0
2661  NE      
CG2867 FBgn00
04901 
Prat 
BL43296 
HMS0
2669  NE      
CG1169 FBgn00
37428 
Osi18 
BL43302 
HMS0
2675  NE      
CG6467 FBgn02
50815 
Jon65Aiv 
BL43306 
HMS0
2689  NE      
CG3321
7 
FBgn00
53217 
CG33217 
BL43315 
HMS0
2699  NE      
CG1467
6 
FBgn00
37388 
CG14676 
BL43316 
HMS0
2700  NE      
CG4374
4 
FBgn02
64001 
bru-3 
BL43318 
HMS0
2702  NE      
CG3242
3 
FBgn00
52423 
shep 
BL43545 
HMS0
2666  NE      
CG3916 FBgn00
38003 
CG3916 
BL43992 
HMS0
2705  NE      
CG6438 FBgn00
23179 
amon 
BL44001 
HMS0
2715  NE      
CG1167
1 
FBgn00
37562 
CG11671 
BL44003 
HMS0
2717  NE      
CG6939 FBgn00
25802 
Sbf 
BL44004 
HMS0
2718  NE      
CG1115 FBgn00
37299 
CG1115 
BL44010 
HMS0
2724  NE      
CG3219
0 
FBgn00
52190 
NUCB1 
BL44019 
HMS0
2734  NE      
CG1096
7 
FBgn02
60945 
Atg1 
BL44034 
HMS0
2750  NE      
CG3245
1 
FBgn00
52451 
SPoCk 
BL44040 
HMS0
2756  NE      
CG1196
6 
FBgn00
37645 
CG11966 
BL44046 
HMS0
2762 A ME ME   E  
CG5499 FBgn00
01197 
His2Av 
BL44056 
HMS0
2773 MS MS  NE E  NE 
CG3129
3 
FBgn00
03227 
rec 
BL44057 
HMS0
2774  NE      
CG8362 FBgn00
28997 
nmdyn-D7 
BL44058 
HMS0
2775  NE      
374 
 
CG1484
1 
FBgn00
38218 
CG14841 
BL44059 
HMS0
2776  NE      
CG1142
2 
FBgn00
10403 
Obp83b 
BL44065 
HMS0
2782  NE      
CG1469 FBgn00
15221 
Fer2LCH 
BL44067 
HMS0
2784  NE      
CG1954 FBgn00
03093 
Pkc98E 
BL44074 
HMS0
2791  NE      
CG1910 FBgn00
22349 
CG1910 
BL44082 
HMS0
2799  NE      
CG1674
9 
FBgn00
37678 
CG16749 
BL44096 
HMS0
2816  NE      
CG3971 FBgn02
60960 
Baldspot 
BL44101 
HMS0
2821  NE      
CG3066 FBgn00
37515 
Sp7 
BL44108 
HMS0
2829  NE      
CG3397 FBgn00
37975 
CG3397 
BL44115 
HMS0
2837  NE      
CG4029 FBgn00
15396 
jumu 
BL44117 
HMS0
2839  NE      
CG4016
0 
FBgn00
58160 
CG40160 
BL44268 
HMS0
2730  NE      
CG3103
9 
FBgn00
03358 
Jon99Ci 
BL44269 
HMS0
2766  NE      
CG6567 FBgn00
37842 
CG6567 
BL44479 
HMC0
2369  NE      
CG1003
2 
FBgn00
37493 
CG10032 
BL44501 
HMC0
2437 MS MS  NE NE  NE 
CG1005
9 
FBgn00
37481 
MAGE 
BL44514 
HMC0
2904 A ME ME   E  
CG1281
7 
FBgn00
37798 
CG12817 
BL44529 
HMC0
2923  NE      
CG4030
0 
FBgn02
50816 
AGO3 
BL44543 
HMC0
2938  NE      
CG9995 FBgn00
27655 
htt 
BL44550 
HMS0
2845  NE      
CG1558
9 
FBgn00
37409 
Osi24 
BL44564 
HMS0
2860  NE      
CG1468
3 
FBgn00
37822 
CG14683 
BL44571 
HMS0
2867  NE      
CG1119 FBgn00
04913 
Gnf1 
BL44572 
HMS0
2868  NE      
CG3237
2 
FBgn00
52372 
ltl 
BL44577 
HMS0
2873  NE      
CG4017
8 
FBgn00
58178 
CG40178 
BL44578 
HMS0
2874  NE      
CG5553 FBgn02
59676 
DNApol-alpha60 
BL44584 
HMS0
2881  NE      
CG6672 FBgn00
37875 
CG6672 
BL44586 
HMS0
2884  NE      
CG2019 FBgn00
29088 
disp 
BL44633 
HMS0
2877  NE      
CG9920 FBgn00
38200 
CG9920 
BL44657 
HMC0
2438  NE      
CG2747 FBgn00
37541 
CG2747 
BL44662 
HMS0
2848  NE      
CG1025
0 
FBgn00
02922 
nau 
BL50607 
HMC0
2974  NE      
CG6706 FBgn00
27575 
GABA-B-R2 
BL50608 
HMC0
2975  NE      
CG1263 FBgn02
61602 
RpL8 
BL50610 
HMC0
2977 A E E   E  
CG3326
5 
FBgn00
53265 
Muc68E 
BL50618 
HMC0
2985  NE      
CG3106
2 
FBgn00
16061 
side 
BL50642 
HMC0
3042  NE      
CG9459 FBgn00
37764 
CG9459 
BL50647 
HMC0
3047  NE      
CG5214 FBgn00
37891 
CG5214 
BL50650 
HMC0
3051  NE      
375 
 
CG1003
7 
FBgn00
86680 
vvl 
BL50657 
HMC0
3058 A ME ME   ME  
CG1030 FBgn00
03339 
Scr 
BL50662 
HMC0
3063  NE      
CG7895 FBgn00
04110 
tin 
BL50663 
HMC0
3064  NE      
CG3332
3 
FBgn00
37475 
Fer1 
BL50672 
HMC0
3073  NE      
CG2988 FBgn00
00576 
ems 
BL50673 
HMC0
3074  NE      
CG1454
8 
FBgn00
02733 
HLHmbeta 
BL50674 
HMC0
3075  NE      
CG3235
4 
FBgn00
52354 
CG32354 
BL50693 
HMC0
3095  NE      
CG1295
1 
FBgn00
37677 
CG12951 
BL50698 
HMC0
3100  NE      
CG3103
4 
FBgn00
03356 
Jon99Cii 
BL50705 
HMC0
3107  NE      
CG2781 FBgn00
37534 
CG2781 
BL50710 
HMC0
3112  NE      
CG5931 FBgn02
63599 
l(3)72Ab 
BL50716 
HMS0
2950 A ME ME   E  
CG4389
4 
FBgn02
64486 
CG43894 
BL50718 
HMS0
2952  NE      
CG3124
0 
FBgn00
11701 
repo 
BL50735 
HMS0
2971  NE      
CG2189 FBgn00
00439 
Dfd 
BL50792 
HMC0
3094  NE      
CG1957 FBgn00
27873 
Cpsf100 
BL50893 
HMC0
2355  NE      
CG3435
6 
FBgn00
85385 
CG34356 
BL50912 
HMJ0
3136  NE      
CG3329
0 
FBgn00
53290 
CG33290 
BL50916 
HMJ2
1005  NE      
CG3326
7 
FBgn00
53267 
CG33267 
BL50929 
HMJ2
1023  NE      
CG4316
3 
FBgn02
62719 
CG43163 
BL50958 
HMJ2
1060  NE      
CG1217
3 
FBgn00
37305 
CG12173 
BL50977 
HMJ2
1083  NE      
CG1159
8 
FBgn00
38067 
CG11598 
BL51000 
HMJ2
1113  NE      
CG3397
1 
FBgn00
53971 
Ir62a 
BL51026 
HMJ2
1152  NE      
CG3328
6 
FBgn00
53286 
CG33286 
BL51029 
HMJ2
1156  NE      
CG1465
5 
FBgn00
37275 
CG14655 
BL51031 
HMJ2
1158  NE      
CG3772 FBgn00
25680 
cry 
BL51033 
HMJ2
1160  NE      
CG7129 FBgn00
10877 
l(3)05822 
BL51159 
HMC0
2398  NE      
CG5807 FBgn00
27539 
CG5807 
BL51163 
HMJ0
3117  NE      
CG1164
8 
FBgn00
00015 
Abd-B 
BL51167 
HMJ0
3133  NE      
CG3379 FBgn00
13981 
His4r 
BL51172 
HMJ2
1134  NE      
CG1823
4 
FBgn02
65268 
CG18234 
BL51173 
HMJ2
1135  NE      
CG1000
5 
FBgn00
37972 
CG10005 
BL51174 
HMJ2
1137  NE      
CG4706 FBgn00
37862 
CG4706 
BL51359 
HMC0
3203  NE      
CG4261
0 
FBgn02
61259 
Fhos 
BL51391 
HMJ2
1037  NE      
CG1439
4 
FBgn00
38079 
CG14394 
BL51420 
HMC0
2385  NE      
CG1874
1 
FBgn00
15129 
DopR2 
BL51423 
HMC0
2893  NE      
376 
 
CG6225 FBgn00
38072 
CG6225 
BL51435 
HMC0
3149  NE      
CG3220
3 
FBgn00
52203 
Spn75F 
BL51437 
HMC0
3151  NE      
CG9749 FBgn00
20510 
Abi 
BL51455 
HMC0
3190  NE      
CG3104
5 
FBgn00
26059 
Mhcl 
BL51456 
HMC0
3191  NE      
CG3242
5 
FBgn00
52425 
CG32425 
BL51457 
HMC0
3193  NE      
CG7665 FBgn00
16650 
Lgr1 
BL51465 
HMC0
3205  NE      
CG6096 FBgn00
02631 
HLHm5 
BL51466 
HMC0
3206  NE      
CG5320 FBgn00
01098 
Gdh 
BL51473 
HMC0
3217  NE      
CG1189
9 
FBgn00
14427 
CG11899 
BL51476 
HMC0
3221  NE      
CG1359
8 
FBgn00
16754 
sba 
BL51488 
HMC0
3239  NE      
CG6868 FBgn00
03719 
tld 
BL51507 
HMC0
3275  NE      
CG4233
0 
FBgn02
63219 
Dscam4 
BL51508 
HMC0
3277  NE      
CG5557 FBgn00
10768 
sqz 
BL51509 
HMC0
3279  NE      
CG3723 FBgn00
13812 
Dhc93AB 
BL51511 
HMC0
3281  NE      
CG1216
2 
FBgn00
37329 
CG12162 
BL51514 
HMC0
3291  NE      
CG1840
2 
FBgn00
13984 
InR/IR 
BL51518 
HMS0
3166 E E NE NE E  NE 
CG7910 FBgn00
37547 
CG7910 
BL51702 
HMC0
3182  NE      
CG5663 FBgn00
00455 
Dip-C 
BL51708 
HMC0
3216  NE      
CG4412 FBgn00
16119 
ATPsyn-Cf6 
BL51714 
HMC0
3238  NE      
CG6703 FBgn00
13759 
CASK 
BL51721 
HMC0
3260  NE      
CG9492 FBgn00
37726 
CG9492 
BL51725 
HMC0
3269  NE      
CG4312 FBgn00
02869 
MtnB 
BL51731 
HMC0
3286  NE      
CG7939 FBgn00
02626 
RpL32 
BL51746 
HMC0
2350 A E-L E   E  
CG1034
5 
FBgn00
27562 
CG10345 
BL51751 
HMC0
3302  NE      
CG1677
9 
FBgn00
37698 
CG16779 
BL51756 
HMC0
3308  NE      
CG9458 FBgn00
37765 
CG9458 
BL51757 
HMC0
3309  NE      
CG8333 FBgn00
02735 
HLHmgamma 
BL51762 
HMC0
3315  NE      
CG3228
1 
FBgn00
52281 
CG32281 
BL51764 
HMC0
3318  NE      
CG7524 FBgn02
62733 
Src64B 
BL51772 
HMC0
3327  NE      
CG8103 FBgn02
62519 
Mi-2 
BL51774 
HMC0
3329 A ME ME   ME  
CG5796 FBgn00
20018 
Ppox 
BL51777 
HMC0
3332  NE      
CG1063 FBgn00
10051 
Itp-r83A 
BL51795 
HMC0
3351  NE      
CG3944 FBgn00
17567 
ND23 
BL51797 
HMC0
3353  NE      
CG9741 FBgn00
00447 
Dhod 
BL51801 
HMC0
3359  NE      
CG1520 FBgn00
24273 
WASp 
BL51802 
HMC0
3360 A ME ME   E  
377 
 
CG6303 FBgn00
37808 
Bruce 
BL51814 
HMC0
3385  NE      
CG4225
6 
FBgn02
63218 
Dscam2 
BL51839 
HMC0
3411  NE      
CG5018 FBgn02
63605 
l(3)72Dn 
BL51907 
HMC0
3482  NE      
CG1092 FBgn00
37228 
CG1092 
BL51912 
HMS0
3370  NE      
CG7948 FBgn00
03479 
spn-A 
BL51926 
HMC0
3364  NE      
CG1764
5 
FBgn00
11270 
Pglym87 
BL51939 
HMC0
3367  NE      
CG3237
4 
FBgn00
52374 
CG32374 
BL52870 
HMC0
3608  NE      
CG4234
1 
FBgn02
59243 
Pka-R1 
BL52906 
HMC0
3646  NE      
CG5276 FBgn00
37900 
CG5276 
BL52918 
HMC0
3658  NE      
CG6584 FBgn00
37847 
SelR 
BL52919 
HMC0
3659  NE      
CG1172
2 
FBgn00
37777 
CG11722 
BL52920 
HMC0
3660  NE      
CG1041 FBgn00
37440 
CG1041 
BL52921 
HMC0
3661  NE      
CG6147 FBgn00
26317 
Tsc1 
BL52931 
HMC0
3672  NE      
CG1032
8 
FBgn00
15520 
nonA-l 
BL52934 
HMC0
3676  NE      
CG1274
9 
FBgn00
04237 
Hrb87F 
BL52937 
HMC0
3679  NE      
CG5836 FBgn00
25571 
SF1 
BL52938 
HMC0
3680  NE      
CG1471
5 
FBgn00
37930 
CG14715 
BL52940 
HMJ2
1596  NE      
CG4307
9 
FBgn02
62509 
nrm 
BL52945 
HMJ2
1612  NE      
CG3248
8 
FBgn00
52488 
CG32488 
BL52949 
HMJ2
1618  NE      
CG4254
3 
FBgn02
60660 
mp 
BL52981 
HMJ2
1668  NE      
CG2911 FBgn00
37350 
CG2911 
BL52998 
HMJ2
1713  NE      
CG1451
3 
FBgn00
05596 
yemalpha 
BL53000 
HMJ2
1716  NE      
CG4257
6 
FBgn02
61526 
NT1 
BL53003 
HMJ2
1720  NE      
CG1469
4 
FBgn00
37845 
CG14694 
BL53012 
HMJ2
1734  NE      
CG1470
8 
FBgn00
37910 
CG14708 
BL53020 
HMJ2
1743  NE      
CG3442
0 
FBgn00
85449 
CG34420 
BL53032 
HMJ2
1758  NE      
CG1258
2 
FBgn00
37215 
CG12582 
BL53272 
HMC0
3488  NE      
CG1738
7 
FBgn00
37276 
CG17387 
BL53273 
HMC0
3489  NE      
CG1236 FBgn00
37370 
CG1236 
BL53274 
HMC0
3490 A ME ME   ME  
CG1009
2 
FBgn00
37526 
CG10092 
BL53275 
HMC0
3491  NE      
CG9613 FBgn00
37574 
Coq2 
BL53276 
HMC0
3492  NE      
CG9836 FBgn00
37637 
CG9836 
BL53277 
HMC0
3493  NE      
CG9361 FBgn00
37690 
Task7 
BL53279 
HMC0
3495  NE      
CG9362 FBgn00
37696 
GstZ1 
BL53280 
HMC0
3496  NE      
CG6666 FBgn00
37873 
SdhC 
BL53281 
HMC0
3497  NE      
378 
 
CG8534 FBgn00
37761 
CG8534 
BL53299 
HMC0
3518  NE      
CG1800
5 
FBgn00
37660 
beag 
BL53306 
HMC0
3533  NE      
CG8318 FBgn00
15269 
Nf1 
BL53322 
HMC0
3551  NE      
CG1315 FBgn00
26565 
CG1315 
BL53323 
HMC0
3552  NE      
CG5161 FBgn02
63604 
l(3)72Dh 
BL53328 
HMC0
3557  NE      
CG4649 FBgn00
22359 
Sodh-2 
BL53353 
HMC0
3582  NE      
CG1411 FBgn00
23023 
CRMP 
BL53354 
HMC0
3583  NE      
CG7535 FBgn00
24963 
GluClalpha 
BL53356 
HMC0
3585  NE      
CG1464
2 
FBgn00
37222 
CG14642 
BL53365 
HMC0
3594 
(ME 
POSSIBL
E) NE      
CG1740
4 
FBgn00
38001 
CG17404 
BL53370 
HMC0
3599  NE      
CG1794
4 
FBgn00
37500 
CG17944 
BL53690 
HMJ2
1673  NE      
CG8023 FBgn02
65089 
eIF4E-3 
BL53880 
HMJ2
1195  NE      
CG1037
0 
FBgn00
28684 
Tbp-1 
BL53886 
HMJ2
1204 A E E   E  
CG3103
7 
FBgn00
00247 
ca 
BL53888 
HMJ2
1206 A ME ME   E  
CG1472
3 
FBgn00
37950 
HisCl1 
BL53932 
HMJ2
1280  NE      
CG1690
5 
FBgn00
37762 
eloF 
BL53947 
HMJ2
1310  NE      
CG3215
9 
FBgn02
61799 
dsx-c73A 
BL53964 
HMJ2
1346  NE      
CG7558 FBgn02
62716 
Arp3 
BL53972 
HMJ2
1357  NE      
CG1242
0 
FBgn00
37797 
CG12420 
BL53976 
HMJ2
1365  NE      
CG1128
1 
FBgn00
86916 
snky 
BL53986 
HMJ2
1388  NE      
CG4233
3 
FBgn02
61090 
Sytbeta 
BL53996 
HMJ2
1400  NE      
CG9636 FBgn00
37556 
CG9636 
BL54009 
HMJ2
1432  NE      
CG3223
8 
FBgn00
52238 
CG32238 
BL54016 
HMJ2
1441  NE      
CG5245 FBgn00
38047 
CG5245 
BL54036 
HMJ2
1479  NE      
CG1003
8 
FBgn00
38013 
CG10038 
BL54039 
HMJ2
1482  NE      
CG9285 FBgn00
00454 
Dip-B 
BL54045 
HMJ2
1488  NE      
CG3370
3 
FBgn00
53703 
CG33703 
BL54054 
HMS0
3715  NE      
CG3925 FBgn00
37780 
CG3925 
BL54467 
HMC0
3735  NE      
CG3238
2 
FBgn00
52382 
sphinx2 
BL54468 
HMS0
3736  NE      
CG4264 FBgn00
01219 
Hsc70-4 
BL54810 
HMJ2
1529 ME ME NE S E-L  NE 
CG1331 FBgn00
04778 
Ccp84Af 
BL54821 
HMJ2
1540  NE      
CG1559
6 
FBgn00
37418 
Osi11 
BL54839 
HMJ2
1558  NE      
CG3222
0 
FBgn00
52220 
Csas 
BL54843 
HMJ2
1580  NE      
CG7642 FBgn00
03308 
ry 
BL54845 
HMJ2
1582  NE      
379 
 
CG1331
8 
FBgn00
37627 
CG13318 
BL55143 
HMC0
3739  NE      
CG2098 FBgn00
24891 
ferrochelatase 
BL55146 
HMC0
3757  NE      
CG5099 FBgn00
11666 
msi 
BL55152 
HMC0
3808  NE      
CG8464 FBgn00
38233 
HtrA2 
BL55165 
HMC0
3843  NE      
CG1196
3 
FBgn00
37643 
skap 
BL55168 
HMC0
3847  NE      
CG7878 FBgn00
37549 
CG7878 
BL55170 
HMC0
3850  NE      
CG3593 FBgn00
03257 
r-l 
BL55183 
HMC0
3871  NE      
CG9631 FBgn00
27563 
CG9631 
BL55185 
HMC0
3879  NE      
CG9649 FBgn00
38211 
CG9649 
BL55200 
HMC0
3899  NE      
CG5808 FBgn00
27617 
CG5808 
BL55208 
HMC0
3925  NE      
CG9652 FBgn00
11582 
DopR 
BL55239 
HMC0
2344  NE      
CG9684 FBgn00
37583 
CG9684 
BL55259 
HMC0
3946  NE      
CG9495 FBgn00
03334 
Scm 
BL55278 
HMC0
3965  NE      
CG6913 FBgn00
37937 
Fer3 
BL55300 
HMC0
3987  NE      
CG7672 FBgn00
04618 
gl 
BL55301 
HMC0
3988 LacZ-S MS  S MS  S 
CG8346 FBgn00
02609 
HLHm3 
BL55302 
HMC0
3989  NE      
CG6054 FBgn00
05355 
Su(fu) 
BL55315 
HMC0
4002  NE      
CG3671 FBgn00
11672 
Mvl 
BL55316 
HMC0
4003  NE      
CG6386 FBgn00
27889 
ball 
BL55330 
HMC0
4017  NE      
CG3316
0 
FBgn00
53160 
CG33160 
BL55341 
HMC0
4028  NE      
CG3505 FBgn00
38250 
CG3505 
BL55342 
HMC0
4029  NE      
CG2108 FBgn00
37364 
Rab23 
BL55352 
HMC0
4039  NE      
CG3243
8 
FBgn00
52438 
Smc5 
BL55371 
HMC0
4059  NE      
CG3150
9 
FBgn00
28396 
TotA 
BL55378 
HMC0
4066  NE      
CG1361 FBgn00
00094 
Anp 
BL55385 
HMC0
4073  NE      
CG3325 FBgn00
03480 
spn-B 
BL55403 
HMC0
4091  NE      
CG1069
3 
FBgn00
03429 
slo 
BL55405 
HMC0
4093  NE      
CG3238
3 
FBgn00
52383 
sphinx1 
BL55601 
HMC0
3898  NE      
CG3305
2 
FBgn00
53052 
CG33052 
BL55610 
HMC0
3748 A E ME   E  
CG9363 FBgn00
37697 
CG9363 
BL55634 
HMC0
3781  NE      
CG5215 FBgn02
63603 
Zn72D 
BL55635 
HMC0
3782  NE      
CG3352
2 
FBgn02
61872 
scaf6 
BL55644 
HMC0
3793  NE      
CG1109
4 
FBgn00
00504 
dsx 
BL55646 
HMC0
3795  NE      
CG3100
0 
FBgn00
11224 
heph 
BL55655 
HMC0
3805  NE      
CG6354 FBgn00
04903 
Rb97D 
BL55662 
HMC0
3817  NE      
380 
 
CG9776 FBgn00
27866 
CG9776 
BL55673 
HMC0
3831  NE      
CG1438 FBgn00
15032 
Cyp4c3 
BL55687 
HMC0
3873  NE      
CG3305
7 
FBgn00
53057 
CG33057 
BL55699 
HMC0
3914  NE      
CG1718
7 
FBgn00
37882 
CG17187 
BL55702 
HMC0
3923  NE      
CG7887 FBgn00
04622 
Takr99D 
BL55732 
HMC0
3749  NE      
CG1166
8 
FBgn00
38113 
CG11668 
BL55733 
HMC0
3756  NE      
CG1167
0 
FBgn00
38114 
CG11670 
BL55738 
HMC0
3877  NE      
CG3315
9 
FBgn00
53159 
CG33159 
BL55739 
HMC0
3893 A ME ME   E  
CG8383 FBgn00
37737 
Pnn 
BL55743 
HMC0
3928  NE      
CG3227
7 
FBgn00
52277 
CG32277 
BL55857 
HMC0
3895  NE      
CG3104
3 
FBgn00
26239 
gukh 
BL55858 
HMC0
3681  NE      
CG1206
6 
FBgn00
00274 
Pka-C2 
BL55859 
HMC0
4129  NE      
CG1024
4 
FBgn00
22800 
Cad96Ca 
BL55877 
HMC0
4150  NE      
CG6011 FBgn00
27784 
Prp18 
BL55915 
HMC0
4201  NE      
CG3326
3 
FBgn00
53263 
CG33263 
BL55954 
HMC0
4243  NE      
CG3327
6 
FBgn00
53276 
CG33276 
BL55955 
HMC0
4244  NE      
CG1464
3 
FBgn00
37225 
TwdlG 
BL55975 
HMC0
4271  NE      
CG5207 FBgn00
37889 
scpr-A 
BL55976 
HMC0
4272  NE      
CG3230
4 
FBgn00
52304 
obst-I 
BL55998 
HMC0
4294  NE      
CG3231
3 
FBgn00
52313 
CG32313 
BL55999 
HMC0
4295  NE      
CG3132
2 
FBgn00
27083 
Aats-met 
BL56005 
HMC0
4301  NE      
CG8956 FBgn00
15011 
Ahcy89E 
BL56009 
HMC0
4305  NE      
CG8327 FBgn00
37723 
SpdS 
BL56011 
HMC0
4307  NE      
CG5192 FBgn00
19940 
Rh6 
BL56029 
HMC0
4325  NE      
CG6474 FBgn00
00617 
e(y)1 
BL32345 
HMS0
0336  NE      
CG3923 FBgn00
01337 
Exp6 
BL32347 
HMS0
0338  NE      
CG7073 FBgn00
38947 
sar1 
BL32364 
HMS0
0355 A E-L E-L   E-L  
CG1250 FBgn02
62125 
sec23 
BL32365 
HMS0
0356  NE      
CG6987 FBgn00
40284 
SF2 
BL32367 
HMS0
0358 MS MS  S S  NE 
CG7660 FBgn02
61987 
Pxt 
BL32382 
HMS0
0374  NE      
CG5745 FBgn00
38855 
CG5745 
BL32394 
HMS0
0388  NE      
CG3354
6 
FBgn02
50732 
gfzf 
BL32399 
HMS0
0394  NE      
CG4147 FBgn00
01218 
Hsc70-3 
BL32402 
HMS0
0397 A E E   E  
CG7050 FBgn00
38975 
Nrx-1 
BL32408 
HMS0
0403  NE      
CG4574 FBgn00
04611 
Plc21C 
BL32438 
HMS0
0436  NE      
381 
 
CG4235
8 
FBgn02
59704 
CG42358 
BL32440 
HMS0
0438  NE      
CG1710 FBgn00
39904 
Hcf 
BL32453 
HMS0
0452 E E NE NE ME  NE 
CG5121 FBgn00
39337 
MED28 
BL32459 
HMS0
0458  NE      
CG4448 FBgn00
39067 
wda 
BL32469 
HMS0
0469  NE      
CG3111
9 
FBgn00
51119 
HdacX 
BL32480 
HMS0
0483  NE      
CG5085 FBgn00
38788 
Sirt2 
BL32482 
HMS0
0485  NE      
CG1130
5 
FBgn00
39631 
Sirt7 
BL32483 
HMS0
0486  NE      
CG1464 FBgn00
05558 
ey 
BL32486 
HMS0
0489  NE      
CG3115
6 
FBgn00
51156 
CG31156 
BL32495 
HMS0
0498  NE      
CG1137
5 
FBgn00
39227 
polybromo 
BL32840 
HMS0
0531  NE      
CG4562 FBgn00
38740 
CG4562 
BL32842 
HMS0
0623  NE      
CG1569
7 
FBgn00
38834 
RpS30 
BL32851 
HMS0
0636 A E E   E  
CG4548 FBgn00
39338 
XNP 
BL32894 
HMS0
0683  NE      
CG5874 FBgn00
38872 
Nelf-A 
BL32897 
HMS0
0686  NE      
CG1976 FBgn00
39883 
RhoGAP100F 
BL32946 
HMS0
0740  NE      
CG6898 FBgn00
38412 
Zip3 
BL32954 
HMS0
0748  NE      
CG1861
6 
FBgn02
60444 
CG18616 
BL32957 
HMS0
0751  NE      
CG3319
3 
FBgn00
53193 
sav 
BL32965 
HMS0
0760  NE      
CG2152 FBgn00
86768 
Pcmt 
BL32971 
HMS0
0768  NE      
CG5834 FBgn00
51354 
Hsp70Bbb 
BL33000 
HMS0
0800  NE      
CG1185
6 
FBgn00
39302 
Nup358 
BL33003 
HMS0
0803  NE      
CG7940 FBgn00
38576 
Arp5 
BL33009 
HMS0
0809  NE      
CG1081
1 
FBgn00
23213 
eIF4G 
BL33049 
HMS0
0762 ME ME NE ME MS NE NE 
CG1450
7 
FBgn00
39655 
CG14507 
BL33345 
HMS0
0211  NE      
CG3309
5 
FBgn00
53095 
CG33095 
BL33352 
HMS0
0223  NE      
CG5646 FBgn00
39525 
CG5646 
BL33360 
HMS0
0232  NE      
CG4231
2 
FBgn02
59212 
cno 
BL33367 
HMS0
0239 A E E   E  
CG1639 FBgn00
01491 
l(1)10Bb 
BL33380 
HMS0
0255  NE      
CG4314
0 
FBgn02
62614 
pyd 
BL33386 
HMS0
0263  NE      
CG1106
4 
FBgn00
87002 
Rfabg 
BL33388 
HMS0
0265  NE      
CG4755 FBgn00
38747 
RhoGAP92B 
BL33391 
HMS0
0268  NE      
CG3348
5 
FBgn00
38282 
dpr9 
BL33409 
HMS0
0288  NE      
CG4231
6 
FBgn02
59216 
RhoGAP102A 
BL33425 
HMS0
0309  NE      
CG4267
0 
FBgn02
61552 
ps 
BL33426 
HMS0
0310  NE      
CG3954 FBgn00
00382 
csw 
BL33619 
HMS0
0012 A ME ME   E  
382 
 
CG3218 FBgn00
00810 
fs(1)K10 
BL33630 
HMS0
0027  NE      
CG6946 FBgn02
59139 
glo 
BL33668 
HMS0
0079  NE      
CG3435
4 
FBgn00
85383 
CG34354 
BL33674 
HMS0
0538  NE      
CG1118
6 
FBgn00
19650 
toy 
BL33679 
HMS0
0544  NE      
CG5383 FBgn00
38948 
PSR 
BL33700 
HMS0
0576  NE      
CG3121
2 
FBgn00
86613 
Ino80 
BL33708 
HMS0
0586  NE      
CG1224
1 
FBgn00
38304 
CG12241 
BL33729 
HMS0
0612  NE      
CG5451 FBgn00
38666 
Smu1 
BL33739 
HMS0
1075  NE      
CG1458 FBgn00
62442 
CG1458 
BL33749 
HMS0
1088  NE      
CG1487 FBgn00
40206 
krz 
BL33880 
HMS0
0817  NE      
CG7922 FBgn00
38889 
CG7922 
BL33889 
HMS0
0827  NE      
CG3102
2 
FBgn00
39776 
PH4alphaEFB 
BL33896 
HMS0
0835  NE      
CG1670
5 
FBgn00
39102 
SPE 
BL33926 
HMS0
0873 A E E   E  
CG1216
3 
FBgn02
60462 
CG12163 
BL33955 
HMS0
0910  NE      
CG1184
8 
FBgn00
39282 
Bili 
BL33956 
HMS0
0911  NE      
CG6990 FBgn00
39019 
HP1c 
BL33962 
HMS0
0919  NE      
CG1081 FBgn00
41191 
Rheb 
BL33966 
HMS0
0923  NE      
CG1042
0 
FBgn00
39296 
CG10420 
BL33968 
HMS0
0925  NE      
CG3122
4 
FBgn00
51224 
CG31224 
BL33969 
HMS0
0926  NE      
CG1800 FBgn00
39861 
pasha 
BL33972 
HMS0
0929  NE      
CG3142
6 
FBgn00
41588 
ligatin/eIF2D 
BL33995 
HMS0
0958  NE      
CG1152
2 
FBgn00
39857 
RpL6 
BL34004 
HMS0
0967 A E-L E-L   E  
CG1223
0 
FBgn00
00257 
car 
BL34007 
HMS0
0972  NE      
CG4976 FBgn00
39559 
Mes-4 
BL34033 
HMS0
1004  NE      
CG4963 FBgn00
39561 
mfrn 
BL34038 
HMS0
1013  NE      
CG4236 FBgn02
63979 
Caf1 
BL34069 
HMS0
0051  NE      
CG3665 FBgn00
00635 
Fas2 
BL34084 
HMS0
1098  NE      
CG9746 FBgn02
60935 
ird1 
BL34092 
HMS0
0908  NE      
CG1973 FBgn02
60990 
yata 
BL34100 
HMS0
1005  NE      
CG4572 FBgn00
38738 
CG4572 
BL34337 
HMS0
1325  NE      
CG2241 FBgn00
39788 
Rpt6R 
BL34342 
HMS0
1330  NE      
CG5520 FBgn00
39562 
Gp93 
BL34346 
HMS0
1334  NE      
CG3590 FBgn00
38467 
CG3590 
BL34347 
HMS0
1336  NE      
CG6057 FBgn00
40283 
SMC1 
BL34351 
HMS0
1340  NE      
CG5706 FBgn00
39175 
CG5706 
BL34356 
HMS0
1345  NE      
383 
 
CG3103
3 
FBgn00
39705 
CG31033 
BL34358 
HMS0
1347  NE      
CG1000
7 
FBgn02
60744 
Tango9 
BL34364 
HMS0
1353  NE      
CG3104
8 
FBgn02
64324 
spg 
BL34367 
HMS0
1356  NE      
CG6560 FBgn00
38916 
dnd 
BL34383 
HMS0
1373  NE      
CG7719 FBgn02
60399 
gwl 
BL34525 
HMS0
0834  NE      
CG5527 FBgn00
39564 
CG5527 
BL34531 
HMS0
1076  NE      
CG3509 FBgn00
38252 
CG3509 
BL34548 
HMS0
1020  NE      
CG4510 FBgn00
38746 
Surf6 
BL34563 
HMS0
1035  NE      
CG6015 FBgn00
38927 
CG6015 
BL34565 
HMS0
1037 A E E   E  
CG3310
6 
FBgn00
43884 
mask 
BL34571 
HMS0
1045  NE      
CG4278
8 
FBgn02
61859 
CG42788 
BL34594 
HMS0
1068  NE      
CG9617 FBgn02
60939 
Sgt1 
BL34605 
HMS0
0566  NE      
CG4332
0 
FBgn02
63025 
CG43320 
BL34606 
HMS0
0577  NE      
CG1862 FBgn00
40324 
Ephrin 
BL34614 
HMS0
1289  NE      
CG7952 FBgn00
01150 
gt 
BL34631 
HMS0
1105  NE      
CG1027
8 
FBgn00
38391 
GATAe 
BL34641 
HMS0
1116  NE      
CG1901 FBgn00
39914 
mav 
BL34650 
HMS0
1125  NE      
CG3139
0 
FBgn00
51390 
MED7 
BL34663 
HMS0
1140 S S  S S  NE 
CG7957 FBgn00
38578 
MED17 
BL34664 
HMS0
1141 S S  S MS  NE 
CG6921 FBgn02
60942 
bond 
BL34676 
HMS0
1154  NE      
CG4401
5 
FBgn02
64785 
Hph 
BL34717 
HMS0
1196  NE      
CG3125
1 
FBgn00
51251 
CG31251 
BL34721 
HMS0
1200  NE      
CG7700 FBgn00
44871 
Gos28 
BL34724 
HMS0
1203  NE      
CG1729
9 
FBgn02
64357 
SNF4Agamma 
BL34726 
HMS0
1205  NE      
CG9768 FBgn02
61434 
hkb 
BL34736 
HMS0
1216  NE      
CG1345 FBgn00
39580 
Gfat2 
BL34740 
HMS0
1220  NE      
CG9012 FBgn00
00319 
Chc 
BL34742 
HMS0
1222  NE      
CG4266
8 
FBgn02
61550 
CG42668 
BL34743 
HMS0
1223  NE      
CG6892 FBgn00
39225 
Ets96B 
BL34783 
HMS0
0092  NE      
CG1198
5 
FBgn00
40534 
CG11985 
BL34788 
HMS0
0097 E E NE ME ME  NE 
CG5441 FBgn02
63118 
tx 
BL34792 
HMS0
0101  NE      
CG3199
2 
FBgn00
51992 
gw 
BL34796 
HMS0
0105 A E E   E  
CG1200
0 
FBgn02
50746 
Prosbeta7 
BL34812 
HMS0
0122 A E-L E   E  
CG1229
7 
FBgn00
38928 
BG4 
BL34813 
HMS0
0123  NE      
CG5454 FBgn02
61792 
snRNP-U1-C 
BL34822 
HMS0
0137  NE      
384 
 
CG1694
1 
FBgn00
38464 
CG16941 
BL34840 
HMS0
0157 E E NE NE ME  NE 
CG1192
0 
FBgn00
39274 
CG11920 
BL34860 
HMS0
0178  NE      
CG4376 FBgn00
00667 
Actn 
BL34874 
HMS0
0193  NE      
CG4109
9 
FBgn00
39955 
CG41099 
BL34883 
HMS0
1228  NE      
CG1834
7 
FBgn02
60743 
CG18347 
BL34890 
HMS0
1235  NE      
CG8933 FBgn00
00611 
exd 
BL34897 
HMS0
1242  NE      
CG1233
4 
FBgn00
38539 
Atg8b 
BL34900 
HMS0
1245  NE      
CG1618 FBgn00
00346 
comt/NSF 
BL34913 
HMS0
1261  NE      
CG1450
8 
FBgn00
39651 
CG14508 
BL34916 
HMS0
1264  NE      
CG1894 FBgn00
39585 
CG1894 
BL34925 
HMS0
1274  NE      
CG1385
2 
FBgn00
38965 
mats 
BL34959 
HMS0
0475  NE      
CG4223
3 
FBgn02
50755 
CG42233 
BL34986 
HMS0
1396  NE      
CG1157
9 
FBgn00
00117 
arm 
BL35004 
HMS0
1414 A E E   E  
CG3247
4 
FBgn00
39411 
dys 
BL35010 
HMS0
1420  NE      
CG4225
0 
FBgn02
61279 
lqfR 
BL35013 
HMS0
1423  NE      
CG6688 FBgn00
39038 
CG6688 
BL35021 
HMS0
1434  NE      
CG1922 FBgn00
28996 
onecut 
BL35025 
HMS0
1438  NE      
CG3421 FBgn00
38853 
RhoGAP93B 
BL35027 
HMS0
1440  NE      
CG3100
9 
FBgn00
39709 
Cad99C 
BL35037 
HMS0
1451  NE      
CG2919 FBgn02
61004 
asl 
BL35039 
HMS0
1453  NE      
CG1054
5 
FBgn00
01105 
Gbeta13F 
BL35041 
HMS0
1455  NE      
CG1666 FBgn00
01565 
Hlc 
BL35308 
HMS0
1424  NE      
CG4254
2 
FBgn02
60659 
CG42542 
BL35736 
HMS0
1478  NE      
CG5429 FBgn02
64325 
Atg6 
BL35741 
HMS0
1483  NE      
CG5466 FBgn00
38815 
CG5466 
BL35758 
HMS0
1504  NE      
CG1489
2 
FBgn00
38447 
CG14892 
BL35766 
HMS0
1515  NE      
CG9743 FBgn00
39756 
CG9743 
BL36675 
HMS0
1563  NE      
CG7929 FBgn00
41102 
ocn 
BL36681 
HMS0
1569 A E ME   E  
CG1042
3 
FBgn00
39300 
RpS27 
BL36692 
HMS0
1581  NE      
CG1518
0 
FBgn02
50846 
glob2 
BL36693 
HMS0
1582  NE      
CG5083 FBgn00
38390 
Rbf2 
BL36697 
HMS0
1586  NE      
CG1486
6 
FBgn00
38315 
CG14866 
BL36706 
HMS0
1596  NE      
CG3201
8 
FBgn00
11642 
Zyx 
BL36716 
HMS0
1606  NE      
CG6963 FBgn02
50823 
gish 
BL36719 
HMS0
1609  NE      
CG3106
0 
FBgn00
46886 
Gr98c 
BL36735 
HMS0
1626  NE      
385 
 
CG6668 FBgn00
39213 
atl 
BL36736 
HMS0
1627  NE      
CG4583 FBgn02
61984 
Ire1 
BL36743 
HMS0
3003  NE      
CG3114
0 
FBgn00
51140 
CG31140 
BL36746 
HMS0
3006  NE      
CG1710
0 
FBgn02
59938 
cwo 
BL36756 
HMS0
3016  NE      
CG1553
3 
FBgn00
39768 
CG15533 
BL36761 
HMS0
3022  NE      
CG1553
4 
FBgn00
39769 
CG15534 
BL36762 
HMS0
3023  NE      
CG1471 FBgn00
39774 
CDase 
BL36764 
HMS0
3025  NE      
CG6755 FBgn00
39066 
EloA 
BL37017 
HMS0
1255 LacZ-S S  S S  MS 
CG5887 FBgn00
86687 
desat1 
BL37512 
HMS0
1654  NE      
CG8228 FBgn02
61049 
Vps45 
BL38252 
HMS0
1696  NE      
CG3412
7 
FBgn00
83963 
CG34127 
BL38264 
HMS0
1709  NE      
CG3413
9 
FBgn00
83975 
CG34139 
BL38265 
HMS0
1710  NE      
CG8454 FBgn02
61241 
Vps16A 
BL38271 
HMS0
1716 A ME E   E  
CG9579 FBgn00
00084 
AnnX 
BL38272 
HMS0
1720  NE      
CG7467 FBgn02
61885 
osa 
BL38285 
HMS0
1738  NE      
CG6637 FBgn02
60940 
lsn 
BL38289 
HMS0
1747  NE      
CG4931 FBgn00
38320 
Sra-1 
BL38294 
HMS0
1754  NE      
CG7670 FBgn00
38608 
WRNexo 
BL38297 
HMS0
1758  NE      
CG1189
7 
FBgn00
39644 
CG11897 
BL38318 
HMS0
1782  NE      
CG2096 FBgn00
00711 
flw 
BL38336 
HMS0
1803  NE      
CG1363
6 
FBgn00
39232 
CG13636 
BL38362 
HMS0
1831  NE      
CG6383 FBgn02
59685 
crb 
BL38373 
HMS0
1842  NE      
CG1349 FBgn00
39802 
dj-1beta 
BL38378 
HMS0
1847  NE      
CG3114
8 
FBgn00
51148 
CG31148 
BL38379 
HMS0
1848  NE      
CG6733 FBgn00
39052 
CG6733 
BL38520 
HMS0
1668  NE      
CG1811
2 
FBgn00
39702 
Vps16B 
BL38527 
HMS0
1732  NE      
CG3525 FBgn00
00536 
eas 
BL38528 
HMS0
1734  NE      
CG6525 FBgn00
82831 
pps 
BL38529 
HMS0
1741  NE      
CG5802 FBgn02
50820 
CG5802 
BL38938 
HMS0
1771  NE      
CG1490
3 
FBgn00
38446 
CG14903 
BL38949 
HMS0
1863  NE      
CG3152
2 
FBgn00
51522 
CG31522 
BL38952 
HMS0
1866  NE      
CG9623 FBgn00
01250 
if 
BL38958 
HMS0
1872  NE      
CG1500 FBgn00
01083 
fw 
BL38975 
HMS0
1891  NE      
CG3141
4 
FBgn00
51414 
CG31414 
BL38977 
HMS0
1893  NE      
CG5798 FBgn00
38862 
Ubpy 
BL38982 
HMS0
1898 A ME ME S E E  
386 
 
CG1359 FBgn02
60860 
Bet5 
BL38993 
HMS0
1909  NE      
CG1454
2 
FBgn00
39402 
vps2 
BL38995 
HMS0
1911  NE      
CG1907 FBgn00
39674 
CG1907 
BL38998 
HMS0
1914  NE      
CG4322
6 
FBgn02
62871 
lute 
BL39011 
HMS0
1929  NE      
CG7727 FBgn00
00108 
Appl 
BL39013 
HMS0
1931  NE      
CG5483 FBgn00
38816 
Lrrk 
BL39019 
HMS0
1937  NE      
CG6738 FBgn00
39053 
CG6738 
BL39020 
HMS0
1938  NE      
CG2520 FBgn00
86372 
lap 
BL39021 
HMS0
1939  NE      
CG1725 FBgn00
01624 
dlg1 
BL39035 
HMS0
1954  NE      
CG1778
5 
FBgn00
39188 
Golgin84 
BL39039 
HMS0
1959  NE      
CG6323 FBgn00
39465 
Tsp97E 
BL39047 
HMS0
1967  NE      
CG1070 FBgn02
61238 
Alh 
BL39057 
HMS0
1977  NE      
CG7156 FBgn00
38588 
CG7156 
BL39063 
HMS0
1983  NE      
CG1511 FBgn00
25936 
Eph 
BL39066 
HMS0
1986  NE      
CG5055 FBgn00
00163 
baz 
BL39072 
HMS0
1992  NE      
CG4339
8 
FBgn02
63289 
scrib 
BL39073 
HMS0
1993  NE      
CG1711
9 
FBgn00
39045 
CG17119 
BL40823 
HMS0
0213  NE      
CG4849 FBgn00
39566 
CG4849 
BL40828 
HMS0
1994  NE      
CG3440
3 
FBgn00
85432 
pan 
BL40848 
HMS0
2015  NE      
CG4328
6 
FBgn02
62975 
cnc 
BL40854 
HMS0
2021  NE      
CG1187
7 
FBgn00
39636 
CG11877 
BL40858 
HMS0
2025  NE      
CG7331 FBgn02
61108 
Atg13 
BL40861 
HMS0
2028  NE      
CG1906 FBgn00
86361 
alph 
BL40873 
HMS0
2040  NE      
CG2118 FBgn00
39877 
CG2118 
BL40874 
HMS0
2041  NE      
CG3105
7 
FBgn00
51057 
tau 
BL40875 
HMS0
2042  NE      
CG4108
7 
FBgn00
69947 
CG41087 
BL40876 
HMS0
2043  NE      
CG4413 FBgn00
38767 
trem 
BL40881 
HMS0
2049  NE      
CG3114
6 
FBgn00
51146 
Nlg1 
BL40883 
HMS0
2131  NE      
CG1746
1 
FBgn00
39925 
Kif3C 
BL40886 
HMS0
2134  NE      
CG1425
0 
FBgn00
39448 
TwdlQ 
BL40893 
HMS0
2141  NE      
CG5864 FBgn00
39132 
AP-1sigma 
BL40895 
HMS0
2143  NE      
CG4401
2 
FBgn02
64754 
btsz 
BL40898 
HMS0
2146  NE      
CG1037
1 
FBgn00
39111 
Plip 
BL40913 
HMS0
2161  NE      
CG3678 FBgn00
38461 
CG3678 
BL40920 
HMS0
2168  NE      
CG3962 FBgn00
38475 
Keap1 
BL40932 
HMS0
2180 A E-L E-L   E  
387 
 
CG1022
5 
FBgn00
39110 
RanBP3 
BL40948 
HMS0
2196  NE      
CG1743 FBgn00
01145 
Gs2 
BL40949 
HMS0
2197  NE      
CG1114
4 
FBgn00
19985 
mGluRA 
BL41668 
HMS0
2201  NE      
CG2246 FBgn00
39790 
CG2246 
BL41694 
HMS0
2259  NE      
CG4231
7 
FBgn02
62081 
Csk 
BL41712 
HMS0
2277  NE      
CG1341
8 
FBgn00
38903 
RpI12 
BL41715 
HMS0
2280  NE      
CG5148 FBgn00
38478 
cal1 
BL41716 
HMS0
2281  NE      
CG1539 FBgn00
82582 
tmod 
BL41718 
HMS0
2283  NE      
CG3333
6 
FBgn00
39044 
p53 
BL41720 
HMS0
2286  NE      
CG5407 FBgn00
38504 
Sur-8 
BL41883 
HMS0
2299  NE      
CG6189 FBgn00
01341 
l(1)1Bi 
BL41916 
HMS0
2313  NE      
CG4815 FBgn00
39568 
CG4815 
BL41919 
HMS0
2316  NE      
CG1359
7 
FBgn00
39124 
CG13597 
BL41924 
HMS0
2321  NE      
CG3134
3 
FBgn00
51343 
CG31343 
BL41925 
HMS0
2322  NE      
CG1799
8 
FBgn02
61988 
Gprk2 
BL41933 
HMS0
2330  NE      
CG3122
1 
FBgn00
51221 
CG31221 
BL41953 
HMS0
2350  NE      
CG7794 FBgn00
38565 
CG7794 
BL41970 
HMS0
2367  NE      
CG1738
0 
FBgn00
39077 
CG17380 
BL41973 
HMS0
2371 E-L E-L NE MS E-L  NE 
CG4203 FBgn00
38300 
CG4203 
BL41976 
HMS0
2374  NE      
CG4037
8 
FBgn00
58378 
CG40378 
BL41980 
HMS0
2378  NE      
CG4370 FBgn00
39081 
Irk2 
BL41981 
HMS0
2379  NE      
CG2041 FBgn00
39907 
lgs 
BL41983 
HMS0
2381  NE      
CG2316 FBgn00
39890 
CG2316 
BL41984 
HMS0
2382  NE      
CG7769 FBgn02
60962 
pic 
BL41997 
HMS0
2398  NE      
CG3249
0 
FBgn00
41605 
cpx 
BL42017 
HMS0
2442 A E ME   ME  
CG1106
2 
FBgn00
24913 
Actbeta 
BL42493 
HMJ0
2057  NE      
CG1225
4 
FBgn00
38760 
MED25 
BL42501 
HMJ0
2066  NE      
CG1150
4 
FBgn00
39733 
CG11504 
BL42509 
HMJ0
2074  NE      
CG1229
0 
FBgn00
39419 
CG12290 
BL42520 
HMJ0
2086  NE      
CG1519
1 
FBgn00
00618 
e(y)2 
BL42524 
HMJ0
2090  NE      
CG4656 FBgn00
39055 
Rassf 
BL42534 
HMJ0
2102  NE      
CG1142
0 
FBgn00
00826 
png 
BL42535 
HMJ0
2104  NE      
CG1095
1 
FBgn00
45980 
niki 
BL42543 
HMJ0
2114  NE      
CG4280
3 
FBgn02
64495 
gpp 
BL42556 
HMJ0
2129 A ME ME   ME  
CG3350 FBgn00
39509 
bigmax 
BL42559 
HMJ0
2215  NE      
388 
 
CG1385
0 
FBgn00
38961 
CG13850 
BL42574 
HMJ0
2233  NE      
CG4255
1 
FBgn02
61618 
larp 
BL42578 
HMJ0
2239  NE      
CG4907 FBgn00
39010 
CG4907 
BL42602 
HMS0
2435  NE      
CG7292 FBgn00
38269 
Rrp6 
BL42604 
HMS0
2437  NE      
CG7146 FBgn00
38593 
CG7146 
BL42605 
HMS0
2438  NE      
CG3837 FBgn00
38279 
CG3837 
BL42609 
HMS0
2444  NE      
CG3112
7 
FBgn00
46685 
Wsck 
BL42628 
HMS0
2463  NE      
CG3119
5 
FBgn00
51195 
CG31195 
BL42632 
HMS0
2468 E-L E-L NE MS E  NE 
CG1040
7 
FBgn00
38395 
CG10407 
BL42636 
HMS0
2472  NE      
CG4415
9 
FBgn02
65042 
Irk1/ir 
BL42644 
HMS0
2480  NE      
CG4027 FBgn00
00042 
Act5C 
BL42651 
HMS0
2487 A E E   E  
CG1451
4 
FBgn00
39654 
Brd8 
BL42658 
HMS0
2494 ME ME NE NE E-L  NE 
CG3144
5 
FBgn00
51445 
CG31445 
BL42660 
HMS0
2496  NE      
CG1489
5 
FBgn00
44826 
Pak3 
BL42664 
HMS0
2500  NE      
CG9373 FBgn02
60010 
rump 
BL42665 
HMS0
2501  NE      
CG1747
7 
FBgn00
38479 
CG17477 
BL42821 
HMS0
2503  NE      
CG5934 FBgn00
39505 
CG5934 
BL42822 
HMS0
2504  NE      
CG1397
7 
FBgn00
39519 
Cyp6a18 
BL42824 
HMS0
2506  NE      
CG4854 FBgn00
38766 
CG4854 
BL42833 
HMS0
2525  NE      
CG4390 FBgn00
38771 
CG4390 
BL42836 
HMS0
2528  NE      
CG7715 FBgn00
38646 
CG7715 
BL42837 
HMS0
2529  NE      
CG3140
7 
FBgn00
51407 
CG31407 
BL42840 
HMS0
2532 A E E   E  
CG1067
5 
FBgn00
39328 
CHKov2 
BL42843 
HMS0
2535  NE      
CG1558
2 
FBgn00
46878 
Obp83cd 
BL42844 
HMS0
2536  NE      
CG1187
3 
FBgn00
39633 
CG11873 
BL42847 
HMS0
2539  NE      
CG6353 FBgn00
38893 
CG6353 
BL42851 
HMS0
2543  NE      
CG3332
9 
FBgn00
53329 
Sp212 
BL42858 
HMS0
2550  NE      
CG4677 FBgn00
39039 
lmd 
BL42871 
HMS0
2564  NE      
CG1221
3 
FBgn02
60742 
CG12213 
BL42872 
HMS0
2565  NE      
CG4282
7 
FBgn02
62009 
CG42827 
BL42878 
HMS0
2571  NE      
CG6588 FBgn02
62742 
Fas1 
BL42887 
HMS0
2580  NE      
CG1244
9 
FBgn00
27341 
Gfat1 
BL42892 
HMS0
2585  NE      
CG1019
2 
FBgn02
60634 
eIF4G2 
BL42893 
HMS0
2586  NE      
CG1383
8 
FBgn00
39041 
CG13838 
BL42898 
HMS0
2591  NE      
CG4792 FBgn00
39016 
Dcr-1 
BL42901 
HMS0
2594  NE      
389 
 
CG7832 FBgn00
86686 
l(3)L1231 
BL42907 
HMS0
2600  NE      
CG6265 FBgn00
39478 
Nep5 
BL42909 
HMS0
2602  NE      
CG3101
6 
FBgn00
51016 
CG31016 
BL42911 
HMS0
2604  NE      
CG3773 FBgn00
38692 
CG3773 
BL42917 
HMS0
2610 A ME ME MS  ME  
CG6420 FBgn00
39451 
CG6420 
BL42920 
HMS0
2613  NE      
CG1774
3 
FBgn00
02521 
pho 
BL42926 
HMS0
2619  NE      
CG1183
7 
FBgn00
39627 
CG11837 
BL42932 
HMS0
2625  NE      
CG7993 FBgn00
38585 
CG7993 
BL42935 
HMS0
2628  NE      
CG1522
4 
FBgn00
00259 
CkIIbeta 
BL42943 
HMS0
2636  NE      
CG1451
6 
FBgn00
39640 
CG14516 
BL42947 
HMS0
2640  NE      
CG3796 FBgn00
00022 
ac 
BL42953 
HMS0
2646  NE      
CG3180 FBgn02
62955 
RpII140 
BL43282 
HMC0
2681  NE      
CG1183
6 
FBgn00
39272 
CG11836 
BL43308 
HMS0
2692  NE      
CG1544 FBgn00
39827 
CG1544 
BL43310 
HMS0
2694  NE      
CG8147 FBgn00
43791 
CG8147 
BL43314 
HMS0
2698  NE      
CG3310
0 
FBgn00
53100 
eIF4EHP 
BL43990 
HMS0
2703  NE      
CG4282
8 
FBgn02
62010 
CG42828 
BL43996 
HMS0
2710  NE      
CG1195
6 
FBgn02
63236 
SP1029 
BL43997 
HMS0
2711  NE      
CG3200
0 
FBgn00
52000 
CG32000 
BL44005 
HMS0
2719  NE      
CG5127 FBgn00
39335 
Vps33B 
BL44006 
HMS0
2720  NE      
CG1397
8 
FBgn00
39518 
CG13978 
BL44008 
HMS0
2722  NE      
CG5166 FBgn00
41188 
Atx2 
BL44012 
HMS0
2726 A ME ME E  ME  
CG3106
5 
FBgn00
51065 
CG31065 
BL44013 
HMS0
2727  NE      
CG1836 FBgn00
26777 
Rad23 
BL44031 
HMS0
2747  NE      
CG1115
2 
FBgn00
39937 
fd102C 
BL44045 
HMS0
2761  NE      
CG3121
6 
FBgn00
51216 
Naam 
BL44053 
HMS0
2770  NE      
CG5432 FBgn00
39425 
CG5432 
BL44062 
HMS0
2779 E E NE MS E  NE 
CG1983 FBgn00
39751 
CG1983 
BL44064 
HMS0
2781  NE      
CG7265 FBgn00
38272 
CG7265 
BL44066 
HMS0
2783  NE      
CG1082
3 
FBgn00
38880 
SIFR 
BL44068 
HMS0
2785  NE      
CG3111
8 
FBgn00
51118 
RabX4 
BL44070 
HMS0
2787  NE      
CG3144
6 
FBgn00
51446 
CG31446 
BL44071 
HMS0
2788  NE      
CG6535 FBgn00
45035 
tefu 
BL44073 
HMS0
2790  NE      
CG4367 FBgn00
38783 
CG4367 
BL44077 
HMS0
2794  NE      
CG5510 FBgn00
39160 
CG5510 
BL44080 
HMS0
2797 MS MS ME S E ME NE 
390 
 
CG1385
7 
FBgn00
38958 
CG13857 
BL44083 
HMS0
2800  NE      
CG1109
3 
FBgn00
39932 
CG11093 
BL44085 
HMS0
2802  NE      
CG3320
3 
FBgn00
53203 
CG33203 
BL44088 
HMS0
2805  NE      
CG1184
3 
FBgn00
39630 
CG11843 
BL44092 
HMS0
2809  NE      
CG3578 FBgn00
00179 
bi 
BL44095 
HMS0
2815  NE      
CG3114
1 
FBgn00
51141 
CG31141 
BL44107 
HMS0
2828  NE      
CG7829 FBgn00
39703 
CG7829 
BL44112 
HMS0
2834  NE      
CG1188
0 
FBgn00
39637 
CG11880 
BL44113 
HMS0
2835 A ME ME   ME  
CG1488
3 
FBgn00
38432 
CG14883 
BL44114 
HMS0
2836  NE      
CG1778
0 
FBgn00
39197 
CG17780 
BL44119 
HMS0
2841  NE      
CG5791 FBgn00
40582 
CG5791 
BL44121 
HMS0
2843  NE      
CG6439 FBgn00
38922 
CG6439 
BL44475 
HMC0
2361  NE      
CG3121
7 
FBgn00
51217 
modSP 
BL44476 
HMC0
2363  NE      
CG1727
1 
FBgn00
38829 
CG17271 
BL44480 
HMC0
2370  NE      
CG4257
4 
FBgn02
60794 
ctrip 
BL44481 
HMC0
2371  NE      
CG1172 FBgn02
64712 
CG1172 
BL44500 
HMC0
2436  NE      
CG5278 FBgn00
38986 
CG5278 
BL44515 
HMC0
2905  NE      
CG3285
3 
FBgn00
45442 
mthl12 
BL44516 
HMC0
2906  NE      
CG3311
0 
FBgn00
53110 
CG33110 
BL44519 
HMC0
2909  NE      
CG1383
0 
FBgn00
39054 
CG13830 
BL44530 
HMC0
2924  NE      
CG1360
4 
FBgn00
39137 
CG13604 
BL44537 
HMC0
2932  NE      
CG1909 FBgn00
39911 
CG1909 
BL44538 
HMC0
2933  NE      
CG3354
7 
FBgn00
53547 
Rim 
BL44541 
HMC0
2936  NE      
CG7212 FBgn02
61532 
cdm 
BL44551 
HMS0
2846  NE      
CG3258 FBgn00
00137 
ase 
BL44552 
HMS0
2847  NE      
CG3281 FBgn02
60741 
CG3281 
BL44555 
HMS0
2851  NE      
CG3309
9 
FBgn00
53099 
CG33099 
BL44559 
HMS0
2855  NE      
CG5266 FBgn00
86134 
Pros25 
BL44560 
HMS0
2856  NE      
CG4336
9 
FBgn02
63112 
Mitf 
BL44561 
HMS0
2857  NE      
CG7695 FBgn00
38631 
CG7695 
BL44568 
HMS0
2864  NE      
CG3285
0 
FBgn00
52850 
CG32850 
BL44570 
HMS0
2866  NE      
CG3429
0 
FBgn00
85319 
CG34290 
BL44573 
HMS0
2869  NE      
CG1555
6 
FBgn00
39821 
CG15556 
BL44574 
HMS0
2870  NE      
CG6432 FBgn00
39184 
CG6432 
BL44575 
HMS0
2871  NE      
CG5326 FBgn00
38983 
CG5326 
BL44659 
HMC0
2892  NE      
391 
 
CG1937 FBgn00
39875 
sip3 
BL50609 
HMC0
2976  NE      
CG4210 FBgn00
38302 
CG4210 
BL50615 
HMC0
2982  NE      
CG1969 FBgn00
39690 
CG1969 
BL50616 
HMC0
2983  NE      
CG7816 FBgn00
39714 
CG7816 
BL50635 
HMC0
3033  NE      
CG1449 FBgn00
04607 
zfh2 
BL50643 
HMC0
3043  NE      
CG2229 FBgn00
39777 
Jon99Fii 
BL50648 
HMC0
3049  NE      
CG1036
7 
FBgn02
63782 
Hmgcr 
BL50652 
HMC0
3053 A E-L E-L   E-L  
CG3107
5 
FBgn00
51075 
CG31075 
BL50654 
HMC0
3055  NE      
CG5737 FBgn00
38851 
dmrt93B 
BL50656 
HMC0
3057  NE      
CG3148
1 
FBgn00
51481 
pb 
BL50664 
HMC0
3065  NE      
CG1820
8 
FBgn00
38653 
CG18208 
BL50678 
HMC0
3079  NE      
CG1550
4 
FBgn00
39683 
dmrt99B 
BL50687 
HMC0
3088  NE      
CG6919 FBgn00
38980 
oa2 
BL50701 
HMC0
3103  NE      
CG1401 FBgn00
39632 
Cul-5 
BL50707 
HMC0
3109  NE      
CG1552
5 
FBgn00
39732 
CG15525 
BL50708 
HMC0
3110  NE      
CG4223
5 
FBgn02
50757 
CG42235 
BL50724 
HMS0
2960  NE      
CG3109
4 
FBgn00
66101 
LpR1 
BL50737 
HMS0
2973  NE      
CG4232
0 
FBgn02
59220 
Doa 
BL50903 
HMJ0
3121  NE      
CG1205
4 
FBgn00
39831 
CG12054 
BL50910 
HMJ0
3134  NE      
CG1431
3 
FBgn00
38579 
CG14313 
BL50915 
HMJ2
1004  NE      
CG1015
7 
FBgn00
39099 
CG10157 
BL50938 
HMJ2
1033  NE      
CG6904 FBgn00
38293 
CG6904 
BL50956 
HMJ2
1058  NE      
CG5952 FBgn00
38402 
Fer2 
BL50971 
HMJ2
1077  NE      
CG4003 FBgn00
40078 
pont 
BL50972 
HMJ2
1078  NE      
CG1055
9 
FBgn00
39323 
CG10559 
BL50975 
HMJ2
1081  NE      
CG3631 FBgn00
38268 
CG3631 
BL50997 
HMJ2
1110  NE      
CG3369
8 
FBgn02
61291 
CheA86a 
BL51001 
HMJ2
1115  NE      
CG7911 FBgn00
39735 
CG7911 
BL51021 
HMJ2
1147  NE      
CG1363
4 
FBgn00
39224 
CG13634 
BL51024 
HMJ2
1150  NE      
CG7789 FBgn00
39698 
CG7789 
BL51028 
HMJ2
1155  NE      
CG6277 FBgn00
39475 
CG6277 
BL51030 
HMJ2
1157  NE      
CR3464
9 
FBgn00
85056 
tre-1 
BL51032 
HMJ2
1159  NE      
CG1783
6 
FBgn02
61113 
Xrp1 
BL51054 
HMJ2
1189 E-L E-L NE E E  NE 
CG1188
6 
FBgn00
41186 
Slbp 
BL51171 
HMJ2
1114  NE      
CG6196 FBgn00
38323 
Trs33 
BL51393 
HMJ2
1139 S S  S MS  NE 
392 
 
CG2126 FBgn00
39876 
CG2126 
BL51424 
HMC0
2894  NE      
CG1275
3 
FBgn00
38427 
ema 
BL51426 
HMC0
2913  NE      
CG1069
4 
FBgn00
39147 
CG10694 
BL51434 
HMC0
3147  NE      
CG6271 FBgn00
39476 
CG6271 
BL51436 
HMC0
3150 MS MS  S S  NE 
CG3437
6 
FBgn00
85405 
CG34376 
BL51439 
HMC0
3153  NE      
CG3839 FBgn00
02561 
l(1)sc 
BL51443 
HMC0
3157  NE      
CG1580
3 
FBgn00
38606 
CG15803 
BL51449 
HMC0
3179  NE      
CG7834 FBgn00
39697 
CG7834 
BL51464 
HMC0
3204 A ME ME   E  
CG5237 FBgn00
38693 
unc79 
BL51471 
HMC0
3213  NE      
CG6657 FBgn00
15562 
veg 
BL51478 
HMC0
3223  NE      
CG3106
4 
FBgn00
51064 
CG31064 
BL51494 
HMC0
3246  NE      
CG3152
3 
FBgn00
51523 
CG31523 
BL51495 
HMC0
3248  NE      
CG6283 FBgn00
39474 
CG6283 
BL51498 
HMC0
3253  NE      
CG3396
7 
FBgn02
62127 
kibra 
BL51499 
HMC0
3256  NE      
CG1184
9 
FBgn00
39286 
dan 
BL51501 
HMC0
3259  NE      
CG3128
4 
FBgn02
60005 
wtrw 
BL51503 
HMC0
3264  NE      
CG4322
4 
FBgn02
62869 
mun 
BL51505 
HMC0
3267  NE      
CG6930 FBgn02
65276 
l(3)neo38 
BL51515 
HMC0
3292  NE      
CG7242 FBgn00
87021 
Spc25 
BL51516 
HMS0
3161  NE      
CG2003 FBgn00
39886 
CG2003 
BL51699 
HMC0
3148  NE      
CG6660 FBgn00
39030 
CG6660 
BL51707 
HMC0
3202  NE      
CG4162
4 
FBgn00
86917 
spok 
BL51718 
HMC0
3254  NE      
CG1783 FBgn00
24728 
Slip1 
BL51724 
HMC0
3268  NE      
CG1195
1 
FBgn00
39656 
CG11951 
BL51735 
HMS0
3163 
(MS 
POSSIBL
E) NE  NE    
CG7262 FBgn00
38274 
CG7262 
BL51758 
HMC0
3310 A ME ME E  ME  
CG6995 FBgn00
39229 
Saf-B 
BL51759 
HMC0
3311  NE      
CG6295 FBgn00
39471 
CG6295 
BL51760 
HMC0
3312  NE      
CG1131
8 
FBgn00
39818 
CG11318 
BL51792 
HMC0
3348  NE      
CG1065 FBgn00
04888 
Scsalpha 
BL51807 
HMC0
3366  NE      
CG4360 FBgn00
38787 
CG4360 
BL51813 
HMC0
3384  NE      
CG3731 FBgn00
38271 
CG3731 
BL51822 
HMC0
3394  NE      
CG5911 FBgn00
38874 
ETHR 
BL51828 
HMC0
3400  NE      
CG2171 FBgn00
86355 
Tpi 
BL51829 
HMC0
3401  NE      
CG1226
5 
FBgn02
64291 
Det 
BL51837 
HMC0
3409  NE      
393 
 
CG3438
3 
FBgn00
85412 
CG34383 
BL51917 
HMS0
3376  NE      
CG1183
9 
FBgn00
39271 
CG11839 
BL51924 
HMS0
3375  NE      
CG5588 FBgn00
39532 
Mtl 
BL51932 
HMC0
3186  NE      
CG4053 FBgn00
38482 
CG4053 
BL52872 
HMC0
3610  NE      
CG5255 FBgn00
38485 
CG5255 
BL52874 
HMC0
3612  NE      
CG5909 FBgn00
39495 
CG5909 
BL52876 
HMC0
3614  NE      
CG1023
2 
FBgn00
39108 
CG10232 
BL52891 
HMC0
3629  NE      
CG1747
5 
FBgn00
38481 
CG17475 
BL52895 
HMC0
3634  NE      
CG7142 FBgn00
38595 
CG7142 
BL52899 
HMC0
3638  NE      
CG3359 FBgn02
60745 
mfas 
BL52905 
HMC0
3645  NE      
CG4625 FBgn00
40212 
Dhap-at 
BL52914 
HMC0
3654  NE      
CG1552
3 
FBgn00
39727 
CG15523 
BL52915 
HMC0
3655  NE      
CG1487
0 
FBgn00
38342 
CG14870 
BL52916 
HMC0
3656  NE      
CG5044 FBgn00
38326 
CG5044 
BL52917 
HMC0
3657  NE      
CG5896 FBgn00
39494 
grass 
BL52946 
HMJ2
1613  NE      
CG3430
7 
FBgn00
85336 
CG34307 
BL52953 
HMJ2
1622  NE      
CG4342
7 
FBgn02
63346 
CG43427 
BL52982 
HMJ2
1669  NE      
CG4538 FBgn00
38745 
CG4538 
BL52989 
HMJ2
1681  NE      
CG5514 FBgn00
39560 
CG5514 
BL52994 
HMJ2
1706  NE      
CG4232
7 
FBgn02
59227 
CG42327 
BL52997 
HMJ2
1710  NE      
CG7582 FBgn00
39681 
CG7582 
BL53002 
HMJ2
1718  NE      
CG4673 FBgn00
39348 
Npl4 
BL53004 
HMJ2
1721  NE      
CG1489
4 
FBgn00
38428 
CG14894 
BL53005 
HMJ2
1722  NE      
CG3125
9 
FBgn00
51259 
CG31259 
BL53009 
HMJ2
1727  NE      
CG3363
0 
FBgn00
53630 
CG33630 
BL53015 
HMJ2
1738  NE      
CG6768 FBgn02
64326 
DNApol-epsilon 
BL53016 
HMJ2
1739  NE      
CG7709 FBgn00
38642 
Muc91C 
BL53018 
HMJ2
1741  NE      
CG7850 FBgn02
43512 
puc 
BL53019 
HMJ2
1742 
(MS 
POSSIBL
E) NE    ME  
CG3117
8 
FBgn00
64912 
CG31178 
BL53024 
HMJ2
1748  NE      
CG1756
5 
FBgn00
38424 
CG17565 
BL53029 
HMJ2
1755  NE      
CG5073 FBgn00
38331 
CG5073 
BL53283 
HMC0
3499  NE      
CG4225 FBgn00
38376 
Hmt-1 
BL53284 
HMC0
3500  NE      
CG5220 FBgn00
38471 
CG5220 
BL53285 
HMC0
3501  NE      
CG1801
2 
FBgn00
38552 
CG18012 
BL53286 
HMC0
3502  NE      
394 
 
CG4703 FBgn00
38742 
Arc42 
BL53287 
HMC0
3503  NE      
CG4159 FBgn00
38811 
CG4159 
BL53288 
HMC0
3504  NE      
CG1592
3 
FBgn00
38814 
CG15923 
BL53289 
HMC0
3505  NE      
CG5097 FBgn00
38790 
MtnC 
BL53292 
HMC0
3508  NE      
CG7622 FBgn00
02579 
RpL36 
BL53302 
HMC0
3529 A E E   E  
CG4260
1 
FBgn02
61053 
Cad86C 
BL53314 
HMC0
3543  NE      
CG5634 FBgn00
39528 
dsd 
BL53318 
HMC0
3547  NE      
CG1726
9 
FBgn00
38827 
Fancd2 
BL53329 
HMC0
3558  NE      
CG4917 FBgn00
39003 
wfs1 
BL53330 
HMC0
3559  NE      
CG5977 FBgn00
39141 
spas 
BL53331 
HMC0
3560  NE      
CG3111
6 
FBgn00
51116 
ClC-a 
BL53337 
HMC0
3566  NE      
CG6349 FBgn02
59113 
DNApol-
alpha180 BL53341 
HMC0
3570  NE      
CG3249
8 
FBgn00
00479 
dnc 
BL53344 
HMC0
3573  NE      
CG1198
7 
FBgn02
64075 
tgo 
BL53351 
HMC0
3580  NE      
CG1890 FBgn00
39869 
CG1890 
BL53677 
HMJ2
1731  NE      
CG3105
0 
FBgn00
51050 
CG31050 
BL53691 
HMJ2
1674  NE      
CG1426
0 
FBgn00
39504 
CG14260 
BL53698 
HMJ2
1719 A ME ME   E  
CG1364
6 
FBgn00
39255 
CG13646 
BL53701 
HMJ2
1732  NE      
CG3116
4 
FBgn00
51164 
Ir94a 
BL53703 
HMJ2
1737  NE      
CG1690
1 
FBgn02
63396 
sqd 
BL53891 
HMJ2
1209  NE      
CG3143
8 
FBgn00
51438 
CheB93b 
BL53911 
HMJ2
1244  NE      
CG3141
8 
FBgn00
51418 
CG31418 
BL53914 
HMJ2
1247  NE      
CG3294
4 
FBgn00
52944 
CG32944 
BL53916 
HMJ2
1251  NE      
CG1432
6 
FBgn00
38528 
CG14326 
BL53952 
HMJ2
1318  NE      
CG7362 FBgn00
38258 
CG7362 
BL53954 
HMJ2
1320  NE      
CG5913 FBgn00
39385 
CG5913 
BL53965 
HMJ2
1347  NE      
CG5692 FBgn00
40080 
raps 
BL53968 
HMJ2
1351  NE      
CG3126
2 
FBgn00
51262 
CG31262 
BL53970 
HMJ2
1355  NE      
CG1738
2 
FBgn00
39080 
Ir94h 
BL53975 
HMJ2
1363  NE      
CG5377 FBgn00
38974 
CG5377 
BL53977 
HMJ2
1366  NE      
CG4803 FBgn00
39015 
Takl2 
BL53985 
HMJ2
1386  NE      
CG6066 FBgn00
39488 
CG6066 
BL53997 
HMJ2
1401  NE      
CG3124
4 
FBgn00
51244 
CG31244 
BL54011 
HMJ2
1435  NE      
CG3247
3 
FBgn00
52473 
CG32473 
BL54013 
HMJ2
1437  NE      
CG2219 FBgn00
39889 
CG2219 
BL54014 
HMJ2
1438  NE      
395 
 
CG3145
3 
FBgn00
51453 
pch2 
BL54022 
HMJ2
1448 MS MS  S E  NE 
CG1366
4 
FBgn00
39294 
Cad96Cb 
BL54029 
HMJ2
1472  NE      
CG1710
9 
FBgn00
39051 
CG17109 
BL54033 
HMJ2
1476  NE      
CG1454
9 
FBgn00
39403 
Sld5 
BL54047 
HMJ2
1490  NE      
CG5292 FBgn00
38491 
CG5292 
BL54052 
HMS0
3523  NE      
CG3093 FBgn00
00482 
dor 
BL54460 
HMS0
3720  NE      
CG3109
2 
FBgn00
51092 
LpR2 
BL54461 
HMS0
3722  NE      
CG1433
2 
FBgn00
38509 
CG14332 
BL54800 
HMJ2
1494  NE      
CG5677 FBgn00
39172 
Spase22-23 
BL54801 
HMJ2
1495  NE      
CG6447 FBgn00
39437 
TwdlL 
BL54804 
HMJ2
1498  NE      
CG3125
8 
FBgn00
86697 
Cenp-C 
BL54806 
HMJ2
1500 A ME ME   ME  
CG1429
8 
FBgn00
38654 
CG14298 
BL54807 
HMJ2
1501  NE      
CG8495 FBgn02
61599 
RpS29 
BL54822 
HMJ2
1541 A ME ME   E  
CG1712
1 
FBgn00
39043 
CG17121 
BL54830 
HMJ2
1549  NE      
CG6073 FBgn00
39417 
CG6073 
BL54844 
HMJ2
1581  NE      
CG4334
3 
FBgn02
63048 
CG43343 
BL54848 
HMJ2
1585  NE      
CG1182
0 
FBgn00
39270 
PQBP1 
BL54852 
HMJ2
1589  NE      
CG3104
0 
FBgn00
51040 
Cog7 
BL55147 
HMC0
3758  NE      
CG9733 FBgn00
39759 
CG9733 
BL55149 
HMC0
3774  NE      
CG6422 FBgn00
39261 
CG6422 
(dYTHDF1) BL55151 
HMC0
3791 A ME ME   E  
CG1087
7 
FBgn00
38804 
CG10877 
BL55160 
HMC0
3835  NE      
CG2177 FBgn00
39902 
Zip102B 
BL55162 
HMC0
3837 MS MS  S ME  NE 
CG1249 FBgn02
61789 
SmD2 
BL55163 
HMC0
3839  NE      
CG6178 FBgn00
39156 
CG6178 
BL55166 
HMC0
3844  NE      
CG4334 FBgn00
38312 
CG4334 
BL55167 
HMC0
3846  NE      
CG3136
8 
FBgn00
51368 
CG31368 
BL55172 
HMC0
3852  NE      
CG1131
3 
FBgn00
39798 
CG11313 
BL55197 
HMC0
3894  NE      
CG1464
8 
FBgn02
63594 
lost 
BL55201 
HMC0
3901  NE      
CG1109 FBgn00
46222 
CG1109 
BL55249 
HMC0
3936  NE      
CG6300 FBgn00
38730 
CG6300 
BL55264 
HMC0
3951  NE      
CG1139
1 
FBgn00
38732 
CG11391 
BL55266 
HMC0
3953  NE      
CG1145
3 
FBgn00
38734 
CG11453 
BL55267 
HMC0
3954  NE      
CG1165
9 
FBgn00
38731 
CG11659 
BL55268 
HMC0
3955  NE      
CG7946 FBgn00
39743 
CG7946 
BL55274 
HMC0
3961  NE      
CG1587 FBgn00
24811 
Crk 
BL55277 
HMC0
3964  NE      
396 
 
CG6006 FBgn00
63649 
CG6006 
BL55282 
HMC0
3969 E E NE S E  NE 
CG1647 FBgn00
39602 
CG1647 
BL55292 
HMC0
3979  NE      
CG3407
3 
FBgn00
13672 
mt:ATPase6 
BL55297 
HMC0
3984  NE      
CG3119
9 
FBgn00
51199 
CG31199 
BL55339 
HMC0
4026  NE      
CG3120
0 
FBgn00
51200 
CG31200 
BL55340 
HMC0
4027 A E E   E  
CG1875
4 
FBgn00
42106 
CG18754 
BL55348 
HMC0
4035  NE      
CG1225
0 
FBgn02
61287 
ymp 
BL55356 
HMC0
4043  NE      
CG4272
4 
FBgn02
61641 
CG42724 
BL55357 
HMC0
4044  NE      
CG1420 FBgn00
39626 
Slu7 
BL55366 
HMC0
4054  NE      
CG7907 FBgn00
38887 
CG7907 
BL55370 
HMC0
4058  NE      
CG4934 FBgn00
00221 
brn 
BL55386 
HMC0
4074  NE      
CG5555 FBgn00
38686 
CG5555 
BL55402 
HMC0
4090  NE      
CG5246 FBgn00
38484 
CG5246 
BL55410 
HMC0
4098  NE      
CG3339 FBgn00
39510 
CG3339 
BL55605 
HMC0
3741  NE      
CG5938 FBgn00
46247 
CG5938 
BL55613 
HMC0
3752  NE      
CG1255
8 
FBgn00
39599 
CG12558 
BL55615 
HMC0
3754  NE      
CG1184
2 
FBgn00
39629 
CG11842 
BL55617 
HMC0
3760  NE      
CG1187
6 
FBgn00
39635 
CG11876 
BL55619 
HMC0
3762  NE      
CG7883 FBgn00
39726 
eIF2B-alpha 
BL55624 
HMC0
3768  NE      
CG3132
6 
FBgn00
51326 
CG31326 
BL55630 
HMC0
3777  NE      
CG1785
6 
FBgn00
39576 
CG17856 
BL55631 
HMC0
3778  NE      
CG3415
7 
FBgn02
60003 
Dys 
BL55641 
HMC0
3789  NE      
CG1021
0 
FBgn00
39117 
tst 
BL55647 
HMC0
3796  NE      
CG7903 FBgn00
39730 
CG7903 
BL55651 
HMC0
3800 A ME ME   ME  
CG1964 FBgn00
39688 
Kul 
BL55653 
HMC0
3803  NE      
CG7598 FBgn00
39689 
CG7598 
BL55660 
HMC0
3815  NE      
CG1029
3 
FBgn02
64491 
how 
BL55665 
HMC0
3820  NE      
CG5338 FBgn00
39129 
RpS19b 
BL55670 
HMC0
3825  NE      
CG4685 FBgn00
39349 
Ssadh 
BL55683 
HMC0
3868  NE      
CG1713
6 
FBgn02
60944 
Rbp1 
BL55688 
HMC0
3902  NE      
CG7698 FBgn02
61065 
Cpsf73 
BL55696 
HMC0
3910  NE      
CG4047
8 
FBgn00
27101 
Dyrk3 
BL55882 
HMC0
4155  NE      
CG7125 FBgn00
38603 
PKD 
BL55898 
HMC0
4179  NE      
CG1017
7 
FBgn00
39083 
CG10177 
BL55900 
HMC0
4182  NE      
CG1206
9 
FBgn00
39796 
CG12069 
BL55901 
HMC0
4183  NE      
397 
 
CG1153
3 
FBgn00
39908 
Asator 
BL55902 
HMC0
4184  NE      
CG3142
1 
FBgn00
46689 
Takl1 
BL55903 
HMC0
4186  NE      
CG3109
6 
FBgn00
39354 
Lgr3 
BL55910 
HMC0
4196  NE      
CG5728 FBgn00
39182 
CG5728 
BL55916 
HMC0
4202  NE      
CG3403
4 
FBgn00
54034 
CG34034 
BL55956 
HMC0
4245  NE      
CG3412
9 
FBgn00
83965 
CG34129 
BL55959 
HMC0
4253  NE      
CG4546 FBgn00
38373 
CG4546 
BL55977 
HMC0
4273  NE      
CG1488
0 
FBgn00
38422 
CG14880 
BL55978 
HMC0
4274  NE      
CG7629 FBgn00
38530 
AttD 
BL55979 
HMC0
4275 A E E   E  
CG1383
7 
FBgn00
39042 
CG13837 
BL55980 
HMC0
4276  NE      
CG6173 FBgn00
39155 
Kal1 
BL55981 
HMC0
4277  NE      
CG1185
3 
FBgn00
39298 
to 
BL55982 
HMC0
4278  NE      
CG6403 FBgn00
39453 
CG6403 
BL55983 
HMC0
4279  NE      
CG3348 FBgn00
40609 
CG3348 
BL55985 
HMC0
4281  NE      
CG1855
0 
FBgn00
41710 
yellow-f 
BL55988 
HMC0
4284  NE      
CG3107
7 
FBgn00
51077 
CG31077 
BL55991 
HMC0
4287  NE      
CG3128
6 
FBgn00
51286 
CG31286 
BL55992 
HMC0
4288  NE      
CG3129
6 
FBgn00
51296 
CG31296 
BL55993 
HMC0
4289  NE      
CG1488
2 
FBgn00
38429 
CG14882 
BL56006 
HMC0
4302  NE      
CG1364
3 
FBgn00
40601 
CG13643 
BL56017 
HMC0
4313  NE      
CG4743 FBgn00
39357 
CG4743 
BL56025 
HMC0
4321  NE      
CG6126 FBgn00
38407 
CG6126 
BL56038 
HMC0
4346 MS MS  NE E  NE 
CG2559 FBgn00
02562 
Lsp1alpha 
BL56039 
HMC0
4347  NE      
CG4090 FBgn00
38492 
Mur89F 
BL56041 
HMC0
4349  NE      
CG1719
2 
FBgn00
39472 
CG17192 
BL56042 
HMC0
4350  NE      
CG4281
3 
FBgn02
61995 
CG42813 
BL56045 
HMS0
4248  NE      
CG6194 FBgn00
38325 
CG6194 
BL56046 
HMS0
4249  NE      
CG8433 FBgn00
29175 
Ext2 
BL52883 
HMC0
3621  NE      
CG3350
2 
FBgn00
53502 
CG33502 
BL52907 
HMC0
3647  NE      
CG4030 FBgn00
34585 
CG4030 
BL52996 
HMJ2
1709  NE      
CG7300 FBgn00
32286 
CG7300 
BL53927 
HMJ2
1272  NE      
CG1332
3 
FBgn00
33788 
CG13323 
BL53969 
HMJ2
1352  NE      
CG9249 FBgn00
32922 
CG9249 
BL54042 
HMJ2
1485  NE      
CG1317 FBgn00
35333 
CG1317 
BL54802 
HMJ2
1301  NE      
CG4307
3 
FBgn02
62483 
Rbp 
BL54828 
HMJ2
1547  NE      
398 
 
CG1414
5 
FBgn00
36118 
blos2 
BL54835 
HMJ2
1554  NE      
CG5953 FBgn00
32587 
CG5953 
BL57287 
HMJ2
1225  NE      
CG5336 FBgn00
32409 
Ced-12 
BL58153 
HMJ2
2104  NE      
CG3312 FBgn00
14024 
Rnp4F 
BL58168 
HMJ2
2145  NE      
CG1403
0 
FBgn00
31696 
Bub1 
BL58185 
HMJ2
2162  NE      
CG1472
4 
FBgn00
19624 
CoVa 
BL58282 
HMJ2
2367  NE      
CG3041
1 
FBgn00
50411 
CG30411 
BL58318 
HMJ2
2443  NE      
CG8628 FBgn02
50836 
CG8628 
BL58343 
HMJ2
2474  NE      
CG8034 FBgn00
31011 
CG8034 
BL32340 
HMS0
0331  NE      
CG4365
8 
FBgn02
63706 
CG43658 
BL32341 
HMS0
0332  NE      
CG1223
8 
FBgn00
87008 
e(y)3 
BL32346 
HMS0
0337  NE      
CG1279
4 
FBgn00
28583 
lcs 
BL32353 
HMS0
0344  NE      
CG1412 FBgn00
31118 
RhoGAP19D 
BL32361 
HMS0
0352  NE      
CG1698
2 
FBgn00
25638 
Roc1a 
BL32362 
HMS0
0353  NE      
CG3051 FBgn00
23169 
SNF1A 
BL32371 
HMS0
0362  NE      
CG8805 FBgn00
41087 
wun2 
BL32381 
HMS0
0372  NE      
CG4200 FBgn00
03416 
sl 
BL32385 
HMS0
0377  NE      
CG7041 FBgn00
30082 
HP1b 
BL32401 
HMS0
0396  NE      
CG4227
6 
FBgn02
59171 
Pde9 
BL32412 
HMS0
0407  NE      
CG1094
4 
FBgn02
61592 
RpS6 
BL32418 
HMS0
0413 E E NE S MS  NE 
CG3595 FBgn00
03514 
sqh 
BL32439 
HMS0
0437  NE      
CG1212
4 
FBgn02
60789 
mxc 
BL32446 
HMS0
0444  NE      
CG7065 FBgn00
30091 
CG7065 
BL32449 
HMS0
0448  NE      
CG7098 FBgn00
30891 
dik 
BL32451 
HMS0
0450  NE      
CG3480 FBgn00
23509 
mip130 
BL32462 
HMS0
0462  NE      
CG9156 FBgn00
03132 
Pp1-13C 
BL32465 
HMS0
0465  NE      
CG4336 FBgn00
03302 
rux 
BL32467 
HMS0
0467  NE      
CG1142
7 
FBgn00
03210 
rb 
BL32477 
HMS0
0479  NE      
CG1210
9 
FBgn00
30054 
Caf1-180 
BL32478 
HMS0
0480  NE      
CG1444
6 
FBgn02
62730 
CG14446 
BL32487 
HMS0
0490  NE      
CG1633 FBgn00
40309 
Jafrac1 
BL32498 
HMS0
0501  NE      
CG4303 FBgn00
25463 
Bap60 
BL32503 
HMS0
0507  NE      
CG1636 FBgn00
30030 
CG1636 
BL32508 
HMS0
0512  NE      
CG7556 FBgn00
30990 
CG7556 
BL32511 
HMS0
0515  NE      
CG4453 FBgn00
61200 
Nup153 
BL32837 
HMS0
0527  NE      
399 
 
CG9057 FBgn00
30608 
Lsd-2 
BL32846 
HMS0
0629  NE      
CG1810 FBgn00
30556 
mRNA-cap 
BL32847 
HMS0
0631 LacZ-S MS ME MS MS E MS 
CG2998 FBgn00
30136 
RpS28b 
BL32850 
HMS0
0635  NE      
CG3354
2 
FBgn00
53542 
upd3 
BL32859 
HMS0
0646  NE      
CG1331
7 
FBgn00
44046 
Ilp7 
BL32862 
HMS0
0649  NE      
CG1698
3 
FBgn00
25637 
skpA 
BL32870 
HMS0
0657  NE      
CG3455 FBgn00
28685 
Rpt4 
BL32874 
HMS0
0661 A ME ME   E  
CG3226 FBgn00
29882 
CG3226 
BL32875 
HMS0
0662  NE      
CG5599 FBgn00
30612 
CG5599 
BL32876 
HMS0
0663  NE      
CG1336
3 
FBgn00
25639 
Hmt4-20 
BL32892 
HMS0
0681  NE      
CG8915 FBgn00
30833 
CG8915 
BL32908 
HMS0
0697  NE      
CG1337
4 
FBgn00
11822 
pcl 
BL32943 
HMS0
0737  NE      
CG2272 FBgn00
30018 
slpr 
BL32948 
HMS0
0742  NE      
CG7107 FBgn00
04169 
up 
BL32949 
HMS0
0743  NE      
CG1743
7 
FBgn00
40066 
wds 
BL32952 
HMS0
0746  NE      
CG4313 FBgn00
25632 
CG4313 
BL32960 
HMS0
0755  NE      
CG1594 FBgn00
04864 
hop 
BL32966 
HMS0
0761  NE      
CG1214
1 
FBgn00
27084 
Aats-lys 
BL32967 
HMS0
0763  NE      
CG4078 FBgn00
29798 
CG4078 
BL32973 
HMS0
0770  NE      
CG8128 FBgn00
30668 
CG8128 
BL33012 
HMS0
0812  NE      
CG1158
5 
FBgn00
30543 
CG11585 
BL33337 
HMS0
0203  NE      
CG1481
6 
FBgn00
23517 
Pgam5 
BL33346 
HMS0
0212  NE      
CG1826
2 
FBgn00
30012 
CG18262 
BL33348 
HMS0
0215  NE      
CG3414
5 
FBgn00
83981 
RunxA 
BL33353 
HMS0
0224  NE      
CG8289 FBgn00
30854 
CG8289 
BL33361 
HMS0
0233  NE      
CG1099
8 
FBgn00
31142 
r-cup 
BL33387 
HMS0
0264  NE      
CG4049
4 
FBgn00
25836 
RhoGAP1A 
BL33390 
HMS0
0267  NE      
CG1849
2 
FBgn00
26323 
Tak1 
BL33404 
HMS0
0282  NE      
CG5227 FBgn00
21764 
sdk 
BL33412 
HMS0
0292  NE      
CG3711 FBgn00
40344 
CG3711 
BL33422 
HMS0
0306  NE      
CG6903 FBgn00
29737 
CG6903 
BL33423 
HMS0
0307  NE      
CG3917 FBgn00
26430 
Grip84 
BL33548 
HMS0
0627  NE      
CG1273
7 
FBgn00
25864 
Crag 
BL33594 
HMS0
0241  NE      
CG3936 FBgn00
04647 
N 
BL33611 
HMS0
0001 A E-L E-L   E-L  
CG2759 FBgn00
03996 
w 
BL33613 
HMS0
0004 A E-L E-L   E-L  
400 
 
CG1579
3 
FBgn00
10269 
Dsor1 
BL33639 
HMS0
0037  NE      
CG1560 FBgn00
04657 
mys 
BL33642 
HMS0
0043  NE      
CG7035 FBgn00
22942 
Cbp80 
BL33648 
HMS0
0052  NE      
CG2577 FBgn00
30384 
CG2577 
BL33649 
HMS0
0054  NE      
CG9096 FBgn00
10315 
CycD 
BL33653 
HMS0
0059  NE      
CG4266
6 
FBgn02
61548 
CG42666 
BL33665 
HMS0
0075  NE      
CG1841
2 
FBgn00
04861 
ph-p 
BL33669 
HMS0
0082  NE      
CG5993 FBgn00
04956 
os 
BL33680 
HMS0
0545  NE      
CG1404
9 
FBgn00
44047 
Ilp6 
BL33684 
HMS0
0549  NE      
CG2221 FBgn00
28331 
l(1)G0289 
BL33690 
HMS0
0558  NE      
CG3025 FBgn00
14340 
mof 
BL33698 
HMS0
0573  NE      
CG3171 FBgn00
46687 
Tre1 
BL33718 
HMS0
0599  NE      
CG1637 FBgn00
30245 
CG1637 
BL33733 
HMS0
0616  NE      
CG3410
4 
FBgn00
83940 
CG34104 
BL33738 
HMS0
0622  NE      
CG6223 FBgn00
08635 
betaCop 
BL33741 
HMS0
1079 A E-L E-L   E-L  
CG2186 FBgn00
30243 
CG2186 
BL33750 
HMS0
1090  NE      
CG2655 FBgn00
11276 
HLH3B 
BL33758 
HMS0
1101  NE      
CG4399 FBgn02
61954 
east 
BL33879 
HMS0
0816  NE      
CG4044
0 
FBgn00
46697 
Ppr-Y 
BL33882 
HMS0
0819  NE      
CG1109
2 
FBgn00
27537 
CG11092 
BL33908 
HMS0
0850  NE      
CG2286 FBgn00
17566 
ND75 
BL33910 
HMS0
0853  NE      
CG1422
4 
FBgn00
31057 
Ubqn 
BL33917 
HMS0
0860  NE      
CG9907 FBgn02
64255 
para 
BL33923 
HMS0
0868  NE      
CG1194
1 
FBgn00
26175 
skpC 
BL33925 
HMS0
0871  NE      
CG1096
1 
FBgn00
26318 
Traf6 
BL33931 
HMS0
0880  NE      
CG1070
1 
FBgn00
11661 
Moe 
BL33936 
HMS0
0886  NE      
CG4261
1 
FBgn02
61260 
mgl 
BL33940 
HMS0
0891  NE      
CG1221
2 
FBgn00
03053 
peb 
BL33943 
HMS0
0894  NE      
CG5988 FBgn00
30904 
upd2 
BL33949 
HMS0
0901  NE      
CG1099
2 
FBgn00
30521 
CtsB1 
BL33953 
HMS0
0906  NE      
CG1453 FBgn00
30268 
Klp10A 
BL33963 
HMS0
0920  NE      
CG1138
7 
FBgn00
04198 
ct 
BL33967 
HMS0
0924 A E E   E  
CG8649 FBgn00
24238 
Fim 
BL33977 
HMS0
0937  NE      
CG6222 FBgn00
03575 
su(s) 
BL33982 
HMS0
0942  NE      
CG3441
2 
FBgn00
86899 
tlk 
BL33983 
HMS0
0943 A E E   E  
401 
 
CG3187 FBgn00
29783 
Sirt4 
BL33984 
HMS0
0944  NE      
CG2033 FBgn00
10198 
RpS15Aa 
BL34005 
HMS0
0968 A E-L E   E  
CG2947 FBgn00
29676 
HIP-R 
BL34018 
HMS0
0988  NE      
CG9609 FBgn00
30787 
CG9609 
BL34030 
HMS0
1000  NE      
CG1274
3 
FBgn00
03023 
otu 
BL34065 
HMS0
0038  NE      
CG7486 FBgn00
20381 
Dredd 
BL34070 
HMS0
0063  NE      
CG6170 FBgn00
26428 
HDAC6 
BL34072 
HMS0
0077  NE      
CG1825
9 
FBgn00
30956 
CG18259 
BL34081 
HMS0
1089  NE      
CG4013 FBgn02
63865 
Smr 
BL34087 
HMS0
0842 A E E   E  
CG9774 FBgn00
26181 
rok 
BL34324 
HMS0
1311  NE      
CG1215
4 
FBgn00
04102 
oc 
BL34327 
HMS0
1314  NE      
CG1447
6 
FBgn00
27588 
CG14476 
BL34334 
HMS0
1322  NE      
CG3267
2 
FBgn00
52672 
Atg8a 
BL34340 
HMS0
1328  NE      
CG1270
3 
FBgn00
31069 
Pmp70 
BL34349 
HMS0
1338  NE      
CG4332 FBgn00
30456 
CG4332 
BL34352 
HMS0
1341  NE      
CG7053 FBgn00
30960 
CG7053 
BL34360 
HMS0
1349 A ME ME   E  
CG3004 FBgn02
64691 
Lst8 
BL34361 
HMS0
1350 MS MS ME S S ME NE 
CG1749 FBgn00
30305 
CG1749 
BL34363 
HMS0
1352  NE      
CG3267
0 
FBgn00
52670 
Rab9Fb 
BL34374 
HMS0
1364  NE      
CG2849 FBgn00
15286 
Rala 
BL34375 
HMS0
1365 A ME E E E-L E  
CG9355 FBgn00
04511 
dy 
BL34382 
HMS0
1372  NE      
CG4377
0 
FBgn02
64270 
Sxl 
BL34393 
HMS0
0609  NE      
CG1578
4 
FBgn00
29766 
CG15784 
BL34529 
HMS0
0983  NE      
CG9581 FBgn00
31093 
CG9581 
BL34547 
HMS0
1018  NE      
CG3239 FBgn00
29769 
CG3239 
BL34558 
HMS0
1030  NE      
CG4330 FBgn00
30452 
MFS10 
BL34562 
HMS0
1034  NE      
CG3034 FBgn00
40339 
MED22 
BL34573 
HMS0
1047  NE      
CG4269
9 
FBgn02
61610 
CG42699 
BL34591 
HMS0
1065  NE      
CG4528 FBgn00
03449 
snf 
BL34593 
HMS0
1067 
(ME 
POSSIBL
E) NE NE NE NE NE  
CG3585 FBgn00
23458 
Rbcn-3A 
BL34612 
HMS0
1287  NE      
CG9022 FBgn00
14868 
Ost48 
BL34628 
HMS0
1303  NE      
CG1206
5 
FBgn00
30052 
CG12065 
BL34636 
HMS0
1111  NE      
CG6407 FBgn00
10194 
Wnt5 
BL34644 
HMS0
1119  NE      
CG1336
6 
FBgn00
25633 
CG13366 
BL34656 
HMS0
1133  NE      
402 
 
CG1573
5 
FBgn00
30364 
CG15735 
BL34666 
HMS0
1143  NE      
CG4206 FBgn00
24332 
Mcm3 
BL34686 
HMS0
1164  NE      
CG3291 FBgn00
20261 
pcm 
BL34690 
HMS0
1169  NE      
CG1052
1 
FBgn00
15774 
NetB 
BL34698 
HMS0
1177  NE      
CG1849 FBgn00
03300 
run 
BL34707 
HMS0
1186  NE      
CG1490 FBgn00
30366 
Usp7 
BL34708 
HMS0
1187  NE      
CG7033 FBgn00
30086 
CG7033 
BL34711 
HMS0
1190  NE      
CG1489 FBgn00
20369 
Pros45 
BL34712 
HMS0
1191  NE      
CG3573 FBgn00
23508 
Ocrl 
BL34722 
HMS0
1201  NE      
CG9784 FBgn00
30761 
CG9784 
BL34723 
HMS0
1202  NE      
CG1210
1 
FBgn00
15245 
Hsp60 
BL34729 
HMS0
1209  NE      
CG3129 FBgn00
15794 
Rab18 
BL34734 
HMS0
1214  NE      
CG1770 FBgn00
41210 
HDAC4 
BL34774 
HMS0
0083  NE      
CG8264 FBgn00
04856 
Bx42 
BL34777 
HMS0
0086 A E-L E   E  
CG2995 FBgn00
40372 
G9a 
BL34817 
HMS0
0127  NE      
CG7434 FBgn00
15288 
RpL22 
BL34828 
HMS0
0143 A E E   E  
CG3606 FBgn00
11571 
caz 
BL34839 
HMS0
0156  NE      
CG9177 FBgn00
30719 
eIF5 
BL34841 
HMS0
0159 S S  MS NE  NE 
CG1430 FBgn00
10292 
bys 
BL34876 
HMS0
0196 E E NE NE NE  
(ME 
possible) 
CG9212 FBgn00
30724 
Nipsnap 
BL34887 
HMS0
1232  NE      
CG7359 FBgn02
60855 
Sec22 
BL34893 
HMS0
1238  NE      
CG1643 FBgn00
29943 
Atg5 
BL34899 
HMS0
1244  NE      
CG1691
6 
FBgn00
28686 
Rpt3 
BL34917 
HMS0
1265  NE      
CG1269
0 
FBgn00
29504 
CHES-1-like 
BL34928 
HMS0
1277  NE      
CG8989 FBgn00
04828 
His3.3B 
BL34940 
HMS0
0148  NE      
CG3277
5 
FBgn00
66114 
GlcAT-I 
BL34946 
HMS0
0289  NE      
CG1784
1 
FBgn00
28480 
CG17841 
BL34948 
HMS0
0305  NE      
CG1213
5 
FBgn00
40235 
c12.1 
BL34952 
HMS0
0382 A ME ME   ME  
CG1422
8 
FBgn00
86384 
Mer 
BL34958 
HMS0
0459  NE      
CG1691 FBgn02
62735 
Imp 
BL34977 
HMS0
1168  NE      
CG1220
2 
FBgn00
31020 
Nat1 
BL34990 
HMS0
1400  NE      
CG4259
4 
FBgn02
60971 
CG42594 
BL35006 
HMS0
1416  NE      
CG2934 FBgn00
28665 
VhaAC39-1 
BL35029 
HMS0
1442 A ME E   E  
CG1204
7 
FBgn00
02873 
mud 
BL35044 
HMS0
1458  NE      
CG3346 FBgn00
25739 
pon 
BL35046 
HMS0
1460  NE      
403 
 
CG9045 FBgn00
02914 
Myb 
BL35053 
HMS0
1467  NE      
CG9038 FBgn00
26076 
UBL3 
BL35745 
HMS0
1487  NE      
CG1545
9 
FBgn00
31108 
CG15459 
BL35757 
HMS0
1503  NE      
CG1479
1 
FBgn00
25382 
Rab27 
BL35774 
HMS0
1523  NE      
CG1343 FBgn00
20378 
Sp1 
BL35777 
HMS0
1526  NE      
CG3325
3 
FBgn00
30992 
CG33253 
BL36106 
HMS0
0158  NE      
CG1139
8 
FBgn00
40366 
CG11398 
BL36109 
HMS0
0201  NE      
CG3270
3 
FBgn00
52703 
Erk7 
BL36110 
HMS0
0222  NE      
CG4227
3 
FBgn02
59168 
mnb 
BL36657 
HMS0
1545 A E ME   E  
CG1694
4 
FBgn00
03360 
sesB 
BL36661 
HMS0
1549  NE      
CG6352 FBgn00
26058 
OdsH 
BL36666 
HMS0
1554  NE      
CG1531
9 
FBgn02
61617 
nej 
BL36682 
HMS0
1570 A E ME   E  
CG8002 FBgn00
31006 
rictor 
BL36699 
HMS0
1588  NE      
CG1803 FBgn00
30362 
regucalcin 
BL36708 
HMS0
1598  NE      
CG1592
9 
FBgn00
29800 
lin-52 
BL36712 
HMS0
1602  NE      
CG6269 FBgn00
24184 
unc-4 
BL36713 
HMS0
1603  NE      
CG8184 FBgn00
30674 
CG8184 
BL36714 
HMS0
1604  NE      
CG1681 FBgn00
30484 
GstT4 
BL36717 
HMS0
1607  NE      
CG4380 FBgn00
03964 
usp 
BL36729 
HMS0
1620  NE      
CG3972 FBgn00
10019 
Cyp4g1 
BL36737 
HMS0
1628  NE      
CG3861 FBgn02
61955 
kdn 
BL36740 
HMS0
1631  NE      
CG7413 FBgn00
15799 
Rbf 
BL36744 
HMS0
3004  NE      
CG1747 FBgn00
30300 
Sk1 
BL36747 
HMS0
3007  NE      
CG1583 FBgn00
30013 
GIIIspla2 
BL36757 
HMS0
3017  NE      
CG4262
8 
FBgn02
61379 
rad 
BL36758 
HMS0
3018  NE      
CG1753 FBgn00
31148 
Cbs 
BL36767 
HMS0
3028  NE      
CG1376
2 
FBgn00
40333 
brv3 
BL36774 
JF023
89  NE      
CG1808
5 
FBgn00
03366 
sev 
BL36778 
JF023
93  NE      
CG1536
5 
FBgn00
30077 
CG15365 
BL36856 
HMS0
0293  NE      
CG3848 FBgn00
23518 
trr 
BL36916 
HMS0
1019  NE      
CG1810
2 
FBgn00
03392 
shi 
BL36921 
HMS0
0154  NE      
CG1634 FBgn02
64975 
Nrg 
BL37496 
HMS0
1638  NE      
CG9904 FBgn00
40336 
Seipin 
BL37501 
HMS0
1643  NE      
CG3275
8 
FBgn00
52758 
CG32758 
BL38225 
HMS0
1669  NE      
CG6873 FBgn00
30951 
CG6873 
BL38226 
HMS0
1670  NE      
404 
 
CG4898 FBgn00
03721 
Tm1 
BL38232 
HMS0
1676  NE      
CG1026
0 
FBgn02
61922 
PI4KIIIalpha 
BL38242 
HMS0
1686  NE      
CG7925 FBgn00
03714 
tko 
BL38251 
HMS0
1695  NE      
CG9938 FBgn00
30500 
Ndc80 
BL38260 
HMS0
1704  NE      
CG4523 FBgn00
29891 
Pink1 
BL38262 
HMS0
1707  NE      
CG9195 FBgn00
40285 
Scamp 
BL38277 
HMS0
1728  NE      
CG1685 FBgn00
15527 
pen 
BL38290 
HMS0
1748  NE      
CG2621 FBgn00
03371 
sgg 
BL38293 
HMS0
1751 A E E   E  
CG1209
2 
FBgn02
61675 
Npc1b 
BL38296 
HMS0
1757  NE      
CG3395
0 
FBgn02
61451 
trol 
BL38298 
HMS0
1759  NE      
CG9214 FBgn00
28397 
Tob 
BL38299 
HMS0
1760  NE      
CG1782
8 
FBgn00
16038 
mod(r) 
BL38304 
HMS0
1766  NE      
CG4234
3 
FBgn02
59245 
CG42343 
BL38310 
HMS0
1774  NE      
CG9968 FBgn00
30749 
Anxb11 
BL38311 
HMS0
1775  NE      
CG1826 FBgn00
30228 
CG1826 
BL38324 
HMS0
1788  NE      
CG6606 FBgn00
27335 
Rip11 
BL38325 
HMS0
1792  NE      
CG3632 FBgn00
30735 
CG3632 
BL38341 
HMS0
1808  NE      
CG1421
1 
FBgn00
31044 
MKP-4 
BL38342 
HMS0
1809  NE      
CG1421
6 
FBgn00
31054 
Ssu72 
BL38344 
HMS0
1811  NE      
CG1759
8 
FBgn00
31194 
CG17598 
BL38345 
HMS0
1812  NE      
CG1375
8 
FBgn02
60753 
Pdfr 
BL38347 
HMS0
1815  NE      
CG1172
7 
FBgn02
62740 
CG11727 
BL38350 
HMS0
1818  NE      
CG1718 FBgn00
31170 
CG1718 
BL38353 
HMS0
1821  NE      
CG3412
0 
FBgn00
83956 
CG34120 
BL38356 
HMS0
1824 E-L E-L ME E E-L ME NE 
CG1673 FBgn00
30482 
CG1673 
BL38363 
HMS0
1832  NE      
CG6899 FBgn00
04368 
Ptp4E 
BL38369 
HMS0
1838  NE      
CG3250
5 
FBgn00
23177 
Pp4-19C 
BL38372 
HMS0
1841  NE      
CG3281
4 
FBgn00
52814 
CG32814 
BL38383 
HMS0
1852  NE      
CG9198 FBgn00
04391 
shtd 
BL38531 
HMS0
1744 A E E   E  
CG5870 FBgn02
50788 
beta-Spec 
BL38533 
HMS0
1746  NE      
CG1554 FBgn00
03277 
RpII215 
BL38537 
HMS0
1761  NE      
CG1775
4 
FBgn00
30114 
CG17754 
BL38539 
HMS0
1830  NE      
CG9984 FBgn00
10416 
TH1 
BL38934 
HMS0
0283  NE      
CG3269
7 
FBgn00
28341 
l(1)G0232 
BL38935 
HMS0
0731  NE      
CG1480
4 
FBgn00
14411 
Vps26 
BL38937 
HMS0
1769  NE      
405 
 
CG3262
6 
FBgn00
52626 
CG32626 
BL38953 
HMS0
1867  NE      
CG4224
9 
FBgn02
59101 
CG42249 
BL38955 
HMS0
1869  NE      
CG3279
1 
FBgn00
52791 
CG32791 
BL38965 
HMS0
1879  NE      
CG9819 FBgn00
30758 
CanA-14F 
BL38966 
HMS0
1880  NE      
CG3274
4 
FBgn00
86558 
Ubi-p5E 
BL38967 
HMS0
1881  NE      
CG1215
1 
FBgn00
29958 
Pdp 
BL38972 
HMS0
1888  NE      
CG1812 FBgn00
31119 
CG1812 
BL38974 
HMS0
1890  NE      
CG1061
7 
FBgn02
61085 
Syt12 
BL38978 
HMS0
1894  NE      
CG3271
7 
FBgn02
61873 
sdt 
BL38988 
HMS0
1904  NE      
CG1817 FBgn00
04370 
Ptp10D 
BL39001 
HMS0
1917  NE      
CG5884 FBgn00
26192 
par-6 
BL39010 
HMS0
1928  NE      
CG1107 FBgn00
37218 
aux 
BL39017 
HMS0
1935  NE      
CG1589
9 
FBgn02
64386 
Ca-alpha1T 
BL39029 
HMS0
1948  NE      
CG3842 FBgn00
29866 
CG3842 
BL39030 
HMS0
1949  NE      
CG8916 FBgn00
30707 
CG8916 
BL39031 
HMS0
1950  NE      
CG1514 FBgn00
29976 
snz 
BL39036 
HMS0
1956  NE      
CG3318
1 
FBgn00
53181 
CG33181 
BL39056 
HMS0
1976  NE      
CG1462
2 
FBgn00
25641 
DAAM 
BL39058 
HMS0
1978  NE      
CG7893 FBgn00
40068 
vav 
BL39059 
HMS0
1979  NE      
CG1092
0 
FBgn00
29963 
CG10920 
BL39068 
HMS0
1988  NE      
CG2984 FBgn00
22768 
Pp2C1 
BL40827 
HMS0
1887  NE      
CG1219
9 
FBgn00
31016 
kek5 
BL40830 
HMS0
1996  NE      
CG3259
3 
FBgn02
64078 
Flo-2 
BL40833 
HMS0
1999  NE      
CG3438
7 
FBgn02
59108 
futsch 
BL40834 
HMS0
2000  NE      
CG7192 FBgn00
30894 
CG7192 
BL40838 
HMS0
2004  NE      
CG9650 FBgn00
29939 
CG9650 
BL40852 
HMS0
2019  NE      
CG2124 FBgn00
30217 
CG2124 
BL40868 
HMS0
2035  NE      
CG9842 FBgn00
11826 
Pp2B-14D 
BL40872 
HMS0
2039  NE      
CG2647 FBgn00
03068 
per 
BL40878 
HMS0
2045  NE      
CG1141
5 
FBgn00
24361 
Tsp2A 
BL40899 
HMS0
2147  NE      
CG3351
3 
FBgn00
53513 
Nmdar2 
BL40928 
HMS0
2176  NE      
CG1444
7 
FBgn00
29830 
Grip 
BL40930 
HMS0
2178  NE      
CG1441
1 
FBgn00
30582 
CG14411 
BL40935 
HMS0
2183  NE      
CG8590 FBgn00
11606 
Klp3A 
BL40944 
HMS0
2192  NE      
CG2262 FBgn00
25800 
Smox 
BL41670 
HMS0
2203  NE      
406 
 
CG4690 FBgn00
29837 
Tsp5D 
BL41681 
HMS0
2245  NE      
CG3257
7 
FBgn00
42650 
disco-r 
BL41683 
HMS0
2247  NE      
CG4286
4 
FBgn02
62111 
f 
BL41687 
HMS0
2251  NE      
CG4365
7 
FBgn02
63705 
Myo10A 
BL41691 
HMS0
2255 A E NE NE NE E NE 
CG2252 FBgn00
04656 
fs(1)h 
BL41693 
HMS0
2257 A E E   E  
CG4532 FBgn00
29903 
pod1 
BL41705 
HMS0
2270  NE      
CG2028 FBgn00
15024 
CkIalpha 
BL41711 
HMS0
2276 A ME ME   E  
CG1858
2 
FBgn00
25743 
mbt 
BL41713 
HMS0
2278  NE      
CG7113 FBgn00
21765 
scu 
BL41884 
HMS0
2305  NE      
CG1442
6 
FBgn00
04143 
nullo 
BL41905 
HMS0
2297  NE      
CG4320 FBgn00
29840 
raptor 
BL41912 
HMS0
2306  NE      
CG4521 FBgn00
30766 
mthl1 
BL41930 
HMS0
2327  NE      
CG4252 FBgn00
04367 
mei-41 
BL41934 
HMS0
2331  NE      
CG1421
7 
FBgn00
31030 
Tao 
BL41936 
HMS0
2333  NE      
CG1106
3 
FBgn00
30530 
jub 
BL41938 
HMS0
2335  NE      
CG3274
3 
FBgn02
63968 
nonC 
BL41945 
HMS0
2342  NE      
CG8394 FBgn00
33911 
VGAT 
BL41958 
HMS0
2355  NE      
CG3299 FBgn00
04397 
Vinc 
BL41959 
HMS0
2356  NE      
CG1126
5 
FBgn00
30049 
Trf4-1 
BL41966 
HMS0
2363  NE      
CG2111 FBgn00
30223 
CG2111 
BL41969 
HMS0
2366  NE      
CG3269
4 
FBgn00
52694 
CG32694 
BL41975 
HMS0
2373  NE      
CG9806 FBgn00
30222 
CG9806 
BL41994 
HMS0
2395  NE      
CG1442
4 
FBgn00
25644 
CG14424 
BL41995 
HMS0
2396  NE      
CG6927 FBgn00
29733 
CG6927 
BL42001 
HMS0
2402  NE      
CG1573
0 
FBgn00
30395 
CG15730 
BL42002 
HMS0
2403  NE      
CG1211
5 
FBgn00
30097 
CG12115 
BL42003 
HMS0
2404  NE      
CG7206 FBgn00
30892 
CG7206 
BL42004 
HMS0
2405 A E ME   ME  
CG1591
6 
FBgn00
30704 
CG15916 
BL42008 
HMS0
2409  NE      
CG1535
0 
FBgn00
14465 
Cp7Fb 
BL42009 
HMS0
2410  NE      
CG4653 FBgn00
30776 
CG4653 
BL42012 
HMS0
2413  NE      
CG1664 FBgn00
03321 
sbr/NXF1 
BL42013 
HMS0
2414 S S  S MS  NE 
CG2890 FBgn00
30208 
PPP4R2r 
BL42015 
HMS0
2416  NE      
CG1270
1 
FBgn02
59789 
vfl 
BL42016 
HMS0
2441  NE      
CG8142 FBgn00
30871 
CG8142 
BL42489 
HMJ0
2051  NE      
CG1657 FBgn00
30286 
CG1657 
BL42490 
HMJ0
2054  NE      
407 
 
CG8924 FBgn00
30710 
CG8924 
BL42491 
HMJ0
2055  NE      
CG1574
4 
FBgn00
30466 
CG15744 
BL42497 
HMJ0
2061  NE      
CG1830 FBgn00
11754 
PhKgamma 
BL42500 
HMJ0
2065  NE      
CG1716 FBgn00
30486 
Set2 
BL42511 
HMJ0
2076  NE      
CG2116 FBgn00
30003 
CG2116 
BL42512 
HMJ0
2077  NE      
CG1108
5 
FBgn00
30408 
CG11085 
BL42516 
HMJ0
2082  NE      
CG2061 FBgn00
27498 
CG2061 
BL42519 
HMJ0
2085  NE      
CG4937 FBgn00
30808 
RhoGAP15B 
BL42527 
HMJ0
2093  NE      
CG4400 FBgn00
30434 
CG4400 
BL42533 
HMJ0
2100  NE      
CG7122 FBgn00
30893 
RhoGAP16F 
BL42541 
HMJ0
2111  NE      
CG3011
5 
FBgn00
50115 
GEFmeso 
BL42545 
HMJ0
2116  NE      
CG3272
1 
FBgn00
27553 
NELF-B 
BL42547 
HMJ0
2119  NE      
CG4394 FBgn00
30748 
Traf-like 
BL42549 
HMJ0
2121  NE      
CG6506 FBgn00
30874 
CG6506 
BL42552 
HMJ0
2125  NE      
CG3308
0 
FBgn00
53080 
CG33080 
BL42554 
HMJ0
2127  NE      
CG1422
5 
FBgn00
31055 
et 
BL42557 
HMJ0
2213  NE      
CG1331
6 
FBgn00
23215 
Mnt 
BL42558 
HMJ0
2214  NE      
CG1848 FBgn00
41203 
LIMK1 
BL42576 
HMJ0
2235  NE      
CG1873
4 
FBgn00
04598 
Fur2 
BL42577 
HMJ0
2236  NE      
CG9065 FBgn00
30610 
CG9065 
BL42595 
HMS0
2427  NE      
CG3466 FBgn00
11576 
Cyp4d2 
BL42600 
HMS0
2432  NE      
CG3285
8 
FBgn00
03447 
sn 
BL42615 
HMS0
2450  NE      
CG6824 FBgn00
03028 
ovo 
BL42627 
HMS0
2462  NE      
CG1480
2 
FBgn00
26873 
MED18 
BL42634 
HMS0
2470  NE      
CG9900 FBgn00
04643 
mit(1)15 
BL42643 
HMS0
2479  NE      
CG4590 FBgn00
27108 
inx2 
BL42645 
HMS0
2481  NE      
CG2045 FBgn00
19929 
Ser7 
BL42649 
HMS0
2485  NE      
CG1857
2 
FBgn00
03189 
r 
BL42828 
HMS0
2510  NE      
CG3252
8 
FBgn00
52528 
CG32528 
BL42831 
HMS0
2523  NE      
CG1217
5 
FBgn00
30502 
tth 
BL42849 
HMS0
2541  NE      
CG1481
5 
FBgn00
23516 
Pex5 
BL42854 
HMS0
2546  NE      
CG1253
0 
FBgn00
10341 
Cdc42 
BL42861 
HMS0
2553  NE      
CG1442
1 
FBgn00
29644 
CG14421 
BL42865 
HMS0
2558 E E NE NE E  NE 
CG5966 FBgn00
29831 
CG5966 
BL42869 
HMS0
2562  NE      
CG1299
3 
FBgn00
30840 
p-cup 
BL42876 
HMS0
2569  NE      
408 
 
CG3056 FBgn00
24987 
ssx 
BL42881 
HMS0
2574  NE      
CG2056 FBgn00
30051 
spirit 
BL42882 
HMS0
2575  NE      
CG7766 FBgn00
30087 
CG7766 
BL42890 
HMS0
2583  NE      
CG9164 FBgn00
30634 
CG9164 
BL42899 
HMS0
2592  NE      
CG1532 FBgn00
31143 
CG1532 
BL42900 
HMS0
2593  NE      
CG1786 FBgn00
30369 
Cyp318a1 
BL42904 
HMS0
2597  NE      
CG6847 FBgn00
30884 
CG6847 
BL42908 
HMS0
2601  NE      
CG3044 FBgn00
29913 
Cht11 
BL42927 
HMS0
2620  NE      
CG1733
3 
FBgn00
30239 
CG17333 
BL42933 
HMS0
2626  NE      
CG1529
6 
FBgn00
30215 
CG15296 
BL42946 
HMS0
2639  NE      
CG1336
5 
FBgn00
29529 
CG13365 
BL42951 
HMS0
2644 A E-L E-L   E-L  
CG1207
5 
FBgn00
30065 
CG12075 
BL42952 
HMS0
2645  NE      
CG3446 FBgn00
29868 
CG3446 
BL43279 
HMC0
2678  NE      
CG9053 FBgn02
64389 
opm 
BL43280 
HMC0
2679  NE      
CG1474 FBgn00
23506 
Es2 
BL43285 
HMS0
2657  NE      
CG9675 FBgn00
30774 
spheroide 
BL43295 
HMS0
2668  NE      
CG3325
0 
FBgn00
65035 
AlkB 
BL43300 
HMS0
2673  NE      
CG1211
1 
FBgn00
30050 
CG12111 
BL43311 
HMS0
2695  NE      
CG3268
5 
FBgn00
52685 
ZAP3 
BL43317 
HMS0
2701  NE      
CG3977 FBgn00
62413 
Ctr1A 
BL44000 
HMS0
2714  NE      
CG1300
5 
FBgn00
30794 
CG13005 
BL44018 
HMS0
2733  NE      
CG2071 FBgn00
11834 
Ser6 
BL44026 
HMS0
2741  NE      
CG6998 FBgn00
11760 
ctp 
BL44044 
HMS0
2760  NE      
CG3039 FBgn00
04646 
ogre 
BL44048 
HMS0
2764 A ME ME   E  
CG1504
2 
FBgn00
30937 
CG15042 
BL44049 
HMS0
2765  NE      
CG2715 FBgn00
24980 
Syx4 
BL44054 
HMS0
2771  NE      
CG4407 FBgn00
30431 
CG4407 
BL44055 
HMS0
2772  NE      
CG4394
7 
FBgn02
64598 
PsGEF 
BL44061 
HMS0
2778  NE      
CG3268
3 
FBgn00
52683 
CG32683 
BL44079 
HMS0
2796  NE      
CG1440
6 
FBgn00
30595 
CG14406 
BL44081 
HMS0
2798  NE      
CG1987 FBgn00
30479 
Rbp1-like 
BL44100 
HMS0
2820  NE      
CG3266
6 
FBgn00
52666 
Drak 
BL44102 
HMS0
2822  NE      
CG4413
2 
FBgn02
64981 
mamo 
BL44103 
HMS0
2823  NE      
CG1782
9 
FBgn00
25635 
CG17829 
BL44104 
HMS0
2824  NE      
CG3280
8 
FBgn00
52808 
CG32808 
BL44270 
HMS0
2812  NE      
409 
 
CG4122 FBgn00
04648 
svr 
BL44487 
HMC0
2395  NE      
CG2675 FBgn00
24994 
Csat 
BL44488 
HMC0
2402  NE      
CG1479
6 
FBgn00
25390 
Mur2B 
BL44489 
HMC0
2403  NE      
CG1847 FBgn00
30345 
CG1847 
BL44490 
HMC0
2409  NE      
CG4678 FBgn00
30778 
CG4678 
BL44491 
HMC0
2413  NE      
CG1440 FBgn00
30038 
CG1440 
BL44521 
HMC0
2912  NE      
CG4096 FBgn00
29791 
CG4096 
BL44522 
HMC0
2914 MS MS  S MS  NE 
CG4030
5 
FBgn00
44872 
FucTC 
BL44540 
HMC0
2935  NE      
CG1771 FBgn00
04456 
mew 
BL44553 
HMS0
2849  NE      
CG1404 FBgn00
20255 
ran 
BL44587 
HMS0
2885 A ME E   E  
CG1706
3 
FBgn00
27107 
inx6 
BL44663 
HMS0
2883  NE      
CG4766 FBgn00
27546 
CG4766 
BL50605 
HMC0
2404  NE      
CG1055
5 
FBgn00
30034 
CG10555 
BL50606 
HMC0
2408  NE      
CG3024 FBgn00
25615 
Torsin 
BL50620 
HMC0
2987  NE      
CG3351
7 
FBgn00
53517 
D2R 
BL50621 
HMC0
2988  NE      
CG2263 FBgn00
30007 
CG2263 
BL50624 
HMC0
2991  NE      
CG2155 FBgn00
03965 
v 
BL50641 
HMC0
3041  NE      
CG4746 FBgn00
29003 
mab-21 
BL50644 
HMC0
3044  NE      
CG3275
1 
FBgn00
52751 
CG32751 
BL50653 
HMC0
3054  NE      
CG1252
9 
FBgn00
04057 
Zw 
BL50667 
HMC0
3068 A ME ME   ME  
CG1733
6 
FBgn00
10240 
Lcch3 
BL50668 
HMC0
3069  NE      
CG4136 FBgn02
63511 
Vsx1 
BL50684 
HMC0
3085  NE      
CG1597 FBgn00
30289 
CG1597 
BL50699 
HMC0
3101  NE      
CG1129
3 
FBgn00
34889 
CG11293 
BL50728 
HMS0
2964  NE      
CG6157 FBgn00
15926 
dah 
BL50733 
HMS0
2969  NE      
CG9802 FBgn00
15615 
Cap 
BL50899 
HMJ0
3116  NE      
CG1272
3 
FBgn00
30459 
CG12723 
BL50917 
HMJ2
1006  NE      
CR3265
8 
FBgn00
40859 
CR32658 
BL50928 
HMJ2
1022  NE      
CG9565 FBgn00
31081 
Nep3 
BL50930 
HMJ2
1024  NE      
CG2861 FBgn00
29728 
CG2861 
BL50931 
HMJ2
1025  NE      
CG3258
8 
FBgn00
52588 
CG32588 
BL50935 
HMJ2
1030  NE      
CG1515 FBgn02
60858 
Ykt6 
BL50937 
HMJ2
1032  NE      
CG4557 FBgn00
29912 
CG4557 
BL50953 
HMJ2
1054  NE      
CG2254 FBgn00
29994 
CG2254 
BL50999 
HMJ2
1112  NE      
CG1698
9 
FBgn00
25621 
CG16989 
BL51017 
HMJ2
1141  NE      
410 
 
CG6961 FBgn00
30959 
CG6961 
BL51022 
HMJ2
1148  NE      
CG1441
6 
FBgn00
40352 
CG14416 
BL51047 
HMJ2
1181  NE      
CG3253
8 
FBgn00
86778 
gfA 
BL51049 
HMJ2
1183  NE      
CG1573
6 
FBgn00
43001 
Chrac-16 
BL51155 
HMC0
2362  NE      
CG3002 FBgn00
30141 
Gga 
BL51170 
HMJ2
1093  NE      
CG1478
9 
FBgn00
27791 
O-fut2 
BL51392 
HMJ2
1038  NE      
CG1117
2 
FBgn00
30505 
NFAT 
BL51422 
HMC0
2411 
(ME 
POSSIBL
E) NE      
CG3262
7 
FBgn00
52627 
NnaD 
BL51430 
HMC0
3138  NE      
CG4315
4 
FBgn02
62684 
CG43154 
BL51431 
HMC0
3139  NE      
CG1037
9 
FBgn00
15513 
mbc 
BL51446 
HMC0
3172  NE      
CG3276
3 
FBgn00
26702 
l(1)G0045 
BL51448 
HMC0
3178  NE      
CG1079
8 
FBgn02
62656 
dm 
BL51454 
HMC0
3189 E-L E-L NE MS E-L  NE 
CG3260
2 
FBgn00
52602 
Muc12Ea 
BL51467 
HMC0
3207  NE      
CG1461 FBgn00
30558 
CG1461 
BL51470 
HMC0
3212  NE      
CG1165
4 
FBgn00
14455 
Ahcy13 
BL51477 
HMC0
3222  NE      
CG4317 FBgn00
26060 
Mipp2 
BL51482 
HMC0
3229  NE      
CG1574
3 
FBgn00
30465 
CG15743 
BL51486 
HMC0
3233  NE      
CG3973 FBgn00
29881 
pigs 
BL51490 
HMC0
3241  NE      
CG1889 FBgn00
30164 
CG1889 
BL51512 
HMC0
3288  NE      
CG4368
9 
FBgn02
63772 
CG43689 
BL51513 
HMC0
3290  NE      
CG1759
6 
FBgn02
62866 
S6kII 
BL51694 
HMC0
3140  NE      
CG1074
2 
FBgn00
40334 
Tsp3A 
BL51706 
HMC0
3196  NE      
CG1799 FBgn00
03204 
ras 
BL51717 
HMC0
3250  NE      
CG4234
6 
FBgn02
59677 
CG42346 
BL51719 
HMC0
3255  NE      
CG4318 FBgn00
30455 
CG4318 
BL51720 
HMC0
3257  NE      
CG1791 FBgn00
30163 
CG1791 
BL51727 
HMC0
3271  NE      
CG3270
2 
FBgn00
52702 
CG32702 
BL51736 
HMS0
3167  NE      
CG2685 FBgn00
24998 
CG2685 
BL51750 
HMC0
3301  NE      
CG4279
7 
FBgn02
61931 
CG42797 
BL51767 
HMC0
3322  NE      
CG3277
2 
FBgn00
52772 
CG32772 
BL51768 
HMC0
3323  NE      
CG1173
4 
FBgn00
31107 
HERC2 
BL51773 
HMC0
3328  NE      
CG4094 FBgn00
28336 
l(1)G0255 
BL51779 
HMC0
3334  NE      
CG1093
2 
FBgn00
29969 
CG10932 
BL51785 
HMC0
3340  NE      
CG1885 FBgn00
30066 
CG1885 
BL51786 
HMC0
3341  NE      
411 
 
CG9220 FBgn00
30662 
CG9220 
BL51787 
HMC0
3343  NE      
CG8909 FBgn00
30706 
CG8909 
BL51788 
HMC0
3344  NE      
CG9653 FBgn00
24250 
brk 
BL51789 
HMC0
3345  NE      
CG9413 FBgn00
30574 
CG9413 
BL51791 
HMC0
3347  NE      
CG9209 FBgn00
03969 
vap 
BL51793 
HMC0
3349  NE      
CG1140
3 
FBgn00
26876 
CG11403 
BL51800 
HMC0
3357  NE      
CG6358 FBgn00
04832 
Xpac 
BL51806 
HMC0
3365  NE      
CG1417 FBgn00
03423 
slgA 
BL51811 
HMC0
3382  NE      
CG1077
8 
FBgn00
29980 
CG10778 
BL51815 
HMC0
3386  NE      
CG4349 FBgn00
30449 
Fer3HCH 
BL51825 
HMC0
3397  NE      
CG1135
4 
FBgn00
26411 
Lim1 
BL51831 
HMC0
3403  NE      
CG6172 FBgn02
61930 
vnd 
BL51833 
HMC0
3405  NE      
CG1744
0 
FBgn00
30120 
CG17440 
BL51843 
HMC0
3416  NE      
CG1795 FBgn00
27864 
Ogg1 
BL51852 
HMC0
3426  NE      
CG8948 FBgn00
30685 
Graf 
BL51853 
HMC0
3427  NE      
CG3415 FBgn00
30731 
Mfe2 
BL51854 
HMC0
3428 A ME ME   E  
CG5703 FBgn00
30853 
CG5703 
BL51855 
HMC0
3429  NE      
CG1467 FBgn00
31106 
Syx16 
BL51856 
HMC0
3430  NE      
CG1217
6 
FBgn00
30506 
Lig4 
BL51933 
HMC0
3211  NE      
CG3926 FBgn00
14031 
Spat 
BL51935 
HMC0
3220  NE      
CG1689
2 
FBgn00
30122 
CG16892 
BL51938 
HMC0
3342  NE      
CG4039 FBgn00
25815 
Mcm6 
BL52111 
HMC0
3356  NE      
CG6367 FBgn00
30926 
psh 
BL52877 
HMC0
3615  NE      
CG1141
8 
FBgn00
24360 
CG11418 
BL52881 
HMC0
3619  NE      
CG1815
5 
FBgn00
29945 
CG18155 
BL52884 
HMC0
3622  NE      
CG9676 FBgn00
30773 
CG9676 
BL52901 
HMC0
3641  NE      
CG3125 FBgn02
61383 
IntS6 
BL52904 
HMC0
3644 A E E   E  
CG9126 FBgn00
45073 
Stim 
BL52911 
HMC0
3651  NE      
CG4211 FBgn00
04227 
nonA 
BL52933 
HMC0
3675  NE      
CG1059
8 
FBgn00
03057 
CG10598 
BL52948 
HMJ2
1617  NE      
CG1264
0 
FBgn00
30202 
CG12640 
BL52952 
HMJ2
1621 A E E   E  
CG5529 FBgn00
11758 
B-H1 
BL52954 
HMJ2
1623  NE      
CG1263
7 
FBgn00
30224 
CG12637 
BL52978 
HMJ2
1665  NE      
CG3656 FBgn00
05670 
Cyp4d1 
BL52979 
HMJ2
1666  NE      
CG5254 FBgn00
40383 
CG5254 
BL52990 
HMJ2
1682  NE      
412 
 
CG3258
0 
FBgn00
52580 
Muc14A 
BL53011 
HMJ2
1730  NE      
CG1078
8 
FBgn00
10295 
ng3 
BL53026 
HMJ2
1751  NE      
CG1871 FBgn00
11586 
e(r) 
BL53301 
HMC0
3528  NE      
CG1762
9 
FBgn00
01314 
kl-3 
BL53317 
HMC0
3546  NE      
CG3149 FBgn00
27564 
CG3149 
BL53324 
HMC0
3553  NE      
CG1220
3 
FBgn00
31021 
CG12203 
BL53325 
HMC0
3554  NE      
CG2194 FBgn00
86450 
su(r) 
BL53339 
HMC0
3568  NE      
CG4396 FBgn00
86675 
fne 
BL53340 
HMC0
3569  NE      
CG1234
8 
FBgn00
03380 
Sh 
BL53347 
HMC0
3576  NE      
CG3835 FBgn00
23507 
CG3835 
BL53355 
HMC0
3584  NE      
CG1304 FBgn00
31141 
CG1304 
BL53363 
HMC0
3592  NE      
CG1632 FBgn00
30027 
CG1632 
BL53368 
HMC0
3597  NE      
CG6854 FBgn02
62707 
CTPsyn 
BL53378 
HMJ0
2094  NE      
CG1205
7 
FBgn00
30098 
CG12057 
BL53686 
HMJ2
1609 E E NE NE E  NE 
CG3269
5 
FBgn00
52695 
CG32695 
BL53687 
HMJ2
1616  NE      
CG1519
6 
FBgn00
30296 
CG15196 
BL53688 
HMJ2
1648  NE      
CG1520
1 
FBgn00
30272 
CG15201 
BL53689 
HMJ2
1672  NE      
CG9034 FBgn00
40931 
CG9034 
BL53700 
HMJ2
1729  NE      
CG8023 FBgn00
35860 
eIF4E-3 
BL53880 
HMJ2
1195  NE      
CG1070
6 
FBgn00
29761 
SK 
BL53881 
HMJ2
1196 A ME ME S E ME  
CG2151 FBgn00
20653 
Trxr-1 
BL53883 
HMJ2
1198  NE      
CG3457 FBgn00
24984 
CG3457 
BL53885 
HMJ2
1203  NE      
CG8944 FBgn00
30680 
CG8944 
BL53889 
HMJ2
1207  NE      
CG1422
6 
FBgn00
43903 
dome 
BL53890 
HMJ2
1208  NE      
CG9916 FBgn00
04432 
Cyp1 
BL53894 
HMJ2
1213  NE      
CG8198 FBgn00
26666 
l(1)G0136 
BL53909 
HMJ2
1239  NE      
CG3265
4 
FBgn00
52654 
Sec16 
BL53917 
HMJ2
1252 A E-L E-L   E-L  
CG1788
5 
FBgn00
29521 
Or1a 
BL53926 
HMJ2
1271  NE      
CG2885 FBgn00
30200 
RabX2 
BL53928 
HMJ2
1273  NE      
CG2941 FBgn00
29686 
CG2941 
BL53989 
HMJ2
1393  NE      
CG4331
3 
FBgn02
63005 
CG43313 
BL53990 
HMJ2
1394  NE      
CG1615 FBgn00
17561 
Ork1 
BL53994 
HMJ2
1398  NE      
CG1215
6 
FBgn00
29959 
Rab39 
BL53995 
HMJ2
1399 A E ME S E E  
CG3263
3 
FBgn00
52633 
CG32633 
BL54008 
HMJ2
1431  NE      
CG1989 FBgn00
26749 
Yippee 
BL54020 
HMJ2
1446  NE      
413 
 
CG3401
5 
FBgn00
54015 
CG34015 
BL54031 
HMJ2
1474  NE      
CG1461
5 
FBgn00
31184 
CG14615 
BL54044 
HMJ2
1487  NE      
CG3203 FBgn00
29897 
RpL17 
BL54048 
HMS0
3519  NE      
CG4268
4 
FBgn02
61570 
CG42684 
BL54056 
HMS0
3717  NE      
CG1478
2 
FBgn00
25381 
rush 
BL54057 
HMJ2
1364  NE      
CG1079
0 
FBgn00
03086 
Pig1 
BL54058 
HMJ2
1201  NE      
CG3278
9 
FBgn02
60484 
HIP 
BL54458 
HMS0
3718  NE      
CG1628 FBgn00
30218 
CG1628 
BL54464 
HMC0
3731  NE      
CG8952 FBgn00
30688 
CG8952 
BL54469 
HMS0
3737  NE      
CG8497 FBgn00
26374 
Rhp 
BL54474 
HMS0
3725  NE      
CG1423
1 
FBgn00
31060 
CG14231 
BL54799 
HMJ2
1493  NE      
CG4393
4 
FBgn02
64562 
Hr4 
BL54803 
HMJ2
1497  NE      
CG4337
4 
FBgn02
63132 
Cht6 
BL54823 
HMJ2
1542  NE      
CG1248
1 
FBgn00
30542 
CG12481 
BL54826 
HMJ2
1545  NE      
CG2930 FBgn00
28491 
CG2930 
BL54827 
HMJ2
1546 A ME ME S  ME  
CG3259
4 
FBgn00
52594 
be 
BL54834 
HMJ2
1553  NE      
CG1492 FBgn00
30361 
CG1492 
BL54838 
HMJ2
1557  NE      
CG3021 FBgn00
40337 
CG3021 
BL55144 
HMC0
3742  NE      
CG9998 FBgn00
05411 
U2af50 
BL55153 
HMC0
3810 A ME ME   E  
CG1776
4 
FBgn00
29751 
CG17764 
BL55156 
HMC0
3829  NE      
CG6999 FBgn00
30085 
CG6999 
BL55157 
HMC0
3830  NE      
CG6361 FBgn00
30925 
CG6361 
BL55174 
HMC0
3855  NE      
CG3019 FBgn00
03638 
su(w[a]) 
BL55175 
HMC0
3856 
(ME 
POSSIBL
E) NE      
CG1641 FBgn00
03411 
sisA 
BL55181 
HMC0
3864  NE      
CG3869 FBgn00
29870 
Marf 
BL55189 
HMC0
3883  NE      
CG4542 FBgn00
29906 
CG4542 
BL55190 
HMC0
3884  NE      
CG3435
9 
FBgn00
85388 
IP3K2 
BL55240 
HMC0
2364  NE      
CG1591 FBgn00
29133 
REG 
BL55248 
HMC0
3935  NE      
CG3253
3 
FBgn00
52533 
CG32533 
BL55255 
HMC0
3942  NE      
CG9009 FBgn00
27601 
pdgy 
BL55272 
HMC0
3959  NE      
CG6531 FBgn00
30941 
wgn 
BL55275 
HMC0
3962  NE      
CG3704 FBgn00
40346 
CG3704 
BL55294 
HMC0
3981  NE      
CG4315
5 
FBgn02
62685 
CG43155 
BL55299 
HMC0
3986  NE      
CG3697 FBgn00
02707 
mei-9 
BL55313 
HMC0
4000  NE      
414 
 
CG6146 FBgn00
04924 
Top1 
BL55314 
HMC0
4001  NE      
CG1211
7 
FBgn00
14032 
Sptr 
BL55317 
HMC0
4004  NE      
CG3806 FBgn00
23512 
eIF2B-epsilon 
BL55321 
HMC0
4008  NE      
CG1789
6 
FBgn00
23537 
CG17896 
BL55323 
HMC0
4010  NE      
CG2658 FBgn00
24992 
CG2658 
BL55324 
HMC0
4011  NE      
CG1480
8 
FBgn00
25391 
Scgdelta 
BL55325 
HMC0
4012 A E E   E  
CG1210
8 
FBgn00
30057 
Ppt1 
BL55331 
HMC0
4018  NE      
CG1573
8 
FBgn00
30352 
CG15738 
BL55332 
HMC0
4019  NE      
CG7010 FBgn00
28325 
l(1)G0334 
BL55345 
HMC0
4032  NE      
CG1677 FBgn00
29941 
CG1677 
BL55355 
HMC0
4042 S S  S E  NE 
CG8565 FBgn00
30697 
CG8565 
BL55368 
HMC0
4056  NE      
CG1582 FBgn00
30246 
CG1582 
BL55373 
HMC0
4061  NE      
CG1780 FBgn00
26415 
Idgf4 
BL55381 
HMC0
4069  NE      
CG1205
6 
FBgn00
30099 
CG12056 
BL55382 
HMC0
4070  NE      
CG7876 FBgn00
31000 
Muc18B 
BL55394 
HMC0
4082  NE      
CG1880
9 
FBgn00
42132 
CG18809 
BL55399 
HMC0
4087  NE      
CG8544 FBgn00
03345 
sd 
BL55404 
HMC0
4092 ME ME NE MS E-L  NE 
CG2212 FBgn00
03656 
sws 
BL55406 
HMC0
4094  NE      
CG1659 FBgn00
25549 
unc-119 
BL55604 
HMC0
3736  NE      
CG3252
3 
FBgn00
52523 
CG32523 
BL55607 
HMC0
3745  NE      
CG4044
4 
FBgn00
01315 
kl-5 
BL55609 
HMC0
3747  NE      
CG1478
0 
FBgn00
25383 
CG14780 
BL55616 
HMC0
3759  NE      
CG1504
6 
FBgn00
30927 
CG15046 
BL55620 
HMC0
3764  NE      
CG7288 FBgn00
30969 
CG7288 
BL55632 
HMC0
3779  NE      
CG6227 FBgn00
30631 
CG6227 
BL55638 
HMC0
3786  NE      
CG1622 FBgn00
30468 
CG1622 
BL55648 
HMC0
3797  NE      
CG4119 FBgn00
28474 
CG4119 
BL55668 
HMC0
3823 A E-L E-L   E-L  
CG2677 FBgn00
24996 
eIF2B-beta 
BL55675 
HMC0
3838  NE      
CG6340 FBgn00
30648 
CG6340 
BL55677 
HMC0
3842  NE      
CG2845 FBgn00
03079 
phl/raf 
BL55679 
HMC0
3854  NE      
CG5877 FBgn00
30625 
CG5877 
BL55690 
HMC0
3904  NE      
CG1717
0 
FBgn00
03559 
su(f) 
BL55693 
HMC0
3907  NE      
CG1716
8 
FBgn00
39943 
CG17168 
BL55703 
HMC0
3926  NE      
CG1231
1 
FBgn00
86368 
tw 
BL55735 
HMC0
3806  NE      
CG1574
7 
FBgn00
30474 
CG15747 
BL55747 
HMC0
3934 A ME ME MS E ME NE 
415 
 
CG3135 FBgn00
03390 
shf 
BL55867 
HMC0
4137  NE      
CG4290 FBgn00
25625 
Sik2 
BL55880 
HMC0
4153  NE      
CG3274
2 
FBgn00
28360 
l(1)G0148 
BL55884 
HMC0
4157  NE      
CG5941 FBgn00
29833 
MCTS1 
BL55920 
HMC0
4207  NE      
CG2979 FBgn00
05391 
Yp2 
BL55931 
HMC0
4219  NE      
CG6186 FBgn00
22355 
Tsf1 
BL55936 
HMC0
4224  NE      
CG4666 FBgn00
29838 
CG4666 
BL55939 
HMC0
4227  NE      
CG1564
1 
FBgn00
30643 
CG15641 
BL55940 
HMC0
4228  NE      
CG6788 FBgn00
30880 
CG6788 
BL55941 
HMC0
4229  NE      
CG2918 FBgn00
23529 
CG2918 
BL55962 
HMC0
4256  NE      
CG3269
8 
FBgn00
52698 
CG32698 
BL56000 
HMC0
4296  NE      
CG1519
9 
FBgn00
30270 
CG15199 
BL56024 
HMC0
4320  NE      
CG1520
2 
FBgn00
30271 
CG15202 
BL56026 
HMC0
4322  NE      
CG6190 FBgn00
61469 
Ube3a 
BL57151 
HMC0
4528  NE      
CG5387 FBgn00
27491 
Cdk5alpha 
BL57290 
HMJ2
1283  NE      
CG1214 FBgn00
03295 
ru 
BL58065 
HMJ2
1921  NE      
CG1792
2 
FBgn00
34656 
CG17922 
BL58072 
HMJ2
1964  NE      
CG1241
3 
FBgn00
39588 
CG12413 
BL58096 
HMJ2
2011  NE      
CG3002
0 
FBgn00
50020 
CG30020 
BL58110 
HMJ2
2046  NE      
CG7962 FBgn00
10350 
CdsA 
BL58118 
HMJ2
2055  NE      
CG1377
2 
FBgn00
31866 
neuroligin 
BL58128 
HMJ2
2077  NE      
CG8532 FBgn00
28582 
lqf 
BL58130 
HMJ2
2079  NE      
CG1488
6 
FBgn00
38436 
Gyc-89Db 
BL58139 
HMJ2
2088  NE      
CG3940 FBgn00
37788 
CG3940 
BL58160 
HMJ2
2111  NE      
CG3167
3 
FBgn00
51673 
CG31673 
BL58161 
HMJ2
2112  NE      
CG1112
5 
FBgn00
33174 
CG11125 
BL58164 
HMJ2
2141  NE      
CG1738
3 
FBgn00
39350 
jigr1 
BL58173 
HMJ2
2150  NE      
CG9913 FBgn00
38205 
Kif19A 
BL58193 
HMJ2
1855  NE      
CG2346 FBgn00
00715 
 
BL58197 
HMJ2
2167  NE      
CG1828
7 
FBgn00
39679 
ppk19 
BL58203 
HMJ2
2173  NE      
CG9793 FBgn00
37620 
ranshi 
BL58206 
HMJ2
2176  NE      
CG8598 FBgn00
35766 
eco 
BL58221 
HMJ2
2229  NE      
CG3118
3 
FBgn00
51183 
CG31183 
BL58224 
HMJ2
2232  NE      
CG3134 FBgn00
03009 
ord 
BL58228 
HMJ2
2248  NE      
CG6620 FBgn00
24227 
ial 
BL58308 
HMJ2
2415  NE      
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CG5656 FBgn00
37083 
CG5656 
BL58334 
HMJ2
2464  NE      
CG9634 FBgn00
27528 
CG9634 
BL58344 
HMJ2
2475  NE      
CG3281
0 
FBgn00
25394 
inc 
BL58346 
HMJ2
2477  NE      
CG9272 FBgn00
32907 
CG9272 
BL58348 
HMJ2
2479  NE      
CG8994 FBgn00
00615 
 
BL58351 
HMS0
4331  NE      
CG1287
8 
FBgn00
45862 
btz 
BL58353 
HMS0
4337  NE      
CG8947 FBgn02
50848 
26-29-p 
BL32887 
HMS0
0675  NE      
CG1287
6 
FBgn00
86346 
ALiX 
BL33417 
HMS0
0298  NE      
CG2982 FBgn00
29704 
CG2982 
BL33596 
HMS0
0680  NE      
CG1149
1 
FBgn00
00210 
br 
BL33641 
HMS0
0042 A E-L E-L   E-L  
CG5488 FBgn00
04854 
B-H2 
BL33647 
HMS0
0048  NE      
CG4739 FBgn00
40257 
Ugt86Dc 
BL34095 
HMS0
0954  NE      
CG1223
7 
FBgn00
31048 
CG12237 
BL38343 
HMS0
1810  NE      
CG7103 FBgn00
30964 
Pvf1 
BL39038 
HMS0
1958  NE      
CG3262
8 
FBgn00
52628 
CG32628 
BL44036 
HMS0
2752  NE      
CG9737 FBgn00
39758 
CG9737 
BL52880 
HMC0
3618  NE      
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Chapter 3: Supplementary tables  
 
Table S3-1: Full genotypes 
Fig. 1C Genotype (driver: HS-GAL4, BL2077)  Includes   
LDS-(G4C2)CTRLGR-
GFP 
w1118, UAS-LDS-(G4C2)4,9,12GR-GFP/w*; GAL4-
Hsp70/+; 
    
LDS-(G4C2)EXPGR-
GFP 
w1118/w*; GAL4-Hsp70/+; UAS-LDS-(G4C2)4,42,44GR-
GFP/+ 
    
Fig. 1D and Sup. 
Fig. 1 
Genotype (driver: GMR-GAL4YH3) Includes Temp 
LDS-(G4C2)CTRLGR-
GFP 
w1118, UAS-LDS-(G4C2)4,9,12GR-GFP/w1118;; GMR-
GAL4YH3/+ 
UAS-
DSRED 
26ᵒC 
LDS-(G4C2)EXPGR-
GFP 
w1118;; UAS-LDS-(G4C2)4,42,44GR-GFP/GMR-GAL4YH3   26ᵒC 
GFP CTRL w1118;; UAS-GFP.NLS/GMR-GAL4YH3 BDSC 
#4776 
26ᵒC 
Neg CTRL w1118;; GMR-GAL4YH3/+   26ᵒC 
Fig. 1E Genotype (driver: GMR-GAL4YH3) Includes Temp 
Positive Control w1118/Y; UAS-DSRED/+; GMR-GAL4YH3/+ UAS-
DSRED 
26ᵒC 
LDS-(G4C2)CTRLGR-
GFP 
w1118, UAS-LDS-(G4C2)4,9,12GR-GFP/Y;; GMR-
GAL4YH3/+ 
  26ᵒC 
LDS-(G4C2)EXPGR-
GFP 
w1118/Y;; UAS-LDS-(G4C2)4,42,44GR-GFP/GMR-
GAL4YH3 
  26ᵒC 
Fig. 1F Genotype (driver: GMR-GAL4YH3) Includes Temp 
DSRED w1118/Y; UAS-DSRED/+; GMR-GAL4YH3/+ UAS-
DSRED 
26ᵒC 
LDS-(G4C2)CTRLGR-
GFP 
w1118, UAS-LDS-(G4C2)4,9,12GR-GFP/Y;; GMR-
GAL4YH3/+ 
  26ᵒC 
LDS-(G4C2)EXPGR-
GFP 
w1118/Y;; UAS-LDS-(G4C2)4,42,44GR-GFP/GMR-
GAL4YH3 
  26ᵒC 
Fig. 2A - external 
eye toxicity 
Genotype (driver: GMR-GAL4YH3) Includes Temp 
LDS-(G4C2)EXPGR-
GFP w/ eIF4B RNAi 
w1118/Y; UAS-eIF4B RNAiHMS04503/+; UAS-LDS-
(G4C2)4,42,44GR-GFP, GMR-GAL4YH3/+ 
BDSC 
#57305 
26ᵒC 
LDS-(G4C2)EXPGR-
GFP w/ Control RNAi 
w1118/Y;; UAS-LDS-(G4C2)4,42,44GR-GFP, GMR-
GAL4YH3/UAS-Luc RNAiJF01355 
BDSC 
#31603 
26ᵒC 
LDS-(G4C2)EXPGR-
GFP w/ eIF3B RNAi 
w1118/Y;; UAS-LDS-(G4C2)4,42,44GR-GFP, GMR-
GAL4YH3/UAS-eIF3B RNAiHMS00668 
BDSC 
#32880 
26ᵒC 
(GR)36 w/ eIF4G1 
RNAi 
w1118/y1, sc*, v1; UAS-(GR)36/+; GMR-GAL4YH3/UAS-
eIF4G1 RNAiHMS00762 
BDSC 
#33049 
24ᵒC 
(GR)36 w/ Control 
RNAi 
w1118/y1, v1; UAS-(GR)36/+; GMR-GAL4YH3/UAS-Luc 
RNAiJF01355 
BDSC 
#31603 
24ᵒC 
(GR)36 w/ eIF4B 
RNAi 
w1118/y1, sc*, v1; UAS-(GR)36/UAS-eIF4B 
RNAiHMS04503; GMR-GAL4YH3/+ 
BDSC 
#57305 
24ᵒC 
Fig. 2A - external 
eye GR-GFP 
Genotype (driver: GMR-GAL4YH3) Includes Temp 
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LDS-(G4C2)EXPGR-
GFP w/ eIF4B RNAi 
w1118/y1, sc*, v1; UAS-eIF4B RNAiHMS04503/+; UAS-
LDS-(G4C2)4,42,44GR-GFP, GMR-GAL4YH3/+ 
BDSC 
#57305 
26ᵒC 
LDS-(G4C2)EXPGR-
GFP w/ Control RNAi 
w1118/y1, v1;; UAS-LDS-(G4C2)4,42,44GR-GFP, GMR-
GAL4YH3/UAS-Luc RNAiJF01355 
BDSC 
#31603 
26ᵒC 
LDS-(G4C2)EXPGR-
GFP w/ eIF3B RNAi 
w1118/y1, sc*, v1;; UAS-LDS-(G4C2)4,42,44GR-GFP, 
GMR-GAL4YH3/UAS-eIF3B RNAiHMS00668 
BDSC 
#32880 
26ᵒC 
Fig. 3A Genotype (driver: Da-GAL4, III) Includes Temp 
Control RNAi w1118/Y;; UAS-Luc RNAiJF01355/Da-GAL4 BDSC 
#31603 
26ᵒC 
eIF4B RNAi w1118/Y; UAS-eIF4B RNAiHMS04503/+; Da-GAL4/+ BDSC 
#57305 
26ᵒC 
eIF4H1 RNAi w1118/Y; UAS-eIF4H1 RNAiHMS04504/+; Da-GAL4/+ BDSC 
#57306 
26ᵒC 
Fig. 3B Genotype (driver: Da-GAL4, III) Includes Temp 
progeny with eIF4B 
RNAi 
UAS-eIF4B RNAiHMS04503/+; Da-GAL4/+ BDSC 
#57305 
26ᵒC 
progeny without 
eIF4B RNAi 
CyO/+; Da-GAL4/+   26ᵒC 
progeny with 
eIF4H1 RNAi 
UAS-eIF4B RNAiHMS04504/+; Da-GAL4/+ BDSC 
#57306 
26ᵒC 
progeny without 
eIF4H1 RNAi 
CyO/+; Da-GAL4/+   26ᵒC 
Fig. 4A-B and 5A-B Genotype (driver: GMR-GAL4YH3) Includes Temp 
LDS-(G4C2)EXPGR-
GFP w/ Control RNAi 
w1118/Y;; UAS-LDS-(G4C2)4,42,44GR-GFP, GMR-
GAL4YH3/UAS-Luc RNAiJF01355 
BDSC 
#31603 
26ᵒC 
LDS-(G4C2)EXPGR-
GFP w/ eIF4B RNAi 
w1118/Y; UAS-eIF4B RNAiHMS04503/+; UAS-LDS-
(G4C2)4,42,44GR-GFP, GMR-GAL4YH3/+ 
BDSC 
#57305 
26ᵒC 
LDS-(G4C2)EXPGR-
GFP w/ eIF4H1 RNAi 
w1118/Y; UAS-eIF4H1 RNAiHMS04504/+; UAS-LDS-
(G4C2)4,42,44GR-GFP, GMR-GAL4YH3/+ 
BDSC 
#57306 
26ᵒC 
Fig. 4C-D Genotype (driver: GMR-GAL4YH3) Includes Temp 
(GR)36 w/ Control 
RNAi 
w1118/y1, v1; UAS-(GR)36/+; GMR-GAL4YH3/UAS-Luc 
RNAiJF01355 
BDSC 
#31603 
24ᵒC 
(GR)36 w/ eIF4B 
RNAi 
w1118/y1, sc*, v1; UAS-(GR)36/UAS-eIF4B 
RNAiHMS04503; GMR-GAL4YH3/+ 
BDSC 
#57305 
24ᵒC 
(GR)36 w/ eIF4B 
RNAi 
w1118/y1, sc*, v1; UAS-(GR)36/UAS-eIF4B 
RNAiHMS04504; GMR-GAL4YH3/+ 
BDSC 
#57306 
24ᵒC 
Fig. 4E-F Genotype (driver: GMR-GAL4YH3) Includes Temp 
Control RNAi w1118/Y;; GMR-GAL4YH3/UAS-Luc RNAiJF01355 BDSC 
#31603 
26ᵒC 
eIF4B RNAi w1118/Y; UAS-eIF4B RNAiHMS04503/+; GMR-
GAL4YH3/+ 
BDSC 
#57305 
26ᵒC 
eIF4H1 RNAi w1118/Y; UAS-eIF4H1 RNAiHMS04504/+; GMR-
GAL4YH3/+ 
BDSC 
#57306 
26ᵒC 
Fig. 5C-D Genotype (driver: GMR-GAL41104) Includes Temp 
DsRed w/ Control 
RNAi 
w1118/Y; UAS-DsRed, GMR-GAL4/+; UAS-Luc 
RNAiJF01355/+ 
BDSC 
#31603 
26ᵒC 
DsRed w/ eIF4B 
RNAi 
w1118/Y, v1; UAS-DsRed, GMR-GAL4/UAS-eIF4B 
RNAiHMS04503;  
BDSC 
#57305 
26ᵒC 
DsRed w/ eIF4B 
RNAi 
w1118/Y; UAS-DsRed, GMR-GAL4/UAS-eIF4B 
RNAiHMS04504;  
BDSC 
#57306 
26ᵒC 
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Fig. 5E Genotype (driver: GMR-GAL41104) Includes Temp 
LacZ w/ Control 
RNAi 
w1118/Y; UAS-LacZ, GMR-GAL4/+; UAS-Luc 
RNAiJF01355/+ 
BDSC 
#31603 
26ᵒC 
LacZ w/ eIF4B 
RNAi 
w1118/Y, v1; UAS-LacZ, GMR-GAL4/UAS-eIF4B 
RNAiHMS04503;  
BDSC 
#57305 
26ᵒC 
LacZ w/ eIF4B 
RNAi 
w1118/Y; UAS-LacZ, GMR-GAL4/UAS-eIF4B 
RNAiHMS04504;  
BDSC 
#57306 
26ᵒC 
Sup. Fig. 2 Genotype (driver: GMR-GAL4YH3) Includes Temp 
Control RNAi w1118/Y;; UAS-LDS-(G4C2)4,42,44GR-GFP, GMR-
GAL4YH3/UAS-Luc RNAiJF01355 
BDSC 
#31603 
26ᵒC 
eIF5B RNAi w1118/Y;; UAS-LDS-(G4C2)4,42,44GR-GFP, GMR-
GAL4YH3/UAS-eIF5B RNAiGL01593 
BDSC 
#57305 
26ᵒC 
eIF5 RNAi w1118/Y;; UAS-LDS-(G4C2)4,42,44GR-GFP, GMR-
GAL4YH3/UAS-eIF5 RNAiHMS00159 
BDSC 
#34841 
26ᵒC 
eIF2β RNAi w1118/Y;; UAS-LDS-(G4C2)4,42,44GR-GFP, GMR-
GAL4YH3/UAS-eIF2β RNAiHMC02396 
BDSC 
#53268 
26ᵒC 
eIF2Bα RNAi w1118/Y; UAS-eIF2Bα RNAiHMC03768/+; UAS-LDS-
(G4C2)4,42,44GR-GFP, GMR-GAL4YH3/+ 
BDSC 
#55624 
26ᵒC 
eIF3g1 RNAi w1118/Y;; UAS-LDS-(G4C2)4,42,44GR-GFP, GMR-
GAL4YH3/UAS-eIF3g1 RNAiGLC01430 
BDSC 
#43243 
26ᵒC 
eEFSec RNAi w1118/Y;; UAS-LDS-(G4C2)4,42,44GR-GFP, GMR-
GAL4YH3/UAS-eIF3g1 RNAiGL01178 
BDSC 
#42805 
26ᵒC 
Sup. Fig. 3A Genotype (driver: Da-GAL4, III) Includes Temp 
w1118 w1118/Y;; Da-GAL4/+    26ᵒC 
eIF4B RNAi-2 w1118/Y; UAS-eIF4B RNAi330010/+; Da-GAL4/+ VDRC 
#330010 
26ᵒC 
eIF4H1 RNAi-2 w1118/Y; UAS-eIF4H1 RNAi108805/+; Da-GAL4/+ VDRC 
#100817 
26ᵒC 
Sup Fig. 3B-E Genotype (driver: GMR-GAL4YH3) Includes Temp 
Control RNAi w1118/Y;; UAS-LDS-(G4C2)4,42,44GR-GFP, GMR-
GAL4YH3/UAS-Luc RNAiJF01355 
BDSC 
#31603 
26ᵒC 
eIF4B RNAi-2 w1118/Y; UAS-eIF4B RNAi330010/+; UAS-LDS-
(G4C2)4,42,44GR-GFP, GMR-GAL4YH3/+ 
VDRC 
#330010 
26ᵒC 
eIF4H1 RNAi-2 w1118/Y; UAS-eIF4H1 RNAi108805/+; UAS-LDS-
(G4C2)4,42,44GR-GFP, GMR-GAL4YH3/+ 
VDRC 
#100817 
26ᵒC 
Sup. Fig. 3F Genotype (driver: GMR-GAL41104) Includes Temp 
LacZ w/ Control  w1118/Y; UAS-LacZ, GMR-GAL4/UAS-DSRED; UAS-
DSRED 
26ᵒC 
LacZ w/ eIF4B 
RNAi-2 
w1118/Y, v1; UAS-LacZ, GMR-GAL4/UAS-eIF4B 
RNAi330010;  
VDRC 
#330010 
26ᵒC 
LacZ w/ eIF4B 
RNAi-2 
w1118/Y; UAS-LacZ, GMR-GAL4/UAS-eIF4B 
RNAi1088057;  
VDRC 
#100817 
26ᵒC 
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Table S3-2: Full screen 
Color scheme: Suppressor
Mild 
Suppressor No Effect Mild Enhancer Enhancer
Lethal 
Enhancer not tested  
(GR)36 Alone
Toxicity
GR-GFP 
levels
Toxicity Phenotype
eIF4B EIF4B 57305
y1 sc* v1; 
P{TRiP.HMS04503}attP40
RNAi
Candidate RAN-
translation factor
eIF4H1 EIF4H 57306
y1 sc* v1; 
P{TRiP.HMS04504}attP40
RNAi
Candidate RAN-
translation factor
eIF4E3 EIF4E 53880
y1 v1; 
P{TRiP.HMJ21195}attP40
RNAi
Candidate RAN-
translation factor
eIF4E4 EIF4E 50951
y1 v1; 
P{TRiP.HMJ21052}attP40
RNAi
Candidate RAN-
translation factor
eIF4E7 EIF4E 33471 P{EP}eIF4E7G1355 w* mutant
Candidate RAN-
translation factor
eIF5B EIF5B 44418
y1 sc* v1; 
P{TRiP.GL01593}attP2/TM3, 
RNAi
Candidate RAN-
translation factor
eIF5 EIF5 34841
y1 sc* v1; 
P{TRiP.HMS00159}attP2
RNAi
Candidate RAN-
translation factor
eIF2β EIF2S2 53268
y1 sc* v1; 
P{TRiP.HMC02396}attP2/TM3, 
RNAi
Candidate RAN-
translation factor
eIF3d1 (eIF-
3p66)
EIF3D 20072
y1 w67c23; 
P{EPgy2}eIF3d1EY05735/TM3, 
mutant
Candidate RAN-
translation factor
eIF4E5 EIF4E 66332
y1 sc* v1; 
P{TRiP.HMC06261}attP40
RNAi
Candidate RAN-
translation factor
eIF3i (eIF3-S2) EIF3I 34978
y1 sc* v1; 
P{TRiP.HMS01387}attP2
RNAi
Candidate RAN-
translation factor
eIF3K EIF3K 44493
y1 sc* v1; 
P{TRiP.HMC02415}attP2
RNAi
Potential RAN-
translation factor
eIF2Bγ EIF2B3 41948
y1 sc* v1; 
P{TRiP.HMS02345}attP40
RNAi G4C2 Suppressor
eEF2 EEF2 21351
y1 w67c23; 
P{EPgy2}eEF2EY02807/CyO
mutant G4C2 Suppressor
eIF2Bδ EIF2B4 15441
y1 w67c23; 
P{EPgy2}eIF2BδEY03558
mutant G4C2 Suppressor
eEF1β EEF1B2 16371
y1 w67c23; 
P{EPgy2}eEF1βEY05513
mutant G4C2 Suppressor
eIF4G1 EIF4G3 33049
y1 sc* v1; 
P{TRiP.HMS00762}attP2
RNAi GR suppressor
eIF3b (eIF3-
S9)
EIF3B 32880
y1 sc* v1; 
P{TRiP.HMS00668}attP2
RNAi GR Enhancer
eIF3l EIF3L 50959
y1 v1; 
P{TRiP.HMJ21061}attP40/CyO
RNAi GR Enhancer
eIF4E1 EIF4E 34096
y1 sc* v1; 
P{TRiP.HMS00969}attP2
RNAi GR Enhancer
NAT1 EIF4G2 32357
y1 sc* v1; 
P{TRiP.HMS00348}attP2
RNAi GR Enhancer
eIF5C BZW1 27248 y1 v1; P{TRiP.JF02556}attP2 RNAi GR Enhancer
eIF1 EIF1B 57174
y1 sc* v1; 
P{TRiP.HMC04556}attP40
RNAi No Effect
eIF2Bα EIF2B1 55624
y1 sc* v1; 
P{TRiP.HMC03768}attP40
RNAi No Effect
eIF2Bβ EIF2B2 55675
y1 sc* v1; 
P{TRiP.HMC03838}attP40
RNAi No Effect
eIF2Bε EIF2B5 55321
y1 v1; 
P{TRiP.HMC04008}attP40
RNAi No Effect
eIF2D EIF2D 33995
y1 sc* v1; 
P{TRiP.HMS00958}attP2
RNAi No Effect
eIF3c (eIF3-S8) EIF3CL 16857
y1 w67c23; 
P{EPgy2}eIF3cEY07713/CyO
mutant No Effect
eIF3f1 (eIF3-
S5)
EIF3F 33980
y1 sc* v1; 
P{TRiP.HMS00940}attP2
RNAi No Effect
eIF3g1 (eIF3-
S4)
EIF3G 43243
y1 sc* v1; 
P{TRiP.GLC01430}attP2
RNAi No Effect
BDSC stock 
#
Genotype of stock
Control (LacZ) 
expression
Fly Gene
Human 
orthologue
LOF 
line 
type
Final Call
LDS-(G4C2)EXP
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eIF3h (eIF-
3p40)
EIF3H 55603
y1 sc* v1; 
P{TRiP.GL01831}attP2
RNAi No Effect
eIF4AIII EIF4A3 32444
y1 sc* v1; 
P{TRiP.HMS00442}attP2
RNAi No Effect
eIF4G2
EIF4G1, 
EIF4G3
42893
y1 sc* v1; 
P{TRiP.HMS02586}attP40
RNAi No Effect
eIF4H2 EIF4H v32191
w1118; 
P{GD8011}v32191/CyO
RNAi No Effect
eEF1α1 EEF1A2 33960
y1 sc* v1; 
P{TRiP.HMS00917}attP2
RNAi No Effect
eEF1α2 EEF1A2 64659
y1 sc* v1; 
P{TRiP.HMC05694}attP40
RNAi No Effect
eEF1γ EEF1G 31811
w1118; 
P{EP}eEF1γG16379/TM6C, Sb1
mutant No Effect
eEF1δ EEF1D 29605 y1 v1; P{TRiP.JF03284}attP2 RNAi No Effect
eEFSec EEFSEC 42805 y1 v1; P{TRiP.GL01178}attP2 RNAi No Effect
eRF1 ETF1 17265
w1118; 
P{EP}eRF1EP3195/TM6B, Tb1
mutant No Effect
eRF3 GSPT1 36703
y1 sc* v1; 
P{TRiP.HMS01592}attP2
RNAi No Effect
eIF4EHP EIF4E2 43990
y1 sc* v1; 
P{TRiP.HMS02703}attP40
RNAi No Effect
eIF1A EIF1AY 29316 y1 v1; P{TRiP.JF02475}attP2 RNAi
Unspecific 
enhancer
eIF2α EIF2S1 44449
y1 v1; 
P{TRiP.GLC01598}attP2/TM3, 
RNAi
Unspecific 
enhancer
eIF2γ EIF2S3 33401
y1 sc* v1; 
P{TRiP.HMS00279}attP2
RNAi
Unspecific 
enhancer
eIF3a (eIF3-
S10)
EIF3A 34353
y1 sc* v1; 
P{TRiP.HMS01342}attP2
RNAi
Unspecific 
enhancer
eIF3m EIF3M 32879
y1 sc* v1; 
P{TRiP.HMS00667}attP2
RNAi
Unspecific 
enhancer
eIF4A EIF4A1 33970
y1 sc* v1; 
P{TRiP.HMS00927}attP2
RNAi
Unspecific 
enhancer  
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Table S3-3: Fibroblast cell lines 
Fibroblast 
cell line #
NINDS/Coriell 
Code
Mutation Diagnosis
Age at 
onset
Age at 
sampling
Gender Source
1 ND29178 n/a healthy n/a 66 M Rutgers
2 ND29510 n/a healthy n/a 55 F Rutgers
3 ND34769 n/a healthy n/a 68 F Rutgers
4 ND36320 n/a healthy n/a 71 F Rutgers
5 ND38530 n/a healthy n/a 55 M Rutgers
6 ND40069
C9orf72: 
Intermediate
Parkinsonism 71 75 F Rutgers
7 ND42496 C9orf72 FTD At Risk 57 M Rutgers
8 ND42504 C9orf72 FTD At Risk 53 F Rutgers
9 ND42506 C9orf72 FTD At Risk 46 F Rutgers  
 
 
 
Table S3-4: Patient details 
All ALS ALS/FTLD FTLD
Number of cases 66 19 21 26
Gender (male) 38 (57.58%) 7 (36.84%) 12 (57.14%) 19 (73.08%)
Age at onset 61 (41, 55, 67, 79) 56 (41, 49, 61, 69) 58 (50, 54, 65, 74) 66 (44, 57, 70, 79)
Age at death 64 (43, 59, 72, 90) 60 (43, 51, 64, 72) 62 (51, 60, 68, 80) 72 (52, 65, 78, 90)
Disease duration 3.9 (1.0, 2.3, 6.7, 14.5) 2.1 (1.0, 1.5, 3.1, 6.3) 4.8 (1.1, 2.7, 6.7, 10.4) 7.3 (2.4, 5.8, 9.4, 14.5)
All ALS ALS/FTLD FTLD
Number of cases 46 21 9 16
Gender (male) 21 (45.65%) 10 (47.62%) 3 (33.33%) 8 (50.00%)
Age at onset 66 (45, 57, 73, 86) 59 (45, 49, 66, 76) 70 (46, 57, 70, 78) 73 (57, 66, 80, 86)
Age at death 72 (47, 64, 83, 100) 66 (47, 59, 71, 83) 73 (49, 63, 78, 85) 85 (66, 78, 89, 100)
Disease duration 4.6 (0.6, 2.9, 8.6, 21.9) 3.4 (0.9, 2.0, 4.8, 21.5) 2.9 (0.6, 1.8, 7.8, 21.9) 8.5 (3.9, 8.2, 10.1, 20.5)
Number of cases 22
Gender (male) 12 (54.54%)
Age at death 79 (57, 64, 89, 99)
C9orf72 -positive
C9orf72 -negative
Healthy controls
The sample median (minimum, 25th percentile, 75th percentile, and maximum) is given for age at onset, age at death 
and disease duration, all given in years. 
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Table S3-5: Fly lines 
Name Location Source ID # Full genotype
Gmr-GAL4 (III) 3 Matthew Freeman n/a w*;; Gmr-GAL4YH3/TM3,Sb
Gmr-GAL4 (II) 2 BDSC 1104 w*; Gmr-GAL4;
Da-GAL4 3 BDSC 55851 w*;; Da-GAL4
HS-GAL4 3 BDSC 1799 w[*];; P{w[+mC]=GAL4-Hsp70.PB}89-2-1
Control (DSRED) 2 Nancy Bonini n/a w[1118]; UAS-DSRED;
LDS-(G4C2)12GR-GFP 3 Nancy Bonini n/a w[1118];; UAS-LDS-(G4C2)4,9,12[GR-GFP]
LDS-(G4C2)44GR-GFP 3 Nancy Bonini n/a w[1118];; UAS-LDS-(G4C2)4,42,44[GR-GFP]
Control (w1118) n/a BDSC 5905 w[1118];;
Control RNAi 3 BDSC 31603 y[1] v[1];; P{y[+t7.7] v[+t1.8]=TRiP.JF01355}attP2
(GR)36 2 BDSC 58692 w[1118]; P{y[+t7.7] w[+mC]=UAS-poly-GR.PO-36}attP40;
eIF4B RNAi 2 BDSC 57305 y1 sc* v1; P{TRiP.HMS04503}attP40;
eIF4B RNAi-2 2 VDRC 330010 w*; P{VSH330010}attP40;
eIF4H1 RNAi 2 BDSC 57306 y1 sc* v1; P{TRiP.HMS04504}attP40;
eIF4H1 RNAi-2 2 VDRC 100817 w*; P{KK108805}VIE-260B;
BDSC = Bloomington Drosophila  Stock Center
VDRC = Vienna Drosophila  Resource Center  
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Table S3-5: Primers 
Target Speci
es 
Ass
ay 
Forward (5'-3') Reverse  (5'-3') Reference 
LDS-
G4C2 
Dmel. PCR ACTCGCTGAGGGTGAACAAG CGACTCCTGAGTTCCA
GAGC 
Goodman et al, Nat 
Neuro, 2019 
GFP tag Dmel. qPC
R 
ACGTAAACGGCCACAAGTTC AAGTCGTGCTGCTTCAT
GTG 
Goodman et al, Nat 
Neuro, 2019 
RP49 Dmel. qPC
R 
TGTCCTTCCAGCTTCAAGATG
ACCATC 
CTTGGGCTTGCGCCAT
TTGTG 
Gabler, M. et al., 2005 
eIF4B Dmel. qPC
R 
CGCATTGAGCTATCGAATGA CCAATTTCCGGAATCCC
TAT  
this paper 
eIF4H1 Dmel. qPC
R 
GGGAAACGGATCAGTTCAAA CTTCTGGAAACCGTCTC
TGC   
this paper 
EIF4H Hsap. qPC
R 
GGTGGCTTTGGATTCAGAAA CCCTGAAGCCAGAATT
GAAG 
this paper 
EIF4B Hsap. qPC
R 
AGCTCAGACACAGAGCAGCA CTTTCCTTCCTGGTCCT
TCC 
this paper 
RPLP0 Hsap qPC
R 
TCTACAACCCTGAAGTGCTTG
AT 
CAATCTGCAGACAGAC
ACTGG 
Goodman et al, Nat 
Neuro, 2019 
GAPDH Hsap qPC
R 
GTTCGACAGTCAGCCGCATC GGAATTTGCCATGGGT
GGA 
Goodman et al, Nat 
Neuro, 2019 
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Chapter 3: Supplementary figures and legends 
 
 
 
Figure S3-1 
 
Supplementary Figure S3-1: Extended LDS-G4C2 fly line characterization. 
Western immunoblots were used to confirm GR dipeptide is produced and successfully 
tagged with GFP in expanded G4C2 flies (Fig. 3-1D). Blots were overexposed to see if 
GR/GFP dipeptide could be detected in control G4C2 flies. Shown is a representative 
image of the original blot, imaged at > 4X the original exposure.  > 10X the original 
exposure also showed no GR/GFP dipeptide in control G4C2 flies (data not shown). 
Note that the faint band at a molecular weight below GFP alone in the LDS-(G4C2)EXP 
lane is a non-specific band that is found in multiple lanes of the complete western 
immunoblot (see Supplementary Fig. S3-4 for Uncropped westerns). 
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Figure S3-2 
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Supplementary Figure S3-2: Extended translation factor screen data. 
A. External eye and GR-GFP imaging in LDS-(G4C2)EXP animals co-expressing control 
(Luc) RNAi. B. Additional examples of candidate RAN-translation factors, showing 
suppression of toxicity in the external eye and reduced GR-GFP levels. Note, eIF2β 
RNAi only mildly altered toxicity in the external eye. C. Examples of RNAi targeting 
translation factors that did not significantly alter LDS-(G4C2)EXP toxicity nor GR-GFP 
levels. RNAi lines: control (JF01355), eIF5B (GL01593), eIF5 (HMS00159), eIF2β 
(HMC02396), eIF2Bα (HMC03768), eIF3g1 (GLC01430), eEFSec (GL01178). For full 
genotypes see Supplementary Table S3-1. Shown: representative images while all 
RNAi were tested 2+ times for effects on LDS-(G4C2)EXP toxicity and GR-GFP levels. 
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Figure S3-3 
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Supplementary Figure S3-3: eIF4B and eIF4H1 RNAi-2 data.  
eIF4B and eIF4H1 downregulation in LDS-(G4C2)EXP flies using a second set of RNAi 
lines show similar results. A. RNA levels produced from eIF4B or eIF4H1 were assessed 
by qPCR in flies ubiquitously expressing RNAi-2 (by Daughterless-GAL4 driver). Shown: 
individual data points with mean±SD. B. Using GMR-GAL4, RNAi-2-mediated depletion 
of eIF4B or eIF4H1 in LDS-(G4C2)EXP expressing flies results in reduced toxicity in both 
the external and internal eye: seen  externally by recovered pigment and ommatidial 
structure, seen internally by recovered retinal tissue integrity. C. Blinded quantification of 
internal retina tissue was done by measuring the total surface area of tissue present and 
by measuring the depth of the tissue at the position of the optic chiasm. n=4 animals per 
genotype. Shown: individual data points each representing 1 animal, with mean±SD. D. 
Fluorescence imaging in LDS-(G4C2)EXP expressing flies co-expressing eIF4B or eIF4H 
RNAi-2 results in reduced GR-GFP levels (GMR-GAL4). E. Blinded quantification of GR-
GFP signal in LDS-(G4C2)EXP animals relative to signal in control RNAi animals. Note 
that eIF4H1 RNAi-2 did not cause a significant reduction in GR-GFP puncta number, 
likely due to this RNAi only causing a 50% downregulation of eIF4H1; it did reduce 
puncta size and total GR-GFP fluorescence. n=6-7 animals per genotype. Shown: 
individual data points each representing 1 animal from two independent experiments 
with mean±SEM. F. A representative western immunoblot image for β-Galactosidase in 
LacZ flies co-expressing a control transgene, eIF4B RNAi-2, or eIF4H1 RNAi-2. 
Uncropped westerns (Sup. Fig. S3-4). Statistics: one-way ANOVAs with Tukey’s 
multiple comparison correction, p-values ****<0.0001, ***<0.001, **<0.01, *<0.05, no 
significance >0.05. RNAi lines: control (JF01355), eIF4B RNAi-2 (VSH330010), eIF4H1 
RNAi-2 (KK108805). For full genotypes see Supplementary Table S3-1. 
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Figure S3-4 
 
Supplementary Figure S3-4: full Western immunoblot images for Fig. 3-1D, Sup. Fig. 
S3-1, Fig. 3-4D, Fig. 3-6A and Sup. Fig. S3-4E, including ladder, Novex sharp Protein 
Standard (Invitrogen #LC5800). 
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APPENDIX 4: DETAILED PROTOCOLS FOR SELECT EXPERIMENTS 
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gDNA extraction (flies) 
 
Methods 1: High quality DNA (Puregene Kit) 
 REAGENTS/MATERIALS 
• Gentra Puregene Tissue Kit (Qiagen #158667), prepare stock solutions 
according to company’s instructions 
• phenol: chloroform:isoamyl alcohol 
• isopropanol 
• 70% ethanol (200 proof ethanol + milliQ water) 
• pellet/pestle disposable blue microcentrifuge tubes (Kimble # 749520-0000) 
• pellet/pestle cordless motor (Kimble # 749540-0000) 
• microcentrifuge tubes 
PROTOCOL 
1. Prep: 
a. Pre-chill 500ul cell lysis buffer per sample on ice for 10 min.  
b. set a heat block to 65ᵒC 
c. set a heat block to 37ᵒC 
d. (optional) pre-chill refrigerated microcentrifuge 
2. Collect 15-30 transgenic flies and transfer to a blue tube for use with the plastic 
disposable pestles.  Immediately add 100ul of chilled lysis buffer and grind the 
tissue using pellet pestles.  When completely homogenized, add an additional 
200ul of chilled lysis buffer and vortex briefly to mix.  Place the tube back on ice 
until next step.  
3. Heat the lysate at 65ᵒC for 30min to inactivate endogenous DNase.   
4. Transfer lysates to an ice-bucket containing ice and incubate for 5min.   
5. Add 1.5μl of RNase A soln. Mix well by inverting 25X and incubate the lysate at 
37ᵒC for 30-60 min. 
6. Add 200μl of prechilled lysis buffer and incubate on ice for 1min. 
7. Add 180μl of protein precipitation buffer to the RNAase A-treated lysate. 
Immediately vortex at max speed for 30 sec.  
8. Incubate lysate on ice for 10 min.    
9. Centrifuge at 20,000 x g for 10 min at 4ᵒC. 
Note:  samples tend to still have chunks of stuff within the supernatant.  
Repeating the protein precipitation steps does not seem to help.  Just 
move forward.  
10. Transfer supernatant to a new 1.5ml tube by dumping the solution from 1 tube 
into the next.  Be gentle so as to avoid accidently dislodging the pellet. 
11. Add 650μl phenol: chloroform:isoamyl alcohol (be sure to take solution from the 
bottom of the container as the top is an aqueous layer). Immediately mix by 
inverting 50X. Incubate at RT 5min. 
12. Centrifuge at 16000 x g for 10 min.  
13. Transfer upper aqueous layer (~580μl) to a new 1.5ml tube. 
14. Add 700μl isopropanol into the tube. Mix the sample by inverting gently 50X.  
15. Centrifuge at 16000 x g for 10 min. Remove supernatant by pouring it into a 
waste container – be sure to keep the tube inverted (!) and dab the edge on 
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clean paper towel to remove the supernatant. Pellet may be loose so use caution 
not to lose it during pouring off supernatant. 
16. Wash the DNA pellet once with 300μl 70% ethanol by gently adding the EtOH 
than immediately removing it with the same pipet tip. Pellet may be loose so use 
caution not to lose it during ethanol removal.  Using a tabletop centrifuge, 
centrifuge the samples briefly to collect residual liquid.  Remove it with a pipette. 
17. Air dry pellet for 10 min. Add 3μl/animal DNA hydration solution (or TE buffer) to 
dissolve it. Mix by pipette if necessary to make sure that pellet is fully dissolved.   
a. If necessary, samples can be stored overnight at 4ᵒC to allow them to 
dissolve completely.  Store the genomic DNA at -20ᵒC.  
b. Do not store your isolated DNA in water. DNA is an acid and is best 
stored under buffered conditions. The standard TE will work. The EDTA 
concentration can be reduced, however, it is usually diluted to a 
concentration that does not inhibit the PCR or other downstream 
reactions. 
18. Assess DNA quality 
a. Check the quantity & quality of DNA on the Nanodrop. The A260/280 
ratios should be around 1.8 for DNA. Note: A260/230 ratios maybe <2.0 
due to phenol contamination. This does not typically affect PCRs. 
b. (optional) Check the quality of genomic DNA on 1.0% agarose TAE gel 
with a 1kb ladder.   
i. Run for ~30-60 min on a 0.8-1% gel at 100 V.  If you see a thick 
and well-defined band that barely migrates (is genomic DNA and it 
is extremely heavy to migrate), it is your DNA and it is in good 
shape. The blurrier it looks, the more degraded your DNA is. If the 
band has a thick smear it is very degraded.   It does not matter if 
the genomic DNA is totally intact for PCR as long as the smear 
extends above the expected length of your amplicon and the DNA 
does not have any PCR inhibitors.   
 
Method 2: Squash Buffer 
 
NOTES 
- Good for  
o Rapid genotyping of a fly line 
o Genotyping single animals (e.g. determining if a single, potential 
recombinant male indeed has the desired genotype) 
- Does not work on LDS-G4C2 fly model w/ G4C2 PCR protocol 
- May need to reduce amount of supernatant used per PCR reaction to 1μl 
depending on your PCR reaction 
 
 REAGENTS/MATERIALS 
• 1M Tris-HCl, pH 8.0 
• 0.5M EDTA, pH 8.0 
• 5M NaCl 
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• proteinase K (Roche cat# 12445700, 20mg/ml) 
• microcentrifuge tubes 
• pellet/pestle disposable blue microcentrifuge tubes (Kimble # 749520-0000) 
• pellet/pestle cordless motor (Kimble # 749540-0000) 
 
PROTOCOL 
1. Prepare: 
a. Squash Buffer Stock (10 mM Tris-HCl, pH 8.0; 1 mM EDTA; 25 mM NaCl) 
- can make 50mL in a conical and store long-term at room temperature 
b. Preheat two heat-blocks: one to 37ᵒC, one to 95ᵒC 
2. Prepare Working Squash Buffer by adding 5μl proteinase K to 250ul of Squash 
Buffer Stock (need 30μl per sample). 
3. Place 1-2 flies in a pre-labeled, blue microcentrifuge tube. Using disposable 
pestle and motor, grind the fly for 5-10 sec in 30μl of Working Squash Buffer. 
4. Incubate tubes at 37ᵒC for 40min. 
5. Incubate tubes at 95ᵒC for 5min to inactivate protease K.  
6. Pellet cuticle by centrifuging samples at 12,000xg for 5-10 min.  
7. Transfer supernatant to a fresh, prelabeled microcentrifuge tube with a 200μL 
pipette, making sure to avoid pellet. 
8. Store at -20ᵒC. 
9. Use 2μl of aqueous supernatant as PCR template for 10μl PCR reaction.  
 
 
PCR reactions for UAS, GAL4, GS transgenes 
 TRANSGENE-SPECIFIC REACTIONS 
- pUAS transgenes (flanking primers)  
o UAS-(GR)36 parameters 
▪ annealing temperature: 59 ᵒC 
▪ DNA template per reaction: 100ng  
▪ PCR product: ~520bp by agarose gel 
o Other pUAS transgenes parameters 
▪ annealing temperature: Run a gradient temperature reaction from 
55-52ᵒC on a positive sample to define the best annealing 
temperature  
▪ DNA template per reaction: test 100 and 200ng 
▪ PCR product: ~300bp + the size of the transgene 
o Forward primer: 5’- AGCAACCAAGTAAATCAACTGC -3’ 
o Reverse primer: 5’- TTCATCAGTTCCATAGGTTGG -3’ 
- GAL4 transgenes  
o Parameters 
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▪ annealing temperature: 58 ᵒC 
▪ DNA template per reaction: 200ng  
▪ PCR product: ~420bp by agarose gel 
o Forward primer: 5’- GTCTTCTATCGAACAAGCATGCGA -3’ 
o Reverse primer: 5’- TGACCTTTGTTACTACTCTCTTCC -3’ 
- GAL4[geneswitch] transgenes  
o Parameters 
▪ annealing temperature: 62 ᵒC 
▪ DNA template per reaction: 100ng  
▪ PCR product: ~520bp by agarose gel 
o Forward primer: 5'-GGGCTACGAAGTCAAACCCA-3' 
o Reverse primer: 5'-TCTGCCCAGAAGGAAACACC-3' 
 
 REAGENTS/MATERIALS 
• Fly genomic DNA (see General protocols: gDNA extraction (flies)) 
• FastStart PCR Master Mix (Roche # 04710436001) 
• 6X Gel Loading Dye (New England biolabs #B7021S) 
• MilliQ water 
 
SUPPLEMENTARY FILE:  PCR reactions for UAS-GAL4 transgenes.xlsx  
 
 PROTOCOL 
1. Thaw the following at RT 
a. Fly genomic DNA 
b. FastStart PCR Master Mix (Roche # 04710436001) 
2. Prepare a master mix using the Supplementary file to automatically calculate the 
volumes of each reagent to add. Be sure to include a no-template (water only) 
control and a positive control. 
Master Mix Component Final concentration 
2X FastStart Master Mix 1X 
Forward Primer (3μM) 0.3μM 
Reverse Primer (3μM) 0.3μM 
Genomic DNA  
Volume is based on your 
samples, typically 1-2μl 
MilliQ water (must be room temperature) 
Volume is based on your 
desired end volume, typically 
10μl 
  Notes 
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▪ Make sure you have a no-template (water) control and a 
positive control.  If using the plasmid construct as the positive 
control, only use 5-20ng of purified plasmid per reaction. 
3. pipette the correct amount of master mix into desired # of PCR tubes. Typically, 
8-9μl of master mix/tube.  
4. add genomic DNA to the PCR tubes, being sure to keep track of the order. 
Typically, 1-2μl of 100ng/μl genomic DNA per tube. 
5. Place tubes into a thermocycler.  Press firmly down on each tube’s lid to make 
sure they are sealed. Run the following program:  
Step Temperature Time 
Number 
Cycles 
Initial denaturation 95 °C 6 min 1 
Denaturation 95 °C 30 sec 
35 Primer annealing varies 30 sec 
Extension 72 °C 1min 
Final Extension 72 °C 7min 1 
Cooling 4 °C Hold 1 
6. PCR samples can be stored at -20ᵒC for future use. 
7. Run PCR products on a 1% TAE agarose gel 
a. Prepare a 1% TAE agarose gel 
i. prep the agarose gel casting equipment with an appropriate size 
comb – includes placing the tray in the mount and adding the 
comb then making sure it’s all level with a level 
ii. add desired volume of 1X TAE to a Erlenmeyer flask (for mini gel 
this is 70ml, for a midi gel this is 200ml) 
iii. add agarose powder to the TAE for a final concentration of 1% 
(w/v) (for a mini gel this is 0.7g, for a midi gel this is 2g) 
iv. place a kimwipe or paper towel into the mouth of the flask and 
microwave the agarose until it has COMPLETELY melted.  
Usually ~3min, swirl flask every minute to mix. At the end, confirm 
there are no unmelted pieces within the solution – it should have 
no particles floating in it.  microwave more as needed. 
v. add SYBR safe DNA stain to the melted agarose to 1x volume 
(7μl for mini gel, 20μl for midi gel).  Swirl flask gently until stain is 
well mixed – be sure to avoid creating bubbles 
vi. gently pour the agarose into the prepared gel casting tray making 
sure to avoid bubbles.  If bubbles to form, try to remove them or at 
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least move them to the sides using a pipette tip. Bubbles around 
the comb can be a particular problem. 
vii. Cover the gel loosely with Al foil to avoid light exposure (do not 
seal it! this is just to protect it from light but you want it to cool as if 
the foil was absent) 
viii. let agarose gel solidify for 45min-90min 
b. Prepare samples 
i. Thaw an aliquot an appropriate sized DNA ladder 
ii. Dilute PCR products into 6X diluted sample buffer and mix 
thoroughly 
1. If running PCR products prepared from high-quality DNA, 
run ~5μl of PCR product per lane.  
2. If running PCR products prepared from Squash Method 
DNA preps, run 5-10μl of PCR product per lane 
c. Run Gel 
i. Prepare gel running equipment 
1. Gently remove comb from the solidified gel 
2. Place gel into the electrophoresis tank and add 1x TAE 
until it covers the top of the gel 
ii. Add 5μl of each DNA ladder and 5-10μl of prepared PCR products 
per lane into the pre-determined lanes, being sure to keep track of 
which samples are in which lanes 
iii. run the gel 
1. put the lid onto the electrophoresis tank paying special 
attention to the position of the electrodes. The 
black/negative electrodes at the top and the red/positive 
electrodes at the bottom. 
2. Plug the electrodes into a power-source, again paying 
special attention to the position of the electrodes – black-
to-black and red-to-red. 
iv. run the power supply at 100V for 40-75min until the blue indicator 
dye is ~2/3 of the way down the gel.  DO NOT OVERRUN THE 
GELS AS THIS REDUCES TO SIGNAL STRENGTH.  YOU CAN 
ALWAYS STOP THE GEL, CHECK IT ON THE UV IMAGER AND 
RUN IT MORE IF NEEDED TO GET SEPERATION OF BANDS. 
d. Image the gel using the UV imager.  The Bonini lab imager is significantly 
better while bands from these reactions should be relatively bright.  Also, 
be prepared to look visually at the gel and to play around with exposure if 
bands are faint. If needed, you can soak the gel in 1X SYBR Safe DNA 
stain in TAE buffer for 10min and reimage.  
e. Estimate the size of the PCR product(s) based on the DNA ladders. 
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Repeat-length determination 
G4C2 PCR Reaction  
 NOTES 
- Protocols for isolating genomic DNA from flies are in “General Protocols” 
- Primers were designed that flank the repeat 
o UAS-G4C2 lines  
▪ a 350bp PCR product is expected for 49 repeats 
▪ Forward primer: 5’-GAATTCGAGCTCAGATCTCCCG-3’ 
▪ Reverse primer: 5’-
TCTAGAGGATCCGGTACCGAGTCTCGAG-3’ 
o UAS-LDS-G4C2 lines  
▪ a 461bp PCR product is expected for 49 repeats 
▪ Forward primer: 5'-CTCGCTGAGGGTGAACAAGA-3' 
▪ Reverse primer: 5'-ACTTGTGGCCGTTTACGTCG-3' 
 
 REAGENTS 
• Fly genomic DNA (see General protocols: gDNA extraction (flies)) 
• KAPA HiFi Hotstart Kit (KAPA Biosystems #KK 2501) 
• DMSO 
• 5M Betaine (Sigma #B0300-1VL, stored at 4ᵒC) 
• MilliQ water 
 
SUPPLEMENTARY FILE:  G4C2 PCR Reaction (KAPA HiFi Hot-start Kit).xlsx  
 
 PROTOCOL 
1. Thaw the following at RT 
a. From Kapa HiFi Kit 
i. 5X GC Buffer 
ii. KAPA dNTP mix (10mM) 
b. Working stocks for primers (at 10μM) 
c. Genomic DNA samples 
2. (recommended) Update the G4C2 PCR Reaction (KAPA HiFi Hot-start Kit) 
supplementary file with relevant information and print the excel sheet for use at 
bench. 
3. Prepare a master mix using the Supplementary file to automatically calculate the 
volumes of each reagent to add. Be sure to include a no-template (water only) 
control and a positive control. 
Master Mix Component Final concentration 
5X GC Buffer 1X 
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KAPA dNTP mix (10mM) 0.3mM 
Forward Primer (10uM) 0.3μM 
Reverse Primer (10uM) 0.3μM 
DMSO 5% 
Betaine (5M) 1M 
KAPA HiFi Hotstart DNA 
polymerase (1 U/μl) 0.02 U/1μl rxn 
Genomic DNA (200ng) 
Volume is based on your 
samples, typically 2μl 
MilliQ water (must be room 
temperature) 
Volume is based on your desired 
end volume, typically 10μl 
 
Notes:  
▪ It is important that the reaction mix remain at room 
temperature as DMSO freezes at 4ᵒC.  Accordingly, use RT 
water and let the reaction mix reach RT before adding the 
enzyme. 
▪ Make sure you have a no-template (water) control and a 
positive control.  If using the plasmid construct as the positive 
control, only use 20ng of purified plasmid per reaction. 
4. pipette the correct amount of master mix into desired # of PCR tubes. Typically, 
8μl of master mix/tube.  
5. add genomic DNA to the PCR tubes, being sure to keep track of the order. 
Typically, 2μl of 100ng/μl genomic DNA per tube. 
6. Place tubes into a thermocycler.  Press firmly down on each tube’s lid to make 
sure they are sealed. Run the following program: in Eppendorf PCR Machine #3 
under Lindsey > G4C2 PCR > Kapa hotstart. 
Step Temperature Time 
Number 
Cycles 
Initial denaturation 95 °C 5 min 1 
Denaturation 98 °C 20 sec 
35 
Primer annealing 61 °C 30 sec 
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Extension 72 °C 1min 
Final Extension 72 °C 5min 1 
Cooling 4 °C Hold 1 
7. PCR samples can be stored at -20ᵒC for future use. 
 
Estimate repeat length: agarose gel 
REAGENTS 
• KAPA-HiFi PCR products 
• 2X diluted sample buffer 
o 20μl of 6X Gel Loading Dye (New England biolabs #B7021S) 
o 6.6μl of 1M Tris-HCL, pH=8.0 to 6.6mM 
o 100μl of 50% glycerol to 5% 
o 873.4μl of MilliQ water to 1ml 
• SYBR Safe DNA stain 
• 50bp DNA ladder 
• 25bp DNA ladder 
• 1X TAE buffer 
• Standard melting point agarose (Invitrogen #16500500) 
 
PROTOCOL 
1. Prepare a 1.5% TAE agarose gel 
a. prep the agarose gel casting equipment with an appropriate size comb – 
includes placing the tray in the mount and adding the comb then making 
sure it’s all level with a level 
b. add desired volume of 1X TAE to a Erlenmeyer flask (for mini gel this is 
70ml, for a midi gel this is 200ml) 
c. add agarose powder to the TAE for a final concentration of 1.5% (w/v) (for 
a mini gel this is ~1g, for a midi gel this is 3g) 
d. place a kimwipe or paper towel into the mouth of the flask and microwave 
the agarose until it has COMPLETELY melted.  Usually ~3min, swirl flask 
every minute to mix. At the end, confirm there are no unmelted pieces 
within the solution – it should have no particles floating in it.  microwave 
more as needed. 
e. add SYBR safe DNA stain to the melted agarose to 1x volume (7μl for 
mini gel, 20μl for midi gel).  Swirl flask gently until stain is well mixed – be 
sure to avoid creating bubbles 
f. gently pour the agarose into the prepared gel casting tray making sure to 
avoid bubbles.  If bubbles to form, try to remove them or at least move 
them to the sides using a pipette tip. Bubbles around the comb can be a 
particular problem. 
442 
 
g. Cover the gel loosely with Al foil to avoid light exposure (do not seal it! 
this is just to protect it from light but you want it to cool as if the foil was 
absent) 
h. let agarose gel solidify for 45min-90min 
2. Prepare samples 
a. Thaw an aliquot of 25bp and 50bp DNA ladder 
b. Dilute PCR products into 2X diluted sample buffer and mix thoroughly 
i. If running PCR products prepared from high-quality DNA, run 5-
10μl of PCR product per lane. Be sure to save 5μl of PCR product 
for Bioanalyzer analysis if desired. If you are not running a 
bioanalyzer, its best to use more PCR product in the gel as the 
bands are not always bright. 
ii. If running PCR products prepared from Squash Method DNA 
preps, run 10-20μl of PCR product per lane 
3. Run Gel 
a. Prepare gel running equipment 
i. Gently remove comb from the solidified gel 
ii. Place gel into the electrophoresis tank and add 1x TAE until it 
covers the top of the gel 
b. Add 5μl of each DNA ladder and 10-20μl of prepared PCR products per 
lane into the pre-determined lanes, being sure to keep track of which 
samples are in which lanes 
c. run the gel 
i. put the lid onto the electrophoresis tank paying special attention to 
the position of the electrodes. The black/negative electrodes at the 
top and the red/positive electrodes at the bottom. 
ii. Plug the electrodes into a power-source, again paying special 
attention to the position of the electrodes – black-to-black and red-
to-red. 
d. run the power supply at 100V for 40-75min until the blue indicator dye is 
~2/3 of the way down the gel.  DO NOT OVERRUN THE GELS AS THIS 
REDUCES TO SIGNAL STRENGTH.  YOU CAN ALWAYS STOP THE 
GEL, CHECK IT ON THE UV IMAGER AND RUN IT MORE IF NEEDED 
TO GET SEPERATION OF BANDS. 
4. Image the gel using the UV imager.  The Bonini lab imager is significantly better 
for seeing these PCR products as they can be faint. Other imagers don’t always 
work.  Also, be prepared to look visually at the gel and to play around with 
exposure if bands are faint. If needed, you can soak the gel in 1X SYBR Safe 
DNA stain in TAE buffer for 10min and reimage.  
5. Estimate the size of the PCR product(s) based on the DNA ladders. Calculate the 
# of repeats present 
a. For UAS-G4C2 lines: [(PCR product length) – (49bp of non-G4C2 
sequence)] ÷ 6 = X 
b. For UAS-LDS-G4C2[GA-GFP] lines: [(PCR product length) – (203bp of 
non-G4C2 sequence)] ÷ 6 = X 
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c. For UAS-LDS-G4C2[GR-GFP] lines: [(PCR product length) – (205bp of 
non-G4C2 sequence)] ÷ 6 = X 
 
Calculate repeat length: Bioanalyzer 
1. add 1μl of PCR products to 4μl MilliQ water in pre-labeled PCR tubes. Samples 
can be stored at -20ᵒC until you’ve accumulated a whole chip’s worth of samples.  
Keep the remaining 4μl of the PCR product for future use. You may need to 
resubmit samples at a higher concentration.  
2. Submit samples to the CHOP DNA core for analysis using the Agilent DNA 1000 
chip/protocol.  
3. From the PCR product lengths reported by the Bioanalyzer, calculate the # of 
repeats present 
a. For UAS-G4C2 lines: [(PCR product length) – (49bp of non-G4C2 
sequence)] ÷ 6 = X 
b. For UAS-LDS-G4C2[GA-GFP] lines: [(PCR product length) – (203bp of 
non-G4C2 sequence)] ÷ 6 =  
c. For UAS-LDS-G4C2[GR-GFP] lines: [(PCR product length) – (205bp of 
non-G4C2 sequence)] ÷ 6 = X 
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RNA extraction (flies) 
 
Total RNA extraction (Trizol) 
 
NOTES: Typical yield for fly heads with 20min incubation at RT for step 11  
Yield 
 total ng/head 
mean 531 
median 496 
min 423 
max 721 
 
REAGENTS/MATERIALS 
- Tissue 
o Use 5-10 whole larvae or flies per sample  
o Use 20-30 fly heads per sample 
- Trizol 
- Isopropanol 
- 75% ethanol (200 proof ethanol + MilliQ water) 
- DEPC-treated water 
- RNaseZAP  
- Ambion RNase free 1.5 mL microcentrifuge tubes (Thermo Sci # AM12400) 
- RNase-free pellet/pestle disposable blue microcentrifuge tubes (Fisher Sci # 
12-141-368) 
o Alternative: the standard pellet/pestle disposable blue microcentrifuge 
tubes (Kimble # 749520-0000) can be used if the bag is maintained for 
RNA work 
- pellet/pestle cordless motor (Kimble # 749540-0000) 
- RNaseZap (Thermo Sci # AM9780) 
- Filtered pipette tips 
 
PROTOCOL 
1. Prepare an RNase-free work space: 
a. Place a clean piece of plastic wrap on counter of your work station 
b. Spray pipettes with RNaseZAP 
c. Obtain filtered pipette tips 
d. In general, it is good practice to spray hands with RNaseZAP after 
touching non-treated surfaces (like centrifuges) and to exchange gloves 
periodically, never grabbing them by the fingertips. 
2. Using mortar & pestle, homogenize tissue in 100μl Trizol extraction buffer in blue 
microcentrifuge tubes.  
* if using frozen tissue, keep on dry ice until adding Trizol 
3. Add an additional 900μl Trizol and vortex. 
4. Repeat for all samples and then incubate at RT for 5min allowing complete 
dissociation of the nucleoprotein complex (so some samples will have sat longer 
than 5min.  This does not seem to effect results.) 
* homogenate can be stored at -80 C for 1mo.  To thaw, place at RT for 
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5-10min until have equilibrated fully. 
5. Add 200μl chloroform to each tube (in the hood) 
6. Vortex for 20sec and incubate at RT for 2-3min. 
*  With some samples, the cuticle ends up separating into the aqueous 
portion during this time.  If this occurs, re-vortex. 
7. Centrifuge for 15min at 15000xg, 4ᵒC.  (treat rotor with RNase-Zap before use if 
not using a RNA-designated centrifuge) 
8. Prep: label RNase-free microcentrifuge tubes 
9. Immediately, gently remove tubes from centrifuge.  Remove upper aqueous 
phase while avoiding the organic layer or lower red phenol-chloroform phase.  
Put into fresh tube, pre-labeled with sample name.   
* Usually remove ~450ul and leave ~50ul of aqueous layer so as to avoid 
the other layers. 
10. Add equal volume of 100% isopropanol (or more).  Turn tube upside down 40-
60X to mix. 
* Usually add ~600-650μl isopropanol 
** Do not vortex as this breaks RNA strands and can result in degraded 
sample 
11. Incubate RNA in isopropanol 
a. For whole animals: incubation at RT for 20min is sufficient 
b. For fly heads: store samples overnight at -80ᵒC to increase yield (must 
become frozen for a significant effect) 
19. Centrifuge tubes at 12,000xg for 20min.  Remove supernatant by pouring it into a 
waste container – be sure to keep the tube inverted (!) and dab the edge on 
clean paper towel to remove excess supernatant. Pellet may be loose so use 
caution not to lose it during pouring off supernatant. 
12. Wash pellet by adding 1ml 75% EtOH and turn tubes upside down a couple of 
times until pellet detaches from side of tube.  If pellet does not detach, use a P-
20 pipet to gently knock it lose.  
13. Centrifuge at 7500xg for 5min (4ᵒC).  Remove supernatant by pouring it into a 
waste container – be sure to keep the tube inverted (!) and dab the edge on 
clean paper towel to remove excess supernatant. Pellet may be loose so use 
caution not to lose it during pouring off supernatant. 
14. Repeat EtOH wash and centrifugation.  Remove supernatant. 
15. Centrifuge tubes briefly to collect residual supernatant to the bottom. Carefully 
pipet off residual EtOH using P20 or P200 pipet. Do not touch the pellets. 
16. Dry pellets at room temperature for ~2-3min  
17. Add 2μl DEPC-water per whole animal or 0.5μl DEPC-water per head (total 10-
50ul) and incubate at RT for 5-10min. 
18. Resuspend pellet by pipetting and place on ice.  
* pellets should dissolve completely. Add more DEPC water if necessary. 
1. (optional) perform DNase treatment (below). DNase treatment is not needed for 
Northerns but is good practice for qRT-PCR particularly if primers do not span 
exons. 
2. Assess RNA concentration and quality by nanodrop and by gel (optional). 
3. Store samples at -80ᵒC.  
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DNase Treatment  
REAGENTS/MATERIALS 
- Turbo DNA free kit (Ambion AM1907) 
- Microcentrifuge tubes 
 
PROTOCOL 
1. Prepare an RNase-free work space: 
a. Place a clean piece of plastic wrap on counter of your work station 
b. Spray pipettes with RNaseZAP 
c. Obtain filtered pipette tips 
d. In general, it is good practice to spray hands with RNaseZAP after 
touching non-treated surfaces (like centrifuges) and to exchange gloves 
periodically, never grabbing them by the fingertips 
2. Add 0.1 volume 10X TURBO DNase Buffer and 1ul TURBO DNase to the RNA, 
and mix gently.  
Tip: You can make a master mix of 10X TURBO DNase Buffer and 
TURBO DNase. 
3. Incubate at 37°C for 20–30 min. 
4. Add resuspended DNase Inactivation Reagent (0.1 volume) and mix well. 
5. Incubate 2-5 min at room temp, mixing occasionally. 
6. Centrifuge at 10,000 x g for 1.5 min and transfer the RNA to a fresh, pre-labeled 
microcentrifuge tubes tube. 
7. Assess RNA concentration and quality (below) 
 
 
 
Assessing RNA quality 
1. If samples are frozen, thaw them on ice and mix by tapping the side of the tube. 
(Do not vortex as this can break RNA strands.) 
2. Measure concentration by Nanodrop. A260/280 ratio should be around 2.0. 
Note: A260/230 ratios maybe <2.0 due to trizol contamination. This does 
not seem to affect qRT-PCRs or northerns.  
a. Normalize the concentration of the RNA so all samples are the same (typically 
200ng/μl) 
3. (optional) run samples on a gel 
i. When learning how to get outstanding quality RNA, run ~0.5-1μg/lane of 
RNA on a 1% Agarose TBE gel (use RNase free water. Ideally DEPC-
treated water, but Millipore water should also work). 
4. (optional) run samples on a Bioanalyzer to confirm outstanding quality using 
Agilent RNA 6000 Nano Kit. Please note that this is very sensitive.
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qRT-PCR (SYBR Green) 
 
DNA Primer design 
IDEAL PRIMERS 
- are 19-21bp long 
- For RNA expression studies: are exon spanning (so selective for RNA/cDNA 
in case there’s contaminating genomic DNA) 
- produce 50-100bp products (can go up to 200bp if necessary) 
- are specific to your target gene (are not predicted to produce < 500bp 
product from an off-target gene) 
- are not predicted to form primer-dimers 
 
PROTOCOL 
1. Look up gene sequence on Flybase or NCBI. It’s nice to use the CDS sequence. 
2. Copy sequence into Primer3: http://bioinfo.ut.ee/primer3-0.4.0/.   
a. I usually set product to 50-150bp.  If this doesn’t return primers than you 
can go up to 200bp for qPCR 
b. I typically buy 2 exon spanning primer sets to test. And then after 
checking their melt curves and running them on a gel, I pick the best set 
for my studies. 
3. For RNA expression studies: check if primers are exon spanning  
a. (best approach) input primer sequences into 
http://projects.insilico.us/SpliceCenter/PrimerCheck.jsp with the gene 
target.  
b. Check primers against the total gene sequence to see which ones span 
an exon. 
i. For flies, go to flybase.com and click on “Get genome region” 
ii. For human, use NCBI’s website 
4. To confirm primer specificity, input primers into 
https://www.ncbi.nlm.nih.gov/tools/primer-blast/ . Be sure to select the right 
species. 
 
- Alternative approaches: 
o Look up publication which have done qPCR for your target. They 
should publish their primer sequences in the methods section. 
o Look up the gene on Applied Biosystem’s website and copy their 
forward and reverse primers for you target that they designed for 
Taqman.  Taqman also uses a probe, which you don’t use w/ Sybr 
Green but the same primers should work for both assays.  
▪ http://www.thermofisher.com/us/en/home/life-science/pcr/real-
time-pcr/real-time-pcr-assays/taqman-gene-expression.html 
- If you need to take the reverse complement for the reverse primer -- 
http://reverse-complement.com/ 
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cDNA preparation 
 NOTES 
- I find it convenient to prepare cDNA in PCR plates to keep them well organized 
and labeled. However, for small numbers of samples, PCR strips may be better. 
- I tend to organize data so the RNA prep is the first tab of an excel worksheet. 
Then the cDNA prep is the following tab, then a tab for the qRT-PCR plate setup 
and a final tab for results.  Additional qRT-PCR experiments on the same 
RNA/cDNA preps will be added as additional tabs so everything is together.  
 
 REAGENTS/MATERIALS 
• Total RNA samples (see General Protocols: RNA extraction (flies) or Fibroblasts: 
RNA extraction) 
o DNase-treated RNA is recommended at all times 
o DNase-treated RNA is required if your primers are not exon spanning 
• High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems # 4368814) 
• RNaseZap (Thermo Sci # AM9780) 
• RNase-free PCR tubes or plates 
• RNase-free Microcentrifuge tubes 
• Filtered pipette tips 
• MilliQ water 
 
 SUPPLEMENTARY FILE:  cDNA prep.xlsx  
 
 PROTOCOL 
1. Prepare an RNase-free work space: 
a. Place a clean piece of plastic wrap on counter of your work station 
b. Spray pipettes with RNaseZAP 
c. In general, it is good practice to spray hands with RNaseZAP after 
touching non-treated surfaces (like centrifuges) and to exchange gloves 
periodically, never grabbing them by the fingertips. 
2. Thaw on ice: RNA samples, 10X RT buffer, 10X RT Random Primers, 25X dNTP 
mix. 
3. (recommended) Update the cDNA prep supplementary file with relevant 
information: experiment purpose and sample details, # samples, plate template. 
Print the excel sheet for use at bench. 
4. Prepare a master mix using filtered pipette tips 
a. For 10ul/reaction 
  Master mix (μl) 
10✕ RT Buffer 1 
10✕ RT Random Primers 1 
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25✕ dNTP Mix (100 mM) 0.4 
Reverse Transcriptase 0.5 
Total RNA (200-400ng) (up to 7.1μl) 
MilliQ water (to 10μl final volume) 
b. For 20ul/reaction 
  Master mix (μl) 
10✕ RT Buffer 2 
10✕ RT Random Primers 2 
25✕ dNTP Mix (100 mM) 0.8 
Reverse Transcriptase 1 
Total RNA (200-400ng) (up to 14.2μl) 
MilliQ water (to 20μl final volume) 
c. Notes:  
i. add the reverse transcriptase last, making sure it stays close to -
20ᵒC 
ii. it is vital to mix thoroughly 
iii. Controls: 
1. No template (water) control: add water in place of template 
RNA, tests if there is contaminants in reagents and if 
primers can react together (primer dimers) 
2. No Reverse Transcriptase control: add template RNA but 
no enzyme, tests if there is DNA contamination and if 
primers amplify DNA 
5. Aliquot master mix and RNA samples into a pre-labeled PCR strip or plate using 
filtered pipette tips. 
6. Run cDNA reactions on a thermocycler, making sure the lids are completely 
closed on samples. 
Step Temperature Time 
initiation 25 °C 10 min 
cDNA reactions 37 °C 120 min 
denaturation 85 °C 5min 
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Cooling 4 °C Hold 
7. (optional) Dilute cDNA 1:10 by adding MilliQ water. Vortex tubes to mix samples 
thoroughly. Centrifuge to collect samples to bottom of tubes. 
o If target gene is lowly expressed, you may not want to dilute cDNA. In this 
case, it’ll likely be necessary to increase reaction volumes to 20ul so you 
have enough sample for analysis 
8. cDNA can be stored at -20ᵒC for future use. When thawing samples, be rigorous 
about making sure they are fully mixed.  This is a common source of variability 
during qRT-PCR.  
 
Primer optimization 
 NOTES 
- Variables that we typically change when optimizing new primers 
o Amount of template added 
o Amount of primer added (can go as low as 0.05μM). this typically 
reduces the presence of primer dimers 
- Useful websites for troubleshooting qRT-PCR 
o https://www.slideshare.net/idtdna/understanding-melt-curves-for-
improved-sybr-green-assay-analysis-and-troubleshooting 
o https://www.sigmaaldrich.com/technical-
documents/articles/biology/troubleshooting.html 
o https://toptipbio.com/calculate-primer-efficiencies/  
 
 REAGENTS/MATERIALS 
• For RNA expression studies: cDNA prepared from samples expressing the target 
gene (typically RNA prepared from whole larvae or flies can work while this 
avoids any variability in tissue-specific expression) 
• Forward and Reverse primers for target gene  
• Forward and Reverse primers for 1-3 housekeeping gene(s)  
• SYBR Green Fast Master Mix (Applied Biosystems # 4385612) 
• Microcentrifuge tubes 
• Fast optical qRT-PCR plates (384- or 96-well) 
• MilliQ water 
 
 SUPPLEMENTARY FILE:  qRT-PCR primer optimization.xlsx  
 
 PROTOCOL 
1. If not done yet, resuspend primers in MilliQ water to 100μM and prepare a 1:10 
dilution for a 10μM working stock. 
a. Briefly centrifuge tubes containing lypholized primer to pellet. 
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b. Add the appropriate amount of MilliQ water to make a 100μM Master 
Stock:  multiply the # nmol value by 10.  For example: if the nmol value is 
38.2, then you will be adding 382μl MilliQ water. 
c. Replace caps on tubes and vortex on a medium speed. Vortex the top 
and the bottom of the tube. Briefly centrifuge to collect solution to the 
bottom of the tube and incubate for 5-10min to fully resuspend primer.  
d. Make a 1:10 dilution for a 10μM working stock by adding 20μl of 100μM 
primer to 180μl MilliQ water into a pre-labeled microcentrifuge tube. This 
is what you will use for qRT-PCR reactions.   
e. Store the 100μM master stock and the 10μM working stock at -20ᵒC for 
future use. Thaw on ice. 
2. (recommended) Update the qRT-PCR primer optimization supplementary file 
with relevant information. Print the excel sheet for use at bench. 
3. Prepare a master mix and serial dilutions for your samples in a qRT-PCR optical 
plate. When done, seal the plate with optical film.  
a. Standard 10ul reaction 
  μl Final concentration 
SYBR Fast mix (2X) 5 1X 
Forw Primer (10uM) 0.5 0.5μM 
Rev Primer (10uM) 0.5 0.5μM 
template 1-4 Varies 
MilliQ water (to 10μl final volume) 
b. Notes: 
i. Typical serial dilutions are 1:2 of your template + master mix into a 
qRT-PCR plate. Run 3-5 dilutions so you can calculate primer 
efficiency accurately. 
ii. Be sure to include a no template (water) control and a 
housekeeping gene to make sure the template is good 
iii. Typically we run all reactions in duplicate or triplicate 
iv. Avoid wells on the edge of the qRT-PCR plate, leaving a 2-well 
barrier, when possible 
4. Centrifuge qRT-PCR plate to collect sample to the bottom of the tubes. 
5. Run qRT-PCR reactions on a real-time thermocycler 
a. Turn on machine and lobin to ABI software.  It maybe necessary to restart 
the computer and/or the machine.  
b. Go to “Set up” and select “Fast 384-well block”, “comparative CT”, “SYBR 
Green”, “Fast”. Check the item: include melt curve. Select “standard 
curve” in experiment properties 
c. Go to define  
i. enter primer (targets) names  
ii. Enter sample names  
d. Go to Assign  
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i. choose “define and set up standard”  
ii. Enter # of point 
iii. # replicate wells (Repeats) 
iv. Start quantity: 1 
v. Select correct serial dilution 
e. click next and change reaction volume to 10ul 
f. Put qRT-PCR plate into the machine. Be careful there’s nothing will be hit 
by the plate and the position of the plate is correct). Save and press Run 
6. Analyze curves within the software 
a. Run software analysis: 
i. Select the target for this standard curve one by one. Select wells 
 Apply  Close 
ii. Go to “Analysis”  Standard curve 
iii. Select all needed samples  analyze 
iv. Go to “Analysis setting”, “Standard curve setting” to check slopes, 
which should be ~-3.7. 
b. Look closely at the melt curves for anything abnormal. You want to see 1 
strong peak in samples containing template and no peaks in no template 
controls and no RT controls (if you ran these). Small peaks to the left of 
the strong peak are typically primer dimers and should be avoided if 
possible.  
c. Look closely at the amplification curves for anything abnormal. You want 
the replicate wells to be on top of each other and the serial dilutions to be 
obvious as you look at the different samples. Curves should be between 
Ct values of 16 to 30. Typically, anything after 32 is considered noise (no 
template controls tend to amplify at this point).  
d. Select the best c/DNA dilution for your primers - want a Ct value around 
20-22. 
e. Export the data and save it for your records 
Notes:  
o It is appropriate to manually adjust the threshold if the auto-threshold 
for a primer set is not at the best position. You want the threshold to 
be within the linear region of the amplification curves and high enough 
to avoid any noise. 
o By running a couple of wells for a housekeeping gene, you can control 
for any technical issues not related to the specific primers.  For 
example, if there are no curves in these wells, then there may be 
something wrong with your c/DNA or your SYBR green master mix.  
7. (optional) calculate the primer efficiency in excel using the Ct values for each 
dilution. See supplementary file qRT-PCR primer optimization.xlsx. 
8. (optional) run qRT-PCR products on a 1% TAE agarose gel to confirm that there 
is 1 PCR product and that it is at the expected size. Primer dimers will show up at 
the bottom of the well. 
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qRT-PCR Assays 
 NOTES 
- Useful websites for understanding how to analyze qRT-PCR 
o https://dharmacon.horizondiscovery.com/uploadedfiles/resources/delt
a-cq-solaris-technote.pdf 
o https://bitesizebio.com/24894/4-easy-steps-to-analyze-your-qpcr-data-
using-double-delta-ct-analysis/ 
o https://toptipbio.com/delta-delta-ct-pcr/ 
 REAGENTS/MATERIALS 
• cDNA prepared from control and experimental samples 
• 10μM working stocks of DNA primers (see primer optimization) 
o Forward and Reverse primers for target gene(s) 
o Forward and Reverse primers for 1-3 housekeeping gene(s)  
• SYBR Green Fast Master Mix (Applied Biosystems # 4385612) 
• Microcentrifuge tubes 
• Fast optical qRT-PCR plates (384- or 96-well) 
• MilliQ water 
 
 SUPPLEMENTARY FILE:  qRT-PCR.xlsx  
 
 PROTOCOL 
1. Thaw: primers and cDNA samples on ice. cDNA samples need to be vigorously 
mixed before use as the samples tend to become heterogonous. Typically, vortex 
and spin samples 2-3 times before use. 
2. (recommended) Update the qRT-PCR supplementary file with relevant 
information. Print the excel sheet for use at bench. 
3. Prepare a master mix for each of your target genes and pipette the master mix 
then your samples into a qRT-PCR optical plate at the correct volumes. When 
done, seal the plate with optical film. 
a. Standard 10ul reaction 
  μl Final concentration 
SYBR Fast mix (2X) 5 1X 
Forw Primer (10uM) 0.5 0.5μM 
Rev Primer (10uM) 0.5 0.5μM 
cDNA template 1-4 Varies 
MilliQ water (to 10μl final volume) 
b. Notes: 
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i. Be sure to include a no template (water) control for each primer 
set 
ii. Typically we run all reactions in duplicate or triplicate 
iii. Avoid wells on the edge of the qRT-PCR plate, leaving a 2-well 
barrier, when possible 
iv. Pipette master mixes then cDNA samples: Its best to pipette 
duplicate or triplicate wells and replicate cDNA samples at the 
same time to avoid unnecessary variability 
4. Centrifuge qRT-PCR plate to collect sample to the bottom of the tubes. 
5. While plate spins, setup the experiment on the real-time thermocycler 
a. Turn on machine and login to ABI software.  It may be necessary to 
restart the computer and/or the machine.  
b. Go to “Set up” and select “Fast 384-well block”, “comparative CT”, “SYBR 
Green”, “Fast”. Check the item: include melt curve.  
c. Go to define  
i. enter primer (targets) names  
ii. Enter sample names  
d. Go to Assign  
i. Assign sample names to appropriate wells 
ii. Assign targets to appropriate wells 
e. click next and change reaction volume to 10ul 
f. Put qRT-PCR plate into the machine. Be careful there’s nothing will be hit 
by the plate and the position of the plate is correct). Save and press Run 
6. Analyze curves within the software 
a. Look closely at the melt curves for anything abnormal. You want to see 1 
strong peak in samples containing template and no peaks in no template 
controls and no RT controls (if you ran these). Small peaks to the left of 
the strong peak are typically primer dimers and should be avoided if 
possible.  
b. Look closely at the amplification curves for anything abnormal. You want 
the replicate wells to be on top of each other. Curves should be between 
Ct values of 16 to 30. Typically, anything after 32 is considered noise (no 
template controls tend to amplify at this point).  
c. (optional) manually adjust the threshold if the auto-threshold for a primer 
set is not at the best position. You want the threshold to be within the 
linear region of the amplification curves and high enough to avoid any 
noise. 
d. Export the data and analyze in excel on your computer 
7. Analyze data in excel using the ΔΔCt method 
a. Import the data  
b. Take mean of replicate wells 
c. For each sample, calculate ΔCt = (Mean Ct)gene-of-interest - (Mean 
Ct)housekeeping gene 
▪ If using multiple housekeeping genes: (Mean Ct)housekeeping gene 
will = average[(Mean Ct)housekeeping gene 1, (Mean Ct)housekeeping gene 
2, (Mean Ct)housekeeping gene 3] 
d. Calculate ΔΔCt = (ΔCt)treated – (ΔCt)control 
▪ Examples of “treated” 
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• RNAi to gene-of-interest to be compared to control 
sample (not expressing a RNAi or expressing a control 
RNAi) 
• Animals expressing a disease gene to be compared to 
control sample (not expressing a disease gene or 
expressing a control gene) 
▪ If you have technical replicate samples (3 samples collected in 
parallel) then (ΔCt)control will = average [(ΔCt)control 1, (ΔCt)control 2, 
(ΔCt)control 3] 
▪ (ΔCt)control is the sample that everything is relevant. The ΔΔCt 
for this sample should be 0:  ΔΔCt = (ΔCt)control – (ΔCt)control. If 
you are using technical replicate samples, then calculate ΔΔCt 
the same way you calculate it for the treated samples. This will 
result in an average ΔΔCt of 0 for the technical replicates while 
individual points can be above or below 0. 
e. Calculate the Fold Change = 2 ^(- ΔΔCt).  
▪ For control(s) this should equal 1.  
f. Report Fold Change as a bar graph, using the average Fold change 
between technical replicates when applicable. 
8. (optional) run qRT-PCR products on a 1% TAE agarose gel to confirm that there 
is 1 PCR product and that it is at the expected size. Primer dimers will show up at 
the bottom of the well. 
 
Optimized Primers 
 
Target 
Specie
s 
Assay 
Forward 
Primer (5'-3') 
Reverse 
Primer (5'-3') 
spans 
exons 
μM 
primer
s 
cDNA 
dilution* 
Ref. 
 Housekeeping genes 
 
Actin5C Dmel. 
qRT-
PCR; 
ChIP 
CGAAGAAGT
TGCTGCTCT
GGTTGT 
GGACGTCC
CACAACGAT
GGGAAG 
N 0.5 1:100 [1] 
 
PGK Dmel. 
qRT-
PCR; 
ChIP 
ATCACCAGC
AACCAGAGA
ATTG 
TGCCAGGG
TGTACTGAT
GTT 
N 0.5 1:100  
M
a
in
 RP49 
(RpL32) 
Dmel. 
qRT-
PCR 
TGTCCTTCC
AGCTTCAAG
ATGACCATC 
CTTGGGCTT
GCGCATTTG
TG 
Y 0.5 1:100 [2] 
 
RpS20 Dmel. 
qRT-
PCR 
CCGCATCAC
CCTGACATC
C 
TGGTGATGC
GAAGGGTCT
TG 
Y 0.5 1:100 [3] 
 
βTub56D Dmel. 
qRT-
PCR 
CATCCAAGC
TGGTCAGTG 
GCCATGCTC
ATCGAGAT 
Y 0.5 1:100 [4] 
 
βTub56D Dmel. ChIP 
GCAGTTCAC
CGCTATGTT
CA 
CACCAGATC
GTTCATGTT
GC 
N 0.5 n/a [5] 
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ACTB Hsap.  
qRT-
PCR 
CATGTACGT
TGCTATCCA
GGC 
CTCCTTAAT
GTCACGCAC
GAT 
N 0.5 1:100  
M
a
in
 
GAPDH Hsap.  
qRT-
PCR 
GTTCGACAG
TCAGCCGCA
TC 
GGAATTTGC
CATGGGTG
GA 
Y 0.5 1:100  
RPLP0 Hsap.  
qRT-
PCR 
TCTACAACC
CTGAAGTGC
TTGAT 
CAATCTGCA
GACAGACAC
TGG 
Y 0.5 1:100 [6] 
 Intergenic sequences 
 
II171a (2L) Dmel. ChIP 
GTTGGAGAA
ACTAAGAGC
C 
CCATACTCA
ATCGGACC 
n/a 0.5 n/a [7] 
 
GenBank: 
AC277990.1 
Hsap.  ChIP 
CCAACTGG
GTGCTGCCT
AGA  
AGGGTGCC
CATCACAGA
TGG  
n/a 0.5 n/a [8] 
 Endogenous targets 
d
P
A
F
1
C
  
Atms (dPaf1) Dmel. 
qRT-
PCR 
CCAAAGCTT
CCAAGGGC
TAC 
CGATAGCG
CTGCATACG
ATG 
Y 0.5 1:20 [5] 
Atu (dLeo1) Dmel. 
qRT-
PCR 
ACGGCTGAT
CGACACTGA
TA 
TGGCTCTCG
ACTTTATCC
CG 
Y 0.5 1:20 [5] 
Ctr9 Dmel. 
qRT-
PCR 
ATTGCGCAC
GTTTATGTC
GA 
GACGGGCC
TTAAGTAGC
ACT 
N 0.5 1:20 [5] 
CG3909 
(dWdr61) 
Dmel. 
qRT-
PCR 
AGTTGCGCC
ACAAACTAA
AAGG 
GCAATGGTC
TGTCCATCG
GAA 
Y 0.5 1:20 [5] 
CDC73 Dmel. 
qRT-
PCR 
AGCGTGAA
GACCAACTA
TCTCA 
CGCACGTA
GACCGAGT
GTT 
Y 0.5 1:20 [5] 
Rtf1 Dmel. 
qRT-
PCR 
CGGACGCA
ATCCCTGAT
CG 
CCGTTTGGG
GCTTCTTTC
G 
Y 0.5 1:20 [5] 
S
tr
e
s
s
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Chord Dmel. 
qRT-
PCR 
TATTTCCCG
AGCAGGAC
AAC 
TTGCATTGC
TCACATTCA
CA 
Y 0.5 1:40 [9] 
Fkbp59 Dmel. 
qRT-
PCR 
GCTCCAAAC
TACGCTTAC
GG 
TGGTTGGGA
CTCAAATCC
TC 
Y 0.5 1:40 [9] 
HSF Dmel. 
qRT-
PCR 
ATCGCTTGA
TTTGCTGGA
CC 
GAAGCTGG
CCATGTTGT
TGT 
Y 0.5 1:40 [9] 
HSP27 Dmel. 
qRT-
PCR 
GGCCACCA
CAATCAAAT
GTCAC 
CTCCTCGTG
CTTCCCCTC
TACC 
N 0.5 1:40 [3] 
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DnaJ-1 
(dHSP40) 
Dmel. 
qRT-
PCR 
GAGATCATC
AAGCCCACC
ACAAC 
CGGGAAACT
TAATGTCGA
AGGAGAC 
N 0.5 1:40 [3] 
HSP68 Dmel. 
qRT-
PCR 
GAAGGCACT
CAAGGACG
CTAAAATG 
CTGAACCTT
GGGAATAC
GAGTG 
N 0.5 1:40 [3] 
HSP70 Dmel. 
qRT-
PCR 
GGCACCTG
CTGGCAAAT
T 
CGGATAGTG
TCGTTGCAC
TTGT 
N 0.5 1:40 [9] 
HSP83 Dmel. 
qRT-
PCR 
GGACAAGG
ATGCCAAGA
AGAAGAAG 
CAGTCGTTG
GTCAGGGAT
TTGTAG 
N 0.5 1:40 [3] 
Stip1 Dmel. 
qRT-
PCR 
TGGCCTAAG
GGTTACTCA
CG 
GCATTCGTG
GGATCGTAC
TT 
Y 0.5 1:40 [9] 
Stv Dmel. 
qRT-
PCR 
GTACGCCTA
CCTGG 
CGAGA 
CAACTGCAC
CTGTGTCAA
CC 
Y 0.5 1:40 [9] 
c
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eIF2B Dmel. 
qRT-
PCR 
CGATGGCC
AAAAAGAAG
AAG 
ACCAGGTTG
AGCTGTTGT
CC 
Y 0.5 1:20  
eIF3i Dmel. 
qRT-
PCR 
GACCATCAT
CACAG 
TCACG 
TCCTTGCTC
AACTGCATG
TC   
Y 0.5 1:20  
eIF4A Dmel. 
qRT-
PCR 
GCAGGAGA
ACTGGAAAC
TGG 
ACATCTCCT
GGGTCAGTT
GG 
Y 0.5 1:100  
eIF4B Dmel. 
qRT-
PCR 
CGCATTGAG
CTATCGAAT
GA 
CCAATTTCC
GGAATCCCT
AT  
N 0.5 1:20 [10] 
eIF4H1 Dmel. 
qRT-
PCR 
GGGAAACG
GATCAGTTC
AAA 
CTTCTGGAA
ACCGTCTCT
GC   
Y 0.5 1:20 [10] 
eIF4H2 Dmel. 
qRT-
PCR 
CCACTCGAG
GTGGTTTCA
AT 
ATAGTTGCC
GCCTCCATT
TA 
Y 0.5 1:20  
eIF5: 
variants A-G 
Dmel. 
qRT-
PCR 
GACGCTGTT
CGATCACAA
GA 
CTCGGGGC
ATAACACAA
ACT 
Y 0.5 1:20  
eIF5B Dmel. 
qRT-
PCR 
GTTCGTTGG
AGGCTCTTC
TG 
CCTCGTGTT
CCAACATTG
TG  
Y 0.5 1:20  
eIF5C: 
variants A-G 
Dmel. 
qRT-
PCR 
TCAAGCAAG
AGAAGGGC
ATT 
TTGTTCGGT
GGGAAAAA
GTC 
Y 0.5 1:20  
  
Rpb1 Dmel. 
qRT-
PCR 
CGTCAGAC
GTTCGAGAA
TGTTGACCC
ACACAAGCA
Y 0.5 1:100  
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CAA AT 
 
Rps25 Dmel. 
qRT-
PCR 
GTCTCCGAG
CGTCTGAAG
AT 
GCTTGATCA
GACCCTTCT
CG 
Y 0.5 1:100  
C
9
o
rf
7
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C9: intron 1, 
3' of repeat 
Hsap.  
qRT-
PCR, 
ChIP 
CCTGATAGG
AGATAACAG
GATTCCAC 
CGACATCAC
TGCATTCCA
ACTGTC 
N 0.5 2:5 [11] 
C9: intron 1, 
5' of repeat 
Hsap.  
qRT-
PCR 
GCAAGAGC
AGGTGTGG
GTTTAG 
CCTCAGCGA
GTACTGTGA
GAGC 
N 0.5 2:5 [11] 
C9: Total  
(V1-3) 
Hsap.  
qRT-
PCR 
AACTGGAAT
GGGGATCG
CA 
CTGATCTTC
CATTCTCTC
TGTGCC 
Y 0.5 2:5 [6] 
C9: variant 1 Hsap.  
qRT-
PCR 
CCACGTAAA
AGATGACGC
TTGATA 
TGGGCAAA
GAGTCGACA
TCA 
Y 0.5 2:5 [6] 
C9: variant 2 Hsap.  
qRT-
PCR 
CGGTGGCG
AGTGGATAT
CTC 
TGGGCAAA
GAGTCGACA
TCA 
Y 0.5 2:5 [6] 
C9: variant 3 Hsap.  
qRT-
PCR 
GCAAGAGC
AGGTGTGG
GTTT 
TGGGCAAA
GAGTCGACA
TCA 
Y 0.5 2:5 [6] 
R
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EIF4B Hsap. 
qRT-
PCR 
AGCTCAGAC
ACAGAGCA
GCA 
CTTTCCTTC
CTGGTCCTT
CC 
Y 0.5  [10] 
EIF4H Hsap. 
qRT-
PCR 
GGTGGCTTT
GGATTCAGA
AA 
CCCTGAAGC
CAGAATTGA
AG 
Y 0.5  [10] 
h
P
A
F
1
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CDC73 Hsap.  
qRT-
PCR 
GGGGCACT
GCAATTAGT
GTT 
CTGCACAAA
AACGGCTAC
AA  
Y 0.5 1:20 [5] 
LEO1 Hsap.  
qRT-
PCR 
CAAGTGGTC
AGATGGAAG
CA 
TGGGGCTTT
GTACACATC
AA  
Y 0.5 1:20 [5] 
PAF1 Hsap.  
qRT-
PCR 
CCACTGAGT
TCAACCGTT
ATGG 
TCCTCGGTA
AACTGCTGC
TTC  
Y 0.5 1:20 [5] 
RTF1 Hsap.  
qRT-
PCR 
GGTGTCACA
TGCCCTTCT
TT 
GTAATCTCA
GCGACCCG
GTA 
Y 0.5 1:20 [5] 
 
p21 Hsap.  
Leo1 
ChIP 
CCAGGAAG
GGCGAGGA
AA 
GGGACCGA
TCCTAGACG
AACTT 
N 0.5 n/a [12] 
 
SUPT4H1 Hsap.  
qRT-
PCR 
TTGCGATGA
TGAGTCCAG
AG 
TGGATTTGT
AGGCCACTC
CT 
Y 0.5 1:20 [6] 
 UAS transgenes 
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LDS-G4C2: 
5' LDS 
Dmel. 
qRT-
PCR 
CGCTGAGG
GTGAACAAG
AA 
CGACTCCTG
AGTTCCAGA
GC 
n/a 0.5 1:100  
 
LDS-G4C2: 
3' GFP tag 
Dmel. 
qRT-
PCR 
ACGTAAACG
GCCACAAGT
TC 
AAGTCGTGC
TGCTTCATG
TG 
n/a 0.5 1:100 [5] 
 
GFP tag: 
mCD8 
Dmel. 
qRT-
PCR 
TATGGCTTC
ATCCCACAA
CA 
GACTGGCA
CGACAGAAC
TGA 
n/a 0.5 1:100  
 
G4C2 Dmel. 
qRT-
PCR; 
ChIP 
AGACTCGGT
ACCGGATCC
TC 
GCTCCCATT
CATCAGTTC
CA  
n/a 0.05 1:100 [5] 
 
TDP-43 Dmel. 
qRT-
PCR 
TGTCTTCAT
CCCCAAGC
CAT 
TGTGCTTAG
GTTCGGCAT
TG 
n/a 0.5 1:100 [13] 
* cDNA dilution: the final concentration of cDNA added to the qRT-PCR reaction (e.g. 2:5 = 4μl of undiluted cDNA 
added to a 10μl reaction; 1:100 = 1μl of cDNA that had been diluted 1:10 and added to a 10μl reaction) 
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Defining transgene expression 
 
Heat-shock induced expression of UAS transgenes  
 
HS-GAL4 FLY LINES 
• BL1799/TM3 (w[*];;GAL4-Hsp70/TM3,Sb) 
• BL2077/Cy (w[*];GAL4-Hsp70/Cy;) - the Cy phenotype is super weak even at 
26ᵒC.  I recommend used BL1799  
 
PROTOCOL 
1. Setup crosses at 21ᵒC. Setup crosses in bottles or if using vials, flip parents into 
fresh vials after 3d and again after 2d to increase # of progeny 
a. Controls to be run with every set of crosses:  BL5905, UAS-mCD8-GFP 
2. Collect newly eclosed progeny with the desired genotype and age to 1-2d at 
21ᵒC.  
a. It can be convenient to collect males for protein and females for RNA 
b. For every genotype, a minimum of 3 replicate samples are needed (5-10 
animals per sample) 
3. Heat-shock 1-2d progeny 
a. Turn on water bath to 37ᵒC.  Be sure to check the temperature with the 
same thermometer and to use the same water bath for all samples and all 
subsequent assays. 
b. Anesthetize animals on a CO2 pad and transfer 5-10 flies to a 1.5ml 
microcentrifuge tube for each sample. Be sure to label tubes with 
genotype, experiment date, gender, and any other pertinent information.  
Immediately, use a small piece of cotton to create a plug that will prevent 
flies from being above the waters surface during heat shock. It is vital that 
there are no crevasses that the flies can use to crawl above the waterline. 
Poke a hole in the top of the tube using a pushpin so there is an air-hole.   
c. Let animals recover for 30-45min from CO2.   
d. Heat shock flies at 37ᵒC for 30 min.  
e. Transfer flies to a 25ᵒC incubator and incubate for exactly 3 hours. Any 
deviations from this time will effect expression of the transgene! 
f. Immediately transfer tubes to dry ice to freeze the flies and then into a -
80ᵒC freezer. (can also flash-freeze them with LN2, but I didn’t find this 
necessary as expression data in replicates were consistent.) 
4. Isolate RNA and protein as needed for transgene analysis.  
a. Analyze protein expression by western blot (antibody needed) 
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b. Assays to analyze RNA expression 
i. SV40 Northern blots (see General Protocols): use probes 
targeting the common SV40 terminal tail or probes designed to 
target your transgene. SV40 can be used for most pUAS 
transgenes. 
ii. qRT-PCR (see General Protocols): use primers designed to target 
the UAS-G4C2 or UAS-LDS-G4C2 transgenes.  
Note on SV40 and qRT-PCR: I have consistent data on DaGS 
> UAS transgenes showing that SV40 primers do not 
differentiate the pUAS transgene and Gal4 transgenes as both 
have SV40 terminal sequences. Importantly, the DaGS only 
sample had strong SV40 signal. 
5. Compare RNA expression levels using Northern blots and SV40 probe or qRT-
PCR using primers targeting the transgene 
 
 
mRNA Northern blots 
REAGENTS/MATERIALS 
• Total RNA samples (see General Protocols: RNA extraction (flies)) 
o DNase treated is recommended at all times 
• UltraPure Agarose (Invitrogen #16500-100) 
• NorthernMax 10X Denaturing Gel Buffer, stored at 4ᵒC (Thermo Sci #AM8676) 
• NorthernMax 10x Running Buffer (MOPS), stored at 4ᵒC (Thermo Sci #AM8671) 
• RNA SYBR Green II stain, stored at -20ᵒC (ThermoSci # S7564) 
• RNA ladder: 
o 50-1000bp ladder (NEB # N0364S), stored at -80ᵒC 
o 500-9000bp ladder (NEB # N0362S), stored at -80ᵒC 
o Note: Must use their protocol and loading buffer for an accurate ladder 
• Whatman 3MM chromatography sheets, 18 x 34cm, thickness: 0.34mm (GE 
Whatman #3030-221) 
• NorthernMax Transfer Buffer, stored at RT (Thermo Sci #AM8672) 
• Hybond N+ nylon membrane (GE HealthCare#RPN303B) 
• Hybridization buffer (depends on your probe), stored at 4ᵒC 
• NorthernMax Formaldehyde loading buffer, stored in -20ᵒC (Thermo Sci # 
AM8552) 
• RNaseZap (Thermo Sci # AM9780) 
• Ambion RNase-free 1.5 mL microcentrifuge tubes (Thermo Sci # AM12400) 
• 20X SSC buffer 
• 20% SDS solution 
• filtered pipette tips 
• Paper towels 
• Plastic wrap 
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PROTOCOL 
Day 1 
1. Make RNA denaturing gel 
a. Prep: 
i. Warm to RT: RNA SYBR green (protected from light), an aliquot of 
NorthernMax 10X Denaturing Gel Buffer (mini gel: 7ml transferred 
into a 15ml conical; midi gel: 20ml transferred into a 50ml conical) 
ii. Thaw on ice: RNA samples, Formaldehyde loading buffer, RNA 
ladder + NEB loading buffer 
iii. Warm: a water bath to 58ᵒC, a heat block to 70ᵒC 
iv. Prepare RNase-free workstation and equipment 
1. Spray with RNaseZap: gel tray, gel comb, gel casting box, 
gel electrophoresis chamber, Erlenmeyer flask (mini: 
250ml; midi: 500ml flask), graduated cylinder (mini: 50ml; 
midi: 250ml). Rinse with MilliQ water twice. 
2. Place plastic wrap on bench 
3. Spray pipettes with RNaseZap 
4. Obtain filtered pipette tips 
v. Setup gel-casting station by securing gel tray between casting 
plates and adding the comb. This should be setup on a bench 
covered with plastic wrap to prevent RNase contamination.  
b. Make 1% gel: 
i. Add MilliQ water to the RNase-free Erlenmeyer flask and add 
agarose (Mini: 0.7g agarose + 68ml water; midi: 2g agarose + 
190ml water). Swirl to mix. 
Note: stated volumes of water account for evaporation 
later. 
ii. Place kimwipe loosely into top of flask to prevent boiling-over 
during microwaving. Microwave for 1.5-3min until agarose is 
completely melted. There cannot be any flakes as this will cause 
blurry bands! 
iii. Place flask into 58ᵒC water bath to reduce temperature (mini: 6.5-
7min; midi: 8min – timing is essential for sharp bands while you 
don’t want solution to be > 60ᵒC as formaldehyde will evaporate 
out at this temperature). 
c. Pour RT Denaturing Gel Buffer into flask containing 58ᵒC, molten 
agarose. Add RNA SYBR green (mini: 7μl; midi: 20μl). Swirl gently (to 
prevent bubble formation) to mix and immediately pour into gel tray. 
d. Loosely cover gel with aluminum foil to protect it from light. Do not seal! 
You want it cool without disruptions. 
e. Allow gel to solidify at room temperature for 30-45min. 
2. Prepare RNA 
a. Add RNA into RNase-free microcentrifuge tubes. The amount of RNA to 
be used should be determined empirically for each target you are 
detecting.   
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i. Most human protocols recommended 10-20μg total RNA or 0.5-
1μg mRNA. 
ii. For flies, 1-2μg total RNA worked well for highly expressed targets 
(e.g. transgenes). Can increase to 5-10μg RNA for weaker 
targets. 
b. Add more than equal volume of Formaldehyde Loading dye into each 
tube. For example, if you have 5μl of RNA sample, you should add at 
least 5μl of loading dye.  Mix well. 
c. Heat the samples at 70°C for 15min, cool down on ice for 1min. 
3. Prepare RNA ladder, following NEB protocol 
a. Combine into a RNase-free microcentrifuge tube: 2μl ssRNA ladder for 
1μg, 3μl DEPC water, 5μl provided RNA loading buffer (do not use the 
same buffer as samples) 
b. Heat at 70ᵒC for 5min. 
c. Chill on ice for 1min 
4. Run RNA on the denaturing gel 
a. Make 250ml of 1x Running Buffer: 225ml MilliQ water + 25ml of 10x 
NorthernMax 10x Running Buffer (MOPS). 
b. Pour a small amount of running buffer onto top of solidified gel within the 
casting box and gently remove comb while gel is still locked into casting 
box. Remove gel/tray from casting box and transfer to the gel 
electrophoresis chamber. 
c. Pour remaining running buffer over the top of the gel (effectively cleaning 
out the wells) until solution is ~1-2mm above gel.  
d. Load prepared RNA samples and ladder into designated lanes. 
e. Run at 100V for 1~1.5h until loading dye is ~1inche from the bottom of 
the gel. 
f. Image gel using the Bonini lab imager. You should see bands of 18s 
rRNA (2kb), and RNA size ladder. Note that the top band of the RNA 
ladder can be very faint and some imagers don’t capture it.  
5. Setup transfer 
a. Put a piece of plastic wrap onto bench (if not already done) and stack 
paper towels to ~10cm tall (mini: cut standard towels in half; midi: align 2 
stacks of paper towels side-by-side along long side and place 1-2 pieces 
on top of the stack to traverse the crevice between the two stacks) onto 
the plastic wrap. 
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b. Cut 5 pieces of Whatman paper and 1 piece of Hybnd+ membrane to the 
size of the gel, accounting for wells being removed.   
c. Center 3 Whatman papers onto the paper towels. 
d. Pour NorthernMax transferring buffer into a container (such as empty 
pipet tip box for mini gel or a plastic tub for a midi gel). Filling up to ~2cm 
from the bottom should be enough. 
e. Wet 1 piece of Whatman paper with transferring buffer, put onto the stack 
of paper towels/Whatman papers. 
f. Soak membrane in the transferring buffer and cut a notch in the top right 
corner as a reference. Place on top of the pre-soaked Whatman paper. 
Roll out any bubbles that may have formed between layers with a 4” 
blotting roller (ThermoFisher #84747). 
g. Cut wells off the top of the gel using a razor and discard. Place the gel on 
top of the pre-soaked membrane. Roll out any bubbles that may have 
formed between layers with a blotting roller. Note: it can help to add a 
little transfer buffer to the membrane using a transfer pipet. Then “roll” the 
gel over the membrane, effectively squeezing out bubbles. 
h. Add a little transfer buffer onto top of gel with a transfer pipet. Pre-soak 
the last piece of filter paper with transferring buffer and “roll” it onto the 
top of the gel. Roll out any bubbles that may have formed between layers 
with a 4” blotting roller.  
i. Cut a long piece of filter paper so it is the same width as the gel, this will 
be the Whatman paper bridge. Put one side of the paper on top of the 
filter paper/gel and roll our any bubbles. Soak the other end of the paper 
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bridge in the transfer buffer so it is submerged. 
 
j. Place a gel tray on top of the bridge/transfer stack. Stack glass dissection 
plates onto the gel tray as a weight (or a textbook or plastic bottle of 
buffer). Make sure the stack/weights are balanced using a bullseye level 
so that it won't fall over and the transfer is even. 
k. Place plastic wrap loosely over the top of the tank to help reduce 
evaporation. Be sure it doesn’t disrupt the bridge! 
l. Transfer until the gel is completely flat.  Typically overnight.  You cannot 
over transfer (as long as you don’t let it dry out). 
m. Clean all tools that came in contact with the transfer buffer thoroughly 
with distilled water to remove salts. 
 
An alternative way to put the transfer stack together (f-g): (1) place the cut 
gel upside down onto a piece of Whatmann paper that is bigger than the 
gel. (2) add a little transfer buffer to the membrane using a transfer pipet. 
(3) “roll” the pre-soaked membrane upside-down over the gel, effectively 
squeezing out bubbles. (4) Roll out any bubbles that may have formed 
between layers with a 4” blotting roller. Then turn the membrane/gel 
upside-up and place this on top of the filter papers on the paper towels.   
 
Day 2: (written for a mini-gel. Scale volumes up for a midi gel) 
1. Crosslinking and Pre-Hybridization 
a. While transferring is ongoing, warm the hybridization buffer to 68°C in one 
of the Northern incubators.  
b. Carefully remove membrane from the transfer stack, making sure not to 
touch “top” (the side that was facing the gel where the RNA is located). 
Place it in a dry plastic tray that is larger than the membrane.  
c. Discard gel, all paper towels, and Whatman papers, and transfer buffer.  
Clean container thoroughly if it will be reused. 
d. (optional) check the membrane in the gel imager for 18s rRNA signal. 
Mark the edge of the membrane with a pencil at the position of 18s rRNA 
(2kb), if visible, and the dark blue and light blue dye indicators (these will 
not be visible after hybridization).  This will help you to later match the gel 
picture and the position of the gel on the membrane for sizing with the 
ladder. 
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e. UV crosslink the RNA onto the membrane in the UV Stratalinker 1800 
(Press "AutoCrosslink" (1200u joules x100) and start). Make sure to keep 
the transferred side facing up. You can keep the membrane in the tray.  
f. Gently, transfer the membrane, RNA-side facing inward into a 
hybridization bottle. Add ~7 ml of pre-warmed hybridization buffer.  
g. Pre-hybridize membrane with rotation at 68ᵒC for 30-60min. 
 
Notes:  
o The type of hybridization buffer is dependent on the probe.   
o It can be convenient to synthesize the probe at this time 
 
2. Hybridize membrane: perform all steps in accordance with EHRS radioactivity 
safety protocols. 
a. Add the probe the pre-hybridized membrane.  
b. Incubate overnight with rotation at the specified temperature for the 
probe.  
Day 3 (written for a mini-gel. Scale volumes up for a midi gel) 
1. Prepare wash buffers 
a. Make 2xSSC/0.1% SDS using MilliQ water. 
b. Make 0.2xSSC/0.1% SDS using MilliQ water. 
Notes 
o Buffers should be relatively fresh. If I’m running a lot of northerns, I’ll 
make 500mL at once and store it at RT. 
o Be careful that the SDS has not precipitated out of solution.  If this 
occurs, warm it in the incubator with the membrane until SDS 
dissolves. 
2. Washing and exposure: perform all steps in accordance with EHRS radioactivity 
safety protocols. 
a. Perform 3 washes with ~20ml of 2xSSC/0.1% SDS: Add buffer to the 
membrane/bottle. Close lid.  Shake ~5 times.  Remove lid and pour buffer 
directly into drain with warm water running.   
b. Add ~20ml of 2xSSC/0.1% SDS to bottle and rotate for 30min at the 
hybridization temperature.  Let water run in sink during this time. 
c. Perform 3 washes with ~20ml of 0.2xSSC/0.1% SDS: Add buffer to the 
membrane/bottle. Close lid.  Shake ~5 times.  Remove lid and pour buffer 
directly into drain with warm water running.   
d. Add ~20ml of 0.2xSSC/0.1% SDS to bottle and rotate for 60min at the 
hybridization temperature.  Let water run in sink during this time. 
3. Prep:  blank a phosphor screen by exposing it to a UV lamp for 30min to remove 
any signal from previous studies. 
4. Place membrane into cassette and expose the membrane onto phosphor screen 
(2h~overnight) 
a. Carefully remove membrane from the bottle with tweezers and transfer it 
to a hybridization bag cut ~2cm larger than the membrane. Squeeze out 
any bubbles and seal the hybridization bag.  
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b. Retrieve phosphor screen and place over membrane, being careful not to 
slide it around. Close cassette and expose screen for desired exposure 
time, dependent on the probe. 
5. Scan the phosphor screen with a Typhoon imager to get image. Quantify band 
densities in ImageJ. 
6. (optional) reprobe membrane for additional targets 
a. Carefully remove membrane from the cassette and hybridization bag. 
Transfer it to a glass bottle.  
b. Repeat steps Day 2: 1.g thru Day 3: 6 for the new probe 
7. Label membranes/hybridization bag with experiment date, probes used, etc. 
Store membranes at RT in plastic shielded containers until P32 has fully 
decayed. You can reprobe membranes after long-term storage.  
 
 
 
SV40 probe 
NOTES 
- It is convenient to probe a membrane with SV40 and then re-probe with 18S 
for loading. Because SV40 requires 42ᵒC for hybridization, the probe loses 
binding at 68ᵒC, the temperature required for 18S hybridization. 
 
REAGENTS 
- FastStart PCR Master Mix (Sigma # 4710436001) 
- DNA Primers 
o forward:  5′-TGTGGTGTGACATAATTGGACA-3′   
o reverse:  5′-AGATGGCATTTCTTCTGAGCA-3′   
- vector template: purified plasmid containing a SV40 terminal sequence. For 
G4C2, I used pUAST-KAN-(G4C2)12 vector. 
- MinElute PCR Purification Kit (Qiagen # 28004) 
- High Prime DNA Labeling Kit (Sigma # 11585584001) 
- 50μCi [P32-α] labeled dCTP (from EHRS) 
- UltraHyb Hybridization Buffer (Thermo Sci # AM8670) 
 
PROTOCOL  
1. PCR template synthesis and purification 
a. Thaw: FastStart Master Mix, primers, and template vector 
b. Mix the following reagents together in PCR tube 
Master Mix Component μl Final concentration 
2X FastStart Master Mix 25 1X 
Forward Primer (3μM) 5 0.3μM 
469 
 
Reverse Primer (3μM) 5 0.3μM 
vector template  (varies) 50ng 
MilliQ water to final volume of 50μl 
c. Run sample on Thermocycler using the following program: 
Step Temperature Time 
Number 
Cycles 
Initial denaturation 95 °C 6 min 1 
Denaturation 95 °C 30 sec 
30 Primer annealing 58 ᵒC 30 sec 
Extension 72 °C 1min 
Final Extension 72 °C 7min 1 
Cooling 4 °C Hold 1 
d. Run 5μl of PCR product on 2% TAE agarose gel using appropriate 
marker.  Expected size = 204bp. 
e. Purify PCR product from remaining reaction volume using Qiagen’s 
MinElute PCR Purification Kit – follow the company’s protocol.  End 
volume = 10μl.  This is your PCR template for probe synthesis. 
f. Measure concentration of end PCR template on Nanodrop. 
g. PCR templates can be frozen at -20ᵒC for future use. 
2. Probe synthesis: perform all steps in accordance with EHRS radioactivity safety 
protocols. 
a. Thaw: PCR template, materials from High Prime DNA Labeling kit 
(Reaction mix, dATP, dTTP, dGTP) 
b. In a 1.5ml microcentrifuge tube, mix ~35ng of PCR template in MilliQ 
water for end volume of 10μl.  Denature at 95ᵒC for 10min.  Immediately 
place on ice for 2+ min. (Do not let it cool slowly as it will re-nature.) 
c. Centrifuge sample briefly and add the following to the tube (from High 
Prime DNA Labeling Kit) 
i. 8μl of High Prime Reaction Mix 
ii. 6μl each of dATP, dTTP, dGTP 
iii. 4μl of 50μCi [P32-α] labeled dCTP 
iv. MilliQ water to an end volume of 40μl 
d. Tap tube to mix thoroughly. 
e. Incubate reaction at 37ᵒC for 60-75min. 
f. Increase temperature on heat block to 99ᵒC and heat sample for 10min to 
stop synthesis reaction and denature.  Immediately place on ice for 2+ 
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min. Probes can be stored at 4ᵒC for ~2wks (until the P32 signal 
degrades).  
5. Hybridization 
a. Pre-hybridize membrane in UltraHyb Hybridization Buffer at 68ᵒC for 30+ 
min. 
b. Centrifuge probe briefly and add to pre-hybridized membrane.  Amount of 
probe depends on your target and freshness of probe. Use 5-10μl of fresh 
probe for UAS-G4C2 with 2μg RNA per lane. (Increase the amount of 
probe based on 2-wk P32 decay rate and amount of RNA.) 
c. Hybridize overnight at 42ᵒC. 
d. Wash hybridized membrane at 42ᵒC 
e. Exposure is usually ~4hrs. 
 
 
G4C2 probe 
NOTES 
- It is convenient to probe a membrane with G4C2 and then re-probe with 18S 
for loading. Because G4C2 requires 50ᵒC for hybridization, the probe binding 
reduces at 68ᵒC, the temperature required for 18S hybridization. 
 
REAGENTS 
- T4 polynucleotide kinase (PNK) Kit, stored in -20ᵒC (NEB # M201S) 
- 50μCi [γ-32 P] ATP (from EHRS #2P32GATP) (equal to 62.5pmol) 
- (G2C4)4 oligo:  5’- GGCCCCGGCCCCGGCCCCGGCCCC -3’ 
- UltraHyb hybridization Oligo buffer (Thermo Sci # AM8670) 
 
PROTOCOL 
1. Thaw T4 PNK buffer and G4C2 probe working stock. 
2. Synthesize P32-labeled probe 
a. Mix the following reagents in a microcentrifuge tube: 
Component μl Final concentration 
10X T4 PNK Buffer 2.5 1X 
(G2C4)4 oligo (10μM) 2.5 1μM 
MilliQ water 15 -- 
T4 PNK 1 10units 
50μCi [γ-32 P] ATP 4 50pmol 
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Note: add enzyme at the freezer to make sure it stays as close to -
20ᵒC as possible 
b. Incubate at 37°C for 45-60min. 
c. Store at 4°C for 2wks. (calculate amount to add based on 2-wk half-
life of P32) 
3. Hybridization 
a. Pre-hybridize membrane in UltraHyb Oligo Hybridization Buffer at 
68ᵒC for 30+ min. 
b. Centrifuge probe briefly and add to pre-hybridized membrane.  
Amount of probe depends on your target and freshness of probe. Use 
5μl for 1-2μg RNA per lane. (Increase the amount of probe based on 
P32 decay rate.) 
c. Hybridize overnight at 50ᵒC. 
d. Wash hybridized membrane at 50ᵒC 
e. Exposure is usually ~4hrs. 
 
18S probe (Loading) 
REAGENTS 
- DNA Primers 
o T7-F Core: 5'- gataatacgactcactatagggaga -3' 
o T7 18S: 5'-
AGGGAGCCTGAGAAACGGCTACCACATCTAAGGAAtctccctatagtga
gtcgtattatc-3' 
o Lower case: T7-sequence, upper case: target gene sequence 
- MAXIscript T7 Transcription Kit (Ambion # AM1312) 
- 50μCi [P32-α] labeled CTP (from EHRS) (not dCTP) 
- UltraHyb Hybridization Buffer (Thermo Sci # AM8670) 
 
PROTOCOL 
1. Anneal primers  
a. Add T7-4 core and T7-18S primers to a microcentrifuge tube with MilliQ 
water. Target concentration is 2μM. 
b. Boil 400 ml of water in a large glass beaker on a hotplate.  
c. Incubate the tube of oligonucleotides in the boiling water for 5 minutes.  
d. Turn off the hotplate, leaving the oligonucleotides in the beaker on the 
hotplate to slowly cool to room temperature. 
e. store at -20ᵒC for future use. 
2. Synthesize P32-labeled probe: perform all steps in accordance with EHRS 
radioactivity safety protocols. 
a. Thaw: Annealed primers, components of the MAXIscript T7 Transcription 
Kit (Transcription Buffer, CTP, ATP, UTP, GTP) 
Note: Reaction mix tends to form a precipitate. This can be fully 
dissolved at room temperature with strong vortexing. 
b. Mix the following in a 1.5ml microcentrifuge tube: 
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i. 2μl Annealed 2μM T7-18S rRNA 
ii. 2μl 10X Transcription Buffer (to 1X) 
iii. 1μl each of 10mM CTP, ATP, UTP, and GTP 
Note: Still add non-P32 labeled CTP to reduce signal strength 
iv. 7μl water 
v. 2μl T7 enzyme mix 
Note: add enzyme at the freezer to make sure it stays as close 
to -20ᵒC as possible 
vi. 3μl of 50μCi [P32-α] labeled CTP   
c. Incubate at 37°C for 1 hour. 
d. Add 2μl TurboDNase (from kit) and incubate an additional 15min at 37°C. 
e. Raise temperature to 95°C and incubate an additional 5min (denaturing). 
f. Store at 4°C for 4wks  (calculate amount to add based on 2-wk half-life of 
P32) 
3. Hybridization 
a. Pre-hybridize membrane in UltraHyb Hybridization Buffer at 68ᵒC for 30+ 
min. 
b. Centrifuge probe briefly and add to pre-hybridized membrane.  Amount of 
probe depends on your target and freshness of probe. Use 1μl for 1-2μg 
RNA per lane. (Increase the amount of probe based on P32 decay rate.) 
c. Hybridize overnight at 68ᵒC. 
d. Wash hybridized membrane at 68ᵒC 
e. Exposure is usually ~2hrs. 
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Protein extraction (flies) 
MATERIALS 
- pellet/pestle disposable blue microcentrifuge tubes (Kimble # 749520-0000)  
- pellet/pestle cordless motor (Kimble # 749540-0000) 
 
TISSUE PREPARATION 
1. For heads 
a. Collect heads as described in Fly Work 
b. Heads should be collected into blue microcentrifuge tubes to be used with 
the disposable pestles 
c. Typically, I prepare 3 replicate samples from 1 cross. Target 5-10 heads 
per sample. Keep track of the exact # of heads per sample. 
d. Keep frozen heads on dry ice and immediately extract protein using one 
of the 2 methods below.  
2. For whole larvae or adult animals:  
a. transfer 3-5 animals into blue microcentrifuge tubes to be used with the 
disposable pestles. Keep track of the exact # of animals per tube. 
b. Typically, I prepare 3 replicate samples from 1 cross.  
c. If you are immediately extracting protein, do not let animals sit in the tube 
long term. Rather, ass the lysis buffer and homogenize the tissue 
immediately. 
d. Animals can be frozen on dry ice and stored for future use in at -80ᵒC. 
Keep the tissue frozen until the moment you add the lysis buffer and 
homogenize the tissue with the disposable pellet as described below. 
 
Method 1: LDS sample buffer 
 NOTES 
- This is the standard protocol in the lab and works well for the majority of 
targets. 
- This protocol works well for heads from the following genotypes 
o Gmr-Gal4> LacZ  
o Gmr-Gal4> TDP-43(37M) 
 
REAGENTS/MATERIALS 
- fly tissue (note tissue preparation above) 
- NuPAGE LDS sample buffer, 4X (Thermo # NP0008) 
- β-mercaptoethanol (β-ME) 
 
PROTOCOL 
1. Make 1X sample buffer  
a. 1250μl of 4X LDS sample buffer to 1X 
b. 125μl of B-ME (add in hood) to 2.5% 
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c. 3625μl of MilliQ water 
d. Store at -20ᵒC for future use. 
2. Prep: pre-warm heat block to 95ᵒC 
3. Add the calculated amount of 1X sample buffer to the first sample and 
immediately homogenize the tissue using a disposable pestle and motor. 
Transfer the tube to wet ice. Repeat for each subsequent sample. Store 
samples on ice until done with all samples. Samples must be kept cold from 
this step forward.  
a. 7ul of 1X sample buffer per head 
b. 10ul of 1X sample buffer per whole animal 
Note: When removing the pestle from the tube it is good practice to lift it 
just above the solution while the tip is still in the tube and spin it with the 
motor. This will effectively fling any residual solution of the pestle onto the 
walls of the tube so it isn’t lost. By briefly spinning the sample in the 
centrifuge, the solution will all be collected to the bottom of the tube. 
4. Incubate samples on ice for ~5min 
5. Boil samples for 5min at 95ᵒC 
6. Centrifuge at RT for 5min, 15,000xg to pellet debris.  For whole animals, 
transfer the supernatant to a fresh pre-labeled microcentrifuge tube and 
discard the pellet. For heads, there is typically very little debris so this doesn’t 
seem to be necessary. 
7. Samples can be frozen at -20ᵒC for future use. thaw on ice and boil them for 
2min before loading them into a gel. Typically we load 5μl of sample per lane 
for a western blot. 
 
 
Method 2: RIPA lysis 
 NOTES 
- this protocol must be used for assessing DPR levels. Grinding tissue directly 
into LDS sample buffer produces variable results. 
- this protocol works well for heads from the following genotypes 
o Gmr-Gal4> LDS-(G4C2)44[GR-GFP]  
o elavGS> LDS-(G4C2)44[GR-GFP] 
o Gmr-Gal4> (G4C2)n 
o elavGS> (G4C2)n  
- this protocol works well for whole adult animals, daGS> (G4C2)n  
 
REAGENTS/MATERIALS 
- fly tissue (note tissue preparation above) 
- RIPA lysis buffer  
o 10mL of 1M Tris-HCL (pH 7.5) to 50mM 
o 6mL of 5M NaCl to 150mM   
o 2mL NP-40 to 1%    
o 0.42g NaF to 50mM 
o 2mL of 10% SDS to 0.1% 
o 1g Sodium Deoxycholate (DOC) to 0.5% 
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o dH2O to 200mL   
o Filter through a 250ml filter system, 0.22μm, PES 
o store at 4ᵒC. Check pH every 6-8mo.  
- 5X cOmplete ULTRA Tablets, mini, EASYpack protease inhibitor cocktail 
(Sigma # 05892970001) 
o 1 tablet dissolved in 1500μl of milliQ water 
o prepare 100μl aliquots  
o store in -20ᵒC. After thawing, precipitate may form and need to be 
resuspended into solution. 
- (optional) 25X PhosSTOP Phosphotase inhibitor cocktail (Sigma # 
04906845001) 
o 1 tablet dissolved in 400μl of MilliQ water 
o prepare 25μl aliquots  
o store in -20ᵒC. After thawing, precipitate may form and need to be 
resuspended into solution. 
- 100mM PMSF  
o 0.1742g of PMSF 
o 10mL of isopropanol 
o Filter through a 0.22μm PES filter (Fisher Sci # 09-720-511) using a 
luer-lock syringe 
o prepare 500μl aliquots  
o store in -20ᵒC. Before use, bring to RT and vortex until precipitate 
goes back into solution 
- 1M DTT  
o 1.5425g of DTT (Dithiothreitol) 
o 10mL MilliQ water 
o Filter through a 0.22μm PES filter (Fisher Sci # 09-720-511) using a 
Luer-lock syringe 
o prepare 500μl aliquots  
o store in -20ᵒC 
▪ before use, bring to RT and vortex until precipitate goes back 
into solution 
 
PROTOCOL 
1. Prepare working lysis Buffer: (must be made fresh!) 
a. Calculate the total amount of lysis buffer you will need.  
• For western blot: use 4μl per head or 10μl per whole animal.  
• For dot blot: use 0.2μl per head or 3ul per whole animal.   
b. For every 500μl of working lysis buffer needed, add the following 
protease and phosphatase inhibitors. Make a minimum of 500μl of 
working lysis buffer then prepare additional 100μl as needed. 
• 400μL 0.5% RIPA Lysis Buffer Stock 
• 100μL of 5X cOmplete ULTRA protease inhibitor Stock to ~1X 
• 20μL of 25X PhosSTOP Phosphotase inhibitor cocktail Stock 
to ~1X 
• 5μL of 100mM PMSF to ~1mM 
• 0.5μL of 1M DTT for ~1mM 
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2. Add the calculated amount of lysis buffer to the first sample and immediately 
homogenize the tissue using a disposable pestle and motor. Transfer the 
tube to wet ice. Repeat for each subsequent sample. Store samples on ice 
until done with all samples. Samples must be kept cold from this step 
forward.  
Notes:  
o when removing the pestle from the tube it is good practice to lift it just 
above the solution while the tip is still in the tube and spin it with the 
motor. This will effectively fling any residual solution of the pestle onto 
the walls of the tube so it isn’t lost. By briefly spinning the sample in 
the centrifuge, the solution will all be collected to the bottom of the 
tube. 
o Unused working lysis buffer can be stored at 4ᵒC for use during 
protein quantification. 
3. Incubate samples at 4ᵒC 45min with agitation. (min: 30min, max: 2hr) 
Note: Samples can be frozen at -20ᵒC at this step if needed.  Thaw 
samples on ice. 
4. Prep: label new microcentrifuge tubes (standard tubes, not blue tubes). 
5. Centrifuge the samples at 4ᵒC for 10min, 15,000xG to pellet debris.  
6. Keeping the samples on ice, transfer the supernatant from tubes into pre-
labeled microcentrifuge tubes. Discard the pellet.  
7. follow Protein quantification protocol below if desired. It is best to immediately 
quantify protein and/or denature samples in LDS sample buffer. However, 
natured protein lysates can be stored at -20ᵒC if needed. Thaw samples on 
ice and then perform protein quantification and/or denature samples in LDS 
sample buffer. 
 
Protein quantification (Bradford) 
  
NOTE: cannot be done on denatured protein (e.g. samples prepared directly into 
LDS sample buffer. 
 
REAGENTS/MATERIALS 
- Bradford Ultra (Expedeon # BFU05L) 
- Disposable cuvettes Semi-micro (Fisher Sci # 14-955-128) 
- UltraPure BSA, 50mg/ml (Thermo # AM2616) 
 
PROTOCOL 
1. Prep:  
a. Thaw: BSA, protein samples on ice that were prepared using RIPA 
lysis buffer 
b. Pre-warm a heat-block to 95ᵒC 
2. Prepare 2mg/ml BSA working stock 
a. 2.8μl of 50mg/ml 
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b. 67.2μl RIPA lysis buffer  
3. Quantify the amount of protein in each sample using Bradford kit 
a. prepare Bradford standards into cuvettes 
▪ transfer 5 cuvettes into an empty cuvette tray.  
Notes:  
• cuvettes should only be touched on the 2 sides that are 
frosted! 
• You cannot label the cuvettes so it is important to 
organize them in a way that is logical and consistent in 
the tray so you can keep track of which is cuvette 
contains what. For large numbers of samples, you can 
write a list of the samples 1-? on a piece of paper and 
then make sure the cuvettes are in the tray in that 
order 
▪ prepare standards as follows, adding the Bradford reagent first 
then the 2mg/ml BSA working stock 
μl 
Bradford 
μl of 
2mg/ml 
BSA 
Final 
concentration 
(mg/ml) 
Final 
volume 
(μl) 
1500 0.0 0.0 1500 
1499 0.75 0.001 1500 
1498 2.25 0.003 1500 
1494 6.00 0.008 1500 
1481 18.75 0.025 1500 
1462 37.5 0.050 1500 
b. prepare protein dilutions for each of your samples to be analyzed: add 
1495μl of Bradford and then 5μl of protein lysate to one cuvette (1:300 
dilution) 
c. Analyze samples on the cuvette-based spectrophotometer 
▪ Prior to putting the cuvette into the machine, use a piece of 
parafilm pressed on top of the cuvette as a lid, and turn upside 
down and back upright 3X to effectively mix the samples. Be 
sure to move the parafilm to a fresh region between cuvettes. 
Also be careful not to touch the portion of the cuvettes where 
the light will shine through to read the absorbance.  
▪ measure the samples twice using Bradford settings.  
▪ Save data onto a USB 
▪ Steps for running the machine 
• Turn it on and pick “Coomassie/Bradford Micro” 
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• Edit information so have mg/ml units, 4 standards, and 
correct # of samples, save data to USB and internal 
memory (put in a USB), test name 
• Click “Run standards” 
o Edit each standard so they are the correct value 
based on the table above (mg/ml column) 
• Measure blank by placing the cuvette clear side facing 
you 
• Measure each of the standards 
• When done with standards, click “Run Test” 
• Run each of the samples 
• When done running samples, save data – it should 
safe to your USB as a txt file 
d. In excel, setup a standard curve from your standards. Average the 2 
readings from the spectrophotometer per cuvette.  
▪ You should have an R^2 of > 0.90 (if not, then your standard 
curve is bad and you need to repeat them.) you will need the 
formula for the line to calculate protein levels in your samples  
 
e. Calculate the total mg/ml present in samples using the y = m x + b 
formula obtained from your standard curve (y = mean absorbance of 2 
readings from the spectrophotometer, x = mg/ml). Be sure to 
compensate for the fact that your samples were diluted 1:300 (by 
multiplying x by 300)! 
4. There are 2 approaches to preparing protein for western blot or dot blot.  
Follow the one that makes most sense for your experiment 
a. Remove the desired μg of protein per sample and transfer to a fresh, 
prelabeled microcentrifuge tube. Bring the volumes for all samples up 
to the same value (≤ 20μl) using leftover RIPA lysis buffer containing 
inhibitors (if available) or RIPA stock to dilute samples. 
▪ For western blot:  
• the amount of protein will depend on your target. 10-
20μg of protein is typically run on a western blot per 
lane. Overall, when performing an experiment for the 
first time it is best to start with 20μg. Also, I’ve seen 
different results when I ran 10μg vs 20μg protein.  
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• End volume will depend on the gel’s well size. ≤ 20μl is 
standard. 
• If you are running samples on multiple wells in a gel or 
on multiple gels, scale calculations up so you prepare 
everything at once. 
▪ For dot-blot: it is essential to maintain protein at a high 
concentration, as close to 10μg of protein in 1.6μl of end 
volume as possible 
▪ It can be convenient to make multiple aliquots of your protein 
and freeze them for future use. 
b. Normalize the μg/μl of protein between each sample by diluting all of 
the samples to the lowest value of μg/μl across your samples.  Use 
leftover RIPA lysis buffer containing inhibitors (if available) or RIPA 
stock to dilute samples. 
5. Add 4X LDS sample buffer to 1X (so 6.6μl of 4X LDS sample buffer for 20μl 
of sample). Mix and spin down samples briefly. 
6. Boil at 95ᵒC for 5min. 
7. Samples can be frozen at -20ᵒC for future use. thaw on ice and boil them for 
2min before loading them into a gel 
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Western blot 
NOTES 
- Other people in the lab use a different protein standard.  However, these do not 
include as wide of a range of markers which may be required when cutting a 
membrane to probe it for 2 immunobands simultaneously. Specifically, for β-gal 
westerns, this ladder allows you to cut accurately at ~70kDa so you can stain the 
bottom half with tubulin (at 50kDa) and top half with β-gal (at 110kDa).  
 
REAGENTS/MATERIALS 
- Protein samples (see General Protocols: Protein extraction (Flies) or Fibroblasts: 
Protein extraction) 
o If using samples prepared with RIPA lysis buffer, you must perform protein 
quantification (Bradford) 
- 1X TBST  
o Prepare 1L from packets (Sigma # T9039) 
o Or make it from 10X TBS stock: 100mL 10X TBS, 900mL MilliQ water, 500μL of 
Tween-20 
- Non-fat milk powder 
- Novex Sharp PreStained Protein Standard (Invitrogen # LC5800) 
- NuPAGE 4-12% Bis-Tris Protein Gels, 1.5mm, 15-well (Invitrogen #NP0336) 
- NuPAGE MES SDS Running Buffer, 20X (Invitrogen #NP0002) 
- XCell SureLock Mini-Cell (Invitrogen #EI0001) 
- Gel Knife (Invitrogen #EI9010) 
- (optional) Buffer Dam for XCell SureLock Mini-Cell (Invitrogen #EI0012) 
- (optional) ponceau S (can be reused 10 times) 
 
PROTOCOL  
Note: standard protocol for XCell SureLock Mini-Cell can be found in the company’s 
manual: HERE. All images are taken from this protocol. 
 
Day 1 
1. Prep  
i. if samples are frozen: thaw samples for 5-10m on ice while you prewarm a 
heat-block set to 95ᵒC. Re-boil samples for 2-3 minutes to make sure they 
are completely thawed and that the SDS is dissolved into solution. Typically I 
do this while I’m setting up the tank (below). After 2-3 minutes at 95ᵒC, 
samples can sit at RT until loaded into gel.   
ii. Thaw your protein standard.  If a precipitate has formed, briefly boil the 
standard at 95ᵒC for 1-2min until dissolved.  
iii. Make 1X MES running buffer:  50mL of 20X stock + 950mL MilliQ water. 
Leftover buffer can be stored for future use. Buffer can be reused 3 times as 
long as loading was clean and no protein samples got into the buffer.  
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2. Run western using standard 4-12% Bis-Tris premade gels and 1X MES running 
buffer (for 1L: 50mL 20X MES running buffer, 950mL DI water). Usually run at 
120V for ~90min. 
i. Setup a tank (“lower buffer chamber”) with a gel tension wedge and buffer 
core. If you are running 1 gel, a buffer dam must be positioned where the 
second gel would have gone.  
 
ii. Obtain a premade gel from the fridge. Open the package and remove the gel. 
REMOVE THE WHITE STICKER FROM THE BOTTOM OF THE GEL. 
iii. Place the gel along the buffer core in the tank, effectively creating an inner 
chamber. The comb side of the gel must face the inner chamber. Close the 
gel tension wedge. 
 
iv. Pour 1X MES running buffer into the inner chamber, allowing it to run out of 
the inner chamber and into the outer chamber until the outer chamber is half-
way full of buffer (~500mL total). 
v. Gently remove the comb from the gel, making sure to pull it straight up and to 
not disrupt the gel that makes the lanes.  
vi. Clean out the wells using a P1000 pipette set to 800ul. Draw up buffer from 
the outer chamber and gently shoot buffer into each of the wells – BE 
CAREFUL TO WATCH THE SIDES OF THE WELLS AS THEY WILL MOVE 
IN OLDER GELS AND YOU WILL GENTLY NEED TO REPOSITION THEM 
INTO THE CORRECT PLACE USING A P10 PIPETTE TIP. 
vii. Using a P10 or P20 load pre-boiled sample into appropriate wells. Load 8μl of 
protein standard last. Try to avoid the edge wells if you can.  
viii. position the top onto the tank and plug in the cathode and anode wires into a 
power source – be sure to match red-to-red and black-to-black! 
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ix. Turn on power source and set to 120V. start power source and a timer for 
60m.  you will likely run it for closer to 90m but it’s good to check the gel 
periodically. You are done when the blue dye in the samples is at the very 
bottom of the gel. You can run samples longer as needed to get better 
separation between larger proteins. It is okay to lose small proteins through 
the bottom of the gel if you are not interested in them. 
3. Prep:   
i. make 5% milk (for 2 gels: 2.5g of dry milk in 50mL TBST; for >2 gels: 5g of 
dry milk in 100mL TBST). Place on spin plate for the entire time you are 
transferring the gel (Minimum of 30min).  
ii. Make 1X TBST as needed 
4. (optional) Prep: if doing a wet transfer 
i. Make 1X NuPAGE transfer buffer with 20% methanol and 1X reducing agent  
(for 500mL: 25mL 20X transfer buffer, 100mL Methanol, 500ul NuPAGE 
Antioxidant (optional), 375mL DI water) 
ii. Soak 6 sponges per gel in transfer buffer for ~30min in a Tupperware 
container to remove all air bubbles 
iii. cut 1 piece of PVDF membrane per gel  
iv. cut 2 pieces of normal thickness Whatman paper per gel 
5. Transfer protein from the gel to a membrane based on the optimized protocol for 
the target. Importantly, when testing new antibodies, a wet transfer is typically 
used. Only targets used regularly in the lab (e.g. β-Gal, TDP-43) have been 
optimized for an iBLOT transfer. I’ve also had success with GFP. 
6. When transfer is done, remove membrane, noting where the protein is located on 
the membrane. Immediately place the membrane into blocking solution. (DO NOT 
LET THE MEMBRANE DRY OUT, particularly if you are using PVDF – IT WANTS 
TO!) Cut the top left corner so we always know the proper orientation.  
i. For 2 membranes, I will cut the top left corner for gel #1 and then cut the 2 
top corners and left bottom corner for gel #2 so we can distinguish them. 
ii. (optional) If you want to make sure the transfer was successful or for a 
loading control, you can stain the membrane with Ponceau S to detect 
protein. This must be done before the membrane is exposed to TBST. To do 
this: 
a. Incubate membrane in Ponceau S for 5-20min or until bands can be 
easily seen (the longer the incubation the darker the bands but you 
will also have to do more washes to remove background).   
b. Rinse the membrane repeatedly in ddH2O until the background is 
clean and bands are still visible. 
c. Take a picture of the membrane with your camera phone or on the gel 
imager with the colorimetric setting.  
d. Wash membrane 3x for 5min in TBST to remove Ponceau S. 
Continue to blocking step.  
7. Incubate the membrane in 5% Non-fat milk/TBST (blocking solution) for 30+ min 
on a rocker at RT.  
8. Incubate the membrane with primary antibody solution (diluted in blocking solution 
or 3% BSA/0.01% NaAzide/1XTBST) overnight in the cold room on a rocker.   
i. If using % BSA/0.01% NaAzide/1XTBST, rinse milk thoroughly off of the 
membrane with TBST before putting into primary antibody solution. 
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Day 2 
1. Prep:  
a. put blocking buffer on spinning plate!  It needs to spin for a minimum of 20m 
prior to being used. Make more blocking buffer as needed. 
b. Make sure you have enough TBST for washes. If not, make more. 
2. Obtain membranes from cold room. Using a transfer pipette, remove primary 
antibody and put it into appropriately labeled 50mL conicals for future use.  
3. Rinse membrane 3X in TBST and perform 3x 5min washes with TBST at RT on the 
rocker (higher speed).   
4. Pour off TBST and add 16mL blocking buffer.  Add HRP-conjugated secondary 
antibody to the tray at the desired concentration. Incubate on rocker for 2hr.   
5. Rinse membrane 3X in TBST.  Wash in TBST 4 times for 15 min each on rocker.  
a. Membranes can be left in the last wash for long periods of time. 
b. You can reduce the time of washes for very good antibodies (e.g. 3 x 10min). 
6. Prep:  
a. turn on imager so the camera has time to warm up 
b. put blocking buffer on spinning plate if you will be reprobing the same 
membrane.  It needs to spin for a minimum of 20m prior to being used. 
7. Image membrane 
a. Prepare ECL Prime reagent (2000ul per membrane total; if membranes are 
cut, you will use less) by adding reagent B to reagent A at 1:1 ratio and 
pipetting up and down repeatedly to mix.  
Note: not adding enough ECL is a common factor for variability – 
particularly obvious when you getting faded signal in portions of the 
membrane 
b. Lay a piece of parafilm down on flat surface and dot ECL Prime working 
solution onto the parafilm. 
c. Using forceps to hold membrane, touch corner of membrane to clean tissue 
repeatedly to remove excess TBST. Lay membrane down flat onto ECL 
Prime reagent making sure to cover the entire membrane with solution. 
Incubate for 1.5-2 min. 
d. Quickly remove membrane from ECL Prime Reagent and touch corner to 
clean tissue to remove excess reagent. Image on Imager. 
i. I usually start with an auto exposure. If the time frame is too long, I then do 
incremental exposures.  BE SURE TO GET A COLORIMETRIC PICTURE 
OF THE MEMBRANE. 
8. Once imaged, rinse membrane 3X in TBST and perform 3x 5min washes with 
TBST at RT on the rocker (higher speed).   
a. Membranes can be stored in sealed film for future use. 
9. If reprobing the same membrane, quench the signal with H2O2 or stripping buffer 
(protocols below). When done, incubate the membrane in 5% Non-fat milk/TBST 
(blocking solution) for 30-60min on a rocker.  Add desired primary on overnight and 
repeat Day 2 steps above. 
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Transfer methods 
iBLOT  
- iBlot Transfer, nitrocellulose, mini (Fisher Sci # IB301002) 
- Blotting roller (ThermoFisher #84747) 
- iBlot 1 Dry Blotting system 
 
PROTOCOL 
Note: standard protocol for iBlot can be found in the company’s manual: HERE.  
 
1. When the gel is done running, gather the materials needed for the iBlot 
transfer:  
i. From the iBlot kit: Bottom stack, top stack, sponge, 1 piece of 
whatman paper 
ii. a membrane-sized tray containing DI water 
iii. forceps, gel knife, blotting roller 
2. Setup transfer for 1 gel at a time.  
i. Remove the bottom stack from the packaging, keeping it in the 
transparent plastic tray – only toach the plastic tray. Place it in the 
iBlot box, so it is within the barriers and in the correct position. (tab 
should be on the right.) 
ii. Remove the gel from western blot tank/apparatus, crack apart the 
plates using the gel knife, cut off the bottom portion of the gel.  
Optional: remove wells. 
iii. Gently lift gel from the bottom (top is too fragile) and place the gel 
on top of the white nitrocellulose membrane of the bottom stack, 
using a rolling method to avoid bubbles. Roll out any bubbles with 
the blotting roller.  
iv. Using forceps, wet the piece of Whatman paper with DI water. Using 
a rolling method to avoid bubbles, place it on top of the gel. Roll out 
any bubbles with the blotting roller. 
v. Remove the top stack from the packaging and from the red plastic 
tray. Carefully place it on top of the whatman paper, using a rolling 
method to avoid bubbles. Roll out any bubbles with the blotting 
roller. 
 
3. Place the sponge into the lid of the iBlot box, making sure that the metal tab 
is aligned with the metal plate within the bottom of the lid (right side, further 
point when lid is open). 
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4. Carefully, yet forcefully, close the lid and secure the clasp. 
5. Set the desired program and time on the iBlot and clisk start.  Set a timer for 
the same amount of time so you remove the gel quickly once it is done 
transferring. 
6. For 2 gels: remove the first gel and immediately place it into a tray containing 
blocking buffer. Then setup the second transfer.  
7. Continue with Day 1: step 6 of the western protocol 
 
WET  
ADDITIONAL REAGENTS/MATERIALS 
- XCell II Blot Module (Invitrogen #EI9051) 
- Sponge pad for Blotting (Invitrogen #EI9052) 
- NuPAGE Transfer Buffer, 20X (Invitrogen #NP0006) 
- (optional) NuPAGE Antioxidant (Invitrogen #NP0005) 
- Blotting roller (ThermoFisher #84747) 
- Methanol 
- PVDF membrane 
- Whatman 3MM chromatography sheets, 18 x 34cm, thickness: 0.34mm (GE 
Whatman #3030-221) 
 
PROTOCOL 
Note: standard protocol for XCell SureLock Mini-Cell can be found in the 
company’s manual: HERE. All images are taken from this protocol. 
1. Prep: 30min before gel is done running 
i. Make 1X NuPAGE transfer buffer with 20% methanol and 1X reducing 
agent (for 500mL: 25mL 20X transfer buffer, 100mL Methanol, 500ul 
NuPAGE Antioxidant (optional), 375mL DI water) 
ii. Soak 6 sponges per gel in transfer buffer for ~30min in a Tupperware 
container to remove all air bubbles 
iii. cut 1 piece of PVDF membrane per gel  
iv. cut 2 pieces of normal thickness Whatman paper per gel 
2. When gel is done running, setup transfer using wet transfer apparatus at 30V 
for 1hr 
i. Gather the materials needed: 1 pre-cut piece of PVDF, 2 pre-cut pieces 
of whatman paper, forceps, gel knife, blotting roller, 1 membrane-sized 
tray containing methanol, 1 transfer pipet, new tank with a tension 
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wedge in place, a top and bottom transfer plate, a empty Tupperware 
large enough to hold the transfer plates; For each gel, setup a new tank 
with a gel tension wedge in position.  If running 2 gels, you will need 2 
separate tanks.  
ii. Activate the PVDF membrane in the 100% methanol -- gently shake for 
30-60sec in methanol, pour methanol out, do ~3 rapid rinses in dH2O, 
add transfer buffer. Rotate for ~2-5min until membrane no longer floats 
(usually the amount of time it takes to setup everything else) 
YOU MUST MOVE RELATIVELY QUICKLY ONCE THE PVDF 
MEMBRANE IS ACTIVATED AS IT TENDS TO QUICKLY DRY 
OUT WHICH CAN RUIN THE EXPERIMENT. 
iii. setup transfer, rolling out bubbles after each layer 
FOR EACH GEL, RUN THEM IN SEPARATE TANKS! PUTTING 
THEM TOGETHER IN THE SAME TANK DOES NOT WORK 
(DESPITE INVITROGEN’S PROTOCOL SAYING IT CAN BE 
DONE) 
  
a. place the cathode plate used for transfer in an empty Tupperware 
container 
b. position 2 pre-soaked sponges on top of each other in the bottom 
of the cathode plate.  
c. Using forceps, wet a piece of Whatman paper in transfer buffer 
and place it on top of the sponge stack. Roll out any bubbles using 
a blotting roller. Pour 1-2mL of transfer buffer over the top with a 
transfer pipet. 
d. remove gel from apparatus, crack apart the plates using the gel 
knife, cut off the bottom portion of the gel.  Optional: remove wells. 
e. Gently lift gel from the bottom (top is too fragile) and place the gel 
on top of the whatman paper using a rolling method to avoid 
bubbles. Roll out any bubbles with the blotting roller. Pour 1-2mL 
of transfer buffer over the top with the transfer pipet. 
f. Using forceps, place a piece of activated PVDF membrane on top 
of the gel using a rolling method to avoid bubbles. Roll out any 
bubbles with the blotting roller. Pour 1-2mL of transfer buffer over 
the top with the transfer pipet. 
g. Using forceps, wet a piece of Whatman paper with transfer buffer 
and place it on top of the membrane using a rolling method to 
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avoid bubbles. Roll out any bubbles with the blotting roller. Pour 1-
2mL of transfer buffer over the top with the transfer pipette. 
h. place 2+ pre-soaked sponges on top of the whatman paper until 
there is ~1mm above the top of the cathode plate. Additional 
sponges maybe needed so there is resistance when you put the 
anode plate on top of the stack. the tighter the stack the better the 
transfer. 
i. Put the anode plate on top (there should be resistance), lining up 
the edges of the 2 plates. Squeeze the stack shut (DO NOT LET 
GO!) and place it into the pre-prepped tank. Clasp the apparatus 
shut with the tension wedge effectively creating an outer and inner 
chamber.  
j. Repeat for a second gel. 
iv. fill the inner cavity with transfer buffer -- only until ~2mm above the 
stack.  fill the outer tank with ~650ml of cold DI water -- ~1cm below the 
top.  
v. position the lid(s) onto the tank(s) and plug in the cathode and anode 
wires into a power source – be sure to match red-to-red and black-to-
black!   
vi. Turn on power source and set to 30V. start power source and a timer 
for 1hr.  Both tanks can be plugged into the same power source as long 
as a constant voltage is used.  Be sure to stop then restart the power 
current if you add a second tank to the same power source if it has 
already been running.  Alternatively use two power sources, 1 for each 
gel.  
3. Continue with Day 1: step 6 of the western protocol 
 
Reprobing methods 
NOTES:  
- When reprobing a blot, it’s important to consider the species of your primary 
antibodies. If the two antibodies are from the same species (e.g. Rabbit IgG) 
then they will both be stained with the Rabbit-HRP secondary antibody. Thus 
they must be a obviously different sizes so you can distinguish the two 
immunobands.  
- It is best to use antibodies from a different species when reprobing. As most 
of our target use Rabbits to make the antibodies, most of the loading controls 
I use are mouse-derived antibodies (e.g. Tubulin or GAPDH mouse 
antibodies) or are directly conjugated with HRP (e.g. Tubulin-HRP).  
- I find that using H2O2 over stripping buffer allows me to reprobe the same 
blot more times with continuing to see strong signal. This method is further 
preferred when reprobing the same position (e.g. modified H3 versus total 
H3). 
- The stripping time and method may vary between antibodies. When 
quenching/stripping the membrane, you can re-expose it to ECL and image it 
again to confirm that you have successfully removed the original signal. You 
can increase/decrease the time as needed. 
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- Striping/quenching reduces the ladder strength so make sure you already 
have a good image of the ladder. 
 
QUENCH HRP (preferred) 
REFERENCE: Sennepin AD1, Charpentier S, Normand T, Sarré C, Legrand A, 
Mollet LM. Multiple reprobing of Western blots after inactivation of peroxidase 
activity by its substrate, hydrogen peroxide. (Oct 2009) Anal Biochem. 
1;393(1):129-31.  
 
REAGENTS 
- 30% hydrogen peroxide (H2O2) solution 
- TBST 
 
PROTOCOL 
1. Incubate the membrane in ~5-10mL of H2O2 with rotation for 20min. It’s best 
to do this at 37ᵒC. I tend to use the 37ᵒC room across the hall from the Bonini 
lab and place the membrane/tray on a rotator at a relatively low speed for the 
machine. 
2. Obtain membranes from the 37ᵒC room. Pour off the H2O2 and add TBST.   
3. Rinse membrane 3X in TBST and perform 3x 5-10min washes with TBST at 
RT on the rocker (higher speed).   
4. Pour off TBST and add blocking buffer. Continue with western blot protocol:  
Block membrane for 30min at RT. Add primary antibody and incubate 
overnight at 4ᵒC. Continue with western blot Day 2, step 1. 
 
STRIP 
 REAGENTS 
- Restore Western Blot stripping buffer (ThermoFisher #21059) 
- TBST 
 
PROTOCOL 
1. Incubate the membrane in ~5-10mL of stripping buffer with rotation for 20min, 
RT. 
2. Pour off the stripping buffer and add TBST.   
3. Rinse membrane 3X in TBST and perform 3x 5-10min washes with TBST at 
RT on the rocker (higher speed).   
4. Pour off TBST and add blocking buffer. Continue with western blot protocol:  
Block membrane for 30min at RT. Add primary antibody and incubate 
overnight at 4ᵒC. Continue with western blot Day 2, step 1. 
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Optimized antibodies 
Target Species 
Catalog 
Number 
kDa Dilution 
Protein 
prep 
protein/
lane 
Transfer 
method 
Ref. 
Primary Antibodies 
CDC73/Hyx 
(Dmel.) 
Rat Lis Lab 61 1:3000 LDS 
5μl 
lysate 
Wet 
[1] 
CDC73D38E12 
(Hsap.) 
Rabbit 
Cell 
Signaling 
#8126 
61 
1:1000 RIPA 20μg Wet 
[3] 
eIF4B (Hsap.) 
Rabbit Cell 
Signaling
#3592 
80 
1:1000 RIPA 20μg Wet 
[2] 
eIF4B 
Phospho- 
Ser422 
(Hsap.) 
Rabbit 
Cell 
Signaling
#3591 
80 
1:1000 RIPA 20μg Wet 
[2] 
eIF4HD85F2 
(Hsap.) 
Rabbit Cell 
Signaling
#3469 
27 
1:1000 RIPA 20μg Wet 
[2] 
β-
Galactosidase 
(Dmel.) 
Rabbit 
Promega 
#Z3781 
110 1:2000 LDS 
5μl 
lysate 
iBlot: P2, 
8min 
 
GAPDH71.1 
(Hsap.) 
Ms IgM 
Sigma# 
G8795 
37 1:5000 RIPA All work Wet 
 
GFPJL8 (for 
GR-GFP, 
Dmel., Hsap.) 
Ms IgG 
Takara#
632380 
Varies 1:10000 RIPA 20μg Wet [2] 
(GR)15 (Dmel) Rabbit 
V. Lee 
Lab 
#2316 
Varies 1:1000 RIPA 20μg Wet [2] 
Leo1 (Mmus., 
Hsap.) 
Rabbit 
ProteinT
ech 
#12281-
1-AP 
100 1:1000 RIPA 20μg Wet 
[3] 
Paf1D9G9X 
(Hsap.) 
Rabbit 
Cell 
Signaling 
#12883 
70 1:1000 RIPA 20μg Wet 
[3] 
Rtf1 (Dmel.) Rabbit Lis Lab 88 1:1000 LDS 
5μl 
lysate 
Wet [1] 
Rtf1D7V3W 
(Hsap.) 
Rabbit 
Cell 
Signaling 
#14737 
60 1:2000 RIPA 20μg Wet 
[3] 
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TDP-43 
(Dmel., Hsap.) 
Rabbit 
ProteinT
ech 
#10782-
2-AP, 
Lot# 
0000945
3 
43 1:2000 LDS 
5μl 
lysate 
iBlot (P0, 
7min) 
 
α-Tubulin 
(Dmel., Hsap.) 
Ms IgG 
DSHB# 
AA4.3 
55 1:2000 All work All work All work  
α-Tubulin11H10-
HRP (Dmel., 
Hsap.) 
Rabbit 
Cell 
Signaling 
#9099 
55 1:1000 All work All work All work  
Secondary antibodies 
Mouse-HRP Goat 
Jackson 
Labs#11
5-035-
146 
Varies 1:5000 All work All work All work 
 
Rabbit-HRP Goat 
Jackson 
Labs#11
1-035-
144 
Varies 1:5000 All work All work All work 
 
Rat-HRP Goat 
Thermo 
#A10549 
Varies 1:5000 All work All work All work 
 
 
REFERENCES 
1. Adelman K, Wei W, Ardehali MB, Werner J, Zhu B, Reinberg D, et al. Drosophila Paf1 
Modulates Chromatin Structure at Actively Transcribed Genes. Mol Cell Biol. 
2006;26:250–60.  
2. Goodman LD, Prudencio M, Srinivasan AR, Rifai OM, Lee VM-Y, Petrucelli L, et al. 
eIF4B and eIF4H mediate GR production from expanded G4C2 in a Drosophila model 
for C9orf72-associated ALS. Acta Neuropathol Commun. 2019;  
3. Goodman LD, Prudencio M, Kramer NJ, Martinez-Ramirez LF, Srinivasan AR, Lan M, 
et al. Expanded GGGGCC repeat transcription is mediated by the PAF1 complex in 
C9orf72-associated FTD. Nature Neuroscience; accepted in principle; 2019.  
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Behavioral fly assays 
 
RU486-infused food 
DISCLAIMER:  do not use RU486 if you are pregnant or trying to get pregnant.  
This is the drug used to induce abortions. 
 
REAGENTS 
- RU486 (Mifepristone) powder (Sigma # M8046) 
- 200pf Ethanol (newly opened bottle)  
 
PROTOCOL 
1. Make RU486 stock and working solution 
a. Make 40mg/ml RU486 stock solution in 100% EtOH. Store in -20ᵒC up to 
3mo, covered from light. 
b. Dilute the stock solution to 4 mg/ml working solution in 100% EtOH. Store 
at 4ᵒdeg covered in aluminum to protect it from light. 
 
NOTE: the 40mg/ml RU486 stock solution can form crystals if old EtOH was 
used to make it. ALWAYS USE FRESH EtOH. If this occurs, the stock can 
still be used, you just have to re-dissolve the crystals. 
▪ Check it ~30min before prepping the dilute working solution. If 
crystals have formed, incubate the 40mg/ml RU486 stock solution 
at RT with agitation for ~30min or until it goes into solution.   
▪ You may need to spin it down to collect all the crystals to the 
bottom.  To do this, spin in a centrifuge at ~3000 x g for ~1min. 
2. Make RU486-infused food 
a. Drop 100μl of 4mg/ml working stock to the top of each fly food vial. 
Concentration depends on how strong of expression you want while 
typically 50-100μl is used. Use a repeat pipettor for large numbers of 
vials. 
b. Cover the top of the vials with a piece of cheesecloth and a large rubber 
band, making sure that the cloth expands past the vials so as to prevent 
flies from getting into the vials.  (For small numbers of vials, you can also 
just use a cotton plug instead of cheesecloth.) 
c. Rotate vials for 1-3d on a circular rocker  
i. I find I get the most consistent results when I use a slow speed, 
~2, on the rocker. When the vials are rotated rapidly, the drug 
precipitates out of solution and forms clumps in the vials. If this 
occurs, the food is still usable. 
ii. I check the vials daily to see if the EtOH has fully evaporated. The 
time it takes seems to depend on the humidity.  Once dry, the 
vials are transferred to the 18ᵒC fly room and can be stored for up 
to 2wks. 
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EXPERIMENT DESIGN NOTES 
1. For controls, you may want to consider making EtOH only vials (no drug). 
However, I prefer to use control flies on RU486-infused food as the 
Gal4[GS]/UAS system seems to have low expression even in the absence of 
drug. 
2. There has been some question in the lab as to the consistency of the RU486 
drug’s ability to infuse into the food.  For short terms experiments, I recommend 
flipping the flies a minimum of every 2d to help to remove this variable with the 
logic that the more vials the flies are exposed to the less “noise”.   
3. For more “immediate” activation of transgene expression it may be necessary to 
starve the flies overnight before flipping them onto RU486-infused food. It has 
also been observed that using RU486-infused yeast paste can be ideal for rapid 
studies. 
a. Starve flies overnight (18-24h) at 25ᵒC in empty vials with a piece of 
Kimwipe paper wet by water at the bottom.   
b. Transfer starved flies to empty vials with RU486 yeast paste on the wall. 
Feed flies for 48h at 25ᵒC to induce transgene expression.   
4. I recommend flipping the flies every 2d (3d max) onto a fresh RU486-infused vial. 
The older the flies are, the more vital it is to flip them frequently.   
 
REFERENCES 
- Practical Recommendations for the Use of the GeneSwitch Gal4 System to 
Knock-Down Genes in Drosophila melanogaster. Scialo, F. et al. PLoS One. 
2016 Aug 29;11(8):e0161817. 
- A conditional tissue-specific transgene expression system using inducible GAL4. 
Osterwalder, T. et al. Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12596-601. 
- Mitochondrial electron transport chain dysfunction during development does not 
extend lifespan in Drosophila melanogaster. Rera et al. Mechanisms of Ageing 
and Development 131 (2010) 156–164. 
- The steroid hormone receptor EcR finely modulates Drosophila lifespan during 
adulthood in a sex-specific manner. Tricoire et al. Mechanisms of Ageing and 
Development 130 (2009) 547–552. 
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Lifespans 
REAGENTS 
- Standard molasses fly food 
- RU486-infused food 
 
SUPPLEMENTARY FILE: Lifespan Template.xls 
 
PROTOCOL 
1. Setup crosses with DaGS or ElavGS drivers. Raise and maintain progeny at 
24ᵒC.  
a. It is good practice to include a negative control of Driver > control 
transgene (ie. DSRED or BL31603: Luc RNAi). This is a better control 
than a RU-negative control due to leakiness of the Gal4[geneswitch]/UAS 
system. 
b. When checking modifiers, it’s important to test them for effects alone by 
expressing the modifier transgene using the driver in the absence of a 
disease gene. 
2. Setup 10 vials of male progeny with the correct genotype/phenotype with 20 
animals per vial. Age to 1-2d. It is convenient to use lab tape labeled with the vial 
identifier and date so you can just transfer this piece of tape to new vials every 
time you flip the flies. 
3. Transfer progeny onto RU486-infused food. Be sure to update the # of animals 
within the vial if any were dead or lost before putting the animals onto RU so your 
data is accurate. 
4. Transfer the vials to the experimental temperature. I’ve found that  24ᵒC for 
DaGS and 29ᵒC for ElavGS produce the most consistent lifespans between 
experiments. 
5. Age flies on RU486-food, flipping every 2d and making sure they are maintained 
at the same temperature. With every flip, record any animals that have died from 
natural causes. Censor any animals that escaped or died due to unnatural 
events: squished during flipping; became wedged between the food and the vial 
wall in a manner that even a healthy fly would not have been able to survive.  
a. For DaGS: it is essential to record the # of dead flies every day until all 
flies are dead as this is considered a “rapid” lifespan. You still flip every 
2d. 
b. It is important to note any dead/censored flies that get transferred into the 
new vial on the vial so they do not get accidently counted a 2nd time 
6. Once all animals have died, update the information in the supplementary file and 
use this to produce a survival curve and the define any statistical differences 
between genotypes in GraphPad Prism. 
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Negative geotaxis 
REAGENTS/MATERIALS 
- Standard molasses fly food 
- RU486-infused food 
- Nikon D3200 Camera w/ 2 fully charged batteries 
- Marked, empty vials:  standard fly vials with lines marked at 1, 3, and 6cm using 
permanent marker.  These vials can be reused so hold onto them! 
 
PROTOCOL 
1. Setup crosses with ElavGS. Raise and maintain progeny at 24ᵒC.  
a. It is good practice to include a negative control of Driver > control 
transgene (ie. DSRED or BL31603: Luc RNAi). This is a better control 
than a RU-negative control due to leakiness of the Gal4[geneswitch]/UAS 
system. 
b. When checking modifiers, it’s important to test them for effects alone by 
expressing the modifier transgene using the driver in the absence of a 
disease gene. 
2. Setup 6 vials of desired progeny with the correct genotype/phenotype with 20 
animals per vial. Age to 1-2d. It is convenient to use lab tape labeled with the vial 
identifier and date so you can just transfer this piece of tape to new vials every 
time you flip the flies. (It is good practice to use males to avoid issues with w+ vs 
w- on X when comparing multiple RNAi lines from different backgrounds. 
However females can have stronger climbing deficits.) 
3. Transfer progeny onto RU486-infused food. Be sure to update the # of animals 
within the vial if any were dead or lost before putting the animals onto RU so your 
data is accurate. 
4. Transfer the vials to the experimental temperature. I typically use 24ᵒC. 
5. Age flies on RU486-food, flipping every 2d and making sure they are maintained 
at the same temperature. With every flip, it is important to record any dead or 
censored animals so you know how many are in each vial.  
6. At the desired time point(s), performing climbing assay. THIS MUST BE DONE 
AT THE SAME TIME EVERY DAY. It is best to perform climbing assays ~10am 
as this is when the flies are most active. Further, it is convenient to define your 
time points as days that coincide with flip-days. Last, I like to record the animals 
using a camera so I can accurately quantify the data later. 
a. Transfer flies from each vial into a marked, empty vial.  (I tend to keep the 
tape with the vial identifier on this vial and then taped above the vial when 
recording animals for climbing so there is no confusion.) 
b. Let the flies recover for 30min in the incubator set to the experimental 
temperature.  I’ve found with ElavGS > (G4C2)n animals that they an get 
hypersensitive to light.  To avoid issues in regards to this, I let them 
recover in a white or yellow rack so they are used to reflective light. 
Alternatively, traditionally negative geotaxis studies are done in a dark 
room with a red light.  
c. Prep: setup the camera by sitting it on the lab bench ~ 12” from where the 
vials will be placed during the assay. Mark a piece of paper with 3 “X”s 
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evenly spaced apart and tape this to the lab bench where the vials will be. 
Each vial will then be placed on top of a “X”, ensuring that they are within 
the visual range of the camera and allowing data from 3 vials to be 
recorded simultaneously. I also setup an empty fly tray as the backdrop 
so the flies are against a white background making it easier to see them 
in the videos. 
 
d. Perform round 1 of the climbing assay: place 1 vial on each of the Xs and 
the tape with the vial identifier on the backdrop above the vial so you 
know which is which. Set the camera to record. Tap the flies in each vial 
one at a time down to the bottom of the vial (~3-5 taps). Immediately set 
the vial down and let the animals recover and climb. Stop recording after 
~45-60s. Repeat this for all vials of flies. 
e. Let the flies recover for 30min in the incubator set to the experimental 
temperature. 
f. Perform round 2 of the climbing assay as described above.  
g. Let the flies recover for 30min in the incubator set to the experimental 
temperature 
h. Perform round 3 of the climbing assay as described above.  
i. Once done, anesthetize the flies in each vial one at a time onto a CO2 
pad. Record the number of flies present so you have an accurate n. 
transfer flies into a fresh RU486-infused vial. 
j. Place the flies back into the correct incubator set to the experimental 
temperature until the next time point. Discard the flies when you have 
recorded data from the last time point.  
k. Transfer the video files to your computer for analysis. 
7. Analyze the climbing data from the videos, carefully defining the best parameters 
for your experiment.  Typically, I use the 3cm line and record any flies that are 
unable to climb to this line within 15 or 20sec. For quantification, the final value 
will be reported as the average % of animals that could climb per vial, using the 
average from the 3 rounds to compensate for natural variability.  
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External fly eye imaging 
 
Eye morphology  
 
SUPPLEMENTARY FILE: External Eye Imaging Lab Notebook.xlsx 
 
PROTOCOL 
1. Collect flies and age them to desired time point 
a. Collect the progeny with the desired genotype and place them into a new 
vial. Typically, we image 3-5 flies of the same gender per genotype, thus 
it’s good to collect 4-7 flies in case 1-2 of them get damaged or lost during 
imaging.  Be sure to match the genders and ages of the controls and 
samples.  It is best to collect the progeny at the same time each day in 
order to ensure they are approximately the same age. By imaging 3 
animals, you can then score the samples for quantification in the future. 
Notes 
i. It is best to separate the flies for external eye imaging into 
different vials than those used for other assays, such as internal 
sections, as you will be anesthetizing all the flies in the vial during 
external eye imaging.   
ii. When collecting flies, it’s good to visually note any inconsistencies 
between phenotypes of flies with the same genotype. If there is 
variation in the external eyes for flies with the same genotypes, 
gender, and similar age then take 3 images of each different type 
of eye and note the frequencies of each phenotype to be 
compared to expected results.  
iii. Typically, we image males for UAS-(G4C2)49 and females for 
UAS-(GR)36 and UAS-TDP43 (37M). It can be useful to image 
both sexes for UAS-(G4C2)49 as the milder eye of females 
promotes the detection of enhancers while the more extreme eye 
phenotype of males promotes the detection of suppressors. 
b. Age flies for 1 day by placing them back into the incubator from which 
they came.  If you end up imaging them after >1dy, make sure you are 
consistent between all genotypes, particularly the controls vs samples, for 
accurate comparisons.  Avoid imaging flies >3dyo for typical studies.    
Fly Aging: the flies are 1-2dyo at when imaging as you collected flies 
when they were 0-1dyo and then aged them by a day making them 1-
2dyo. So if you aged them for 2dys then they would be 2-3dyo (another 
common age to image flies). 
2. Imaging the external eyes of Drosophila 
a. In the fume hood, pour 1-2 splashes (about 2 mL) of ethyl ether into the 
bottom of a plastic bottle containing cotton balls in the fume hood. Make 
sure you wear gloves during imaging – ether is toxic when in direct 
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contact with your skin! Immediately recap the ether bottle so as to 
prevent evaporation.  
b. Turn the microscope on by logging into the computer (Password: 
drosophila) and opening the LAS program. Gently take the red cover off 
the microscope and, when prompted, click OK on the computer. The 
microscope should now move up and down by itself -- if it does not move 
there is something wrong and you need to contact the person in charge of 
the APO16! Turn the microscope light on by pressing the switch in the 
bottom front of the light source.  
Notes 
i. Be sure to switch the light source off when you are not actively 
imaging to conserve the bulb.  This includes if you stop imaging 
for 30+min with the intention of coming back. 
ii. The microscope and camera should always be on so you should 
never deal with anything except the computer and the light source.  
c. In the fume hood, transfer the flies to be imaged into the white chamber of 
the pre-prepped ether bottle by flipping them. Immediately place the 
plastic lid on top of the bottle. Tap the flies to the bottom of the white 
chamber repeatedly until they remain at the bottom – otherwise they will 
not all be anesthetized equally. Let the flies incubate for 5-10 minutes in 
order to anaesthetize them.  
Notes 
i. It is best to turn the microscope on before incubating your flies 
with ether so you can make sure the microscope is functioning 
normally before anesthetizing precious animals. 
ii. You can use CO2 to knock out the flies before transferring them to 
the white chamber if you are uncomfortable flipping them.  This 
also ensures that precious flies won’t escape or accidently get 
crushed.  
iii. Do not incubate animals more than 15min – this starts to dry out 
the eye tissue while highly degenerative eyes will collapse due to 
a lack of internal tissue (e.g. YH3 > UAS-(G4C2)49 flies). 
d. In the LAS software on the computer, you will need to designate the file in 
which you want images saved.  Under the “Browse” tab, find the folder in 
which you would like to save your images. Click the folder, and then click 
“set capture location” – a red dot should appear on your target folder. If 
you need to create a new folder, name the folder  
Note: It is convenient to name the folders based on the experiment 
date, in the order YEAR-MONTH-DAY, and a brief description of the 
experiment. This way, the computer will chronologically organize the 
folders.  Example: “151019 G4C2 TRiP screen”. 
e. Prepare a slide with double sided tape if you do not already have one.  
f. Once the flies are fully anesthetized, gently pour them onto the 
microscope pad or a paper towel – be sure to check the bottle for any 
flies stuck in the bottom. Using needle-nose forceps, grab one of the flies 
by the wings and place it onto the double-sided tape with the animal 
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facing right (see example slide below). Setup 3-4 flies at a time (if you do 
more they sit too long and the eyes either move and/or collapse if they 
are highly degenerative). It is easier to perform this step on a separate 
dissecting microscope than the APO16 – this also allows you to setup a 
second set of flies while the first set is being imaged on the APO16, 
significantly speeding things up (see LARGE-SCALE, RAPID ANALYSIS,   
below).  Reference videos for how to position flies onto double sided tape. 
Briefly, use a pair of needle-nose forceps to push the fly’s abdomen down 
onto the tape. This should put the eye in a good position for imaging. 
Keep manipulating the abdomen until the fly’s eye is parallel to the plane 
of the image, not tilted upward or downward. Images have been included 
below in order to illustrate proper and improper alignments for the fly’s 
eye. If pushing the abdomen no longer causes movement of the head, 
you can carefully (without touching the eyes) use the tweezers to move 
fly’s head into the correct position and potentially press on the thorax. Do 
this for each fly one at a time while placing all the flies of the same 
genotype in a row (see example slide below). 
NOTE: there are 3 videos demonstrating this technique that are 
saved on the APO16 computer: M-external imaging.avi 
i. Step 1: position the fly on the slide by grabbing the wings with 
needle nose forceps and placing the animal on its side, facing 
right. Be careful not to disrupt the head/eyes.  
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ii. Step 2: Using the forceps, apply pressure onto the fly’s abdomen.  
It’s best to not close the forceps fully, so the abdomen will rupture. 
If you do not do this, animals may become swollen while imaging 
and this will cause the eye to move and blurry images. 
 
500 
 
 
 
iii. Step 3: Manipulate the abdomen, head and proboscis with the 
forceps to get the eye into a level position for imaging, starting 
with the abdomen. It may be necessary to fold the wing closes to 
you down over the ruptured tissue so the forceps don’t get stuck. 
Your goal is to get the tissue surrounding the eye to be in the 
same visual plane. Reference images in Troubleshooting for 
examples. Be careful not to touch the eye with the forceps!  Also, 
if there is debris on the eye (seen as white flakes), it can be gently 
brushed away with a paint brush or forceps.  
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Example Slide:  Animals are organized with all of one genotype in 
a column to keep track of samples. Importantly, you cannot place 
flies to the right on the one you are imaging as this will create a 
shadow.  Animals are organized with all of one genotype in a 
column to keep track of samples.  
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g. Place the slide with the flies on the microscope pad of the APO16. The 
large/bottom wheel on the microscope is the coarse focus (zooms in and 
out of the image) and the small/top wheel is the fine focus (makes the 
image clearer). Zoom out using the coarse focus and adjust the slide so 
that the head of your fly is in the image on the computer.  
h. Once the fly’s head is in the image, slowly zoom in using the coarse focus 
until it reaches maximum, 115x. You may have to periodically adjust the 
slide while zooming to ensure that the fly’s head stays within the image.  
Note: When you get good at this, you may be able to put the flies in 
the correct position without zooming in/out. This will significantly save 
time, while you need to be careful that you are imaging the intended 
animal.  Check this by waving the point of the forceps above the 
intended animal. You should be able to see the forcepsp in the scope. 
i. On the computer, click on the tab that says “Acquire”. You will now be 
performing a z-stack, which takes pictures of the eye with different areas 
in focus, “different visual planes”, and compiles them into a single image 
with the whole eye in focus.  
j. Under the Z-stack tab, click the orange/brown button labeled “Start” once 
to set the first focus image to be taken. The button should turn black. At 
this point, adjust the fine focus on the microscope while watching the 
image on the computer screen so that the center/distal of the eye is just 
coming into focus. Everything besides the center/distal of the eye should 
be blurry. Once you are happy with the focus, click the “Start” button 
again and it should turn orange/brown.   
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k. Set the “End” focus setting by the same method. Click the orange/brown 
button labeled “End”, which should turn black, and then adjust the fine 
focus. This time, the center/distal of the eye should be blurry, but the 
tissue surrounding the external eye should just be in focus.  All the tissue 
on all sides of the eye should be in focus in this visual plane or the eye is 
tilted (see Troubleshooting). Adjust the eye as needed. Once you are 
happy with the focus and eye position, click the end button and it should 
once again turn orange/brown.  
 
Notes 
i. Make sure that the z-step setting is set to 15 steps and the 
“optimize step size” setting is turned off.  
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ii. The best images have the background as overexposed and the 
eye is just below being overexposed.  Use the exposure button to 
detect over/under exposed areas. Go into Acquire and select the 
“Camera” tab. Click “show under/over exposure” button (which is 
blue and red). The background should be red indicating it is 
overexposed while the eye tissue should only have red speckles 
at bright spots where the ommatidia are reflecting the light.  
iii. Preferred settings for external eye images are as follows.  The 
light exposure time will likely change if the light source is moved.  
The Hue and Sat are not at 0 which creates a slightly bluer image 
– better for detecting pigment loss as the reds are less robust in 
the final image. 
   Exposure: 132ms (varies with light position) 
   Gain: 2.0x 
   Saturation: 1.4 
   Gamma: 0.6 
   Hue: 180 
   Sat: 6 
l. Under sequence name, enter image name.   
Note: It is convenient to keep track of the genotype, age, and gender 
of the fly here.  Example: “FLY LINE x MODIFIER_Sex_age_Temp_” 
= “49#3.1 x BL31603_M_1-2dyo_26C_”.  Also, by ending the image 
name with a “_” the software will automatically add numbers to 
replicate images so you don’t have to change the name for each 
animal but rather just between genotypes. 
m. Place the eyepiece cover (an old pipet tip box) over the eyepieces. Click 
“Acquire Multifocus” and allow the Z-stack to proceed.  
Note: At 60% completion, you can move the slide without harming the 
image (the software is compiling the Z-stacks at this time), so to 
speed things up you can go ahead and start putting the next animal 
into position for imaging. 
 
n. When done, close the software (your images will automatically be saved 
into the selected folder during imaging). Turn of the light source. Gently, 
place the red cover over the miscroscope while long imaging sessions 
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may leave the camera (back portion) hot so it may be best not to cover 
this region up – only covert he eye pieces and main microscope region. 
You may turn off the computer. DO NOT TURN OFF ANY OTHER 
SWITCHED -- THE MICROSCOPE OR CAMERA!  Remove your images 
from the computer promptly. 
 
LARGE-SCALE, RAPID ANALYSIS   
I typically have 2 slides during one imaging session, 1 slide has flies being 
imaged on the APO16 while I will be mounting flies onto the second slide under a 
normal dissection scope.  Also, for large scale screens, image 2 flies per 
genotype, not 3, unless there are inconsistent results. Also, it may be helpful to 
use the gender differences, particularly for UAS-(G4C2)49, to your advantage. 
For example, the females of YH3 > UAS-(G4C2)49 tend to have a less severe 
phenotype than males. So for looking at mild enhancement, females are most 
useful while males are most useful for looking for suppression. You will be 
repeating potential hits and that is when you can increase your n.  
 
1. Setup 3 bottles of ether and flip live flies from their vials into the bottles in 
order – bottle A, bottle B, bottle C. KEEP THE EMPTY VIAL NEXT TO THE 
CORRESPONDING FLIES AT ALL TIMES UNTIL THE FLIES HAVE BEEN 
IMAGED SO YOU KEEP TRACK OF WHICH FLIES ARE WHERE.   
2. After the flies are anesthetized (~8min), setup the first genotype of flies from 
bottle A onto slide 1 under a normal dissection scope. Then, start imaging 
these samples on the APO16. KEEP THE VIAL FOR THESE FLIES NEXT 
TO THE APO16 SO YOU KNOW WHAT FLIES ARE BEING IMAGED. 
3. While they are being imaged, flip a new genotype into the empty bottle A so 
they will start to be anesthetized and place this bottle behind bottle C, 
effectively creating a conveyer belt-like system to keep track of everything.  
MOVE THE CORRESPONDING VIALS SO THEY REMAIN NEXT TO THEIR 
CORRESPONDING BOTTLE AT ALL TIMES SO YOU KNOW WHICH FLIES 
ARE IN THE BOTTLE.  
4. Start to setup the next genotype of flies from bottle B onto a second slide 
under the dissection scope, stopping intermittently to image the next fly on 
slide 1 on the APO16.  KEEP THE VIAL FOR THESE FLIES NEXT TO THE 
DISSECTION SCOPE SO YOU KNOW WHAT FLIES ARE BEING SETUP 
FOR IMAGING. When all the flies on slide 1 are imaged, I then start to image 
the flies on slide 2. BE SURE TO RENAME THE NEW SET OF FLIES 
CORRECTLY IN THE SOFTWARE SO YOU DON’T GET GENOTYPES 
MIXED UP.  
5. As before, I flip the next set of live flies from their vial into the empty bottle B 
and move the bottles so now bottle C is in the front and B in the back of the 
conveyer belt-like line – KEEPING THE VIALS NEXT TO THE CORRECT 
BOTTLES.   
6. Repeat this system, setting up the flies from bottle C onto slide 1 while the 2nd 
set of flies are being imaged on the APO16, stopping intermittently to image 
the next fly.  Repeat until done.  
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Note: some people move slower than others. 3 bottles is standard, but if you 
are faster, you may find that you need to add a fourth bottle so the flies are 
effectively anesthetized by the time you get to them.  You want the flies to 
incubate in the ether for ~8min. You may also want to use less bottles if you 
are imaging more animals per sample than 3 as the flies will be in the ether 
bottles for longer than 15min. For some genotypes, like (G4C2)49 you cannot 
keep them in ether for >20min as the eyes will start to collapse. 
 
TROUBLESHOOTING 
The APO16 tends to have a problem with the fine focus drifting to the max 
position over time. You can tell this is happening as the arrow indicating the 
position of the fine focus drive (the top line on the wheel) will be at the far right 
edge. When this occurs you need to readjust the position of the fine focus drive. 
1. Go into Acquire and select the “Z16APOA” tab. Click “FF” and “C”.  
2. On the wheel pad, move the wheel position for the fine focus drive back to 
the left. Move the wheel until the arrow is between the 9:00 and 10:00 
position. DO NOT move it all the way to the edge.  
3. On the computer, click “MF” and refocus the sample using the arrows on the 
screen (not the wheel!).  This effectively resets the main focus drive position 
based on the changes you made to the fine focus drive position so you can 
image.  
4. Reclick “FF” and “F” in the software.  Continue imaging like normal. 
 
POSITION AND LIGHT SETTINGS 
Below are 3 examples of good images. The center of the eye is parallel with the 
page and in full focus. The top and bottom of the eye are also focused. The eye is 
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not tilted as is indicated by the tissue surrounding the external eye being in the 
same visual plane. Further, in these images, it is easy to follow a row of ommatidia 
across the eye, while the sizes of the ommatida is consistent with the concave 
nature of the eye. The background is mostly overexposed while the external eye 
tissue is at the correct exposure. 
 
Correct position and light settings 
 
 
Incorrect position and light settings 
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Eye Morphology Quantification 
During my investigations, I performed a large number of modifier crosses to YH3 > 
(G4C2)49, (GR)36, and TDP-43 flies. From these data, I compiled the below scales to 
create a scoring method based on the severity of the external eye phenotype.  
 
External eye quantification scale for Gmr-GAL4YH3 > (G4C2)49 
 
REFERENCE 
Kramer NJ, Carlomagno Y, Zhang Y-J, Almeida S, Cook CN, Gendron TF, et al. 
Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant 
transcripts associated with c9FTD/ALS. Science. 2016;353:708–12.  
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External eye quantification scale for Gmr-GAL4YH3 > (GR)36 
 
REFERENCE 
Mordes DA, Prudencio M, Goodman LD, Klim JR, Moccia R, Limone F, et al. 
Dipeptide repeat proteins activate a heat shock response found in C9ORF72-
ALS/FTLD patients. Acta Neuropathol Commun [Internet]. 2018 [cited 2018 Nov 
28];6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031111/ 
 
 
 
External eye quantification scale for Gmr-GAL4YH3 > TDP-4337M 
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Fluorescence (GFP) 
NOTES 
- When performing multiple assays on the same cross (external eye imaging for 
morphology and GFP, plus collecting eyes for internal eye analysis), it is easiest 
to separate the flies for each assay into different vials.   
- Typically, we image females as they are larger and easier to image. Further, 
females tend to have less of an external eye phenotype so we are able to avoid 
any loss is signal due to reduced tissue integrity. 
- For YH3 > LDS-(G4C2)44GR-GFP flies, it is essential that you match the white gene 
between crosses and controls (either image all flies with mutant white or all flies 
with wild-type white). The mini-white gene seems to look the same as white 
mutant flies. 
- For modification of extreme degenerative phenotypes, like YH3 > LDS-
(G4C2)42GA-GFP#2S, consider if any reduced fluorescence is the result of 
suppression of toxicity caused by a modifier and thus recovered pigmentation 
versus actual reduced fluorescence. (this is not a concern with YH3 > LDS-
(G4C2)44GR-GFP flies as pigment loss is relatively weak.) 
 
FLY LINE: Gmr-GAL4YH3 (III) 
 
PROTOCOL  
1. Collect flies and age them to desired time point (typically 1-2d) 
a. Collect the progeny with the desired genotype and place them into a new 
vial. Typically, we image 3-4 flies of the same gender per genotype for 
screening and 6-10 flies for quantification, thus it’s good to collect a few 
extra flies in case 1-2 of them get damaged or lost during imaging.  Be 
sure to match the genders and ages of the controls and samples.  It is 
best to collect the progeny at the same time each day in order to ensure 
they are approximately the same age. By imaging 3+ animals, you can 
then score the samples for quantification in the future. 
Note: When collecting flies, it’s good to visually note any 
inconsistencies between phenotypes of flies with the same genotype. 
If there is variation in the external eyes for flies with the same 
genotypes, gender, and similar age then take 3 images of each 
different type of eye and note the frequencies of each phenotype to be 
compared to expected results.  
b. Age flies for 1 day by placing them back into the incubator from which 
they came.  If you end up imaging them after >1dy, make sure you are 
consistent between all genotypes, particularly the controls vs samples, for 
accurate comparisons.  Avoid imaging flies >3dyo for typical studies.    
Note: It is essential that all flies are the same age. 1-2d vs 2-3d YH3 > 
LDS-(G4C2)44GR-GFP flies have different GFP-signal strength 
depending on their age. I tend to use 1-2d animals.  
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2. GFP Imaging 
b. Prepare a 10cc or 20cc luer-lock syringe with Vaseline by filling the 
syringe with Vaseline – pull out the plunger and fill the syringe with 
Vaseline using a spatula. Replace the plunger and add a 20G needle. 
Squeeze out the air until you start to get a thin stream of Vaseline. Use a 
Kimwipe to clean away excess Vaseline. Very carefully, recap the needle.  
c. In the microscope room, turn on the Leica DM6000 B microscope by 
flipping the switch on the main microscope (right side box) and the 
fluorescence lamp (left side box) on the shelf. The microscope should 
start making noise as it turns on.  After it is fully on, open the primary 
software on the computer, LAS AF, making sure that the configuration is 
set to “DefaultDynamicWidefieldTree”. Press OK and the system will turn 
on completely.   
Notes:  
i. Be sure to turn the microscope off when you are done! 
ii. Be sure to keep the fluorescence lamp on for a minimum of 
30min.  Turning it off too soon can damage the bulb. 
d. In the LAS software on the computer, click on the “Experiments” tab and 
click “new” to start a new experiment. Label the experiment file. Click the 
“Acquisition” tab and click “z” to turn on Z-stacks. Setup 2 channel 
imaging with GFP being the first channel then brightfield the second 
channel.  IT IS IMPORTANT THAT GFP IS IMAGED FIRST AS THE 
SIGNAL QUENCHES RELATIVELY EASILY. Typical settings for GFP: 
0.1-1s exposure, 1.0 gain.  Typical settings for brightfield: 50ms 
exposure, 1.0 gain. Z-stacks are set to 1um stacks. 
Notes 
i. It is convenient to name the folders based on the experiment date, 
in the order YEAR-MONTH-DAY, and a brief description of the 
experiment. This way, the computer will chronologically organize 
the folders while you know which experiment is which.  Example: 
“151019 G4C2 TRiP screen”. 
ii. It is convenient to simply open up a previous experiment. Right 
click on one of the samples and select “properties”. Then click 
“apply settings”. This will automatically set the software’s settings 
to those desired – z-stack, correct exposure, etc.  Further, this 
ensures consistency between different time points for the same 
experiment as the settings will all be the same between time 
points. You will still need to manually change the objective, etc on 
the microscope. 
iii. It is important to record the exact settings you used for each 
experiment.  For example, the exposure time may be different 
between experiments so you should have recorded exactly what 
was done. This also means you can recheck that everything is 
correct as settings may have been changed by other users.  This 
includes settings in the software, but more importantly settings on 
the microscope (e.g. intensity and field). 
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e. Prepare the microscope by turning the settings to normal brightfield. Use 
the 20X objective with a 1x optical zoom.   
f. Turn CO2 tanks on by turning the knob (by the door). Turn on the CO2 for 
the dissecting scope next to the fluorescent microscope by unclipping the 
white clip on the hose so it is going through the CO2 pad (you should be 
able to hear it, but don’t want it to be too strong as it’s a waste of CO2). 
Transfer the flies to be imaged onto the white CO2 pad by flipping the vial 
so the opening faces the CO2 pad and tapping the flies onto the pad.  The 
CO2 should be running just strong enough to keep the flies anesthetized. 
g. Once the flies are fully anesthetized, squeeze a thin line of Vaseline onto 
a clean microscope slide; I usually make the stripe the length of the slide 
and then save the slide for serial imaging sessions. Reference videos for 
how to position fly heads into Vaseline for imaging. Briefly, using 2 pairs 
of needle-nose forceps, decapitate the first animal by squeezing the 
“shoulders” together with one pair and grabbing the neck with the second 
pair. Transfer the head to the slide, placing it next to the Vaseline and 
facing upwards.  Flip the head onto one side so the head is being held in 
place by the Vaseline while one eye is facing upward for imaging.  Be 
careful not to get Vaseline on the eye to be imaged as this will create a 
blotchy image. Setup 2-5 heads at a time, depending on your speed.  
Notes:  
i. The heads must be imaged within 15min or the cells start to 
decay, reducing the image quality.  
ii. Try to avoid too much light exposure while setting up the heads by 
turning the dissection scope light off when you are not actively 
using it.  Also, I let samples sit for ~1-2min before imaging to allow 
any quenched signal to recover. 
h. Step 1: position the fly for decapitation by grabbing it by the “shoulders” 
with one hand, squeezing gently to make the head “pop-out” and expose 
the neck. With your dominant hand, grab the “neck” of the fly and tear at 
an angle (must be at an angle to effectively sever the ganglia and 
organs).  
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i. Step 2: Position the isolated head against a ~1-1.5cm line of Vaseline on 
a clean microscope slide. Sit the head on the slide then move the eye 
closest to the Vaseline into the Vaseline. Then move the other eye 
upward effectively positioning the head for imaging on its side.  
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j. Step 3: To ensure that the head remains in position during imaging with 
immersion oil, wrap a small amount of the Vaseline around the proboscis 
effectively holding the head in place. Be sure to avoid getting Vaseline on 
the eye tissue as this will result in blurred images and/or higher 
background. 
 
519 
 
 
 
520 
 
  
k. Place the slide on the stage of the DM6000 and turn on the brightfeild 
light.  Move the first head into a position close to the light beam so you 
are relatively in the correct location while looking from the side of the 
microscope – you can tell as the light will turn darker with slight reddish 
hue when it is directly above the head. While looking through the 
eyepiece, slowly move the course focus into position above the eye until 
you can start to make out the external eye. On the microscope, click “live” 
set the top and bottom Z-stacks so you capture the entire external eye 
surface in the image. To avoid taking pictures when the GFP signal is 
quenched, let the head sit for 1-2min without being exposed to any light. 
Once the fly’s head is ready for imaging click “start”.   
Note: Normally I image both with the eyepiece and camera open 
(middle position of the knob on the left of the eyepiece).  However, on 
dimmer samples it may be necessary to adjust the knob so the image 
is going through only the camera or the eyepiece depending on what 
you are doing.   
l. Rename the image sequence under “Experiments” based on the 
genotype and any other relevant information.   
m. When done, be sure to save the experiment and close the software. Turn 
off the microscope. 
2. Quantify data in ImageJ using the Z-stacked image:  
a. Open images from the .lif file in FIJI (ImageJ) 
b. Create compiled Z-stack: Click Image > stacks > Z project 
c. Measure total fluorescence: 
https://sciencetechblog.wordpress.com/2011/05/24/measuring-cell-
fluorescence-using-imagej/ 
d. Measure particle # and size 
i. Click Analyze > set scale: Record scale value (should be 
2.7151pixels/micron if images taken with 20X objective lens and 
1.25X zoom) 
ii. Click Image > stacks > Z project (should be set to “Max Intensity”) 
> OK  (should be a 8-bit, gray-scale image) 
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iii. Click Image > adjust > threshold   
1. Set threshold 45-255  (settings may change depending on 
the assay) 
2. Click “Apply” > “X” > “Cancel” on pop-up box that says, 
“convert stack to Binary”   
iv. Click Analyze > Analyze particles 
1. Set size (micron^2) to “0.5-infinity” 
2. Under “Show” click “outlines” – check that the objects 
outlined are accurate.  If foci are being merged into 1 
object, increase threshold.  If you are missing foci, 
decrease threshold. 
3. Check: Display results, Clear results, summarize 
4. Click “OK”. It will ask if you want to analyze 2 images. Click 
No (but doesn’t really matter) 
v. Copy Area data to Excel 
1. Report number of objects per eye 
2. Report Mean Area of objects per eye 
3. For publication, I use the compiled Z-stack image of the GFP.  I then use the 
lowest stack from the brightfield image to determine where the eye tissue is 
within the GFP image, drawing a dotted line around the eye tissue.  It is also 
useful to determine if there is increased GFP expression by setting the exposure 
on the controls to just right below overexposure using the LUT image setting.  
Then when you image the samples of interest, if the GFP signal is indeed 
brighter, there will be blue overexposed regions.  
 
Example of final image with LUT setting: LUT allows for detection of increased GFP 
with mild changes. Combined external eye images from the APO16 with these GFP 
images allow for analysis of GFP levels in comparison to how toxicity in the eye is 
changed with modifiers. 
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Internal fly eye imaging 
NOTE: The lab tends to use Cytoseal/Hysto-clear for mounting coverslips onto 
slides.  Herein, I use Permount/xylenes.  Permount is significantly easier to handle 
and is used by pathologists in the clinic! Either will work and the protocol doesn’t 
change overall. Note that Permount can be removed by soaking the slides in 
xylenes; this can be convenient if something goes wrong during this step.  Also, 
Permount requires xylenes (cannot be used with histoclear). 
 
RECORD KEEPING 
The standard way of keeping track of paraffin-embedded tissue is to assign a coded 
number to each sample. I used “GC###” for G4C2-project while most people use 
their initials. I maintain an excel sheet summarizing all samples. I recommend 
recording the following information: Experiment Date, parental flies, genotype, 
gender, n, temperature, age, days on Bouin’s, date of processing, days in EtOH after 
leaching, date that they were sectioned (n). It is convenient to keep track of dates in 
case reagents go bad or for any other troubleshooting.  
 
REAGENTS/MATERIALS 
- Bouin’s Fixative (Sigma # HT10132) 
- Salinized Glass Wool (Sigma # 20411) 
- Disposable Transfer pipettes 
o Standard: 2.5mL (Thermo Sci # 212) 
o Fine Tip: 1.5mL (Fisher Sci # 13-711-25) 
- Leaching buffer:  
o 50ml of 1M Tris, ph8.0 to 50mM (Invitrogen Cat# 15568-025) 
o 8.7g of NaCl to 150mM  
o Water to 1L 
- Lid from a 6- or 12-welled tissue culture (TC-) plate 
- Permount (Fisher Sci # SP15-100) 
- Xylenes (Fisher Sci. # X5S-4) 
- 25 x 75mm glass slides (positively charged) 
- 22 x 50mm cover slips 
- Embedding paraffin, medium (Leica # 3801320) 
- Lens paper, cut into ~1.5” x 2” sheets (fisher Sci # 11-996) 
- Embedding cassette (Fisher Sci # 15-200-402) 
- Embedding rings (EMS # 62350) 
- Metal molds (EMS # 62527-16) 
- Slide rack (EMS # 62543-06) 
- Staining dish (EMS # 62541) 
- Microtome blades (Leica # 63065-HP) 
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PROTOCOL 
Day 0 
1. Fixing Heads for Paraffin Sections 
a. Collect flies. Typically 6-8 flies/genotype is sufficient. 
i. For Gmr-gal4 studies, it is best to collect 1-3 day old animals as 
these have reached full maturation 
ii. Females are larger so there is a size advantage to using them.  
Setting/ checking sectioning orientation is more difficult with 
males.  However, males and females can show differences in 
transgene expression which can be useful in screening 
enhancers vs suppressors.   
b. Using forceps, decapitate the animals and put their heads into the pre-
labeled microcentrifuge tube containing ~1.0ml Bouin’s fixative.  
i. Anesthetize the flies with CO2.  With one pair of needle-nose 
forceps, squeeze a fly at the “shoulders” which causes the head 
to prop outward revealing the neck. With a second pair of 
foceps, cut the head off at the neck. Clean up the head prep by 
removing any crop, foregut or other tissue still attached to the 
head, being cautious to avoid any damage to the eyes and 
head.   
ii. Immediately, transfer heads to the Bouin’s/tube. 
iii. Collect additional heads  
c. Slowly submerge a bean-sized piece of glass wool into the 
microcentrifuge tube, allowing air to move around the glass wool. 
Effectively this submerges the heads into Bouin’s and acts as a plug.  
Note: I’ve found that a looser ball of wool is better. Tighter plugs result 
in air bubbles forming between the wool and the Bouin’s surface. 
 
2. Repeat these steps for each genotype until all heads are collected.   
3. Incubate tubes at RT for 5d with slow agitation.  
Note:  you may need to check the samples after 24h to remove bubbles that 
form below the plug. To do this, using forceps squish the glass wool to one 
side and gently push down, effectively squeezing the bubble out from the side 
of the tube free of the wool.  
 
Day 5 
a. Leach samples for paraffin embedding. Note: It is convenient to transfer heads to 
cassettes and leach them at the end of the day so they are ready to be 
processed in the morning. 
a. Prep: Collect the following reagents into the fume hood 
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i. Pre-cut lens paper (1 per sample) 
ii. Staining dish filled half-way with leaching buffer 
iii. 2 pairs of needle-nose forceps 
iv. TC-plate lid  
v. pre-labeled plastic cassettes (labeled with pencil!) 
vi. a transfer pipettes (both sizes) 
vii. a waste container for formaldehyde waste 
viii. samples that have been on fixative for 5d. 
b. Using forceps, carefully remove the glass wool from your first sample. 
Using the fine tip transfer pipette, immediately remove all the Bouin’s. 
Using a standard transfer pipette, immediately add ~500-1000μl of 
leaching buffer. Make sure not to squish or lose any heads. Repeat for all 
samples.  
Note; The heads typically sink to the bottom of the tubes when fixed, 
but this is not necessary. I have had great images using heads that 
floated at this stage. 
c. Perform 2-3 washes with leaching buffer using the fine tip transfer pipette 
to remove buffer in the tube and using the standard transfer pipette to add 
fresh leaching buffer. When on last wash, keep all samples in leaching 
buffer.  
b. Transfer fixed heads to a plastic cassette 
a. Position the TC-plate lid so the cell-side is facing you and it is at ~20ᵒ 
angle. Wet a piece of lens paper placed on top it using a standard 
transfer pipette – just need a few drops to get the paper to stick to the lid.  
Notes:  
▪ the angle allows excess buffer to roll to the bottom of the plate when 
transferring heads to the paper. The edges of the lid help to collect 
the buffer at the bottom while the ridges for each well create small 
barriers which are useful for keeping heads in place. 
▪ do not add too much buffer when wetting the lens paper. This can 
make it difficult later when trying to keep heads in the center of the 
paper. 
b. Using the standard transfer pipette, gently transfer the heads to the 
center of the pre-wet lens paper on the lid. Fold the lens paper around the 
heads using forceps, effectively creating a package with them trapped 
inside. Try to avoid any bubbles forming between or around heads as this 
will prevent chemical access later.  
Notes 
▪ It is vital that the heads are fully enclosed or you will lose them! 
▪ it is important to position the heads so that they do not fall into any 
creases when the paper is folded as this prevents processing 
chemicals from accessing the heads.   
▪ It is preferable to separate the heads from each other for better 
chemical access.   
▪ It is preferable to not align the edges of the lens paper as this will 
make it more difficult to access the heads within the lens paper 
later.   
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c. transfer the heads/lens paper to a pre-labeled embedding cassette. 
Immediately transfer to the staining dish.   
 
d. Repeat steps for all samples, adding more leaching buffer to the staining 
dish as needed to keep cassettes submerged.  
c. Leach samples for 4-10h with agitation at RT.  
 
Notes:  
o samples can be stored at 4ᵒC in 70% ethanol for ~5d prior to 
processing. (This is useful for accumulating multiple samples.) 
o I have had success leaching samples overnight in the tubes and then 
transferring the heads to cassettes the next morning for processing.  
 
Day 6: Embed samples into paraffin 
1. Prepare  
a. ethanol (EtOH) and xylene solutions (can be reused ~10 times)  
• 70% EtOH 
• 90% EtOH (it is convenient to simply use 190pf EtOH if available) 
• 95% EtOH 
• 100% EtOH I 
• 100% EtOH II 
• Xylenes I (in fume hood) 
• Xylenes II (in fume hood) 
b. make sure paraffin tanks are on (should be ~61ᵒC) and there is sufficient 
paraffin in them.  Add more paraffin as needed (so ~1.5” deep). 
2. Pour leaching buffer out of staining dish containing leached samples and pour in 
70% EtOH. Incubate for 30min at RT with agitation.  
3. Pour 70% EtOH out of staining dish and pour in 90% EtOH. Incubate for 30min at 
RT with agitation. Continue 30min incubations with the subsequent EtOH 
solutions: 95% EtOH → 100% EtOH I → 100% EtOH II. 
4. In the fume hood, pour 100% EtOH II out of staining dish and pour in Xylenes I. 
Incubate for 30min within the fume hood. Continue 30min incubation with 
Xylenes II. 
5. Transfer cassettes to paraffin I tank (closest to fume hood), making sure they are 
all fully submerged. Incubate for 1h. Note: It is convenient to use the metal 
cassette-rack that is stored above the paraffin tanks to hold cassettes together.  
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6. Transfer cassettes to paraffin II tank, making sure to let the paraffin drain 
between tanks (<1min) and that they are all fully submerged once in the new 
tank. Incubate for 1h. 
7. Remove cassettes from paraffin tank II and let them cool to RT in the fume hood. 
It can be convenient to cool them on a cardboard fly-vial rack insert, as they tend 
to stick together or to paper towels.  
8. Store cassettes at RT for future use. 
 
Section paraffin-embedded fly heads 
1. Block heads 
 
a. Prepare 
i. Pre-warm metal molds on the blocking station so they reach 
~61ᵒC. (The Bonini lab uses a Shandon Histocentre2 station.) 
Need 1 per head. 
ii. Pre-label embedding rings with your sample name using pencil (!). 
Usually we cut 4-10 heads per genotype. 
b. Thoroughly clean excess wax off of 3 molds using a kimwipe. Fill each 
mold with molten paraffin to the top of the chamber. Maintain these on a 
~61ᵒC surface of the blocking station to keep paraffin melted. 
c. Ex
pose your first cassette containing paraffin-embedded heads to a ~61ᵒC 
surface of the blocking station, just enough to where the cassette can be 
opened and the heads/lens paper removed. 
d. Expose the heads/lens paper to a ~61ᵒC surface of the blocking station, 
just enough to where you can open-up the lens paper and expose the 
heads. DO NOT FULLY MELT THE HEADS/PARAFFIN AS THIS CAN 
DISRUPT THE TISSUE’S INTEGRITY. Use pre-warmed needle-nose 
forceps as needed.  
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e. Transfer 1 head into each of the prepared molds using pre-warmed 
forceps to “cut” them out of the wax. The heads should sink at this stage.  
If a head does not sink it has not been properly embedded and should be 
discarded.  
 
f. Position the head within the mold so the proboscis is facing one of the 
wings of the mold. Move the head/mold to a RT surface of the blocking 
station and allow the wax to cool just enough that the head can be held in 
place. Using prewarmed forceps, flip the head by pushing up on the 
proboscis so it is sitting on the superior part of the head, with the inferior 
side facing the surface of the molten paraffin. This creates horizontal 
sections.  
 
g. Carefully place a pre-labeled embedding ring on top of the mold so the 
wings of the mold are on opposing side from the wings on the ring. Make 
sure the edges are sealed together.  Fill the ring/mold with molten paraffin 
to the top of the ring by pouring the paraffin at an edge of the mold (not 
center where the head is located. IT IS VITAL THAT YOU DO NOT 
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DISTURB THE HEAD BY LETTING THE FRESH MAX MELT THE 
COOLED WAX AROUNG THE HEAD! 
h. Transfer to the cold-plate of the blocking station while you block additional 
heads. (do not turn it on, yet.) 
i. Repeat blocking of each head for all heads/samples.    
j. When done blocking, turn on the cold-plate of the blocking station and 
incubate samples for ~30min until the molds can be easily separated from 
the paraffin/ring. (they typically make a popping sound when the seal is 
broken.)  BE SURE TO TURN THE COLD-PLATE OFF WHEN DONE!  
k. Blocks can be stored long-term at RT. 
2. Trim blocks:  Using a sharp razor blade, cut excess wax away from the head 
within a room-temperature block, creating a small trapezoid around the head that 
is ~3mm (top edge) x 4mm (bottom edge). Be cautious of the position of the 
trapezoid in relation to the wings of the mold – the top edge should be 
perpendicular to the wings and angled-sides should run (relatively) parallel to the 
wings. Top and bottom edges should be as close to parallel as possible to avoid 
the ribbon from curling later. Trimmed blocks can be stored long-term at RT.  
Note: it can be convenient to keep the trapezoid a little larger than the final 
shape to leave room for further trimming the block during sectioning.  
 
3. Section heads (8μm thickness) 
 
a. Preparation: 
i. Clean excess wax out of the water bath next to the microtome, fill 
it with water, and pre-warm it to 52ᵒC.  
529 
 
ii. Position a new microtome blade onto the microtome. (One blade 
can be used to section ~15 heads and then it needs to be 
replaced.) To insert a new knife, loosen the red handle clamping 
the knife into the knife holder and use the magnet at the opposite 
end of the course brush to pull out the old knife.  Take a new knife 
from the pack and insert.  Use the handle of a fly brush to press 
the knife into the correct position and tighten the knife clamp  
iii. Fill a small beaker with ice and chill 2-3 pairs of needle-nose 
forceps.  
iv. Pre-label glass slides using pencil (!) 
v. Obtain and slide rack, paper towels, and a piece of dark poster-
board or napkin.  
b. In an ice-bucket full of ice, place the blocks tissue-side down into the ice. 
Chill blocks for 30+ minutes. 
 
c. With the microtome wheel locked and the blade safety bar in place, 
position a chilled block into the block holder on the microtome and firmly 
tightening the knob. The wings of the embedding ring should be on the 
left/right sides; in other words, The parallel edges of the blocks (top and 
bottom) should be parallel to the knife.  MAKE SURE THE BLOCK 
HOLDER IS POSITIONED FAR ENOUGH BACK THAT WHEN YOU 
START THE MICROTOME YOU DON’T CUT THE PORTION 
CONTAINING THE HEAD OFF OF THE BLOCK! 
d. Unlike the wheel and advance the tissue forward to where it is just barely 
touching the blade (little flakes of paraffin come off of the block).  
e. Start the microtome at a low speed (~2), using the control pad. Run the 
microtome enough to get a sense of whether any adjustments need to be 
made to the trapezoid shape with the goal of a relatively straight ribbon 
being formed by the tissue sections. Brush off excess paraffin from the 
blade using a large paintbrush (move the grain of the brush along the 
edge of the blade, not against, or you will damage the blades’ edge). 
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f. Run the microtome on continuous at ~5 until you reach the head tissue. 
Stop the microtome and discard the ribbon thus-far as this is just wax (no 
tissue).  
g. Run the microtome on continuous at ~2 until you reach the end of the 
head tissue. When running the microtome, guide the ribbon with small 
paint brushes, or else it will not stay straight. Stop the microtome when 
you no longer see red eye tissue. 
h. Using 2 small paintbrushes, gently free the last section of the ribbon from 
the blade and transfer the whole ribbon to a piece of dark napkin; matte 
side of the ribbon should be facing up.  Cut the ribbon into 2-3 smaller 
sections using a sharp razor-blade.   
 
Notes 
▪ I tend to measure the ribbon with a glass slide to see how 
short to cut the sections 
▪ Be aware that when you cut the ribbon with the blade, the wax 
can cut stuck onto the napkin. Gently free the ribbon with the 
small paintbrushes.  
▪ It is convenient to remove sections on the ends of the ribbon 
that do not contain any red-eye tissue.   
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i. Transfer each section of the ribbon, one at a time, into the water bath; 
matte side up. I usually achieve this by using 1 small paintbrush to lift 1 
side of the section up and onto the tip of a closed, pre-chilled forcep. It is 
essential that the forceps be cold or the tissue/paraffin with stick to it! 
also, it is convenient to use maintain any small droplets of cold water that 
have formed on the tip of the forceps as this can help “hold” onto the 
ribbon.  
j. Using cold forceps, gently bring the sections together. The edges should 
interact, so the sections stay together. It is vital that you frequently switch 
forceps so they stay cold. A good strategy for imaging later is to place the 
two ribbons next to each other in an antiparallel fashion so the adjacent 
regions of the ribbons are next to each other on the slide.   
 
k. Gently transfer the sections onto a pre-labeled glass slide, guiding the 
sections with a pair of chilled forceps.  
l. Tap the slide onto paper towels to remove excess water. Dry slide in a 
slide rack while you section additional samples. 
 
m. When sectioning is complete, place the wheel of the microtome in the 
locked position and put the blade guard back up.  Turn off the water bath, 
microtome and clean up paraffin debris.    
n. Dry slides at room temperature (overnight or more).  
4. Mount coverslips onto slides 
a. Preparation 
i. Warm an incubator or oven to 60ᵒC 
ii. Prep: Collect the following reagents into the fume hood 
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▪ 2 slide dishes filled with Xylenes – labeled Xylenes (I) and 
Xylenes (II).  Xylenes can be reused ~10 times when stored in 
bottles. 
▪ Paper towels 
▪ 22 x 50mm cover slips 
▪ Permount 
▪ A standard transfer pipette 
b. Incubate slides/slide rack at 60ᵒC for ~60min. (termed: baking) 
c. Allow slides to cool for 30+ min.  
d. Transfer slides/slide rack to the slide dish containing Xylenes I. Incubate 
in the fume hood for 10min. 
e. Transfer slides/slide rack to the slide dish containing Xylenes II. Incubate 
in the fume hood for 10min.  DO NOT REMOVE SLIDES/SLIDE RACK 
FROM THE XYLENES UNTIL THE MOMENT THAT YOU ARE 
MOUNTING THE COVERSLIP ON EACH INDIVIDUAL SLIDE. Tissue is 
ruined if it is allowed to dry out at this stage. 
f. Mount cover slips onto slides 
i. Align 1-3 coverslips along a paper towel. Using the transfer 
pipette, add 3 small drops of Permount onto each coverslip so 
they are evenly distributed length-wise.  DO NOT USE EXCESS 
PERMOUNT.  It does not take much! them using a disposable 
pipet.  
ii. remove 1 slide from the slide rack/xylenes. Wipe away excess 
xylenes from the back of the slide. Place the slide tissue-side 
down onto the prepared coverslip.  The xylenes should help the 
permount to evenly distribute across the coverslip. 
iii. Dab the edges of the slides on a piece of paper towel to remove 
excess solution and the straighten the coverslip. Also, check for 
any bubbles that maybe in the same position as the tissue.  
bubbles can be gently squeezed out from between the slide and 
coverslip using the lead tip of an automatic pencil. 
iv. Place the mounted slide coverslip side up onto a piece of 
cardboard to dry 1-2d in the fume hood. (It is convenient to use 
old fly-bottle trays and to angle the slides slightly with paper 
towels.) 
v. repeat steps i-iv for remaining slides.  
2. Image slides on the DM6000 microscope using a 20X dry objective with 1.25 
zoom and 588 fluorescence (looking at auto-fluorescence of the tissue).  For 
internal eyes, use anatomical landmarks to define the tissue region for fair 
comparisons between samples. Typically, I image the tissue when I can see the 
following landmarks: AL + LH + optic chiasma.    
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3. Quantify internal eye tissue depth and total surface area in ImageJ. 
a. Open eye images taken on a microscope in Fuji (ImageJ). If you open 
from the original .lif file, the scale bar will already be set.  
b. (if not using the .lif file) Click “Analyze” > “Set scale”.  
c. Measuring the tissue depth 
i. Using the line tool, draw a line the depth of the eye tissue at the 
optic chiasm. 
ii. Click “Analyze” > “Measure” 
iii. Copy and paste the length measurement into excel. This is in 
units you previously set for the scale. 
iv. Example 
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d. Measuring the total surface area of the retina tissue  
i. Using the Freehand selection tool, trace the outer edges of the 
internal eye tissue. Click “Analyze” > “Measure”. This will give you 
the Area in the units you previously set for the scale. 
ii. Copy and paste the Area measurement into excel. 
iii. For any pockets in the eye tissue, repeat steps a-b while tracing 
around these pockets. The area values given should then be 
subtracted from the total area measurement to give an accurate, 
final measurement. 
iv. Examples 
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TROUBLESHOOTING 
- After much trial and error, we’ve found that 5d on Bouin’s results in the best 
tissue integrity.  4 and 6d can also produce some good sections while the 
percent of good sections reduces. 
- When cleaning the microtome blade, it is essential to only use upward-strokes 
with a brush to avoid dulling the knife.   
- It is advisable to change to a new knife on the microtome and to track the areas 
that have previously been used.  A sharp knife will alleviate many sectioning 
problems.   
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FIBROBLASTS 
 
Thawing, culturing, freezing 
REAGENTS/MATERIALS 
- DMSO, sterile (Sigma # D2650) 
- heat-inactivated, sterile Fetal Bovine Serum (FBS) 
- 50X MEM Amino Acids Solution (Invitrogen # 11130051) 
- Pen/Strep solution 
- DMEM - high glucose 4.5g/L and Sodium Pyruvate 
- 0.25% Trypsin-EDTA 
- dPBS without Ca/Mg 
- 500mL filter system (PES, 0.22μm)  
- 50mL filter system (PES, 0.22μm) (Corning # 430320) 
- Standard tissue-culture materials 
 
MEDIA 
Note: all media must be prepared in the TC-cabinet under sterile conditions. 
- Culture media 
o 75mL heat-inactivated, sterile Fetal Bovine Serum (FBS) to 15% 
o 5mL of 50X MEM Amino Acids Solution to 1X 
o 5mL of Pen/Strep solution to 1% 
o 415mL DMEM - high glucose 4.5g/L and Sodium Pyruvate 
o Filter through a 500mL filter system  
o Store at 4ᵒC for up to 2mo.  (Alternatively, discard media when it changes 
colors based on the pH indicator within the DMEM.) 
 
- Freezing media 
o 5mL of DMSO (sterile) to 10% 
o 45mL heat-inactivated, sterile Fetal Bovine Serum (FBS) 
o Filter through a 50mL filter system 
o Store at 4ᵒC for up to 2mo. 
 
PROTOCOL 
Notes:  
- Cells are maintained in a standard tissue culture incubator with 5% CO2 and at 
37ᵒC. 
- the following represents general protocols while adjustments may need to be 
made for specific lines, etc.  
- For all steps, it is vital to maintain sterility, spraying materials and hands regularly 
with 70% EtOH, etc. All steps must be performed in the tissue culture (TC-) room 
and when applicable, in the TC-cabinet.  
- the following protocol uses TC- flasks while cells can also be grown in TC-dishes 
if desired. 
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1. Thaw 1 vial of cells: 
a. Obtain a vial of cells from the LN2 tank and maintain it on dry ice. If 
necessary, you can do this 1-3d before thawing the cells and store the 
vial in the -80ᵒC.  
b. Prep: label a T25 (or T75) flask with the cell line name, date, and the 
passage number on the vial.  It is vital that you keep track of the passage 
number! Note that it doesn’t start at “1” for when you start growing the 
cells – as the cells have already been grown for a number of passages 
(P) prior to you culturing it.  All cells must be discarded once you reach 
P20-25. 
c. Thaw the vial of cells in a 37ᵒC water bath. When the ice is almost 
completely gone (~a pea size), transfer the vial to the TC-cabinet after 
spraying it thoroughly with 70% EtOH to sterilize it.  
d. Immediately, carefully remove the cap from the vial and transfer the cell 
suspension to the prepared flask. It is vital that this is done relatively 
quickly. 
e. Transfer the flask to a 37ᵒC incubator overnight to allow the viable cells to 
adhere to the bottom of the flask. The next morning, remove all of the 
media and add fresh, pre-warmed culture media to the flask, effectively 
removing the freezing media and cell debris. 
f. Transfer the flask back to the 37ᵒC incubator and check on the cells every 
2-3d. when the cells reach 90-100% confluence, passage them 1:2 for the 
first passage after thawing. After that you can increase the passage 
dilution as needed. It is good practice to passage the cells 1-2x before 
using them for experiments to allow them to fully recover.  
2. Passage cells when they reach 90-100% confluence.   
a. Prep: pre-warm Culture media and Trypsin to 37ᵒC; make sure dPBS is at 
RT. 
b. Remove growth media and wash cells 1x with dPBS. Add just enough 
trypsin to cover the monolayer of cells (1.5-2mL for a T25 flask; 3mL for a 
T75 flask). Incubate cells at 37ᵒC for 5-10min. 
c. Prep:  
i. label new flask(s) with the cell line name, passage number, date, 
and dilution. It is vital to track passage number. Typically 1:5 
dilutions are used for healthy fibroblast lines.  However, some 
lines may require 1:2 dilutions to maintain viability. (1:2 = 1 
confluent flask can be split into as many as 2 new flasks; 1: = 1 
confluent flask can be split into as many as 5 new flasks) 
ii. Add a minimal amount of growth media to the flasks (~3mL for 
T25; ~10mL for T75). It is important to consider how much of the 
cell suspension you will be adding later so you don’t add too much 
volume. You want ~4-6mL end volume in a T25 or ~12-15mL end 
volume in a T75. 
d. When cells have lifted off the flask, add growth media to stop the reaction 
(~3mL for T25; ~5-7mL for T75). It is best to pipette the media along the 
cell-side of the flask to wash all cells to the bottom. Pipette up/down ~5x 
to fully suspend cells. Transfer a defined volume of the cell suspension 
into the prepared flasks based on the dilution.   
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e. Discard the old flask in the biomedical waste container. Transfer the new 
flask(s) to the 37ᵒC incubator.  Every 2-3d, check on the cells to make 
sure they are growing well. Passage again (or use them for experiments) 
when they reach 90-100% confluence.  
Note: for slow growing line, you may need to change the media every 
~5d. To do this by removing ½ of the current growth media and replacing 
it with new, pre-warmed media.  
3. It is vital to maintain a good freezer stock for every cell line.  A good rule of 
thumb is to always replace a thawed vial with a new vial of frozen cells. To freeze 
cells: 
a. Prep: pre-warm culture media, trypsin, and freezing media to 37ᵒC; make 
sure dPBS at RT is available; get a ice-bucket full of dry ice.  
Note: it is vital that the freezing media be pre-warmed as it contains 
DMSO which crystalizes at 4ᵒC.  
b. Remove growth media and wash cells 1x with dPBS. Add just enough 
trypsin to cover the monolayer of cells (1.5-2mL for a T25 flask; 3mL for a 
T75 flask). Incubate cells at 37ᵒC for 5-10min. 
c. Prep:  
i. label cryo-vial with the following information: cell line name, date, 
passage number, # cells (can be an estimate like “½ T75”) 
ii. obtain a sterile 50mL conical and label it with the cell line name 
(particularly important if you are handling multiple cell lines 
simultaneously) 
d. When cells have lifted off the flask, add growth media to stop the reaction 
(~3mL for T25; ~5-7mL for T75). Pipette up/down ~5x to fully suspend 
cells. Transfer cells into the pre-labeled 50mL conical. 
e. Centrifuge the cells/50mL conical for 5min at 15,000 RPM to pellet the 
cells.  
f. Remove the supernatant and add 1mL of freezing media for each vial. 
Pipette up/down ~10x to fully suspend cells. Transfer cells into the pre-
labeled vial(s).  Immediately cap the vial and transfer it to the bucket of 
dry ice, making sure the vial is fully surrounded by the ice. Immediately 
transfer the vial to a -80ᵒC freezer overnight.  
Note: Freezing media has DMSO which is toxic to cells. It is vital that all 
steps where cells are exposed to the freezing media be performed 
relatively quickly to get them frozen as fast as possible.  
g. In the morning, transfer the vial to the LN2 tank for long-term storage. 
Optional: you can maintain vials at -80ᵒC for ~1wk to accumulate multiple 
vials before transferring them to the LN2. 
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Protein extraction 
REAGENTS 
- RIPA lysis buffer  
o 10mL of 1M Tris-HCL (pH 7.5) to 50mM 
o 6mL of 5M NaCl to 150mM   
o 2mL NP-40 to 1%    
o 0.42g NaF to 50mM 
o 2mL of 10% SDS to 0.1% 
o 1g Sodium Deoxycholate (DOC) to 0.5% 
o dH2O to 200mL   
o Filter through a 250ml filter system, 0.22μm, PES 
o store at 4ᵒC. Check pH every 6-8mo.  
- 5X cOmplete ULTRA Tablets, mini, EASYpack protease inhibitor cocktail (Sigma 
# 05892970001) 
o 1 tablet dissolved in 1500μl of milliQ water 
o prepare 100μl aliquots  
o store in -20ᵒC. After thawing, precipitate may form and need to be 
resuspended into solution. 
- (optional) 25X PhosSTOP Phosphotase inhibitor cocktail (Sigma # 
04906845001) 
o 1 tablet dissolved in 400μl of MilliQ water 
o prepare 25μl aliquots  
o store in -20ᵒC. After thawing, precipitate may form and need to be 
resuspended into solution. 
- 100mM PMSF  
o 0.1742g of PMSF 
o 10mL of isopropanol 
o Filter through a 0.22μm PES filter (Fisher Sci # 09-720-511) using a luer-
lock syringe 
o prepare 500μl aliquots  
o store in -20ᵒC. Before use, bring to RT and vortex until precipitate goes 
back into solution 
- 1M DTT  
o 1.5425g of DTT (Dithiothreitol) 
o 10mL MilliQ water 
o Filter through a 0.22μm PES filter (Fisher Sci # 09-720-511) using a Luer-
lock syringe 
o prepare 500μl aliquots  
o store in -20ᵒC 
▪ before use, bring to RT and vortex until precipitate goes back into 
solution 
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PROTOCOL 
1. Prepare working lysis Buffer: (must be made fresh! Store on ice.) 
a. Calculate the total amount of lysis buffer you will need. Typically, 50μl per 
well of a 6-welled plate when using cell pellet method (step 2).  
b. For every 500μl of working lysis buffer needed, add the 
following protease and phosphatase inhibitors. Make a minimum of 500μl 
of working lysis buffer then prepare additional 100μl as needed. 
• 400μL 0.5% RIPA Lysis Buffer Stock 
• 100μL of 5X cOmplete ULTRA protease inhibitor Stock to ~1X 
• 20μL of 25X PhosSTOP Phosphotase inhibitor cocktail Stock to 
~1X 
• 5μL of 100mM PMSF to ~1mM 
• 0.5μL of 1M DTT for ~1mM 
2. Lyse cells using one of two methods. (Written for a 6-welled plate. Scale up as 
needed.) 
a. Prepare a cell pellet 
i. Advantages  
1. can split up cells from the same plate into multiple assays 
2. cell pellet is prepared in a microcentrifuge tube so lysing 
no protein will be lost when lysis buffer is added 
3. can lyse cells in small volumes 
ii. Disadvantages  
1. Can lose cells during every centrifuge step 
2. slower 
iii. Protocol 
1. Prep: pre-warm Culture media and Trypsin to 37ᵒC; make 
sure dPBS is at RT. 
Note: it is good practice to use an aliquot of culture 
media in a sterile conical to prevent contaminating 
your primary stock of media 
2. Remove growth media and wash cells 1x with dPBS. Add 
just enough trypsin to cover the monolayer of cells 
(~0.5mL per well). Incubate cells at 37ᵒC for 5-10min. 
3. Prep: label 15mL conical 
Note: you will need multiple conicals if you are 
splitting the cells up for different assays. 
4. When cells have lifted off the plate, add growth media to 
stop the reaction (~1mL), using a P1000 pipet with tip. 
Pipette up/down ~5x to fully suspend cells. Transfer the 
cell suspension into the prepared conical(s).   
5. Using a fresh tip on the P1000 pipet, wash the plate while 
holding it at an angle so any remaining cells will collect to 
the bottom. Collect all solution into the conical. 
6. Repeat for remaining wells. 
7. Pellet cells by centrifugation at 5000rpm for 5min. 
8. Prep: label 1.5mL microcentrifuge tubes 
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9. Wash cells 2x to remove media and typsin by removing 
supernatant, resuspend cells in 3mL of dPBS, and 
pelleting cells by centrifugation at 5000rpm for 5min. 
10. Remove supernatant. Resuspend cells in desired volume 
of working lysis buffer. 
Note: other cell pellets can be immediately frozen on 
dry ice for future use (e.g. RNA extraction). 
11. Lyse cells for 20-40min at 4ᵒC with agitation/rotation. 
12. Prep: label 1.5mL microcentrifuge tubes 
13. Pellet cell debris by centrifuging samples at 15,000xg for 
10min. 
14. Transfer supernatant to the fresh prelabeled 
microcentrifuge tube. 
15. Quantify protein concentration by Bradford. 
b. Lyse cells directly on the TC-plate 
i. Advantages 
1. Faster 
2. Can get more protein from a single preparation 
ii. Disadvantage 
1. Requires larger volumes of lysis buffer, resulting in more 
dilute protein preparations 
2. If you’re not good about washing the plate to collect 
residual lysate, you will lose protein 
iii. Protocol 
1. Prep: label 1.5mL microcentrifuge tubes 
2. Remove growth media and wash cells 2x with dPBS. 
3. Add desired volume of working lysis buffer (typically ~100-
150μL per well) 
4. Using cell scrapers, scrape off cells from the bottom of the 
plate, making sure to get all edges. 
5. Using a P1000 pipet with tip, transfer all solution to the pre-
labeled microcentrifuge tube. Note: it will be gunky. 
6. Using a fresh tip on the P1000 pipet, wash the plate with 
100-150μL of lysis buffer while holding it at an angle so 
any remaining solution will collect to the bottom. Collect all 
solution into the tube. You should get all the gunky stuff – 
this is the lysed cells. 
7. Repeat for remaining wells. 
8. Lyse cells for 20-40min at 4ᵒC with agitation/rotation. 
9. Prep: label 1.5mL microcentrifuge tubes 
10. Pellet cell debris by centrifuging samples at 15,000xg for 
10min. 
11. Transfer supernatant to the fresh prelabeled 
microcentrifuge tube. 
12. Quantify protein concentration by Bradford. 
